Anti-respiratory syncytial virus antibodies, methods of their generation and use

ABSTRACT

Provided are antibodies or antigen binding polypeptides characterized by the ability to neutralize respiratory syncytial virus (RSV). Specifically, the antibodies or antigen binding polypeptides are characterized by high affinity binding to RSV fusion glycoprotein (RSVF). Further provided are methods for their identification, isolation, generation, preparation, and use, as well as the heavy chain and light chain sequences of the antibodies provided.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a national stage filing under 35 U.S.C. § 371 of International PCT Application No. PCT/US2018/055750 filed Oct. 12, 2018, which claims the benefit of U.S. Provisional Application No. 62/572,400 filed Oct. 13, 2017, the contents of all of which are herein incorporated by reference in their entirety.

SEQUENCE LISTING

This application contains a Sequence Listing filed herewith in ASCII format named 2009186_0296_SL.txt, created on Aug. 18, 2021 and 2,383,864 bytes in size. The Sequence Listing is incorporated by reference herein.

FIELD OF THE INVENTION

The invention is related to human antibodies and antigen-binding fragments thereof that specifically bind to Respiratory Syncytial Virus fusion glycoprotein (RSV F) (“anti-RSV F antibodies”), in particular infant anti-RSV F antibodies, compositions comprising these antibodies, and methods for the preparation and use of these antibodies.

BACKGROUND OF THE INVENTION

Respiratory syncytial virus (RSV) is a ubiquitous pathogen that causes bronchiolitis and pneumonia in infants and the elderly and substantial morbidity and mortality in infants, the elderly, and immunocompromised individuals. Recent estimates indicate that RSV causes nearly 60,000 deaths annually in children under the age of five (Shi et al., 2017). Currently, the only preventive measure available for RSV is passive prophylaxis with the monoclonal antibody Synagis® (Group, 1998). Unfortunately, prophylaxis with Synagis® is costly, requires multiple doses per RSV season, and is only modestly efficacious (Group, 1998; Homaira et al., 2014; Kamal-Bahl et al., 2002). These factors restrict its use to high-risk infants and limit its availability in developing countries where the greatest burden of RSV-associated mortality exists. Therefore, the development of an effective RSV vaccine and next-generation monoclonal antibodies is of great importance and ongoing clinical trials are evaluating numerous candidates (Griffin et al., 2017; PATH, 2017; Reichert, 2016; Zhu et al., 2017).

The development of an RSV vaccine has proven to be particularly challenging, due in part to the young age at which primary infection occurs (Glezen et al., 1986), a history of vaccine-enhanced disease in infants (Chin et al., 1969; Fulginiti et al., 1969; Kapikian et al., 1969; Kim et al., 1969), and a lack of long-lived immunity in response to natural infection, resulting in frequent reinfections (Hall et al., 1991; Henderson et al., 1979). Although there are no clinically approved RSV vaccines, there are 43 vaccine candidates in development, of which 19 are in clinical stage development (Center for Vaccine Innovation and Access, PATH available on the world wide web at path.org/programs/center-for-vaccine-innovation-and-access/). Most of these vaccines seek to induce neutralizing antibodies that recognize the RSV fusion (F) glycoprotein, which is targeted by the prophylactic antibody palivizumab and the majority of RSV-specific neutralizing antibodies in human sera.

The goal of most vaccination efforts against RSV is not to prevent infection, but to reduce the risk of RSV-related complications in high-risk populations, such as infants and the elderly. Five target age groups for vaccination have been proposed—infants under six months of age, infants over six months of age, school-aged children, pregnant women, and adults over 65 years old—with the goal of either directly or indirectly protecting at-risk populations (Anderson et al., 2013). These target age groups have different immunological characteristics that may require different vaccination strategies for optimal protection. Although multiple modalities for an RSV vaccine are currently being pursued, most vaccination strategies share a common goal: to elicit neutralizing antibodies that recognize the RSV fusion glycoprotein (RSV F), which is targeted by the majority of RSV-neutralizing activity in human sera (Magro et al., 2012; Sastre et al., 2005).

RSV F is a class I fusion protein that mediates viral entry into host cells by converting from a metastable prefusion conformation (preF) to a highly stable postfusion (postF) conformation. On the surface of the virus, RSV F exists in a metastable trimeric prefusion conformation (preF) before undergoing a dramatic structural rearrangement that results in the insertion of a hydrophobic fusion peptide into the host-cell membrane. This intermediate state of RSV F tethers the viral and host-cell membranes before collapsing to form the stable six-helix bundle that is characteristic of the postfusion conformation (postF). Fusion of the viral and host-cell membranes is driven by these conformational changes, and the antigenic topology of RSV F is substantially altered during this transition. Over the past several years, epitope mapping studies using both human and murine monoclonal antibodies have defined at least 6 major antigenic sites on the RSV F protein. Some groups of epitopes, referred to as antigenic sites, are generally conserved on both the preF and postF, whereas others antigenic sites are preferentially or exclusively expressed on only one conformation (Graham, 2017; McLellan et al., 2013; McLellan et al., 2011; Swanson et al., 2011). Molecules that prevent these structural changes can prevent viral fusion and have potential as therapeutics for RSV (Battles et al., 2016; Huang et al., 2010; Lambert et al., 1996; McLellan et al., 2013). Recent studies have shown that the vast majority of highly potent neutralizing antibodies target epitopes that are exclusively expressed on preF. Hence, vaccines that specifically induce preF-specific antibodies may have great clinical potential.

The first characterized RSV F-reactive antibodies bound to structural elements shared by both preF and postF and were F-conformation-independent. These include Synagis®, which recognizes a helix-turn-helix motif called antigenic site II (Beeler and van Wyke Coelingh, 1989; McLellan et al., 2010b), and 101F, which recognizes the β-strand-rich antigenic site IV (McLellan et al., 2010a; Wu et al., 2007). Antibodies that preferentially bind to postF at antigenic site I were also among the first to be isolated, but were only weakly neutralizing (Anderson et al., 1986; Garcia-Barreno et al., 1989). The first preF-specific antibodies to be described recognized antigenic site Ø, present at the apex of the preF trimer, and were shown to be extremely potent (McLellan et al., 2013). A second class of potently neutralizing antibodies, epitomized by MPE8, was later described and shown to recognize antigenic site III (Corti et al., 2013). Although the secondary structure elements that form site III are present on both preF and postF, they adopt a different spatial arrangement in postF that dramatically decreases the affinity of site III-directed antibodies for this conformation and results in preferential binding to preF (Corti et al., 2013; Rossey et al., 2017; Wen et al., 2017). Antigenic site V, located between sites Ø and III, was recently identified and shown to be the target of additional preF-specific antibodies that are also potently neutralizing (Gilman et al., 2016; Mousa et al., 2017). The isolation and characterization of preF-specific antibodies spurred the development of second-generation prophylactics, such as MEDI8897, which recognizes site Ø (Griffin et al., 2017; Zhu et al., 2017) and is currently in late-phase clinical trials as a potential replacement for Synagis®.

An effective RSV vaccine will likely require the elicitation of potent neutralizing antibodies and balanced cellular responses (Kristjansson et al., 2005; Lambert et al., 2014; Legg et al., 2003; Saravia et al., 2015; Zhang et al., 2017). Infants present a number of unique challenges for vaccine development, including suppression of B cell responses by maternally derived antibody (Gans et al., 2001; Sande et al., 2014; Trang et al., 2014; Troisi et al., 1997; Wang et al., 2017) and immunological immaturity that results in reduced levels of T cell help, antibody class-switching, and somatic hypermutation (SHM) (Siegrist and Aspinall, 2009). Studies of convalescent infant sera have demonstrated that infants generally produce low titers of RSV-neutralizing antibodies after natural infection (Esposito et al., 2016; Murphy et al., 1986; Sande et al., 2014) but that these titers are higher when levels of maternal antibody are low (Shinoff et al., 2008), suggesting that infants are capable of mounting neutralizing antibody responses to RSV under certain circumstances. Serum studies have also suggested that different epitopes may be targeted as children age into adulthood (Fuentes et al., 2016), but little is known about how these changes are associated with antibody sequence or neutralization potency. In addition, sequencing studies have demonstrated that the antibody variable genes cloned from RSV-specific B cells in infants under three months of age contain little to no SHM, but the corresponding antibodies were not produced and characterized (Williams et al., 2009).

RSV replicates exclusively in respiratory epithelial cells, initiating infection in the upper respiratory tract and in some cases progressing to the lower respiratory tract. Therefore, an effective RSV vaccine may induce systemic and mucosal immune responses that protect both the upper and lower respiratory tracts (Varga, Current Opinion in Virology, 2014). A substantial body of literature suggests that RSV-specific mucosal antibody levels correlate more strongly with protection against RSV infection than serum antibody titers (Mills J T J Immnology 1971; Singleton R et al, JVI, 2003; walsh EE et al, JID, 2004; Habibi, AJRCCM 2015; Bagga JID, 2015; Vissers, CVI 2016; Watt P J Vaccine 1990). For example, experimental RSV challenge studies in adult donors have shown that nasal antibody strongly predicts protection from RSV infection (Habibi, AJRCCM 2015). In addition, a recent study in a clinical pediatric cohort showed that high levels of RSV-specific mucosal IgG correlated with reduced viral load and inflammation, whereas plasma IgG levels were not predictive of either (Vissers, CVI 2016). Finally, preclinical immunogenicity and efficacy studies utilizing a live-attenuated vaccine candidate, RGΔM2-2, showed that the protective efficacy of this vaccine was significantly higher when delivered by the intrasanal route compared to the intramuscular route, despite both vaccines inducing comparable serum antibody titers. These studies provide compelling evidence that mucosal immunity may be required for efficient protection against RSV. However, relatively little is known about the anatomic location(s) of RSV-specific memory B cells within mucosa-associated lymphoid tissues, the specificities and functional properties of these antibodies, and if/how the RSV-specific mucosal antibody response differs from the systemic antibody response. A better understanding of these aspects of RSV infection and immune responses may provide useful information for the development of effective RSV vaccines.

SUMMARY OF THE INVENTION

An improved understanding of the specificities and functional activities of antibodies induced by natural RSV infection in young infants could facilitate the design of vaccine antigens that are less susceptible to interference by maternal antibodies and that focus the response on epitopes associated with neutralizing activity. RSV is a leading cause of infant mortality, and there are currently no licensed vaccines to protect this vulnerable population. A comprehensive understanding of infant antibody responses to natural RSV infection will facilitate vaccine development.

Applicant has discovered, isolated, and characterized an extensive panel of RSV F-specific monoclonal antibodies from several RSV-infected infants, some of which antibodies recognize antigenic sites distinct from those sites that dominate adult responses. In particular, over 450 RSV F-specific antibodies from the peripheral B cells of seven RSV-infected infants were isolated and characterized and, additionally, over 800 RSV F-specific antibodies from paired peripheral blood and adenoid tissues of 6 young children were isolated and characterized.

Binding and functional studies of the isolated anti-RSV F infant antibodies generally demonstrate binding to 2 primary antigenic sites and different neutralization potentials, i.e., non-neutralizing antibodies that bind to site I on postfusion F and neutralizing antibodies that bind to site III or site V on postfusion F. Structural studies provide a molecular basis for the conserved features of antibodies recognizing these sites. A subset of antibodies targeting one of the sites displayed potent neutralizing activity despite lacking somatic mutations, suggesting such antibodies can be induced in young infants with suitably designed vaccine antigens. Accordingly, Applicant provides fundamental insights into infant antibody responses in different immune compartments (e.g., mucosal and systemic) and, thus, provides a blueprint for the rational design of infant vaccine immunogens that selectively elicit desired B cell responses in infants.

In some embodiments, the present disclosure provides isolated antibodies or antigen-binding polypeptides comprising a VH CDR3 having an amino acid sequence according to an antibody number in Table 9B.

In some embodiments, the present disclosure provides isolated antibodies or antigen-binding polypeptides comprising a VH CDR3 having an amino acid sequence according to an ADI listed in Table 8.

In some embodiments, the present disclosure provides isolated antibodies or antigen binding polypeptides characterized by ability to neutralize respiratory syncytial virus (RSV).

In some embodiments, antibodies or antigen binding polypeptides are characterized by high affinity binding to RSV F.

In some embodiments, antibodies or antigen binding polypeptides are characterized by high affinity binding to RSV prefusion F (preF).

In some embodiments, isolated antibodies have an amino acid sequence according to:

(i) Antibody Number 2, 71, 112, 217, 227, 228, 249, 466, 467, 469, 470, 832, 471, 516, 527, 532, 543, 544, 551, 554, 571, 578, 581, 592, 615, 641, 843, 868, or 870;

(ii) an Antibody Number of (i) with no more than 3 amino acid substitutions, additions, or deletions;

(iii) an Antibody Number of (i) with no more than 3, 2, or 1 amino acid substitution(s), addition(s), or deletion(s) in a CDR; or

(iv) an Antibody Number of (i) with no more than 3, 2, or 1 amino acid substitution(s), addition(s), or deletion(s) in CDRH3.

In some embodiments, antibodies or antigen-binding polypeptides have an IC50 of less than 300 pM, less than 200 pM, or less than 100 pM for neutralization of RSV.

In some embodiments, antibodies or antigen-binding polypeptides are characterized by binding affinity to pre-F with a kD of less than 10 nM.

In some embodiments, antibodies or antigen-binding polypeptides characterized by a binding affinity to pre-F that is at least 10, 100, or 1000 fold greater than binding affinity to post-F.

In some embodiments, antibodies or antigen-binding polypeptides are characterized by high affinity binding to RSV F site III.

In some embodiments, the present disclosure provides an antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRH3 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRH3 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

The present disclosure also provides an antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRH2 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRH2 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

The present disclosure further provides an antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRH1 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRH1 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

The present disclosure also provides an antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRL3 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRL3 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

The present disclosure further provides an antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRL2 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRL2 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

The present disclosure also provides an antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRL1 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRL1 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In some embodiments, the anti-RSV F antibody comprises (i) the CDRH3 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (ii) the CDRH2 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (iii) the CDRH1 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (iv) the CDRL3 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (v) the CDRL2 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (vi) the CDRL1 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; or (vii) any combination of two or more of (i), (ii), (iii), (iv), (v), and (vi).

In other embodiments, the antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising (i) a heavy chain variable region (VH) that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a V_(H) amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5, and/or (ii) a light chain variable region (V_(L)) that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a V_(L) amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In yet other embodiments, the anti-RSV F antibody comprises (i) the V_(H) amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; and/or (ii) the V_(L) amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the anti-RSV F antibody is selected from the group consisting of Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In some embodiments, the anti-RSV F antibody binds to an epitope comprising site Ø, site I, site II, site III, site IV, or site V of RSV F. In one embodiment, the anti-RSV F antibody binds to an epitope on prefusion F (preF), preferably antigenic site III. In other embodiments, the anti-RSV F antibody binds to an epitope on postfusion F (post F), preferably antigenic site I.

In some embodiments, the anti-RSV F antibody binds to prefusion F (preF) with high affinity but does not bind to or binds with low affinity to postfusion F (postF).

In some embodiments, the anti-RSV F antibody does not compete with D25 for binding to RSV F. In some embodiments, the anti-RSV F antibody competes with MPE8 and/or motavizumab for binding to RSV F.

In some embodiments, the anti-RSV F antibody is a neutralizing antibody. In a certain embodiment, the anti-RSV F antibody has a neutralizing activity (IC₅₀) of less than 100 μg/ml, 50 μg/ml, 25 μg/ml, 10 μg/ml, 5 μg/ml, 1 μg/ml, 0.5 μg/ml, 0.1 μg/ml, or 0.05 μg/ml.

In some embodiments, the anti-RSV F antibody binds to RSV prefusion F with a K_(D) value of less than 50 nM, 25 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, or 0.1 nM as measured by surface plasmon resonance.

In some embodiments, the anti-RSV F antibody binds to RSV prefusion F through one or both of the following interactions: a) Tyr33 in CDRL1 and Tyr93 in CDRL3 both contact the α6-α7 loop of RSV prefusion F; and b) five consecutive serine residues, preferably followed by a tyrosine residue (Tyr56), in CDRH2 form a network of hydrogen bonds with Asp310 on β6 of RSV prefusion F.

In some embodiments, the anti-RSV F antibody has a clean or low polyreactivity profile.

In some embodiments, the anti-RSV F antibody is a full-length IgG1 monoclonal antibody.

In some embodiments, the anti-RSV F antibody is a human antibody.

In some embodiments, the anti-RSV F antibody comprises a Fc region that has been modified to alter effector function, half-life, proteolysis, and/or glycosylation.

In some embodiments, the anti-RSV F antibody is derivatized.

The present disclosure further encompasses a nucleic acid sequence or nucleic acid sequences encoding the anti-RSV F antibodies described herein; expression vectors comprising the isolated nucleic acid sequence(s); and host cell(s) comprising the isolated nucleic acid sequence(s) or the expression vector(s). In some embodiments, the host cell is a mammalian cell, a bacterial cell, a fungal cell, a yeast cell, or an insect cell.

Additionally, the present disclosure encompasses a method for producing an isolated human antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) comprising expressing the nucleic acid sequence(s) described herein or culturing the host cell(s) described herein (e.g., a yeast cell or a mammalian cell) under conditions that provide for expression of the anti-RSV F antibody and optionally recovering the anti-RSV F antibody from the host cell and/or culture medium.

The present disclosure also contemplates a pharmaceutical composition comprising (i) an anti-RSV F antibody(ies) described herein, the nucleic acid sequence(s) described herein, the expression vector(s) described herein, or the host cell(s) described herein; and (ii) a pharmaceutically acceptable carrier and/or excipient. The pharmaceutical composition can be used for preventing or treating a RSV infection in a subject. In one embodiment, the subject is a human, preferably an infant.

Furthermore, the present disclosure encompasses a method of preventing or treating a Respiratory Syncytial Virus (RSV) infection in a subject (e.g., a human or a non-human), comprising administering to the subject in need thereof an effective amount of the anti-RSV F antibody(ies) described herein, the isolated nucleic acid sequence(s) described herein, the expression vector(s) described herein, or the host cell(s) described herein, optionally in association with a further prophylactic and/or therapeutic agent. In one embodiment, the further prophylactic and/or therapeutic agent is selected from an antiviral agent; a vaccine specific for RSV; a vaccine specific for influenza virus; a vaccine specific for metapneumovirus (MPV); an siRNA specific for a RSV antigen; an siRNA specific for a MPV antigen; a second anti-RSV antibody; an anti-MPV antibody; an anti-IL4R antibody; an anti-influenza antibody; and a NSAID. In some embodiments, the subject is a human, preferably an infant.

Also provided herein is a method of preventing or treating a Respiratory Syncytial Virus (RSV) infection in a human subject (e.g., an infant) comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition described herein.

Additionally provided herein is a method for detecting a Respiratory Syncytial Virus (RSV) infection in a subject (e.g., a human or a non-human) comprising obtaining a sample from the subject; contacting the sample with the anti-RSV F antibody(ies) described herein; and detecting the presence of a complex between the anti-RSV F antibody and the RSV fusion glycoprotein (F), wherein detection of the complex indicates the presence of RSV. In one embodiment, the subject is a human subject, preferably an infant.

Other features and advantages of the instant invention will be apparent from the following detailed description and examples which should not be construed as limiting. The contents of all cited references, including scientific articles, patents and patent applications cited throughout this application, are expressly incorporated herein by reference.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-1C show the single B cell sorting strategy. FIG. 1A shows the gating strategy for a representative infant ≥6 months (Infant 2042), and FIG. 1B shows the gating strategy for a representative infant <3 months (Infant 2026). Lymphocytes were gated based on forward and side scatter, followed by a live/dead gate and selection of CD3⁻ CD8^(− CD)14⁻ cells. B cells were identified by gating on CD19⁺/CD20⁺ cells. IgG⁺ or IgA⁺ B cells or CD19/CD20⁺ B cells that showed reactivity with RSV F were single-cell sorted for antibody cloning. B cell reactivity with subtype A and subtype B is shown in the top and middle rows, respectively. The index sorting analysis is shown in the bottom panel. SSC-A, side scatter area; FSC-A, forward scatter area. FIG. 1C shows the percentage of RSV F-specific, class-switched B cells for each infant (FIG. 1C). Values were calculated based on flow cytometry data.

FIGS. 2A-2E show that anti-RSV F antibodies isolated from infant B cells display limited somatic hypermutation (SHM) and biased V_(H) and V_(L) gene usage. A representative flow plot is shown for the RSV F-specific B cell response in an infant <3 months of age (FIG. 2A) and an infant >6 months of age (FIG. 2B). Prior to sorting on double positive staining with dual labeled RSV F probes, the plot was gated on CD3⁻ CD19⁺ CD20⁺ B cells (FIG. 1A) or CD3 CD19⁺ CD20⁺ IgG/IgA⁺ B cells (FIG. 2B). RSV F-specific B cells are in the upper right quadrant of the plots. FIG. 2C shows the results of index sort analysis of the surface markers expressed on B cells from which RSV F-reactive antibodies were isolated. FIG. 2D shows the number of V_(H) nucleotide substitutions for antibodies isolated from RSV F-specific class-switched B cells (the red bars indicate medians). In both FIG. 2C and FIG. 2D, infants are ordered from youngest to oldest, left to right. FIG. 2E shows a heat map of V_(H) and V_(L) germline gene usage for all infants (left panel), showing only genes for which at least one V_(H)/V_(L) pairing was utilized in ≥0.5% of all antibodies isolated. The percent total of antibodies with the designated V_(H)/V_(L) pairing is provided (right panel).

FIGS. 3A-3D show that a subset of RSV F-specific infant antibodies binds with high affinity to RSV F and neutralizes RSV. The fraction of isolated antibodies from each infant that binds with weak, low, medium, or high apparent affinity for preF (FIG. 3A) or postF (FIG. 3B) is shown for each antibody that displayed detectable binding in this assay. Infants are ordered from youngest to oldest, left to right. Apparent binding affinities are shown for each antibody. Black bars indicate medians. N.D., not determined. The percentage of antibodies isolated from each infant that shows weak, low, medium, or high neutralization potency is shown (FIG. 3C). Neutralization IC₅₀ values are shown for each antibody with measurable neutralization activity. Top, middle, and bottom dotted lines show IC₅₀ values for motavizumab, MPE8, and D25, respectively. Black bars indicate medians. FIG. 3D shows the apparent affinities for postF plotted against apparent affinities for preF for infants <3 months (left panel) and ≥6 months (right panel).

FIGS. 4A-4C show that RSV-neutralizing, F-conformation-independent antibodies are rare in young infants. The percentage of antibodies that are preF-specific (black), preF- and postF-reactive (grey), or postF-specific (light grey) is shown for each infant (FIG. 4A). N.D., not-determined (white). Infants are ordered from youngest to oldest, left to right. The percentage of antibodies with high, medium, low, or weak neutralization potency is plotted for each group in infants <3 mo. (left panel) and ≥6 mo. (right panel) (FIG. 4B). Neutralization IC₅₀s are shown for antibodies in each group that displayed measurable neutralization activity (FIG. 4C). Black bars indicate medians. In FIGS. 4B and 4C, antibodies for which preF and postF binding affinities were measured are grouped according to preF or postF specificity.

FIGS. 5A and 5B show that polyreactivity of infant antibodies decreases with increasing levels of somatic hypermutation. The percent of antibodies with high, medium, low, or undetectable polyreactivity is shown for each infant (FIG. 5A). Four panels of control antibodies, each with a variety of specificities, are shown for comparison: 364 RSV F-specific antibodies previously isolated from healthy adults, 138 antibodies currently in clinical trials, 39 antibodies that are approved for clinical use, and 14 broadly neutralizing HIV-1 antibodies. Infant antibodies are grouped according to the number of nucleotide mutations present in the VH gene (FIG. 5B).

FIGS. 6A-6C show that infant responses are focused toward two antigenic sites with different neutralization sensitivities. FIG. 6A shows the preF structure with two protomers as grey molecular surfaces and one protomer as ribbons colored according to the antigenic site. FIG. 6B shows the percentage of isolated antibodies that recognize each antigenic site, plotted for each donor. Infants are ordered from youngest to oldest, left to right. FIG. 6C shows antibodies isolated from infants <3 months (left panel) and ≥6 months (right panel) grouped according to neutralization potency and antigenic site. N.N., non-neutralizing.

FIGS. 7A-7E show antibodies directed towards sites I and III utilize convergent sequence features and preferentially bind to different conformations of RSV F. Heat map of VH and VL germline gene usage for all site I-directed antibodies for which at least one VH/VL pairing was used in ≥0.5% of the antibodies directed against site I (FIG. 7A). A heat map of VH and VL germline gene usage for all site III-directed antibodies for which at least one VH/VL pairing was used in ≥0.5% of the antibodies directed against site III (FIG. 7B). WebLogos showing the CDR H3 sequence motifs for site I-directed (top) and site III-directed (bottom) antibodies (FIG. 7C). Apparent binding affinities for postF are plotted against apparent affinities for preF for antibodies directed against site I and site III (FIG. 7D, left panel). Antibodies that are preF-specific are boxed in. Apparent preF affinity for preF-specific antibodies is shown (FIG. 7D, right panel). Antibodies are grouped according to antigenic site and the percentage of antibodies in each group with high, medium, low, or weak neutralization potency is shown (FIG. 7E, left panel). Neutralization IC₅₀s is plotted for the antibodies in each group with detectable neutralization activity (FIG. 7E, right panel). Top, middle, and bottom dotted lines show IC₅₀s for motavizumab, MPE8 and D25, respectively.

FIGS. 8A-8D show that germline antibodies targeting antigenic site III can potently neutralize RSV and are present in the naïve B cell repertoire. FIG. 8A shows the neutralization potency (IC₅₀) of antibodies lacking VH or VL nucleotide substitutions, grouped according to antigenic site. Top, middle, and bottom dotted lines show the IC₅₀ value for motavizumab, MPE8, and D25, respectively. N.N., non-neutralizing. No antibodies against site Ø lacking substitutions were obtained. FIG. 8B shows the results of index sort analysis of the surface markers expressed on cells from which RSV-reactive antibodies were isolated in infants <3 months. The percentage of B cells in each group is shown for all antibodies, neutralizing antibodies that lack somatic mutations (germline neut.), and neutralizing antibodies that contain somatic mutations (mutated neut.). FIG. 8C contains pie charts showing the fraction of RSV F-reactive naïve B cells isolated from the cord blood of four donors (top panel) and peripheral blood from two donors (bottom panel) that utilized VH3-21/VL1-40 or VH3-11/VL1-40 germline gene pairing. Naïve B cells were defined as CD3 CD14 CD19⁺ CD20⁺ IgM⁺ IgG⁻ CD27⁻ cells. The number in the center of the pie (top and bottom) indicates the total number of antibodies with detectible binding to RSV F when produced as full-length IgG. FIG. 8D shows the apparent affinity for preF for each of these antibodies and colored according to germline usage. Black bars indicate medians. IC₅₀ values for antibodies that displayed detectible neutralizing activity.

FIGS. 9A-9D shows the non-neutralizing antibody ADI-14359 uses a convergent CDR H3 motif and germline features of the VK1-39 light chain for binding to antigenic site Ion postF. FIG. 9A shows a crystal structure of infant antibody ADI-14359 (VH2-70/VK1-39) in complex with postF. FIG. 9B shows a magnified view of the CDRH3 of ADI-14359 inserted into a groove on the surface of postF. The variable region of ADI-14359 and one RSV F protomer are shown as ribbons and the C-α atom of Pro389, a residue associated with viral escape from site I-directed antibodies, is shown as a sphere. FIG. 9C shows a magnified view of the antibody interface, highlighting the features of the convergent CDR H3 motif that mediate recognition of site I (left panel), whereas a 180° rotation highlights the CDR H2 contacts made with postF (right panel). The sequence logo for the convergent CDR H3 motif is shown (generated using WebLogo, described by Crooks et al., 2004). FIG. 9D shows the binding of ADI-14359 to postF as measured by surface plasmon resonance (top panel). Rate constants for the germline-reverted variant (R50L) binding to postF were too fast to be accurately determined (top middle panel) and, therefore, the equilibrium responses were plotted against the concentration of Fab and fit to a steady-state affinity model (bottom middle panel). Binding of ADI-14359 to the K390A variant of postF was too weak to determine an affinity (bottom panel).

FIGS. 10A-10D show that the light chain mediates postF preference of ADI-14359. The crystal structure of ADI-14359 (VH2-70/VK1-39) in complex with postF is shown at a 180° rotation with respect to FIG. 9 (FIG. 10A). Two protomers of postF are shown as molecular surfaces and the third protomer and ADI-14359 are shown as ribbons. The ADI-14359 heavy chain is gray and the light chain is white. The position of the fused viral and host-cell membranes is shown for orientation. The predicted interaction between preF and ADI-14359 was predicted by aligning the unbound preF structure to the ADI-14359-bound postF structure (FIG. 10B). The unfused viral membrane is shown for orientation. A magnified view of the ADI-14359-postF interface (FIG. 10C). One protomer is shown in ribbons. The ADI-14359 light chain CDR1 and FW3 form hydrogen bonds with two residues on β1 (Glu31 and Tyr33). A magnified view of the predicted ADI-14359-preF interface (FIG. 10D). In preF, (322 blocks access to (31 and would clash with the ADI-14359 light chain FW3 and CDR1. In addition, Glu31 is rotated away from ADI-14359 in preF, which would prevent hydrogen bonding with this residue.

FIGS. 11A-11C show that neutralizing antibody ADI-19425 uses germline-encoded features for high-affinity binding to antigenic site III on preF. FIG. 11A shows a crystal structure of ADI-19425 in complex with preF viewed along (left panel) and above (right panel) the viral membrane. FIG. 11B shows a magnified view of the interface with the variable region of ADI-19425 and one RSV F protomer shown in ribbon (left panel) and a 90-degree rotation showing the interactions between the light chain of ADI-19425 and the α6-α7 loop of antigenic site II (right panel). FIG. 11C shows the binding of ADI-19425 and the Y33A, Y93A and Y56A variants to preF as measured by surface plasmon resonance.

FIGS. 12A-12D show ADI-19425 and MPE8 utilize similar germline-encoded features to recognize preF. A ternary crystal structure of preF, 3 AM22 Fabs, and 3 ADI-19425 Fabs was generated (FIG. 12A, left and right panels). The right panel shows the same complex in the left panel, but rotated by 90° to show the view looking toward the viral membrane. Neutralization of two strains of RSV (A2 and B10895) by ADI-19425 IgG was measured using the fluorescence plate reader assay (FIG. 12B). The preF-bound MPE8 Fv was aligned to preF bound by ADI-19425 (FIG. 12C, left and right panels). The right panel is rotated by 90° relative to the left panel to show the top view. The MPE8 Fv is aligned to that of ADI-19425 (FIG. 12D, left and right panels). The right panel shows the binding interface between preF and ADI-19425, with the same orientation shown in FIG. 11B. The CDR loops are shown for both ADI-19425 and MPE8.

FIGS. 13A-C show analysis of RSV F-specific B cell responses in the adenoids and peripheral blood of young children. RSV F-specific B cells were measured in adenoid and peripheral blood by flow cytometry (FIG. 13A, left, middle, and right panels). The left panel shows the frequency of RSV F-specific B cells among CD19⁺ B cells in adenoid for a representative donor. The middle panel shows the frequency of RSV F-specific B cells among CD19⁺ B cells in PBMCs for a representative donor. The frequency of RSV F-reactive B cells within the CD14⁻CD3⁻CD8⁻ CD19⁺ CD20⁺ population is shown next to the gate. The right panel shows a summary for all 6 donors analyzed. Index sort analysis of surface markers expressed on B cells from which RSV F-reactive antibodies were isolated (FIG. 13B). Percentage of RSV F-reactive B cells within each memory B cell subset that express FCRL4 (FIG. 13C). Asterisks indicate B cell responses that were below the limit of detection.

FIGS. 14A-B show the lack of a clear correlation between the frequency of RSV F-reactive B cells in either compartment and serum neutralization titer. FIG. 14A shows the percentage of RSV F-specific B cells among CD19⁺ B cells in the adenoids and PBMCs for a representative donor. FIG. 14B shows the percentage of RSV F-specific B cells among CD19⁺ B cells in the adenoids (left panel) and in the PBMCs (right panel) for a representative donor.

FIGS. 15A-C characterize the RSV-specific mucosal B cell response. FIG. 15A shows that the RSV F-specific antibody repertoires were highly diverse in both compartments (adenoids and PBMCs) in all donors, each containing few to no expanded clonal lineages. FIG. 15B shows the CDRH3 length distribution of the antibodies isolated from PBMCs and adenoids. FIG. 15C shows a comparable VH germline gene usage between the two compartments, though there was an enrichment for VH5-51 and VH1-69 in the adenoid-derived antibodies and an enrichment for VH4-34 and VH3-30 in the PBMC-derived antibodies.

FIGS. 16A-E show the level of somatic mutation in the antibodies was varied among the 4 donors. FIG. 16A shows the median number of VH nucleotide substitutions ranged from 8-11 in the adenoid-derived antibodies and 7-9 in the PBMC-derived antibodies. **** indicates that the difference in number of substitutions in the adenoid-derived antibodies relative to the PBMC-derived antibodies reached statistical significance in Donor 2665. FIG. 16B compares the levels of SHM within each individual B cell subset in adenoids (left panel) and PBMCs (right panel). FIG. 16C shows the percentage of antibodies derived from IgG-IgA-CD27-peripheral blood B cells containing SHM. FIG. 16D shows a subset of somatically mutated antibodies derived from IgG-IgA-CD27-peripheral blood B cells that contained lower levels of SHM compared to antibodies derived from IgG-IgA-CD27-adenoid B cells. FIG. 16E shows the IgM and IgD expression profiles of RSV F-specific IgG-IgA-CD27-adenoid B cells.

FIGS. 17A-D show the number of VH nucleotide substitutions in the adenoid-derived antibodies and PBMC-derived antibodies for each donor. FIG. 17A shows the number of VH nucleotide substitutions for Donor 2635. FIG. 17B shows the number of VH nucleotide substitutions for Donor 2665. **** indicates that the difference in number of substitutions in the adenoid-derived antibodies relative to the PBMC-derived antibodies reached statistical significance in Donor 2665. FIG. 17C shows the number of VH nucleotide substitutions for Donor 2666. FIG. 17D shows the number of VH nucleotide substitutions for Donor 2849.

FIGS. 18A-B show the binding properties of the adenoid and PBMC-derived antibodies. FIG. 18A shows the percentage of antibodies that bind RSV preF, postF, and preF & postF using biolayer interferometry. FIG. 18B shows the percentage of antibodies that bind preF with weak (>50 nm), low (>5 to 50 nM), medium (>0.5 to 5 nM), and high (<0.5 nM) binding affinities.

FIGS. 19A-D show the neutralizing activity of the adenoid and PBMC-derived antibodies against RSV-A2. FIG. 19A shows the amount of detectable neutralizing activity (IC50<25 μg/mL) for adenoid and PBMC-derived antibodies using a luciferase-based assay. FIG. 19B shows the neutralization actity of preF-specific antibodies, postF-specific antibodies, and preF and PostF reactive antibodies isolated from both adenoids and PBMCs. FIG. 19C shows the memory B cell subsets for the adenoid-derived and PBMC-derived neutralizing antibodies. FIG. 19D shows the apparent preF K_(D) (left panel) and the virus neutralization IC50 for each memory B cell subset.

FIGS. 20A-C shows the levels of polyreactivity and binding affinities of the antibodies derived from the adenoid and PBMC samples. FIG. 20A shows the percentage of antibodies having low and high levels of polyreactivity. FIG. 20B shows the percentage of low and high polyreactive clones across different B cell subsets within each compartment (left panel shows adenoid-derived antibodies and right panel shows PBMC-derived antibodies). FIG. 20C shows the percentage of antibodies having no binding or low, medium, or high affinity to RSV F.

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure relates anti-RSV F infant antibodies, compositions comprising such antibodies, and methods for obtaining and using such antibodies. In some embodiments, the antibodies are neutralizing antibodies and, thus, the anti-RSV F neutralizing antibodies and compositions comprising such antibodies can be used as a vaccine. For infants, in particular, the subject anti-RSV F antibodies may provide advantageous protection.

Definitions

In order that the present disclosure may be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

As used herein, the term “about,” when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. For example, as used herein, the expression “about 100” includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

“Respiratory Syncytial Virus fusion glycoprotein”, also referred to as “RSV F”, is a type I transmembrane surface protein that has an N terminal cleaved signal peptide and a membrane anchor near the C terminus (Collins, P. L. et al., (1984), PNAS (USA) 81:7683-7687). The RSV F protein is synthesized as an inactive 67 KDa precursor denoted as F0 (Calder, L. J.; et al., Virology (2000), 277, 122-131. The F0 protein is activated proteolytically in the Golgi complex by a furin-like protease at two sites, yielding two disulfide linked polypeptides, F2 and F1, from the N and C terminal, respectively. There is a 27 amino acid peptide released called “pep27”. There are furin cleavage sites (FCS) on either side of the pep27 (Collins, P. L.; Mottet, G. (1991), J. Gen. Virol., 72: 3095-3101; Sugrue, R. J, et al. (2001), J. Gen. Virol., 82, 1375-1386). The F2 subunit consists of the Heptad repeat C (HRC), while the F1 contains the fusion polypeptide (FP), heptad repeat A (HRA), domain I, domain II, heptad repeat B (HRB), transmembrane (TM), and cytoplasmic domain (CP) (See Sun, Z. et al. Viruses (2013), 5:21 1-225). The RSV F protein plays a role in fusion of the virus particle to the host cell membrane by irreversible protein refolding from the labile prefusion conformation (herein referred to as “prelusion F” or “preF”) to the stable postfusion conformation (herein referred to as “postfusion F” or “postF”). RSV F is expressed on the surface of infected cells. Accordingly, it plays a role in cell to cell transmission of the virus and syncytia formation. The amino acid sequence of the RSV F protein is provided in GenBank as accession number AAX23994.

A stabilized variant of the PreF trimeric conformation of RSV F, termed “RSV-DS-Cav1” or “DS-Cav1” disclosed in, inter alia, Stewart-Jones et al., PLos One, Vol. 10(6)):e0128779. doi: 10.1371/journal.pone.0128779 and WO 2011/050168 was used in the identification, isolation, and characterization of the disclosed antibodies.

The term “laboratory strain” as used herein refers to a strain of RSV (subtype A or subtype B) that has been passaged extensively in in vitro cell culture. A “laboratory strain” can acquire adaptive mutations that may affect their biological properties. The term “clinical strain” as used herein refers to an RSV isolate (subtype A or subtype B), which is obtained from an infected individual and has been isolated and grown in tissue culture at low passage.

The term “IC₅₀” refers to the “half maximal inhibitory concentration”, which value measures the effectiveness of compound (e.g., anti-RSV F antibody) inhibition towards a biological or biochemical utility. This quantitative measure indicates the quantity required for a particular inhibitor to inhibit a given biological process by half. In certain embodiments, RSV virus neutralization potencies for anti-RSV neutralizing antibodies disclosed herein are expressed as neutralization IC₅₀ values.

The term “infant”, as used herein, generally refers to a young child between one month and one year (12 months) of age; however, it can also apply to a child older than 1 year (12 months). In one embodiment, the infant is at least (≥) 6 months of age. In another embodiment, the infant is under 3 months of age.

The term “subject”, as used herein, refers to a human or a nonhuman. The term “nonhuman” includes, but is not limited to, domestic animals (such as horses, dogs and cats) and livestock (such as cattle, sheep, swine, and poultry). In some embodiments, the subject is a human (and, more preferably, a human infant). The term “subject” may be interchangeably used with the term “patient” in the context of the present disclosure.

“Motavizumab”, also referred to as “NUMAX™”, is an enhanced potency RSV F-specific humanized monoclonal antibody derived by in vitro affinity maturation of the CDRs of the heavy and light chains of palivizumab. For reference purposes, the amino acid sequence of the NUMAX™ antibody is disclosed in U.S. Patent Publication 2003/0091584; U.S. Pat. No. 6,818,216; Wu et al., (2005) J. Mol. Bio. 350(1):126-144; and Wu, et al. (2007) J. Mol. Biol. 368:652-665.

“Palivizumab”, also referred to as “SYNAGIS®”, is a humanized anti-RSV F antibody with heavy and light chain variable domains having the amino acid sequences as set forth in U.S. Pat. Nos. 7,635,568 and 5,824,307. Palivizumab immunospecifically binds to the RSV F protein, and is currently FDA-approved for the passive immunoprophylaxis of serious RSV disease in high-risk children. It is administered intramuscularly at recommended monthly doses of 15 mg/kg of body weight throughout the RSV season (November through April in the northern hemisphere). SYNAGIS® is composed of 95% human and 5% murine antibody sequences. See also Johnson et al., (1997), J. Infect. Diseases 176:1215-1224.

“MPE8” is a human monoclonal antibody (MPE8), generated by Humabs BioMed SA, that binds to antigenic site III of RSV F and potently cross-neutralizes RSV and HMPV. For reference purposes, the amino acid sequence of the MPE8 antibody is disclosed in Corti et al., 2013.

“D25” is a human IgG1 kappa monoclonal antibody, developed by AIMM Therapeutics B.V. in partnership with MedImmune, which binds to antigenic site Ø on RSV F and neutralizes RSV with high efficiency. For reference purposes, the amino acid sequence of the D25 antibody is disclosed in U.S. Pat. No. 8,562,996.

As used herein, the terms “treat,” “treatment,” and “treating” refer to the reduction, alleviation, or amelioration of the progression, development, recurrence, severity, and/or duration of an upper and/or lower respiratory tract RSV infection or a symptom, complication, respiratory condition related thereto (such as pneumonia or bronchiolitis) resulting from the administration of one or more therapies (including, but not limited to, the administration of one or more prophylactic or therapeutic agents alone or in combination). In certain embodiments, such terms refer to the reduction or inhibition of the replication of RSV, the inhibition or reduction in the spread of RSV to other tissues or subjects (e.g., the spread to the lower respiratory tract), the inhibition or reduction of infection of a cell with a RSV, or the amelioration of one or more symptoms associated with an upper and/or lower respiratory tract RSV infection.

As used herein, the terms “prevent,” “preventing,” and “prevention” refer to the prevention or inhibition of the development or onset of an upper and/or lower respiratory tract RSV infection or a respiratory condition related thereto resulting from the administration of one or more therapies (including, but not limited to, the administration of one or more prophylactic or therapeutic agents alone or in combination).

The term “antibody” (“Ab”), as used herein, refers to an immunoglobulin molecule that binds specifically to an antigen and comprises four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds (i.e., “full antibody molecules”) or an antigen-binding fragment thereof. Each heavy chain is comprised of a heavy chain variable region (“HCVR” or “V_(H)”) and a heavy chain constant region (comprised of domains C_(H)1, C_(H)2, and C_(H)3). Each light chain is comprised of a light chain variable region (“LCVR” or “V_(L)”) and a light chain constant region (C_(L)). The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

The V_(H) and V_(L) regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Each V_(H) and V_(L) is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments of the invention, the FRs of the antibody (or antigen binding fragment thereof) may be identical to the human germline sequences, or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs. Accordingly, the CDRs in a heavy chain are designated “CHRH1”, “CDRH2”, and “CDRH3”, respectively, and the CDRs in a light chain are designated “CDRL1”, “CDRL2”, and “CDRL3”.

Substitution of one or more CDR residues or omission of one or more CDRs is also possible. Antibodies have been described in the scientific literature in which one or two CDRs can be dispensed with for binding. Analysis of the contact regions between antibodies and their antigens, based on published crystal structures, concluded that only about one fifth to one third of CDR residues actually contact the antigen (Padlan et al. (1995 FASEB J. 9:133-139). Also, it has been shown that in many antibodies one or two CDRs had no amino acids in contact with an antigen (see also, Vajdos et al. 2002 J Mol Biol 320:415-428).

CDR residues not contacting antigen can be identified based on previous studies (for example, residues H60-H65 in CDRH2 are often not required), from regions of Kabat CDRs lying outside Chothia CDRs, by molecular modeling and/or empirically. If a CDR or residue(s) thereof is/are omitted, it is usually substituted with an amino acid occupying the corresponding position in another human antibody sequence or a consensus of such sequences. Positions for substitution within CDRs and amino acids to substitute can also be selected empirically.

The fully human monoclonal antibodies disclosed herein may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy and light chain variable domains as compared to the corresponding germline sequences. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases. The present invention includes antibodies, and antigen-binding fragments thereof, that are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are referred to herein collectively as “germline mutations”). A person of ordinary skill in the art, starting with the heavy and light chain variable region sequences disclosed herein, can easily produce numerous antibodies and antigen-binding fragments which comprise one or more individual germline mutations or combinations thereof. In certain embodiments, all of the framework and/or CDR residues within the V_(H) and/or V_(L) domains are mutated back to the residues found in the original germline sequence from which the antibody was derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues found within CDR1, CDR2 or CDR3. In other embodiments, one or more of the framework and/or CDR residue(s) are mutated to the corresponding residue(s) of a different germline sequence (i.e., a germline sequence that is different from the germline sequence from which the antibody was originally derived). Furthermore, the antibodies of the present invention may contain any combination of two or more germline mutations within the framework and/or CDR regions, e.g., wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence. Once obtained, antibodies and antigen-binding fragments that contain one or more germline mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present invention.

An immunoglobulin may derive from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG, and IgM. IgG subclasses are well known to those in the art and include, but are not limited to, human IgG1, IgG2, IgG3, and IgG4. “Isotype” refers to the antibody class or subclass (e.g., IgG1) that is encoded by the heavy chain constant region genes. The term “antibody” includes, by way of example, both naturally occurring and non-naturally occurring antibodies; monoclonal antibodies (“mAb”) and polyclonal antibodies; chimeric and humanized antibodies; human or non-human antibodies; wholly synthetic antibodies; and single chain antibodies. Where not expressly stated, and unless the context indicates otherwise, the term “antibody” includes an antigen-binding fragment or an antigen-binding portion of any of the aforementioned immunoglobulins, a monovalent and a divalent fragment or portion, and a single chain antibody.

The term “human antibody”, as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences (and, thus, does not include antibodies in which CDRs derived from the germline of another mammalian species (e.g., mouse) have been grafted onto human FR sequences). The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs, in particular CDR3.

The term “humanized antibody”, as used herein, refers to a human antibody in which one or more CDRs have been replaced with one or more corresponding CDRs obtained a non-human derived (e.g., mouse, rat, rabbit, primate) antibody. Humanized antibodies may also include certain non-CDR sequences or residues derived from such non-human antibodies as well as the one or more non-human CDR sequence. Such antibodies may also be referred to as “chimeric antibodies”.

The term “recombinant” generally refers to any protein, polypeptide, or cell expressing a gene of interest that is produced by genetic engineering methods. The term “recombinant” as used herein with respect to a protein or polypeptide, means a polypeptide produced by expression of a recombinant polynucleotide. The proteins used in the immunogenic compositions of the invention may be isolated from a natural source or produced by genetic engineering methods.

The antibodies of the invention may, in some embodiments, be recombinant human antibodies. The term “recombinant human antibody”, as used herein, is intended to include all antibodies (including human or humanized antibodies) that are prepared, expressed, created, or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below); antibodies isolated from a recombinant, combinatorial human antibody library (described further below); antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295); or antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the V_(H) and V_(L) regions of the recombinant antibodies are sequences that, while derived from and related to human germline V_(H) and V_(L) sequences, may not naturally exist within the human antibody germline repertoire in vivo.

The terms “specifically binds” or “binds specifically to” are used interchangeably and mean that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiologic conditions. Specific binding can be characterized by an equilibrium dissociation constant of at least about 1×10⁻⁶ M or less (e.g., a smaller K_(D) denotes a tighter binding). Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. As described herein, antibodies have been identified by surface plasmon resonance, e.g., BIACORE™, biolayer interferometry measurements using, e.g., a ForteBio Octet HTX instrument (Pall Life Sciences), which bind specifically to RSV F. Moreover, multi-specific antibodies that bind to RSV F protein and one or more additional antigens, or a bi-specific that binds to two different regions of RSV F, are nonetheless considered antibodies that “specifically bind”. In certain embodiments, the antibodies disclosed herein display equilibrium dissociation constants (and hence specificities) of about 1×10⁻⁶ M; about 1×10⁻⁷ M; about 1×10⁻⁸ M; about 1×10⁻⁹ M; about 1×10⁻¹⁰ M about 1×10⁻¹¹ M; about 1×10⁻¹² M; between about 1×10⁻⁷M and about 1×10⁻¹¹ M; or between about 1×10⁻⁸M and about 1×10⁻¹⁰ M.

The term “high affinity antibody” refers to those antibodies having a binding affinity to RSV F (preF or postF) of about ≤0.5 nM as measured by surface plasmon resonance, e.g., BIACORE™, biolayer interferometry measurements using, e.g., a ForteBio Octet HTX instrument (Pall Life Sciences).

The term “medium affinity antibody” refers to those antibodies having a binding affinity to RSV F of about >0.5 to 5 nM as measured by surface plasmon resonance, e.g., BIACORE™, biolayer interferometry measurements using, e.g., a ForteBio Octet HTX instrument (Pall Life Sciences).

The term “low affinity antibody” refers to those antibodies having a binding affinity to RSV F of about >5 to 50 nM as measured by surface plasmon resonance, e.g., BIACORE™, biolayer interferometry measurements using, e.g., a ForteBio Octet HTX instrument (Pall Life Sciences).

The term “weak affinity antibody” refers to those antibodies having a binding affinity to RSV F of about >50 nM as measured by surface plasmon resonance, e.g., BIACORE™, biolayer interferometry measurements using, e.g., a ForteBio Octet HTX instrument (Pall Life Sciences).

The terms “antigen-binding portion” and “antigen-binding fragment” are used interchangeably and refer to any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. In certain embodiments, the terms “antigen-binding portion” and “antibody fragment” refer to one or more fragments of an antibody that retains the ability to bind to RSV F.

An antibody fragment may include a Fab fragment, a F(ab′)2 fragment, a Fv fragment, a dAb fragment, a fragment containing a CDR, or an isolated CDR. Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and (optionally) constant domains. Such DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add, or delete amino acids, etc.

Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab′)2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed by “antigen-binding fragment” and “antigen-binding portion”.

An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain may be of any size or amino acid composition and will generally comprise at least one CDR, which is adjacent to or in frame with one or more framework sequences. In antigen-binding fragments having a V_(H) domain associated with a V_(L) domain, the V_(H) and V_(L) domains may be situated relative to one another in any suitable arrangement. For example, the variable region may be dimeric and contain V_(H)-V_(H), V_(H)-V_(L), or V_(L)-V_(L) dimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric V_(H) or V_(L) domain.

In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting, exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present invention include: (i) V_(H)-C_(H)1; (ii) V_(H)-C_(H)2; (iii) V_(H)-C_(H)3; (iv) V_(H)-C_(h)1-C_(h)2; (v) V_(H)-C_(h)1-C_(h)2-C_(h)3; (vi) V_(H)-C_(H)2-C_(H)3; (vii) V_(H)-C_(L); (viii) V_(L)-C_(H)1; (ix) V_(L)-C_(H)2; (x) V_(L)-C_(H)3; (xi) V_(L)-C_(H)1-C_(H)2; (xii) V_(L)-C_(H)1-C_(H)2-C_(H)3; (xiii) V_(L)-C_(H)2-C_(H)3; and (xiv) V_(L)-C_(L). In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region. A hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids, which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule. Moreover, an antigen-binding fragment of an antibody of the present invention may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric V_(H) or V_(L) domain (e.g., by disulfide bond(s)).

As with full antibody molecules, antigen-binding fragments may be mono-specific or multi-specific (e.g., bi-specific). A multi-specific antigen-binding fragment of an antibody typically comprises at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multi-specific antibody format, including the exemplary bi-specific antibody formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an antibody of the present invention using routine techniques available in the art.

In certain embodiments, the antibody or antibody fragment is mono-specific, bi-specific, or multi-specific. Multi-specific antibodies may be specific for different epitopes of one target polypeptide or may contain antigen-binding domains specific for epitopes of more than one target polypeptide. An exemplary bi-specific antibody format that can be used in the context of the present invention involves the use of a first immunoglobulin (Ig) C_(H)3 domain and a second Ig C_(H)3 domain, wherein the first and second Ig C_(H)3 domains differ from one another by at least one amino acid, and wherein at least one amino acid difference reduces binding of the bi-specific antibody to Protein A as compared to a bi-specific antibody lacking the amino acid difference. In one embodiment, the first Ig C_(H)3 domain binds Protein A and the second Ig C_(H)3 domain contains a mutation that reduces or abolishes Protein A binding such as an H95R modification (by IMGT exon numbering; H435R by EU numbering). The second C_(H)3 may further comprise an Y96F modification (by IMGT; Y436F by EU). Further modifications that may be found within the second C_(H)3 include: D16E, L18M, N44S, K52N, V57M, and V82I (by IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU) in the case of IgG1 monoclonal antibodies; N44S, K52N, and V82I (IMGT; N384S, K392N, and V422I by EU) in the case of IgG2 monoclonal antibodies; and Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (by IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I by EU) in the case of IgG4 monoclonal antibodies. Variations of these bi-specific antibody formats are also encompassed within the scope of the present invention.

The antibodies provided herein can be derivatized or linked to another functional molecule (e.g., another peptide or protein). Accordingly, the antibodies of the invention are intended to include derivatized and otherwise modified forms of the anti-RSV F antibodies described herein. For example, an antibody can be functionally linked (e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate associate of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).

One type of derivatized antibody is produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies, which is also discussed below).

Exemplary detectable agents with which an antibody of the invention may be derivatized include fluorescent compounds (such as, but not limited to, fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-1-napthalenesulfonyl chloride, phycoerythrin and the like). An antibody may also be derivatized with detectable enzymes (such as, but not limited to, alkaline phosphatase, horseradish peroxidase, glucose oxidase and the like). When an antibody is derivatized with a detectable enzyme, it can be detected by adding additional reagents that the enzyme uses to produce a detectable reaction product (e.g., when the detectable agent horseradish peroxidase is present, the addition of hydrogen peroxide and diaminobenzidine leads to a colored reaction product, which is detectable). An antibody may also be derivatized with biotin, and detected through indirect measurement of avidin or streptavidin binding. Such derivatized anti-RSV F antibodies may be useful for the detection and/or diagnosis of RSV in a subject.

The specific embodiments, antibodies, or antibody fragments of the invention may be conjugated to a therapeutic moiety (“immunoconjugate”), such as an antibiotic, a second anti-RSV F antibody, a vaccine, a toxoid, or any other therapeutic moiety useful for treating an RSV infection.

The antibodies of the invention can also be modified by pegylation. An antibody can be pegylated to, for example, increase the biological (e.g., serum) half-life of the antibody. To pegylate, an antibody typically is reacted with a polyethylene glycol (PEG) reagent, such as a reactive ester or aldehyde derivative of PEG, under conditions in which one or more PEG groups become attached to the antibody or antibody fragment. Preferably, the pegylation is carried out via an acylation reaction or an alkylation reaction with a reactive PEG molecule (or an analogous reactive water-soluble polymer). As used herein, the term “polyethylene glycol” is intended to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono (C1-C10) alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide. In certain embodiments, the antibody to be pegylated is an aglycosylated antibody. Methods for pegylating proteins are known in the art and can be applied to the antibodies described herein. See for example, EP 0154316 by Nishimura et al. and EP 0401384 by Ishikawa et al.

The term an “isolated antibody”, as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds RSV F, or a fragment thereof, is substantially free of antibodies that specifically bind antigens other than RSV F).

The term a “blocking antibody” or a “neutralizing antibody”, as used herein (or an “antibody that neutralizes RSV F”), is intended to refer to an antibody whose binding to RSV F results in inhibition of at least one biological activity of RSV F. For example, such an antibody may aid in blocking the fusion of RSV to a host cell, prevent syncytia formation, and/or prevent the primary disease caused by RSV. Alternatively, or in addition, such an antibody may demonstrate the ability to ameliorate at least one symptom of the RSV infection. This inhibition of the biological activity of RSV F can be assessed by measuring one or more indicators of RSV F biological activity using standard in vitro assays (such as a neutralization assay) or in vivo assays known in the art (such as animal models to look at protection from challenge with RSV following administration of one or more of the antibodies described herein).

The term “surface plasmon resonance”, as used herein, refers to an optical phenomenon that allows for the analysis of real-time biomolecular interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIACORE™ system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.).

The term “K_(D)”, as used herein, is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.

The term “epitope”, as used herein, refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects. The term “epitope” also refers to a site on an antigen to which B and/or T cells respond. It also refers to a region of an antigen that is bound by an antibody. Epitopes may be defined as structural or functional. Functional epitopes are generally a subset of the structural epitopes and have those residues that directly contribute to the affinity of the interaction. Epitopes may also be conformational, that is, composed of non-linear amino acids. In certain embodiments, epitopes may include determinants that are chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, in certain embodiments, may have specific three-dimensional structural characteristics, and/or specific charge characteristics.

The terms “substantial identity” and “substantially identical” are used interchangeably herein and, when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 90%, and more preferably at least about 95%, 96%, 97%, 98%, or 99% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST, or GAP, as discussed below. Accordingly, nucleic acid sequences that display a certain percentage identity share that percentage identity and/or are that percentage identical to one another. A nucleic acid molecule having substantial identity to a reference nucleic acid molecule may, in certain instances, encode a polypeptide having the same or substantially similar amino acid sequence as the polypeptide encoded by the reference nucleic acid molecule.

In certain embodiments, the disclosed antibody nucleic acid sequences are, e.g., at least 70% identical; at least 75% identical; 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99%; and/or all percentages of identity in between, to other sequences and/or share such percentage identities with one another (or with certain subsets of the herein-disclosed antibody sequences).

As applied to polypeptides, the term “substantial identity” or “substantially identical” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 90% sequence identity, even more preferably at least 95%, 96%, 97%, 98%, or 99% sequence identity. Accordingly, amino acid sequences that display a certain percentage identity share that percentage identity and/or are that percentage identical to one another. Accordingly, amino acid sequences that display a certain percentage identity share that percentage identity and/or are that percentage identical to one another.

In certain embodiments, the disclosed antibody amino acid sequences are, e.g., at least 70% identical; at least 75% identical; 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99%; and/or all percentages of identity in between, to other sequences and/or share such percentage identities with one another (or with certain subsets of the herein-disclosed antibody sequences).

Preferably, residue positions, which are not identical, differ by conservative amino acid substitutions. A “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. (See, e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331). Examples of groups of amino acids that have side chains with similar chemical properties include: 1) aliphatic side chains: glycine, alanine, valine, leucine and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartate and glutamate, and 7) sulfur-containing side chains: cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine. Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256: 1443 45. A “moderately conservative” replacement is any change having a non-negative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG software contains programs such as GAP and BESTFIT which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. See, e.g., GCG Version 6.1. Polypeptide sequences also can be compared using FASTA with default or recommended parameters; a program in GCG Version 6.1. FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson (2000) supra). Another preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program BLAST, especially BLASTP or TBLASTN, using default parameters. (See, e.g., Altschul et al. (1990) J. Mol. Biol. 215: 403 410 and (1997) Nucleic Acids Res. 25:3389 402).

The phrase “therapeutically effective amount” refers to an amount of a therapeutic agent (e.g., an anti-RSV F antibody disclosed herein) that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease or promotes disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays. The exact amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, for example, Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

The term “immunogenic composition” refers to a composition containing an antigen/immunogen, e.g., a microorganism (such as a virus or a bacterium) or a component thereof, a protein, a polypeptide, a fragment of a protein or polypeptide, a whole cell inactivated, subunit or attenuated virus, a polysaccharide, or combination thereof, that is administered to stimulate the recipient's humoral and/or cellular immune systems to one or more of the antigens/immunogens present in the immunogenic composition. The immunogenic compositions of the present invention can be used to treat a human susceptible to RSV infection, or suspected of having or being susceptible to RSV infection, by means of administering the immunogenic compositions via a systemic route. These administrations can include injection via the intramuscular (i.m.), intradermal (i.d.), intranasal, inhalation, or subcutaneous (s.c.) routes; application by a patch or other transdermal delivery device. In one embodiment, the immunogenic composition may be used in the manufacture of a vaccine or in the elicitation of polyclonal or monoclonal antibodies that could be used to passively protect or treat a subject.

The terms “vaccine” or “vaccine composition”, which are used interchangeably, refer to a composition comprising at least one immunogenic composition that induces an immune response in a subject (e.g., a mammal, e.g., a human).

In certain embodiments, a protein of interest comprises an antigen. The terms “antigen,” “immunogen,” “antigenic,” “immunogenic,” “antigenically active,” and “immunologically active”, when made in reference to a molecule, refer to any substance that is capable of inducing a specific humoral and/or cell-mediated immune response. In one embodiment, the antigen comprises an epitope.

“Immunologically protective amount”, as used herein, is an amount of an antigen effective to induce an immunogenic response in the recipient that is adequate to prevent or ameliorate signs or symptoms of disease, including adverse health effects or complications thereof. Either humoral immunity or cell-mediated immunity or both can be induced. The immunogenic response of an animal to a composition can be evaluated, e.g., indirectly through measurement of antibody titers, lymphocyte proliferation assays, or directly through monitoring signs and symptoms after challenge with the microorganism. The protective immunity conferred by an immunogenic composition or vaccine can be evaluated by measuring, e.g., reduction of shed of challenge organisms, reduction in clinical signs such as mortality, morbidity, temperature, and overall physical condition, health and performance of the subject. The immune response can comprise, without limitation, induction of cellular and/or humoral immunity. The amount of a composition or vaccine that is therapeutically effective can vary, depending on the particular organism used, or the condition of the animal being treated or vaccinated.

The terms “immune response” or “immunological response”, as used herein, refer to the development of a humoral immune response, a cellular-immune response, or a humoral and a cellular immune response to an antigen/immunogen. A “humoral immune response” refers to one that is, at least in part, mediated by antibodies. A “cellular immune response” is one mediated by T-lymphocytes and/or other white blood cells and includes the production of cytokines, chemokines, and similar molecules produced by activated T-cells and/or white blood cells. Immune responses can be determined using standard immunoassays and neutralization assays, which are known in the art.

The term “immunogenicity”, as used herein, refers to the capability of a protein or polypeptide to elicit an immune response directed specifically against a bacteria or virus that causes the identified disease.

Preparation of Human Antibodies

As disclosed herein, anti-RSV F infant antibodies may be obtained through B cell sorting techniques available to the artisan as well as those methods exemplified in the EXAMPLES below. Methods for generating human antibodies in transgenic mice are also known in the art and may also be employed to derive antibodies in accordance with the present disclosure. Any such known methods can be used in the context of the present invention to make human antibodies that specifically bind to RSV F (see, for example, U.S. Pat. No. 6,596,541).

The antibodies of the instant invention can possess affinities (K_(D)) ranging from about 1.0×10⁻⁷ M to about 1.0×10⁻¹² M, when measured by binding to antigen either immobilized on solid phase or in solution phase. In some embodiments, the antibodies of the invention possess affinities (K_(D)) ranging from about 1×10⁻⁷M to about 1×10⁻¹⁰ M, when measured by binding to antigen either immobilized on solid phase or in solution phase. In other embodiments, the antibodies of the invention possess a K_(D) of less than 50 nM, 25 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, or 0.1 nM, as measured by surface plasmon resonance.

The anti-RSV F antibodies and antibody fragments of the instant invention encompass proteins having amino acid sequences that may vary from the sequences of the described antibodies but, nonetheless, retain the ability to bind (and, in some cases, neutralize) RSV F. Such variant antibodies and antibody fragments comprise one or more additions, deletions, or substitutions of amino acids when compared to a parent sequence (i.e., amino acid sequence of a described antibody), but exhibit biological activity that is essentially equivalent to that of the described antibodies. Likewise, the antibody-encoding DNA sequences of the present invention encompass sequences that comprise one or more additions, deletions, or substitutions of nucleotides when compared to the disclosed sequence, but that encode an antibody or antibody fragment that is essentially bioequivalent to an antibody or antibody fragment described herein.

Two antigen-binding proteins (e.g., antibodies) are considered bioequivalent if, for example, they are pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not show a significant difference when administered at the same molar dose under similar experimental conditions, either single does or multiple dose. Some antibodies will be considered equivalents or pharmaceutical alternatives if they are equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered bioequivalent because such differences in the rate of absorption are intentional and are reflected in the labeling, are not essential to the attainment of effective body drug concentrations on, e.g., chronic use, and are considered medically insignificant for the particular drug product studied.

In one embodiment, two antigen-binding proteins (e.g., antibodies) are bioequivalent if there are no clinically meaningful differences in their safety, purity, and/or potency.

In another embodiment, two antigen-binding proteins (e.g., antibodies) are bioequivalent if a patient can be switched one or more times between the proteins (e.g., antibodies) without an expected increase in the risk of adverse effects, including a clinically significant change in immunogenicity, or diminished effectiveness, as compared to continued therapy without such switching.

In yet another embodiment, two antigen-binding proteins (e.g., antibodies) are bioequivalent if both proteins (e.g., antibodies) act by a common mechanism or mechanisms of action for the condition or conditions of use, to the extent that such mechanisms are known.

Bioequivalence may be demonstrated by in vivo and/or in vitro methods. Bioequivalence measures include, e.g., (a) an in vivo test in humans or other mammals, in which the concentration of the antibody or its metabolites is measured in blood, plasma, serum, or other biological fluid as a function of time; (b) an in vitro test that has been correlated with and is reasonably predictive of human in vivo bioavailability data; (c) an in vivo test in humans or other mammals in which the appropriate acute pharmacological effect of the antibody (or its target) is measured as a function of time; and (d) a well-controlled clinical trial that establishes safety, efficacy, bioavailability, and/or bioequivalence of an antibody.

Bioequivalent variants of the antibodies of the invention may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences (which may occur in the variable or binding regions as well as framework regions) not needed for biological activity. In some embodiments, it is contemplated that the anti-RSV F antibodies may contain inter alia one or more additional amino acid residue substitutions, mutations and/or modifications in the constant region (i.e., the Fc region) which result in preferred characteristics including, but not limited to: altered pharmacokinetics, increased serum half life, increase binding affinity, reduced immunogenicity, increased production, altered Fc ligand binding to an Fc receptor (FcR), enhanced or reduced ADCC (antibody-dependent cell mediated cytotoxicity) or CDC (complement-dependent cytotoxicity) activity, altered glycosylation and/or disulfide bonds and modified binding specificity. In this regard it will be appreciated that these Fc variants may advantageously be used to enhance the effective anti-neoplastic properties of the disclosed modulators. For example, cysteine residues not essential for biological activity can be deleted or replaced with other amino acids to prevent formation of unnecessary or incorrect intramolecular disulfide bridges upon renaturation. In other contexts, bioequivalent antibodies may include antibody variants comprising amino acid changes that modify the glycosylation characteristics of the antibodies, e.g., mutations that eliminate or remove glycosylation. In still other contexts, bioequivalent antibodies may include antibody variants comprising amino acid changes that modify the Fc region. Such Fc variant may have increased half-life, improved stability, and/or modified effector function(s).

Biological and Biophysical Characteristics of the Antibodies

In certain embodiments, the antibodies and antigen-binding fragments thereof specifically bind to RSV F, wherein at least one of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and/or CDRL3 amino acid sequences of such antibody or the antigen-binding fragment thereof is at least 70% identical; at least 75% identical; 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99%; and/or all percentages of identity in between, to at least one of the CDRH1, a CDRH2, a CDRH3, a CDRL1, a CDRL2, and/or a CDRL3 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

Without wishing to be bound by any theory, it is believed that the inventive antibodies and antigen-binding fragments thereof may function by binding to RSV F, preferably in the PreF conformation, and in so doing act to block the fusion of the viral membrane with the host cell membrane. The antibodies of the present invention may also function by binding to RSV F and in so doing block the cell to cell spread of the virus and block syncytia formation associated with RSV infection of cells. Subtype A is responsible for the majority of hospitalizations for RSV and RSV-related complications. Advantageously, RSV subtype A or both RSV subtype A and RSV subtype B are effectively blocked, or neutralized, by the majority of the anti-RSV antibodies disclosed herein.

In certain embodiments, the inventive antibodies and antigen-binding fragment thereof display better binding affinity for the prefusion (PreF) form of RSV F relative to the postfusion (PostF) form of RSV F. Indeed, in some embodiments, the anti-RSV F antibodies disclosed herein bind to PreF (e.g., with high affinity) but do not bind to PostF or bind to PostF with low affinity. In other embodiments, the antibodies and antigen-binding fragments thereof disclosed herein display better binding affinity for PostF than PreF.

Antibodies with a range of polyreactivity (high, medium, low, or undetectable) are disclosed. In some embodiments, the inventive antibodies and antigen-binding fragments thereof advantageously display a clean or low polyreactivity profile (see, e.g., WO 2014/179363 and Xu et al., Protein Eng Des Sel, Oct; 26(10):663-70. doi: 10.1093/protein/gzt047), and are thus particularly amenable to development as safe, efficacious, and developable therapeutic and/or prophylactic anti-RSV treatments.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof, without wishing to be bound by any theory, may function by blocking or inhibiting RSV fusion to the cell membrane by binding to any one or more of antigenic Sites Ø, I, II, III, IV, and/or Site V of the F protein. In certain embodiments, the antibodies disclosed herein display antigenic site specificity for Site III of (preF) RSV F and, generally, such antibodies are neutralizing antibodies (in some instances, e.g., ADI-19425, potently neutralizing). In other embodiments, the antibodies disclosed herein display antigenic site specificity for Site I of (postF) RSV F and, generally, such antibodies are non-neutralizing antibodies.

In certain embodiments, at least a portion of the epitope with which the inventive antibodies and antigen-binding fragments thereof interacts comprises the loop connecting α6 to α7 of PreF and/or β6 of PreF. In certain embodiments, the heavy chain (e.g., CDRL3) and the light chain (e.g., CDRH2) of the inventive antibodies interact with the epitope of PreF. In a particular embodiment, Tyr33 in CDRL1 and Tyr93 in CDRL3 both contact the α6-α7 loop of RSV preF and/or five consecutive serine residues, preferably followed by a tyrosine residue (Tyr56), in CDRH2 form a network of hydrogen bonds with Asp310 on β6 of RSV preF. In still further embodiments, the CDRH3 of the inventive antibodies have relatively few sequence (composition and/or length) restrictions.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof display an in vitro neutralization potency (IC₅₀) of greater than 0.5 ug/ml (referred to as “weak neutralization potency”); between about 0.5 ug/ml to about 5 ug/ml (referred to as “low neutralization potency”); between about 0.05 ug/ml to about 0.5 ug/ml (referred to as “medium neutralization potency”); or less than about 0.05 mg/ml (referred to as “high neutralization potency”). Neutralization potency can be measured using standard assays well known in the field, including, but not limited to, a high-throughput fluorescence plate reader neutralization assay (as described herein, see EXAMPLES).

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof display at least about 2-fold; at least about 3-fold; at least about 4-fold; at least about 5-fold; at least about 6-fold; at least about 7-fold; at least about 8-fold; at least about 9-fold; at least about 10-fold; at least about 15-fold; at least about 20-fold; at least about 25-fold; at least about 30-fold; at least about 35-fold; at least about 40-fold; at least about 50-fold; at least about 55-fold; at least about 60-fold; at least about 70-fold; at least about 80-fold; at least about 90-fold; at least about 100-fold; greater than about 100-fold; and folds in between any of the foregoing; greater neutralization potency (IC₅₀) than motavizumab, MPE8, and D25.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise the CDRH3 amino acid sequence of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise the CDRH2 amino acid sequence of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise the CDRH1 amino acid sequence of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise the CDRL3 amino acid sequence of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise the CDRL2 amino acid sequence of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise the CDRL1 amino acid sequence of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise any combination of two or more of the CDRH3, CDRH2, CDRH1, CDRL3, CDRL2, and CDRL1 amino acid sequences of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. By way of example only, the inventive antibodies and antigen-binding fragments thereof comprise the CDRL3 and the CDRH2 of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise a heavy chain (HC) amino acid sequence of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise a light chain (LC) amino acid sequence of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise a heavy chain (HC) amino acid sequence and a light chain (LC) amino acid sequence of any one of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof are each selected from the group consisting antibodies that are at least 70% identical; at least 75% identical; 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99%; and/or all percentages of identity in between; to any one of the antibodies designated as Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, the inventive antibodies and antigen-binding fragments thereof comprise are each selected from the group consisting of the antibodies designated as Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

In certain embodiments, isolated nucleic acid sequences are provided that encode antibodies (or antigen-binding fragments thereof) that specifically bind to RSV F, wherein at least one of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and/or CDRL3 amino acid sequences of the antibody or the antigen-binding fragment thereof is at least 70% identical; at least 75% identical; 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99%; and/or all percentages of identity in between; to at least one of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and/or CDRL3 amino acid sequences of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, such nucleic acid sequences are selected from those nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences that encode the CDRH3 amino acid sequence of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, such nucleic acid sequences are selected from those nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences that encode the CDRH2 amino acid sequences of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, such nucleic acid sequences are selected from those nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences that encode the CDRH1 amino acid sequences of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, such nucleic acid sequences are selected from those nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences that encode the CDRL3 amino acid sequences of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, such nucleic acid sequences are selected from those nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences that encode the CDRL2 amino acid sequences of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, such nucleic acid sequences are selected from those nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences that encode the CDRL1 amino acid sequences of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, such nucleic acid sequences are selected from those nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences that encode the heavy chain (HC) amino acid sequences of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, such nucleic acid sequences are selected from those nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences that encode the light chain (LC) amino acid sequences of the antibodies designated Antibody Number 1 through Antibody Number 947 as disclosed in Table 5. In certain embodiments, such nucleic acid sequences are selected from those nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences that are each selected from the group consisting of sequences that are at least 70% identical; at least 75% identical; 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99%; and/or all percentages of identity in between; to any one of the nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, isolated nucleic acid sequences are provided that encode the inventive antibodies and antigen-binding fragments thereof, wherein such nucleic acid sequences comprise sequences selected from the nucleic acid sequences that are disclosed in Table 5 and compliments thereof.

In certain embodiments, expression vectors are provided comprising the isolated nucleic acid sequences disclosed herein. In some embodiments, a single expression vector comprises the isolated nucleic acid sequences (e.g., V_(H) and V_(L), or HC and LC, are contained in the same vector). In this case, host cells are transfected, transformed, or transduced with a single expression vector. However, in other embodiments, more than one expression vector comprises the isolated nucleic acid sequences (e.g., V_(H) and V_(L), or HC and LC, are each contained in a different vector). In this case, host cells are transfected, transformed, or transduced with more than one expression vector.

Host cells transfected, transformed, or transduced with the nucleic acid sequences and/or the expression vectors themselves are also encompassed by the subject invention.

Epitope Mapping and Related Technologies

As described above and as demonstrated in the EXAMPLES, Applicant has characterized inter alia the epitope binding of the inventive antibodies and antigen-binding fragments thereof. In addition to the methods utilized by Applicant, various other techniques are available to the skilled artisan that can be used to carry out such characterization or to otherwise ascertain whether an antibody “interacts with one or more amino acids” within a polypeptide or protein. Exemplary techniques include, for example, a routine cross-blocking assay such as that described Antibodies, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., N.Y.) can be performed. Other methods include alanine scanning mutational analysis, peptide blot analysis (Reineke (2004) Methods Mol Biol 248:443-63), peptide cleavage analysis crystallographic studies and NMR analysis. In addition, methods such as epitope excision, epitope extraction and chemical modification of antigens can be employed (Tomer (2000) Protein Science 9: 487-496). Another method that can be used to identify the amino acids within a polypeptide with which an antibody interacts is hydrogen/deuterium exchange detected by mass spectrometry. In general terms, the hydrogen/deuterium exchange method involves deuterium-labeling the protein of interest, followed by binding the antibody to the deuterium-labeled protein. Next, the protein/antibody complex is transferred to water and exchangeable protons within amino acids that are protected by the antibody complex undergo deuterium-to-hydrogen back-exchange at a slower rate than exchangeable protons within amino acids that are not part of the interface. As a result, amino acids that form part of the protein/antibody interface may retain deuterium and therefore exhibit relatively higher mass compared to amino acids not included in the interface. After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry analysis, thereby revealing the deuterium-labeled residues that correspond to the specific amino acids with which the antibody interacts. See, e.g., Ehring (1999) Analytical Biochemistry 267 (2):252-259; Engen and Smith (2001) Anal. Chem. 73:256A-265A.

As the artisan will understand, an epitope can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation.

Modification-Assisted Profiling (MAP), also known as Antigen Structure-based Antibody Profiling (ASAP) is a method that categorizes large numbers of monoclonal antibodies (mAbs) directed against the same antigen according to the similarities of the binding profile of each antibody to chemically or enzymatically modified antigen surfaces (see, e.g., US 2004/0101920). Each category may reflect a unique epitope either distinctly different from or partially overlapping with epitope represented by another category. This technology allows rapid filtering of genetically identical antibodies, such that characterization can be focused on genetically distinct antibodies. When applied to hybridoma screening, MAP may facilitate identification of rare hybridoma clones that produce mAbs having the desired characteristics. MAP may be used to sort the antibodies of the invention into groups of antibodies binding different epitopes.

As the artisan understands, one can easily determine whether an antibody binds to the same epitope as, or competes for binding with, a reference anti-RSV F antibody by using routine methods available in the art. For example, to determine if a test antibody binds to the same epitope as a reference RSV F antibody of the invention, the reference antibody is allowed to bind to a RSV F protein or peptide under saturating conditions. Next, the ability of a test antibody to bind to the RSV F molecule is assessed. If the test antibody is able to bind to RSV F following saturation binding with the reference anti-RSV F antibody, it can be concluded that the test antibody binds to a different epitope than the reference anti-RSV F antibody. On the other hand, if the test antibody is not able to bind to the RSV F molecule following saturation binding with the reference anti-RSV F antibody, then the test antibody may bind to the same epitope as the epitope bound by the reference anti-RSV F antibody of the invention.

To determine if an antibody competes for binding with a reference anti-RSV F antibody, the above-described binding methodology is performed in two orientations. In a first orientation, the reference antibody is allowed to bind to a RSV F molecule under saturating conditions followed by assessment of binding of the test antibody to the RSV F molecule. In a second orientation, the test antibody is allowed to bind to a RSV F molecule under saturating conditions followed by assessment of binding of the reference antibody to the RSV F molecule. If, in both orientations, only the first (saturating) antibody is capable of binding to the RSV F molecule, then it is concluded that the test antibody and the reference antibody compete for binding to RSV F. As will be appreciated by a person of ordinary skill in the art, an antibody that competes for binding with a reference antibody may not necessarily bind to the identical epitope as the reference antibody, but may sterically block binding of the reference antibody by binding an overlapping or adjacent epitope.

Two antibodies bind to the same or overlapping epitope if each competitively inhibits (blocks) binding of the other to the antigen. That is, a 1-, 5-, 10-, 20-, or 100-fold excess of one antibody inhibits binding of the other by at least 50% but preferably 75%, 90% or even 99% as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. (1990) 50:1495-1502). Alternatively, two antibodies have the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

Additional routine experimentation (e.g., peptide mutation and binding analyses) can then be carried out to confirm whether the observed lack of binding of the test antibody is in fact due to binding to the same epitope as the reference antibody or if steric blocking (or another phenomenon) is responsible for the lack of observed binding. Experiments of this sort can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art.

Immunoconjugates

The invention encompasses a RSV F antibody conjugated to a therapeutic moiety (“immunoconjugate”), such as an agent that is capable of reducing the severity of primary infection with RSV, or ameliorating at least one symptom associated with RSV infection, including coughing, fever, pneumonia, or the severity thereof. Such an agent may be a second different antibody to RSVF or a vaccine. The type of therapeutic moiety that may be conjugated to the anti-RSV F antibody and will take into account the condition to be treated and the desired therapeutic effect to be achieved. Alternatively, if the desired therapeutic effect is to treat the sequelae or symptoms associated with RSV infection, or any other condition resulting from such infection, such as, but not limited to, pneumonia, it may be advantageous to conjugate an agent appropriate to treat the sequelae or symptoms of the condition, or to alleviate any side effects of the antibodies of the invention. Examples of suitable agents for forming immunoconjugates are known in the art, see for example, WO 05/103081.

Multi-specific Antibodies

The antibodies of the present invention may be mono-specific, bi-specific, or multi-specific. Multi-specific antibodies may be specific for different epitopes of one target polypeptide or may contain antigen-binding domains specific for more than one target polypeptide. See, e.g., Tutt et al., 1991, J. Immunol. 147:60-69; Kufer et al., 2004, Trends Biotechnol. 22:238-244. As discussed above, the antibodies of the present invention can be linked to or co-expressed with another functional molecule, e.g., another peptide or protein. For example, an antibody or fragment thereof can be functionally linked (e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody or antibody fragment to produce a bi-specific or a multi-specific antibody with a second binding specificity.

An exemplary bi-specific antibody format that can be used in the context of the present invention involves the use of a first immunoglobulin (Ig) C_(H)3 domain and a second Ig C_(H)3 domain, wherein the first and second Ig C_(H)3 domains differ from one another by at least one amino acid, and wherein at least one amino acid difference reduces binding of the bi-specific antibody to Protein A as compared to a bi-specific antibody lacking the amino acid difference. In one embodiment, the first Ig C_(H)3 domain binds Protein A and the second Ig C_(H)3 domain contains a mutation that reduces or abolishes Protein A binding such as an H95R modification (by IMGT exon numbering; H435R by EU numbering). The second C_(H)3 may further comprise a Y96F modification (by IMGT; Y436F by EU). Further modifications that may be found within the second C_(H)3 include: D16E, L18M, N44S, K52N, V57M, and V82I (by IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU) in the case of lgG1 antibodies; N44S, K52N, and V82I (IMGT; N384S, K392N, and V422I by EU) in the case of lgG2 antibodies; and Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (by IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I by EU) in the case of lgG4 antibodies. Variations on the bi-specific antibody format described above are contemplated within the scope of the present invention.

Therapeutic Administration and Formulations

The invention provides therapeutic compositions comprising the inventive anti-RSV F antibodies or antigen-binding fragments thereof. The administration of therapeutic compositions in accordance with the invention will be administered with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. “Compendium of excipients for parenteral formulations” PDA (1998) J Pharm Sci Technol 52:238-311.

The dose of each of the antibodies of the invention may vary depending upon the age and the size of a subject to be administered, target disease, conditions, route of administration, and the like. When the antibodies of the present invention are used for treating a RSV infection in a patient, or for treating one or more symptoms associated with a RSV infection, such as the cough or pneumonia associated with a RSV infection in a patient, or for lessening the severity of the disease, it is advantageous to administer each of the antibodies of the present invention intravenously or subcutaneously normally at a single dose of about 0.01 to about 30 mg/kg body weight, more preferably about 0.1 to about 20 mg/kg body weight, or about 0.1 to about 15 mg/kg body weight, or about 0.02 to about 7 mg/kg body weight, about 0.03 to about 5 mg/kg body weight, or about 0.05 to about 3 mg/kg body weight, or about 1 mg/kg body weight, or about 3.0 mg/kg body weight, or about 10 mg/kg body weight, or about 20 mg/kg body weight. Multiple doses may be administered as necessary. Depending on the severity of the condition, the frequency and the duration of the treatment can be adjusted. In certain embodiments, the antibodies or antigen-binding fragments thereof of the invention can be administered as an initial dose of at least about 0.1 mg to about 800 mg, about 1 to about 600 mg, about 5 to about 300 mg, or about 10 to about 150 mg, to about 100 mg, or to about 50 mg. In certain embodiments, the initial dose may be followed by administration of a second or a plurality of subsequent doses of the antibodies or antigen-binding fragments thereof in an amount that can be approximately the same or less than that of the initial dose, wherein the subsequent doses are separated by at least 1 day to 3 days; at least one week, at least 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; at least 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; at least 10 weeks; at least 12 weeks; or at least 14 weeks.

Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu et al. (1987) J. Biol. Chem. 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings {e.g., oral mucosa, nasal mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. It may be delivered as an aerosolized formulation (See U.S. Publication No. 2011/0311515 and U.S. Publication No. 2012/0128669). The delivery of agents useful for treating respiratory diseases by inhalation is becoming more widely accepted (See A. J. Bitonti and J. A. Dumont, (2006), Adv. Drug Deliv. Rev, 58:1 106-1 1 18). In addition to being effective at treating local pulmonary disease, such a delivery mechanism may also be useful for systemic delivery of antibodies (See Maillet et al. (2008), Pharmaceutical Research, Vol. 25, No. 6, 2008).

The pharmaceutical composition can be also delivered in a vesicle, in particular a liposome (see, for example, Langer (1990) Science 249:1527-1533).

In certain situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used. In another embodiment, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose.

The injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by methods publicly known. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled in an appropriate ampoule.

A pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery device readily has applications in delivering a pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition of the present invention. Examples include, but certainly are not limited to AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), DISETRONIC™ pen (Disetronic Medical Systems, Burghdorf, Switzerland), HUMALOG MIX 75/25™ pen, HUMALOG™ pen, HUMALIN 70/30™ pen (Eli Lilly and Co., Indianapolis, Ind.), NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, N.J.), OPTIPEN™, OPTIPEN PRO™ OPTIPEN STARLET™, and OPTICLIK™ (sanofi-aventis, Frankfurt, Germany), to name only a few. Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition of the present invention include, but certainly are not limited to the SOLOSTAR™ pen (sanofi-aventis), the FLEXPEN™ (Novo Nordisk), and the KWIKPEN™ (Eli Lilly), the SURECLICK™ Autoinjector (Amgen, Thousands Oaks, Calif.), the PENLET™ (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.P.) and the HUMIRA™ Pen (Abbott Labs, Abbott Park, Ill.), to name only a few.

Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of the aforesaid antibody contained is generally about 5 to about 500 mg per dosage form in a unit dose; especially in the form of injection, it is preferred that the aforesaid antibody is contained in about 5 to about 100 mg and in about 10 to about 250 mg for the other dosage forms.

Administration Regimens

According to certain embodiments, multiple doses of an antibody to RSV F may be administered to a subject over a defined time course. The methods according to this aspect of the invention comprise sequentially administering to a subject multiple doses of an antibody to RSV F. As used herein, “sequentially administering” means that each dose of antibody to RSV F is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The present invention includes methods which comprise sequentially administering to the patient a single initial dose of an antibody to RSV F, followed by one or more secondary doses of the antibody to RSV F and, optionally, followed by one or more tertiary doses of the antibody to RSV F.

The terms “initial dose,” “secondary doses,” and “tertiary doses,” refer to the temporal sequence of administration of the antibody to RSV F. Thus, the “initial dose” is the dose which is administered at the beginning of the treatment regimen (also referred to as the “baseline dose”); the “secondary doses” are the doses which are administered after the initial dose; and the “tertiary doses” are the doses which are administered after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of antibody to RSV F, but generally may differ from one another in terms of frequency of administration. In certain embodiments, however, the amount of antibody to RSV F contained in the initial, secondary and/or tertiary doses vary from one another (e.g., adjusted up or down as appropriate) during the course of treatment. In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered at the beginning of the treatment regimen as “loading doses” followed by subsequent doses that are administered on a less frequent basis (e.g., “maintenance doses”).

In one exemplary embodiment of the present invention, each secondary and/or tertiary dose is administered 1 to 26 (e.g., 1, 1½, 2, 2½, 3, 3½, 4, 4½, 5, 5½, 6, 6½, 7, 7½, 8, 8½, 9, 9½, 10, 10½, 11, 11½, 12, 12½, 13, 13½, 14, 14½, 15, 15½, 16, 16½, 17, 17½, 18, 18½, 19, 19½, 20, 20½, 21, 21 ½, 22, 22½, 23, 23½, 24, 24½, 25, 25½, 26, 26½, or more) weeks after the immediately preceding dose. The phrase “the immediately preceding dose,” as used herein, means that in a sequence of multiple administrations, the dose of antibody to RSV F, which is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.

The methods according to this aspect of the invention may comprise administering to a patient any number of secondary and/or tertiary doses of an antibody to RSV F. For example, in certain embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient. Likewise, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient.

In embodiments involving multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 1 to 2 weeks after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to the patient 2 to 4 weeks after the immediately preceding dose. Alternatively, the frequency at which the secondary and/or tertiary doses are administered to a patient can vary over the course of the treatment regimen. The frequency of administration may also be adjusted during the course of treatment by a physician depending on the needs of the individual patient following clinical examination.

Accordingly, in certain embodiments are provided pharmaceutical compositions comprising: one or more of the inventive antibodies or antigen-binding fragments thereof disclosed herein and throughout and a pharmaceutically acceptable carrier and/or one or more excipients. In certain other embodiments are provided pharmaceutical compositions comprising: one or more nucleic acid sequences encoding one or more inventive antibodies or antigen-binding fragments thereof; or one or more the expression vectors harbouring such nucleic acid sequences; and a pharmaceutically acceptable carrier and/or one or more excipients.

Therapeutic Uses of the Antibodies

Due to their binding to and interaction with RSV F, it is believed that the inventive antibodies and antigen-binding fragments thereof are useful for preventing fusion of the virus with the host cell membrane, preventing cell to cell virus spread, and/or inhibiting syncytia formation. Additionally, a subset of the inventive anti-RSV antibodies and antigen-binding fragments thereof display specificity for RSV (i.e., epitopic specificity) that is unique from the specificity of adult anti-RSV antibodies. Therefore, the inventive antibodies and antigen-binding fragments thereof may be advantageous for preventing and/or treating an RSV infection in an infant. As such, the antibodies of the invention are contemplated for prophylactic use in infant, particularly pre-term infants and full-term infants born during RSV season (late fall to early spring). It is contemplated that the antibodies of the invention may be used alone, or in conjunction with one or more additional agents, for treating or preventing RSV infection or at least one symptom or complication associated with RSV infection. The second or third agents may be delivered concurrently with or separately (before or after) from the antibodies of the invention. The one or more additional agents may be an anti-viral (e.g., ribavirin), an NSAID or other agents to reduce fever or pain, another antibody that specifically binds RSV-F, an agent (e.g. an antibody) that binds to another RSV antigen (e.g., RSV G), a vaccine against RSV, and/or an siRNA specific for an RSV antigen.

In yet a further embodiment of the invention, the present antibodies are used for the preparation of a pharmaceutical composition for treating patients suffering from a RSV infection. The pharmaceutical composition can reduce the severity of a primary infection with RSV, reduce the duration of the infection, and/or reduce at least one symptom associated with the RSV infection. In a further embodiment, the anti-RSV F antibodies disclosed herein are used as adjunct therapy with any other agent useful for treating an RSV infection, including an antiviral, a toxoid, a vaccine, a second RSV-F antibody, or another antibody specific for an RSV antigen, including an RSV-G antibody, or any other palliative therapy known to those skilled in the art.

Accordingly, the disclosure provides methods of treating or preventing RSV infection, or at least one symptom associated with RSV infection, comprising administering to a patient in need thereof (or suspected of being in need thereof) one or more of the inventive antibodies or antigen-binding fragments thereof, e.g., one or more of the anti-RSV F antibodies disclosed in Table 5, such that the RSV infection is treated or prevented, or the at least on symptom associated with RSV infection is treated, alleviated, or reduced in severity.

Other embodiments provide methods of treating or preventing a RSV infection, or at least one symptom associated with RSV infection, comprising administering to a patient in need thereof (or suspected of being in need thereof) a nucleic acid sequence encoding one or more of the inventive antibodies or antigen-binding fragments thereof, such nucleic acid sequenced disclosed in Table 5 and compliments thereof, such that the RSV infection is treated or prevented, or the at least on symptom associated with RSV infection is treated, alleviated, or reduced in severity.

Additional embodiments provide methods of treating or preventing a RSV infection, or at least one symptom associated with RSV infection, comprising administering to a patient in need thereof (or suspected of being in need thereof) a host cell harboring a nucleic acid sequence or an expression vector comprising such a nucleic acid sequence, wherein such nucleic acid sequences is selected from the group consisting of sequences disclosed in Table 5 and compliments thereof, such that the RSV infection is treated or prevented, or the at least one symptom associated with RSV infection is treated, alleviated, or reduced in severity.

Further embodiments provide methods of treating or preventing a RSV infection, or at least one symptom associated with RSV infection, comprising administering to a patient in need thereof (or suspected of being in need thereof) a pharmaceutical composition comprising one or more of the inventive antibodies or antigen-binding fragments thereof as disclosed in Table 5, or one or more nucleic acid sequences or an expression vectors comprising such a nucleic acid sequence, wherein such nucleic acid sequences are selected from the group consisting of sequences disclosed in Table 5 and compliments thereof; one or more host cells harboring one or more nucleic acid sequences or an expression vectors comprising such one or more nucleic acid sequences, wherein such nucleic acid sequences are selected from the group consisting of sequences disclosed in Table 5 and compliments thereof; and a pharmaceutically acceptable carrier and/or one or more excipients, such that the RSV infection is treated or prevented, or the at least on symptom associated with RSV infection is treated, alleviated, or reduced in severity.

The anti-RSV F antibodies disclosed herein may also be suitable for therapeutic and/or prophylactic use in non-humans, e.g., cattle, swine, sheep, or poultry.

Combination Therapies

As noted above, according to certain embodiments, the disclosed methods comprise administering to the subject one or more additional therapeutic agents in combination with an antibody to RSV F. As used herein, the expression “in combination with” means that the additional therapeutic agents are administered before, after, or concurrent with the pharmaceutical composition comprising the anti-RSV F antibody. The term “in combination with” also includes sequential or concomitant administration of the anti-RSV F antibody and a second therapeutic agent.

For example, when administered “before” the pharmaceutical composition comprising the anti-RSV F antibody, the additional therapeutic agent may be administered about 72 hours, about 60 hours, about 48 hours, about 36 hours, about 24 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, about 30 minutes, about 15 minutes or about 10 minutes prior to the administration of the pharmaceutical composition comprising the anti-RSV F antibody. When administered “after” the pharmaceutical composition comprising the anti-RSV-F antibody, the additional therapeutic agent may be administered about 10 minutes, about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours or about 72 hours after the administration of the pharmaceutical composition comprising the anti-RSV F antibodies. Administration “concurrent” or with the pharmaceutical composition comprising the anti-RSV F antibody means that the additional therapeutic agent is administered to the subject in a separate dosage form within less than 5 minutes (before, after, or at the same time) of administration of the pharmaceutical composition comprising the anti-RSV F antibody, or administered to the subject as a single combined dosage formulation comprising both the additional therapeutic agent and the anti-RSV F antibody.

Combination therapies may include an anti-RSV F antibody of the invention and any additional therapeutic agent that may be advantageously combined with an antibody of the invention, or with a biologically active fragment of an antibody of the invention.

For example, a second or third therapeutic agent may be employed to aid in reducing the viral load in the lungs, such as an antiviral, for example, ribavirin. The antibodies may also be used in conjunction with other therapies, as noted above, including a toxoid, a vaccine specific for RSV, a second antibody specific for RSV F, or an antibody specific for another RSV antigen, such as RSV G.

Diagnostic Uses of the Antibodies

The inventive anti-RSV antibodies and antigen-binding fragments thereof may also be used to detect and/or measure RSV in a sample, e.g., for diagnostic purposes. It is envisioned that confirmation of an infection thought to be caused by RSV may be made by measuring the presence of the virus through use of any one or more of the antibodies of the invention. Exemplary diagnostic assays for RSV may comprise, e.g., contacting a sample, obtained from a patient, with an anti-RSV F antibody of the invention, wherein the anti-RSV F antibody is labeled with a detectable label or reporter molecule or used as a capture ligand to selectively isolate the virus containing the F protein from patient samples. Alternatively, an unlabeled anti-RSV F antibody can be used in diagnostic applications in combination with a secondary antibody which is itself detectably labeled. The detectable label or reporter molecule can be a radioisotope, such as ³H, ¹⁴C, ³²P ³⁵S, or ¹²⁵I; a fluorescent or chemiluminescent moiety such as fluorescein isothiocyanate, or rhodamine; or an enzyme such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure RSV containing the F protein in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (MA), and fluorescence-activated cell sorting (FACS).

Samples that can be used in RSV diagnostic assays according to the present invention include any tissue or fluid sample obtainable from a patient, which contains detectable quantities of RSV F protein, or fragments thereof, under normal or pathological conditions. Generally, levels of RSV F in a particular sample obtained from a healthy patient (e.g., a patient not afflicted with a disease or condition associated with the presence of RSV F) will be measured to initially establish a baseline, or standard, level of the F protein from RSV. This baseline level of RSV F can then be compared against the levels of RSV F measured in samples obtained from individuals suspected of having an RSV infection or symptoms associated with such infection.

EXAMPLES Example 1. Isolation and Characterization of Anti-RSV F-Specific Human Infant Antibodies from Memory B Cells

Applicant has comprehensively profiled the human infant antibody response to RSV F by isolating and characterizing over 450 RSV F-specific monoclonal antibodies from the memory B cells of RSV-infected infants, and used these antibodies to characterize the infant antibody response as well as develop a framework for the rational design of age-specific RSV vaccines. The antibody responses were highly biased, with half of the antibodies recognizing only two antigenic sites. Antibodies targeting both sites showed convergent sequence features, the molecular determinants of which were revealed by X-ray crystallographic studies. A subset of antibodies targeting one of the sites displayed potent neutralizing activity despite lacking somatic mutations, suggesting suitably designed vaccines may be used to induce such antibodies in young infants.

RSV F-Specific Antibodies Isolated from Young Infants have Low Levels of SHM and Biased V_(H) and V_(L) Germline Gene Usage

To analyze infant B cell responses to RSV F, blood samples from seven infants that were hospitalized due to complications associated with RSV infection were obtained. Of the seven infants, five were less than three months (<3 mo.) and two were at least six months (>6 mo.) of age at the time of hospitalization (Table 1). Blood was drawn from seven infants hospitalized with bronchiolitis and confirmed RSV infection.

TABLE 1 Clinical information for infant donors Estimated Age at gestational Birth Hospital Intensity admission Age at blood ID age (weeks) weight (kg) stay (days) of care^(a) Intubation (months) draw (months) 2308 39 3.29 5 R N 0.35 1.35 2026 37 2.41 7 I N 0.96 2.75 2301 40 4.5 4 R CPAP 1.48 3.00 2021 33 2.21 15 I N 1.61 4.46 2201 39 4.39 3 I N 2.54 12.35 856 32.5 2.07 3 I N 6.00 10.61 2042 38 3.29 1 I Y 26.64 29.57 ^(a)R, routine; I, intensive, all patients were administered O₂.

Six out of the seven infants were infected during the first RSV season of their life and were therefore likely experiencing a primary infection. The remaining donor, who was 29.5 months old at the time of blood draw, was also likely experiencing a primary infection because secondary RSV infections generally do not result in hospitalization (Glezen et al., 1986). To assess the magnitude of the B cell response to RSV F, peripheral blood mononuclear cells (PBMCs) were stained with fluorescently labeled tetramers of preF and postF trimers and analyzed by flow cytometry (FIGS. 1A and 1B). The frequency of class-switched B cells that were RSV F-specific was substantially lower in infants <3 mo. compared with infants ≥6 mo. (FIG. 1C). In infants <3 mo., the frequency of RSV F-specific class-switched B cells ranged from 0.05-0.3%, whereas in infants ≥6 mo. the frequency ranged from 1.2-1.6%. To dissect the RSV F-specific B cell response, between 100 and 300 RSV F-reactive B cells from each donor were single-cell sorted and the antibody variable heavy (VH)- and variable light (VL)-chain sequences were rescued by single-cell PCR (Tiller et al., 2008). Due to the low frequency of RSV F-specific class-switched B cells in the five younger infants, all B cells that reacted with RSV F were single-cell sorted (FIG. 2A). For the two infants that were ≥6 mo., only class-switched B cells were sorted (FIG. 2B). Although all B cells that reacted with RSV F were sorted from infants <3 mo., index sorting was performed in order to analyze the B cell surface markers expressed on each sorted cell. This analysis revealed that 14-60% of the RSV F-specific B cells sorted from infants <3 mo. were class-switched and/or CD27⁺, with the remaining B cells lacking classical memory markers (FIG. 2C), suggesting that RSV infection induces more robust B cell responses in infants ≥6 mo. compared with infants <3 mo.

In total, over 450 cognate VH and VL pairs were cloned and expressed as full-length IgGs in an engineered strain of Saccharomyces cerevisiae (Bornholdt et al., 2016; Swers et al., 2004). As expected, sequence analysis showed that the median level of SHM in class-switched B cells increased as a function of age (FIG. 2D). Also, the majority of antibodies isolated from infants <3 mo. lacked SHM, similar to what was observed previously in postF-reactive B cells (Williams et al., 2009). However, nearly 5% of antibodies isolated from these infants had VH genes containing at least five nucleotide substitutions, consistent with previous studies showing that SHM does occur in young infants, albeit at relatively low frequency (Rechavi et al., 2015; Ridings et al., 1998). The level of SHM in antibodies isolated from the two infants ≥6 mo. was relatively high, with a median of 7 and 13 V_(H) nucleotide substitutions resulting in a median of 6 and 11 amino acid substitutions, respectively (FIG. 2D). Analysis of VH and VL germline gene usage showed that RSV F-reactive infant antibody responses were strongly biased toward either VH3-21/VL1-40 or the highly related VH3-11/VL1-40 gene pairing (FIG. 2E). There was also a more modest preference for the VH1-18/VK2-30, VH1-18/VL3-21, and VH5-51/VL6-57 gene pairs (FIG. 2E). The VH1-18/VK2-30 gene pair was present in 8.5% of RSV F-reactive antibodies isolated from adults and is associated with recognition of site V on prefusion F (Gilman et al., 2016; Mousa et al., 2017). Overall, the results demonstrate that RSV infection induced B cell responses with higher levels of SHM in infants ≥6 mo. compared to <3 mo., and that the responses in both age groups exhibit biased germline gene usage.

A Subset of Infant Antibodies Binds with High Affinity to RSV F and Potently Neutralizes RSV

To further characterize the infant antibodies, the apparent binding affinity of each antibody for preF and postF was determined. For each of the infants <3 mo., 24-34% of the isolated antibodies bound to preF with an apparent affinity of ≤5 nM, compared with 45% and 91% for the two infants ≥6 mo. (FIG. 3A). Although a total of 40 such antibodies were isolated from the youngest three infants, only two antibodies with ≤5 nM affinity for postF were isolated from the same three infants (FIG. 3B). In addition, for every infant the number of antibodies with ≤5 nM affinity for postF was lower than those with ≤5 nM affinity for preF (FIG. 3B). Consistent with this result, the percentage of preF-specific antibodies ranged from 28-63%, whereas substantially smaller percentages (2-17%) were postF-specific (FIG. 4A). Antibodies recognizing both preF and postF comprised about 19-36% of the antibody responses in the four oldest infants, but less than 10% of the response in the three youngest infants. Collectively, these results suggest that young infants generate a preF-biased antibody response that expands to include recognition of postF by six months of age.

Next, the antibodies were tested for neutralizing activity using a high-throughput assay. This analysis revealed that 12-49% of the antibodies isolated from each infant showed neutralizing activity, and a subset of antibodies isolated from six out of the seven infants showed highly potent neutralizing activity (IC₅₀s<0.05 μg/ml) (FIG. 3C). Interestingly, nearly 20% of the neutralizing antibodies lacked VH and VL gene mutations (Table 2), suggesting that extensive affinity maturation is not required for potent neutralization of RSV. The name, donor ID number, sequence information, binding affinity, neutralization IC₅₀, epitope and index sort information for each antibody is shown in the table.

TABLE 2 Summary of antibody characteristics Prefusion Postfusion Prefusion Postfusion Neut IC₅₀ Neut IC₅₀ subtype A subtype A subtype B subtype B (ug/ml) (ug/ml) Name Donor K_(d) (M)* K_(d) (M)* K_(d) (M)* K_(d) (M)* subtype A* subtype B* ADI-25462 Infant 2308 6.42E−10 N.B. 1.71E−09 N.B. 0.15 0.11 ADI-25467 Infant 2308 N.B. 2.53E−08 N.B. 2.62E−08 N.N. N.N. ADI-25468 Infant 2308 2.89E−08 N.B. N.B. N.B. N.N. N.N. ADI-25472 Infant 2308 1.19E−08 N.B. 3.77E−08 N.B. N.N. N.N. ADI-25478 Infant 2308 2.43E−09 N.B. 6.43E−09 N.B. 2.18 3.52 ADI-25479 Infant 2308 1.57E−09 N.B. 4.29E−09 N.B. 0.24 0.29 ADI-25480 Infant 2308 1.27E−09 N.B. 4.27E−09 N.B. 0.17 0.17 ADI-25484 Infant 2308 3.79E−09 N.B. 1.84E−08 N.B. 15.28  8.58 ADI-25491 Infant 2308 3.74E−08 P.F. 2.19E−08 N.B. N.N. N.N. ADI-25495 Infant 2308 8.70E−10 N.B. 6.41E−09 N.B. 0.24 5.60 ADI-25496 Infant 2308 2.08E−08 N.B. N.B. N.B. N.N. N.N. ADI-25497 Infant 2308 5.00E−08 1.84E−08 1.41E−08 1.48E−08 N.N. N.N. ADI-25502 Infant 2308 2.93E−08 P.F. N.B. N.B. N.N. N.N. ADI-25503 Infant 2308 7.02E−09 N.B. N.B. N.B. N.N. N.N. ADI-25505 Infant 2308 P.F. N.B. N.B. N.B. N.N. N.N. ADI-25514 Infant 2308 4.45E−09 N.B. N.B. N.B. N.N. N.N. ADI-25517 Infant 2308 N.B. P.F. N.B. N.B. N.N. N.N. ADI-25518 Infant 2308 5.57E−08 P.F. 3.95E−08 N.B. N.N. N.N. ADI-25524 Infant 2308 8.38E−09 N.B. 2.34E−08 N.B. 1.77 2.09 ADI-25532 Infant 2308 5.87E−10 N.B. 1.56E−09 N.B. 0.04 0.05 ADI-25533 Infant 2308 N.B. P.F. N.B. N.B. N.N. N.N. ADI-25542 Infant 2308 9.05E−09 N.B. N.B. N.B. N.N. N.N. ADI-25547 Infant 2308 N.B. 2.15E−08 2.03E−08 2.31E−08 N.N. N.N. ADI-25548 Infant 2308 1.71E−08 N.B. N.B. N.B. N.N. N.N. ADI-25549 Infant 2308 6.72E−09 N.B. 2.88E−08 N.B. 11.47  6.02 ADI-25555 Infant 2308 1.11E−08 N.B. 4.47E−08 N.B. 18.59  12.08  ADI-25556 Infant 2308 1.19E−08 N.B. 4.20E−08 N.B. N.N. N.N. ADI-25557 Infant 2308 8.29E−09 N.B. 3.33E−08 N.B. N.N. N.N. ADI-25559 Infant 2308 1.27E−08 N.B. 3.33E−08 N.B. N.N. N.N. ADI-25562 Infant 2308 1.69E−09 N.B. 3.32E−09 N.B. 1.18 1.14 ADI-25565 Infant 2308 1.54E−08 N.B. 3.57E−08 N.B. N.N. N.N. ADI-25567 Infant 2308 2.40E−09 N.B. 3.83E−09 N.B. 0.33 1.94 ADI-25569 Infant 2308 N.B. P.F. P.F. P.F. N.N. N.N. ADI-25572 Infant 2308 N.B. N.B. P.F. P.F. N.N. N.N. ADI-25573 Infant 2308 N.B. N.B. N.B. 4.86E−08 N.N. N.N. ADI-25575 Infant 2308 N.B. N.B. N.B. 3.96E−08 5.64 N.N. ADI-25576 Infant 2308 N.B. N.B. N.B. 2.39E−08 N.N. N.N. ADI-25577 Infant 2308 1.40E−08 N.B. 4.42E−08 N.B. N.N. N.N. ADI-25587 Infant 2308 N.B. 9.23E−09 N.B. 7.93E−09 N.N. N.N. ADI-25588 Infant 2308 1.73E−08 N.B. N.B. N.B. N.N. N.N. ADI-25595 Infant 2308 1.27E−08 N.B. N.B. N.B. N.N. N.N. ADI-25598 Infant 2308 N.B. N.B. N.B. P.F. N.N. N.N. ADI-19420 Infant 2026 5.70E−10 N.B. 2.47E−09 N.B. 0.55 0.64 ADI-19421 Infant 2026 7.22E−09 N.B. 5.42E−09 N.B. 10.00  3.30 ADI-19422 Infant 2026 2.23E−09 N.B. 1.08E−08 N.B. 0.73 1.90 ADI-19424 Infant 2026 1.07E−09 N.B. 1.71E−09 N.B. 0.08 0.21 ADI-19425 Infant 2026 4.56E−10 N.B. 1.37E−09 N.B. 0.02 0.04 ADI-19426 Infant 2026 2.87E−09 N.B. 1.29E−08 N.B. N.N. N.N. ADI-19427 Infant 2026 2.78E−10 N.B. 5.00E−10 N.B. 0.01 0.03 ADI-19428 Infant 2026 4.96E−09 N.B. 1.67E−08 N.B. 3.25 N.N. ADI-19429 Infant 2026 1.23E−08 N.B. N.B. N.B. N.N. N.N. ADI-19430 Infant 2026 5.02E−09 N.B. 1.68E−08 N.B. N.N. N.N. ADI-19431 Infant 2026 8.18E−09 N.B. 3.16E−09 N.B. 4.35 0.17 ADI-19432 Infant 2026 P.F. N.B. N.B. N.B. 10.98  N.N. ADI-19433 Infant 2026 3.60E−09 N.B. N.B. N.B. 1.56 N.N. ADI-19435 Infant 2026 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19436 Infant 2026 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19437 Infant 2026 N.B. P.F. N.B. N.B. N.N. N.N. ADI-19439 Infant 2026 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19440 Infant 2026 5.41E−09 N.B. 1.43E−08 N.B. N.N. N.N. ADI-19441 Infant 2026 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19444 Infant 2026 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19445 Infant 2026 N.B. N.B. N.B. P.F. N.N. N.N. ADI-19447 Infant 2026 P.F. N.B. N.B. N.B. N.N. N.N. ADI-19448 Infant 2026 6.08E−09 N.B. 5.58E−09 N.B. 9.64 N.N. ADI-19449 Infant 2026 1.48E−08 N.B. 2.60E−08 N.B. N.N. N.N. ADI-19450 Infant 2026 N.B. N.B. 3.86E−08 N.B. N.N. N.N. ADI-19454 Infant 2026 2.52E−09 N.B. 1.57E−08 N.B. N.N. N.N. ADI-19455 Infant 2026 1.80E−08 N.B. N.B. N.B. N.N. N.N. ADI-19457 Infant 2026 8.29E−09 N.B. 1.67E−08 N.B. N.N. N.N. ADI-19458 Infant 2026 2.15E−10 N.B. 2.43E−10 N.B. 0.04 0.07 ADI-19459 Infant 2026 1.09E−09 N.B. 1.45E−09 N.B. 0.05 0.10 ADI-19460 Infant 2026 7.50E−09 N.B. 6.01E−09 N.B. N.N. N.N. ADI-19461 Infant 2026 N.B. N.B. P.F. N.B. N.N. N.N. ADI-19462 Infant 2026 N.B. P.F. N.B. N.B. N.N. N.N. ADI-19463 Infant 2026 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19465 Infant 2026 2.74E−09 N.B. 1.94E−08 N.B. N.N. N.N. ADI-19506 Infant 2026 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19507 Infant 2026 1.09E−08 N.B. 1.01E−08 N.B. N.N. N.N. ADI-19509 Infant 2026 9.33E−09 N.B. 1.58E−09 N.B. 3.42 1.56 ADI-19510 Infant 2026 2.38E−10 N.B. 2.39E−10 N.B. 0.16 0.83 ADI-19511 Infant 2026 N.B. N.B. N.B. 1.53E−08 N.N. N.N. ADI-24792 Infant 2301 6.52E−10 N.B. 1.83E−09 N.B. 0.27 0.19 ADI-24793 Infant 2301 N.B. N.B. N.B. 2.68E−08 N.N. N.N. ADI-24795 Infant 2301 2.39E−08 N.B. 3.42E−08 N.B. N.N. N.N. ADI-24796 Infant 2301 N.B. N.B. 8.22E−08 N.B. N.N. N.N. ADI-24798 Infant 2301 9.92E−09 N.B. 5.27E−09 N.B. N.N. N.N. ADI-24799 Infant 2301 1.22E−08 N.B. 1.90E−08 N.B. 11.53  N.N. ADI-24800 Infant 2301 2.83E−08 N.B. 5.14E−08 N.B. N.N. N.N. ADI-24801 Infant 2301 5.89E−08 N.B. N.B. N.B. N.N. N.N. ADI-24803 Infant 2301 N.B. 1.20E−09 N.B. 4.42E−10 N.N. N.N. ADI-24805 Infant 2301 3.79E−09 N.B. 4.88E−09 N.B. 0.21 0.71 ADI-24807 Infant 2301 N.B. 1.64E−08 N.B. N.B. N.N. N.N. ADI-24808 Infant 2301 N.B. 1.08E−08 N.B. N.B. N.N. N.N. ADI-24811 Infant 2301 8.10E−09 N.B. 4.29E−09 N.B. N.N. N.N. ADI-24812 Infant 2301 3.51E−09 N.B. 7.58E−09 N.B. 0.18 N.N. ADI-24813 Infant 2301 N.B. N.B. N.B. N.B. N.N. N.N. ADI-24814 Infant 2301 8.11E−09 N.B. 2.39E−09 N.B. 0.73 0.32 ADI-24815 Infant 2301 1.84E−08 N.B. 2.91E−08 N.B. N.N. N.N. ADI-24816 Infant 2301 N.B. N.B. N.B. N.B. N.N. N.N. ADI-24817 Infant 2301 6.80E−09 N.B. 9.23E−09 N.B. 2.20 4.40 ADI-24818 Infant 2301 3.36E−08 6.47E−09 N.B. N.B. N.N. N.N. ADI-24819 Infant 2301 6.52E−09 N.B. 9.44E−09 N.B. 4.33 6.28 ADI-24820 Infant 2301 3.06E−08 N.B. 3.85E−08 N.B. N.N. N.N. ADI-24821 Infant 2301 N.B. N.B. N.B. N.B. N.N. N.N. ADI-24822 Infant 2301 4.65E−08 N.B. N.B. N.B. N.N. N.N. ADI-24823 Infant 2301 4.16E−09 N.B. 6.03E−09 N.B. ND ND ADI-24824 Infant 2301 1.51E−08 N.B. 4.75E−08 N.B. N.N. N.N. ADI-24825 Infant 2301 3.31E−08 3.01E−08 N.B. 2.60E−08 N.N. N.N. ADI-24826 Infant 2301 6.88E−09 N.B. 9.03E−09 N.B. N.N. N.N. ADI-24827 Infant 2301 7.42E−09 N.B. 6.62E−09 N.B. 0.02 N.N. ADI-24828 Infant 2301 3.06E−10 N.B. 3.91E−10 N.B. 0.02 0.04 ADI-24829 Infant 2301 N.B. N.B. N.B. N.B. N.N. N.N. ADI-24830 Infant 2301 N.B. N.B. N.B. N.B. N.N. N.N. ADI-24831 Infant 2301 4.88E−09 N.B. 6.23E−09 N.B. 0.21 3.29 ADI-24832 Infant 2301 1.80E−09 N.B. 1.95E−09 N.B. 0.49 0.24 ADI-24833 Infant 2301 1.93E−08 N.B. 1.14E−08 N.B. N.N. N.N. ADI-24834 Infant 2301 1.12E−09 2.11E−10 7.32E−10 2.60E−10 N.N. N.N. ADI-24835 Infant 2301 4.93E−09 N.B. 5.55E−09 N.B. 0.63 1.06 ADI-24836 Infant 2301 2.87E−09 N.B. 3.44E−09 N.B. N.N. N.N. ADI-24837 Infant 2301 2.75E−08 N.B. N.B. N.B. N.N. N.N. ADI-24838 Infant 2301 N.B. N.B. N.B. N.B. N.N. N.N. ADI-24839 Infant 2301 5.83E−09 N.B. 9.63E−09 N.B. 0.44 4.10 ADI-24840 Infant 2301 7.32E−09 N.B. 7.80E−09 N.B. N.N. N.N. ADI-24841 Infant 2301 N.B. N.B. 2.66E−08 N.B. N.N. N.N. ADI-24842 Infant 2301 5.59E−10 N.B. 2.76E−09 N.B. 0.03 0.03 ADI-24843 Infant 2301 N.B. N.B. N.B. N.B. N.N. N.N. ADI-24845 Infant 2301 1.19E−08 N.B. 3.67E−08 N.B. N.N. N.N. ADI-24846 Infant 2301 N.B. N.B. N.B. 2.91E−08 N.N. N.N. ADI-24847 Infant 2301 N.B. N.B. 4.00E−08 N.B. N.N. N.N. ADI-24848 Infant 2301 2.08E−08 N.B. 3.56E−08 N.B. N.N. N.N. ADI-24849 Infant 2301 1.71E−10 N.B. 1.17E−09 N.B. 0.01 0.03 ADI-24850 Infant 2301 3.84E−09 N.B. 5.56E−09 N.B. 0.94 4.17 ADI-24851 Infant 2301 N.B. 2.09E−08 N.B. N.B. N.N. N.N. ADI-24852 Infant 2301 1.18E−08 9.57E−09 1.90E−08 9.17E−09 N.N. N.N. ADI-24854 Infant 2301 N.B. N.B. 3.03E−08 N.B. N.N. N.N. ADI-24855 Infant 2301 1.79E−08 N.B. 2.80E−08 N.B. N.N. N.N. ADI-24856 Infant 2301 1.35E−08 N.B. 4.91E−09 N.B. N.N. N.N. ADI-24857 Infant 2301 3.20E−09 N.B. 3.71E−09 N.B. 0.18 1.40 ADI-24858 Infant 2301 2.16E−08 N.B. 2.63E−08 N.B. N.N. N.N. ADI-24859 Infant 2301 4.31E−09 N.B. 4.95E−09 N.B. 0.58 N.N. ADI-24860 Infant 2301 1.08E−09 N.B. 1.56E−09 N.B. 0.06 0.09 ADI-24861 Infant 2301 3.01E−10 N.B. 4.61E−10 N.B. N.N. N.N. ADI-24862 Infant 2301 N.B. N.B. N.B. N.B. N.N. N.N. ADI-24863 Infant 2301 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19467 Infant 2021 9.13E−09 N.B. 3.77E−08 N.B. N.N. N.N. ADI-19468 Infant 2021 2.22E−09 N.B. N.B. N.B. N.N. N.N. ADI-19469 Infant 2021 1.74E−08 N.B. N.B. N.B. N.N. N.N. ADI-19470 Infant 2021 2.97E−08 N.B. 1.97E−08 N.B. N.N. N.N. ADI-19471 Infant 2021 3.23E−09 N.B. N.B. N.B. N.N. N.N. ADI-19473 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19474 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19475 Infant 2021 1.43E−09 N.B. 4.25E−09 N.B. 0.05 0.04 ADI-19476 Infant 2021 N.B. 8.01E−10 N.B. 8.38E−10 N.N. N.N. ADI-19478 Infant 2021 N.B. 3.86E−10 N.B. 7.13E−10 N.N. N.N. ADI-19479 Infant 2021 N.B. 3.69E−09 N.B. 2.69E−09 N.N. N.N. ADI-19480 Infant 2021 3.95E−10 1.29E−10 3.83E−10 1.19E−10 N.N. 6.25 ADI-19481 Infant 2021 7.60E−09 N.B. N.B. N.B. N.N. N.N. ADI-19482 Infant 2021 1.28E−09 1.71E−09 1.89E−09 5.55E−10 1.49 2.24 ADI-19483 Infant 2021 1.72E−09 3.21E−10 1.77E−09 1.53E−10 N.N. N.N. ADI-19484 Infant 2021 1.75E−09 3.69E−10 8.92E−09 3.55E−10 N.N. N.N. ADI-19485 Infant 2021 3.56E−09 2.51E−10 N.B. P.F. N.N. N.N. ADI-19486 Infant 2021 3.71E−09 5.25E−10 N.B. 7.55E−09 N.N. N.N. ADI-19487 Infant 2021 N.B. N.B. N.B. N.B. N.N. 7.96 ADI-19488 Infant 2021 9.02E−09 N.B. 1.07E−08 N.B. N.N. 3.38 ADI-19489 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19490 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19491 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19492 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19493 Infant 2021 7.93E−09 N.B. 2.26E−08 N.B. N.N. N.N. ADI-19494 Infant 2021 5.48E−09 N.B. N.B. N.B. 0.86 N.N. ADI-19495 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19496 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19497 Infant 2021 N.B. P.F. N.B. 1.34E−08 N.N. N.N. ADI-19498 Infant 2021 N.B. P.F. N.B. P.F. N.N. N.N. ADI-19499 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19500 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19501 Infant 2021 4.46E−10 N.B. 1.59E−09 N.B. 0.02 0.02 ADI-19502 Infant 2021 N.B. N.B. N.B. N.B. N.N. N.N. ADI-19503 Infant 2021 N.B. N.B. N.B. 1.16E−08 N.N. N.N. ADI-19505 Infant 2021 1.33E−08 4.94E−09 4.44E−08 5.01E−09 N.N. N.N. ADI-22756 Infant 2201 7.85E−09 N.B. 5.58E−08 N.B. N.N. N.N. ADI-22757 Infant 2201 3.10E−10 N.B. 5.38E−10 N.B. 0.06 0.07 ADI-22758 Infant 2201 6.32E−09 N.B. P.F. N.B. N.N. N.N. ADI-22759 Infant 2201 2.97E−10 2.53E−08 3.53E−10 1.01E−08 0.08 0.20 ADI-22760 Infant 2201 5.21E−09 1.19E−09 3.07E−09 1.25E−09 N.N. N.N. ADI-22762 Infant 2201 5.76E−08 P.F. N.B. N.B. N.N. N.N. ADI-22763 Infant 2201 1.58E−09 3.19E−10 1.08E−08 5.33E−09 N.N. N.N. ADI-22764 Infant 2201 2.27E−09 3.34E−10 1.42E−09 1.44E−09 N.N. N.N. ADI-22765 Infant 2201 4.04E−08 N.B. P.F. N.B. N.N. N.N. ADI-22766 Infant 2201 N.B. N.B. N.B. N.B. N.N. N.N. ADI-22767 Infant 2201 1.71E−08 N.B. P.F. N.B. N.N. N.N. ADI-22768 Infant 2201 5.61E−09 3.41E−09 4.57E−09 N.B. N.N. N.N. ADI-22769 Infant 2201 N.B. N.B. N.B. P.F. N.N. N.N. ADI-22770 Infant 2201 N.B. P.F. N.B. P.F. N.N. N.N. ADI-22771 Infant 2201 7.06E−09 N.B. 9.41E−09 N.B. N.N. N.N. ADI-22772 Infant 2201 N.B. N.B. N.B. 5.02E−08 N.N. N.N. ADI-22773 Infant 2201 P.F. N.B. N.B. N.B. N.N. N.N. ADI-22774 Infant 2201 2.06E−09 N.B. 4.28E−09 N.B. 0.29 7.53 ADI-22775 Infant 2201 N.B. 3.00E−08 N.B. P.F. N.N. N.N. ADI-22776 Infant 2201 N.B. N.B. P.F. N.B. N.N. N.N. ADI-22777 Infant 2201 1.80E−09 2.68E−10 7.62E−10 2.24E−10 N.N. N.N. ADI-22778 Infant 2201 6.22E−10 2.09E−10 4.02E−09 2.77E−09 N.N. N.N. ADI-22779 Infant 2201 1.60E−08 6.20E−09 N.B. N.B. N.N. N.N. ADI-22780 Infant 2201 N.B. 7.39E−10 2.38E−08 6.00E−10 N.N. N.N. ADI-22781 Infant 2201 N.B. P.F. P.F. P.F. N.N. N.N. ADI-14333 Infant 856 3.53E−10 N.B. 9.04E−10 N.B. 0.07 0.09 ADI-14334 Infant 856 3.16E−10 N.B. 6.22E−10 N.B. 0.05 0.11 ADI-14335 Infant 856 1.96E−10 N.B. 8.89E−10 N.B. 0.32 0.10 ADI-14336 Infant 856 3.12E−10 N.B. 2.65E−09 N.B. 0.07 0.09 ADI-14337 Infant 856 1.39E−09 N.B. 2.11E−09 N.B. 0.10 0.07 ADI-14338 Infant 856 8.41E−09 5.98E−09 7.04E−09 3.14E−09 N.N. 10.16  ADI-14339 Infant 856 2.45E−08 4.39E−10 1.77E−09 3.76E−10 N.N. N.N. ADI-14340 Infant 856 4.11E−10 N.B. 9.80E−08 N.B. 6.63 1.94 ADI-14341 Infant 856 N.B. 7.13E−10 N.B. 6.12E−10 N.N. 17.46  ADI-14342 Infant 856 1.57E−09 4.95E−10 2.61E−08 P.F. 1.75 8.27 ADI-14343 Infant 856 1.85E−08 2.94E−09 3.81E−08 P.F. N.N. N.N. ADI-14344 Infant 856 1.81E−10 N.B. 5.86E−10 N.B. 8.68 1.20 ADI-14345 Infant 856 6.32E−09 N.B. 5.26E−09 N.B. 2.30 0.87 ADI-14346 Infant 856 3.09E−10 N.B. 9.25E−10 N.B. 0.05 0.07 ADI-14347 Infant 856 4.99E−10 N.B. 2.54E−09 N.B. 0.11 0.05 ADI-14348 Infant 856 1.96E−09 5.66E−09 1.10E−07 N.B. N.N. N.N. ADI-14349 Infant 856 5.33E−09 N.B. 4.07E−09 N.B. N.N. 1.84 ADI-14350 Infant 856 3.73E−09 2.64E−10 5.74E−10 1.48E−10 N.N. 4.82 ADI-14351 Infant 856 2.21E−08 3.61E−10 7.89E−10 2.15E−10 N.N. N.N. ADI-14352 Infant 856 N.B. 4.48E−10 5.54E−09 3.83E−10 N.N. N.N. ADI-14353 Infant 856 1.40E−08 2.60E−10 1.26E−08 P.F. N.N. 14.62  ADI-14354 Infant 856 9.98E−09 1.04E−09 2.53E−08 6.63E−09 N.N. N.N. ADI-14355 Infant 856 6.60E−09 4.80E−10 1.25E−09 3.70E−10 N.N. 4.72 ADI-14356 Infant 856 N.B. 3.90E−09 1.30E−08 4.98E−09 N.N. N.N. ADI-14357 Infant 856 1.76E−10 N.B. 3.06E−10 N.B. 1.24 0.88 ADI-14358 Infant 856 5.91E−09 6.56E−10 6.03E−08 2.75E−08 N.N. N.N. ADI-14359 Infant 856 N.B. 4.11E−09 3.46E−08 P.F. N.N. N.N. ADI-14360 Infant 856 N.B. 5.88E−09 2.68E−08 9.03E−09 N.N. N.N. ADI-14361 Infant 856 N.B. 4.37E−10 5.28E−08 2.93E−10 N.N. N.N. ADI-14362 Infant 856 3.15E−09 1.57E−08 1.19E−07 N.B. N.N. N.N. ADI-14363 Infant 856 3.54E−09 N.B. 5.35E−09 N.B. N.N. N.N. ADI-14364 Infant 856 6.30E−10 N.B. 6.16E−08 N.B. 0.03 2.39 ADI-14365 Infant 856 1.19E−09 1.03E−08 9.62E−10 2.23E−08 0.80 0.49 ADI-14366 Infant 856 6.14E−09 N.B. 1.80E−08 N.B. N.N. N.N. ADI-14367 Infant 856 1.57E−10 N.B. 2.69E−10 N.B. 3.94 0.33 ADI-14368 Infant 856 2.60E−09 2.45E−08 1.21E−09 1.77E−08 N.N. 1.10 ADI-14369 Infant 856 N.B. 1.22E−09 3.38E−09 9.00E−10 N.N. N.N. ADI-14370 Infant 856 8.12E−09 N.B. 4.18E−09 N.B. N.N. 1.38 ADI-14371 Infant 856 N.B. 1.23E−09 8.43E−09 1.07E−09 N.N. N.N. ADI-14372 Infant 856 N.B. 6.59E−10 N.B. 4.43E−09 N.N. N.N. ADI-14373 Infant 856 1.96E−09 1.06E−09 1.59E−08 N.B. N.N. N.N. ADI-14374 Infant 856 4.61E−09 N.B. 2.09E−09 N.B. N.N. 0.86 ADI-14375 Infant 856 N.B. 4.77E−10 3.21E−09 3.31E−09 N.N. N.N. ADI-14376 Infant 856 P.F. P.F. P.F. P.F. N.N. N.N. ADI-14377 Infant 856 6.64E−09 N.B. 5.28E−09 N.B. N.N. 2.13 ADI-14378 Infant 856 5.87E−09 N.B. 6.10E−09 N.B. N.N. 21.58  ADI-14379 Infant 856 N.B. 3.29E−09 N.B. 2.35E−09 N.N. N.N. ADI-14380 Infant 856 6.04E−09 N.B. 1.08E−08 N.B. N.N. N.N. ADI-14381 Infant 856 2.20E−09 7.54E−10 3.67E−08 P.F. ND ND ADI-14382 Infant 856 N.B. 8.46E−10 N.B. N.B. N.N. N.N. ADI-14383 Infant 856 N.B. 4.34E−10 1.75E−09 2.51E−10 N.N. N.N. ADI-14384 Infant 856 3.71E−09 4.69E−10 4.78E−09 N.B. N.N. N.N. ADI-14385 Infant 856 8.72E−08 P.F. P.F. P.F. N.N. N.N. ADI-14386 Infant 856 6.29E−09 1.32E−09 3.04E−09 P.F. N.N. N.N. ADI-14388 Infant 856 5.58E−09 N.B. 5.50E−09 N.B. N.N. 3.07 ADI-14389 Infant 856 N.B. 2.29E−08 8.15E−08 P.F. N.N. N.N. ADI-14390 Infant 856 N.B. N.B. N.B. N.B. N.N. N.N. ADI-14391 Infant 856 6.95E−09 N.B. 5.36E−09 N.B. N.N. 22.25  ADI-14392 Infant 856 7.56E−09 N.B. 7.25E−08 N.B. N.N. N.N. ADI-14393 Infant 856 3.11E−10 N.B. 4.74E−10 1.17E−08 ND ND ADI-14394 Infant 856 1.15E−08 N.B. P.F. N.B. N.N. N.N. ADI-14395 Infant 856 2.49E−08 N.B. P.F. N.B. N.N. N.N. ADI-14396 Infant 856 N.B. N.B. 1.55E−08 N.B. N.N. N.N. ADI-14397 Infant 856 2.85E−08 N.B. P.F. N.B. N.N. N.N. ADI-14399 Infant 856 1.89E−10 N.B. 3.65E−10 N.B. 0.97 0.46 ADI-14400 Infant 856 2.90E−10 N.B. 4.51E−10 N.B. ND 3.71 ADI-14401 Infant 856 1.19E−09 N.B. 2.17E−09 N.B. 0.05 0.06 ADI-14402 Infant 856 2.79E−10 N.B. 4.16E−10 N.B. 0.02 0.03 ADI-14403 Infant 856 5.09E−10 N.B. 6.99E−10 N.B. 0.08 0.N.N.1 ADI-14404 Infant 856 N.B. 6.27E−10 N.B. 4.98E−10 N.N. N.N. ADI-14405 Infant 856 1.42E−10 1.17E−08 2.27E−10 3.80E−08 0.04 0.04 ADI-14406 Infant 856 6.85E−09 3.39E−10 9.06E−10 4.73E−10 N.N. N.N. ADI-14407 Infant 856 6.28E−09 3.78E−10 1.14E−08 P.F. N.N. N.N. ADI-14408 Infant 856 8.53E−09 2.14E−09 1.28E−08 P.F. N.N. N.N. ADI-14409 Infant 856 1.50E−10 N.B. 2.89E−10 N.B. 0.29 0.23 ADI-14410 Infant 856 3.77E−09 N.B. 1.71E−08 N.B. 1.22 2.64 ADI-14411 Infant 856 6.12E−09 N.B. 3.92E−09 N.B. 9.27 1.96 ADI-14412 Infant 856 5.60E−09 N.B. 1.34E−08 N.B. N.N. N.N. ADI-14413 Infant 856 5.45E−09 N.B. 2.71E−09 N.B. 15.13  1.69 ADI-14414 Infant 856 5.00E−09 N.B. 3.07E−09 N.B. N.N. N.N. ADI-14415 Infant 856 4.20E−09 N.B. 3.51E−09 N.B. N.N. N.N. ADI-14416 Infant 856 2.39E−09 1.82E−10 3.69E−10 1.06E−10 N.N. N.N. ADI-14417 Infant 856 N.B. 1.63E−09 N.B. 3.99E−09 ND ND ADI-14418 Infant 856 1.25E−09 4.41E−10 1.58E−09 2.58E−10 0.30 0.66 ADI-14419 Infant 856 2.69E−09 N.B. N.B. N.B. N.N. N.N. ADI-14420 Infant 856 6.35E−09 N.B. 4.32E−09 N.B. N.N. N.N. ADI-14421 Infant 856 N.B. 1.07E−09 2.82E−09 7.40E−10 N.N. N.N. ADI-14422 Infant 856 1.14E−08 4.76E−09 3.39E−08 N.B. N.N. N.N. ADI-14423 Infant 856 9.65E−09 N.B. 3.40E−09 N.B. N.N. N.N. ADI-14424 Infant 856 3.43E−09 N.B. 1.90E−09 N.B. N.N. 2.48 ADI-14425 Infant 856 4.81E−08 7.42E−10 2.03E−08 9.34E−09 N.N. N.N. ADI-14426 Infant 856 2.38E−08 3.96E−10 1.92E−08 P.F. N.N. N.N. ADI-14427 Infant 856 2.34E−10 3.33E−09 1.08E−08 N.B. 0.25 N.N. ADI-14428 Infant 856 4.22E−08 N.B. 1.41E−08 N.B. N.N. N.N. ADI-14654 Infant 856 2.04E−09 N.B. 7.64E−09 N.B. N.N. N.N. ADI-14655 Infant 856 1.69E−08 P.F. 1.40E−08 P.F. N.N. N.N. ADI-14656 Infant 856 P.F. 3.70E−10 2.51E−08 P.F. N.N. N.N. ADI-14657 Infant 856 2.84E−09 N.B. N.B. N.B. N.N. N.N. ADI-14658 Infant 856 N.B. 1.58E−08 N.B. 1.79E−08 N.N. N.N. ADI-14659 Infant 856 4.86E−09 N.B. 3.71E−09 N.B. N.N. 5.56 ADI-14571 Infant 856 2.91E−09 N.B. N.B. N.B. N.N. 3.06 ADI-14572 Infant 856 N.B. 1.70E−08 P.F. N.B. N.N. N.N. ADI-14573 Infant 856 N.B. 3.73E−10 2.10E−08 3.55E−09 N.N. N.N. ADI-14575 Infant 856 1.12E−08 P.F. N.B. N.B. N.N. N.N. ADI-14576 Infant 856 6.97E−09 N.B. 1.93E−08 N.B. 3.11 0.77 ADI-14577 Infant 856 4.39E−10 N.B. 2.19E−09 N.B. 0.04 0.05 ADI-14578 Infant 856 3.29E−09 N.B. 4.02E−09 N.B. N.N. N.N. ADI-14579 Infant 856 7.54E−09 P.F. 3.73E−09 N.B. N.N. N.N. ADI-14580 Infant 856 6.70E−09 N.B. 4.54E−09 N.B. N.N. 3.75 ADI-14581 Infant 856 N.B. N.B. 2.88E−09 N.B. N.N. 6.25 ADI-14582 Infant 856 5.82E−09 N.B. 1.81E−09 N.B. ND ND ADI-14583 Infant 856 4.74E−10 N.B. 1.59E−09 N.B. 0.05 0.06 ADI-14584 Infant 856 P.F. N.B. 4.76E−10 N.B. 1.53 0.65 ADI-14585 Infant 856 2.72E−10 N.B. 4.49E−10 N.B. 0.02 0.03 ADI-14586 Infant 856 4.52E−10 N.B. 6.70E−09 N.B. 0.05 0.50 ADI-14587 Infant 856 6.09E−10 N.B. 8.33E−10 N.B. 0.15 0.11 ADI-14588 Infant 856 3.24E−09 N.B. 1.48E−09 N.B. 13.60  0.59 ADI-14589 Infant 856 6.48E−09 5.96E−10 2.82E−08 1.54E−08 N.N. N.N. ADI-14590 Infant 856 1.32E−08 2.68E−09 5.99E−09 9.67E−10 N.N. N.N. ADI-14591 Infant 856 1.87E−10 N.B. 5.54E−10 N.B. N.N. 9.36 ADI-14592 Infant 856 2.40E−09 1.36E−10 3.01E−10 9.32E−11 N.N. N.N. ADI-14593 Infant 856 2.33E−09 1.61E−10 3.58E−10 1.08E−10 2.28 4.03 ADI-14594 Infant 856 N.B. 2.57E−10 1.82E−08 2.14E−10 N.N. N.N. ADI-14595 Infant 856 2.19E−09 1.30E−09 1.60E−08 1.44E−08 ND ND ADI-14596 Infant 856 1.86E−10 N.B. 1.86E−09 N.B. N.N. N.N. ADI-14597 Infant 856 5.26E−09 N.B. 1.67E−09 N.B. N.N. 3.05 ADI-14598 Infant 856 P.F. 4.52E−10 7.07E−09 4.81E−09 N.N. N.N. ADI-14599 Infant 856 1.02E−10 6.36E−10 6.22E−10 3.58E−10 0.14 1.11 ADI-14600 Infant 856 7.58E−10 N.B. 9.86E−10 N.B. 0.12 0.08 ADI-14601 Infant 856 3.79E−09 N.B. 1.96E−09 N.B. 12.19  3.10 ADI-14602 Infant 856 4.73E−09 N.B. 8.94E−09 N.B. N.N. 6.53 ADI-14603 Infant 856 8.40E−09 N.B. 3.05E−08 N.B. N.N. 2.03 ADI-14604 Infant 856 2.44E−09 N.B. 1.53E−09 N.B. N.N. N.N. ADI-14605 Infant 856 N.B. 9.24E−10 2.72E−09 3.99E−10 N.N. N.N. ADI-14606 Infant 856 N.B. 1.28E−09 N.B. 6.59E−10 0.85 0.29 ADI-14607 Infant 856 1.70E−09 3.81E−10 6.40E−10 2.27E−10 N.N. 0.13 ADI-20959 Infant 2042 3.37E−10 N.B. 4.30E−10 N.B. 0.06 0.28 ADI-20960 Infant 2042 2.20E−10 1.63E−10 2.30E−10 1.63E−10 0.35 0.71 ADI-20961 Infant 2042 3.74E−10 N.B. 5.04E−10 N.B. 0.09 0.32 ADI-20962 Infant 2042 2.89E−10 N.B. 4.63E−10 N.B. 0.07 0.15 ADI-20963 Infant 2042 7.91E−10 9.09E−11 3.14E−09 6.14E−10 N.N. N.N. ADI-20964 Infant 2042 3.60E−10 N.B. 2.49E−09 N.B. 0.06 0.14 ADI-20965 Infant 2042 1.21E−10 P.F. 5.33E−10 P.F. 0.32 0.64 ADI-20966 Infant 2042 3.06E−10 N.B. 8.62E−10 N.B. 0.00 0.13 ADI-20967 Infant 2042 2.23E−09 2.57E−10 4.08E−09 3.45E−09 N.N. N.N. ADI-20968 Infant 2042 1.35E−10 1.57E−10 1.27E−10 1.50E−10 0.14 0.44 ADI-20969 Infant 2042 3.01E−10 N.B. 4.09E−10 N.B. 0.12 0.27 ADI-20970 Infant 2042 1.83E−09 N.B. 2.55E−09 N.B. 2.14 2.92 ADI-20971 Infant 2042 3.33E−10 N.B. 5.44E−10 N.B. N.N. N.N. ADI-20972 Infant 2042 8.88E−10 4.01E−10 6.06E−09 3.48E−09 N.N. N.N. ADI-20973 Infant 2042 3.08E−10 N.B. 4.17E−10 N.B. 0.03 0.19 ADI-20974 Infant 2042 2.91E−10 N.B. 3.60E−10 N.B. 0.00 0.09 ADI-20975 Infant 2042 9.20E−11 1.46E−10 9.58E−11 1.29E−10 0.05 0.49 ADI-20976 Infant 2042 1.86E−09 2.63E−10 9.55E−10 3.04E−10 N.N. N.N. ADI-20977 Infant 2042 1.51E−10 N.B. P.F. N.B. N.N. N.N. ADI-20978 Infant 2042 2.90E−10 N.B. 3.19E−10 N.B. 0.01 0.17 ADI-20979 Infant 2042 9.79E−10 N.B. 4.00E−09 N.B. 0.29 0.21 ADI-20980 Infant 2042 2.00E−10 N.B. 5.42E−10 N.B. N.N. N.N. ADI-20981 Infant 2042 2.34E−09 2.33E−10 2.14E−09 2.95E−10 N.N. N.N. ADI-20982 Infant 2042 4.88E−09 N.B. 5.45E−09 N.B. N.N. N.N. ADI-20983 Infant 2042 2.13E−10 2.05E−09 1.17E−09 P.F. N.N. N.N. ADI-20984 Infant 2042 3.29E−09 N.B. 2.02E−08 N.B. N.N. N.N. ADI-20986 Infant 2042 4.14E−10 N.B. 1.25E−09 N.B. 0.02 0.19 ADI-20987 Infant 2042 4.63E−09 N.B. 3.56E−08 N.B. N.N. N.N. ADI-20988 Infant 2042 2.94E−10 N.B. 1.29E−09 N.B. 0.06 0.27 ADI-20989 Infant 2042 4.80E−09 4.28E−10 6.29E−09 8.09E−10 N.N. N.N. ADI-20990 Infant 2042 1.58E−09 1.78E−10 9.04E−10 3.12E−10 N.N. N.N. ADI-20991 Infant 2042 2.34E−10 N.B. 2.58E−10 N.B. 0.14 0.19 ADI-20992 Infant 2042 9.56E−10 N.B. 1.22E−09 N.B. 0.04 0.64 ADI-20993 Infant 2042 1.38E−09 1.68E−10 7.42E−10 2.73E−10 N.N. N.N. ADI-20994 Infant 2042 8.94E−11 P.F. 1.09E−10 P.F. 0.06 0.18 ADI-20995 Infant 2042 2.60E−09 N.B 1.36E−08 N.B ND ND ADI-20996 Infant 2042 1.03E−09 2.04E−10 1.06E−09 1.12E−09 N.N. N.N. ADI-20997 Infant 2042 1.78E−09 1.97E−10 3.09E−09 6.09E−10 N.N. N.N. ADI-20998 Infant 2042 2.57E−10 N.B. 1.35E−09 N.B. 0.03 N.N. ADI-20999 Infant 2042 4.16E−09 N.B. 2.41E−08 N.B. N.N. N.N. ADI-21000 Infant 2042 1.49E−09 2.95E−10 1.30E−09 6.02E−10 N.N. N.N. ADI-21001 Infant 2042 2.12E−09 2.77E−10 1.85E−09 3.02E−10 N.N. N.N. ADI-21002 Infant 2042 2.36E−09 2.14E−10 8.60E−09 6.39E−09 N.N. N.N. ADI-21003 Infant 2042 4.75E−09 4.40E−10 9.87E−10 4.21E−10 N.N. N.N. ADI-21004 Infant 2042 4.59E−09 5.40E−10 1.02E−08 7.98E−10 N.N. 4.78 ADI-21005 Infant 2042 3.37E−09 N.B. 7.70E−09 N.B. N.N. N.N. ADI-21006 Infant 2042 1.04E−08 N.B. N.B. N.B. N.N. N.N. ADI-21007 Infant 2042 1.48E−09 1.71E−10 1.72E−09 1.71E−10 N.N. N.N. ADI-21008 Infant 2042 5.68E−09 9.18E−10 4.14E−09 1.45E−09 N.N. N.N. ADI-21009 Infant 2042 4.88E−09 N.B. 1.95E−08 N.B. N.N. N.N. ADI-21010 Infant 2042 3.58E−09 N.B. N.B. N.B. N.N. N.N. ADI-21011 Infant 2042 1.41E−09 1.62E−10 9.82E−10 3.56E−10 N.N. N.N. ADI-21012 Infant 2042 3.71E−10 2.14E−10 1.92E−09 2.80E−10 N.N. N.N. ADI-21013 Infant 2042 2.29E−09 N.B. 1.79E−09 N.B. 0.08 0.14 ADI-21014 Infant 2042 4.08E−10 N.B. 3.78E−10 N.B. 0.05 0.17 ADI-21015 Infant 2042 4.41E−09 N.B. 3.24E−08 N.B. 1.46 1.15 ADI-21017 Infant 2042 3.05E−10 N.B. 1.56E−09 N.B. N.N. N.N. ADI-21018 Infant 2042 3.50E−10 N.B. 3.66E−10 N.B. 0.24 0.34 ADI-21019 Infant 2042 1.82E−10 1.54E−10 9.62E−10 1.68E−10 6.25 6.25 ADI-21021 Infant 2042 2.55E−09 N.B. 4.50E−09 N.B. N.N. N.N. ADI-21022 Infant 2042 N.B. 2.56E−10 1.74E−08 3.57E−10 N.N. N.N. ADI-21023 Infant 2042 2.64E−10 N.B. 3.16E−10 N.B. 0.12 0.26 ADI-21025 Infant 2042 2.42E−10 N.B. 2.95E−10 N.B. 0.09 0.19 ADI-21026 Infant 2042 6.35E−09 9.45E−10 3.99E−09 1.43E−09 N.N. N.N. ADI-21027 Infant 2042 2.96E−10 N.B. 3.40E−10 N.B. 0.13 0.27 ADI-21028 Infant 2042 5.45E−09 N.B. 3.33E−09 N.B. N.N. 9.09 ADI-21029 Infant 2042 3.77E−09 N.B. 8.38E−09 N.B. N.N. 0.96 ADI-21030 Infant 2042 2.57E−10 N.B. 3.01E−10 N.B. 0.16 0.26 ADI-21031 Infant 2042 1.07E−09 N.B. 1.50E−09 N.B. 0.31 3.36 ADI-21032 Infant 2042 2.96E−10 N.B. 3.44E−10 N.B. 0.10 0.30 ADI-21033 Infant 2042 1.93E−10 N.B. 1.40E−09 N.B. 4.64 9.20 ADI-21034 Infant 2042 1.45E−10 N.B. 1.74E−10 N.B. N.N. 7.30 ADI-21035 Infant 2042 1.03E−08 N.B. N.B. N.B. N.N. N.N. ADI-21036 Infant 2042 5.52E−09 N.B. N.B. N.B. N.N. N.N. ADI-21037 Infant 2042 1.95E−09 2.48E−10 4.81E−09 3.17E−09 N.N. N.N. ADI-21038 Infant 2042 2.93E−09 1.45E−09 1.60E−08 N.B. N.N. N.N. ADI-21039 Infant 2042 1.71E−09 2.40E−10 1.27E−08 6.31E−09 N.N. N.N. ADI-21040 Infant 2042 N.B. 7.77E−10 N.B. 1.03E−09 N.N. N.N. ADI-21041 Infant 2042 7.30E−09 N.B. N.B. N.B. N.N. N.N. ADI-21042 Infant 2042 2.96E−09 2.87E−10 1.18E−09 3.98E−10 N.N. N.N. ADI-21043 Infant 2042 1.11E−10 1.65E−09 1.54E−10 1.93E−09 0.19 0.08 ADI-21044 Infant 2042 4.51E−09 N.B. 5.85E−09 N.B. N.N. 2.13 ADI-21045 Infant 2042 4.56E−10 N.B. 5.96E−10 N.B. 0.04 0.09 ADI-21046 Infant 2042 1.66E−09 1.87E−10 6.94E−10 2.24E−10 N.N. N.N. ADI-21047 Infant 2042 2.11E−09 2.90E−10 7.56E−10 2.62E−10 N.N. N.N. ADI-21048 Infant 2042 1.11E−10 P.F. P.F. P.F. 0.08 0.16 ADI-21049 Infant 2042 3.97E−10 N.B. 1.27E−09 N.B. 0.62 0.56 ADI-21050 Infant 2042 3.62E−10 N.B. 3.23E−10 N.B. 0.08 0.12 ADI-21051 Infant 2042 2.92E−10 N.B. 3.35E−10 N.B. N.N. N.N. ADI-21052 Infant 2042 1.26E−10 1.84E−08 1.10E−10 P.F. 0.05 0.11 ADI-21053 Infant 2042 7.10E−08 6.37E−09 N.B. 1.18E−07 N.N. N.N. ADI-21054 Infant 2042 1.85E−10 3.72E−10 1.39E−10 3.06E−10 0.09 0.49 ADI-21055 Infant 2042 1.10E−09 1.85E−10 2.98E−09 4.35E−09 ND ND ADI-21056 Infant 2042 2.51E−10 7.22E−08 2.23E−10 6.34E−08 0.00 0.02 ADI-21057 Infant 2042 9.36E−10 N.B. 8.60E−10 N.B. 0.00 0.00 ADI-21058 Infant 2042 9.72E−10 N.B. 5.15E−10 N.B. 0.04 0.48 ADI-21059 Infant 2042 3.05E−09 N.B. 9.43E−09 N.B. N.N. 0.30 ADI-21060 Infant 2042 4.26E−10 N.B. 3.49E−10 N.B. 0.06 0.14 ADI-21061 Infant 2042 1.10E−09 1.42E−10 2.76E−09 2.48E−09 N.N. N.N. ADI-21062 Infant 2042 1.24E−09 2.36E−10 8.27E−10 4.17E−10 N.N. N.N. ADI-21063 Infant 2042 8.34E−10 N.B. 7.77E−10 N.B. 0.04 0.11 ADI-21064 Infant 2042 3.20E−10 N.B. 2.80E−10 N.B. 0.03 0.12 ADI-21065 Infant 2042 1.71E−10 N.B. P.F. N.B. N.N. N.N. ADI-21067 Infant 2042 3.98E−09 N.B 5.90E−09 N.B ND ND ADI-21068 Infant 2042 2.55E−10 1.55E−08 2.38E−10 7.85E−09 0.10 N.N. ADI-21069 Infant 2042 1.23E−10 P.F. 1.19E−10 P.F. 0.11 0.26 ADI-21070 Infant 2042 5.37E−09 N.B. 7.59E−09 N.B. N.N. 2.38 ADI-21071 Infant 2042 1.17E−09 2.16E−10 1.88E−09 1.38E−09 N.N. N.N. ADI-21072 Infant 2042 3.41E−10 N.B. 3.32E−10 N.B. 0.04 0.33 ADI-21073 Infant 2042 4.06E−09 5.80E−10 1.78E−09 6.75E−10 ND 11.15  ADI-21075 Infant 2042 4.07E−10 N.B. 5.15E−10 N.B. 0.03 0.48 ADI-21076 Infant 2042 2.19E−10 7.34E−09 1.96E−10 6.28E−09 0.03 0.30 ADI-21077 Infant 2042 4.28E−10 N.B. 3.83E−10 N.B. 0.06 0.06 ADI-21078 Infant 2042 3.11E−10 N.B. 3.07E−10 N.B. 0.03 0.20 ADI-21079 Infant 2042 3.13E−10 N.B. 3.08E−10 N.B. 0.20 0.29 ADI-21080 Infant 2042 3.60E−10 N.B. 3.72E−10 N.B. 0.10 0.17 ADI-21081 Infant 2042 2.84E−10 N.B. 2.77E−10 N.B. 0.10 0.32 ADI-21082 Infant 2042 2.85E−10 N.B. 2.81E−10 6.17E−09 0.09 0.25 ADI-21083 Infant 2042 2.25E−09 N.B. 2.65E−09 N.B. 0.36 0.79 ADI-21084 Infant 2042 1.09E−10 1.73E−08 1.04E−10 2.29E−08 0.14 0.46 ADI-21085 Infant 2042 3.07E−10 N.B. 3.09E−10 6.24E−09 0.10 0.48 ADI-21086 Infant 2042 2.90E−10 N.B. 2.76E−10 N.B. 0.11 0.47 ADI-21087 Infant 2042 N.B. 5.45E−10 N.B. 4.76E−10 N.N. N.N. ADI-21089 Infant 2042 2.82E−10 N.B. 2.62E−10 3.34E−09 0.27 0.17 ADI-21090 Infant 2042 1.17E−09 1.76E−10 4.89E−10 1.75E−10 ND ND ADI-21091 Infant 2042 7.49E−10 N.B. 1.39E−09 N.B. 0.29 0.92 Number of Number of Antigenic VH LC nucleotide nucleotide Site PSR germline germline substitutions substitutions Name Assignment Score gene usage gene usage in VH in VL ADI-25462 Site III 0.001 VH3-21 VL1-40 1 0 ADI-25467 Unknown 0.000 VH4-59 VK1-39 0 0 ADI-25468 Unknown 0.402 VH5-51 VL3-1 0 0 ADI-25472 Site III 0.000 VH3-21 VL1-40 0 0 ADI-25478 Site III 0.817 VH3-21 VL1-40 0 0 ADI-25479 Site III 0.373 VH3-21 VL1-40 0 0 ADI-25480 Site III 0.340 VH3-21 VL1-40 0 0 ADI-25484 Site III 0.000 VH3-21 VL1-40 0 0 ADI-25491 Site I 0.000 VH4-31 VL3-1 0 0 ADI-25495 Site III 0.000 VH3-21 VL2-14 0 1 ADI-25496 Unknown 0.000 VH3-21 VL1-40 0 0 ADI-25497 Site III 0.000 VH3-7 VK1D-16 0 0 ADI-25502 Site III 0.043 VH1-69 VL3-27 0 1 ADI-25503 Site III 0.277 VH1-69 VL3-1 0 0 ADI-25505 Site III 0.000 VH3-21 VL1-40 0 0 ADI-25514 Site II 0.493 VH1-69 VL3-1 0 0 ADI-25517 Site I 0.107 VH1-2 VL2-14 0 1 ADI-25518 Site I 0.116 VH1-2 VL2-14 0 1 ADI-25524 Site III 0.000 VH3-21 VL1-40 0 0 ADI-25532 Site III 0.000 VH3-21 VL1-40 0 0 ADI-25533 Site I 0.006 VH1-2 VL2-14 0 1 ADI-25542 Site I 0.000 VH3-23 VL8-61 0 0 ADI-25547 Unknown 0.000 VH3-53 VK1-12 0 0 ADI-25548 Unknown 0.010 VH3-53 VL2-11 0 0 ADI-25549 Site III 0.702 VH3-21 VL1-40 0 0 ADI-25555 Site III 0.029 VH3-21 VL1-40 0 0 ADI-25556 Site III 0.000 VH3-21 VL1-40 0 0 ADI-25557 Site III 0.000 VH3-21 VL1-40 0 0 ADI-25559 Site III 0.000 VH3-21 VL1-40 0 0 ADI-25562 Site III 0.105 VH3-11 VL1-40 0 0 ADI-25565 Site III 0.108 VH3-21 VL1-40 0 0 ADI-25567 Site I 0.000 VH4-34 VK4-1 0 0 ADI-25569 Site I 0.000 VH3-74 VL3-25 0 1 ADI-25572 Site IV 0.184 VH1-2 VK2-28 0 0 ADI-25573 Unknown 0.000 VH1-46 VL3-21 0 1 ADI-25575 Unknown 0.000 VH1-46 VL3-21 0 0 ADI-25576 Site I 0.000 VH3-74 VL6-57 0 0 ADI-25577 Site III 0.028 VH3-21 VL1-40 0 0 ADI-25587 Unknown 0.000 VH3-33 VL2-14 0 1 ADI-25588 Site III 0.100 VH3-21 VL1-40 0 0 ADI-25595 Site III 0.012 VH3-21 VL1-40 0 0 ADI-25598 Site I 0.106 VH4-39 VL3-25 5 1 ADI-19420 Site III 0.709 VH3-21 VL1-40 0 0 ADI-19421 Site III 0.120 VH3-30 VL2-14 0 1 ADI-19422 Site IV 0.102 VH3-30 VL3-21 0 0 ADI-19424 Site IV 0.020 VH3-66 VL3-21 4 0 ADI-19425 Site III 0.007 VH3-21 VL1-40 0 0 ADI-19426 Site IV 0.023 VH4-59 VL3-1 0 0 ADI-19427 Site III 0.022 VH3-21 VL1-40 3 4 ADI-19428 Site III 0.058 VH3-21 VL1-40 0 0 ADI-19429 Site I 0.616 VH4-39 VL1-40 0 0 ADI-19430 Site I 0.744 VH1-69 VK2-28 0 0 ADI-19431 Site III 0.068 VH3-21 VL1-40 0 0 ADI-19432 Site IV 0.000 VH1-46 VK1-05 0 0 ADI-19433 Site III 0.000 VH3-21 VL1-40 0 0 ADI-19435 Site I 0.000 VH4-61 VL3-01 0 1 ADI-19436 Site I 0.073 VH4-39 VL3-1 0 0 ADI-19437 Unknown 0.000 VH1-18 VK1-12 0 0 ADI-19439 Site III 0.000 VH3-23 VK1-05 0 0 ADI-19440 Site III 0.000 VH3-48 VL1-40 0 0 ADI-19441 Site I 0.417 VH1-69 VK1-39 0 0 ADI-19444 Site V 0.000 VH1-18 VK4-01 0 0 ADI-19445 Unknown 0.002 VH4-4 VL3-21 0 1 ADI-19447 Site III 0.029 VH4-39 VL3-01 0 0 ADI-19448 Site III 0.000 VH3-21 VL1-40 0 0 ADI-19449 Site III 0.142 VH3-21 VL1-40 0 0 ADI-19450 Unknown 0.000 VH3-23 VK1-05 0 0 ADI-19454 Site III 0.012 VH3-21 VL2-14 0 1 ADI-19455 Site III 0.007 VH3-21 VL1-40 0 0 ADI-19457 Site III 0.000 VH3-21 VL1-40 0 0 ADI-19458 Site III 0.101 VH3-21 VL1-40 3 0 ADI-19459 Site IV 0.026 VH3-66 VL3-21 0 0 ADI-19460 Site I 0.076 VH4-34 VK1-39 0 0 ADI-19461 Site II 0.000 VH3-11 VL3-21 0 0 ADI-19462 Site IV 0.000 VH2-5 VK1-5 0 0 ADI-19463 Unknown 0.065 VH4-304 VK4-1 0 0 ADI-19465 Site III 0.000 VH3-21 VL1-40 0 0 ADI-19506 Unknown 0.424 VH1-18 VK2-28 0 0 ADI-19507 Site III 0.000 VH3-21 VL1-40 0 0 ADI-19509 Site III 0.000 VH3-21 VL1-40 0 0 ADI-19510 Site III 0.108 VH3-21 N/A 6 2 ADI-19511 Unknown 0.444 VH2-5 VK1-17 0 0 ADI-24792 Site III 0.000 VH3-11 VL1-40 5 2 ADI-24793 Site I 0.000 VH5-51 VL6-57 1 2 ADI-24795 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24796 Unknown 0.000 VH3-33 VL3-1 0 0 ADI-24798 Site I 0.000 VH4-59 VL3-1 0 0 ADI-24799 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24800 Site III 0.843 VH3-21 VL1-40 0 2 ADI-24801 Site III 0.158 VH1-18 VL3-1 0 1 ADI-24803 Unknown 0.077 VH3-23 VK3-20 6 3 ADI-24805 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24807 Site I 0.083 VH4-39 VL3-1 0 0 ADI-24808 Site I 0.000 VH1-2 VL2-8 0 0 ADI-24811 Site IV 0.112 VH1-8 VL3-21 0 0 ADI-24812 Site V 0.000 VH3-23 VL3-25 4 1 ADI-24813 Site IV 0.000 VH3-9 VL1-40 0 0 ADI-24814 Site IV 0.117 VH3-30 VK3-20 2 3 ADI-24815 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24816 Site I 0.102 VH1-8 VL3-1 0 0 ADI-24817 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24818 Site I 0.000 VH1-2 VL2-14 0 1 ADI-24819 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24820 Unknown 0.248 VH1-69 VK1-39 0 0 ADI-24821 Site II 0.000 VH3-9 VL1-44 0 0 ADI-24822 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24823 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24824 Site III 0.000 VH4-59 VK1-8 0 0 ADI-24825 Unknown 0.338 VH1-8 VK2-28 0 0 ADI-24826 Site III 0.102 VH3-21 VL2-14 0 1 ADI-24827 Site 0 0.000 VH3-66 VK3-15 1 0 ADI-24828 Site III 0.109 VH3-21 VL1-40 9 2 ADI-24829 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24830 Site V 0.000 VH1-69 VK2-28 0 0 ADI-24831 Site III 0.164 VH3-21 VL1-40 0 0 ADI-24832 Site III 0.360 VH3-21 VL1-40 6 1 ADI-24833 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24834 Site I 0.293 VH3-23 VK1-5 1 1 ADI-24835 Site III 0.000 VH3-21 VL1-40 5 5 ADI-24836 Unknown 0.106 VH3-9 VK1-39 0 0 ADI-24837 Unknown 0.000 VH4-59 VL1-51 0 0 ADI-24838 Site III 0.122 VH3-21 VL1-40 0 0 ADI-24839 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24840 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24841 Unknown 0.144 VH1-3 VK3-15 0 0 ADI-24842 Site III 0.000 VH3-21 VL1-40 0 2 ADI-24843 Unknown 0.039 VH4-304 VK4-1 0 0 ADI-24845 Site III 0.000 VH3-21 VL2-14 0 0 ADI-24846 Unknown 0.000 VH3-21 VL1-47 0 0 ADI-24847 Unknown 0.012 VH3-21 VL1-40 1 0 ADI-24848 Site V 0.644 VH3-21 VL1-40 0 0 ADI-24849 Site 0 0.741 VH3-43 VK1-33 2 0 ADI-24850 Site III 0.574 VH3-21 VL1-40 0 0 ADI-24851 Site I 0.675 VH1-2 VL2-8 0 0 ADI-24852 Site IV 0.277 VH1-3 VL3-1 1 2 ADI-24854 Unknown 0.658 VH3-21 VL1-40 0 0 ADI-24855 Site III 0.600 VH3-21 VL1-40 0 0 ADI-24856 Site I 0.101 VH1-18 VK3-20 0 0 ADI-24857 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24858 Site III 0.119 VH3-21 VL1-40 0 0 ADI-24859 Site III 0.000 VH3-21 VL1-40 0 0 ADI-24860 Site III 0.000 VH3-11 VL1-40 4 2 ADI-24861 Site III 0.000 VH3-21 VL1-40 2 0 ADI-24862 Unknown 0.000 VH4-31 VL3-1 0 0 ADI-24863 Site III 0.000 VH3-21 VL1-40 1 0 ADI-19467 Site III 0.010 VH3-21 VL1-40 0 0 ADI-19468 Site I 0.000 VH4-39 VL6-57 0 0 ADI-19469 Site I 0.143 VH4-b VK3-11 0 0 ADI-19470 Site II 0.110 VH3-30 VL3-1 0 0 ADI-19471 Unknown 0.040 VH3-64 VL6-57 0 0 ADI-19473 Site I 0.063 VH5-51 VL6-57 0 0 ADI-19474 Site I 0.032 VH5-51 VL6-57 0 0 ADI-19475 Site V 0.000 VH1-18 VK2-30 10 2 ADI-19476 Unknown 0.093 VH2-5 VL2-11 2 3 ADI-19478 Unknown 0.033 VH4-39 VL1-36 5 2 ADI-19479 Unknown 0.012 VH1-69 VK2-30 2 3 ADI-19480 Site IV 0.012 VH3-21 VL6-57 6 3 ADI-19481 Unknown 0.000 VH3-43 VK1-39 1 3 ADI-19482 Site II 0.159 VH4-34 VK1-5 11 1 ADI-19483 Site IV 0.050 VH5-51 VL6-57 4 2 ADI-19484 Unknown 0.000 VH4-30 VK1-39 5 2 ADI-19485 Site I 0.039 VH4-31 VK3-15 11 3 ADI-19486 Site I 0.006 VH4-59 VL2-14 5 0 ADI-19487 Unknown 0.104 VH2-70 VK1-39 3 0 ADI-19488 Unknown 0.000 VH1-24 VK2-28 0 0 ADI-19489 Site IV 0.000 VH2-70 VK1-17 2 0 ADI-19490 Unknown 0.000 VH3-15 VK2-28 0 0 ADI-19491 Unknown 0.000 VH2-5 VL1-40 0 0 ADI-19492 Site IV 0.034 VH5-51 VL6-57 1 2 ADI-19493 Site I 0.037 VH4-34 VL3-1 0 0 ADI-19494 Site 0 0.065 VH1-69 VL2-14 4 1 ADI-19495 Unknown 0.047 VH4-59 VK1-12 0 0 ADI-19496 Unknown 0.000 VH3-30 VK4-1 1 1 ADI-19497 Site I 0.002 VH1-46 VL6-57 0 0 ADI-19498 Site I 0.045 VH3-66 VL3-25 1 0 ADI-19499 Site I 0.089 VH4-39 VL6-57 0 0 ADI-19500 Unknown 0.000 VH3-48 VK1-8 0 0 ADI-19501 Site V 0.000 VH1-18 VK2-30 6 2 ADI-19502 Unknown 0.000 VH3-30 VK4-1 5 2 ADI-19503 Site I 0.040 VH1-46 VL3-10 0 0 ADI-19505 Site IV 0.039 VH5-51 VL3-9 5 1 ADI-22756 Unknown 0.171 VH3-30 VK3-20 6 4 ADI-22757 Site V 0.000 VH1-18 VK2-30 7 4 ADI-22758 Site III 0.000 VH3-21 VL1-40 5 3 ADI-22759 Site III 0.018 VH3-21 VL1-40 9 3 ADI-22760 Site II 0.000 VH3-9 VL1-47 5 4 ADI-22762 Site I 0.000 VH6-1 VL1-40 7 4 ADI-22763 Site I 0.000 VH3-48 VK1-39 9 3 ADI-22764 Site I 0.336 VH4-4 VK1-39 5 12 ADI-22765 Site V 0.000 VH3-21 VL1-40 0 0 ADI-22766 Unknown 0.000 VH3-9 VL2-8 0 1 ADI-22767 Site III 0.033 VH3-21 VL1-40 0 0 ADI-22768 Site I 0.000 VH3-48 VK1-39 0 0 ADI-22769 Unknown 0.011 VH3-72 VL3-1 0 0 ADI-22770 Unknown 0.004 VH2-70 VL3-1 0 0 ADI-22771 Site III 0.010 VH3-21 VL1-40 0 0 ADI-22772 Unknown 0.000 VH3-30 VL3-1 0 0 ADI-22773 Site V 0.000 VH1-18 VK2-30 0 0 ADI-22774 Site III 0.000 VH3-21 VL1-40 0 4 ADI-22775 Unknown 0.000 VH3-33 VK1-12 4 2 ADI-22776 Unknown 0.000 VH3-11 VL3-21 0 0 ADI-22777 Site II 0.000 VH1-02 VL3-01 12 13 ADI-22778 Site I 0.109 VH4-59 VK1-39 12 7 ADI-22779 Site I 0.000 VH4-34 VK1-39 7 8 ADI-22780 Site III 0.004 VH4-31 VL2-14 0 2 ADI-22781 Site I 0.033 VH3-48 VL3-01 0 0 ADI-14333 Site III 0.046 VH3-21 VL1-40 7 4 ADI-14334 Site III 0.005 VH3-21 VL1-40 14 4 ADI-14335 Site IV 0.000 VH3-49 VK1-39 4 6 ADI-14336 Site V 0.005 VH1-18 VK2-30 4 5 ADI-14337 Site III 0.000 VH3-21 VL1-40 0 0 ADI-14338 Site I 0.000 VH3-30 VK1-39 13 3 ADI-14339 Site IV 0.040 VH3-30 VL3-25 14 4 ADI-14340 Site 0 0.050 VH3-21 VL3-21 7 5 ADI-14341 Unknown 0.111 VH3-48 VK1-5 7 1 ADI-14342 Site I 0.000 VH2-26 VK1-39 3 6 ADI-14343 Site I 0.003 VH1-69 VK2-28 8 5 ADI-14344 Unknown 0.113 VH3-23 VL3-1 8 7 ADI-14345 Site IV 0.059 VH1-24 VK1-39 9 1 ADI-14346 Site III 0.102 VH3-21 VL1-40 8 1 ADI-14347 Site III 0.040 VH3-21 VL1-40 6 1 ADI-14348 Site I 0.105 VH3-30 VL2-11 10 5 ADI-14349 Unknown 0.000 VH1-69 VK4-1 9 3 ADI-14350 Site II 0.027 VH4-61 VL1-40 13 2 ADI-14351 Site IV 0.027 VH3-74 VL3-21 9 3 ADI-14352 Unknown 0.142 VH4-304 VK3-20 5 3 ADI-14353 Site I 0.051 VH1-69 VL2-14 10 4 ADI-14354 Site I 0.069 VH1-69 VL2-14 8 6 ADI-14355 Site IV 0.038 VH2-5 VL2-14 4 7 ADI-14356 Site I 0.034 VH4-34 VL3-25 0 0 ADI-14357 Unknown 0.000 VH3-30 VK1-39 5 4 ADI-14358 Site I 0.103 VH3-11 VL2-14 7 12 ADI-14359 Site I 0.000 VH2-70 VK1-39 1 0 ADI-14360 Site IV 0.000 VH1-3 VK2-28 2 0 ADI-14361 Unknown 0.068 VH3-23 VL1-40 14 7 ADI-14362 Site I 0.389 VH3-23 VK1-39 2 1 ADI-14363 Site IV 0.000 VH3-11 VK3-20 6 4 ADI-14364 Site 0 0.104 VH5-51 VL3-21 3 0 ADI-14365 Site IV 0.000 VH1-24 VK1-39 8 4 ADI-14366 Unknown 0.000 VH1-18 VK1-39 8 8 ADI-14367 Unknown 0.000 VH3-23 VK3-20 10 2 ADI-14368 Site II 0.106 VH3-15 VL3-21 4 6 ADI-14369 Unknown 0.059 VH1-69 VL1-44 6 6 ADI-14370 Unknown 0.726 VH3-30 VL2-8 6 0 ADI-14371 Unknown 0.000 VH3-23 VK1-39 10 8 ADI-14372 Unknown 0.000 VH3-23 VK1-6 11 3 ADI-14373 Site I 0.000 VH4-34 VK3-15 4 0 ADI-14374 Unknown 0.103 VH3-43 VL3-21 6 13 ADI-14375 Unknown 0.019 VH3-23 VL1-40 10 6 ADI-14376 Site I 0.085 VH3-74 VL3-10 7 3 ADI-14377 Unknown 0.000 VH3-30 VK1-17 5 0 ADI-14378 Unknown 0.000 VH3-74 VK1-39 3 3 ADI-14379 Unknown 0.487 VH3-30 VL3-1 5 11 ADI-14380 Unknown 0.102 VH5-51 VL1-51 5 2 ADI-14381 Site I 0.009 VH3-48 VK1-6 7 1 ADI-14382 Site I 0.118 VH3-33 VL2-14 8 5 ADI-14383 Site II 0.100 VH2-5 VL2-23 6 4 ADI-14384 Site I 0.062 VH4-30 VL3-21 7 7 ADI-14385 Site I 0.028 VH5-51 VL6-57 0 1 ADI-14386 Site I 0.070 VH3-23 VL3-1 6 7 ADI-14388 Unknown 0.147 VH3-30 VL7-43 2 4 ADI-14389 Site I 0.181 VH3-15 VK1-39 12 6 ADI-14390 Unknown 0.129 VH4-b VL2-23 1 3 ADI-14391 Unknown 0.033 VH3-23 VL3-10 11 4 ADI-14392 Unknown 0.000 VH1-69 VK3-11 2 0 ADI-14393 Site III 0.199 VH3-21 VL1-40 14 4 ADI-14394 Site III 0.038 VH3-21 VL1-40 0 0 ADI-14395 Site IV 0.128 VH3-30 VK1-5 0 0 ADI-14396 Unknown 0.000 VH3-30 VK1-33 0 0 ADI-14397 Site IV 0.120 VH3-30 VK1-5 0 0 ADI-14399 Unknown 0.004 VH4-304 VK3-11 7 4 ADI-14400 Unknown 0.000 VH3-30 VK1-6 8 1 ADI-14401 Site III 0.005 VH3-21 VL1-40 9 4 ADI-14402 Site V 0.000 VH1-18 VK2-30 3 2 ADI-14403 Site III 0.010 VH3-11 VL1-40 7 4 ADI-14404 Unknown 0.037 VH3-48 VK1-5 7 5 ADI-14405 Site IV 0.031 VH1-18 VL3-21 11 5 ADI-14406 Site I 0.060 VH5-51 VK2-28 10 1 ADI-14407 Site I 0.000 VH3-33 VK1-39 5 7 ADI-14408 Site I 0.000 VH2-70 VK1-39 5 5 ADI-14409 Unknown 0.014 VH1-18 VK4-1 6 4 ADI-14410 Unknown 0.101 VH4-34 VL1-47 8 6 ADI-14411 Unknown 0.047 VH1-46 VK1-39 7 5 ADI-14412 Site IV 0.000 VH1-18 VK3-20 9 5 ADI-14413 Unknown 0.028 VH3-43 VL1-44 9 6 ADI-14414 Unknown 0.109 VH1-69 VK3-11 15 7 ADI-14415 Unknown 0.000 VH4-59 VK1-9 7 5 ADI-14416 Site IV 0.053 VH5-51 VL6-57 23 5 ADI-14417 Unknown 0.297 VH3-21 VK3-15 9 3 ADI-14418 Site II 0.000 VH1-69 VK1-5 10 3 ADI-14419 Unknown 0.325 VH3-30 VK3-20 9 1 ADI-14420 Site IV 0.000 VH3-43 VK1-5 4 3 ADI-14421 Unknown 0.055 VH5-51 VK3-15 20 2 ADI-14422 Site I 0.000 VH1-69 VL1-40 1 0 ADI-14423 Unknown 0.000 VH3-43 VK1-17 7 0 ADI-14424 Site II 0.051 VH5-51 VL6-57 16 9 ADI-14425 Site I 0.027 VH4-61 VL2-14 5 2 ADI-14426 Site I 0.072 VH3-30 VL3-19 8 5 ADI-14427 Site I 0.108 VH1-69 VL2-11 9 1 ADI-14428 Unknown 0.110 VH3-11 VL3-21 4 2 ADI-14654 Unknown 0.106 VH1-69 VL3-19 10 5 ADI-14655 Site I 0.000 VH3-15 VK1-39 0 0 ADI-14656 Site I 0.050 VH3-30 VL3-19 8 5 ADI-14657 Site IV 0.000 VH1-18 VK1-27 9 1 ADI-14658 Site I 0.040 VH3-33 VL2-14 0 1 ADI-14659 Unknown 0.000 VH3-11 VK3-20 9 10 ADI-14571 Unknown 0.000 VH1-69 VK1-9 10 1 ADI-14572 Unknown 0.148 VH3-15 VL1-44 4 3 ADI-14573 Unknown 0.031 VH1-18 VL3-21 7 3 ADI-14575 Site I 0.096 VH1-69 VL2-14 0 1 ADI-14576 Site V 0.000 VH1-18 VK2-30 0 0 ADI-14577 Site V 0.000 VH1-18 VK2-30 11 3 ADI-14578 Unknown 0.120 VH1-69 VL1-51 6 6 ADI-14579 Site I 0.117 VH5-51 VK1-27 2 0 ADI-14580 Unknown 0.000 VH1-69 VK4-1 12 3 ADI-14581 Unknown 0.000 VH1-69 VK3-15 13 3 ADI-14582 Site II 0.104 VH5-51 VL6-57 15 8 ADI-14583 Site V 0.000 VH1-18 VK2-30 10 4 ADI-14584 Unknown 0.000 VH1-18 VK1-39 20 2 ADI-14585 Site V 0.000 VH1-18 VK2-30 5 5 ADI-14586 Site III 0.000 VH3-11 VL1-40 0 0 ADI-14587 Site III 0.010 VH3-21 VL1-40 3 2 ADI-14588 Site IV 0.000 VH1-24 VK1-39 9 2 ADI-14589 Site I 0.000 VH2-26 VK1-39 6 8 ADI-14590 Site II 0.000 VH5-51 VK1-13 3 2 ADI-14591 Unknown 0.116 VH5-a VK1-39 7 4 ADI-14592 Site IV 0.083 VH5-51 VL6-57 12 4 ADI-14593 Site IV 0.017 VH5-51 VL6-57 7 4 ADI-14594 Unknown 0.030 VH1-18 VL3-21 10 2 ADI-14595 Site I 0.101 VH3-48 VK3-11 10 5 ADI-14596 Unknown 0.052 VH3-23 VK1-39 2 0 ADI-14597 Site IV 0.000 VH3-43 VK3-20 6 1 ADI-14598 Site I 0.000 VH1-69 VK1-27 8 1 ADI-14599 Site IV 0.092 VH3-49 VL6-57 7 2 ADI-14600 Site III 0.069 VH3-11 VL1-40 3 1 ADI-14601 Unknown 0.045 VH3-23 VK1-12 5 5 ADI-14602 Site IV 0.114 VH3-30 VL3-1 6 5 ADI-14603 Unknown 0.036 VH5-51 VK1-27 6 4 ADI-14604 Unknown 0.110 VH3-23 VL1-44 11 7 ADI-14605 Unknown 0.103 VH2-70 VL3-25 5 6 ADI-14606 Unknown 0.000 VH3-66 VK3-15 4 5 ADI-14607 Site IV 0.075 VH3-30 VL3-25 10 8 ADI-20959 Site V 0.000 VH1-18 VK2-30 7 5 ADI-20960 Site II 0.102 VH4-34 VK1-5 14 7 ADI-20961 Site III 0.059 VH3-21 VL1-40 20 5 ADI-20962 Site V 0.000 VH1-18 VK2-30 10 2 ADI-20963 Site I 0.051 VH3-21 VL3-21 17 9 ADI-20964 Site V 0.000 VH1-18 VK2-30 4 2 ADI-20965 site IV 0.109 VH1-18 VL3-21 11 6 ADI-20966 Site III 0.035 VH3-21 VL1-40 20 8 ADI-20967 Site I 0.000 VH3-30 VK2-28 11 1 ADI-20968 site IV 0.000 VH4-34 VK1-33 11 10 ADI-20969 Site III 0.094 VH3-21 VL1-40 13 6 ADI-20970 Unknown 0.000 VH3-15 VK1-33 3 5 ADI-20971 Site I 0.000 VH3-21 VK3-15 20 7 ADI-20972 Site I 0.103 VH4-34 VL2-14 13 5 ADI-20973 Site III 0.096 VH3-21 VL1-40 13 6 ADI-20974 Site III 0.107 VH3-21 VL1-40 18 6 ADI-20975 site IV 0.028 VH1-18 VL3-21 20 8 ADI-20976 Site I 0.000 VH3-23 VK1-39 33 10 ADI-20977 Unknown 0.000 VH3-23 VK3-20 3 1 ADI-20978 Site V 0.000 VH1-18 VK2-30 8 1 ADI-20979 Site 0 0.034 VH4-59 VL2-14 8 5 ADI-20980 Unknown 0.000 VH4-61 VK3-11 9 7 ADI-20981 Unknown 0.352 VH4-304 VK1-12 18 8 ADI-20982 Unknown 0.000 VH4-61 VK1-5 15 7 ADI-20983 Site I 0.000 VH3-64 VK1-33 13 5 ADI-20984 Site IV 0.026 VH1-24 VK1-39 23 32 ADI-20986 Site 0 0.000 VH3-7 VK3-20 9 6 ADI-20987 Unknown 0.000 VH3-33 VK3-20 7 2 ADI-20988 Site V 0.000 VH1-18 VK2-30 12 3 ADI-20989 Site I 0.000 VH4-4 VK1-39 9 9 ADI-20990 Site I 0.000 VH3-30 VK2-28 16 4 ADI-20991 Site III 0.022 VH3-11 VL1-40 8 2 ADI-20992 Site V 0.000 VH3-7 VK1-39 9 6 ADI-20993 Site I 0.135 VH3-30 VK2-28 13 7 ADI-20994 site IV 0.020 VH1-18 VL3-21 16 3 ADI-20995 Unknown 0.000 VH5-51 N/A 9 0 ADI-20996 Site I 0.015 VH2-70 VK1-39 3 8 ADI-20997 Site I 0.000 VH3-30 VK3-20 14 9 ADI-20998 Site 0 0.109 VH3-30 VL2-11 9 5 ADI-20999 Unknown 0.088 VH4-39 VL1-51 15 5 ADI-21000 Site I 0.000 VH2-26 VK1-39 12 4 ADI-21001 Site IV 0.000 VH4-39 VK4-1 10 1 ADI-21002 Site I 0.010 VH4-4 VK1-39 16 7 ADI-21003 Site IV 0.000 VH4-34 VK2-28 4 2 ADI-21004 Site IV 0.000 VH3-33 VK4-1 8 12 ADI-21005 Unknown 0.000 VH3-43 VK3-20 16 6 ADI-21006 Site III 0.000 VH2-5 VK2-30 6 8 ADI-21007 Site IV 0.082 VH1-46 VL6-57 12 3 ADI-21008 Site I 0.000 VH4-34 VK3-11 15 2 ADI-21009 Unknown 0.040 VH1-18 VL2-23 20 9 ADI-21010 Site III 0.000 VH3-33 VK1-5 15 6 ADI-21011 Site I 0.109 VH4-59 VK1-39 23 9 ADI-21012 Site I 0.018 VH2-70 VK1-39 7 7 ADI-21013 Site V 0.000 VH4-39 VK3-20 13 6 ADI-21014 Site 0 0.112 VH4-59 VK1-33 24 10 ADI-21015 Site IV 0.000 VH1-24 VK1-39 15 4 ADI-21017 Site V 0.000 VH1-18 VK2-30 8 4 ADI-21018 Site III 0.031 VH3-21 VL1-40 8 5 ADI-21019 Site IV 0.000 VH3-23 VK2-28 15 3 ADI-21021 Site IV 0.000 VH4-34 VK1-5 10 11 ADI-21022 Unknown 0.003 VH4-59 VL3-21 8 3 ADI-21023 Site III 0.060 VH3-21 VL1-40 16 8 ADI-21025 Site III 0.033 VH3-21 VL1-40 11 4 ADI-21026 Site I 0.225 VH4-31 VK4-1 9 7 ADI-21027 Site III 0.008 VH4-4 VL1-40 15 5 ADI-21028 Unknown 0.000 VH3-11 VK1-5 10 10 ADI-21029 Unknown 0.000 VH5-51 VK1-39 14 3 ADI-21030 Site III 0.060 VH3-11 VL1-40 12 8 ADI-21031 Unknown 0.004 VH4-61 VK3-11 21 7 ADI-21032 Site III 0.054 VH3-21 VL1-40 14 5 ADI-21033 Site 0 0.000 VH5-51 VK1-33 20 8 ADI-21034 Site I 0.015 VH5-a VK3-20 11 5 ADI-21035 Site I 0.033 VH1-18 VK1-5 14 8 ADI-21036 Site I 0.101 VH5-51 VL2-23 16 16 ADI-21037 Site I 0.122 VH3-30 VK2-28 13 4 ADI-21038 Site I 0.000 VH5-51 VK3-20 15 1 ADI-21039 Site I 0.102 VH1-46 VK2-28 11 0 ADI-21040 Unknown 0.046 VH4-4 VL1-40 14 6 ADI-21041 Unknown 0.000 VH3-43 VK1-39 3 3 ADI-21042 Site I 0.000 VH4-31 VK1-5 18 7 ADI-21043 Site I 0.059 VH1-18 VL3-21 8 4 ADI-21044 Unknown 0.000 VH5-51 VK1-39 16 6 ADI-21045 Site III 0.032 VH3-21 VL1-40 18 5 ADI-21046 Site IV 0.089 VH5-51 VL1-40 16 7 ADI-21047 Site IV 0.000 VH4-34 VK1-33 14 4 ADI-21048 site IV 0.087 VH1-18 VL3-21 8 3 ADI-21049 Site III 0.102 VH3-21 VL1-40 7 3 ADI-21050 Site V 0.000 VH1-18 VK2-30 10 7 ADI-21051 Unknown 0.000 VH4-61 VK3-11 14 6 ADI-21052 site IV 0.085 VH1-18 VL3-21 2 3 ADI-21053 Site I 0.027 VH4-31 VK1-39 37 1 ADI-21054 Site IV 0.000 VH3-30 VK1-5 21 9 ADI-21055 Site I 0.110 VH3-33 VL1-44 12 10 ADI-21056 Site III 0.020 VH3-21 VL1-40 15 6 ADI-21057 Site 0 0.000 VH5-51 VK3-15 13 1 ADI-21058 Site III 0.000 VH4-304 VK3-15 20 3 ADI-21059 Unknown 0.000 VH5-51 VK1-39 14 8 ADI-21060 Site III 0.105 VH3-11 VL1-40 26 6 ADI-21061 Site I 0.084 VH1-69 VL2-14 22 8 ADI-21062 Site I 0.000 VH3-21 VK1-39 20 9 ADI-21063 Site V 0.000 VH3-64 VK1-39 7 3 ADI-21064 Site V 0.000 VH1-18 VK2-30 16 3 ADI-21065 Unknown 0.000 VH3-23 VK3-20 7 2 ADI-21067 Site IV 0.000 VH4-34 N/A 11 0 ADI-21068 Site III 0.021 VH4-4 VL1-40 19 3 ADI-21069 site IV 0.000 VH1-18 VL3-21 16 5 ADI-21070 Site II 0.000 VH3-23 VK3-15 12 3 ADI-21071 Site I 0.019 VH3-33 VK1-39 14 7 ADI-21072 Site III 0.010 VH3-21 VL1-40 16 3 ADI-21073 Site I 0.000 VH3-48 VK1-39 18 8 ADI-21075 Site III 0.021 VH3-21 VL1-40 17 2 ADI-21076 Site III 0.015 VH3-21 VL1-40 16 7 ADI-21077 Site III 0.018 VH3-11 VL1-40 9 2 ADI-21078 Site III 0.017 VH3-11 VL1-40 10 5 ADI-21079 Site III 0.064 VH3-11 VL1-40 5 1 ADI-21080 Site III 0.006 VH3-11 VL1-40 16 2 ADI-21081 Site III 0.031 VH3-11 VL1-40 12 5 ADI-21082 Site III 0.004 VH3-21 VL1-40 13 5 ADI-21083 Site 0 0.101 VH4-4 VL2-11 12 6 ADI-21084 site IV 0.100 VH1-18 VL3-21 19 6 ADI-21085 Site III 0.167 VH3-21 VL1-40 9 6 ADI-21086 Site III 0.024 VH3-11 VL1-40 16 4 ADI-21087 Unknown 0.000 VH3-48 VK1-5 7 1 ADI-21089 Site III 0.065 VH3-21 VL1-40 11 3 ADI-21090 Site IV 0.000 VH3-11 VK3-15 28 6 ADI-21091 Site I 0.005 VH5-a VL1-51 13 6

Analysis of the relationship between binding affinity and neutralization potency demonstrated that the majority of highly potent neutralizing antibodies bound with high apparent affinity to preF (K_(D)<1.0 nM) and failed to bind to postF (FIG. 3D). In addition, although approximately 20% of the neutralizing antibodies isolated from infants ≥6 mo. recognized both preF and postF, this type of neutralizing antibody was very rare in infants <3 mo. (FIGS. 3D and 4B), demonstrating that nearly all neutralizing antibodies in very young infants are preF-specific.

Next, the polyreactivity of the infant antibodies was assessed using a previously described assay (Jain et al., 2017; Kelly et al., 2015; Xu et al., 2013). Although the fraction of medium-to-highly polyreactive antibodies was relatively low (≤15%) for all infants, there was a higher frequency of polyreactive antibodies in the infants <3 mo. compared to the infants ≥6 mo. (FIG. 5A). This result could be related to differences in tolerance mechanisms in these two infant populations or to the higher frequency of antibodies containing little to no SHM in the younger infants. In support of the latter hypothesis, stratification of the antibodies based on their SHM levels showed that 12% of antibodies that lacked SHM displayed medium-to-high levels of polyreactivity, compared with only 2% of antibodies that contained >5 VH gene substitutions (FIG. 5B). This result is consistent with a prior study showing that the process of affinity maturation can result in decreased polyreactivity of human antibodies (Reed et al., 2016).

Infant Antibody Responses are Focused Primarily on Two Antigenic Sites that have Different Neutralization Sensitivity

To define the epitopes targeted by the infant antibodies, each antibody was tested for competition with other known RSV F-specific antibodies and assigned to an antigenic site based on the resulting competition profile (FIGS. 6A and 6B). In the three youngest infants, responses were dominated by antibodies directed against site III, whereas in the other infants, a larger proportion of the responses were directed against site I, and in some cases site IV (FIG. 6B). The proportion of antibodies recognizing preF-specific sites Ø and V at the apex of the preF molecule was low, particularly in the three youngest infants. Interestingly, analysis of the VH and VL germline gene usage for the site I-directed antibodies revealed that over 25% of the antibodies that recognized site I utilized the VK1-39 light chain gene (FIG. 7A). Although these site I-directed antibodies utilized a variety of VH genes, many possessed a convergent CDR H3 motif, generated from recombination of the DH3-22 and JH-4 genes (FIG. 7C). In contrast, nearly 85% of antibodies that recognized site III utilized either the VH3-21/VL1-40 or the related VH3-11/VL1-40 germline gene pairing (FIG. 7B) and did not show evidence of a convergent CDR H3 sequence.

The majority of site III-directed antibodies were preF-specific and neutralizing, whereas antibodies that recognized site I preferentially bound to postF and tended to be weak or non-neutralizing (FIGS. 6C, 7D, and 7E). In infants <3 mo., 60% of antibodies that displayed highly potent neutralizing activity (IC₅₀<0.05 ug/ml) were directed against site III (FIG. 6C). Therefore, although antibodies against both sites I and III are readily elicited during natural RSV infection in infants, site III-directed antibodies can potently neutralize RSV whereas site I-directed antibodies are typically non-neutralizing.

Site III-Directed Antibodies can Potently Neutralize RSV in the Absence of SHM and are Present in the Naïve B Cell Repertoire

Next, the epitope specificities of the neutralizing antibodies that lacked SHM were analyzed (FIG. 8A). Of the 33 germline antibodies that displayed RSV-neutralizing activity, 27 targeted antigenic site III. Analysis of the index sort data revealed that approximately half of these antibodies originated from naïve b cells (IgG⁻IgA⁻CD27⁻) and the other half originated from memory B cells that expressed IgG, IgA, or CD27 (FIG. 8B). The identification of neutralizing site III-directed antibodies from B cells that lacked both SHM and classical memory B cell markers led to an investigation of the occurrence of these antibody specificities in the naïve B cell repertoire. Therefore, 112 and 19 antibodies from RSV F-reactive cord blood B cells and adult naïve B cells, respectively, were cloned and expressed. Due to the low affinity of naïve B cell-derived antibodies, only 22/112 (20%) antibodies sorted from cord blood and 9/19 (47%) antibodies from adult naïve B cells bound with measurable affinity to RSV F as full-length IgGs. However, 11/22 (50%) and 7/9 (78%) of the RSV F binding antibodies from cord blood and adult naïve B cells, respectively, utilized VH3-21/VL1-40 or VH3-11/VL1-40 germline gene pairing (FIG. 8C). Of these 18 antibodies, the 13 with binding affinities that allowed for analysis in a competition assay were all shown to recognize antigenic site III (Table 3). Antibodies derived from naïve B cells isolated from cord blood or the PMBCs of healthy adults were tested for competition with three control IgGs and displayed profiles consistent with recognition of antigenic site III. Results are expressed as the fold reduction in antigen binding in the presence of saturating concentrations of competitor Fab relative to an antigen-only control. N.D.; not determined due to low binding affinity.

TABLE 3 Naïve B cells that utilize the VH3-21/VL1-40 and VH3-11/VL1-40 gene pairs recognize site III Competitor Fab D25 MPE8 Motavizumab (Antigenic site ∅) (Antigenic site III) (Antigenic site II) Control D25 153 1 1 IgGs MPE8 1 228 20 Motavizumab 1 1 39 IgGs derived ADI-32365 8 11 19 from naïve ADI-28517 11 23 55 B cells ADI-32361 7 50 169 ADI-32367 7 13 35 ADI-31917 3 69 190 ADI-31918 2 11 30 ADI-31919 1 55 159 ADI-28537 3 52 156 ADI-31921 3 37 112 ADI-32360 2 128 416 ADI-32362 3 117 370 ADI-32363 2 176 537 ADI-32366 3 61 10 ADI-28522 N.D. N.D. N.D. ADI-31920 N.D. N.D. N.D. ADI-28523 N.D. N.D. N.D. ADI-28526 N.D. N.D. N.D. ADI-28527 N.D. N.D. N.D.

The apparent binding affinities of these antibodies for preF were relatively high, ranging from 1.0-60 nM (FIG. 8C). In addition, approximately 40% of these site-III directed antibodies displayed neutralizing activity, with IC₅₀s ranging from 1.5-4.0 μg/mL (FIG. 8C). In contrast, none of the naïve B cell-derived antibodies that utilized other germline gene combinations showed detectible neutralizing activity (FIG. 8C). Collectively, these results indicate that site III-directed antibodies can neutralize RSV in the absence of SHM and that these types of antibodies are present in the naïve B cell repertoire.

A Site I-Directed Non-Neutralizing Antibody Recognizes postF Using a Convergent CDR H3 Motif and Germline-Encoded Regions of the VK1-39 Light Chain

The structure of a site I-directed antibody, ADI-14359, in complex with postF was characterized to define the molecular determinants of the convergent antibody features (FIG. 9A) (Table 4).

TABLE 4 Crystallographic data collection and refinement statistics Prefusion RSV F + Postfusion RSV F + ADI-19425 ADI-19425 Fab + ADI-14359 Fab Fab AM22 Fab PDB ID 6APB 6APC 6APD Data collection Space group P2₁2₁2₁ P2₁2₁2₁ P4₁2₁2 Cell constants a, b, c (Å) 88.5, 99.0, 323.3 61.2, 66.5, 126.0 229.5, 229.5, 304.1 α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 Wavelength (Å) 1.1809 0.9792 0.9793 Resolution (Å)  51.1-3.0 (3.08-3.00)  26.1-1.7 (1.73-1.70)  50.9-4.1 (4.20-4.10) Unique reflections 57,978 (4,439)  57,347 (2,940)  64,175 (4,439)  R_(merge) 0.449 (1.662) 0.069 (0.328) 0.364 (1.545) R_(pim) 0.177 (0.650) 0.028 (0.153) 0.108 (0.443) I/σI 5.2 (1.6) 16.8 (4.2)  6.3 (1.9) CC_(1/2) 0.952 (0.564) 0.998 (0.930) 0.995 (0.609) Completeness (%) 100.0 (100.0) 99.9 (99.4)  99.9 (100.0) Redundancy 7.3 (7.4) 6.8 (5.5) 12.2 (13.0) Wilson B-factors 11.5 29.4 117.9 Refinement Resolution (Å)  51.1-3.0 (3.05-3.00)  26.1-1.7 (1.73-1.70)  50.9-4.1 (4.16-4.10) Unique reflections 57,820 (2,724)  57,181 (2,645)  64,084 (2,497)  R_(work)/R_(free) (%) 22.0/25.3 17.4/20.4 20.9/26.1 No. atoms Protein 13,264 3,233 30,005 Ligand/ion 42 10 — Water — 692 — B-factors Protein 37.2 15.9 167.2 Ligand/ion 76.5 21.3 — Water — 30.2 — R.m.s. deviations Bond lengths (Å) 0.004 0.003 0.003 Bond angles (°) 0.91 0.667 0.632 Ramachandran Favored (%) 95.9 97.5 95.1 Allowed (%) 3.8 2.1 4.7 Outliers (%) 0.4 0.5 0.2 Values in parentheses are for the highest-resolution shell.

The structure revealed that the CDR H3, generated from the convergent usage of DH3-22/JH-4, is inserted into a small groove near the top of the postF trimer (FIG. 9B) and makes a number of hydrogen bonds with postF residues in and around this groove (FIG. 9C). CDR H3 residues Tyr100c and Tyr100d (Kabat numbering), which are uncommon in D genes other than DH3-22, form hydrogen bonds with postF residues Glu31 and Glu378, respectively, which are located on the ridge surrounding the site I groove. The tip of the CDR H3 loop is composed of three small amino acids that allow the loop to fit into the groove and make hydrogen bonds with residues Lys42, Asp344, and Asn380 of postF. These small residues also allow the CDR H3 to stack against Trp314, which is positioned at the floor of the groove. In addition, ADI-14359 heavy chain residue Tyr100g, which is unique to the JH4 gene, stacks against Tyr49 in the light chain, which may help properly orient the CDR H3.

Antibodies that utilized this convergent CDR H3 also showed a strong bias towards pairing with the VK1-39 light chain gene. Several germline-encoded residues within CDR L1 and the framework region 3 of VK1-39 form hydrogen bonds with Glu31 on postF (FIG. 9C). In addition, Tyr92 at the start of the CDR L3 is a unique feature of VK1-39, and forms a hydrogen bond with Ser35 on the F2 subunit of postF. The light chain of ADI-14359 is predicted to clash substantially with β22 of preF, which rearranges during the transition to postF to allow formation of the six-helix bundle (FIG. 10 ). Therefore, preferential binding to postF by this type of antibody is mediated by the light chain.

Although site I-directed antibodies did not show convergent VH gene usage, the heavy chain utilized by ADI-14359 also makes critical interactions with postF (FIG. 9C). The only residue that is mutated from germline in ADI-14359, Arg50, forms a salt bridge with Asp52 in the CDR H2 and appears to assist in coordinating the electrostatic interaction between Asp52, Asp56 and Asp58 of the CDR H2 with Lys390 on postF. Arg50 also forms a hydrogen bond with light chain residue Tyr96, a residue that is unique to the IGK-J2 gene utilized by ADI-14359. To investigate the contribution of these VH gene-mediated interactions to binding, the binding affinity of ADI-14359 Fab and the germline reverted variant (R50L) to postF was measured using surface plasmon resonance (SPR). This analysis revealed that the affinity of the germline reverted variant was reduced by more than 30-fold (FIG. 9D). Also, it was found that substitution of Lys390 on postF with alanine (K390A) almost entirely ablated ADI-14359 binding (FIG. 9D). The presence of three acidic residues in the CDR H2 therefore appears to be critical for the interaction of ADI-14359 with postF. However, the contribution of the CDR H2 to binding may vary among other members of this group, since many of the VH germlines utilized lack this acidic motif.

A Site 111-Directed Neutralizing Antibody Utilizes Germline-Encoded Features of the VH3-21 and VL1-40 Genes for High-Affinity Recognition of preF

To investigate the molecular basis of preferential germline gene pairing in antibodies targeting site III, the crystal structure of ADI-19425 bound to a preF-stabilized variant of RSV F (PR-DM) was determined (FIGS. 11A and 12A, Table 4) (Krarup et al., 2015). This antibody, which was isolated from a 2.8-month old infant, showed potent neutralizing activity despite lacking SHM (Table 2, FIG. 12B). The structure revealed that the majority of contacts between ADI-19425 and preF are formed by the light chain, particularly Tyr31 in CDR L1 and Tyr91 in CDR L3, both of which contact the loop connecting α6 to α7 (FIG. 11B). Tyr91 is the only residue in the CDR L3 that directly interacts with F, although contacts between Asp94 and Ser96 may play a role in positioning this loop and preventing a steric clash between ADI-19425 and antigenic site II (α6-α7) of RSV F. Consistent with the structural analysis, substitution of Tyr31 or Tyr91 with alanine resulted in greater than 20- or 80-fold reductions in affinity, respectively, as measured by SPR (FIG. 11C).

In addition to the contacts formed by the light chain, CDR H2 contains a stretch of five consecutive serine residues that form a network of hydrogen bonds with Asp310 on β6 of preF. Notably, the VH3-11 germline gene, which has 92% sequence identity with VH3-21, was utilized by site III-directed antibodies at a much lower frequency than VH3-21 (11% compared with 76%). One explanation for this could be the presence of a tyrosine residue directly following the polyserine motif in VH3-21, but not VH3-11. The structure shows that this residue (Tyr56) is buried in a small groove neighboring antigenic site II (FIG. 11B). Consistent with these observations, substitution of Tyr56 with alanine resulted in a more than 150-fold decrease in affinity (FIG. 11C). Interestingly, although the VH3-48 germline gene also contains the polyserine motif and is present in the naïve B cell repertoire at approximately the same frequency as VH3-11 (DeKosky et al., 2013), only a single site III-directed antibody (ADI-19440) that utilizes VH3-48/VL1-40 was isolated (see Table 2).

The structure also shows that Tyr56 of ADI-19425 is buried in a small groove neighboring antigenic site II on preF (FIG. 11B). Consistent with these observations, substitution of Tyr56 with alanine resulted in a more than 150-fold decrease in affinity (FIG. 11C).

In contrast to the clear VH- and VL-specific features highlighted above, there were fewer restrictions on the sequences of the CDR H3s of site III antibodies, and sequence analysis demonstrated that the CDR H3s varied in length, with some preference towards usage of glycine, serine and tyrosine residues at positions 96-100c (FIG. 7C). The structure reveals that although the ADI-19425 CDR H3 buries approximately 250 Å of preF, it does not form hydrogen bonds or salt bridges with either protomer (FIG. 11B). Notably, the cross-neutralizing antibody MPEG, which has recently been structurally characterized (Wen et al., 2017), utilizes the V_(H)3-21 and V_(L)1-40 germline gene pair to recognize site III with a binding mode nearly identical to that of ADI-19425, despite substantial differences in the sequences of the two CDR H3s (FIGS. 12C and 12D). This is consistent with our observation that multiple CDR H3 sequences can be utilized by this family of antibodies to recognize preF.

Discussion

Although RSV causes substantial mortality in infants, little is known about the specificities and functional characteristics of the infant antibody response to natural RSV infection. Here, it is shown that infant antibody responses to RSV F differ substantially from those of healthy adults, not only in affinity and neutralization potency, but also in the patterns of epitope recognition. The infant responses were focused on two major regions of the RSV F trimer—antigenic sites I and III—neither of which are dominant in adult responses (Gilman et al., 2016). These differences were the most extreme in infants under three months of age, with infants older than six months exhibiting responses that began to resemble healthy adults. This observation is consistent with previous studies showing that the infant immune system begins to mature at around six months of age, but does not attain stable, adult-like characteristics until later in life, at around six years of age (IJspeert et al., 2016; Ridings et al., 1998).

The majority of antibodies that recognized antigenic site III utilized the same VH and VL germline gene pairing, but were not restricted in D- and J-gene usage. Importantly, a subset of these antibodies showed potent neutralizing activity despite containing little to no SHM. Approximately half of these antibodies were derived from memory B cells and the other half were derived from B cells that lacked surface expression of CD27, IgG and IgA, suggesting that they originated from naïve B cells.

Recent work has shown that polyclonal IgM antibodies purified from RSV naive infant sera are capable of neutralizing RSV and it was suggested that these antibodies may represent natural anti-RSV antibodies that react with the N- and O-linked glycans present on the RSV surface glycoproteins (Jans et al., 2016). However, unlike natural IgM antibodies—which rely on avidity, typically recognize common surface antigens, and exhibit some degree of polyreactivity (Panda and Ding, 2015)—the site III-directed antibodies described here bind with high affinity in an IgG backbone, specifically recognize an epitope on RSV F that lacks N-linked glycans, and generally show limited polyreactivity, suggesting that they are distinct from previously described natural antibodies. In addition, the presence of this class of antibodies in the memory compartment of older infants and adults indicates that these B cells can be activated in response to antigen exposure and undergo affinity maturation. Similar germline-mediated recognition in the adaptive immune response has also been described for other viral pathogens, including influenza (Ekiert et al., 2009; Kashyap et al., 2008; Sui et al., 2009; Throsby et al., 2008), hepatitis C virus (Bailey et al., 2017) and human cytomegalovirus (Thomson et al., 2008), and for bacterial pathogens such as Staphylococcus aureus (Yeung et al., 2016). The presence of functional germline antibodies in the human antibody repertoire has been proposed to serve as a type of innate humoral response to life-threatening pathogens that are likely to be encountered early in life (Lerner, 2011). The isolation of this class of antibodies from all seven infants studied here, as well as from cord blood B cells, adult naïve B cells, and memory B cells from previously characterized adult donors (Gilman et al., 2016), suggests that the naïve B cell precursors encoding these antibody specificities are likely present in most individuals. The results suggest that expansion of these cells may be a feasible goal for infant vaccination strategies (in contrast to, e.g., certain types of HIV-neutralizing antibodies, whose inferred germline precursors display limited reactivity with native HIV Env antigens only develop in a subset of HIV-1 infected individuals, and require complex vaccination strategies to elicit (Doria-Rose et al., 2010; Gray et al., 2011; Jardine et al., 2016; Sather et al., 2009; Simek et al., 2009; Sok et al., 2016; Yacoob et al., 2016)).

Antibody responses directed specifically against preF are associated with potent neutralization of RSV in human sera (Magro et al., 2012; Ngwuta et al., 2015), and monoclonal antibodies that bind exclusively to preF have been shown to be substantially more potent than antibodies that recognize both preF and postF (Corti et al., 2013; Gilman et al., 2016; Gilman et al., 2015; McLellan et al., 2013; Mousa et al., 2017). Interestingly, neutralizing antibodies that react with both preF and postF were identified in healthy adults and infants over 6 months old, but were almost entirely absent in the youngest infants analyzed here. Although postF antigens are capable of eliciting neutralizing antibodies that also bind to preF, their inability to elicit preF-specific antibodies would likely prove problematic for use in a young infant population. In addition, our results show that a large fraction of the infant antibody response (15-30%) is directed against antigenic site I, which is preferentially expressed on postF. Since antibodies targeting this site generally showed poor neutralizing activity, vaccination with a postF antigens could drive infant antibody responses toward ineffective recognition of RSV F. Recently, it was shown that formalin inactivated RSV (FI-RSV), the preparation that resulted in vaccine-enhanced disease when administered to infants in the 1960s, displays an abundance of postF on the surface of the virus (Killikelly et al., 2016). Although many factors contribute to the development of vaccine-enhanced disease (Acosta et al., 2015), the high abundance of postF on FI-RSV could result in the induction of high levels of site I-directed antibodies and a low fraction of neutralizing antibodies, which are properties previously associated with the formation of immune complexes that contribute to lung pathology in vaccine-enhanced illness (Murphy and Walsh, 1988; Polack et al., 2002).

An age-dependent increase in the response against antigenic sites Ø and V, which are both present near the apex of the preF trimer, was also observed. Although infant antibodies that targeted these epitopes tended to be potently neutralizing, they were present at low abundance in the responses analyzed here, particularly in infants under three months of age. These data suggest that although the presence of site Ø is likely important for generating neutralizing antibody responses later in life, eliciting a neutralizing response in young infants will likely depend on the presentation of antigenic site III. The observed differences in the dominant epitopes targeted by infant and adult responses provides a unique opportunity for prevention strategies that seek to combine passive and active immunization. For example, vaccines could be designed to preferentially elicit site III antibodies, which would not compete for binding with certain second-generation prophylactic antibodies that target antigenic site Ø, such as MEDI8897. In addition, antibodies elicited by a site-III-specific vaccine would not block access to the apex of the preF trimer on infectious virions, allowing the development of neutralizing antibodies directed against antigenic sites in this region to occur during natural RSV infection.

Materials & Methods

Human Subjects

Families of infants were approached at the time of hospitalization for documented RSV infection. At that point a Dartmouth Committee for the Protection of Human Subjects approved consent was signed to obtain 5-10 cc of blood approximately 1 month after discharge from the Children's Hospital at Dartmouth (CHaD). Families were contacted at the planned time for phlebotomy and arrangements made for blood to be drawn either at CHaD or at a medical facility closer to their home.

Plasma Neutralization Titers

Infant plasma samples were tested for RSV neutralization in microtiter assays using an RSV construct containing green fluorescent protein (GFP) and luciferase reporter genes (RSV-GFP1-Luc2, ViraTree). Hep2 cells were added to 96-well plates at a density of 1.8×10⁴ cells per well in 100 μL of MEM with 2% FBS/1X penicillin-streptomycin solution (2% MEM) and allowed to adhere overnight at 37° C. On the day of the assay, plasma samples were serially diluted two-fold (1:4 to 1:128,000) in 2% MEM containing RSV-GFP1-Luc2 and incubated for 1 hr at 37° C. Culture media was aspirated from the Hep2 cells followed by the addition of 100 μL/well of the plasma-RSV-GFP1-Luc2 mixture to triplicate wells. Cultures were maintained at 37° C. for 24 hrs and luciferase expression was quantified in cell lysates using the Renilla-Glo® assay system (Promega). Relative light units (RLU) were measured on a BioTek Synergy 2 microplate reader. Neutralization is expressed as the reciprocal of the highest plasma dilution to yield a 60% reduction in RLU as compared to control wells with no added plasma

Production of RSV F Sorting Probes

To generate sorting probes with high avidity, and uniformly oriented F proteins, preF (DS-Cav1) and postF (F ΔFP) trimers with a single biotinylated C-terminal AviTag were produced before coupling to streptavidin-PE or -APC (Gilman et al., 2016).

Single B-Cell Sorting from Infants Less than 3 Months of Age

Peripheral blood mononuclear cells from RSV-infected infants were stained using anti-human IgG (BV605), IgA (FITC), CD27 (BV421), CD8 (PerCP-Cy5.5), CD14 (PerCP-Cy5.5), CD19 (PECy7), CD20 (PECy7) and a mixture of dual-labeled preF and postF tetramers (50 nM each). For naïve B cell sorting, cord blood or peripheral blood mononuclear cells were stained with anti-human IgG (BV605), IgM (FITC), CD27 (BV421), CD8 (PerCP-Cy5.5), CD14 (PerCP-Cy5.5), CD19 (PECy7), CD20 (PECy7) and a mixture of dual-labeled preF and postF tetramers (50 nM each). Tetramers were prepared fresh for each experiment. Single cells were sorted on a BD fluorescence-activated cell sorter Aria II into 96-well PCR plates (BioRad) containing 20 μL/well of lysis buffer [5 μL of 5X first strand cDNA buffer (Invitrogen), 0.25 μL RNaseOUT (Invitrogen), 1.25 μL dithiothreitol (Invitrogen), 0.625 μL NP-40 (New England Biolabs), and 12.6 μL dH2O]. Plates were immediately frozen on dry ice before storage at −80° C.

Amplification and Cloning of Antibody Variable Sequences

Single B cell PCR and cloning were performed as described previously (Gilman et al., 2016). Briefly, antibody variable genes were amplified by RT-PCR and PCR reactions using cocktails of IgG⁻ and IgA⁻ specific primers and then cloned into S. cerevisiae using the lithium acetate method for chemical transformation (Gietz and Schiestl, 2007). Transformation reactions contained 20 μL of unpurified heavy chain and light chain PCR product and 200 ng of digested heavy and light chain plasmids. After transformation, yeast cells were plated and individual yeast colonies were picked for sequencing and characterization.

Production of Full-Length Human Antibodies

Anti-RSV F IgGs were expressed in S. cerevisiae as described previously (Gilman et al., 2016). Briefly, S. cerevisiae cultures were grown in 24-well plates, and after six days of growth the yeast culture supernatants were harvested by centrifugation and purified over protein A.

High-Throughput Antibody Affinity Measurements

IgG binding affinities for preF and postF were determined by BLI measurements as described previously (Gilman et al., 2016).

Antibody Competition Experiments

Antibody competition assays were performed as previously described (Gilman et al., 2016). The degree of competition was analyzed by measuring the fold reduction in antigen binding in the presence of competitor Fab relative to an antigen-only control. Antibodies that showed a greater than five-fold reduction in binding in the presence of competitor Fab were considered competitors.

Polyreactivity Assay

Antibody polyreactivity was performed essentially as described previously (Jain et al., 2017). Yeast-expressed IgGs were incubated with biotinylated CHO cell membrane preparations and incubated on ice for 20 minutes. Cells were then washed and re-suspended in secondary antibody mix (Extravidin-R-PE, anti-human LC-FITC, and propidium iodide). The mixture was incubated on ice for 20 minutes and then washed twice with PBSF. Cells were then re-suspended in PBSF and run on a FACSCanto II (BD Biosciences). The mean fluorescence intensities of binding were normalized using control antibodies that display high, medium, or low polyreactivity to assess non-specific binding.

High-Throughput Fluorescence Plate Reader Neutralization Assay

A total of 2.4×10⁴ HEp-2 cells/well in 30 μL culture medium were seeded in 384-well black optical-bottom plates (Nunc®384-well plates, Thermo Scientific). Antibodies were diluted four-fold starting at 100 μg/mL. An equal volume of recombinant mKate-RSV A2 or mKate-RSV B 18537 was then added and incubated at 37° C. for 1 hour. After incubation, 50 μl of the antibody-virus mixture was added to the HEp-2 cells and incubated at 37° C. for 22-24 hours. After incubation, the fluorescence intensity of each well was measured using a microplate reader at an excitation of 588 nm and an emission of 635 nm (SpectraMax Paradigm). Neutralization IC₅₀s were calculated using GraphPad Prism (GraphPad Software Inc.).

Production of ADI-14359, ADI-19425, and AM22 Fabs and Variants

Plasmids encoding the heavy and light chains of ADI-14359, ADI-19425 or AM22 were co-transfected at a 1:1 ratio into Expi293F cells. Point mutants were generated using MegaPrimer PCR and were expressed in FreeStyle 293-F cells. Fabs were purified using CaptureSelect IgG-CH1 affinity matrix (Life Technologies) and were further purified by size-exclusion chromatography on a Superdex 200 column (GE Healthcare).

Production of Protein Complexes for Crystallization

A mammalian expression vector encoding RSV F ΔFP (postF) with a C-terminal HRV 3C cleavage site, 8X HisTag and StrepTagII was transfected into FreeStyle 293-F cells and 5 μM kifunensine was added approximately 4 hours after transfection. The secreted protein was purified using Strep-Tactin resin (IBA), then treated with 10% (wt/wt) EndoH to remove N-linked glycans, followed by 10 U/mg of HRV 3C to remove tags. The protein was then purified by size-exclusion chromatography using a Superdex 200 column (GE) in buffer containing 2 mM Tris pH 8, 200 mM NaCl and 0.02% NaN₃.

To produce the ADI-14359 Fab-postF complex, purified F ΔFP was combined with a 1.5-fold molar excess of ADI-14359 Fab and incubated at room temperature for approximately 30 minutes. Excess Fab was separated from the complex by size-exclusion chromatography using a Superose 6 column (GE Healthcare Biosciences) in buffer containing 2 mM Tris pH 8, 200 mM NaCl and 0.02% NaN₃. The complex eluted with a retention volume indicative of a complex with 1-2 Fabs bound per postF trimer, suggesting that ADI-14359 Fab may bind sub-stoichiometrically to postF.

To produce the ADI-19425-AM22-preF ternary complex, purified PR-DM was combined with a 1.5-fold molar excess of both ADI-19425 Fab and AM22 Fab. Binding took place at room temperature for roughly 30 minutes before the ternary complex and excess Fab were separated by size-exclusion chromatography using a Superdex 200 column (GE Healthcare) in 2 mM Tris pH 8, 200 mM NaCl and 0.02% NaN₃.

Crystallization and Data Collection

The ADI-14359 Fab-postF complex was crystallized by the hanging-drop vapor-diffusion method by mixing 1.33 μL of protein at a concentration of 4.45 mg/mL with 0.67 μL of reservoir solution composed of 13% polyethylene glycol (PEG) 8000 and 0.43 M ammonium citrate pH 8.5. Cryo-preservation was performed by hanging the looped crystal over a 1 M sodium chloride solution for approximately 2 minutes prior to plunge freezing in liquid nitrogen. Data were collected to 3.0 Å resolution at SSRL (Stanford Synchrotron Radiation Lightsource, National Accelerator Laboratory)

The unbound ADI-19425 Fab was initially crystallized using the sitting-drop vapor-diffusion method using 50 nL protein at 8.78 mg/ml and 100 nL reservoir solution containing 2.0 M ammonium sulfate and 0.1 M HEPES pH 7.5. These crystals were used to generate a seek solution and the final crystals were obtained using 50 nL protein at 8.78 mg/ml, 50 nL seed solution and 100 nL reservoir solution containing 1.5 M ammonium sulfate, 0.1 M sodium chloride, and 0.1 M Bis-Tris pH 6.5. Crystals were soaked in a solution of reservoir containing a final concentration of 2.5 M ammonium sulfate before being frozen in liquid nitrogen. Data were collected to 1.7 Å resolution at the SBC beamline 19-ID (Advanced Photon Source, Argonne National Laboratory).

The ADI-19425-AM22-preF ternary complex was crystallized by the sitting-drop vapor-diffusion method using 100 nL of protein solution at a concentration of 4.80 mg/mL and 100 nL of reservoir solution containing 0.1 M sodium citrate pH 5.5, 10% isopropanol and 10% PEG4000. Crystals were soaked in a cryoprotectant solution containing reservoir solution plus 15% 2R,3R-butanediol before being frozen in liquid nitrogen. Data were collected to 4.3 Å at the SBC beamline 19-ID (Advanced Photon Source, Argonne National Laboratory).

Structure Determination, Model Building and Refinement

Diffraction data were indexed and integrated using iMOSFLM (Battye et al., 2011) and merged and scaled with AIMLESS (Evans and Murshudov, 2013). Molecular replacement solutions were obtained with PHASER (McCoy et al., 2007) and the structures were refined using PHENIX (Adams et al., 2002) and built manually using Coot (Emsley and Cowtan, 2004). Software used for processing and visualization of X-ray diffraction data was curated by SBGrid and accessed using the CCP4i interface (Collaborative Computational Project, 1994; Morin et al., 2013; Potterton et al., 2003). Data collection and refinement statistics for the three crystal structures are presented in Table 2.

The ADI-14359-postF complex formed crystals in space group P2₁2₁2₁ and a molecular replacement solution was found using the previously solved postF structure (PDB ID: 3RRT), the heavy chain from 2D1 Fab (PDB ID: 3QHZ), and the light-chain from 5-51/O12 Fab (PDB ID: 4KMT) as search models. The asymmetric unit contained one postF trimer with only one ADI-14359 Fab bound per trimer. The model was built manually in Coot and refined in PHENIX using non-crystallographic symmetry (NCS) and reference model restraints to an Rwork/Rfree of 22.0/25.3%.

The unbound ADI-19425 Fab also formed crystals in P212121, and the heavy chain from MJ5 Fab (PDB ID: 3EYQ) and the light chain from LDLR competitive Fab (PDB ID: 3H42) were used as search models in molecular replacement. The structure was manually built in Coot and refined in PHENIX to an Rwork/Rfree of 17.4/20.4%. The ADI-19425-AM22-preF complex formed crystals in space group P41212 and a molecular replacement solution was found using the refined structures of the unbound ADI-19425 Fab and the complex of preF bound to AM22 Fab as search ensembles. The asymmetric unit contained a single preF trimer bound by three molecules of AM22 Fab and three molecules of 19425 Fab. The model was built manually in Coot and refined in PHENIX using non-crystallographic symmetry (NCS) and reference model restraints to an Rwork/Rfree of 22.2/25.5%.

Fab Affinity Measurements for ADI-14359, ADI-19425, and Variants

The affinity of ADI-14359 Fab for postF was measured using surface plasmon resonance (SPR). Purified postF (RSV F ΔFP) with a C-terminal HRV 3C cleavage site, 8X HisTag and StrepTagII was captured on the sample flow cell of an NTA sensor chip to approximately 115 RU per cycle using a Biacore X100 (GE Healthcare). The NTA chip was regenerated between each cycle with

0.35 M EDTA followed by 0.5 mM NiCl₂. A buffer-only reference sample (HBS-P+pH 8) was injected over both flow cells, followed by a 2-fold serial dilution of ADI-14359 Fab from 800 nM to 6.25 nM, starting with the lowest concentration, and a duplication of the 100 nM sample. The data were double-reference subtracted, then fit to a 1:1 binding model using Scrubber. Binding of ADI-14359 Fab to the postF K390A variant was measured in a similar manner, with capture of approximately 100 RU per cycle and injection of a buffer-only reference, followed by a 2-fold serial dilution of Fab from 1.6 μM to 6.25 nM, with a duplication of the 100 nM concentration. The data were double-reference subtracted, but the total response was too low to allow an affinity to be calculated. For the germline variant of ADI-14359 (R50L), approximately 115 RU of postF was captured on the NTA chip before injection of a buffer-only reference, followed by a 2-fold serial dilution of ADI-14359 R50L Fab from 20 μM to 78 nM. The data were double reference subtracted and fit using a steady-state affinity model in Scrubber.

Similar SPR experiments were performed to measure the binding between ADI-19425 Fab and preF. Purified preF (DS-Cav1) with a C-terminal 8X HisTag and AviTag was captured on the sample flow cell of an NTA sensor chip to approximately 150 RU. A buffer-only reference sample (HBS-P+pH 8.0) was injected over both the sample and reference flow cells, followed by a 2-fold serial dilution of ADI-19425 Fab from 40 nM to 1.25 nM, with a duplication of the 10 nM concentration. For the ADI-19425 Fab variants (heavy chain Y56A, light chain Y31A, and light chain Y91A), roughly 150 RU of preF was captured on the NTA chip before the injection of a buffer-only reference, followed by a 2-fold serial dilution of ADI-19425 Fab variant from 1000 nM to 31.25 nM, with a duplication of the 250 nM concentration. The data were double reference subtracted and fit using a 1:1 binding model in Scrubber.

Data Resources

Antibody sequences will be deposited in GenBank. Atomic coordinates and structure factors for the 14359-postF complex structure, the unbound 19425 Fab, and the 19425-AM22-preF complex structure have been deposited with the Protein Data Bank under accession codes 6APB, 6APC, and 6APD.

REFERENCES

All references cited herein including, without limitation, patents, patent applications, and non-patent references and publications referenced throughout, are hereby expressly incorporated by reference in their entireties for all purposes.

-   Acosta, P. L., Caballero, M. T., and Polack, F. P. (2015). Brief     History and Characterization of Enhanced Respiratory Syncytial Virus     Disease. Clin Vaccine Immunol 23, 189-195. -   Adams, P. D., Grosse-Kunstleve, R. W., Hung, L. W., Ioerger, T. R.,     McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C.,     Sauter, N. K., and Terwilliger, T. C. (2002). PHENIX: building new     software for automated crystallographic structure determination.     Acta Crystallogr D Biol Crystallogr 58, 1948-1954. -   Anderson, L. J., Dormitzer, P. R., Nokes, D. J., Rappuoli, R., Roca,     A., and Graham, B. S. (2013). Strategic priorities for respiratory     syncytial virus (RSV) vaccine development. Vaccine 31 Suppl 2,     B209-215. -   Anderson, L. J., Hierholzer, J. C., Stone, Y. O., Tsou, C., and     Fernie, B. F. (1986). Identification of epitopes on respiratory     syncytial virus proteins by competitive binding immunoassay. J Clin     Microbiol 23, 475-480. -   Bailey, J. R., Flyak, A. I., Cohen, V. J., Li, H., Wasilewski, L.     N., Snider, A. E., Wang, S., Learn, G. H., Kose, N., Loerinc, L., et     al. (2017). Broadly neutralizing antibodies with few somatic     mutations and hepatitis C virus clearance. JCI Insight 2. -   Battles, M. B., Langedijk, J. P., Furmanova-Hollenstein, P.,     Chaiwatpongsakorn, S., Costello, H. M., Kwanten, L., Vranckx, L.,     Vink, P., Jaensch, S., Jonckers, T. H., et al. (2016). Molecular     mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem     Biol 12, 87-93. -   Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R., and     Leslie, A. G. (2011). iMOSFLM: a new graphical interface for     diffraction-image processing with MOSFLM. Acta Crystallogr D Biol     Crystallogr 67, 271-281. -   Beeler, J. A., and van Wyke Coelingh, K. (1989). Neutralization     epitopes of the F glycoprotein of respiratory syncytial virus:     effect of mutation upon fusion function. J Virol 63, 2941-2950. -   Bornholdt, Z. A., Turner, H. L., Murin, C. D., Li, W., Sok, D.,     Souders, C. A., Piper, A. E., Goff, A., Shamblin, J. D., Wollen, S.     E., et al. (2016). Isolation of potent neutralizing antibodies from     a survivor of the 2014 Ebola virus outbreak. Science 351, 1078-1083. -   Chin, J., Magoffin, R. L., Shearer, L. A., Schieble, J. H., and     Lennette, E. H. (1969). Field evaluation of a respiratory syncytial     virus vaccine and a trivalent parainfluenza virus vaccine in a     pediatric population. Am J Epidemiol 89, 449-463. -   Collaborative Computational Project, N. (1994). The CCP4 suite:     programs for protein crystallography. Acta Crystallogr D Biol     Crystallogr 50, 760-763. -   Corti, D., Bianchi, S., Vanzetta, F., Minola, A., Perez, L., Agatic,     G., Guarino, B., Silacci, C., Marcandalli, J., Marsland, B. J., et     al. (2013). Cross-neutralization of four paramyxoviruses by a human     monoclonal antibody. Nature 501, 439-443. -   Crooks, G. E., Hon, G., Chandonia, J. M., and Brenner, S. E. (2004).     WebLogo: a sequence logo generator. Genome Res 14, 1188-1190. -   DeKosky, B. J., Ippolito, G. C., Deschner, R. P., Lavinder, J. J.,     Wine, Y., Rawlings, B. M., Varadarajan, N., Giesecke, C., Dorner,     T., Andrews, S. F., et al. (2013). High-throughput sequencing of the     paired human immunoglobulin heavy and light chain repertoire. Nat     Biotechnol 31, 166-169. -   Doria-Rose, N. A., Klein, R. M., Daniels, M. G., O'Dell, S., Nason,     M., Lapedes, A., Bhattacharya, T., Migueles, S. A., Wyatt, R. T.,     Korber, B. T., et al. (2010). Breadth of human immunodeficiency     virus-specific neutralizing activity in sera: clustering analysis     and association with clinical variables. J Virol 84, 1631-1636. -   Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H.,     Jongeneelen, M., Throsby, M., Goudsmit, J., and Wilson, I. A.     (2009). Antibody recognition of a highly conserved influenza virus     epitope. Science 324, 246-251. -   Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for     molecular graphics. Acta Crystallogr D Biol Crystallogr 60,     2126-2132. -   Esposito, S., Scarselli, E., Lelii, M., Scala, A., Vitelli, A.,     Capone, S., Fornili, M., Biganzoli, E., Orenti, A., Nicosia, A., et     al. (2016). Antibody response to respiratory syncytial virus     infection in children <18 months old. Hum Vaccin Immunother 12,     1700-1706. -   Evans, P. R., and Murshudov, G. N. (2013). How good are my data and     whatis the resolution? Acta Crystallogr D Biol Crystallogr 69,     1204-1214. -   Fuentes, S., Coyle, E. M., Beeler, J., Golding, H., and Khurana, S.     (2016). Antigenic Fingerprinting following Primary RSV Infection in     Young Children Identifies Novel Antigenic Sites and Reveals Unlinked     Evolution of Human Antibody Repertoires to Fusion and Attachment     Glycoproteins. PLoS Pathog 12, e1005554. -   Fulginiti, V. A., Eller, J. J., Sieber, O. F., Joyner, J. W.,     Minamitani, M., and Meiklejohn, G. (1969). Respiratory virus     immunization. I. A field trial of two inactivated respiratory virus     vaccines; an aqueous trivalent parainfluenza virus vaccine and an     alum-precipitated respiratory syncytial virus vaccine. Am J     Epidemiol 89, 435-448. -   Gans, H., Yasukawa, L., Rinki, M., DeHovitz, R., Forghani, B.,     Beeler, J., Audet, S., Maldonado, Y., and Arvin, A. M. (2001).     Immune responses to measles and mumps vaccination of infants at 6,     9, and 12 months. J Infect Dis 184, 817-826. -   Garcia-Barreno, B., Palomo, C., Penas, C., Delgado, T., Perez-Brena,     P., and Melero, J. A. (1989). Marked differences in the antigenic     structure of human respiratory syncytial virus F and G     glycoproteins. J Virol 63, 925-932. -   Gietz, R. D., and Schiestl, R. H. (2007). High-efficiency yeast     transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc     2, 31-34. -   Gilman, M. S., Castellanos, C. A., Chen, M., Ngwuta, J. O., Goodwin,     E., Moin, S. M., Mas, V., Melero, J. A., Wright, P. F., Graham, B.     S., et al. (2016). Rapid profiling of RSV antibody repertoires from     the memory B cells of naturally infected adult donors. Sci Immunol     1. -   Gilman, M. S., Moin, S. M., Mas, V., Chen, M., Patel, N. K., Kramer,     K., Zhu, Q., Kabeche, S. C., Kumar, A., Palomo, C., et al. (2015).     Characterization of a Prefusion-Specific Antibody That Recognizes a     Quaternary, Cleavage-Dependent Epitope on the RSV Fusion     Glycoprotein. PLoS Pathog 11, e1005035. -   Glezen, W. P., Taber, L. H., Frank, A. L., and Kasel, J. A. (1986).     Risk of primary infection and reinfection with respiratory syncytial     virus. Am J Dis Child 140, 543-546. -   Graham, B. S. (2017). Vaccine development for respiratory syncytial     virus. Curr Opin Virol 23, 107-112. -   Gray, E. S., Madiga, M. C., Hermanus, T., Moore, P. L., Wibmer, C.     K., Tumba, N. L., Werner, L., Mlisana, K., Sibeko, S., Williamson,     C., et al. (2011). The neutralization breadth of HIV-1 develops     incrementally over four years and is associated with CD4+ T cell     decline and high viral load during acute infection. J Virol 85,     4828-4840. -   Griffin, M. P., Khan, A. A., Esser, M. T., Jensen, K., Takas, T.,     Kankam, M. K., Villafana, T., and Dubovsky, F. (2017). Safety,     Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory     Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an     Extended Half-Life, in Healthy Adults. Antimicrob Agents Chemother     61. -   Group, T. I.-R. S. (1998). Palivizumab, a humanized respiratory     syncytial virus monoclonal antibody, reduces hospitalization from     respiratory syncytial virus infection in high-risk infants.     Pediatrics 102, 531-537. -   Hall, C. B., Walsh, E. E., Long, C. E., and Schnabel, K. C. (1991).     Immunity to and frequency of reinfection with respiratory syncytial     virus. J Infect Dis 163, 693-698. -   Henderson, F. W., Collier, A. M., Clyde, W. A., Jr., and     Denny, F. W. (1979). Respiratory-syncytial-virus infections,     reinfections and immunity. A prospective, longitudinal study in     young children. N Engl J Med 300, 530-534. -   Homaira, N., Rawlinson, W., Snelling, T. L., and Jaffe, A. (2014).     Effectiveness of Palivizumab in Preventing RSV Hospitalization in     High Risk Children: A Real-World Perspective. Int J Pediatr 2014,     571609. -   Huang, K., Incognito, L., Cheng, X., Ulbrandt, N.D., and Wu, H.     (2010). Respiratory syncytial virus-neutralizing monoclonal     antibodies motavizumab and palivizumab inhibit fusion. J Virol 84,     8132-8140. -   IJspeert, H., van Schouwenburg, P. A., van Zessen, D.,     Pico-Knijnenburg, I., Driessen, G. J., Stubbs, A. P., and van der     Burg, M. (2016). Evaluation of the Antigen-Experienced B-Cell     Receptor Repertoire in Healthy Children and Adults. Front Immunol 7,     410. -   Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J.     H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017).     Biophysical properties of the clinical-stage antibody landscape.     Proc Natl Acad Sci USA 114, 944-949. -   Jans, J., Pettengill, M., Kim, D., van der Made, C., de Groot, R.,     Henriet, S., de Jonge, M. I., Ferwerda, G., and Levy, 0. (2016).     Human newborn B cells mount an interferon-alpha/beta     receptor-dependent humoral response to respiratory syncytial virus.     J Allergy Clin Immunol. -   Jardine, J. G., Kulp, D. W., Havenar-Daughton, C., Sarkar, A.,     Briney, B., Sok, D., Sesterhenn, F., Ereno-Orbea, J., Kalyuzhniy,     O., Deresa, I., et al. (2016). HIV-1 broadly neutralizing antibody     precursor B cells revealed by germline-targeting immunogen. Science     351, 1458-1463. -   Kamal-Bahl, S., Doshi, J., and Campbell, J. (2002). Economic     analyses of respiratory syncytial virus immunoprophylaxis in     high-risk infants: a systematic review. Arch Pediatr Adolesc Med     156, 1034-1041. -   Kapikian, A. Z., Mitchell, R. H., Chanock, R. M., Shvedoff, R. A.,     and Stewart, C. E. (1969). An epidemiologic study of altered     clinical reactivity to respiratory syncytial (RS) virus infection in     children previously vaccinated with an inactivated RS virus vaccine.     Am J Epidemiol 89, 405-421. -   Kashyap, A. K., Steel, J., Oner, A. F., Dillon, M. A., Swale, R. E.,     Wall, K. M., Perry, K. J., Faynboym, A., Ilhan, M., Horowitz, M., et     al. (2008). Combinatorial antibody libraries from survivors of the     Turkish H5N1 avian influenza outbreak reveal virus neutralization     strategies. Proc Natl Acad Sci USA 105, 5986-5991. -   Kelly, R. L., Sun, T., Jain, T., Caffry, I., Yu, Y., Cao, Y.,     Lynaugh, H., Brown, M., Vasquez, M., Wittrup, K. D., et al. (2015).     High throughput cross-interaction measures for human IgG1 antibodies     correlate with clearance rates in mice. MAbs, 0. -   Killikelly, A. M., Kanekiyo, M., and Graham, B. S. (2016).     Pre-fusion F is absent on the surface of formalin-inactivated     respiratory syncytial virus. Sci Rep 6, 34108. -   Kim, H. W., Canchola, J. G., Brandt, C. D., Pyles, G., Chanock, R.     M., Jensen, K., and Parrott, R. H. (1969). Respiratory syncytial     virus disease in infants despite prior administration of antigenic     inactivated vaccine. Am J Epidemiol 89, 422-434. -   Krarup, A., Truan, D., Furmanova-Hollenstein, P., Bogaert, L.,     Bouchier, P., Bisschop, I. J., Widjojoatmodjo, M. N., Zahn, R.,     Schuitemaker, H., McLellan, J. S., et al. (2015). A highly stable     prefusion RSV F vaccine derived from structural analysis of the     fusion mechanism. Nat Commun 6, 8143. -   Kristjansson, S., Bjarnarson, S. P., Wennergren, G., Palsdottir, A.     H., Arnadottir, T., Haraldsson, A., and Jonsdottir, I. (2005).     Respiratory syncytial virus and other respiratory viruses during the     first 3 months of life promote a local TH2-like response. J Allergy     Clin Immunol 116, 805-811. -   Lambert, D. M., Barney, S., Lambert, A. L., Guthrie, K., Medinas,     R., Davis, D. E., Bucy, T., Erickson, J., Merutka, G., and     Petteway, S. R., Jr. (1996). Peptides from conserved regions of     paramyxovirus fusion (F) proteins are potent inhibitors of viral     fusion. Proc Natl Acad Sci USA 93, 2186-2191. -   Lambert, L., Sagfors, A. M., Openshaw, P. J., and Culley, F. J.     (2014). Immunity to RSV in Early-Life. Front Immunol 5, 466. -   Legg, J. P., Hussain, I. R., Warner, J. A., Johnston, S. L., and     Warner, J. O. (2003). Type 1 and type 2 cytokine imbalance in acute     respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med     168, 633-639. -   Lerner, R. A. (2011). Rare antibodies from combinatorial libraries     suggests an S.O.S. component of the human immunological repertoire.     Mol Biosyst 7, 1004-1012. -   Magro, M., Mas, V., Chappell, K., Vazquez, M., Cano, O., Luque, D.,     Terron, M. C., Melero, J. A., and Palomo, C. (2012). Neutralizing     antibodies against the preactive form of respiratory syncytial virus     fusion protein offer unique possibilities for clinical intervention.     Proc Natl Acad Sci U S A 109, 3089-3094. -   McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D.,     Storoni, L. C., and Read, R. J. (2007). Phaser crystallographic     software. J Appl Crystallogr 40, 658-674. -   McLellan, J. S., Chen, M., Chang, J. S., Yang, Y., Kim, A.,     Graham, B. S., and Kwong, P. D. (2010a). Structure of a major     antigenic site on the respiratory syncytial virus fusion     glycoprotein in complex with neutralizing antibody 101F. J Virol 84,     12236-12244. -   McLellan, J. S., Chen, M., Kim, A., Yang, Y., Graham, B. S., and     Kwong, P. D. (2010b). -   Structural basis of respiratory syncytial virus neutralization by     motavizumab. Nat Struct Mol Biol 17, 248-250. -   McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang,     Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013).     Structure of RSV fusion glycoprotein trimer bound to a     prefusion-specific neutralizing antibody. Science 340, 1113-1117. -   McLellan, J. S., Yang, Y., Graham, B. S., and Kwong, P. D. (2011).     Structure of respiratory syncytial virus fusion glycoprotein in the     postfusion conformation reveals preservation of neutralizing     epitopes. J Virol 85, 7788-7796. -   Morin, A., Eisenbraun, B., Key, J., Sanschagrin, P. C., Timony, M.     A., Ottaviano, M., and Sliz, P. (2013). Collaboration gets the most     out of software. Elife 2, e01465. -   Mousa, J. J., Kose, N., Matta, P., Gilchuk, P., and Crowe, J. E.,     Jr. (2017). A novel pre-fusion conformation-specific neutralizing     epitope on the respiratory syncytial virus fusion protein. Nat     Microbiol 2, 16271. -   Murphy, B. R., Alling, D. W., Snyder, M. H., Walsh, E. E.,     Prince, G. A., Chanock, R. M., Hemming, V. G., Rodriguez, W. J.,     Kim, H. W., Graham, B. S., et al. (1986). Effect of age and     preexisting antibody on serum antibody response of infants and     children to the F and G glycoproteins during respiratory syncytial     virus infection. J Clin Microbiol 24, 894-898. -   Murphy, B. R., and Walsh, E. E. (1988). Formalin-inactivated     respiratory syncytial virus vaccine induces antibodies to the fusion     glycoprotein that are deficient in fusion-inhibiting activity. J     Clin Microbiol 26, 1595-1597. -   Ngwuta, J. O., Chen, M., Modjarrad, K., Joyce, M. G., Kanekiyo, M.,     Kumar, A., Yassine, H. M., Moin, S. M., Killikelly, A. M.,     Chuang, G. Y., et al. (2015). Prefusion F-specific antibodies     determine the magnitude of RSV neutralizing activity in human sera.     Sci Transl Med 7, 309ra162. -   Panda, S., and Ding, J. L. (2015). Natural antibodies bridge innate     and adaptive immunity. J Immunol 194, 13-20. -   PATH (2017). RSV Vaccine and mAb Snapshot. -   Polack, F. P., Teng, M. N., Collins, P. L., Prince, G. A., Exner,     M., Regele, H., Lirman, D. D., Rabold, R., Hoffman, S. J., Karp, C.     L., et al. (2002). A role for immune complexes in enhanced     respiratory syncytial virus disease. J Exp Med 196, 859-865. -   Potterton, E., Briggs, P., Turkenburg, M., and Dodson, E. (2003). A     graphical user interface to the CCP4 program suite. Acta Crystallogr     D Biol Crystallogr 59, 1131-1137. -   Rechavi, E., Lev, A., Lee, Y. N., Simon, A. J., Yinon, Y., Lipitz,     S., Amariglio, N., Weisz, B., Notarangelo, L. D., and Somech, R.     (2015). Timely and spatially regulated maturation of B and T cell     repertoire during human fetal development. Sci Transl Med 7,     276ra225. -   Reed, J. H., Jackson, J., Christ, D., and Goodnow, C. C. (2016).     Clonal redemption of autoantibodies by somatic hypermutation away     from self-reactivity during human immunization. J Exp Med 213,     1255-1265. -   Reichert, J. M. (2016). Antibodies to watch in 2016. MAbs 8,     197-204. -   Ridings, J., Dinan, L., Williams, R., Roberton, D., and Zola, H.     (1998). Somatic mutation of immunoglobulin V(H)6 genes in human     infants. Clin Exp Immunol 114, 33-39. -   Rossey, I., Gilman, M. S., Kabeche, S. C., Sedeyn, K., Wrapp, D.,     Kanekiyo, M., Chen, M., Mas, V., Spitaels, J., Melero, J. A., et al.     (2017). Potent single-domain antibodies that arrest respiratory     syncytial virus fusion protein in its prefusion state. Nat Commun 8,     14158. -   Sande, C. J., Cane, P. A., and Nokes, D. J. (2014). The association     between age and the development of respiratory syncytial virus     neutralising antibody responses following natural infection in     infants. Vaccine 32, 4726-4729. -   Saravia, J., You, D., Shrestha, B., Jaligama, S., Siefker, D.,     Lee, G. I., Harding, J. N., Jones, T. L., Rovnaghi, C., Bagga, B.,     et al. (2015). Respiratory Syncytial Virus Disease Is Mediated by     Age-Variable IL-33. PLoS Pathog 11, e1005217. -   Sastre, P., Melero, J. A., Garcia-Barreno, B., and Palomo, C.     (2005). Comparison of affinity chromatography and adsorption to     vaccinia virus recombinant infected cells for depletion of     antibodies directed against respiratory syncytial virus     glycoproteins present in a human immunoglobulin preparation. J Med     Virol 76, 248-255. -   Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn,     G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., et al.     (2009). Factors associated with the development of cross-reactive     neutralizing antibodies during human immunodeficiency virus type 1     infection. J Virol 83, 757-769. -   Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F.,     Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio,     S., Aguayo, C., et al. (2017). Global, regional, and national     disease burden estimates of acute lower respiratory infections due     to respiratory syncytial virus in young children in 2015: a     systematic review and modelling study. Lancet. -   Shinoff, J. J., O'Brien, K. L., Thumar, B., Shaw, J. B., Reid, R.,     Hua, W., Santosham, M., and Karron, R. A. (2008). Young infants can     develop protective levels of neutralizing antibody after infection     with respiratory syncytial virus. J Infect Dis 198, 1007-1015. -   Siegrist, C. A., and Aspinall, R. (2009). B-cell responses to     vaccination at the extremes of age. Nat Rev Immunol 9, 185-194. -   Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E.,     Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro,     G., et al. (2009). Human immunodeficiency virus type 1 elite     neutralizers: individuals with broad and potent neutralizing     activity identified by using a high-throughput neutralization assay     together with an analytical selection algorithm. J Virol 83,     7337-7348. -   Sok, D., Briney, B., Jardine, J. G., Kulp, D. W., Menis, S.,     Pauthner, M., Wood, A., Lee, E. C., Le, K. M., Jones, M., et al.     (2016). Priming HIV-1 broadly neutralizing antibody precursors in     human Ig loci transgenic mice. Science 353, 1557-1560. -   Sui, J., Hwang, W. C., Perez, S., Wei, G., Aird, D., Chen, L. M.,     Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009).     Structural and functional bases for broad-spectrum neutralization of     avian and human influenza A viruses. Nat Struct Mol Biol 16,     265-273. -   Swanson, K. A., Settembre, E. C., Shaw, C. A., Dey, A. K., Rappuoli,     R., Mandl, C. W., Dormitzer, P. R., and Carfi, A. (2011). Structural     basis for immunization with postfusion respiratory syncytial virus     fusion F glycoprotein (RSV F) to elicit high neutralizing antibody     titers. Proc Natl Acad Sci USA 108, 9619-9624. -   Swers, J. S., Kellogg, B. A., and Wittrup, K. D. (2004). Shuffled     antibody libraries created by in vivo homologous recombination and     yeast surface display. Nucleic Acids Res 32, e36. -   Thomson, C. A., Bryson, S., McLean, G. R., Creagh, A. L., Pai, E.     F., and Schrader, J. W. (2008). Germline V-genes sculpt the binding     site of a family of antibodies neutralizing human cytomegalovirus.     EMBO J 27, 2592-2602. -   Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L. L., Alard,     P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., Guan,     Y., et al. (2008). Heterosubtypic neutralizing monoclonal antibodies     cross-protective against H5N1 and H1N1 recovered from human IgM+     memory B cells. PLoS One 3, e3942. -   Tiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M. C.,     and Wardemann, H. (2008). Efficient generation of monoclonal     antibodies from single human B cells by single cell RT-PCR and     expression vector cloning. J Immunol Methods 329, 112-124. -   Trang, N. V., Braeckman, T., Lernout, T., Hau, V. T., Anh le, T. K.,     Luan le, T., Van Damme, P., and Anh, D. D. (2014). Prevalence of     rotavirus antibodies in breast milk and inhibitory effects to     rotavirus vaccines. Hum Vaccin Immunother 10, 3681-3687. -   Troisi, C. L., Hollinger, F. B., Krause, D. S., and Pickering, L. K.     (1997). Immunization of seronegative infants with hepatitis A     vaccine (HAVRIX; SKB): a comparative study of two dosing schedules.     Vaccine 15, 1613-1617. -   Wang, J., He, Y., Jin, D., Liu, J., Zheng, J., Yuan, N., Bai, Y.,     Yan, T., Yang, Y., Liu, Y., et al. (2017). No response to hepatitis     B vaccine in infants born to HBsAg(+) mothers is associated to the     transplacental transfer of HBsAg. Infect Dis (Lond), 1-8. -   Wen, X., Mousa, J. J., Bates, J. T., Lamb, R. A., Crowe, J. E., Jr.,     and Jardetzky, T. S. (2017). Structural basis for antibody     cross-neutralization of respiratory syncytial virus and human     metapneumovirus. Nat Microbiol 2, 16272. -   Williams, J. V., Weitkamp, J. H., Blum, D. L., LaFleur, B. J., and     Crowe, J. E., Jr. (2009). The human neonatal B cell response to     respiratory syncytial virus uses a biased antibody variable gene     repertoire that lacks somatic mutations. Mol Immunol 47, 407-414. -   Wu, S. J., Schmidt, A., Beil, E. J., Day, N.D., Branigan, P. J.,     Liu, C., Gutshall, L. L., Palomo, C., Furze, J., Taylor, G., et al.     (2007). Characterization of the epitope for anti-human respiratory     syncytial virus F protein monoclonal antibody 101F using synthetic     peptides and genetic approaches. J Gen Virol 88, 2719-2723. -   Xu, Y., Roach, W., Sun, T., Jain, T., Prinz, B., Yu, T. Y., Torrey,     J., Thomas, J., Bobrowicz, P., Vasquez, M., et al. (2013).     Addressing polyspecificity of antibodies selected from an in vitro     yeast presentation system: a FACS-based, high-throughput selection     and analytical tool. Protein Eng Des Sel 26, 663-670. -   Yacoob, C., Pancera, M., Vigdorovich, V., Oliver, B. G., Glenn, J.     A., Feng, J., Sather, D. N., McGuire, A. T., and Stamatatos, L.     (2016). Differences in Allelic Frequency and CDRH3 Region Limit the     Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing     Antibody Precursors. Cell Rep 17, 1560-1570. -   Yeung, Y. A., Foletti, D., Deng, X., Abdiche, Y., Strop, P.,     Glanville, J., Pitts, S., Lindquist, K., Sundar, P. D., Sirota, M.,     et al. (2016). Germline-encoded neutralization of a Staphylococcus     aureus virulence factor by the human antibody repertoire. Nat Commun     7, 13376. -   Zhang, X., Zhivaki, D., and Lo-Man, R. (2017). Unique aspects of the     perinatal immune system. Nat Rev Immunol. -   Zhu, Q., McLellan, J. S., Kallewaard, N. L., Ulbrandt, N.D.,     Palaszynski, S., Zhang, J., Moldt, B., Khan, A., Svabek, C.,     McAuliffe, J. M., et al. (2017). A highly potent extended half-life     antibody as a potential RSV vaccine surrogate for all infants. Sci     Transl Med 9

Example 2. Isolation and Characterization of Anti-RSV F-Specific Human Infant Antibodies from Adenoid and PBMCs

Applicant has comprehensively profiled the human infant antibody response to RSV F by isolating and characterizing over 800 RSV F-specific monoclonal antibodies from paired nasopharyngeal adenoid (adenoid) and peripheral blood samples (PBMCs) of RSV-infected infants, and used these antibodies to characterize the infant antibody response as well as develop a framework for the rational design of age-specific RSV vaccines. RSV F-specific memory B cell responses were detected in the adenoids of all 6 children, and the adenoid-derived antibodies showed overall higher binding affinities and neutralization potencies compared to antibodies isolated from paired peripheral blood samples. Approximately 25% of the neutralizing antibodies isolated from adenoid tissue were derived from a unique population of IgM⁺ and/or IgD⁺ memory B cells that contained a high load of somatic mutations but lacked expression of classical memory B cell markers. The collective results provide insight into the mucosal B cell response to RSV and have implications for the development of vaccines that stimulate potent local responses.

Isolation of RSV F-Specific B Cells from Paired Adenoid and Peripheral Blood Samples

To analyze and compare the mucosal and systemic B cell response to natural RSV infection, paired adenoid tissue and peripheral blood samples were obtained from 6 young children between the ages of 2 and 4 years old who were undergoing tonsillectomy (Supplementary Table 1). Adenoids were used as a representative source of respiratory mucosal lymphocytes because this lymphoid tissue has been previously shown to be an important induction site for B cells that migrate to the respiratory tract and associated glands (Czerkinsky et al 1994, McGhee 2000, Brandtzaeg P1. 2011). The adenoid's location at the site of entry into the upper respiratory tract also suggests a role in anti-RSV immunity. Although none of the children had a documented history of RSV infection, previous studies have shown that essentially all children have been infected by RSV at least once by the age of 2. Consistent with the notion of prior RSV exposure, serum samples obtained from all six children displayed neutralizing activity against RSV-A2 (Supplementary Table 1).

SUPPLEMENTARY TABLE 1 Neutralizing activity against RSV-A2 50% RSV neutralization titer Age Adenoid Adenoid Subject Gender (yrs) Plasma filter supernatant 2635 M 3.60 545 9 9 2637 F 3.13 639 <4 13 2665 M 2.82 506 <4 <4 2666 F 3.05 1702 13 177 2849 M 2.79 5133 4 55 2850 M 2.97 720 6 5

To assess the magnitude of the RSV F-specific B cell response in both anatomical compartments, the adenoid and PBMC samples were stained with a panel of B cell markers (CD19, CD20, IgG, IgA, CD27, and FCRL4) and fluorescently-labeled tetramers of RSV preF and postF and analyzed by flow cytometry (FIG. 13A). RSV F-reactive B cells were detected in the adenoid samples from all 6 donors but in only 4 of the 6 corresponding PBMC samples (FIG. 13B). The frequency of RSV F-specific B cells in the adenoid and PBMC samples ranged from 0.03-0.22% and 0-0.19%, respectively. There was no clear correlation between 1) the frequency of RSV F-reactive B cells in peripheral blood and adenoid tissue, and 2) the frequency of RSV F-reactive B cells in either compartment (FIG. 14A) and serum neutralization titer (FIG. 14B). The latter result is consistent with previous studies showing a lack of correlation between the frequencies of antigen-specific memory B cells and serum titers of antigen specific IgG.

Next, between 100-300 RSV F-reactive B cells from both the adenoid and PBMC samples from each of the four donors that had detectable RSV F-specific B cell responses in both compartments were single-cell sorted. Although all RSV F-reactive B cells were sorted, index sorting allowed for the determination of the B cell surface markers expressed on each sorted cell. This analysis showed that the RSV F-specific B cell subset distribution varied considerably between the two compartments and among the four donors (FIG. 13B). For example, in some donors, there was a higher proportion of RSV F-specific IgG⁺ memory B cells in peripheral blood compared to adenoid tissue (e.g. donor 2635 and donor 2849), whereas the converse was observed in other donors (e.g. donor 2665). Notably, in all four donors, there was little to no enrichment for RSV F-specific IgA⁺ B cells in the adenoid samples relative to the corresponding PBMC samples, and in one donor (donor 2665) there was a substantially higher proportion of RSV F-specific IgA⁺ B cells in peripheral blood compared to adenoid tissue (FIG. 13B). Furthermore, in all donors, a considerable proportion (21-52%) of RSV F-specific B cells in both compartments were not class-switched and lacked the expression of the classical memory B cell marker CD27. Since previous studies have shown that the inhibitory receptor FcRL4 is expressed on a proportion of tissue-resident memory B cells (Ehrhardt et al, J Exp Med 2005), it was analyzed whether this marker was preferentially expressed on certain subsets of adenoid-derived B cells. A proportion of B cell clones within most of the subsets in both compartments expressed FcRL4, with the exception of the IgG⁻ IgA⁻CD27⁻ and adenoid-resident IgG⁺ CD27⁻ subsets, and the large majority of FcRL4⁺ B cells in both compartments were of the IgA isotype (FIG. 13C). Therefore, it was concluded that natural RSV infection induces memory B cell responses in the adenoids of young children, and the contribution of different memory B cell populations to the RSV-specific response varies among donors and between the mucosal and systemic compartments.

An Atypical Population of RSV-Specific Memory B Cells is Enriched in Adenoid Tissue

To further characterize the RSV-specific mucosal B cell response, the antibody variable heavy (VH) and variable light (VL) chain sequences from the sorted B cells were amplified by single cell-PCR. Over 800 cognate VH-VL pairs were cloned into an IgG1 expression vector for sequencing and IgG production. Sequence analysis revealed that the RSV F-specific antibody repertoires were highly diverse in both compartments in all donors, each containing few to no expanded clonal lineages (FIG. 15A). Although deeper sequencing would be required to accurately determine the degree of overlap between the RSV F-specific clones in each compartment, one clonal lineage was identified in both the adenoid- and PBMC-derived antibody panels isolated from donor 2635 (supplementary table 2), suggesting that at least a proportion of RSV F-specific B cells recirculate between the mucosal and systemic compartments.

SUPPLEMENTARY TABLE 2 Clonal lineage from donor 2635 VL CDR1 VL FR2 VL CDR2 RSSQSLLHSNGFNYLD (SEQ ID NO:  WYLQKPGQSPQLLIY LGSNRAS 1895) (SEQ ID NO: 1896) (SEQ ID  NO: 1897) RSSQSLLHSNGFNYLD (SEQ ID NO:  WYLQKPGQSPQLLIY LGSNRAS 1895) (SEQ ID NO: 1896) (SEQ ID  NO: 1895) VL FR3 VL CDR3 VL FR4 GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQALQTLT FGPGTKVEIK (SEQ ID NO: 1898) (SEQ ID NO: 1899) (SEQ ID  NO: 1900) GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQALQTLT FGGGTKVEIK (SEQ ID NO: 1898) (SEQ ID NO: 1899) (SEQ ID  NO: 1901)

Next, the CDRH3 length distribution, VH germline gene usage, and load of somatic mutations in the antibodies isolated from the two compartments were analyzed (FIG. 15B). The median CDRH3 lengths of the antibodies isolated from PBMCs and adenoids were 15 and 16 amino acids, respectively, which is consistent with previously reported median CDRH3 lengths for anti-viral antibodies (Gilman et al., Sci Immunol. 2016; Bornholdt et al., Science 2016; Collis and Martin, J M B 2003). Although the VH germline gene usage was also comparable between the two compartments, there was an enrichment for VH5-51 and VH1-69 in the adenoid-derived antibodies and an enrichment for VH4-34 and VH3-30 in the PBMC-derived antibodies across all four donor repertoires (FIG. 15C). The level of somatic mutation in the antibodies varied among the 4 donors, with the median number of VH nucleotide substitutions ranging from 8-11 in the adenoid-derived antibodies and 7-9 in the PBMC-derived antibodies (FIG. 16A and FIG. 17A-D). For 3 out of 4 donors, the load of somatic mutations trended higher in the adenoid-derived antibodies relative to the PBMC-derived antibodies, but this difference only reached statistical significance in donor 2665.

Analysis of the level of SHM within each individual B cell subset revealed that the antibodies derived from the IgG⁻IgA⁻CD27⁻ adenoid B cells contained similar levels of SHM as classical IgG⁺ CD27⁺ and IgA⁺ CD27⁺ memory B cells, providing evidence that these B cells are germinal center-experienced (FIG. 16B). In contrast, the majority of antibodies derived from IgG⁻ IgA⁻CD27⁻ peripheral blood B cells lacked SHM, indicating a naïve B cell origin. In all 4 donors, the percentage of RSV F-specific IgG⁻IgA⁻CD27⁻ B cells containing SHM was significantly higher in adenoids compared to PBMCs (FIG. 16C). Furthermore, even the small subset of somatically mutated antibodies derived from IgG⁻IgA⁻CD27⁻ peripheral blood B cells contained lower levels of SHM compared to antibodies derived from IgG⁻IgA⁻CD27⁻ adenoid B cells (FIG. 16D). To investigate the IgM and IgD expression profiles of the RSV F-specific IgG⁻IgA⁻CD27⁻ adenoid B cells, the adenoid samples were restained with fluorescently labeled RSV F and a panel of secondary antibodies that included anti-human IgG, IgA, IgM, IgD, and CD27. This analysis revealed a high level of heterogeneity in IgM and IgD expression within this population of RSV F-specific B cells, with some of these B cells expressing only IgM or IgD and others co-expressing both markers (FIG. 16E). These B cells appear to belong to a unique population IgM and/or IgD memory B cells that contain somatic mutations but lack expression of previously described memory B cell markers.

A Higher Proportion of Adenoid-Derived Antibodies Display High Affinity Binding and Potent Neutralizing Activity Compared to PBMC-Derived Antibodies

The apparent (IgG) binding affinities of the antibodies for RSV preF and postF were then measured using biolayer interferometry. The percentage of antibodies that bound exclusively to either preF or postF varied across the 4 donors but was similar between the two compartments within individual donors, with the exception of donor 2849, in which preF-specific antibodies were present at higher frequency in PBMCs compared to adenoid tissue (FIG. 18A). As observed in previous studies, a larger proportion of antibodies bound exclusively to preF (16-65%) than to postF (0-15%), demonstrating that the unique surfaces on preF are likely more immunogenic than those on postF. Although finer epitope mapping is required to better resolve the differences in epitope distribution between the two compartments, the results suggest that the relative immunogenicity of the different antigenic surfaces on RSV F is probably more dependent on the donor repertoire and/or immune history than on the anatomical site of B cell activation (FIG. 18A).

In 3 out of 4 donors, a higher proportion of RSV F-specific antibodies isolated from adenoids bound with medium to high affinity to preF (apparent K_(D)<5.0 nM) compared to antibodies derived from RSV F-reactive peripheral blood B cells (FIG. 18B). For example, 70% of the adenoid-derived antibodies cloned from donor 2666 displayed medium to high binding affinity to preF compared to only about 30% of the PBMC-derived antibodies. This result, combined with the observation that two additional donors had detectable RSV F-specific B cell responses in adenoid tissue but not in peripheral blood (FIG. 13B), suggests that the mucosal B cell response to RSV may be more robust than the corresponding systemic B cell response.

Next, the antibodies were tested for neutralizing activity against RSV-A2 using a previously described luciferase-based assay. 14% to 36% of the adenoid-derived antibodies and 0% to 26% of the PBMC-derived antibodies showed detectable neutralizing activity (IC₅₀<25 μg/mL) (FIG. 19A). In all donors, less than 20% of antibodies from both compartments showed highly potent neutralizing activity (IC₅₀<0.05 μg/mL), which is lower than that observed for three previously characterized healthy adult donors, in which 19-38% of isolated antibodies neutralized with high potency. The low fraction of highly potent neutralizing antibodies may be due to the young age of these donors, some of which have likely only experienced a single RSV infection. Consistent with this explanation, the antibody panel isolated from the oldest donor (donor 2635) contained the highest proportion of highly potent antibodies (FIG. 19A).

Consistent with the binding analysis, for 3 out of 4 donors, a larger proportion of adenoid-derived antibodies showed neutralizing activity compared to PBMC-derived antibodies (FIG. 19A). For example, for donor 2665, approximately 15% of adenoid-derived antibodies neutralized with an IC₅₀≤25 pg/mL whereas none of the PBMC-derived antibodies showed detectable activity at this concentration. Analysis of the relationship between preF- and postF binding activity and neutralization potency revealed that 50-60% of preF-specific antibodies isolated from both adenoids and PBMCs showed neutralizing activity compared to only 0-8% of postF-specific antibodies and 10-12% of conformation-independent antibodies (FIG. 19B). Importantly, greater than 90% of highly potent antibodies (IC₅₀<0.05 pg/mL) isolated from both compartments bound exclusively to preF. The antibody characteristics for antibodies derived from adenoid tissue and PBMCs are shown in Tables 6 and 7, respectively.

Finally, the relationship between memory B cell subset and neutralizing activity was analyzed. Approximately 90% of the PBMC-derived neutralizing antibodies originated from only three B cell subsets (IgG⁺CD27⁺, IgG⁺ CD27⁻, and IgG⁻IgA⁻CD27⁺ B cells). In contrast, the adenoid-derived neutralizing antibodies were more evenly distributed across the six different memory B cell populations, with the largest proportion (25%) originating from the atypical IgG⁻IgA⁻CD27⁻ memory B cell subset (FIG. 19C). The antibodies isolated from this atypical memory B cell subset showed similar apparent binding affinities and neutralization potencies compared to the antibodies derived from other memory B cell subsets. These findings demonstrate that 1) adenoid tissue contains a larger proportion of high affinity neutralizing antibodies compared to peripheral blood, 2) a relatively large fraction of RSV F-specific adenoid-derived neutralizing antibodies originate from atypical memory B cells, and 3) the vast majority of neutralizing antibodies isolated from both compartments target epitopes exclusively expressed on preF.

TABLE 6 Summary of antibody characteristics for antibodies isolated from adenoid tissue Neutralization VH VL RSV RSV IC50 (RSV PSR VH VL Protein Protein Name Donor preF KD postF KD subtype A) Specificitiy score Germline Germline Muts Muts ADI-36669 2635   1.09E−09 N.B. 0.02 preF 0.01 VH1-46 VK1-17 11 1 ADI-36670 2635   7.49E−10 N.B. 0.01 preF 0.01 VH1-69 VK3-15 17 5 ADI-36671 2635   7.28E−10 N.B. 0.01 preF 0.05 VH3-11 VL1-40 11 5 ADI-36672 2635   7.03E−10 N.B. 0.02 preF 0.07 VH3-11 VL1-40 13 6 ADI-36674 2635   7.45E−10 N.B. 0.01 preF 0.01 VH3-21 VL1-40 9 8 ADI-36677 2635   5.40E−10 N.B. 0.02 preF 0.05 VH3-48 VK1-33 8 6 ADI-36679 2635   8.78E−10 N.B. 0.01 preF 0.10 VH5-51 VK1-33 13 12 ADI-36680 2635   7.19E−10 N.B. 0.01 preF 0.10 VH5-51 VK3-15 10 10 ADI-36681 2635   1.20E−09 N.B. 0.01 preF 0.08 VH5-51 VK3-15 8 9 ADI-41144 2635   9.40E−10   7.59E−10 0.37 Both 0.52 VH1-2 VK1-16 14 7 ADI-41145 2635 3.18505E−09 8.14745E−10 >25 Both 0.24 VH4-59 VK1-39 4 3 ADI-41146 2635   4.44E−09   7.46E−10 >25 Both 0.23 VH5-51 VK1-12 14 7 ADI-41147 2635  4.6744E−10 N.B. 0.06 preF 0.21 VH3-11 VL1-40 10 7 ADI-41149 2635   4.34E−09   8.57E−10 >25 Both 0.16 VH3-33 VK3-15 6 6 ADI-41153 2635 9.27936E−10 4.45077E−10 >25 Both 0.14 VH3-21 VK1-39 17 12 ADI-41154 2635   4.63E−09   1.35E−09 >25 Both 0.14 VH4-34 VK1-39 9 7 ADI-41155 2635 3.51668E−09 4.77633E−10 >25 Both 0.13 VH4-39 VL1-47 10 5 ADI-41156 2635 N.B. 1.69623E−09 >25 PostF 0.133957365 VH3-48 VK1-39 4 9 ADI-41157 2635   5.07E−10 N.B. 0.22 preF 0.13 VH4-59 VL1-47 6 13 ADI-41158 2635 4.48646E−09 N.B. >25 preF 0.13 VH3-48 VK3-15 9 0 ADI-41159 2635 N.B. 9.86775E−09 >25 PostF 0.13 VH5-51 VK1-39 4 4 ADI-41160 2635 2.41078E−09 3.36863E−10 >25 Both 0.13 VH1-69 VL2-14 3 8 ADI-41161 2635 2.53811E−09 3.63868E−10 >25 Both 0.12 VH3-48 VL2-14 12 12 ADI-41162 2635   4.06E−09   7.48E−10 >25 Both 0.12 VH1-69 VK3-20 12 6 ADI-41163 2635 4.65418E−09 6.03726E−10 >25 Both 0.12 VH3-33 VK2-28 14 5 ADI-41164 2635 N.B. 9.61753E−10 >25 PostF 0.12 VH3-48 VK1-5 10 14 ADI-41165 2635   2.40E−09 N.B. >25 preF 0.11 VH5-51 VK1-33 0 0 ADI-41166 2635 3.15262E−09 4.40318E−10 >25 Both 0.11 VH1-2 VL2-14 19 12 ADI-41168 2635   1.33E−07 N.B. >25 preF 0.11 VH3-30 VL2-14 1 10 ADI-41169 2635 4.94324E−09 1.18611E−09 >25 Both 0.11 VH5-51 VK4-1 13 6 ADI-41170 2635   5.67E−09   2.64E−09 >25 Both 0.11 VH3-23 VK1-5 12 6 ADI-41171 2635   9.80E−09   4.26E−09 >25 Both 0.11 VH4-31 VK3-20 17 9 ADI-41172 2635 3.05696E−09 7.48831E−10 >25 Both 0.11 VH3-64D VK4-1 10 3 ADI-41173 2635 3.15494E−10 2.93512E−10 0.08 Both 0.11 VH1-69 VK1-17 9 3 ADI-41174 2635 N.B. 7.51319E−10 >25 PostF 0.11 VH1-18 VL3-25 11 6 ADI-41175 2635   4.25E−09   1.07E−09 >25 Both 0.10 VH3-33 VK2-28 7 2 ADI-41176 2635 N.B.   4.07E−09 >25 PostF 0.10 VH4-39 VK1-27 13 6 ADI-41177 2635 8.37277E−10 N.B. >25 preF 0.10 VH1-2 VL1-44 5 4 ADI-41178 2635 1.71747E−09 6.01837E−10 >25 Both 0.10 VH1-2 VK3-15 3 0 ADI-41179 2635 9.48366E−10  3.4151E−10 >25 Both 0.10 VH1-69 VL2-11 9 19 ADI-41180 2635 4.70488E−10 N.B. 0.07 preF 0.10 VH3-11 VL1-40 8 9 ADI-41181 2635 1.95174E−09 9.35655E−10 >25 Both 0.10 VH1-69 VL2-14 7 8 ADI-41182 2635  2.5543E−09 4.62114E−10 >25 Both 0.10 VH5-51 VK3-15 6 6 ADI-41183 2635   4.08E−09   1.00E−09 >25 Both 0.10 VH4-34 VK1-39 15 13 ADI-41184 2635 2.84503E−09 5.31986E−10 >25 Both 0.10 VH3-23 VK1-39 7 5 ADI-41185 2635 3.22683E−9  8.08927E−10 >25 Both 0.10 VH4-34 VK3-20 5 6 ADI-41186 2635 3.01027E−09 7.03469E−10 >25 Both 0.10 VH5-51 VK3-15 4 5 ADI-41188 2635 2.23985E−10 N.B. 0.15 preF 0.10 VH4-34 VL1-40 8 12 ADI-41189 2635 2.86473E−09 6.07729E−10 >25 Both 0.10 VH3-21 VL1-40 4 1 ADI-41190 2635   2.29E−09   9.71E−10 >25 Both 0.08 VH1-3 VK3-20 9 5 ADI-41191 2635 5.01606E−10 N.B. 0.07 preF 0.08 VH1-18 VK2-30 8 6 ADI-41192 2635 3.38603E−09 5.89066E−10 >25 Both 0.07 VH1-18 VK1-39 12 3 ADI-41193 2635 7.40214E−10 N.B. 0.07 preF 0.07 VH3-11 VL1-40 13 8 ADI-41194 2635 N.B.   1.16E−09 >25 PostF 0.07 VH4-31 VK3-20 10 7 ADI-41196 2635  2.9157E−09 5.95141E−10 >25 Both 0.07 VH3-23 VK1-39 12 3 ADI-41197 2635   7.95E−10   5.31E−10 0.27 Both 0.07 VH1-2 VK1-39 12 5 ADI-41198 2635   7.56E−10 N.B. 0.32 preF 0.06 VH3-43 VK1-33 18 12 ADI-41199 2635   1.73E−09 N.B. 0.23 preF 0.06 VH3-11 VK3-15 7 24 ADI-41200 2635 3.34299E−10 3.18362E−10 >25 Both 0.05 VH3-23 VK2-28 14 9 ADI-41201 2635 3.82297E−09 6.37241E−10 >25 Both 0.05 VH3-48 VK3-11 15 9 ADI-41202 2635 1.12088E−09 3.32852E−10 >25 Both 0.05 VH1-69 VL2-11 9 19 ADI-41203 2635 3.99236E−10 N.B. 0.01 preF 0.05 VH5-51 VK3-15 9 10 ADI-41204 2635 5.44567E−10 N.B. 0.06 preF 0.04 VH3-21 VL1-40 3 3 ADI-41205 2635 1.16405E−09  5.3591E−10 >25 Both 0.04 VH4-4 VK4-1 3 6 ADI-41206 2635 4.09075E−10 N.B. 0.07 preF 0.04 VH3-21 VL1-40 11 10 ADI-41207 2635 2.53175E−09 4.37767E−10 >25 Both 0.04 VH2-70 VL2-11 3 13 ADI-41208 2635 4.83434E−10 N.B. 0.08 preF 0.04 VH3-11 VL1-40 11 7 ADI-41209 2635   1.32E−09   1.59E−09 2.97 Both 0.03 VH4-34 VK2-28 11 3 ADI-41210 2635 4.70023E−10 N.B. 0.10 preF 0.02 VH1-18 VK2-30 7 4 ADI-41212 2635 3.17532E−09 4.00134E−10 >25 Both 0.02 VH1-2 VL2-14 11 13 ADI-41213 2635  3.4719E−09 5.76926E−10 >25 Both 0.02 VH3-53 VL3-1 4 2 ADI-41214 2635  5.6989E−09 1.01699E−09 >25 Both 0.01 VH3-7 VK1-39 4 5 ADI-41215 2635   4.37E−10   5.63E−10 0.32 Both 0.01 VH3-20 VL2-23 3 10 ADI-41216 2635   9.03E−10 N.B. 0.19 preF 0.01 VH3-11 VL1-40 9 8 ADI-41217 2635 4.88862E−10 N.B. 0.04 preF 0.01 VH3-21 VL1-40 7 5 ADI-41218 2635 N.B. 7.28659E−10 >25 PostF 0.01 VH1-18 VL1-40 10 7 ADI-41219 2635 N.B. 1.28064E−09 >25 PostF 0.01 VH3-48 VK1-39 7 4 ADI-41221 2635 2.98426E−10 3.16654E−10 0.04 Both 0.01 VH3-21 VL2-11 8 18 ADI-41222 2635 4.30995E−10 N.B. 0.02 preF 0.01 VH3-30 VL3-21 10 11 ADI-41223 2635 N.B. 1.80931E−09 >25 PostF 0.00 VH3-30 VL2-14 6 11 ADI-41224 2635   5.24E−10   5.58E−10 0.13 Both 0.00 VH3-49 VL6-57 7 5 ADI-41225 2635   4.15E−09   7.33E−10 >25 Both 0.00 VH3-11 VK1-5 11 8 ADI-41226 2635   8.20E−10 N.B. 0.15 preF 0.00 VH3-11 VL1-40 15 2 ADI-41227 2635   4.62E−09 N.B. >25 preF 0.00 VH1-69 VL1-36 19 0 ADI-41228 2635 4.86239E−09  6.1786E−10 >25 Both 0.00 VH4-59 VL2-14 6 3 ADI-41229 2635   1.14E−09   7.08E−10 0.07 Both 0.00 VH3-30 VK1-33 10 3 ADI-41230 2635   1.83E−09   4.07E−10 24.10 Both 0.00 VH5-51 VL6-57 11 3 ADI-41231 2635   3.05E−09   4.26E−10 >25 Both 0.00 VH5-51 VL6-57 14 8 ADI-41232 2635   7.05E−10 N.B. 0.03 preF 0.00 VH1-18 VK2-30 6 1 ADI-41233 2635   1.06E−09 N.B. 0.15 preF 0.00 VH3-11 VL1-40 5 3 ADI-41234 2635   1.46E−09 N.B. 0.10 preF 0.00 VH3-30 VK2-28 47 4 ADI-41235 2635   4.72E−09   3.24E−09 >25 Both 0.00 VH4-34 VL1-40 8 7 ADI-41236 2635 N.B.   6.13E−08 >25 PostF 0.00 VH3-11 VL1-40 7 14 ADI-41237 2635   7.94E−10 N.B. 0.04 preF 0.00 VH3-11 VL1-40 5 3 ADI-41238 2635   1.03E−09 N.B. 0.13 preF 0.00 VH3-11 VL1-40 5 6 ADI-41239 2635   4.25E−09   1.47E−09 >25 Both 0.00 VH2-5 VK2-28 6 1 ADI-41240 2635   2.15E−09   1.20E−09 >25 Both 0.00 VH4-34 VK1-5 13 10 ADI-41241 2635   3.84E−09   9.27E−10 18.76 Both 0.00 VH1-2 VK1-39 4 6 ADI-41242 2635   4.18E−09   9.07E−10 >25 Both 0.00 VH3-33 VK2-28 12 2 ADI-41243 2635   3.55E−09   4.18E−10 >25 Both 0.00 VH5-51 VL6-57 9 4 ADI-41244 2635 N.B.   8.43E−10 >25 PostF 0.00 VH3-53 VK4-1 7 6 ADI-41245 2635   7.75E−10 N.B. 0.71 preF 0.00 VH3-11 VL1-40 8 2 ADI-41246 2635 3.07945E−09 N.B. >25 preF 0.00 VH4-59 VK3-20 4 6 ADI-41247 2635 2.76078E−09  1.0202E−09 >25 Both 0.00 VH1-2 VL6-57 10 1 ADI-41248 2635 3.35413E−09 3.91839E−10 >25 Both 0.00 VH3-33 VK1-39 7 5 ADI-41249 2635 3.91497E−10 N.B. 0.01 preF 0.00 VH5-51 VK1-33 14 4 ADI-41250 2635 7.30505E−10 5.04204E−10 >25 Both 0.00 VH4-34 VL2-14 10 8 ADI-41251 2635 5.92669E−10 N.B. 0.11 preF 0.00 VH3-11 VL1-40 5 2 ADI-41252 2635  1.3715E−09 1.00354E−09 >25 Both 0.00 VH5-51 VK1-33 11 2 ADI-41253 2635 1.11084E−09 N.B. 0.03 preF 0.00 VH4-39 VK3-20 19 8 ADI-41254 2635 7.75513E−10 N.B. >25 preF 0.00 VH3-48 VL1-44 8 8 ADI-41255 2635 2.04133E−09 1.54027E−09 >25 Both 0.00 VH3-23 VK3-15 6 3 ADI-41256 2635 3.53762E−10 N.B. 0.02 preF 0.00 VH1-69 VK2-30 18 3 ADI-41257 2635 3.81012E−09 N.B. >25 preF 0.00 VH1-69 VK1-39 10 6 ADI-41258 2635 9.68014E−10 N.B. >25 preF 0.00 VH3-23 VL3-25 12 2 ADI-41259 2635 3.35934E−10 N.B. 0.02 preF 0.00 VH3-11 VK2-30 9 8 ADI-41261 2665 3.08217E−09 1.66794E−09 >25 Both 0.33 VH1-69 VK3-20 7 0 ADI-41263 2665 2.90427E−09 3.45081E−10 >25 Both 0.25 VH1-46 VL6-57 13 5 ADI-41264 2665 N.B. 4.83588E−10 >25 PostF 0.15 VH3-15 VL3-10 9 13 ADI-41265 2665 1.50426E−08  3.0791E−09 >25 Both 0.15 VH5-51 VL1-51 15 6 ADI-41266 2665 4.05839E−09 N.B. >25 preF 0.14 VH6-1 VL3-21 0 11 ADI-41267 2665  1.0722E−08 1.09048E−08 >25 Both 0.12 VH4-4 VL3-1 6 10 ADI-41268 2665 5.80544E−10 N.B. 0.176867623 preF 0.11 VH3-21 VL2-14 12 7 ADI-41270 2665 4.91907E−09 6.17282E−10 >25 Both 0.11 VH3-30-3 VL2-23 5 5 ADI-41271 2665 N.B. 3.11283E−09 >25 PostF 0.11 VH6-1 VK4-1 2 3 ADI-41273 2665 3.06182E−09 1.17234E−09 >25 Both 0.11 VH3-48 VL2-11 17 12 ADI-41274 2665 4.79702E−10 N.B. 0.109081031 preF 0.10 VH3-21 VL1-40 11 10 ADI-41275 2665 5.74247E−09 1.32887E−09 >25 Both 0.10 VH3-21 VK2-28 14 7 ADI-41276 2665 N.B. 3.14914E−09 >25 PostF 0.10 VH3-49 VK3-20 7 2 ADI-41277 2665 3.59859E−09 7.80097E−10 >25 Both 0.10 VH4-4 VK1-39 12 6 ADI-41278 2665 1.28256E−09 4.82496E−10 >25 Both 0.10 VH2-70D VK1-39 7 8 ADI-41279 2665 5.04148E−08 4.78337E−08 >25 Both 0.10 VH5-51 VL1-40 16 10 ADI-41280 2665 3.62407E−09 4.82968E−10 >25 Both 0.10 VH4-59 VK3-20 8 8 ADI-41281 2665 6.69584E−09 1.57901E−09 >25 Both 0.10 VH1-3 VK1-39 18 12 ADI-41282 2665 3.24641E−09 1.25067E−09 >25 Both 0.10 VH3-30-3 VK3-20 11 9 ADI-41283 2665 2.74028E−08 7.95247E−09 >25 Both 0.10 VH2-5 VK1-39 4 14 ADI-41284 2665 3.05821E−09 5.47248E−10 >25 Both 0.10 VH3-15 VL1-51 9 3 ADI-41285 2665 5.11231E−10 4.12147E−10 >25 Both 0.10 VH1-69 VL1-47 12 3 ADI-41286 2665 7.59591E−09 5.48535E−09 >25 Both 0.10 VH1-18 VK1-12 4 6 ADI-41287 2665 3.22264E−09 5.97933E−10 5.845176257 Both 0.09 VH3-9 VL2-11 10 4 ADI-41288 2665 8.99143E−09 N.B. >25 preF 0.08 VH3-23 VK3-20 14 12 ADI-41289 2665 N.B. 8.81474E−10 >25 PostF 0.08 VH5-51 VL2-23 8 10 ADI-41291 2665  2.9847E−09 1.20178E−09 >25 Both 0.07 VH4-34 VK1-39 16 9 ADI-41292 2665 8.83038E−07 1.94972E−07 >25 Both 0.06 VH3-30 VK1-5 10 12 ADI-41293 2665 4.95631E−10 4.10968E−10 0.159400369 Both 0.05 VH4-30-4 VK3-20 6 6 ADI-41294 2665 5.11755E−10 N.B. 0.080516504 preF 0.05 VH3-48 VL2-8 10 9 ADI-41296 2665 3.35264E−09 N.B. >25 preF 0.04 VH5-51 VL3-25 20 19 ADI-41297 2665 3.90841E−09 6.27923E−10 >25 Both 0.04 VH1-69 VL2-14 5 6 ADI-41299 2665 3.48237E−09 2.24822E−09 >25 Both 0.04 VH3-30 VL2-23 14 12 ADI-41302 2665 6.54219E−10 N.B. 0.006 preF 0.03 VH3-30 VL2-8 10 7 ADI-41303 2665 2.95589E−09 9.43837E−10 >25 Both 0.03 VH3-23 VK3-20 18 14 ADI-41304 2665 3.37926E−10 3.30067E−10 >25 Both 0.03 VH4-30-4 VL1-44 9 9 ADI-41305 2665 3.63645E−09 4.31019E−10 >25 Both 0.03 VH4-31 VK3-20 7 4 ADI-41306 2665 4.61555E−10 4.54221E−10 0.173227379 Both 0.02 VH4-30-4 VK3-11 21 10 ADI-41307 2665 2.98694E−09 8.29508E−10 >25 Both 0.02 VH3-21 VK3-15 15 14 ADI-41308 2665 4.00249E−09 5.18915E−10 >25 Both 0.02 VH6-1 VL2-14 4 15 ADI-41309 2665 4.33574E−09 1.36177E−09 >25 Both 0.02 VH4-30-4 VK3-20 8 4 ADI-41310 2665  3.3197E−09 N.B. >25 preF 0.02 VH5-51 VL3-25 18 22 ADI-41311 2665 7.53938E−10   5.24E−10 >25 Both 0.01 VH2-70 VK1-39 7 8 ADI-41312 2665 3.37922E−09 8.56857E−10 >25 Both 0.01 VH4-4 VL1-44 8 2 ADI-41313 2665 4.54784E−10 3.41756E−10 >25 Both 0.01 VH1-18 VL3-9 11 13 ADI-41314 2665 2.40926E−09 4.14355E−10 >25 Both 0.01 VH1-69 VL3-25 13 18 ADI-41315 2665 2.93399E−09  1.0343E−09 >25 Both 0.01 VH4-59 VK3-20 8 5 ADI-41316 2665 3.73659E−09 1.04515E−09 >25 Both 0.01 VH3-30 VK3-15 9 5 ADI-41317 2665 4.81624E−08 N.B. 4.657687235 preF 0.01 VH3-7 VL1-40 12 11 ADI-41318 2665 4.26427E−07 3.53944E−08 >25 Both 0.01 VH1-69 VK1-13 16 9 ADI-41319 2665  4.4099E−09 5.86603E−10 >25 Both 0.01 VH4-30-4 VK3-20 4 4 ADI-41320 2665 3.20131E−09 N.B. >25 preF 0.01 VH5-51 VL3-25 24 18 ADI-41322 2665 2.98155E−09 N.B. >25 preF 0.00 VH1-69 VK1-12 9 3 ADI-41323 2665 1.94986E−09 3.30643E−10 >25 Both 0.00 VH3-20 VL6-57 10 5 ADI-41324 2665  2.4749E−09 4.26392E−10 >25 Both 0.00 VH3-66 VK3-20 4 6 ADI-41340 2665 3.50828E−09 N.B. >25 preF 0.00 VH1-69 VL2-14 18 11 ADI-41341 2665 2.83245E−09 1.96942E−09 >25 Both 0.00 VH1-69 VL1-51 6 9 ADI-41342 2665 3.99333E−09 5.90775E−10 >25 Both 0.00 VH1-69 VK3-20 9 7 ADI-41343 2665 7.21165E−10 N.B. 0.177309561 preF 0.00 VH3-21 VL1-40 5 3 ADI-41344 2665 4.94249E−10 N.B. 0.063680457 preF 0.00 VH3-21 VL1-40 7 4 ADI-41345 2665 2.28687E−09 3.48826E−10 >25 Both 0.00 VH5-51 VL6-57 7 2 ADI-41346 2665 1.88377E−09 2.67433E−10 >25 Both 0.00 VH5-51 VL6-57 15 9 ADI-41347 2665 2.60039E−09  5.2114E−10 >25 Both 0.00 VH4-4 VK2-28 11 5 ADI-41348 2665 4.75842E−10  4.3847E−10 0.076469111 Both 0.00 VH4-31 VK1-39 3 9 ADI-41349 2665 6.24824E−09 >25 Both 0.00 VH3-49 VK1-33 12 8 ADI-41350 2665 N.B. 6.01842E−10 >25 PostF 0.00 VH3-23 VL2-14 4 9 ADI-41351 2665 8.86433E−10 N.B. 0.148889821 preF 0.00 VH3-64 VK3-15 15 3 ADI-41352 2665 3.35674E−09 N.B. >25 preF 0.00 VH3-48 VK4-1 4 0 ADI-41353 2665 3.90918E−09 N.B. >25 preF 0.00 VH5-51 VL3-25 19 17 ADI-41354 2665 7.71337E−10 4.28593E−10 >25 Both 0.00 VH3-23 VK1-33 2 19 ADI-41355 2665 3.84279E−09 1.17814E−09 >25 Both 0.00 VH3-11 VL3-21 10 11 ADI-41356 2665 7.24816E−10 N.B. 0.115429214 preF 0.00 VH1-8 VL3-1 4 7 ADI-41357 2665 3.30683E−09 N.B. >25 preF 0.00 VH3-48 VK1-16 7 4 ADI-41358 2665 8.64199E−10 N.B. 0.388841883 preF 0.00 VH3-21 VL1-40 5 4 ADI-41359 2665 5.27247E−10 N.B. >25 preF 0.00 VH3-21 VL1-40 4 4 ADI-41360 2665 2.45821E−09 3.58127E−10 >25 Both 0.00 VH3-48 VL6-57 11 1 ADI-41361 2665 N.B.  3.8252E−10 2.539820038 PostF 0.00 VH3-30 VK3-15 8 3 ADI-41362 2665 3.37246E−09 N.B. 0.910656137 preF 0.00 VH3-7 VK1-33 14 11 ADI-41363 2665 1.84993E−09 N.B. 0.143419355 preF 0.00 VH1-69 VK1-33 5 6 ADI-41364 2665 1.31503E−09 N.B. 0.140467535 preF 0.00 VH1-2 VL2-23 17 6 ADI-41365 2665 2.87064E−09 2.22411E−09 >25 Both 0.00 VH3-11 VL1-40 7 8 ADI-41366 2665 1.79472E−09 2.78051E−10 >25 Both 0.00 VH5-51 VL6-57 10 8 ADI-41367 2665 1.75638E−08  4.7231E−09 >25 Both 0.00 VH1-3 VL2-14 19 13 ADI-41368 2665 3.07672E−09 8.77542E−10 >25 Both 0.00 VH3-30 VK1-5 14 9 ADI-41369 2665 6.84843E−10 3.07855E−10 >25 Both 0.00 VH3-30 VL6-57 6 4 ADI-41370 2665 5.58964E−09 1.63921E−09 >25 Both 0.00 VH3-21 VL3-25 6 6 ADI-41371 2665 2.96473E−09 5.42686E−10 >25 Both 0.00 VH4-30-4 VK3-20 14 11 ADI-41372 2665 2.47619E−09  4.2465E−10 >25 Both 0.00 VH1-69 VL3-25 8 19 ADI-41373 2665 3.71092E−09 1.18174E−09 >25 Both 0.00 VH3-11 VL1-40 15 7 ADI-41374 2665 1.38715E−09 3.69047E−10 >25 Both 0.00 VH1-69 VK1-33 17 9 ADI-41375 2665 2.96439E−09 1.01798E−09 >25 Both 0.00 VH3-30 VK1-13 8 8 ADI-41376 2665 4.15159E−09  7.0539E−10 >25 Both 0.00 VH3-30 VK3-15 8 4 ADI-41377 2665 1.73768E−09 N.B. 0.239614261 preF 0.00 VH6-1 VL3-21 11 15 ADI-41378 2665 2.98284E−09 7.38719E−10 >25 Both 0.00 VH4-4 VK1-39 5 10 ADI-41379 2665 N.B. 1.10788E−09 >25 PostF 0.00 VH5-51 VK1-33 5 6 ADI-41380 2665 2.56169E−10 N.B. 0.054916106 preF 0.00 VH5-51 VK1-33 0 4 ADI-41381 2665 2.60472E−09 1.33733E−09 >25 Both 0.00 VH4-30-4 VK3-20 13 5 ADI-41382 2666 4.91343E−10 N.B. 0.02 preF 0.00 VH3-9 VK3-15 10 2 ADI-41384 2666 3.45299E−09 5.63124E−10 >25 Both 0.20 VH1-69 VK3-20 10 7 ADI-41385 2666 4.52281E−09 6.00686E−10 >25 Both 0.10 VH3-33 VL1-40 3 2 ADI-41386 2666 4.03244E−10 N.B. >25 preF 0.10 VH1-2 VL1-44 11 7 ADI-41389 2666 2.58276E−09 5.12803E−10 >25 Both 0.10 VH3-30-3 VL3-25 7 1 ADI-41390 2666 6.40545E−10 N.B. 0.62 preF 0.10 VH3-21 VL1-40 7 4 ADI-41391 2666 8.82233E−10 4.78533E−10 >25 Both 0.10 VH4-59 VL2-14 3 5 ADI-41392 2666 3.29102E−10 3.58725E−10 0.18 Both 0.10 VH3-30-3 VL2-14 14 8 ADI-41393 2666 1.66525E−09 2.46585E−10 >25 Both 0.10 VH5-51 VL6-57 2 3 ADI-41394 2666 3.06807E−09 N.B. >25 preF 0.10 VH1-69 VL4-60 11 9 ADI-41396 2666  5.1704E−10 N.B. 1.37 preF 0.10 VH3-21 VL1-40 9 3 ADI-41397 2666 5.81313E−10 N.B. 0.09 preF 0.10 VH3-21 VL1-40 10 2 ADI-41398 2666 6.00144E−10 N.B. 0.17 preF 0.09 VH1-18 VK2-30 1 4 ADI-41399 2666 3.14259E−09 N.B. >25 preF 0.09 VH1-3 VL2-14 3 5 ADI-41400 2666 N.B. 5.47444E−10 >25 PostF 0.09 VH3-48 VK1-5 8 4 ADI-41401 2666 3.21615E−09 N.B. >25 preF 0.07 VH3-9 VK1-39 5 5 ADI-41403 2666 3.04427E−09 8.41083E−10 >25 Both 0.04 VH3-21 VK2-28 9 3 ADI-41404 2666 4.73759E−08  1.3574E−08 >25 Both 0.04 VH1-69 VK3-20 8 3 ADI-41405 2666 2.72169E−09 4.58099E−10 >25 Both 0.02 VH3-48 VK3-11 9 2 ADI-41406 2666 N.B. 5.71343E−10 >25 PostF 0.02 VH3-23 VK1-16 8 6 ADI-41407 2666 2.08406E−09 3.71284E−10 >25 Both 0.01 VH3-23 VK1-27 9 7 ADI-41408 2666 2.13579E−09 N.B. >25 preF 0.00 VH5-51 VK1-33 9 7 ADI-41409 2666 6.26652E−10 N.B. 0.29 preF 0.00 VH1-18 VK2-30 4 2 ADI-41414 2666 2.70176E−09  1.1037E−09 >25 Both 0.00 VH3-66 VK1-5 14 4 ADI-41415 2666 1.08103E−09 6.43742E−10 >25 Both 0.11 VH2-70D VK1-39 9 10 ADI-41416 2666 4.43792E−10 N.B. 0.05 preF 0.10 VH3-21 VL1-40 8 5 ADI-41417 2666 9.19338E−10 N.B. 0.71 preF 0.10 VH3-21 VL1-40 3 2 ADI-41418 2666 1.58304E−09 3.41314E−10 >25 Both 0.10 VH3-15 VL3-10 13 5 ADI-41419 2666  3.0463E−10 N.B. 0.01 preF 0.10 VH3-9 VL2-14 4 6 ADI-41420 2666 N.B. 1.09885E−07 >25 PostF 0.10 VH3-30-3 VL2-18 0 0 ADI-41421 2666 2.51681E−09 N.B. 4.78 preF 0.10 VH1-18 VL3-10 18 4 ADI-41423 2666 5.86859E−08 N.B. >25 preF 0.10 VH3-21 VL2-14 0 1 ADI-41424 2666 7.44001E−10 N.B. 0.28 preF 0.00 VH1-18 VK2-30 14 13 ADI-41425 2666 1.13708E−09 4.96097E−10 >25 Both 0.00 VH2-70 VK1-39 13 9 ADI-41427 2666 2.69701E−09 9.17353E−10 >25 Both 0.21 VH4-59 VL2-14 5 1 ADI-41429 2666 3.61957E−09 1.00206E−09 >25 Both 0.10 VH1-69 VL2-14 3 2 ADI-41431 2666 7.44349E−10 3.44594E−10 2.38 Both 0.10 VH1-18 VL1-51 14 7 ADI-41432 2666 2.04914E−09 2.86037E−10 >25 Both 0.10 VH1-69 VL2-11 14 8 ADI-41433 2666 N.B.  1.2267E−09 >25 PostF 0.10 VH3-30 VL2-11 8 4 ADI-41434 2666 6.13319E−10 N.B. >25 preF 0.10 VH3-9 VK3-15 5 3 ADI-41435 2666 N.B. 3.47214E−09 >25 PostF 0.10 VH3-21 VL1-44 6 4 ADI-41436 2666 1.10343E−09  2.3675E−10 >25 Both 0.10 VH3-30-3 VL6-57 11 5 ADI-41437 2666  3.5009E−10 N.B. >25 preF 0.04 VH1-18 VK4-1 13 4 ADI-41438 2666  3.1446E−09 N.B. >25 preF 0.00 VH1-69 VK3-15 22 11 ADI-41439 2666 5.00975E−10 N.B. 0.34 preF 0.00 VH1-18 VK2-30 10 2 ADI-41440 2666 3.18018E−09 1.23422E−09 >25 Both 0.00 VH3-21 VK3-15 8 4 ADI-41441 2666 3.11642E−09 N.B. >25 preF 0.00 VH4-39 VK1-9 12 5 ADI-41442 2666 5.21389E−10 N.B. 0.04 preF 0.00 VH3-9 VK3D-15 3 3 ADI-41443 2666 2.39989E−09 3.73358E−10 >25 Both 0.00 VH3-33 VK2-28 7 7 ADI-41444 2666 3.01394E−09 5.40812E−10 >25 Both 0.00 VH4-30-4 VK1-5 17 10 ADI-41445 2666 3.04263E−09 7.71859E−10 >25 Both 0.19 VH1-69 VK3-20 17 6 ADI-41446 2666 3.60473E−09 7.21955E−10 >25 Both 0.12 VH3-23 VK3-11 10 6 ADI-41447 2666 5.40998E−08 N.B. >25 preF 0.12 VH3-23 VK3-20 4 3 ADI-41448 2666 2.74846E−09 4.28394E−10 >25 Both 0.10 VH1-69 VL2-14 16 12 ADI-41449 2666 5.07579E−10 N.B. 0.16 preF 0.10 VH3-21 VL1-40 10 5 ADI-41450 2666 6.13101E−10 N.B. 0.21 preF 0.10 VH3-21 VL1-40 12 9 ADI-41451 2666 1.82249E−09 1.66981E−09 0.84 Both 0.10 VH3-48 VL3-1 13 16 ADI-41452 2666 3.33249E−09 N.B. >25 preF 0.10 VH1-3 VL2-14 19 6 ADI-41453 2666 2.16827E−09 4.02833E−10 >25 Both 0.10 VH1-8 VL3-9 8 4 ADI-41454 2666 5.87531E−10 N.B. 0.88 preF 0.10 VH1-18 VK2-30 7 4 ADI-41455 2666 1.52555E−09 6.37546E−10 >25 Both 0.08 VH4-30-4 VK3-11 8 1 ADI-41456 2666 1.48371E−09 2.66707E−10 >25 Both 0.08 VH3-74 VL6-57 13 3 ADI-41488 2849 N.B.   6.05E−10 >25 PostF 0.10 VH4-59 VL2-11 12 6 ADI-41489 2849   8.80E−08 N.B. >25 preF 0.10 VH3-30 VK3-15 13 6 ADI-41491 2849   4.39E−10 N.B. >25 preF 0.08 VH3-48 VL3-21 7 4 ADI-41492 2849   1.82E−07   5.48E−08 >25 Both 0.07 VH1-69 VK1-39 11 6 ADI-41493 2849   4.50E−10   3.72E−10 >25 Both 0.06 VH5-51 VL2-8 5 2 ADI-41494 2849   2.61E−09   4.40E−10 >25 Both 0.06 VH3-49 VL2-14 16 7 ADI-41495 2849   7.72E−08   5.73E−08 >25 Both 0.05 VH3-15 VL6-57 12 4 ADI-41496 2849   1.65E−09   1.37E−09 >25 Both 0.04 VH1-8 VL2-23 3 6 ADI-41497 2849   1.44E−09   2.68E−10 >25 Both 0.04 VH3-30 VL3-21 12 7 ADI-41498 2849   1.22E−09   2.20E−10 >25 Both 0.04 VH3-21 VL3-21 13 4 ADI-41499 2849   1.99E−09   2.97E−10 >25 Both 0.04 VH3-43 VL2-11 13 9 ADI-41501 2849   3.21E−09 N.B. >25 preF 0.03 VH1-69 VK4-1 13 4 ADI-41502 2849   1.34E−09   3.08E−10 >25 Both 0.01 VH1-69 VL2-11 12 5 ADI-41503 2849   3.14E−09   4.93E−10 >25 Both 0.01 VH3-23 VL2-14 9 3 ADI-41504 2849   2.80E−09   5.08E−10 >25 Both 0.01 VH4-59 VL1-40 8 3 ADI-41505 2849   2.87E−09   5.23E−10 >25 Both 0.00 VH4-34 VL1-40 11 4 ADI-41507 2849 N.B.   1.40E−07 >25 PostF 0.00 VH2-5 VL1-40 4 5 ADI-41508 2849   4.15E−09   5.55E−10 0.10 Both 0.00 VH1-18 VL3-1 13 6 ADI-41515 2849   3.33E−10 N.B. >25 preF 0.00 VH3-23 VL3-10 13 7 ADI-41516 2849   4.14E−10 N.B. 0.08 preF 0.00 VH4-4 VL1-47 16 7 ADI-41517 2849   5.01E−10 N.B. 0.02 preF 0.00 VH3-23 VL1-40 10 4 ADI-41518 2849   7.76E−10 N.B. >25 preF 0.00 VH3-21 VL1-40 2 0 ADI-41519 2849   9.75E−10 N.B. >25 preF 0.00 VH4-39 VK3-20 15 2 ADI-41520 2849   9.98E−10 N.B. >25 preF 0.00 VH3-20 VK1-39 6 8 ADI-41521 2849   1.68E−09 N.B. >25 preF 0.00 VH3-9 VK3-20 9 11 ADI-41522 2849   2.20E−09 N.B. >25 preF 0.00 VH1-69 VL2-14 10 5 ADI-41523 2849   2.91E−09 N.B. >25 preF 0.00 VH5-51 VK1-39 6 2 ADI-41524 2849   3.18E−09 N.B. >25 preF 0.00 VH3-49 VK2-28 6 3 ADI-41525 2849 N.B.   3.27E−10 >25 PostF 0.00 VH1-69 VL2-14 19 4 ADI-41526 2849   3.01E−10   3.36E−10 >25 Both 0.00 VH1-2 VL1-44 8 6 ADI-41527 2849   7.12E−10   3.37E−10 >25 Both 0.00 VH3-7 VK1-12 4 6 ADI-41528 2849   2.28E−09   3.48E−10 >25 Both 0.00 VH3-30 VL3-1 5 8 ADI-41529 2849   1.03E−09   3.51E−10 >25 Both 0.00 VH1-69 VK3-20 19 7 ADI-41530 2849   1.91E−09   3.55E−10 >25 Both 0.00 VH1-8 VL3-9 10 8 ADI-41531 2849   2.08E−09   3.77E−10 >25 Both 0.00 VH3-23 VK1-33 12 11 ADI-41532 2849   1.92E−09   3.92E−10 >25 Both 0.00 VH5-51 VL1-44 5 3 ADI-41533 2849   1.47E−09   4.23E−10 >25 Both 0.00 VH3-30 VL3-1 10 9 ADI-41534 2849   3.31E−09   4.72E−10 >25 Both 0.00 VH3-30 VL3-1 8 3 ADI-41535 2849   1.93E−09   4.76E−10 >25 Both 0.00 VH2-70D VK1-39 5 6 ADI-41536 2849   3.05E−09   4.76E−10 >25 Both 0.00 VH4-34 VL1-40 10 3 ADI-41537 2849   2.58E−09   4.88E−10 >25 Both 0.00 VH3-23 VK2-28 7 2 ADI-41538 2849   3.44E−09   5.87E−10 >25 Both 0.00 VH3-21 VK4-1 12 4 ADI-41538 2849   3.44E−09   5.87E−10 >25 Both 0.00 VH3-21 VK4-1 12 4 ADI-41539 2849   3.38E−09   6.15E−10 0.18 Both 0.00 VH1-18 VK3-15 6 3 ADI-41540 2849   3.54E−09   6.86E−10 >25 Both 0.00 VH4-34 VK3-20 17 9 ADI-41541 2849   2.47E−09   7.76E−10 >25 Both 0.00 VH2-5 VL3-21 1 2 ADI-41542 2849 N.B.   7.96E−10 0.69 PostF 0.00 VH5-51 VK1-33 9 9 ADI-41543 2849   2.90E−09   7.96E−10 >25 Both 0.00 VH1-2 VK2-28 16 4 ADI-41544 2849 N.B.   8.05E−10 >25 PostF 0.00 VH5-51 VK1-33 6 3 ADI-41545 2849   1.36E−09   8.25E−10 >25 Both 0.00 VH4-59 VL3-21 7 2 ADI-41546 2849 N.B.   1.08E−09 >25 PostF 0.00 VH5-51 VK1-9 4 1 ADI-41547 2849   3.19E−09   1.08E−09 0.05 Both 0.00 VH1-69 VK3-20 11 7 ADI-41548 2849   2.56E−09   1.45E−09 >25 Both 0.00 VH4-4 VK3-15 13 5 ADI-41549 2849   4.08E−10   1.56E−09 >25 Both 0.00 VH3-30 VL2-14 5 2 ADI-41550 2849   2.29E−10   2.57E−08 >25 Both 0.00 VH1-18 VL3-21 10 2 ADI-41551 2849   1.30E−08   2.38E−08 >25 Both 0.00 VH3-74 VL3-1 8 8 ADI-43643 2666   7.66E−08 N.B. >25 preF 0.10 VH3-21 VL1-40 0 0 ADI-43644 2665 2.93206E−08 N.B. >25 preF 0.00 VH3-23 VK3-11 0 0 ADI-43645 2666   8.70E−09 N.B. >25 preF 0.25 VH1-69 VK1-5 0 0 ADI-43646 2635 5.34462E−09 N.B. >25 preF 0 VH3-43D VL2-14 0 1 ADI-43647 2635 N.B.  4.4563E−08 >25 PostF 0 VH3-23 VK1-12 3 0 ADI-43648 2666 N.B.   2.86E−08 >25 PostF 0.10 VH1-8 VL3-9 0 1

TABLE 7 Summary of antibody characteristics for antibodies isolated from PBMCs VH VL RSV preF RSV postF Neutralization IC50 PSR VH VL Protein Protein Name Donor binding KD binding KD (RSV subtype A) Specificiity score Germline Germline Muts Muts ADI-36673 2635 6.20328E−10 N.B. 0.019954073 preF 0.00 VH3-11 VL1-40 7 5 ADI-36675 2635 8.07354E−10 N.B. 0.006 preF 0.00 VH3-23 VL1-51 10 11 ADI-36676 2635 2.82227E−10 N.B. 0.006 preF 0.00 VH3-30 VL3-21 10 5 ADI-36678 2635 7.16249E−10 N.B. 0.006 preF 0.14 VH3-66 VL3-1 14 15 ADI-41552 2635 3.44465E−09 5.21877E−10 >25 Both 0.39 VH3-48 VK3-11 10 4 ADI-41553 2635 N.B. 8.03693E−10 >25 postF 0.22 VH1-18 VK1-5 7 1 ADI-41554 2635 1.34614E−09 1.07074E−09 >25 Both 0.21 VH3-23 VK1-5 8 7 ADI-41555 2635 5.68885E−09 1.12393E−09 25 Both 0.20 VH4-31 VK3-11 8 7 ADI-41556 2635 N.B. 2.27656E−09 >25 postF 0.19 VH3-21 VK3-15 5 3 ADI-41557 2635 3.08525E−08 8.61139E−08 >25 Both 0.17 VH4-59 VK3-15 11 8 ADI-41558 2635 3.01911E−09 7.00004E−10 >25 Both 0.17 VH3-11 VK3-20 14 5 ADI-41561 2635 3.32537E−09 5.15754E−10 >25 Both 0.14 VH2-5 VK1-12 10 8 ADI-41562 2635 N.B. 6.75971E−10 >25 postF 0.12 VH1-18 VK3-15 20 6 ADI-41563 2635 6.02208E−10 N.B. 0.032327297 preF 0.12 VH4-59 VL1-40 11 11 ADI-41564 2635 4.43977E−09 5.95709E−10 >25 Both 0.12 VH1-69 VK3-20 20 0 ADI-41567 2635 7.16511E−10 N.B. 0.050532702 preF 0.11 VH4-34 VK1-9 12 4 ADI-41568 2635 N.B.  2.0658E−09 >25 postF 0.09 VH4-34 VL3-25 7 4 ADI-41569 2635 3.29786E−09 1.60525E−09 >25 Both 0.08 VH1-69 VK3D-15 10 7 ADI-41570 2635 2.97345E−09  1.1235E−09 25 Both 0.08 VH1-69 VL1-51 11 6 ADI-41571 2635 6.27081E−10 N.B. 0.031530527 preF 0.07 VH3-11 VL1-40 14 10 ADI-41574 2635 N.B. 1.23235E−07 >25 postF 0.02 VH2-5 VK1-5 1 7 ADI-41576 2635 N.B. 1.42548E−09 >25 postF 0.01 VH2-5 VK3-11 9 10 ADI-41578 2635 2.48656E−10 N.B. 0.039833521 preF 0.00 VH3-30 VL3-21 11 12 ADI-41579 2635 4.71437E−10 3.59718E−10 0.208709151 Both 0.00 VH1-69 VL2-14 15 13 ADI-41580 2635 2.98246E−09 1.17422E−09 1.107269577 Both 0.00 VH4-34 VK4-1 10 10 ADI-41581 2635  2.7729E−09 3.60691E−10 >25 Both 0.00 VH7-4-1 VK2-28 10 4 ADI-41582 2635 N.B. 9.11488E−10 >25 postF 0.00 VH4-31 VL3-21 6 8 ADI-41583 2635 6.63714E−10 3.80536E−10 >25 Both 0.00 VH1-69 VK1-33 10 1 ADI-41584 2635 3.08613E−09 N.B. >25 preF 0.00 VH1-2 VL1-40 10 5 ADI-41585 2635   6.13E−10 N.B. 0.064052351 preF 0.00 VH3-11 VL1-40 6 3 ADI-41586 2635 5.37539E−10 7.79176E−10 0.401663761 Both 0.00 VH4-34 VK2-28 9 3 ADI-41587 2635  1.4048E−09 2.08899E−09 0.663851609 Both 0.00 VH4-34 VK2-28 8 5 ADI-41588 2635 3.32826E−09 5.04922E−10 >25 Both 0.00 VH2-5 VL3-1 5 2 ADI-41589 2635 4.20258E−09 N.B. >25 preF 0.00 VH3-23 VK4-1 8 8 ADI-41590 2635  3.0202E−09 N.B. >25 preF 0.00 VH3-11 VK1-39 7 10 ADI-41591 2635 4.25861E−09 N.B. >25 preF 0.00 VH3-11 VL1-40 0 2 ADI-41592 2635 3.73679E−09 4.40201E−10 >25 Both 0.00 VH7-4-1 VL3-1 5 13 ADI-41593 2635  1.8323E−09 5.29992E−10 >25 Both 0.00 VH5-51 VK1-8 4 2 ADI-41594 2635 4.13628E−10 N.B. 0.040569222 preF 0.00 VH3-21 VL1-40 10 4 ADI-41595 2635 7.70076E−10 N.B. 0.047476327 preF 0.00 VH3-30 VK1-33 9 11 ADI-41596 2635 3.04558E−10 4.37255E−10 0.053741113 Both 0.00 VH4-34 VK4-1 6 2 ADI-41597 2635 3.56836E−10 N.B. 0.172508371 preF 0.00 VH4-61 VL3-21 6 3 ADI-41598 2635 4.94657E−10 N.B. 0.174094146 preF 0.00 VH4-59 VK1-39 11 11 ADI-41599 2635 7.90767E−10 4.32706E−10 0.636806381 Both 0.00 VH3-48 VK1-39 16 13 ADI-41600 2635 4.93359E−09 7.54853E−10 >25 Both 0.00 VH3-30 VK1D-12 15 9 ADI-41601 2635 5.02595E−10 N.B. >25 preF 0.00 VH3-11 VL1-40 11 10 ADI-41602 2635 2.85465E−09 4.54781E−10 >25 Both 0.00 VH4-59 VL2-14 7 10 ADI-41603 2635 3.49281E−09 4.89905E−10 >25 Both 0.00 VH3-49 VK3-15 10 6 ADI-41604 2635  1.7801E−08 2.92494E−08 >25 Both 0.00 VH1-2 VK1-33 1 0 ADI-41605 2635 3.18275E−09  5.5033E−10 >25 Both 0.00 VH4-31 VK4-1 8 9 ADI-41606 2635 3.38754E−09 1.02586E−09 >25 Both 0.00 VH4-61 VK1D-12 9 7 ADI-41607 2635 4.24282E−09 7.09182E−10 >25 Both 0.00 VH4-31 VL2-11 7 11 ADI-41608 2635 1.93484E−09 2.85427E−10 >25 Both 0.00 VH5-51 VL6-57 15 3 ADI-41609 2635 2.90676E−08 N.B. >25 preF 0.00 VH1-46 VL1-40 14 10 ADI-41610 2635 N.B. 9.78084E−10 >25 postF 0.00 VH3-30 VK1-39 12 1 ADI-41611 2635 3.08502E−09 6.11386E−10 >25 Both 0.00 VH3-21 VK1-39 6 6 ADI-41626 2665   2.60E−09   8.91E−10 >25 Both 0.17 VH4-4 VK1-39 9 9 ADI-41644 2665   3.03E−09   1.10E−09 >25 Both 0.11 VH4-34 VK3D-15 13 14 ADI-41660 2665   2.94E−09   9.55E−10 >25 Both 0.10 VH1-69 VL1-51 5 1 ADI-41662 2665   5.24E−09   1.21E−09 >25 Both 0.10 VH5-51 VL3-10 14 6 ADI-41664 2665   2.94E−09   8.25E−10 >25 Both 0.10 VH1-18 VL3-21 11 5 ADI-41677 2665   1.28E−09   3.39E−10 >25 Both 0.08 VH2-70 VK1-39 5 12 ADI-41678 2665   2.92E−09   1.17E−09 >25 Both 0.08 VH3-30 VL2-8 5 0 ADI-41690 2665 N.B.   8.78E−09 >25 postF 0.03 VH5-51 VK1-33 8 5 ADI-41701 2665   1.93E−09   2.89E−10 >25 Both 0.01 VH5-51 VL6-57 6 9 ADI-41703 2665   4.20E−09   8.43E−10 >25 Both 0.00 VH4-30-2 VK3-20 6 5 ADI-41720 2665   2.20E−08   1.17E−09 >25 Both 0.00 VH3-33 VK1-5 5 2 ADI-41737 2665   3.58E−09   1.58E−09 >25 Both 0.00 VH4-30-4 VK3-20 9 8 ADI-41743 2665   5.45E−09   1.27E−09 >25 Both 0.00 VH4-30-2 VK3-15 14 4 ADI-41756 2665   2.90E−08 N.B. >25 preF 0.00 VH3-30 VL2-14 8 20 ADI-41768 2666 1.61459E−09 3.38298E−10 >25 Both 0.10 VH3-9 VL6-57 6 6 ADI-41772 2666 7.10105E−10 N.B. 0.04 preF 0.10 VH3-11 VL3-10 12 7 ADI-41778 2666 2.75256E−09 5.04199E−10 >25 Both 0.10 VH3-9 VL2-11 5 4 ADI-41781 2666 3.46456E−09 6.53361E−10 >25 Both 0.07 VH1-18 VK1-27 16 4 ADI-41783 2666 5.42456E−10 N.B. 0.25 preF 0.10 VH1-18 VK2-30 7 0 ADI-41787 2666 1.56237E−09 N.B. 0.38 preF 0.10 VH3-30 VL3-10 7 6 ADI-41788 2666  2.755E−10 N.B. 0.47 preF 0.10 VH1-8 VL3-21 8 1 ADI-41790 2666 3.15261E−09 N.B. >25 preF 0.10 VH1-69 VK3-11 7 6 ADI-41792 2666 2.98373E−08 N.B. >25 preF 0.10 VH3-21 VL1-40 2 1 ADI-41794 2666 3.30922E−09 3.01006E−09 >25 Both 0.10 VH4-34 VL1-51 0 3 ADI-41799 2666 3.27629E−09 1.10141E−09 >25 Both 0.14 VH1-69 VK1-5 17 5 ADI-41800 2849   3.24E−09 N.B. >25 preF 0.40 VH1-2 VL2-14 10 5 ADI-41803 2849   1.99E−09   7.11E−10 >25 Both 0.17 VH4-34 VK1-17 16 6 ADI-41804 2849   3.31E−10   4.36E−10 >25 Both 0.15 VH4-34 VK1-27 11 5 ADI-41805 2849 N.B.   2.00E−09 >25 postF 0.14 VH5-51 VL2-14 4 7 ADI-41807 2849   1.50E−09   1.19E−09 >25 Both 0.14 VH2-70 VK1-39 6 10 ADI-41808 2849   1.39E−08   2.25E−08 >25 Both 0.14 VH1-69 VK1-5 21 7 ADI-41809 2849   2.65E−09 N.B. >25 preF 0.12 VH3-23 VL1-47 9 5 ADI-41810 2849   2.03E−09 N.B. >25 preF 0.11 VH3-30 VK3-15 7 8 ADI-41811 2849   1.64E−09   7.44E−10 >25 Both 0.11 VH6-1 VK3-11 10 7 ADI-41812 2849   3.14E−10 N.B. 0.17 preF 0.11 VH3-21 VL1-40 6 1 ADI-41814 2849   3.39E−09   9.15E−10 >25 Both 0.10 VH2-5 VL1-40 3 13 ADI-41815 2849   3.21E−09 N.B. >25 preF 0.10 VH3-21 VK2-28 9 0 ADI-41816 2849   6.56E−10 N.B. 0.91 preF 0.10 VH1-2 VL3-1 8 2 ADI-41817 2849   6.94E−09   1.58E−08 >25 Both 0.09 VH5-51 VL2-14 7 9 ADI-41818 2849   6.76E−10   3.47E−10 >25 Both 0.03 VH3-66 VK3-20 8 2 ADI-41820 2849   6.49E−08 N.B. >25 preF 0.01 VH3-30 VL7-46 11 4 ADI-41827 2849   1.86E−10 N.B. >25 preF 0.00 VH3-30 VL3-1 10 7 ADI-41828 2849   2.41E−10 N.B. 5.53 preF 0.00 VH3-48 VL3-21 9 0 ADI-41829 2849   2.71E−10 N.B. 0.12 preF 0.00 VH3-21 VL1-40 5 2 ADI-41830 2849   2.90E−10 N.B. 0.12 preF 0.00 VH1-18 VK2-28 13 0 ADI-41831 2849   3.29E−10 N.B. 5.21 preF 0.00 VH3-21 VL1-40 8 3 ADI-41832 2849   6.31E−10 N.B. 0.19 preF 0.00 VH3-23 VK3-20 8 4 ADI-41833 2849   7.23E−10 N.B. 0.02 preF 0.00 VH3-23 VK1-27 7 6 ADI-41834 2849   1.20E−09 N.B. 0.07 preF 0.00 VH3-66 VK1-33 9 5 ADI-41835 2849   1.43E−09 N.B. 0.45 preF 0.00 VH3-23 VL3-1 3 4 ADI-41836 2849   5.74E−09 N.B. >25 preF 0.00 VH1-3 VL1-40 9 8 ADI-41837 2849   7.09E−09 N.B. >25 preF 0.00 VH1-18 VK2-30 4 3 ADI-41838 2849   3.21E−08 N.B. >25 preF 0.00 VH3-30 VL2-14 8 3 ADI-41839 2849   7.88E−09 N.B. >25 preF 0.00 VH3-30 VL3-21 14 2 ADI-41840 2849   3.33E−09 N.B. >25 preF 0.00 VH1-69 VK3-15 17 3 ADI-41841 2849   1.21E−10   2.65E−10 0.04 Both 0.00 VH3-21 VK1-33 6 8 ADI-41842 2849   7.17E−10   4.42E−10 >25 Both 0.00 VH1-8 VK1-39 14 6 ADI-43638 2665 N.B. 9.93404E−09 >25 postF 0.16 VH4-34 VK4-1 0 0 ADI-43639 2635 N.B. 2.32551E−07 >25 postF 0.00 VH7-4-1 VK1-39 0 0 ADI-43640 2665 2.15586E−08 N.B. >25 preF 0.08 VH3-21 VL1-40 0 0 ADI-43641 2665 3.74656E−08 N.B. >25 preF 0.09 VH3-11 VL1-40 0 0 ADI-43642 2635 4.31745E−08 N.B. >25 preF 0.00 VH3-21 VL1-40 0 0 Adenoid- and PBMC-Derived Antibodies Show Similar Levels of Polyreactivity

The specificity of each antibody was assessed using a previously described polyreactivity assay. In healthy adult donors, a relatively large proportion of memory B cell-derived antibodies have been shown to be polyreactive (Tiller, 2007). Consistent with these findings, approximately 35% of antibodies derived from both the adenoid and PBMC samples showed low levels of polyreactivity (FIG. 20A). The percentage of polyreactive clones was relatively similar across the different B cell subsets within each compartment, although the PBMC-derived IgG⁻IgA⁻CD27⁻ B cell population showed a slighter higher proportion of polyreactive clones compared to many of the other B cell subsets (FIG. 20B). A slight enrichment for polyreactive clones was observed among the group of antibodies that bound with weak affinity to RSV F (FIG. 20C). In conclusion, the mucosal and systemic B cell compartments contain a similar proportion of polyreactive clones, with about a third of RSV F-specific B cells in both compartments showing some degree of polyreactivity.

Discussion

A detailed understanding of mucosal and systemic immune responses to natural RSV infection can facilitate the design and evaluation of RSV vaccine candidates. Although previous studies have shown that mucosal antibody responses are important for protection against RSV in both humans and animal models, the specificities and functional activities of these antibodies have remained undefined. Furthermore, the anatomic location(s) and characteristics of RSV-specific memory B cells within mucosa-associated lymphoid tissues have not been thoroughly investigated. By collecting paired adenoid and blood samples from six young children undergoing elective tonsillectomy and using a high-throughput B cell cloning platform, the local and systemic B cell responses to natural RSV infection were analyzed and compared.

RSV F-specific B cell responses were observed in the adenoids of all 6 donors analyzed, whereas such responses were only detected in the peripheral blood samples of 4 of the 6 donors. In addition, in most donors studied, a higher proportion of adenoid-derived antibodies displayed high affinity binding and potent neutralizing activity compared to PBMC-derived antibodies. These results provide evidence that RSV-specific memory B cells are induced and maintained within adenoid tissue and suggest that this local response may be more robust and/or durable than the corresponding systemic response. Hence, adenoidectomy may result in a reduction of local immune competence against RSV, as previously demonstrated by diminished poliovirus-specific antibody levels in nasal secretions from children following tonsillectomy and adenoidectomy (Ogra P. L. (1971) Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus. N. Engl. J. Med. 284:59-6).

The adenoids of all donors studied contained a high frequency of RSV F-specific memory B cells that displayed mutated v-regions but were not isotype-switched and lacked expression of the classical memory B cell marker CD27. Although RSV F-specific B cells that displayed this surface phenotype were also present in peripheral blood, the frequency was significantly lower than that observed in adenoid tissue and the majority of these B cells encoded antibodies that lacked somatic mutations. Unlike the tissue-based IgG⁺ CD27⁻ FCRL4⁺ memory B cell population that has been previously described in human tonsils, the RSV F-specific IgG⁻IgA⁻CD27⁻ B cells observed in the adenoids of these donors did not express FCRL4 or IgG and were highly heterogeneous with respect to IgM and IgD expression. Previous studies have also described atypical memory B cells in peripheral blood that are isotyped-switched, lack CD27 expression, and display lower levels of SHM compared to their CD27⁺ counterparts. In contrast to this population, the atypical adenoid-derived memory B cell subset described here shows similar levels of SHM compared to classical IgG⁺ CD27⁺ memory B cells, suggesting similar antigenic selection characteristics. A single clonal lineage present in both adenoid and peripheral blood of one donor was identified, and the PBMC-derived clone originated from an IgG⁺CD27⁻ B cell whereas the adenoid-derived clone originated from an IgG⁻IgA⁻CD27⁻ B cell, suggesting a possible relationship between these two atypical B cell subsets. RSV F-specific IgA⁺ memory B cells were detected in both adenoid and peripheral blood for all donors.

Previous studies have shown that RSV antibodies that bind preF-specific surfaces are generally more potent than those that recognize epitopes expressed on both pre- and post-F or only on postF. Correspondingly, in the 4 young children analyzed here, over 90% of the neutralizing antibodies isolated from both adenoid and peripheral blood recognized epitopes exclusively expressed on preF. The high abundance of preF-specific neutralizing antibodies and near absence of postF-reactive neutralizing antibodies in adenoid tissue suggests that mucosal vaccines the preserve preF-specific antigenic surfaces may induce higher titers of protective antibodies than postF-based vaccines. Although the majority of mucosal vaccines are particle- or vector-based, it has been shown that preF can spontaneously trigger to adopt postF conformation on the viral surface, underscoring the importance of carefully evaluating the antigenic properties of such vaccine candidates. The extensive panel of antibodies described here could be used as reagents to measure the prefusion and postfusion F content of these vaccines.

Collectively, this demonstrates that 1) adenoids can serve as a major induction site for RSV-specific memory B cell responses and that a large proportion of this response is comprised of atypical IgM+ and/or IgD+ memory B cells; 2) the vast majority of adenoid-derived neutralizing antibodies target epitopes exclusively expressed on preF, which supports the development of preF-based mucosal vaccines that boost local responses.

Methods

Sample Collection

Heparinized blood and tonsillar tissue were collected from the patient after a planned therapeutic tonsillectomy for clinical indications (parental consent obtained during a pre-operative visit in accordance with approved IRB). Tonsillar tissue consisted of tonsils (palatine tonsils) and adenoids (pharyngeal tonsils), which together make up Waldeyer's ring.

After collection, tonsillar tissue was mechanically disrupted, e.g., grinding of tissue between the fritted glass at the end of microscope slides or by proteolytic digestion of the tissue typically with pronase, and mucosal lymphoid populations were isolated by standard methods, e.g., ficoll gradient. Several methods exist to recover secreted immunoglobulins from the mucosal surface of the tissue, e.g., Pope earwick or ex vivo culture systems. Peripheral blood was separated to recover plasma and then further fractionated to recover lymphoid cells.

Isolated lymphoid cells from paired tonsillar tissue and blood were used to identify and characterize monoclonal antibodies from single B cells.

Production of RSV F Sorting Probes

PreF (DS-Cav1) and postF (F ΔFP) trimers were produced with a single biotinylated C-terminal AviTag and then coupled to streptavidin-PE or APC, as described previously (Gilman et al, Sci Immunol 2016). Expression vectors containing a C-terminal 6x His-tag-AviTag or a C-terminal Strep-tag II were co-transfected into FreeStyle 293-F cells at a 1:2 ratio for each variant. The protein was purified from the cell supernatant using Ni-nitrilotriacetic acid (NTA) resin to remove trimers lacking the 6x His-tag-AviTag, then purified over StrepTactin resin. The resin was washed to remove trimers containing only one StrepTagII, and the remaining proteins were then biotinylated using birA (Avidity). The biotinylated proteins were separated from excess biotin by size-exclusion chromatography using a Superdex 200 column (GE Healthcare) in PBS.

Single B Cell Sorting

PBMCs and adenoids from young children were stained using anti-human CD19 (APC-Cy7), CD20 (APC-Cy7), CD3 (PerCP-Cy5.5), CD8 (PerCP-Cy5.5), CD14 (PerCP-Cy5.5), CD16 (PerCP-Cy5.5), FcRL4 (PECy7), IgG (BV605), IgA (488), CD27 (BV421), and a mixture of dual-labeled preF and postF tetramers (25 nM each). To determine the percentage of RSV-F specific B cells expressing IgM or IgD, the adenoid samples were stained using human CD19 (APC-Cy7), CD20 (APC-Cy7), CD3 (PerCP-Cy5.5), CD8 (PerCP-Cy5.5), CD14 (PerCP-Cy5.5), CD16 (PerCP-Cy5.5), IgM (PECy7), IgD (BV510), IgG (BV605), IgA (488), CD27 (BV421), and a mixture of dual-labeled preF and postF tetramers (25 nM each). Tetramers were prepared fresh for each experiment, and total B cells binding to the RSV F tetramers were single cell sorted. Single cells were sorted using a BD FACS Aria II (BD Biosciences) into 96-well PCR plates (BioRAD) containing 20 uL/well of lysis buffer [5 uL of 5X first strand cDNA buffer (Invitrogen), 0.625 uL of NP-40 (New England Biolabs), 0.25 uL RNaseOUT (Invitrogen), 1.25 uL dithiothreitol (Invitrogen), and 12.6 uL dH2O]. Plates were immediately stored at −80° C.

Amplification and Cloning of Antibody Variable Genes

Antibody variable genes (IgH, IgK, and IgL) were amplified by reverse transcription PCR and nested PCRs using cocktails of IgG-, IgA-, and IgM-specific primers, as described previously (Tiller et al, J Immunol 2008). The primers used in the second round of PCR contained 40 base pairs of 5′ and 3′ homology to the digested expression vectors, which allowed for cloning by homologous recombination into S. cerevisiae. The lithium acetate method for chemical transformation was used to clone the PCR products into S. cerevisiae (Gietz and Schiestl, Nat Protoc 2007). 10 uL of unpurified heavy chain and light chain PCR product and 200 ng of the digested expression vectors were used per transformation reaction. Following transformation, individual yeast colonies were picked for sequencing and characterization.

Expression and Purification of IgGs

IgGs were expressed in S. cerevisiae cultures grown in 24-well plates, as described previously (Bornholdt et al, Science 2016). After 6 days, the cultures were harvested by centrifugation and IgGs were purified by protein A-affinity chromatography. The bound antibodies were eluted with 200 mM acetic acid/50 mM NaCl (pH 3.5) into ⅛th volume 2 M Hepes (pH 8.0), and buffer-exchanged into PBS (pH 7.0).

Biolayer Interferometry Binding Analysis

IgG binding to preF (DS-Cav1) and postF (F ΔFP) was measured by biolayer interferometry (BLI) using a ForteBio Octet HTX instrument (Pall Life Sciences). For high-throughput K_(D) determination, IgGs were immobilized on anti-human IgG quantitation biosensors (Pall Life Sciences) and exposed to 100 nM antigen in PBS with 0.1% BSA (PBSF) for an association step, followed by a dissociation step in PBSF. Data were analyzed using the ForteBio Data Analysis Software 7. Kd values were calculated for antibodies with BLI responses >0.1 nm, and the data were fit to a 1:1 binding model to calculate association and dissociation rate constants. The K_(D) values were calculated using the ratio kd/ka.

Polyreactivity Assay

Polyspecificity reagent binding was assessed as previously described (Xu et al, Protein Eng Des Sel 2013). Briefly, soluble membrane protein (SMP) and soluble cytosolic protein (SCP) fractions were prepared from Chinese hamster ovary cells and biotinylated with NHS-LC-Biotin reagent (Pierce, ThermoFisher Cat #21336). 2 million IgG-presenting yeast were transferred to a 96-well assay plate, pelleted to remove supernatant, then the pellets were resuspended in 50 uL of 1:10 diluted stock of biotinylated SCPs and SMPs and incubated on ice for 20 minutes. Cells were washed twice with ice-cold PBSF, and the samples were incubated in 50 uL of secondary labeling mix (Extravadin-R-PE, goat F(ab′) 2-anti human kappa-FITC, and propidium iodide) on ice for 20 minutes. The samples were analyzed for polyspecificity reagent binding using a FACSCanto II (BD Biosciences) with HTS sample injector. Flow cytometry data were analyzed for mean fluorescence intensity in the R-PE channel and normalized to three control antibodies exhibiting low, medium, and high MFI values.

Plasma Neutralization Assay

Infant plasma samples were tested for RSV neutralization in microtiter assays using a recombinant RSV expressing Renilla luciferase (rA2-Rluc; a gift from Dr. Michael Teng, University of South Florida [Fuentes S, Crim R L, Beeler J, Teng M N, Golding H, Khurana S. Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection. Vaccine. 2013 Aug. 20; 31(37):3987-94.]). Hep2 cells were added to 96-well plates at a density of 1.8×104 cells per well in 100<1 of MEM with 2% FBS/1X penicillin-streptomycin solution (2% MEM) and allowed to adhere overnight at 37° C. On the day of the assay, plasma samples were serially diluted 2-fold (1:200 to 1:128,000) in 2% MEM containing rA2-Rluc and incubated for 30 min at 37° C. Culture media was aspirated from the Hep2 cells followed by the addition of 100<<per well of the plasma+rA2-Rluc mixture to duplicate wells. Cultures were maintained at 37° C. for 24 hrs and luciferase expression was quantified in cell lysates using the Renilla Luciferase Assay System (E2820, Promega, Madison, Wis.). Relative light units (RLU) were measured on a BioTek Synergy 2 microplate reader. Neutralization is expressed as the reciprocal of the highest plasma dilution to yield a 50% reduction in RLU as compared to control wells with no added plasma.

Adenoid Neutralization Assay

Adenoid tissue collected on the day of surgery was placed in a sterile 10 cm culture dish. A 1.8 cm circular disc of soft absorbent filter paper (Leukosorb #BSP0669, Pall Corporation, Port Washington N. Y.) was applied to the mucosal surface of the tissue. One ml of PBS with added protease inhibitors (Bestatin 0.1 ug/ml; Aprotinin 1 ug/ml; AEBSF 0.5 ug/ml; Leupeptin 5 ug/ml; Millipore Sigma, St. Louis Mo.) was added to directly to the tissue to moisten the disc. The tissue was allowed to stand for 30 min at room temperature. Excess PBS+ PI was then pipeted from the tissue into a 15 ml conical tube. The filter paper disc was collected with sterile forceps and placed into a separate 15 ml tube. An additional 0.5 ml of PBS+PI was added and the tube was centrifuged at 1,900×g rpm for 10 min. Supernatant recovered directly from the tissue and from the filter disc was retained and tested for RSV neutralizing activity. Supernatants were serially diluted 2-fold (1:4 to 1:256) and tested using the rA2-Rluc microtiter assay. Data is expressed as the dilution corresponding to a 50% inhibitory concentration (IC₅₀) compared to control wells with rA2-Rluc alone.

Example 3. Cluster Analysis of Neutralizing Antibodies According to Biophysical Characteristics

A set of RSV neutralizing antibodies were analysed for sequences of CDRH3 based on biophysical characteristics using a reduced alphabet scheme (Table 8).

The biophysical characteristics were classified as follows:

1 Group small amino acids with C-beta: AST

2. Backbone flexibility: G

3. Backbone rigidity: P

4. Positive charge: KR

5. Negative charge: ED

6. Medium sized polar NQH

7 Large Aromatic: FWY

8. Aliphatic: ILVMC

TABLE 8 Redcued alphabet consensus sequences of neutralizing antibodies Difference from Parent in Cluster Difference Reduced ADI-Name Parent VH_GL VL_GL H3 H3 Number from Parent alphabet ADI-14583 ADI-14583 VH1-18 VK2-30 AREPPVIAAGDFQH AREPPVIAAGDFQH 1 0 0 (SEQ ID NO: 1902) (SEQ ID NO: 1902) ADI-14336 ADI-14583 VH1-18 VK2-30 AREPPVIAAGDFQH AREPPVIAAGDFQH 1 0 0 (SEQ ID NO: 1902) (SEQ ID NO: 1902) ADI-14402 ADI-14583 VH1-18 VK2-30 AREPPVIAAGDFSH AREPPVIAAGDFSH 1 1 1 (SEQ ID NO: 1903) (SEQ ID NO: 1903) ADI-14576 ADI-14583 VH1-18 VK2-30 ARDPPVIAAGDFQH ARDPPVIAAGDFQH 1 1 0 (SEQ ID NO: 1904) (SEQ ID NO: 1904) ADI-14577 ADI-14583 VH1-18 VK2-30 ARGPPVIAADDFQH ARGPPVIAADDFQH 1 2 2 (SEQ ID NO: 1905) (SEQ ID NO: 1905) ADI-14585 ADI-14583 VH1-18 VK2-30 AREPPVIAAGDFPH AREPPVIAAGDFPH 1 1 1 (SEQ ID NO: 1906) (SEQ ID NO: 1906) ADI-20975 ADI-20975 VH1-18 VL3-21 AREQFKWNDFYFDY AREQFKWNDFYFDY 2 0 0 (SEQ ID NO: 1907) (SEQ ID NO: 1907) ADI-19422 ADI-20975 VH3-30 VL3-21 AKEDYNWNDYYFDY AKEGYNWNDYYFDY 2 5 2 (SEQ ID NO: 1908) (SEQ ID NO: 1908) ADI-41788 ADI-20975 VH1-8 VL3-21 ARGFYKWNDWSFDY ARGFYKWNDWSFDY 2 5 3 (SEQ ID NO: 1909) (SEQ ID NO: 1909) ADI-41191 ADI-41191 VH1-18 VK2-30 AREPPSLSAAATLDY AREPPSLSAAATLDY 3 0 0 (SEQ ID NO: 1910) (SEQ ID NO: 1910) ADI-19501 ADI-41191 VH1-18 VK2-30 ARDPPSEGAAGLFDY ARDPPSEGAAGLFDY 3 6 5 (SEQ ID NO: 1911) (SEQ ID NO: 1911) ADI-20962 ADI-41191 VH1-18 VK2-30 AREPPSDTAAGTGDY AREPPSDTAAGTGDY 3 4 3 (SEQ ID NO: 1912) (SEQ ID NO: 1912) ADI-22757 ADI-41191 VH1-18 VK2-30 ARDPPAV-AASFMDV ARDPPAV-AASFMDV 3 8 3 (SEQ ID NO: 1913) (SEQ ID NO: 1913) ADI-41424 ADI-41191 VH1-18 VK2-30 VRDTPAIAGAATLDF VRDTPAIAGAATLDF 3 8 3 (SEQ ID NO: 1914) (SEQ ID NO: 1914) ADI-41454 ADI-41191 VH1-18 VK2-30 AREPPSTTAAATSDY AREPPSTTAAATSDY 3 3 2 (SEQ ID NO: 1915) (SEQ ID NO: 1915) ADI-20964 ADI-20964 VH1-18 VK2-30 ARDVPVEAATSPEF ARDVPVEAATSPEF 4 0 0 (SEQ ID NO: 1916) (SEQ ID NO: 1916) ADI-20988 ADI-20964 VH1-18 VK2-30 ARDVPVIAAHTFEY ARDVPVIAAHTFEY 4 5 3 (SEQ ID NO: 1917) (SEQ ID NO: 1917) ADI-21050 ADI-20964 VH1-18 VK2-30 AREMGVDAAATFDY AREMGVDAAATFDY 4 9 2 (SEQ ID NO: 1918) (SEQ ID NO: 1918) ADI-20974 ADI-20974 VH3-21 VL1-40 ARALMATAGGLAFDI ARALMATAGGLAFDI 5 0 0 (SEQ ID NO: 1919) (SEQ ID NO: 1919) ADI-24839 ADI-20974 VH3-21 VL1-40 ARVLVATAYGNAFDI ARVLVATAYGNAFDI 5 4 3 (SEQ ID NO: 1920) (SEQ ID NO: 1920) ADI-41203 ADI-41203 VH5-51 VK3-15 VSLYSDYDYGALDY VSLYSDYDYGALDY 6 0 0 (SEQ ID NO: 1921) (SEQ ID NO: 1921) ADI-36680 ADI-41203 VH5-51 VK3-15 VSLFGDYDYGALDY VSLFGDYDYGALDY 6 2 1 (SEQ ID NO: 1922) (SEQ ID NO: 1922) ADI-36681 ADI-41203 VH5-51 VK3-15 VTLYTDYDYGAPDH VTLYTDYDYGAPDH 6 4 2 (SEQ ID NO: 1923) (SEQ ID NO: 1923) ADI-41344 ADI-41344 VH3-21 VL1-40 ARVSSPMIRGYYLDY ARVSSPMIRGYYLDY 7 0 0 (SEQ ID NO: 1924) (SEQ ID NO: 1924) ADI-41343 ADI-41344 VH3-21 VL1-40 ARVDTPMVRGYYFDY ARVDTPMVRGYYFDY 7 4 2 (SEQ ID NO: 1925) (SEQ ID NO: 1925)

Example 4. Exemplary Antibodies

Antibodies were assessed for RSV neutralization activity and polyreactivity. A set of antibodies with exemplary characteristics are provided in Tables 9A-C.

TABLE 9A Antibody binding and functional characteristics neut IC50 neut IC50 neut IC50 Neutralization - (ug/ml) (ug/ml) (ug/ml) Antibody RSV A2 IC50 subtype A subtype B subtype A RSV PreF RSV PostF Polyreactivity No. ADI Name (pM) (graham) (graham) (wright) Antigenic site subtype A KD subtype A KD score Ab 2 ADI-14334 189.2 0.05 0.11 Site III 3.2E−10 N.B. 0.00 Ab 71 ADI-14405 58.3 0.04 0.04 Site IV 1.4E−10 1.2E−08 0.03 (but preF-preferring) Ab 112 ADI-14583 124.6 0.05 0.06 Site V 4.7E−10 N.B. 0 Ab 217 ADI-20964 162.4 0.06 0.14 Site V 3.6E−10 N.B. 0 Ab 227 ADI-20974 75.4 0.003 0.09 Site III 2.9E−10 N.B. 0.11 Ab 228 ADI-20975 67 0.05 0.49 unknown 9.2E−11 1.5E−10 0.03 Ab 249 ADI-20998 74 0.03 >25 Site 0 2.6E−10 N.B. 0.11 Ab 466 ADI-36669 110.9 0.025 1.1E−09 N.B. 0.01 Ab 467 ADI-36670 141 0.008 7.5E−10 N.B. 0.01 Ab 469 ADI-36672 206.7 0.018 Likely site III 7.0E−10 N.B. 0.07 Ab 470 ADI-36674 189.8 0.014 Likely site III 7.5E−10 N.B. 0.01 Ab 832 ADI-36676 130.1 0.006 2.8E−10 N.B. 0 Ab 471 ADI-36677 144.1 0.019 5.4E−10 N.B. 0.05 Ab 516 ADI-41191 154.1 0.071 Likely site V 5.0E−10 N.B. 0.08 Ab 527 ADI-41203 23.9 0.006 4.0E−10 N.B. 0.05 Ab 532 ADI-41208 310.5 0.077 Likely site III 4.8E−10 N.B. 0.04 Ab 543 ADI-41221 65.4 0.040 3.0E−10 3.2E−10 0.01 Ab 544 ADI-41222 39.9 0.016 4.3E−10 N.B. 0.01 Ab 551 ADI-41229 228.2 0.066 1.1E−09 7.1E−10 0 Ab 554 ADI-41232 103.9 0.025 Likely site V 7.1E−10 N.B. 0.00 Ab 571 ADI-41249 51.7 0.006 3.9E−10 N.B. 0 Ab 578 ADI-41256 85.8 0.019 3.5E−10 N.B. 0.00 Ab 581 ADI-41259 122 0.015 3.4E−10 N.B. 0.00 Ab 592 ADI-41274 26.6 0.109 Likely site III 4.8E−10 N.B. 0.10 Ab 615 ADI-41302 132.9 0.006 6.5E−10 N.B. 0.03 Ab 641 ADI-41344 228.6 0.064 Likely site III 4.9E−10 N.B. 0 Ab 843 ADI-41563 139.3 0.032 6.0E−10 N.B. 0.12 Ab 868 ADI-41594 208.3 0.041 Likely site III 4.1E−10 Weak binder 0 (low response) Ab 870 ADI-41596 179.7 0.054 3.0E−10 4.4E−10 0

TABLE 9B Antibody VH sequence information Anti- VH body Germ- No. line VH FR1 VH CDR1 VH FR2 VH CDR2 VH FR3 VH CDR3 VH FR4 Ab 2 VH3-11 EVQLVESGGGLVK VTVSSYYMT WVRQAPGKGL DISSSSTYTNYA RFTISRDNAKSSLYL ARLGITVTGVGYFDL WGRGTLV PGGSLRLSCAASG (SEQ ID  EFIS DSVKG QMNNLRAEDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 1927) (SEQ ID  (SEQ ID  (SEQ ID NO:  1931) (SEQ ID  1926) NO: 1928) NO: 1929) 1930) NO: 1932) Ab 71 VH1-18 QVQLVQSGTEVKK YTFTNYDIS WVRQAPGQGL WISGSTGNTIYA RLTMTTDTSTSTAYM ARDNVGYASGNYFDY WGQGTLV PGASVKVSCKASG (SEQ ID   EWMG QNLQG ELRSLRSDDTAIYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 1934) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  1938) (SEQ ID   1933) NO: 1935) 1936) 1937) NO: 1939) Ab 112 VH1-18 QVQLVQSGAEVKE YTFTNYGIS WVRQAPGQGL WISAYNGNIHYA RVTMTTDTSTSTGFM AREPPVIAAGDFQH WGQGTLV PGASVKVSCKASG (SEQ ID   EWLG QKVQG ELRSLRSDDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 1941) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  1945) (SEQ ID   1940) NO: 1942) 1943) 1944) NO: 1946) Ab 217 VH1-18 QVQLVQSGAEVKK YTFTHYGIS WVRQAPGQGL WISAYNGNTNYA RVTMTTDTSTSTAYM ARDVPVEAATSPEF WGQGTLV PGASVKVSCKASG (SEQ ID   EWMG QKLQG EVRSLRYDDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 1948) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  1952) (SEQ ID   1947) NO: 1949) 1950) 1951) NO: 1953) Ab 227 VH3-21 EVQLVESGGGLVK FSFSSYQIN WVRQAPGKGL SISGGSSYTDYA RFTISRDNAKKSAEL ARALMATAGGLAFDI WGQGTMV PGGSLRLSCAASG (SEQ ID   EWVS DSIKG QMKSLRADDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 1955) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  1959) (SEQ ID   1954) NO: 1956) 1957) 1958) NO: 1960) Ab 228 VH1-18 QVQLVESGTHVKK DTFNNKGIV WVRQAPGQGL WIRPNNGNTKYA RVTMTTDASTNTAYM AREQFKWNDFYFDY WGQGTLV PGASVKVSCEASD (SEQ ID   EWMG QKEQG ELRSLRSGDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 1962) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  1966) (SEQ ID   1961) NO: 1963) 1964) 1965) NO: 1967) Ab 249 VH3-33 QVQLVQSGGGVVQ FTLSTYGMH WVRQAPGKGL VIYYDESNKFYA RFTISRDDSKNTLFL ARESRPRGYSYSDFD WGQGTLV PGRSLRLSCAASG (SEQ ID   EWVA DSVQG QMNSLRAEDTAVYYC S TVSS (SEQ ID NO:  NO: 1969) (SEQ ID   (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   1968) NO: 1970) NO: 1971) 1972) 1973) NO: 1974) Ab 466 VH1-46 EVQLVQSGAEVKK YTFTTYYIH WVRQAPGQGL MINPSGGTTSYA RLTMTGDTSTSTVYM TRDFIYFYGSGDGFD WGQGTLV PGASVRVYCKASG (SEQ ID   EWMG QKFQG ELNYLRSEDTAVYYC Y TVSS (SEQ ID NO:  NO: 1976) (SEQ ID   (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   1975) NO: 1977) NO: 1978) 1979) 1980) NO: 1981) Ab 467 VH1-69 QVQLVQSGAEVKK GTFSTYTIN WVRQAPGQGL RITPSLGVPLSA RITISADKSTTTAYM ASLNYYDTTDYYLGY WGQGTLV PGSSVKVSCKASG (SEQ ID   EWMG QKFQG ELSSLGSEDTAVYYC SDS TVSS (SEQ ID NO:  NO: 1983) (SEQ ID   (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   1982) NO: 1984) NO: 1985) 1986) 1987) NO: 1988) Ab 469 VH3-11 EVQLVESGGGLVK FAFNNYYMN WVRQAPGKGL SISSASTYTDYA RFTISRDNAKNSLYL ARDYYGSGNYYNPKP WGQGTTV PGGSLRLSCAASG (SEQ ID   EWVS DSVKG HLNSLRAEDTAVYYC LDV TVSS (SEQ ID NO:  NO: 1990) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   1989) NO: 1991) 1992) 1993) 1994) NO: 1995) Ab 470 VH3-21 EVQLLESGGGLVK FKFRSYSMN WVRQAPGKGL SISSSSSYVDYA RFTISRDNAENSLYL ARAGSVPVAGTYNDY WGQGTLV PGGSLRLSCAASG (SEQ ID   EWVS GSEKG QMNSLRAEDTAMYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 1997) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  2001) (SEQ ID   1996) NO: 1998) 1999) 2000) NO: 2002) Ab 832 VH3-30 EVQLLESGGGVVQ FSFRNYDMH WVRQAPGKGL IISYDGSNK- RFTISRDTSKNTLYL ARADSSGYYKGSEYF WGQGTLV PGRSLRLSCAASG (SEQ ID   EWVA YADSVKG QMNSLRVEDTAVYYC QH TVSS (SEQ ID NO:  NO: 2004) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   2003) NO: 2005) 2006) 2007) 2008) NO: 2009) Ab 471 VH3-48 QVQLVQSGGGLVQ FTFSSYEMN WVRQAPGKGL YISSSGDTKYYA RFTVSRDNAKYSLYL ASLYDSRGYYWVFDY WGQGTLV PGGSLRLSCAASG (SEQ ID   EWIS DSVKG QMDSLRAEDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 2011) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  2015) (SEQ ID   2010) NO: 2012) 2013) 2014) NO: 2016) Ab 516 VH1-18 QVQLVQSGAEVKR YIFSHYGIS WVRQAPGQGL WISAYNGNTNYA RVTVTTDTSTSTAYM AREPPSLSAAATLDY WGQGTLV PGASVKVSCKASG (SEQ ID   EWMA QKLQG ELRSLRSDDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 2018) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  2022) (SEQ ID   2017) NO: 2019) 2020) 2021) NO: 2023) Ab 527 VH5-51 QVQLVQSGAEVRK YRFTNYWIG WVRQMPGKGL VIYPGDSDTRYS QVTMSADKSTNTAYL VSLYSDYDYGALDY WGQGTLV PGESLKISCKASG (SEQ ID   EWMG PSFQG QWSSLKASDTAIYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 2025) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  2029) (SEQ ID   2024) NO: 2026) 2027) 2028) NO: 2030) Ab 532 VH3-11 QVQLVESGGDLVK FTLSGHYMS WIRQPPGKGL SISGSSTYTNYA RFTISRDNAENSLYL ARLAYSDYGPFYFDL WGRGTLV PGGSLRLSCAASG (SEQ ID   EWVS DSVKG QMNSLRAEDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 2032) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  2036) (SEQ ID   2031) NO: 2033) 2034) 2035) NO: 2037) Ab 543 VH3-21 EVQLLESGGGLVK FTFSDYTMN WVRQAPGKGL SISITSSHIYYA RFTISRDNAKNSLYL ARELGFASSSYSYYY WGQGTTV PGGSLRLSCAASG (SEQ ID   EWVS DSVKG QINSLRAEDTAAYYC GMDV TVSS (SEQ ID NO:  NO: 2039) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   2038) NO: 2040) 2041) 2042) 2043) NO: 2044) Ab 544 VH3-30 QVTLKESGGGVVQ FNFHNYAMH WVRQAPGKGL VISYDGSNKNFA RFTISRDNSKNTLNL VRDIVRGSPLFDY WGQGTLV PGRSQRLSCTASG (SEQ ID   EWVA DSVKG QMNNLRAEDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 2046) (SEQ ID   (SEQ ID   (SEQ ID NO:  2050) (SEQ ID   2045) NO: 2047) NO: 2048) 2049) NO: 2051) Ab 551 VH3-30 QVQLVDSGGGVVQ FTFKSYGMH WVRQAPGKGL VISYDEINKYYA RFTISRDYSKNTLSL AKPKTTGYYYLDAFD WGQGTMV PGRSLKLSCAASG (SEQ ID   EWVA DSVKG QMNSLTTEDTAMYYC F TVSS (SEQ ID NO:  NO: 2053) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   2052) NO: 2054) 2055) 2056) 2057) NO: 2058) Ab 554 VH1-18 QVQLVQSGAEVKK YTFTHYGIS WVRQAPGQGL WISAYNGNTNYA RVTVTTDTSTSTAYM ARDSMGGTTLFDY WGQGTLV PGASVKVSCKASG (SEQ ID   EWMA QKLQD ELRSLRSDDTALYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 2060) (SEQ ID   (SEQ ID   (SEQ ID NO:  2064) (SEQ ID   2059) NO: 2061) NO: 2062) 2063) NO: 2065) Ab 571 VH5-51 QVQLVQSGAEVKK DTSTTYWIG WVRQMPGKGL IIFPGDSDTRYS QVTISADKSIMTAYL ATQALRGAFDI WGQGTMV PGESLKISCQVSR (SEQ ID   EWMG PSFQG QLTSLKASDTAMYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 2067) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  2071) (SEQ ID   2066) NO: 2068) 2069) 2070) NO: 2072) Ab 578 VH1-69 QVQLVQSGAEVKS GTFGSYGIS WVRQAPGQGL AIMPMFGTINYA RVTMTADESTSTVYM VRDVFYDILTGYYDA WGKGTTV PGSSATVSCKASG (SEQ ID   EWIG QKFQG DVSSLRPDDTAVYYC DYYHHYMDV TVSS (SEQ ID NO:  NO: 2074) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   2073) NO: 2075) 2076) 2077) 2078) NO: 2079) Ab 581 VH3-11 QVQLVESGGRLVK FTFSDFYMS WIRQAPGKGL YISSSGDDPNYA RFTISRDNSKNSLYL ARDEVGWNNLDYYFG WGQGTTV PGGSLRLSCAASG (SEQ ID   EWVS DSVKG QMNSLRAEDTAVYYC MDV TVSS (SEQ ID NO:  NO: 2081) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   2080) NO: 2082) 2083) 2084) 2085) NO: 2086) Ab 592 VH3-21 EVQLVESGGGLVK FSFSSYAMN WVRQAPGKGL SISAGSSYIDYA RFTISRDNAENSLFL ARVGSYTHGYEFDY WGQGTLV PGGSLRLSCAASG (SEQ ID   QWVS DSVKG QMNSLRVEDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 2088) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  2092) (SEQ ID   2087) NO: 2089) 2090) 2091) NO: 2093) Ab 615 VH3-30 QVQLVESGGGVVQ FTFSSYAMQ WVRQAPGKGL VMTNDGDDKYYA RFTISRDNSKNTLYL ARDLFEWWELLGYCY WGQGTTV PGRSLRLSCAASG (SEQ ID   EWVA DSVRG QMNNLRPEDTAVYYC AMDV TVSS (SEQ ID NO:  NO: 2095) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   2094) NO: 2096) 2097) 2098) 2099) NO: 2100) Ab 641 VH3-21 EVQLVESGGGLVK SSFSSYYMN WVRQAPGKGL SISSSSTYIDYA RFTISRDNAKNSLFL ARVSSPMIRGYYLDY WGQGTLV PGGSLRLSCAASG (SEQ ID   EWVS DSVKG QMNSLRAEDTAVYYC (SEQ ID NO:  TVSS (SEQ ID NO:  NO: 2102) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  2106) (SEQ ID   2101) NO: 2103) 2104) 2105) NO: 2107) Ab 843 VH4-59 QVQLYESGPGLVK DSITNNFWT WIRQPPGKGL YIYYSGSTNYNP RITNSVDLSKNQFSL ARLTSGGVDY WGQGTLV PSETLSLTCTVSD (SEQ ID   EWIG SLKS KLSSVTAADTAVYYC TVSS (SEQ ID NO:  NO: 2109) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   2108) NO: 2110) 2111) 2112) 2113) NO: 2114) Ab 868 VH3-21 EVQLVESGGGLVK FSFSSYYMN WVRQAPGKGL SISPSSSYTNYA RFTISRDNAKDSLYL ARDGLLGITIFGVVQ WGQGTLV PGGSLRLSCAASG (SEQ ID   EWVS DSVKG QMNSLRAEDTAVYYC DY TVSS (SEQ ID NO:  NO: 2116) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   2115) NO: 2117) 2118) 2119) 2120) NO: 2121) Ab 870 VH4-34 QVQLQQWGAGLLK DSFSGYFWT WIRQPPGKGL EINLSGSTNYNP RVTILVDTSKNQFSL ARGLHVSDDQDSSGY WGQGTLV PSETLSLTCAVYG (SEQ ID   EWIG SLKS KLSSVTAADTAVYYC YFHPGSFDY TVSS (SEQ ID NO:  NO: 2123) (SEQ ID   (SEQ ID NO:  (SEQ ID NO:  (SEQ ID NO:  (SEQ ID   2122) NO: 2124) 2125) 2126) 2027) NO: 2128)

TABLE 9C Antibody VL sequence information Anti- VL body Germ- No. line VL FR1 VL CDR1 VL_FR2 VL CDR2 VL FR3 VL CDR3 VL FR4 Ab 2 VL1-40 QPGLTQPPSVSGA TGSSSNIGAGY WYQQLPGTAP DNNNRPS GVPDRFSGSKSGTSASL QSYDSSLSNYV FGTGTKL PGQRVTISC DVH KLLIN (SEQ  AITGLQVEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO:  (SEQ ID NO: 2133) 2134) (SEQ ID 2129) 2130) 2131) 2132) NO: 2135) Ab 71 VL3-21 SYVLTQPPSVSVA GGNNIGSKSVH WYQQRPGQAP YDSVRPS GIPERFSGSNSGNTATL QVWDSSRDHEV FGGGTKL PGKTARIPC VLVIY (SEQ  TISTVEAGDEADPYC TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: (SEQ ID NO: (SEQ ID  2136) 2137) 2138) 2139) 2140) 2141) NO: 2142) Ab 112 VK2-30 ETTLTQSPLSLPV RSSQSLVHSNG WFQQRPGQSP RVSNRDS GVPDRFSGSGSGTDFTL MQGTHWPPD FGQGTRL TLGQPASISC NTYLS RRLIY (SEQ  KISRVEAEDVGLYYC (SEQ ID NO: EIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2148) (SEQ ID  2143) 2144) 2145) 2146) 2147) NO: 2149) Ab 217 VK2-30 DIVMTQTPLSLPV RSSQSLVYSDG WFQQRPGQSP KVSNRDS GVPNRFSGSGSGTDFTL VQNTHWPAYT FGQGTKV TLGQPASISC NTYLS RRLIY (SEQ  KISRVEAEDVGVYYC (SEQ ID NO: EIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2155) (SEQ ID  2150) 2151) 2152) 2153) 2154) NO: 2156) Ab 227 VL1-40 QPVLTQPPSVSGA TGSGSNIGAGY WYQQVPGTAP RNTNRPS GVPDRFSGSKSGTSASL QSYDRSLSVV FGGGTKL PGQRVTISC DVH KLLIL (SEQ  AITGLQAEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2162) (SEQ ID  2157) 2158) 2159) 2160) 2161) NO: 2163) Ab 228 VL3-21 SYELMQPPSVSVA GGSNIGSETVH WYQQKPGQAP DDTDRPS GIPERFSGSNSGNTATL QVRDSRTDDVV FGGGTKL PGQTATITC (SEQ ID NO: VLVVH (SEQ  TISGVEAGDEADFYC (SEQ ID NO: TVL (SEQ ID NO: 2165) (SEQ ID NO: ID NO: (SEQ ID NO: 2169) (SEQ ID  2164) 2166) 2167) 2168) NO: 2170) Ab 249 VL2-11 QPGLTQPRSVSGS TGTSSDVGTFN WYQQHPGKAP DVNQRPS GVPDRFSGSKSGNTASL CAYAGYYS FGGGTKL PGQSVTISC YVS KLMIY (SEQ TISGLQAEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2176) (SEQ ID  2171) 2172) 2173) 2174) 2175) NO: 2177) Ab 466 VK1-17 EICMTQSPSAMSA RASQGISNYLA WFQQKPGKVP AASSLQS GVPSRFSGSGSGTEFTL LQHNSYPFT FGPGTKV SVGDRVTITC (SEQ ID NO: KRLIY (SEQ  TITSLQPEDFATYYC (SEQ ID NO: EIK (SEQ ID NO: 2179) (SEQ ID NO: ID NO: (SEQ ID NO: 2183) (SEQ ID  2178) 2180) 2181) 2182) NO: 2184) Ab 467 VK3-15 DIVLTQTPATLSV RASHSVSNNLA WYQQKPGQAP SASTRAT GIPARFSGRGSGTEFTL QQYNNWPPEYT FGQGTKV SPGERATLSC (SEQ ID NO: RLLIY (SEQ  TISSLQPEDFAVYYC (SEQ ID NO: DIK (SEQ ID NO: 2186) (SEQ ID NO: ID NO: (SEQ ID NO: 2190) (SEQ ID  2185) 2187) 2188) 2189) NO: 2191) Ab 469 VL1-40 QPVLTQPPSVSGA TGSSSNIGAGY WYRQFPGTAP GNTNRPS GVPDRFSGSKSGTSASL QSYDSSLKGV FGGGTKL PGQRVTISC DVH ELLIY (SEQ  AITGLQAEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2197) (SEQ ID  2192) 2193) 2194) 2195) 2196) NO: 2198) Ab 470 VL1-40 QSVLTQPPSVSGA TGSSSNIGAGY WYQHLPGTAP GNNNRPA GVPDRFSGSKSGTSASL QSYDRSLSVL FGGGTKV PGQRVTISC DVH KLLIH (SEQ  VITGLQADDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2204) (SEQ ID  2199) 2200) 2201) 2202) 2203) NO: 2205) Ab 832 VL3-21 SYELTQLPSVSVA GGNNIGTKSVQ WYQHKPGQAP DDSDRPS DIPERFSGSNSGNTATL QVWDSSSDHYV FGTGTKL PGQTARITC (SEQ ID NO: VLVVY (SEQ  TISRVEAGDEADYYC (SEQ ID NO: TVL (SEQ ID NO: 2207) (SEQ ID NO: ID NO: (SEQ ID NO: 2211) (SEQ ID  2206) 2208) 2209) 2210) NO: 2212) Ab 471 VK1-33 DIVMTQSPSSLSA QASQDISTYLN WYQHKPGKAP DASNLEP GVPSRFSGSGSGTDFTF LQHDNLPPT FGQGTKV SVGDRVTITC (SEQ ID NO: NLLIY (SEQ  TISSLQPEDIATYYC (SEQ ID NO: DIK (SEQ ID NO: 2214) (SEQ ID NO: ID NO: (SEQ ID NO: 2218) (SEQ ID  2213) 2215) 2216) 2217) NO: 2219) Ab 516 VK2-30 EIVMTQSPLSLPV RSNQSLVYSDG WFQQRPGQSP KVSNRDS GVPDRFSGSGSGTDFTL MQVTHWPHE FGQGTKL TLGQPASISC NIYLS RRLIY (SEQ  KISRVEAEDVAVYYC (SEQ ID NO: EIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2225) (SEQ ID  2220) 2221) 2222) 2223) 2224) NO: 2226) Ab 527 VK3-15 EIVMTQSPATLSV RASENVGRNLA WYQQKPGQAP GASIRAT GILARFSGSGSGTEYTL QQYHDWPSFT FGPGTKV SPGERATLSC RLLIY (SEQ  TISSLQSEDFAVYYC (SEQ ID NO: DIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2232) (SEQ ID  2227) 2228) 2229) 2230) 2231) NO: 2233) Ab 532 VL1-40 QSVLTQPPSVSGA TGSSSNIGAGY WYQQLTGTAP DNNNRPS GVPDRFSGSKSGTSASL QSYDSRLSAPYV FGTGTKL PGQRVTISC DVH KLLIF (SEQ  AITGLQAEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2239) (SEQ ID  2234) 2235) 2236) 2237) 2238) NO: 2240) Ab 543 VL2-11 QSALTQPRSVSGS TGTSSDVGDYN WYQQHPGTAP DVTQRPS GVPDRFSGSKSANTASL CCSFAGNYV FGTGTKV PGQSVTISC SVS KLIIF (SEQ  TISGLQPEDEADYY- (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2246) (SEQ ID  2241) 2242) 2243) 2244) 2245) NO: 2247) Ab 544 VL3-21 QPVLTQPPSLSVA GGNNIGSKIVH WYQQKPGQAP DDDDRPS GIPERFSGSNSGNTATL QVWDRSSDNYV FGTGTKV PGQTAWITC VVVVY (SEQ  TIRRVEVGDEADYYC (SEQ ID NO: SVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2253) (SEQ ID  2248) 2249) 2250) 2251) 2252) NO: 2254) Ab 551 VK1-33 ETTLTQSPSSLSA QASQDISNYLN WYQQKPGKAP DASNLET GVPSRFSGSGSGTDFTF QQHDNVPPT FGQGTKV SVGDRVTITC KLLIY (SEQ  TISSLQSEDIATYYC (SEQ ID NO: DIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2260) (SEQ ID  2255) 2256) 2257) 2258) 2259) NO: 2261) Ab 554 VK2-30 DIVLTQTPLSLPV RSSQSLVYSDG WFQQRPGQSP KVSNRDS GVPDRFTGSGSGTDFTL MQGTHWPPMYT FGQGTKL TLGQPASISC NTYLN RRLIY (SEQ  KISRVEAEDVGVYYC (SEQ ID NO: EIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2267) (SEQ ID  2262) 2263) 2264) 2265) 2266) NO: 2268) Ab 571 VK1-33 DIRLTQSPSSLSA QASQDISNYLN WYQQKPGKAP DASYLET GVPSRFSGSGSGTDFTF QQYDDLLFT FGPGTKL SVGDRVTITC KLLIY (SEQ  TISSLQPEDFATYYC (SEQ ID NO: EIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2274) (SEQ ID  2269) 2270) 2271) 2272) 2273) NO: 2275) Ab 578 VK2-30 DIVMTQSPLSLPV RSGQSLVHSDG WFQQRPGQSP KVSNRGS GVPDRFSGSGSGTDFTL MQGTHWPRT FGQGTKV TLGQPASISC NTYLN RRLIY (SEQ  KISRVEAEDVGVYFC (SEQ ID NO: DIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 22281) (SEQ ID  2276) 2277) 2278) 2279) 2280) NO: 2282) Ab 581 VK2-30 DIVMTQSPLSLPV RSSQSLVHSDG WFHQRPGQSP KVSNRDS GVPNRFSGGGSGTDFTL MQGTHWQKT FGQGTKV TLGQPASISC NTYLS RRLIY (SEQ  KISRVEAEDVGFFYC (SEQ ID NO: EIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2288) (SEQ ID  2283) 2284) 2285) 2286) 2287) NO: 2289) Ab 592 VL1-40 QPVLTQPPSVSGA TGSNSNIGAGY WYQQLPGTAP ASTIRPS GVPDRFSGSKSGTSASL QSYDRNLSVV FGGGTKV PGQRVTISC DVH KLLIY (SEQ  AITGLQAEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2295) (SEQ ID  2290) 2291) 2292) 2293) 2294) NO: 2296) Ab 615 VL2-8 QSVLTQPPSASGS TGTSSDVGAYN WYQQHPGKAP EVYKRPS GVPDRFFGSKSGNTASL SSYAGSNTLGV FGGGTKV PGQSVTISC YVS KLIIY (SEQ  TVSGLQAEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2302) (SEQ ID  2297) 2298) 2299) 2300) 2301) NO: 2303) Ab 641 VL1-40 QPVLTQPPSVSGA TGSSSNIGAGY WYQQLPGTAP GNSNRPS GVPDRFSGSKSGTSASL QSYDSSLSGSV FGGGTKL PGQRVTISC DVH KLVIH (SEQ  AITGLQDEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2309) (SEQ ID  2304) 2305) 2306) 2307) 2308) NO: 2310) Ab 843 VL1-40 QSVLTQPPSLSGA TGSSSNIGADY WYQQLPGTAP QNTNRPS GVPDRFSASKSGTSVSL QSYDSSLSAWV FGGGTKL PGQRVTISC HVH KLLIY (SEQ  AITGLQAEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2316) (SEQ ID  2311) 2312) 2313) 2314) 2315) NO: 2317) Ab 868 VL1-40 QSVVTQPPSVSGA TGSSSNIGAGY WYQQLPGTAP GNTNRPS GVPDRFSASKSGTSASL QSYDSSLSVV FGGGTKL PGQRVTISC DVH KLLIY (SEQ  AITGLQAEDEADYYC (SEQ ID NO: TVL (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2323) (SEQ ID  2318) 2319) 2320) 2321) 2322) NO: 2324) Ab 870 VK4-1 DIRMTQSPDSLAV KSSQSVLYSSN WYQQKPGQPP WASTRES GVPDRFSGSGSGTDFTL QQYYSTPLT FGGGTKV SLGERATINC NKNYLA KLLIN (SEQ  AISSLQAEDVAVYYC (SEQ ID NO: EIK (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: ID NO: (SEQ ID NO: 2330) (SEQ ID  2325) 2326) 2327) 2328) 2329) NO: 2331)

An informal sequence listing is provided below in Table 5.

TABLE 5 Informal Sequence Listing Antibody SEQ ID No. NO: Sequence Clone # (ADI) Descriptors Ab 1 1 EVQLVETGGGLVKPGGSLRLSCADSGFPFSSYSMHWVRQAPGKGLEWVASISSSSS ADI-14333 Heavy chain variable region FINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYFCAREAACGGDCYGYYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 1 2 QSVVTQPPSASGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKVLISGNSNR ADI-14333 Light chain variable region PSGVPARFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVEGGGTQLTVL (“LC”) amino acid sequence Ab 2 3 EVQLVESGGGLVKPGGSLRLSCAASGVTVSSYYMTWVRQAPGKGLEFISDISSSSTY ADI-14334 Heavy chain variable region TNYADSVKGRFTISRDNAKSSLYLQMNNLRAEDTAVYYCARLGITVTGVGYFDLWG (“HC”) amino acid sequence RGTLVTVSS Ab 2 4 QPGLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIHDNNN ADI-14334 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQVEDEADYYCQSYDSSLSNYVFGTGTKLTVL (“LC”) amino acid sequence Ab 3 5 EVQLVESGGGLVQPGRSLRLSCTASGFTFGDYAMSWVRQAPGKGLEWVGFIRSN ADI-14335 Heavy chain variable region AFGGTSEYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCTRDGIHDYGDSYY (“HC”) amino acid sequence YYGMDVWGQGTTVTVSS Ab 3 6 DIQLTQSPSSLSASVGDRVTITCRASQTVTTYLNWYQQKPGKAPKLLIYGASSLQSG ADI-14335 Light chain variable region VPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQTYSTVTFGPGTKVEIK (“LC”) amino acid sequence Ab 4 7 EVQLLESGGEVKKPGASVKVSCKASGYTFTNYGISWVRQAPGQGLEWMGWISAY ADI-14336 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMEVRRLRSDDTAVYYCAREPPVIAAGDFQ (“HC”) amino acid sequence HWGQGTLVTVSS Ab 4 8 DIVMTQTPLSLPVTLGQPASISCRSSQSLVHSDTNIYLSWFQQRPGQSPRRLIYKVSN ADI-14336 Light chain variable region RDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQGTHWPPDFGQGTRLEIK (“LC”) amino acid sequence Ab 5 9 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-14337 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREYYDSSGYTNWFDP (“HC”) amino acid sequence WGQGTLVTVSS Ab 5 10 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-14337 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLAWVEGGGTQLTVL (“LC”) amino acid sequence Ab 6 11 EVQLVESGGGVVQPGRPLRLSCAASGFTFSTYDLYWVRQAPGKGLDWVAIISPDG ADI-14338 Heavy chain variable region NKKYYADSVKGRFTISRDNSKNTLFLHMNSLRAEDTAVYYCARDYGNYFGSGSYYR (“HC”) amino acid sequence YFDLWGRGTLVTVSS Ab 6 12 DIQLTQSPSSLSASVGDRVTITCRASQSISSHLNWYQQKPGKAPKLLIYASSSLQSGV ADI-14338 Light chain variable region PSRFSGSGSGTDFTLTISGLQPEDFATYYCQQSYSTPFTFGPGTKVEIK (“LC”) amino acid sequence Ab 7 13 QVQLVESGGGVLQPGRSLRLPCEASGFTFNKYAMHWVRQAPGKGLEWVAAVSY ADI-14339 Heavy chain variable region DGGNKFYAESVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCARDRWELLHGLDY (“HC”) amino acid sequence WGLGTLVTVSS Ab 7 14 SYELTQPPSVSVSPGQTARITCSGEALAKQYAYWYQQKPGQAPVLVIYKDNERPSGI ADI-14339 Light chain variable region SERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYVFGTGTKVTVL (“LC”) amino acid sequence Ab 8 15 EVQLVESGGGLVKPGGSLRLSCAASGFTLSSYTMNWVRQAPGRGLEWVSSIYSTSS ADI-14340 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDSQAVTGTDLYFDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 8 16 QPGLTQPPSVSVAPGKTARITCGGNNIGRKNVHWYQQKPGQAPILVIYYDSDRPS ADI-14340 Light chain variable region GIPERFSGSNSGNTATLTISRVEDGDEADYYCQVWDSSNDHVIFGGGTQLTVL (“LC”) amino acid sequence Ab 9 17 QVQLVQSGGGLVQPGGSLRLSCAGSGFTFSDYEMNWVRQAPGKGLEWLSYISSS ADI-14341 Heavy chain variable region GSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTGLYYCARANHRHYYGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 9 18 DIRLTQSPSTLSASVGDRVTITCRASQSIGSWLAWYQQKPGKAPKLLIYKASSLESGV ADI-14341 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGRGTRLEIK (“LC”) amino acid sequence Ab 10 19 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNAKMGVSWIRQPPGKALEWLAYISSND ADI-14342 Heavy chain variable region EKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARILLYDSSGYYLWYFDL (“HC”) amino acid sequence WGRGTLVTVSS Ab 10 20 DIQVTQSPSSLSASVGDRVTITCRASQRITSYLNWYQHKPGKAPKLLIFAASSLHSGV ADI-14342 Light chain variable region PSTFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 11 21 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGVNWVRQAPGQGLEWMGRIIP ADI-14343 Heavy chain variable region MFGTSNYAQKFQGRVTITADGSTSTAYMELSSLRSEDTAVYYCARVGSPTTGAIMG (“HC”) amino acid sequence VWGQGTTVTVSS Ab 11 22 DIVLTQTPLSLPVTPGEPASISCRSSQSLLQSNGFNYLDWYLQKPGQSPKLLIYMGSN ADI-14343 Light chain variable region RASGVPDRFSGSGSGTDFTLIISRVEAEDVGVYYCMQAIESPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 12 23 QVQLVQSGGGLVQPGGSLRLSCAASGFTFRTYALSWVRQAPGKGLEWVSSILGSG ADI-14344 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLQLNSLRAEDTAVYFCAKLAVAGLLHHYYGLD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 12 24 SYELTQPPSVSVSPGQTASITCSGDKLENKYACWYQQKPGQSPVLLIYQDTKRPSGI ADI-14344 Light chain variable region PERFSGSNSGTTATLTISGTQALDEADYYCQAWDSSTASVLFGGGTQLTVL (“LC”) amino acid sequence Ab 13 25 QITLKESGAEVKKPGASVKVSCKVSGYTLSDFSMHWVRQAPGKGLEWMGSFDPE ADI-14345 Heavy chain variable region DGETVDAQKFQGRVTMTEDRSTATAYMELRSLRSEDTAVYYCGTPASAGQVDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 13 26 DIVLTQSPSSLSASVGDRVTITCRASQSISSYLHWYQQKPGKAPKLLIYAASSLQSGVP ADI-14345 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYITPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 14 27 EVQLLESGGGLVKPGGSLRLSCAASGFRFSSYSMNWVRQAPGKWLEWVSSISASSS ADI-14346 Heavy chain variable region YTDYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREDYLSSGSLLHWFD (“HC”) amino acid sequence PWGQGTLVTVSS Ab 14 28 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNR ADI-14346 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSRLSVLFGGGTKVTVL (“LC”) amino acid sequence Ab 15 29 EVQLVESGGGLVKPGGSLRLSCAASGFTFRDYYMNWIRQAPGKGLEWVSDISASSS ADI-14347 Heavy chain variable region YTNYADSVKGRFTISRDNAKTSLYLQMNSLRAEDTAVYYCAREVVTAMGGYYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 15 30 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNN ADI-14347 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSGVFGTGTKVTVL (“LC”) amino acid sequence Ab 16 31 QVQLVESGGGVAQPGGSLRLSCVASGFTFSNYGMHWVRQAPGKGLEWVAFIRSD ADI-14348 Heavy chain variable region GSKKYYGDSGKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARERAGATFAFDIW (“HC”) amino acid sequence GQGTTVTVSS Ab 16 32 QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNFVSWYQHHPGKAPKLMIYDVTN ADI-14348 Light chain variable region RPSGVPDRFSGSKSGNTASLTISGLQADDEADYYCCSYAGGFTFYVFGTGTKVTVL (“LC”) amino acid sequence Ab 17 33 EVQLVESGAEVKKPGSSVKVSCKASGGTLSSYAFSWVRQAPGQGLEWMGGVIPIS ADI-14349 Heavy chain variable region ATSDYAQKFQGRVTITADESTSTVYMELRSLRSEDTAVYYCARDTRYSSGWFYDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 17 34 DIRLTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPNLLIYWA ADI-14349 Light chain variable region STRDSGVPDRFSGSGSGTDFTLTISRLQAEDVAVYYCQQYYSTPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 18 35 EVQLVESGPGLVKPSETLSLTCTVSGDSVSNNNYYWNWIRQSPGKGLEWIGYIYYS ADI-14350 Heavy chain variable region GSTDYNPSLKSRVTISVDTSKNQFSLNLRSVTAADTAIYFCASAPWGMFTILGVVPSY (“HC”) amino acid sequence YYGMDVWGQGTTVTVSS Ab 18 36 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSNR ADI-14350 Light chain variable region PSGVPDRFSGSRSGTSASLAITGLQAEDEADYYCQSYDGSLGVYVFATGTKVTVL (“LC”) amino acid sequence Ab 19 37 EVQLLESGGGLVQPGGSLRLSCSASGFTFSTYWMHWVRQAPGKGLVWVSRINGD ADI-14351 Heavy chain variable region GNDRNYADSVKGRFTISRDNAKNTVYLQMNSLRAEDTAVYYCARGGATGDFYFG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 19 38 SYELTQPPSVSVAPGKTAKITCGGNNIGTKSVHWYQQKPGQAPVLVIYYDTDRPSGI ADI-14351 Light chain variable region PERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSNSDHVGVFGGGTQLTVL (“LC”) amino acid sequence Ab 20 39 EVQLLETGPGLVKPSQTLSLICAVSGGSISSGGYSWSWIRQPPGKGLEWVGYISYSG ADI-14352 Heavy chain variable region STYYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYFCARVDGIYSSGMRFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 20 40 DIQLTQSPGTLSLSPGERATLSCRASQSVSSYYLAWYQQKPGQAPRLLIYGTSSRATG ADI-14352 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSPLFGQGTRLEIK (“LC”) amino acid sequence Ab 21 41 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIKPIIG ADI-14353 Heavy chain variable region IANNAQRFKGRVTITAEKSTGTAYMELSSLTSEDTAVYYCARGGYDYYGMDVWGQ (“HC”) amino acid sequence GTTVTVSS Ab 21 42 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWHQQHPGKAPKLLIYDVSNR ADI-14353 Light chain variable region PSGVSNRFSGSKSGNTASLSISGLQAEDEADYYCSSFTSTSTPYVFGTGTQLTVL (“LC”) amino acid sequence Ab 22 43 QVQLVQSGAEVKKPGSSAKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPFL ADI-14354 Heavy chain variable region GIANYAQKFQGRVTFTADKSTSTVYMDLSRLRSEDTALYYCAREPMYYGGDSYAFD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 22 44 QSVLTQPASMSGSPGHSITISCTGTSSDVGAYNYVSWYQQHPGKAPKLMIYDVSN ADI-14354 Light chain variable region RPSGVSSRFSGSKSGNTASLTISGLQPEDEADYYCSSFTTSSTRVEGTGTKLTVL (“LC”) amino acid sequence Ab 23 45 EVQLVESGPTLVKPTQTLTLICTFSGFSLSTSGVGVGWIRQPPGKALEWLAVIYWD ADI-14355 Heavy chain variable region DDKTYSPSLKSRLTITKDTSKNQVVLTMTNMNPVDTATYYCARCPAPVYSYGVDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 23 46 QSALTQPASVSGSPGQSITISCTATSSDFGGYDYVSWYQQHPGEAPKLMISDVTNR ADI-14355 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSYTTPYVFGTGTKLTVL (“LC”) amino acid sequence Ab 24 47 QVQLQESGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGS ADI-14356 Heavy chain variable region TNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDQRIVVVGAATEPYYYY (“HC”) amino acid sequence YGMDVWGQGTTVTVSS Ab 24 48 QPVLTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSG ADI-14356 Light chain variable region IPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYRVFGGGTKLTVL (“LC”) amino acid sequence Ab 25 49 EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQAPGKGLEWVSIISYDG ADI-14357 Heavy chain variable region SNKYYADSVKGRFTISRDNSKNTLYLQINSLRTEDTAVYYCARARKRIPIVVVTAPYYY (“HC”) amino acid sequence GMDVWGQGTTVTVSS Ab 25 50 DIRVTQSPSSLSASVGDRVTITCRASQSISSYLHWYQQQPGKAPNLLIYAASNLQSG ADI-14357 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPHTFGQGTKVEIK (“LC”) amino acid sequence Ab 26 51 QVQLVQSGGGLVKPGGSLRLSCVASGFTFSDYYMTWIRQAPGKGLEWVSYISGSS ADI-14358 Heavy chain variable region AYTIYADSVKGRFTISRDNAKNSLYLQMNGLRAEDTAVYYCARVSWVRSLDSWGQ (“HC”) amino acid sequence GTLVTVSS Ab 26 52 QSALTQPASVSGSPGQSITISCTGSTSDVGLYNYVSWYQLHPGKAPKLIIYDVRHRPS ADI-14358 Light chain variable region GVSDRFSASKSGNTASLTISGLQAEDEADYYCCSYTSSSTYVFGSGTQLTVL (“LC”) amino acid sequence Ab 27 53 QVQLVQSGPALVKPTQTLTLICTFSGFSLSTSGMCVSWIRQPPGKALEWLARIDW ADI-14359 Heavy chain variable region DDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARATNYDSSGYYSLY (“HC”) amino acid sequence FDYWGQGTLVTVSS Ab 27 54 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSG ADI-14359 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 28 55 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYSMHWVRQAPGQRLEWMGWIN ADI-14360 Heavy chain variable region AGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARDGVGGAYYYG (“HC”) amino acid sequence EMDVWGQGTTVTVSS Ab 28 56 EIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNR ADI-14360 Light chain variable region ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPRFTFGPGTKVEIK (“LC”) amino acid sequence Ab 29 57 EVQLLESGGGFVQPGGSLRLSCAASGFTFSSYAVNWVRQAPGKGLEWVSLISGSGR ADI-14361 Heavy chain variable region TDYTDSVKGRFTISRDNAKNTLFLQMNSLRVEDTAVYYCAKSWGSSGYGYLDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 29 58 QSGLTQPPSVSGAPGQRVTISCTGSSSNIGPGTDVHWYQHFPGTAPKLLIFGNSNR ADI-14361 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEAYYYCQSYDRILSASVFGGGTKLTVL (“LC”) amino acid sequence Ab 30 59 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSG ADI-14362 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLEMNSLRAEDTAVYYCAKRYYYGSGTYTFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 30 60 DIRLTQSPSSLSASVGDRVTITCRASQSIISYLNWYQQKPGKAPKLLIYAASSLQSGVP ADI-14362 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 31 61 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISGGG ADI-14363 Heavy chain variable region TYTKYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCARDVALVGWELRYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 31 62 ETTLTQSPGTLSLSPGERATLSCRARENVNSSYLAWYQQKPGQAPRLLIYGASSRAT ADI-14363 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAISPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 32 63 QVQLVQSGAEVKKPGESLKISCKGSGYSFTSHWIGWVRQMPGKGLEWMGITDPG ADI-14364 Heavy chain variable region DSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAREPRRWMTTETNG (“HC”) amino acid sequence PYYFDNWGQGTLVTVSS Ab 32 64 SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGI ADI-14364 Light chain variable region PERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDNRVFGGGTKVTVL (“LC”) amino acid sequence Ab 33 65 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTKLSMHWVRQAPGKGLEWMGFFDP ADI-14365 Heavy chain variable region EDGDTLYAQKFQGRVTMTEDTSSDTPYMELRSLRSEDTAVYYCASPAAAGQFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 33 66 DIVMTQSPSSLSASVGDRVTITCRASQFISSYLHWYQQKTGKAPKLLIYAASSLQSGV ADI-14365 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNTPRTFGQGTKLEIK (“LC”) amino acid sequence Ab 34 67 QVQLVQSGTEVKKPGASVKVSCKASGYTFNMYGVSWVRQAPGQGLEWMGWIS ADI-14366 Heavy chain variable region AYNGNTNYAQKFQGRVTMTIDTSTTTAYMELRSLRSDDTAMYYCARDFQAEEPLS (“HC”) amino acid sequence NWFDPWGQGTLVTVSS Ab 34 68 DIVMTQTPSSLSASVGDRVIITCRASQSISRYINWYQKKPGKAPKFLIYAVSSLGSGVP ADI-14366 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIK (“LC”) amino acid sequence Ab 35 69 EVQLLESGGGLVQPGGSLRLSCAASGFTFGSYDMNWVRQAPGKGLEWVSGISGS ADI-14367 Heavy chain variable region GDATYYADSVKGRFTISRDNSKNMLYLQMNSLSAEDMAVYYCARDRAFTMKYNS (“HC”) amino acid sequence NWYKIYWGQGTMVTVSS Ab 35 70 EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQQKPGQAPRLLIYGAFSRATG ADI-14367 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHHYGTSRWTFGQGTKVDIK (“LC”) amino acid sequence Ab 36 71 EVQLVESGGGLVKPGGSLRLSCAASGFTFINAWMSWVRQAPGKGLEWVGRIKSK ADI-14368 Heavy chain variable region ADGGTTDDAAPVKGRFTISRDDSKNTLYLQMNSLKIEDTAVYYCATDVLPLYNWNL (“HC”) amino acid sequence GWNFDLWGRGTLVTVSS Ab 36 72 SYVLTQPPSVSVAPGKTARITCGGNNIADKSVHWYQQKPGQAPVLVMYYDTDRPS ADI-14368 Light chain variable region GIPERFSGFNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKVTVL (“LC”) amino acid sequence Ab 37 73 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNAISWVRQAPGQGLEWMGGIIPIF ADI-14369 Heavy chain variable region ATANYAQNFQDRVTITADESTGTAYMELSSLRYEDTAVYYCAKSAIHSGYHGPARS (“HC”) amino acid sequence GFYQNGMDVWGQGTTVTVSS Ab 37 74 SYELTQPPSASGTPGQRVTISCSGSSSNIGINPVNWYQHFPGTAPKLLIYRNNQRPS ADI-14369 Light chain variable region GVPDRFSGSKSGTSASLAISGLQSEDEAVYYCAAWDDRLNGPVFGGGTQLTVL (“LC”) amino acid sequence Ab 38 75 EVQLVESGGGVVQPGKSLRLSCAASGFSFSTFAMHWVRQAPGKGLEWVAVISYD ADI-14370 Heavy chain variable region GSNKFYADSVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARGGYSSGWYVTHF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 38 76 QSVLTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKR ADI-14370 Light chain variable region PSGVPDRFSGSKSGNTASLIVSGLQAEDEADYYCSSYAGSNNLYVEGTGTKLTVL (“LC”) amino acid sequence Ab 39 77 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMTWVRQAPGKGLEWLSSISGSG ADI-14371 Heavy chain variable region GSTYYADSVKGRFTISRDNSRNTLYVQMNSLRVEDTAFYYCAKAFYEYGAGSPGDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 39 78 DIQLTQSPSSLSASVGDRVTITCRASQSIGTNLNWYQQKPGKAPKFLIYAASSLQRG ADI-14371 Light chain variable region VPSRFSGSGSGSEFTLTISSLQPEDFATYYCQQSYSTLPITFGQGTKLEIK (“LC”) amino acid sequence Ab 40 79 QVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGQGLEWVSRISAT ADI-14372 Heavy chain variable region GGSTHYADSVRGRFTISRDNSKNTLYLQMNSLKAEDTAVYYCAKDRGYSRNLTPDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 40 80 ETTLTQSPSSLSASVGDRVTITCRASQGITNDLGWYQKKPGKAPKLLIYVASSLQSGV ADI-14372 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPITFGQGTKVDIK (“LC”) amino acid sequence Ab 41 81 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGSYWSWIRQPPGKGLEWIGEINHSG ADI-14373 Heavy chain variable region STSYNPSLKSRVTISVDTSKKQFSLKLSSMTAADTAVYYCAGGFYYDSSGSYAPHPTF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 41 82 DIVMTQTPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRAT ADI-14373 Light chain variable region GIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 42 83 QVQLVQSGGVVVQPGGSLRLSCAASGFNFDDFTMHWVRQAPGKGLEWVSLITW ADI-14374 Heavy chain variable region DGGITYYADSVKGRFTISRDNGKNSLYLRMNSLRTEDTALYYCAKDGDRYSGYAFLD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 42 84 SYELTQPPSVSVAPGKTARLTCGGNNIGSESVHWYQQRPGQAPVLVSYYNGDRPS ADI-14374 Light chain variable region GIAERISASKSGNTATLTIYRVEAGDEADYYCQVWHSSSDHFVFGTGTQLTVL (“LC”) amino acid sequence Ab 43 85 EVQLVESGGGLVQPGGSLRLSCAVSGFTFSNYAVSWVRQAPGKGLEWVSGISGSG ADI-14375 Heavy chain variable region GTTYYVDSVKGRFTVSRDNSKNTLFLQLNSLKAEDTAVYYCAKDWGYSGGRPYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 43 86 QSVLTQPPSVSGAPGQRVTISCTASSSNIGPIYDVHWYQQLPGTGPKLLIYGNNNRP ADI-14375 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDTSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 44 87 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGPVWVSRINSD ADI-14376 Heavy chain variable region GSTTNYADYMKGRFTISRDNAKNTVYLQMNSLRAEDTAVYYCARDSDSYDDAFDI (“HC”) amino acid sequence WGQGTTVTVSS Ab 44 88 SYELTQPPSVSVSPGQTARISCSGEALPKKYSYWYQQKSGQAPVLVIYEDSKRPSGIP ADI-14376 Light chain variable region ERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHRVFGGGTKVTVL (“LC”) amino acid sequence Ab 45 89 EVQLVESGGGVVQPGGSLRLSCAVSGITFSSYGMHWVRQAPGKGLEWVAFIRYD ADI-14377 Heavy chain variable region GSNKYYGDSLRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDAVGIGGYYGLD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 45 90 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQS ADI-14377 Light chain variable region GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNGYPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 46 91 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLVWVSRINS ADI-14378 Heavy chain variable region DGSSPTYADSVKGRFTISRDNAKNTVFLQMNSLRAEDTAVYYCARESWELIRGDAF (“HC”) amino acid sequence DIWGQGTTVTVSS Ab 46 92 DIQMTQSPSSLSASVGDRVTITCRASQSISSSLNWYQQKPGKAPNLLIYAASTLQSG ADI-14378 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYRTPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 47 93 EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIGND ADI-14379 Heavy chain variable region GTNKYHADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRRVGIMYSGSY (“HC”) amino acid sequence WGGMDVWGQGTTVTVSS Ab 47 94 SYELTQPPSVSVSPGQTASITCSGDKLGGKYVSWYQQKPGQSPVLVMYQDTRRPS ADI-14379 Light chain variable region GIPERLSGSNSGSTATLTISATQAMDEADYYCQAWDITTVHVVFGGGTKLTVL (“LC”) amino acid sequence Ab 48 95 QVQLVQSGAEVKKPGESLKISCKGSGYTFTSYWIGWVRQLPGKGLEWMGVIFPGD ADI-14380 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKAADTAMYYCARTRLGRGFYRFDSW (“HC”) amino acid sequence GQGTLVTVSS Ab 48 96 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPRLLIYENNERPS ADI-14380 Light chain variable region GIPDRFSGSKSGTSATLGITGLQTGDEADYYCATWDSGLSAGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 49 97 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYIGSSS ADI-14381 Heavy chain variable region SSVYYGDSAKGRFTISRDNAKNSLYLQMNSLRDEDTALYYCARVGWLQYCRGGSCY (“HC”) amino acid sequence ASFGMDVWGQGTTVTVSS Ab 49 98 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGIAPKLLIYAASSLQSG ADI-14381 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYDSPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 50 99 EVQLLESGGGVVQPGRSLRLSCAASGFTFSAYGFHWVRQAPGKGLEWVAVIWFD ADI-14382 Heavy chain variable region GNNKYYADSMKGRFIISRDNSKNTLYLQMNSLRAEDTAVYYCARDPKETGEFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 50 100 QSALTQPASVSGSPGQSITISCTGTISDVGRYNYVSWYQQHPGKAPKLMIYDVTNR ADI-14382 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEAVYYCCSYTISSTYVFGTGTKLTVL (“LC”) amino acid sequence Ab 51 101 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDE ADI-14383 Heavy chain variable region DKRYSPSLKTRLTITKDTSRNQVKLTMTNMDPVDTATYYCAHQYYDILTGYPSPGAF (“HC”) amino acid sequence DIWGQGTTVTVSS Ab 51 102 QPVLTQPASVSGSPGQSITISCTGTSSDVVSYNLVSWFQQHPGKAPKLMIYEVTRRP ADI-14383 Light chain variable region SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCAYTGTPVVFGGGTKLTVL (“LC”) amino acid sequence Ab 52 103 QVQLQESGSGLVKPSQTLSLTCTVSGGSISSVGYSWSWIRQPPGKGLEWIGYIYHSG ADI-14384 Heavy chain variable region SPYYSPSLNSRVTISVDRSKNQFSLKLSSVTAADTAVYFCARVFFGGGGAFDIWGQG (“HC”) amino acid sequence TTVTVSS Ab 52 104 QPGLTQPPSVSVAPGQTARITCGGNNIGSKSVQWYQQKPGQAPVLVMYYDSDRP ADI-14384 Light chain variable region SGIPDRFSGSSSGNTATLTITRVEAGDEADYSCQVWDSVNVHPVIFGGGTKLTVL (“LC”) amino acid sequence Ab 53 105 QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGD ADI-14385 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCASSSYSNYFDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 53 106 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRP ADI-14385 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNPWVFGGGTKLTVL (“LC”) amino acid sequence Ab 54 107 EVQLVESGGGLVQPGGSLRLSCAASRFTFSSYAMSWVRQAPGKGLEWVSGIGASG ADI-14386 Heavy chain variable region GTTYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARCEYYYGSGSAGYYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 54 108 SYELTQPPSVSVSPGQTASITCSGDKLGSKFAFWYQQKPGQSPVLVIFQDVKRPSGI ADI-14386 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSGTAVFGGGTKVTVL (“LC”) amino acid sequence Ab 55 109 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPMHWVRQAPGKGLEWVAVISYD ADI-14388 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYSCARAQSAAIFDHWG (“HC”) amino acid sequence QGTLVTVSS Ab 55 110 QAVVTQEPSLTVSPGGTVTLTCASSTGAVTSGYYPNWFQQKPGQAPRALIYTTSKR ADI-14388 Light chain variable region HSWTPARFSGSLLGGKAALTLSGVQPEDEADYYCLLYYGGANWVFGGGTKLTVL (“LC”) amino acid sequence Ab 56 111 EVQLVESGGGLVKPGGSLRLSCAASGFTFINAWMAWVRQAPGKGPEWVGRIKSR ADI-14389 Heavy chain variable region ADGGTTDYAAPVKGRFTISRDDSKNRLFLQMDSLKTDDTAVYFCTTGVRALRFYNG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 56 112 ETTLTQSPSSLSASIGDRVTITCRAGQSISSFLNWYQQKPGKAPKLLIYAASTLQSGVP ADI-14389 Light chain variable region SRFSGSKSGTDFTLTISSLQPEDFATYYCQQSYHTFTFGPGTKVEIK (“LC”) amino acid sequence Ab 57 113 QVQLVESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGNIYHSGS ADI-14390 Heavy chain variable region TYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARATLRFTLVREVVVTACD (“HC”) amino acid sequence AFDIWGQGTTVTVSS Ab 57 114 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKVPKLVIYEVNKRP ADI-14390 Light chain variable region SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTFVVEGGGTKLTVL (“LC”) amino acid sequence Ab 58 115 QVQLVESGGGLVQPGGSLRLSCAAAGFSFSNYAMSWVRQAPGKGLEWVAVISGN ADI-14391 Heavy chain variable region AGSTYYAESVKGRFTISRDNSKNTLHLQMNSLRGEDTAVYYCAKPPGIAVAGEYYW (“HC”) amino acid sequence YFDLWGRGTLVTVSS Ab 58 116 QVQLMQPPSVSVSPGQTARITCSGDALPRENAYWYQQKSGQAPVLVIYEDSKRPS ADI-14391 Light chain variable region GIPERFSGSSSGTMATLTITGAQVEDEADYYCYSTDTSAYHWVFGGGTKLTVL (“LC”) amino acid sequence Ab 59 117 EVQLLESGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFG ADI-14392 Heavy chain variable region TSNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCALDSSGRARYYAMDVW (“HC”) amino acid sequence GQGTTVTVSS Ab 59 118 DIQVTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATG ADI-14392 Light chain variable region IPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNNWPPTFGPGTKVEIK (“LC”) amino acid sequence Ab 60 119 QVQLVESGGGLVKPGGSLRLSCAASGFSFTGFYMNWVRQAPGKGLEWVSSISSSS ADI-14393 Heavy chain variable region TYKNYADSLQGRFTISRDNARSSLYLQMNSLRAEDTAVYYCARTRTEYTYGYYHDF (“HC”) amino acid sequence WGQGTLVTVSS Ab 60 120 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQVPGTAPKLLIYNNNN ADI-14393 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSRLSGVFGGGTKLTVL (“LC”) amino acid sequence Ab 61 121 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-14394 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGSEYYFDYWGQGTL (“HC”) amino acid sequence VTVSS Ab 61 122 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-14394 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVEGGGTKVTVL (“LC”) amino acid sequence Ab 62 123 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYD ADI-14395 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDTYYYDSSGYS (“HC”) amino acid sequence APFDYWGQGTLVTVSS Ab 62 124 DIQVTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGV ADI-14395 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 63 125 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYD ADI-14396 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELRYFDWEYGG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 63 126 EIVLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGV ADI-14396 Light chain variable region PSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPMYTFGQGTKLEIK (“LC”) amino acid sequence Ab 64 127 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYD ADI-14397 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDTYYYDSNGYS (“HC”) amino acid sequence APFDYWGQGTLVTVSS Ab 64 128 DIQVTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGV ADI-14397 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVDIK (“LC”) amino acid sequence Ab 65 129 EVQLLESGPGLVKPSQTLSLTCAVSGGSINSGRYSWSWIRQPPGKGLEWIGYIYYSG ADI-14399 Heavy chain variable region TTYYNPSLESRVTISRDTSKNQFSLNLSSVTAADTAVYYCARTNSADSYASGSHYIRP (“HC”) amino acid sequence QYFDFWGQGTLVTVSS Ab 65 130 DIQLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASNRATGI ADI-14399 Light chain variable region PARFSGSGSGTDFTLTISRLEPEDFAVYYCQQRSNWLTFGGGTKVEIK (“LC”) amino acid sequence Ab 66 131 QVQLVQSGGGVVQPGRSLRLSSAASGFTFSSYAMHWVRQAPGKGLEWVAVISHD ADI-14400 Heavy chain variable region GSKYYADSVKGRFTISRDNSKSTLNLQMNSLRPEDTAVYYCARGGDVRLYDDSNGY (“HC”) amino acid sequence HYDTYYFDYWGQGTLVTVSS Ab 66 132 EIVLTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASTLQSGV ADI-14400 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 67 133 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMHWVRQAPGKGLEWVSSISASS ADI-14401 Heavy chain variable region SYLNYADSVKGRFTISRDNAKKSLYLQLNTLRADDTAVYYCAREDHDSGTYYLNWF (“HC”) amino acid sequence DPWGQGTLVTVSS Ab 67 134 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQFPGTGPKLLIYGNSHR ADI-14401 Light chain variable region PSGVPDRFSGSKSGPSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 68 135 QVQLVQSGAEVKKPGASVKVSCKTSGYTFTNYGISWVRQAPGQGLEWMGWISAY ADI-14402 Heavy chain variable region NGNRNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREPPVIAAGDFS (“HC”) amino acid sequence HWGQGTLVTVSS Ab 68 136 EIVLTQSPLSLPVTLGQPASISCRSSQSLVHSDANTYLSWFQQRPGQSPRRLIYKVSN ADI-14402 Light chain variable region RDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPDFGQGTRLEIK (“LC”) amino acid sequence Ab 69 137 QVQLVESGGGLGKPGGSLRLSCAASGFTFSGYYMSWIRQAPGKGLEWVSDISSGSS ADI-14403 Heavy chain variable region FTNYADSVKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARVPPDSYGSGSYSGD (“HC”) amino acid sequence SWGQGTLVTVSS Ab 69 138 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGNTNR ADI-14403 Light chain variable region PSGVPDRISGSKSGTSASLVITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 70 139 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFEMNWVRQAPGKGLEWVSYISSSG ADI-14404 Heavy chain variable region RIIYYADSVKGRFTISRDNARNSLYVQMNSLRVEDTAVYYCARAKAAAGHDLWGQ (“HC”) amino acid sequence GTLVTVSS Ab 70 140 EIVLTQSPSTLSASVGDRVTITCRASQSISPWLAWYQQKPGKAPKLLIYRASSLESGV ADI-14404 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYNSYLYTFGQGTKVEIK (“LC”) amino acid sequence Ab 71 141 QVQLVQSGTEVKKPGASVKVSCKASGYTFTNYDISWVRQAPGQGLEWMGWISGS ADI-14405 Heavy chain variable region TGNTIYAQNLQGRLTMTTDTSTSTAYMELRSLRSDDTAIYYCARDNVGYASGNYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 71 142 SYVLTQPPSVSVAPGKTARIPCGGNNIGSKSVHWYQQRPGQAPVLVIYYDSVRPSG ADI-14405 Light chain variable region IPERFSGSNSGNTATLTISTVEAGDEADFYCQVWDSSRDHEVFGGGTKLTVL (“LC”) amino acid sequence Ab 72 143 QVQLVQSGAEVKKPGESLKISCKGSGYKFTNYWIAWVRQMPGKGLEWLGVIYPGA ADI-14406 Heavy chain variable region SDITYSPSFQGQVTISADKSISTAYLQWSSLKASDTAIYYCARQGSITAMSYWGQGT (“HC”) amino acid sequence MVTVSS Ab 72 144 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGFNYLDWYLQKPGQSPQLLIYLGSN ADI-14406 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVEIK (“LC”) amino acid sequence Ab 73 145 QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWF ADI-14407 Heavy chain variable region DGNNKEYADSVKGRFAISRDNSKNTLYLQMNSLRAEDTAVYYCARDLIPVTIFGVV (“HC”) amino acid sequence NPYSYYGMDVWGQGTTVTVSS Ab 73 146 EIVMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGTAPKLLIYAASSLESGV ADI-14407 Light chain variable region PSRLSGSGSGTEFILTISSLQREDFATYYCQQSYSTPPTFGQGTKVEIK (“LC”) amino acid sequence Ab 74 147 QVQLVQSGPALVKITQTLTLICTFSGFSLITSGMCVSWIRQPPGKALEWLARIDW ADI-14408 Heavy chain variable region DDDKYYSTSLKTRLTISKDTSKNQVVLTLTNVDPVDTATYYCARMQKYDSSGYYLHY (“HC”) amino acid sequence FDSWGQGTLVTVSS Ab 74 148 DIRLTQSPSSLSASVGDRVTIACRASQSISSYLNWYQQKPGKSPKVLIYAASILQTGVP ADI-14408 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSINQYTFGQGTKVEIK (“LC”) amino acid sequence Ab 75 149 QVQLVQSGGEVKKPGASVKVSCKASGYTFTYYGISWVRQAPGQGLEWMGWISAY ADI-14409 Heavy chain variable region NGNTNYEQKFQGRVTMTTDTSTGTAYMELRSLTSDDTAVYYCARDRIVVVTAANY (“HC”) amino acid sequence YGLDVWGQGTTVTVSS Ab 75 150 DIQLTQSPDSLAVSLGERATINCKSSQSVLYRPNNKNFLAWYQQKPGQPPKLLIYW ADI-14409 Light chain variable region ASTRQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYHTTPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 76 151 QVQLQQWGAGLLKPSETLSLICAIYSGSFSGYYWSWIRQPPGKGLEWIGQINYSGS ADI-14410 Heavy chain variable region AYYTPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVRITMVQGAIVPCAIDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 76 152 SYELTQPPSASGTPGQRVTISCSGSSSNIESNFVYWYQQLPGTAPKLLIHRNDQRPS ADI-14410 Light chain variable region GVPDRFSGSKSGTSASLAISGLRSEDEADYSCAAWDDSLSGVVFGGGTKVTVL (“LC”) amino acid sequence Ab 77 153 QVQLVQSGAEVKKPGASVKLSCKASGYTFTRFYIHWVRQAPGQGLEWMGIINPSG ADI-14411 Heavy chain variable region GGTSYAQNFQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARNGYSTRSLQNNW (“HC”) amino acid sequence FDPWGQGTLVTVSS Ab 77 154 ETTLTQSPSSLSASVGDRVTITCRASQSIDNYLNWYQQKPGKAPKLLIYEASSLQSGV ADI-14411 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSSLPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 78 155 QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISDY ADI-14412 Heavy chain variable region NGNTKNAEKFQGRVTMTTDTYTNIAYMELRSLRSDDTAVYYCARDWWITVGGIIA (“HC”) amino acid sequence PFDYWGQGTLVTVSS Ab 78 156 ETTLIQSPGILSLSPGERATLSCRASQSVSSDYLAWFQQKPGQAPRLLIYGASSRAT ADI-14412 Light chain variable region DIPDRFSGSGSGTDFTLTISRLESEDFAVYYCLHYAGARTFGQGTKVEIK (“LC”) amino acid sequence Ab 79 157 EVQLVESGGVVVQPGGSLRLSCAASGFNFDDYSMHWVRQAPGKGLEWVSVISW ADI-14413 Heavy chain variable region DGGITYYADSVKGRFTMSRDNGKKSLYLQMNSLRTEDTAVYYCGKDGDIYSSSSAG (“HC”) amino acid sequence IDYWGQGTLVTVSS Ab 79 158 SYVLTQPPSASGTPGQRVIISCSGSSSNIGSHTVKWYQQLPGTAPKLLIDRNNQRPS ADI-14413 Light chain variable region GVPDRFSGPKSGTSASLAISGLQSEDEADYYCASWDDSLNGPVFGGGTQLTVL (“LC”) amino acid sequence Ab 80 159 QVQLVQSGAEVKKPGSSMKVSCKASGGSFSSYGISWLRQAPGQAPEWMGGIIPIF ADI-14414 Heavy chain variable region GTINYAQKFQGRITISADESTSTVYMELSSLRIEDTAVYYCARDGRTSPRYYGWDVW (“HC”) amino acid sequence GQGTTVTVSS Ab 80 160 DIRLTQSPATLSLSPGDRATLSCRASQSLYTYLSWYQQKPGQAPRLLIYDASNRATGI ADI-14414 Light chain variable region PARFSGSGSGTDFTLTISSLEPEDFAVYYCHYRSNWPPCTFGGGTKVDIK (“LC”) amino acid sequence Ab 81 161 EVQLVESGPGLVKPSETLSLTCTVSGGSISNYYWTWIRQPPGEGLEWIGYIYYTGST ADI-14415 Heavy chain variable region NYNPSLKNRVTISVDTPKNQFSLKLNSVTAADTAVYYCARGWGYSYGYESYYNGLD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 81 162 DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQLKPGKAPKLLIYAAATLETGVP ADI-14415 Light chain variable region SRFSGSGSGTEFTLTISGLQPEDFATYYCQQLNSFPFTFGPGTKVEIK (“LC”) amino acid sequence Ab 82 163 QVQLVQSGAEVKKPGESLKISCKGSGDTFSRNWIGWVRQMPGKGLEWMGIIWP ADI-14416 Heavy chain variable region GDSDTRYRQFFQGQQGQVIISVDKSISTAYLQWSSLKASDTATYYCATSPYGLGSYY (“HC”) amino acid sequence EHWGQGTLVTVSS Ab 82 164 NFMLTQPHSLSDSPGKTVVISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRP ADI-14416 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNPYVFGTGTKVTVL (“LC”) amino acid sequence Ab 83 165 EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYSMHWVRQAPGKGLEWVSSISGSST ADI-14417 Heavy chain variable region YIYHADSVKGRFTISRDNAERSLHLQMNSLRAEDTAVYYCARDPYSSGWLDSWGQ (“HC”) amino acid sequence GTLVTVSS Ab 83 166 ETTLTQSPATLSVSPGERATLSCRASQSVSGNLAWYQQKPGQAPRLLIYGTSTRATG ADI-14417 Light chain variable region IPARFSGSGSGTEFTLSISSLQSEDFAVYYCQQYNKWPRYTFGQGTKLEIK (“LC”) amino acid sequence Ab 84 167 QVQLVQSGAEVKKPGSSVKVSCKASGGTFTNYNINWVRQAPGQGLQWMGRISP ADI-14418 Heavy chain variable region TFAIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPHSGYDLALDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 84 168 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLQSG ADI-14418 Light chain variable region VPSRFSGSGSGTEFTLTITSLQPDDFATYYCQQYNVYPWTFGQGTKVDIK (“LC”) amino acid sequence Ab 85 169 EVQLVESGGGVVQPGGSLRLSCAASGFSFSDYGMHWVRQAPGKGLEWVSFIRYD ADI-14419 Heavy chain variable region ASYKFYADSVKGRFTISRDNAKNTLYLQINSLRAEDTAVYYCAKEIYGSGSYYYYYYAI (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 85 170 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSHLAWYQQKPGQAPRLLIYGASSRATG ADI-14419 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYFRSAWAFGQGTKVDIK (“LC”) amino acid sequence Ab 86 171 EVQLVESGGVVVQPGGSLRLSCAASGFNFDDYAMHWVRQAPGKGLEWVSLISW ADI-14420 Heavy chain variable region DGGNTYYSDSVKGRFTISRDNGKNSLYLQMNSLRAEDTALYYCAKDIDRYSGYDYV (“HC”) amino acid sequence FHYWGQGTLVTVSS Ab 86 172 DIRLTQSPSTLSAYVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGV ADI-14420 Light chain variable region PSRFTGSGSGTEFTLTISGLQPDDFATYYCQQYNSYSTFGGGTKVDIK (“LC”) amino acid sequence Ab 87 173 QVQLVQSGAEVKKPGESLKISCKGSGYNSSINWIGYWIGWVRQMPGKGLEWMGI ADI-14421 Heavy chain variable region INPGDSDTRYSPSFQGQVTISVDKSISTAYLQWGSLKASDTAMYYCARRAYRSGWH (“HC”) amino acid sequence FDLWGRGTLVTVSS Ab 87 174 EIVMTQSPATLSVSPGERATLTCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRAT ADI-14421 Light chain variable region GIPARFSGSGSGTQFTLTISSLQSEDFAVYYCQHYNNWPPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 88 175 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTINWVRQAPGQGLEWMGRIIPIL ADI-14422 Heavy chain variable region GIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARRHQDTYGMDVWG (“HC”) amino acid sequence QGTTVTVSS Ab 88 176 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-14422 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKVTVL (“LC”) amino acid sequence Ab 89 177 EVQLVESGGVVIQPGGSLRLSCAASGFNFDDYSMHWVRQAPGKGLEWVSLISWD ADI-14423 Heavy chain variable region GGITYYADSVKGRFTISRDNGKKSLYLQMNSLRTEDTALYYCAKDIDIYSDYAGYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 89 178 DIRMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSG ADI-14423 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPFTFGQGTRLEIK (“LC”) amino acid sequence Ab 90 179 QVQLVQSGAEVKKPGESLKISCKGPDSSFSVYWIAWVRQMPGKGLEWMGVIYVG ADI-14424 Heavy chain variable region DSDTRYSPSFRGQVTISADKSMNTAYLQWSSLKASDTAMYFCARHIPPGPFDLWG (“HC”) amino acid sequence QGTMVTVSS Ab 90 180 NFMLTQPHSVSASPGKTITISCTRSSGSIASNSVQWYQQRPGSAPTNVIYEDDQRPL ADI-14424 Light chain variable region GVPNRFSGSIDSSSNSASLTISGLKTEDEADYYCHSYHNSDQVFGGGTKLTVL (“LC”) amino acid sequence Ab 91 181 QVQLQESGPGLVKPSETLSLTCTVSGGSVRSGSYYWSWIRQPPGKALEWIGYIYYSG ADI-14425 Heavy chain variable region STNYNPALESRVTISVDTSKNQFSLMLSSVTAADTAVYYCARSAEGLARLYYFDHWG (“HC”) amino acid sequence QGTLVTVSS Ab 91 182 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIHDVSNR ADI-14425 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSTYRSSNTLVVFGGGTKLTVL (“LC”) amino acid sequence Ab 92 183 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFPMHWVRQAPGKGLEWVAVASYD ADI-14426 Heavy chain variable region GRNNYYAGSVKGRFTISRDNSKNTLYLQINSLRAEDTAVYYCAREVVIAAHFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 92 184 SSELTQEPAVSVALGQTVRITCQGDSLRSFYANWYQQKPGQAPILVIYGKNDRPSGI ADI-14426 Light chain variable region PDRFSGSNSGNTASLTITGAQAEDEADYYCNSRDSSGNHRVFGGGTKVTVL (“LC”) amino acid sequence Ab 93 185 QVQLVQSGAEVKKPGSSVKVSCKASGGTFNSYTINWVRQAPGQGLEWMGRIITIP ADI-14427 Heavy chain variable region GATNYAQKFQGRVTFTADKSTSTAYMELSSLRSEDTAVYFCAKRGTGYYGMDVW (“HC”) amino acid sequence GQGTTVTVSS Ab 93 186 QSVLIQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSER ADI-14427 Light chain variable region PSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSFVGIYILVFGGGTKLTVL (“LC”) amino acid sequence Ab 94 187 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDHYMSWIRQAPGKGLEWVSYISSTSSF ADI-14428 Heavy chain variable region TNYADSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARPYIVALGTRAFDIWG (“HC”) amino acid sequence QGTTVTVSS Ab 94 188 SYVLIQPPSVSVAPGKTARITCGGNNIGSKTVHWYQQKPGQAPVLVSYYDSDRPSG ADI-14428 Light chain variable region IPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDGSSEHYVFGTGTKVTVL (“LC”) amino acid sequence Ab 95 189 QVQLVQSGTEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGGITPM ADI-14564 Heavy chain variable region VGTPNYAQKFQGRVAITADKSTNTAYMELTSLISGDTAVYYCARLVYGSGSHFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 95 190 SSELSQDPAVSVALGQTVRITCQGDSLRSFYASWYQQQPGQAPVLVLYGQDNRPS ADI-14564 Light chain variable region GIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRNSSGHHWVFGGGTKVTVL (“LC”) amino acid sequence Ab 96 191 EVQLLESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKT ADI-14565 Heavy chain variable region DGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTDRFCSSTSCEYY (“HC”) amino acid sequence YYYYGMDVWGQGTTVTVSS Ab 96 192 ETTLIQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-14565 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 97 193 QVQLLESGGGVVQPGRSLRLSCAASGFTFSSFPMHWVRQAPGKGLEWVAVASYD ADI-14566 Heavy chain variable region GRNNYYAGSVKGRFTISRDNSKNTLYLQINSLRAEDTAVYYCAREVVIAAHFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 97 194 SSELTQEPAVSVALGQTVRITCQGDSLRSFYANWYQQKPGQAPILVIYGKNDRPSGI ADI-14566 Light chain variable region PDRFSGSNSGNTASLTITGAQAEDEADYYCNSRDSSGNHRVFGGGTKVTVL (“LC”) amino acid sequence Ab 98 195 QVQLVQSGAEVKKPGASVRVSCKASGYTFNSYSISWVRQAPGQGLEWMGWISVH ADI-14567 Heavy chain variable region NGNTNYTQKFQGRVTMTTDTSTSTTYMELRSLRSDDTAVYYCIFGELLYDVWGQG (“HC”) amino acid sequence TTVTVSS Ab 98 196 DIQLTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPNLLIYAASTLQSG ADI-14567 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPLTFGPGTKVEIK (“LC”) amino acid sequence Ab 99 197 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYD ADI-14568 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDIAAAGTMRAFD (“HC”) amino acid sequence IWGQGTTVTVSS Ab 99 198 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-14568 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVVFGGGTKLTVL (“LC”) amino acid sequence Ab 100 199 QVQLVESGGGFVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWLSYISSTSLF ADI-14569 Heavy chain variable region TYYADSVKGRFTISRDNAKNSLYLQMNSLRADDTAVYYCARAYGKGTMVGYWGQ (“HC”) amino acid sequence GTMVTVSS Ab 100 200 EIVMTQSPGTLSLAPGERATLSCRASQSVSIDYLAWYQHKPGQAPRLLIYTASNRAT ADI-14569 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDVAMYYCQQYGNSPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 101 201 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTYTITWVRQAPGQGLEWMGRIVPIF ADI-14571 Heavy chain variable region GVVNNAQKFLGRLTITADKSTSTAYMELSSLRSEDTAVYYCARIPCSGNCQDYYYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 101 202 DIQLTQSPSFLSASVGDRVTITCRASQGISSYLVWYQQKPGKAPKLLIYAASTLQSGV ADI-14571 Light chain variable region PSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNNYPPTFGPGTKVDIK (“LC”) amino acid sequence Ab 102 203 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSNAWISWVRQAPGKGLEWVGRIKSAT ADI-14572 Heavy chain variable region DGGTTDYAAPVKGRFTISRDDSKNTLYLQMDSLKTEDTAVYYCTTSYPYFDWLPFSV (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 102 204 SYELMQPPSASGTPGQRVTISCSGSNSNIGSNTVSWYQQLPGTAPKLLIYNNNQRP ADI-14572 Light chain variable region SGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 103 205 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYGISWVRQAPGQGLEWMGWISTY ADI-14573 Heavy chain variable region KTYTNYAQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAKVAGGSGSYGDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 103 206 QPVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYLQKPGQAPVLVIYYDSDRPSGI ADI-14573 Light chain variable region PERFSGSNSGNTATLTISRVEAGDEADFFCQVWDSSSDHWVFGGGTKVTVL (“LC”) amino acid sequence Ab 104 207 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILG ADI-14575 Heavy chain variable region IANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARPSSSSFAFDYWGQGT (“HC”) amino acid sequence LVTVSS Ab 104 208 QSVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-14575 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPVVFGGGTKVTVL (“LC”) amino acid sequence Ab 105 209 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAY ADI-14576 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDPPVIAAGDFQ (“HC”) amino acid sequence HWGQGTLVTVSS Ab 105 210 DIVLTQSPLSLPVTLGQPASISCRSSQSLVHSDGNTYLNWFQQRPGQSPRRLIYKVS ADI-14576 Light chain variable region NRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPDFGQGTRLEIK (“LC”) amino acid sequence Ab 106 211 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGITWVRQAPGQGLEWMGWISA ADI-14577 Heavy chain variable region YNGVRNYAQKLQGRVTMTIDTSRTTAYMELKNLRSDDTAMYYCARGPPVIAADDF (“HC”) amino acid sequence QHWGQGTMVIVSS Ab 106 212 DIQMTQSPLSLPVTLGQPASISCRSSQSLVHSNGDTYLNWFQQRPGRSPRRLIYKVS ADI-14577 Light chain variable region NRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPDFGQGTRLEIK (“LC”) amino acid sequence Ab 107 213 QVQLVQSGAEVKKPGSSVKVSCKASGGTFNNYAINWVRQAPGQGLEWMGGIIP ADI-14578 Heavy chain variable region MFGTANYAQKFQGRVTMTADESTSTAYMELSSLRSEDTAVYYCASSQIFVGGNYY (“HC”) amino acid sequence KLEFDNWGQGTLVTVSS Ab 107 214 QSVLTQPPSVSAAPGQKVTISCSGSNSNIGYNDVSWYQQLPGTAPQLLIYDNNKRT ADI-14578 Light chain variable region SGIPDRFSGSKFGTSATLGITGLQTGDEADYYCGTWDSSLSTVIFGGGTKLTVL (“LC”) amino acid sequence Ab 108 215 QVQLVQSGAEVKKPGESLKISCKVSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGD ADI-14579 Heavy chain variable region SDTRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARPAHSSSWYGAFDL (“HC”) amino acid sequence WGQGTTVTVSS Ab 108 216 DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSG ADI-14579 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 109 217 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTINWVRQAPGQGLEWMGRIIPVL ADI-14580 Heavy chain variable region GMASYVQNFQGRVSITADESTSTAYMELSSLTSEDTALYYCAKGAVAAANDVFDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 109 218 DIQMTQSPDSLAVSLGERATINCKSSQSVFYSSNNKHYLAWYQQKPGQPPKLLFY ADI-14580 Light chain variable region WASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYRIPYTFGQGTKVEI (“LC”) amino acid sequence K Ab 110 219 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSHAFSWVRQAPGQGLEWMGGIIPSL ADI-14581 Heavy chain variable region NTANYAQKFQGRVSITADESTGTAYMELSSLRSDDTAVYFCAREVFGYGYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 110 220 ETTLTQSPATLSVSPGERATLSCRASQNVNSNLAWYQQKPGQAPRLLIYGASTRAT ADI-14581 Light chain variable region GIPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYNMWPPFTFGQGTKLEIK (“LC”) amino acid sequence Ab 111 221 QVQLVQSGAEVKKPGESLKISCKGPDSSFSVYWIAWVRQMPGKGLEWMGVIYVG ADI-14582 Heavy chain variable region DSDTRYSPSFRGQVTISADKSINTAYLQWSSLKASDTAMYFCARHIPPGPFDLWGQ (“HC”) amino acid sequence GTTVTVSS Ab 111 222 NFMLTQPHSVSASPGKTITISCTRSSGSIASNSVQWYQQRPGSAPTNVIYEDNQRPL ADI-14582 Light chain variable region GVPNRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYHSSDQVFGGGTKVTVL (“LC”) amino acid sequence Ab 112 223 QVQLVQSGAEVKEPGASVKVSCKASGYTFTNYGISWVRQAPGQGLEWLGWISAY ADI-14583 Heavy chain variable region NGNIHYAQKVQGRVTMTTDTSTSTGFMELRSLRSDDTAVYYCAREPPVIAAGDFQ (“HC”) amino acid sequence HWGQGTLVTVSS Ab 112 224 ETTLTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLSWFQQRPGQSPRRLIYRVSN ADI-14583 Light chain variable region RDSGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQGTHWPPDFGQGTRLEIK (“LC”) amino acid sequence Ab 113 225 QVQLVQSGAEVKKPGASVKVSCKASGFTFTNYGTSYGITWVRQAPGQGLEWMG ADI-14584 Heavy chain variable region WINTSNGNPNYAQKLQGRVTMTADTSTSTAYMELRSLISDDTAVYYCARGHRMV (“HC”) amino acid sequence RGVVPTGYYGLDVWGQGTTVTVSS Ab 113 226 DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIFAASNLQSGV ADI-14584 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYITPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 114 227 QVQLVQSGAEVKKPGASVKVSCKASGYTFANYGIGWVRQAPGQGLEWMGWISA ADI-14585 Heavy chain variable region YNGKTNYAQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREPPVIAAGDFP (“HC”) amino acid sequence HWGQGTLVTVSS Ab 114 228 ETTLTQSPLSLPVTLGQPASISCRSSQSLEHSDLNTYLSWFQQRPGQSPRRLIYKVSN ADI-14585 Light chain variable region RDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQGTHWPPDFGQGTRLEIK (“LC”) amino acid sequence Ab 115 229 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSSS ADI-14586 Heavy chain variable region YTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKRTEYCSSTGCAYYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 115 230 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-14586 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKVTVL (“LC”) amino acid sequence Ab 116 231 EVQLLESGGGLVKPGGSLRLSCAASGFTLTSYSMNWVRQAPGKGLEWVSSISSSSS ADI-14587 Heavy chain variable region YIHYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAGSSLYPPFFDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 116 232 QSVVTQPPSVSGAPGQRVTISCTGSSSNLGAGYDVHWYQQLPGTAPKLLIYGNNN ADI-14587 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSSVVEGGGTKLTVL (“LC”) amino acid sequence Ab 117 233 QVQLVQSGAEVKKPGASVKVSCKVSGDTLTELSIHWVRQAPGKGHEWMGYFDHE ADI-14588 Heavy chain variable region DGEIMYAQKFQGRVTMTGDTSTDTAYMELSSLRSEDTAVYYCATVAAAGQFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 117 234 DIQLTQSPSSLSASVGDRVTITCRARQSISTYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-14588 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSSPYTFGQGTKVDIK (“LC”) amino acid sequence Ab 118 235 QITLKESGPVLVKPSETLTLTCTVSGFSLSNAKMGVSWIRQPPGKALEWLAHIFSND ADI-14589 Heavy chain variable region EKSYNTSLKNRLTISKDTSKSQVVLTMTNMDTVDTATYYCARINYYDSSGYYLANFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 118 236 NIRLTQSPSSLSASVGDRVTITCRASQRIASYLNWYQQKPGHAPKLLIHAASSLQSGV ADI-14589 Light chain variable region PSRFSGSGSGTDFTLTINSLLPEDFATYYCQQSYSSPPHSSPPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 119 237 EVQLVESGAEVKKPGESLKISCKGSGYSFATYWIGWVRQMPGKGLEWMGIIYPGD ADI-14590 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAIYYCARAKLPVAGLYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 119 238 DIQLTQSPSSLSASVGDRVTITCRASQGISSTLAWYQQKPGKAPKLLIYDASSLESGV ADI-14590 Light chain variable region PSRFSGSGSGTDFTLTISSLHPEDFATYYCQQFNTYPTFGGGTKVEIK (“LC”) amino acid sequence Ab 120 239 QVQLVQSGAEVKKPGESLRISCTGSGYTFTNYWISWVRQMPGKGLEWMGRIDPT ADI-14591 Heavy chain variable region DSYTNYSPSFQGHVTISADKSISTAYLQSSSLKASDTATYYCARHRRLVPAAMSRGYY (“HC”) amino acid sequence GMDVWGQGTTVTVSS Ab 120 240 EIVMTQSPSSLSASVGDRATITCRASQSISSYLNWYQQKPGKAPKLLIYAASNLQSGA ADI-14591 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQTYSTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 121 241 QVQLVQSGAEVKKPGESLKISCKGSGYTFTNYWIGWVRQMPGKGLEWMGIIYPD ADI-14592 Heavy chain variable region DSDTRYSPSFQGQVTISVDKSINTAYLQWSSLRASDTAIYYCACSNWPHYFDSWGQ (“HC”) amino acid sequence GTLVTVSS Ab 121 242 NFMLTQPHSVSESPGKTVTISCTRSSGNIAGNYVQWYQQRPGSAPTTVIYEDNQRP ADI-14592 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEAVYYCQSYHPGNWVFGGGTKLTVL (“LC”) amino acid sequence Ab 122 243 QVQLVQSGAEVKKPGESLKISCKGSGYSFSSYWVAWVRQMPGKGLEWMGIIYPA ADI-14593 Heavy chain variable region DSDTRYSPSFQGQVTISADKSDSTAYLQWGSLKASDTAMYYCARSLYGSGDYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 122 244 NFMLTQPHSVSESPGRTVIISCTRSSGSIATNYVQWYQQRPGSAPTTVIYEDNQRPS ADI-14593 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYGSGDVVFGGGTKVTVL (“LC”) amino acid sequence Ab 123 245 QVQLVQSGAEVKKPGASVKLSCKASGYTFTTYTINWVRQAPGQGLEWMGWISGY ADI-14594 Heavy chain variable region NGNTDYAQKLQGRFTMTIDTSTNTAYMELRSLTSDDTAVYYCAKGGGGSESYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 123 246 SYELTQPPSVSVAPGKTARISCGGNNIGSKSVHWYQQKPGQAPVLVIYYDRDRPSGI ADI-14594 Light chain variable region PERFSGSNSGNTATLTISRVEAGDEADYYCQLWDRSSDHPYVFGTGTKVTVL (“LC”) amino acid sequence Ab 124 247 EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWISYISRSGST ADI-14595 Heavy chain variable region IFYADSVKGRFTISRDDAKNSLFLQMTSLRDADTAVYYCARVDCSNNKCYDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 124 248 DIQLTQSPATLSLSPGERATLSCRASQSISSFLAWYQQKPGQAPRLLIYDASKRATGT ADI-14595 Light chain variable region PARFSGGGSGRDFTLTISSLEPEDFAVYYCQQRSSWPLYTFGQGTKVEIK (“LC”) amino acid sequence Ab 125 249 EVQLVESGGVVVQPGGSLRLSCAVSGFNFDDYSMHWVRQLPGKGLEWVSLISWD ADI-14597 Heavy chain variable region GGITYYADSVKGRFTISRDNSKNSLYLQMNSLRTEDTALYYCAKDGNRYSDNDYYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 125 250 DIRLTQSPGILSLSPGERATLSCRASQGVSSSYLAWYQQKPGQAPRLLIYGASSRAT ADI-14597 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLFGPGTKVEIK (“LC”) amino acid sequence Ab 126 251 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIYWVRQAPGQGLECMGGIIPIFG ADI-14598 Heavy chain variable region SANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCATDSLKTTYYYGSSGYFR (“HC”) amino acid sequence DHVWGQGTTVTVSS Ab 126 252 ETTLTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIFAASTLQSGV ADI-14598 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDVATYYCQNFNSVLSFTFGPGTKVDIK (“LC”) amino acid sequence Ab 127 253 EVQLVESGGGLVQPGRSLRLSCKTSGFTFGDYAMSWVRQAPGQGLDWVGFIRTK ADI-14599 Heavy chain variable region AYGGTTEYAASVKGRFTLSRDDSKSIAYLQMNSLKTEDTAVYYCKSGGQFDYWGR (“HC”) amino acid sequence GTLVTVSS Ab 127 254 NFMLTQPHSVSGSPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVICEDNQRP ADI-14599 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDRSNQEVFGGGTKLTVL (“LC”) amino acid sequence Ab 128 255 QVQLVQSGGGLVKPGGSLRLSCAASGFSFSDYYMNWIRQAPGKGLEWVSYISSSSS ADI-14600 Heavy chain variable region YTNYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTAVYYCASQTYSDYARGGAFDI (“HC”) amino acid sequence WGQGTTVTVSS Ab 128 256 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNR ADI-14600 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGIGTKVTVL (“LC”) amino acid sequence Ab 129 257 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSTISGSG ADI-14601 Heavy chain variable region SSTYYADSVEGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCAKEPRDMYIQQWLDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 129 258 GIRLTQSPSSVSASVGDRVIITCRASQGIRSWLAWYQQKPGKAPKLLIYAASRLQSG ADI-14601 Light chain variable region VPSRFSGSGSETDFTLTISSLQPEDFASYYCQQANSFPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 130 259 EVQLVESGGGVVQPGGSLRLSCAASGFSFSSCGMHWVRQVSGKGLEWVAFIRYD ADI-14602 Heavy chain variable region GSNKFYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCAKGGLEDVSTGYSP (“HC”) amino acid sequence HYYYGMDVWGQGTTVTVSS Ab 130 260 QPVLTQPPSVSVSPGQTASITCSGDKLAYKYTCWYQQKPGQSPVLVIFQDSKRPSGI ADI-14602 Light chain variable region PERFSGSNSGNTATLTISGTQALDEADYYCQAWDSSTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 131 261 QVQLVQSGAEVKKPGESLKISCKGSGYTFTNYWIGWVRQMPGKGLEWMGIIYPG ADI-14603 Heavy chain variable region DSDTRYSPSFQGQVTISADKSITTAYLQWRVLKASDTAMYYCATMRGSSSHFHHW (“HC”) amino acid sequence GQGTLVTVSS Ab 131 262 DIQVTQSPSSLSASVGDRVTITCRAGQGIGNYLAWYQQKPGKVPKVLIYAASTLQSG ADI-14603 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPEDVATYYCQKYNNAPYAFGQGTRLEIK (“LC”) amino acid sequence Ab 132 263 EVQLLESGGGLVQPGGSLRLSCSASGFTFNNYVMHWVRQAPGKGLEDASAISSNG ADI-14604 Heavy chain variable region VSTNYADSVKGRFTISRDNSKNTLYLQMRSLRAEDTALYYCVRDLIPHDSSAYYGYH (“HC”) amino acid sequence GMDVWGQGTTVTVSS Ab 132 264 QPVLTQPPSASGTPGQSVTISCSGSSSNIGTNVVNWYQQLPGTAPKLLIYSNDLRPS ADI-14604 Light chain variable region GVPDRFSGSKSGTSASLAISGLQSEDEANYYCAAWDDSLNGVLFGGGTKLTVL (“LC”) amino acid sequence Ab 133 265 EVQLLESGPALVKPTQTLTLICTFSGFSLTTSGMCVSWIRQPPGKALEWLARIDWD ADI-14605 Heavy chain variable region DDQYFSTSLRTRLSISKDTSKNQVVLTMTNMDPVDTATYYCARSALNIAARGFDIW (“HC”) amino acid sequence GQGTTVTVSS Ab 133 266 QPGLTQPPSVSVSPGQTARITCSGDVLPKHFSYWYQQKPGQAPVLVIHRDSERPSG ADI-14605 Light chain variable region IPERFSGSSSGTTVTLTISGVQAEDEADYYCQFSDITNTVFGGGTKLTVL (“LC”) amino acid sequence Ab 134 267 QVQLVQSGGGLVQPGGSLRLSCAASGFTVSSNYMGWVRQAPGKGLEWVSVIYTG ADI-14606 Heavy chain variable region GSTYYADSVKGRFTISRDNFKNTLYLQMNSLRAEDTALYYCARDLYSSGWFGYWG (“HC”) amino acid sequence QGTLVTVSS Ab 134 268 DIRLTQSPATLSVSPGERATLSCRASQSVSINLGWFQQKPGQSPRLLIYGTSTRATGI ADI-14606 Light chain variable region PARFSGSGSGTEFTLTISSLQSEDFAVYYCHQYNNWPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 135 269 EVQLLESGGGVVQSGRSLRLSCAASGFTFNNYAMHWVRQAPGKGLEWVAVISFD ADI-14607 Heavy chain variable region GGNKFYGDSVQGRFTISRDNSKNTLYLQTNSLRPEDTAVYYCARDRWEIQIGLDIW (“HC”) amino acid sequence GQGTTVTVSS Ab 135 270 SYVLTQPPSVSVSPGQTARITCSGDALARQNAYWYQQKPGQAPVLVMYRDTGRPS ADI-14607 Light chain variable region GIPERFSGSSSGTTVTLTISEVQAEDEADYYCQSADSSGAYVFGTGTKVTVL (“LC”) amino acid sequence Ab 136 271 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19420 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGWGYSYGYWFDP (“HC”) amino acid sequence WGQGTLVTVSS Ab 136 272 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19420 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 137 273 EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYD ADI-19421 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDIHHVLRFLDPDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 137 274 QSVLIQPASVSGFPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNR ADI-19421 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL (“LC”) amino acid sequence Ab 138 275 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYD ADI-19422 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGYNWNDYYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 138 276 QPVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-19422 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL (“LC”) amino acid sequence Ab 139 277 EVQLLESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSDIYSGG ADI-19424 Heavy chain variable region RTDYADSVKGRFTISRDNSKNTLDLQMNSLRAEDTAVYYCARETLGMDHWYFDL (“HC”) amino acid sequence WGRGTLVTVSS Ab 139 278 QPGLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-19424 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSTSDHPVFGGGTKLTVL (“LC”) amino acid sequence Ab 140 279 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19425 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGYCSGGSCHFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 140 280 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19425 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGFYVFGIGTKLTVL (“LC”) amino acid sequence Ab 141 281 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGST ADI-19426 Heavy chain variable region NYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGNEELGTGSNWFDPWG (“HC”) amino acid sequence QGTLVTVSS Ab 141 282 SYVLTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-19426 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 142 283 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19427 Heavy chain variable region FISYADSVKGRFTISRDSAKNSLYLQMNSLRAEDTAVYYCARDHPNWNGLAYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 142 284 QSVLTQPPSISGAPGQRVTISCTGSSSNIGAGYDVQWHQQLPGTAPKLLIYGNSNR ADI-19427 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 143 285 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19428 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDSCSGGSCYSPRFDP (“HC”) amino acid sequence WGQGTLVTVSS Ab 143 286 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19428 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 144 287 EVQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGS ADI-19429 Heavy chain variable region TYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTPLYSYGRVVGFYYYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 144 288 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19429 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 145 289 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILG ADI-19430 Heavy chain variable region IANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGGPYYYDSSGYYRL (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 145 290 DIRMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVS ADI-19430 Light chain variable region NRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWTYTFGQGTKLEIK (“LC”) amino acid sequence Ab 146 291 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19431 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARELYDYVWGSYRDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 146 292 QPGLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19431 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKVTVL (“LC”) amino acid sequence Ab 147 293 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDP ADI-19432 Heavy chain variable region EDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATEREEGGYSGYD (“HC”) amino acid sequence DAFDIWGQGTMVTVSS Ab 147 294 DIRMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESG ADI-19432 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGQGTKLEIK (“LC”) amino acid sequence Ab 148 295 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19433 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAPPSVGGWYFDLW (“HC”) amino acid sequence GRGTLVTVSS Ab 148 296 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19433 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLVFGGGTKLTVL (“LC”) amino acid sequence Ab 149 297 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGSYYWSWIRQPAGKGLEWIGRIYTSG ADI-19435 Heavy chain variable region STNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGRGGAFDIWGQGTL (“HC”) amino acid sequence VTVSS Ab 149 298 SYELTQPPSVSVSPGQTARITCSADALPKQYAYWYQQKPGQAPVLVIYKDSERPSGI ADI-19435 Light chain variable region PERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYVVFGGGTQLTVL (“LC”) amino acid sequence Ab 150 299 QVQLVQSGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSG ADI-19436 Heavy chain variable region STYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARSLMNYSNYVLGFDPW (“HC”) amino acid sequence GQGTLVTVSS Ab 150 300 QPVLTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSG ADI-19436 Light chain variable region IPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 151 301 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAY ADI-19437 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDGIAAAGTLFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 151 302 DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSG ADI-19437 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 152 303 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSG ADI-19439 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYSNYGSFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 152 304 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESG ADI-19439 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSTFGQGTKVEIK (“LC”) amino acid sequence Ab 153 305 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSS ADI-19440 Heavy chain variable region TIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGYSGSYGYYFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 153 306 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19440 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGIGTKLTVL (“LC”) amino acid sequence Ab 154 307 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILG ADI-19441 Heavy chain variable region IANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGPLTGYSSSWFDPW (“HC”) amino acid sequence GQGTLVTVSS Ab 154 308 EIVMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-19441 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 155 309 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAY ADI-19444 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDEALVGATFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 155 310 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYW ADI-19444 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 156 311 EVQLVESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSG ADI-19445 Heavy chain variable region STNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARDVETDGYNYGYYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 156 312 SYELIQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSG ADI-19445 Light chain variable region IPGRFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHKVFGGGTKLTVL (“LC”) amino acid sequence Ab 157 313 QVQLQESGPGLVKPSETLSLICTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSG ADI-19447 Heavy chain variable region STYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRVVTTYFDYWGQGT (“HC”) amino acid sequence LVTVSS Ab 157 314 SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGI ADI-19447 Light chain variable region PERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHRVFGGGTKLTVL (“LC”) amino acid sequence Ab 158 315 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19448 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARELLDPGIAAAGFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 158 316 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19448 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVNYVFGTGTKVTVL (“LC”) amino acid sequence Ab 159 317 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19449 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDSGSYLSYAFDIWGQ (“HC”) amino acid sequence GTMVTVSS Ab 159 318 SYELTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRP ADI-19449 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 160 319 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLVWVSRINSD ADI-19450 Heavy chain variable region GSSTSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARAPISILRFLGGYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 160 320 EIVMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGV ADI-19450 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSSFGQGTKLEIK (“LC”) amino acid sequence Ab 161 321 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19454 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYCSGGSCYSHYFQH (“HC”) amino acid sequence WGQGTLVTVSS Ab 161 322 QSVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-19454 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKVTVL (“LC”) amino acid sequence Ab 162 323 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19455 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSQSGSYYSSDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 162 324 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19455 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKVTVL (“LC”) amino acid sequence Ab 163 325 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19457 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQGYCSGGSCYHIDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 163 326 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19457 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 164 327 EVQLVESGGGRVKPGGSLRLSCAASGFTFRSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19458 Heavy chain variable region YINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGSGMTIFGVVIDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 164 328 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19458 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRSLTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 165 329 QVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSG ADI-19459 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREALGMDHWYFDL (“HC”) amino acid sequence WGRGTLVTVSS Ab 165 330 SYELMQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-19459 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPVFGGGTKVTVL (“LC”) amino acid sequence Ab 166 331 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSG ADI-19460 Heavy chain variable region STNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGITAYYYYYGMDVW (“HC”) amino acid sequence GQGTTVTVSS Ab 166 332 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSG ADI-19460 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 167 333 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGS ADI-19461 Heavy chain variable region TIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASSLTVTSRSDAFDIWG (“HC”) amino acid sequence QGTMVTVSS Ab 167 334 QPGLTQLPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-19461 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL (“LC”) amino acid sequence Ab 168 335 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDD ADI-19462 Heavy chain variable region DKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHAANWGYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 168 336 DIVMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESG ADI-19462 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYWTFGQGTKVEIK (“LC”) amino acid sequence Ab 169 337 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSG ADI-19463 Heavy chain variable region STYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRLGIFDYWGQGTLVT (“HC”) amino acid sequence VSS Ab 169 338 EIVLTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWA ADI-19463 Light chain variable region STRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 170 339 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19465 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGSSSWYYFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 170 340 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19465 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPWVFGGGTKLTVL (“LC”) amino acid sequence Ab 171 341 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19467 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASLSSSSELGYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 171 342 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19467 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 172 343 EVQLVESGPGLVKPSETLSLICTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGS ADI-19468 Heavy chain variable region TYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARRDGYNYGWFDPWGQG (“HC”) amino acid sequence TLVTVSS Ab 172 344 NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRP ADI-19468 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNVVFGGGTKVTVL (“LC”) amino acid sequence Ab 173 345 QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGS ADI-19469 Heavy chain variable region TYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARWTVMYYFDYWGQGTL (“HC”) amino acid sequence VTVSS Ab 173 346 EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATG ADI-19469 Light chain variable region IPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGGGTKLEIK (“LC”) amino acid sequence Ab 174 347 EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYD ADI-19470 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGRGDFWSGYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 174 348 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-19470 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKVTVL (“LC”) amino acid sequence Ab 175 349 EVQLVESGGGLVQPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVSAISSNG ADI-19471 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCVKADQGSSGWFPDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 175 350 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPS ADI-19471 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNWVFGGGTKLTVL (“LC”) amino acid sequence Ab 176 351 EVQLVESGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGD ADI-19473 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLIAAAGIDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 176 352 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPS ADI-19473 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNIWVFGGGTKVTVL (“LC”) amino acid sequence Ab 177 353 QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGD ADI-19474 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARPYSGSYYAFDIWGQ (“HC”) amino acid sequence GTTVTVSS Ab 177 354 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPS ADI-19474 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNQVFGGGTKLTVL (“LC”) amino acid sequence Ab 178 355 EVQLLESGAEVKKPGASVKVTCKASGYTFTHFGINWVRQAPGQGLEWLGWISAYN ADI-19475 Heavy chain variable region GNTNYVQKIQGRVTMTTDTSTNTAYMELRSLRSDDTAVYYCARGPPVEAAGTFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 178 356 DIVLTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLTWFQQRPGQSPRRLIYKVSN ADI-19475 Light chain variable region RDSGVPDRFSGSGSGTDFTLQISRVEAEDVGVYYCMQGTHWPFTFGPGTKVEIK (“LC”) amino acid sequence Ab 179 357 QVQLVESGPTLVKPTQTLTLTCTFSGFSLSTSRVGVGWIRQPPGKALEWLALIYWD ADI-19476 Heavy chain variable region DDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTARYYCAHRSTYDILGGYYYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 179 358 QPVLTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWFQQHPGKAPKLMIYDVSK ADI-19476 Light chain variable region RPSGVPNRFSGSKSGNTASLTISGLQAEDEADYFCCSYAGTYEVFGGGTKLTVL (“LC”) amino acid sequence Ab 180 359 QVQLVESGPGVVKPSETLSLICTVSGGPVSSRSYYWGWIRQPPGKGLEWIGSIYYS ADI-19478 Heavy chain variable region GSTYYNTSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAKLQYSTSGFDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 180 360 QPVLTQPPSVSEAPRQRVTISCSGSSSNIGNNAVSWYQQLPGKAPKLLIYYDDLVPS ADI-19478 Light chain variable region GVSDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 181 361 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNAINWVRQAPGQGLEWMGGIIPIF ADI-19479 Heavy chain variable region GTANYAQKFQGRVTITTDESTSTAYMELSSLRSEDTAVYYCATTFYYGSGADYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 181 362 DIQMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNMYLSWFQQRPGQSPRRLIYKVS ADI-19479 Light chain variable region NRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWWTFGQGTKVEIK (“LC”) amino acid sequence Ab 182 363 EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYSMNWVRQAPGKGLEWVSSISSTT ADI-19480 Heavy chain variable region NYISYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDPKYYGLGTYYKDD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 182 364 NFMLTQPHSVSESPGKTVTISCTRSGGSIASNYVQWYQQRPGSSPTTVIYEDNQRP ADI-19480 Light chain variable region SGVPDRFSGSIDSSFNSASLTVSGLKTEDEADYYCQSFDNNNRWVFGGGTKLTVL (“LC”) amino acid sequence Ab 183 365 EVQLVESGGVVVQPGGSLRLSCAASGFTFDDYTMHWVRQAPGKGLEWVSLISWD ADI-19481 Heavy chain variable region GGITYYADSVKGRFTISRDNSKNSLYLQMNSLRTEDTALYYCVKGGYYDGSGYYYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 183 366 DIQMTQSPSSLSASVGDRVTVTCRASQSISSYLNWYQHKPGNAPKLLIYAASSLQSG ADI-19481 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 184 367 QVQLQQWGAGLLKPSETLSLTCGAFHGSFSGYYWSWIRQPPGKGLEWIGEVTHSR ADI-19482 Heavy chain variable region STNYNPSLKSRITISVDTSRNQFSLKLNSVTAADTAVYYCARGSGEWYFDIWGRGTL (“HC”) amino acid sequence VTVSS Ab 184 368 DIQLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGRAPKLLIYKASSLESGV ADI-19482 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSPEIFGQGTKVEIK (“LC”) amino acid sequence Ab 185 369 QVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWIGWVRQMPGKGLEWMGIIFPGD ADI-19483 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYFCARSAFPFGFDIWGQG (“HC”) amino acid sequence TMVTVSS Ab 185 370 SYVLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDHQRPS ADI-19483 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLQTEDEADYYCQSYGSGNPWVFGGGTKVTVL (“LC”) amino acid sequence Ab 186 371 QVQLQESGSGLVKPSQTLSLTCVVSGGSISSGGNSWSWIRQPPGKGLEWIGYIYDS ADI-19484 Heavy chain variable region GNTYYNPSLKSRVTISVDRSKNQFSLKVSSVTAADTAVYYCARGAETGTTGWYDPW (“HC”) amino acid sequence GQGTLVTVSS Ab 186 372 DIRLTQSPSSLSASVGDRVTITCRASQTISSYLNWYQQKPGKAPRLLIYAASSLQSGV ADI-19484 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYGTPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 187 373 QVQLQESGPGLVKPSQTLSLSCTVSGGSISSTNYYWTWIRQHPGKGLEWIGFIYNR ADI-19485 Heavy chain variable region GSTYYNPSLTSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARAPYYYDRNGYYTAFD (“HC”) amino acid sequence IWGQGTTVTVSS Ab 187 374 EIVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYDASTRATDI ADI-19485 Light chain variable region PARFSGGGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGLGTKVDIK (“LC”) amino acid sequence Ab 188 375 QVQLQESGPGLVKPSETLSLTCSVSGGSLTSYYWSWIRQPPGKGLEWIGYIYYSGST ADI-19486 Heavy chain variable region NYNPSLKSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARVGGRGVINVFDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 188 376 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNR ADI-19486 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCDSYRSNSASVVFGGGTKLTVL (“LC”) amino acid sequence Ab 189 377 QVTLKESGPALVKPTQTLTLTCTFSGLSISTSGMCVSWIRQPPGKALEWLARIDWD ADI-19487 Heavy chain variable region DDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARINYYDSSGYYVYYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 189 378 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSG ADI-19487 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPFTFGPGTKVDIK (“LC”) amino acid sequence Ab 190 379 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDP ADI-19488 Heavy chain variable region EDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATARFLEWLSGTN (“HC”) amino acid sequence WFDPWGQGTLVTVSS Ab 190 380 DIQLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-19488 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPPTFGGGTKVEIK (“LC”) amino acid sequence Ab 191 381 QITLKESGPALVKPTQTLTLTCTFSGFSLSTSGMCVSWIRQPPGKALEWLARIDWDD ADI-19489 Heavy chain variable region DKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARMCWGNYVPIDAFDI (“HC”) amino acid sequence WGQGTMVTVSS Ab 191 382 DIQLTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSG ADI-19489 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPPTFGQGTKVDIK (“LC”) amino acid sequence Ab 192 383 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSK ADI-19490 Heavy chain variable region TDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTDSSSGGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 192 384 DIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-19490 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 193 385 QVQLVQSGPTLVKPTQTLTLICTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWD ADI-19491 Heavy chain variable region DDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRRATTVTTGYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 193 386 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19491 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGHYVFGTGTKVTVL (“LC”) amino acid sequence Ab 194 387 QVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWIGWVRQMPGKGLEWMGIIYPG ADI-19492 Heavy chain variable region DSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARSGSHYAFDLWGQ (“HC”) amino acid sequence GTMVTVSS Ab 194 388 NFMLTQPHSVSESPGKTVTISCTRSSGNIASNYVQWYQQRPGSSPTTVLYEDNQRP ADI-19492 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNPWVFGGGTKLTVL (“LC”) amino acid sequence Ab 195 389 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSG ADI-19493 Heavy chain variable region STNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARLIENTRVGEYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 195 390 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-19493 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTQLTVL (“LC”) amino acid sequence Ab 196 391 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYVISWVRQAPGQGLEWMGGIIPIF ADI-19494 Heavy chain variable region GTTYYAQKFQDRVTITTDESTSTAYMELSSLRSEDTAVYYCARDLRYRYNAYDGADA (“HC”) amino acid sequence FDIWGQGTTVTVSS Ab 196 392 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIFEVSNR ADI-19494 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCTSYTKSNSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 197 393 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYTSGST ADI-19495 Heavy chain variable region NYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVGSYYDLQHWGQGTLV (“HC”) amino acid sequence TVSS Ab 197 394 DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSG ADI-19495 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 198 395 EVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYD ADI-19496 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKDATFGYSSSWYN (“HC”) amino acid sequence FDYWGQGTLVTVSS Ab 198 396 DIQMTQSPDSLAVSLGERATINCKSSQSVLFSSNNKNYLAWYQQKPGQPPKLLIYW ADI-19496 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPTFGQGTKVEIK (“LC”) amino acid sequence Ab 199 397 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPS ADI-19497 Heavy chain variable region GGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCSRGYSYGYDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 199 398 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPS ADI-19497 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNWVFGGGTKLTVL (“LC”) amino acid sequence Ab 200 399 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGG ADI-19498 Heavy chain variable region SAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREARISPPQGAFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 200 400 SYVLTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGI ADI-19498 Light chain variable region PERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTLYVFGTGTKVTVL (“LC”) amino acid sequence Ab 201 401 EVQLLESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGS ADI-19499 Heavy chain variable region TYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAVLLYSSSSFDYWGQGTLV (“HC”) amino acid sequence TVSS Ab 201 402 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPS ADI-19499 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNQAVFGGGTQLTVL (“LC”) amino acid sequence Ab 202 403 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSS ADI-19500 Heavy chain variable region TIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGNTVTTFLDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 202 404 DIRLTQSPSSFSASTGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGV ADI-19500 Light chain variable region PSRFSGSGSGTDFTLTISCLQSEDFATYYCQQYYSYPPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 203 405 QVQLVQSGAEVKKPGASVKVSCKASGYAFTNYGVSWVRQAPGQGLEWMGWISV ADI-19501 Heavy chain variable region YNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTALYYCARDPPSEGAAGL (“HC”) amino acid sequence FDYWGQGTLVTISS Ab 203 406 DIVMTQSPLSLPVTLGQPASFSCRSSQSLVYSDGNTYLSWFQQRPGQSPRRLIYKVS ADI-19501 Light chain variable region NRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPCTFGQGTKVEIK (“LC”) amino acid sequence Ab 204 407 EVQLVESGGGVVQPGGSLRLSCAASGFTFSSDGMHWVRQAPGKGLEWVAFIQYD ADI-19502 Heavy chain variable region GTNKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDQGFRYSSSWYA (“HC”) amino acid sequence FDIWGQGTMVTVSS Ab 204 408 EIVMTQSPDSLAVSLGERATINCKSSQSVLFNSNNKNYLAWYQQKPGQPPKLLIYW ADI-19502 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPTFGQGTRLEIK (“LC”) amino acid sequence Ab 205 409 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPS ADI-19503 Heavy chain variable region GGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDSLVNCSGGSCP (“HC”) amino acid sequence GGPDYWGQGTLVTVSS Ab 205 410 SYVLTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGI ADI-19503 Light chain variable region PERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHRVFGGGTKLTVL (“LC”) amino acid sequence Ab 206 411 QVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGITYPG ADI-19505 Heavy chain variable region DSDTRYSPSFQGQVTISADKSISTAHLQWDSLKASDTAMYYCARLRCTGSICYDAFD (“HC”) amino acid sequence IWGQGTTVTVSS Ab 206 412 SYVLTQPLSVSVALGQTARITCGGNNIGSKNVHWYQQKPGQAPVLVIYRDNNRPS ADI-19505 Light chain variable region GIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTGGDVFGAGTKVTVL (“LC”) amino acid sequence Ab 207 413 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAY ADI-19506 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVRSVGRFGELL (“HC”) amino acid sequence YYYYGMDVWGQGTTVTVSS Ab 207 414 DIRLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-19506 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPWTFGQGTKLEIK (“LC”) amino acid sequence Ab 208 415 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19507 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREVLTGDYLGWFDPW (“HC”) amino acid sequence GQGTLVTVSS Ab 208 416 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19507 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSHWVFGGGTKLTVL (“LC”) amino acid sequence Ab 209 417 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-19509 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASSRRSLTGDRGGWFD (“HC”) amino acid sequence PWGQGTLVTVSS Ab 209 418 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-19509 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 210 419 EVQLVESGGGLVKPGGSLRLSCAASGFSLSSYYMNWVRQAPGKGLEWVSSISSSST ADI-19510 Heavy chain variable region YINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGSITIFGVVFDSWG (“HC”) amino acid sequence QGTLVTVSS Ab 210 420 SYELTQPPSVSGAPGQRVTISCTGTSSNIGAGYDVHWYQQLPGTAPKLLIYVNSNRP ADI-19510 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGGVFGTGTKVTVL (“LC”) amino acid sequence Ab 211 421 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDD ADI-19511 Heavy chain variable region DKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHSVYYDFWSGYYVPN (“HC”) amino acid sequence YFDYWGQGTLVTVSS Ab 211 422 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQS ADI-19511 Light chain variable region GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 212 423 EVQLLESGAEVKKPGASVKVSCKTSGYTFSNYGVSWVRQAPGQGLEWLGWISAYN ADI-20959 Heavy chain variable region GNTNYAQKLQGRVTMTTDSSTSTAYMEVRSLRSDDTAVYYCARDVAPVAASLFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 212 424 DIRLTQSPLSLPVTLGQPASISCRSSQSLEFTDGNTYLSWFQQRPGQSPRRLIYKVSN ADI-20959 Light chain variable region RDSGVPDRFSGSGSGTDFTLKINRVEAEDVGVYYCMQGIHWPPTFGPGTKVEIK (“LC”) amino acid sequence Ab 213 425 QVQLQQWGAGVLKPSETLSLTCAVNGRSLSGHYWSWIRQTPGKGLEWIGEINNS ADI-20960 Heavy chain variable region GGTHYSPSLKSRVIISGDTAKNQLSLKLSSVTAADTAVYYCAKGSAEWYFDLWGRGT (“HC”) amino acid sequence LVTVSS Ab 213 426 DIRVTQSPSTLSASVGDRVTITCRASQSVSTWLAWYQQKPGKPPSLLIFKASTLESGV ADI-20960 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYSPWTFGPGTKVEIK (“LC”) amino acid sequence Ab 214 427 QVQLVESGGGLVKPGGSLRLSCAASGFKFSSYYMHWVRQAPGKGLEWVSSVSGG ADI-20961 Heavy chain variable region STYTSYADSVKGRFTISRDNAKHSLFLQLNSLRAEDTAVYHCVRGDYHPSGTSLNWF (“HC”) amino acid sequence DPWGQGTLVTVSS Ab 214 428 QPGLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYKQLPGTVPKLLIYANNNR ADI-20961 Light chain variable region PSGVPDRFSGSESGTSASLAITGLQAEDEADYYCQSYDSSLNAYVFGTGTKVTVL (“LC”) amino acid sequence Ab 215 429 QVQLVQSGAEVKKPGASVKVSCKASGYTFSHYGLSWVRQAPGQGLEWMGWISA ADI-20962 Heavy chain variable region YNHNTNYAQKFQGRVTITTDTSTSTAYLEMRSLRSDDTAVYYCAREPPSDTAAGTG (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 215 430 DIVMTQSPLSLSVTLGQPASISCRSSQSLVYSDGNTYLTWFQQRPGQSPRRLIYKVS ADI-20962 Light chain variable region NRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTQWPRTFGQGTKVDIK (“LC”) amino acid sequence Ab 216 431 EVQLVESGGGLAKPGGSLRLSCAASGFTFSHYNMNWVRQAPGKGLEWVSSISSTG ADI-20963 Heavy chain variable region FHIYYADSVKGRFVISRDNAENSLHLQMNSLRADDTGLYYCVRAEYYYGSGSAGHY (“HC”) amino acid sequence FDSWGQGTLVTVSS Ab 216 432 SYVLTQPPSVSVAPGHTAKITCGGSIIGTKSVHWYQQKPGQAPVLVVYDDSDRPSGI ADI-20963 Light chain variable region PERLSGSRSGNTATLTITRVEAGDEADYYCQVWDSSSEHAGVFGGGTKLTVL (“LC”) amino acid sequence Ab 217 433 QVQLVQSGAEVKKPGASVKVSCKASGYTFTHYGISWVRQAPGQGLEWMGWISAY ADI-20964 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMEVRSLRYDDTAVYYCARDVPVEAATSPE (“HC”) amino acid sequence FWGQGTLVTVSS Ab 217 434 DIVMTQTPLSLPVTLGQPASISCRSSQSLVYSDGNTYLSWFQQRPGQSPRRLIYKVS ADI-20964 Light chain variable region NRDSGVPNRFSGSGSGTDFTLKISRVEAEDVGVYYCVQNTHWPAYTFGQGTKVEIK (“LC”) amino acid sequence Ab 218 435 QVQLVQSGAEVKKPGASVKVSCKASGYNFTNYGISWVRQAPGQGLEWMGWIST ADI-20965 Heavy chain variable region SNGNTHYAQKSQGRITLTTDTSTNTAYMEVRSLRSDDTAVYYCAREGPESTYDWY (“HC”) amino acid sequence HFDSWGQGTLVTVSS Ab 218 436 QSVVTQPPSVSVAPGQTAKITCGGNNIGSKTVHWYQLKAGQAPVLVVYDDSDRPS ADI-20965 Light chain variable region GIPERFSGSNSGNTATLTIRRVEAGDEADYFCQVWESASDHWVFGGGTKLTVL (“LC”) amino acid sequence Ab 219 437 EVQLLESGGGLGKPGGSLRLSCAASGFKLSSYYMHWVRQAPGKGPEWVSSISASSS ADI-20966 Heavy chain variable region YINYADSVRGRFTVSRDNAKNSLFLQMNSLRVDDTAIYYCARGAPLTNFGMVLDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 219 438 QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAGYDVHWYQQVPGRVPKLLIYANNN ADI-20966 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQADDEADYYCQSYDRSLNVVFGGGTKLTVL (“LC”) amino acid sequence Ab 220 439 EVQLLESGGGVVQPGRSVRLSCAASGFSFSSYALHWVRQAPGKGLEWVGVIWYEE ADI-20967 Heavy chain variable region SNKYYADPVKGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARKGVATAGLDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 220 440 EIVLTQSPLSLPVTPGEPASISCRSSQSLLNSNGYNYLDWYLQKPGQSPQLLIYLGSNR ADI-20967 Light chain variable region ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPQTFGPGTKVDIK (“LC”) amino acid sequence Ab 221 441 QVQLQQWGAGLLKPSETLSLTCAMYGGSFSDDYWSWIRQPPGKGLEWIGEVNH ADI-20968 Heavy chain variable region GGSTNYNTSLKSRVTISADTSKKQFSLKLRSVTAADTAVYFCARGWRYCNATTCYSK (“HC”) amino acid sequence AFDIWGQGTMVTVSS Ab 221 442 DIQMTQSPSSLSASVGDRVTITCQASQDIDIYLIWYQQKPGRAPKLLIYDASNLKTGV ADI-20968 Light chain variable region PSRFSGSGSGTEFTFTINNLQPEDFATYYCQQFHDLPLTFGGGTKLEIK (“LC”) amino acid sequence Ab 222 443 EVQLVESGGGLVKPGGSLRLSCAASGFKFSSYTMNWVRQAPGKGLEWVSSVSASS ADI-20969 Heavy chain variable region SYIFYADSVQGRFIISRDNAQNSLYLQMNSLRADDTAVYYCARDQYGPGHYYNPA (“HC”) amino acid sequence WFDPWGQGTLVTVSS Ab 222 444 QPVLTQPPSVSGAPGQRVTISCTGTSSNIGAGYDVHWYKQLPGTAPKVLIYGNTNR ADI-20969 Light chain variable region PSGIPDRFSGSKSGTSASLAITGLKAEDEADYYCQSYDRSGSKVFGTGTKLTVL (“LC”) amino acid sequence Ab 223 445 EVQLLESGGGLVKPGGSLRLSCAVSGFSFSNAWMSWVRQAPGKGLEWVGRIRSKT ADI-20970 Heavy chain variable region DGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAPRYSTSWYPG (“HC”) amino acid sequence YYYYYYMDVWGKGTTVTVSS Ab 223 446 DIQMTQSPSSLSASVGDRVTITCQASQDINFYLNWYQQKPGKAPKLLIYDASNLETG ADI-20970 Light chain variable region VPSRFSGSVSGTDFTFTISSLQPEDFATYYCQQYDDLPAFGGGTKVEIK (“LC”) amino acid sequence Ab 224 447 EVQLVESGGGLVKPGESLRLSCAASGFTFSDYSMTWIRQAPGKGLLEWIAYINSQS ADI-20971 Heavy chain variable region NYMDYADSVKGRFTISRDNAKNSLYLQMNGLRADDTAVYFCARDRRTFVAATLG (“HC”) amino acid sequence WFDPWGQGTLVTVSS Ab 224 448 ETTLTQSPATLSVSPGERATLSCRASQSVSNNVAWYQQKPGQAPRVLIYAASTRAT ADI-20971 Light chain variable region GIPARFSGSESGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKLEIK (“LC”) amino acid sequence Ab 225 449 QVQLQQWGAGLLRPSETLSLTCAVSGGSFSGHYWSWIRQPPGKGLEWIGGINHS ADI-20972 Heavy chain variable region GNTNYSPSLRSRVTMSVDTSRNQFSLMLRSVTAADTAVYFCARNVPNLYGDYPRW (“HC”) amino acid sequence FDPWGQGTLVTVSS Ab 225 450 QSVLTQPASVSGSPGQSITISCTGTSSDVGGFNYVSWYQHHPGKAPKLMIYDVNN ADI-20972 Light chain variable region RPSGASNRFSGSKSGNTASLTISGLQAEDEADYYCSSYRSSDTLYVFGTGTKVTVL (“LC”) amino acid sequence Ab 226 451 EVQLLESGGGLVKPAGSLRLSCAASGFSFSSYYMNWIRQAPGKGLEWVSDISGGSS ADI-20973 Heavy chain variable region YTNYADSVKGRFTVSRDNAKNSVYLQMNSLRGEDTAVYYCARGASTAATYTPTFD (“HC”) amino acid sequence YWGQGILVTVSS Ab 226 452 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLMFGNNN ADI-20973 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLRPEDEADYYCQSYDRRLTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 227 453 EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYQINWVRQAPGKGLEWVSSISGGSS ADI-20974 Heavy chain variable region YTDYADSIKGRFTISRDNAKKSAFLQMKSLRADDTAVYYCARALMATAGGLAFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 227 454 QPVLTQPPSVSGAPGQRVTISCTGSGSNIGAGYDVHWYQQVPGTAPKLLILRNTNR ADI-20974 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 228 455 QVQLVESGTHVKKPGASVKVSCEASDDTFNNKGIVWVRQAPGQGLEWMGWIRP ADI-20975 Heavy chain variable region NNGNTKYAQKFQGRVTMTTDASTNTAYMELRSLRSGDTAVYYCAREQFKWNDFY (“HC”) amino acid sequence FDYWGQGILVTVSS Ab 228 456 SYELMQPPSVSVAPGQTATITCGGSNIGSETVHWYQQKPGQAPVLVVHDDTDRPS ADI-20975 Light chain variable region GIPERFSGSNSGNTATLTISGVEAGDEADFYCQVRDSRTDDVVFGGGTKLTVL (“LC”) amino acid sequence Ab 229 457 QVQLVESGGDLVQKGGSLRLSCAASGFTFDNYAMTWIRQAPGQGLEWVSTVSGF ADI-20976 Heavy chain variable region VLGTGYTTYYADSVKGRFTISRDSSKNTVYLQLNSLRAEDTAVYYCAKCAATRNECL (“HC”) amino acid sequence WDYLQQWGQGTTVTVSS Ab 229 458 EIVMTQSPSSLSASVGDRVTITCRASQSVSIYLNWYQQKGGKAPKLLIYGASALQRG ADI-20976 Light chain variable region VPSRFSGSGSGTDFTLTITSLQPEDFATYFCHQSYSAPQTFGQGTKVDIK (“LC”) amino acid sequence Ab 230 459 EVQLVESGGGLVQPGGSLRLSCAASGFTFTNYAMSWVRQAPGKGLEWVSGISGS ADI-20977 Heavy chain variable region GGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDQGYAVVVADA (“HC”) amino acid sequence TRNLPPRRYGMDVWGQGTTVTVSS Ab 230 460 EIVLTQSPGTLSLSPGERATLSCRASHSVSSSYLAWYQQKPGQAPRLLIYGASSRATGI ADI-20977 Light chain variable region PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 231 461 EVQLVESGAEVKKPGASVKVSCKASGYTFGNYGISWVRQAPGQGLEWMGWISAY ADI-20978 Heavy chain variable region NGNSNYAQKFQGRVTMTTDTSASTAYMEVRSLRSDDTAVYYCARDVPVTAARLLD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 231 462 DIVLTQTPLSLPVTLGQPASISCRSSQSLVYSDGNTYLSWFQQRPGQSPRRLIYKVSN ADI-20978 Light chain variable region RDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQATDWLGYTFGQGTKLEIK (“LC”) amino acid sequence Ab 232 463 EVQLQESGPGLVKPSETLSLTCTVSGGSLRSYYWSWIRQPPGKGLEWIGNIYYGGST ADI-20979 Heavy chain variable region NYNSSLKGRVTISIDTSKNQFSLRLSSVTAADTAVYYCARDGLFPMGEWDYWGQGI (“HC”) amino acid sequence LVTVSS Ab 232 464 QSALTQPASVSGSPGQSITISCTGTSNDVGDYNYVSWYQQHPGEAPKLMIYEVTNR ADI-20979 Light chain variable region PSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSTSVVFGGGTQLTVL (“LC”) amino acid sequence Ab 233 465 QVQLQESGPGLVKPSQTLSLTCSVSGGSVSSGDYYWTWIRQPAGKGLEWIGRIYNS ADI-20980 Heavy chain variable region GGTDYSPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGRGYYESPWGQGTL (“HC”) amino acid sequence VTVSS Ab 233 466 EIVLTQSPATLSLSPGERATLSCRASQSVGIYIGWYQQKPGQAPRLLMYDASNRATG ADI-20980 Light chain variable region IPDRFSGSGSGTDFSLTISSLEPEDFAVYYCQLRSKWLTFGPGTKVEIK (“LC”) amino acid sequence Ab 234 467 QVQLQESGPRLVKPSETLSLICTVSGDSISSRNYFWAWIRQPPGKGLEWIGTIYYSG ADI-20981 Heavy chain variable region NTYSNPSLKSRVTISVDTSKKQFSLNLSSVTAADTAVYYCARGAYGGDAFDIWGQG (“HC”) amino acid sequence TVVTVSS Ab 234 468 DIRVTQSPSSVSASVGDRVTITCRASQGIGTWLAWYQQKPGKAPHLLIYAASRLQS ADI-20981 Light chain variable region GVPSRFSGSGSGTDFTLSISSLHPEDFATYYCQQAYAFPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 235 469 EVQLVESGPGLVKPSQTLSLICSVSGVSISRGSYYWSWIRQPAGGGLEWIGRIYTSG ADI-20982 Heavy chain variable region VTRYNPSLESRVTISLDSSQNQFFLRLSSVTAADTAVYYCATRESASYSSGPDAFDIW (“HC”) amino acid sequence GQGTTVTVSS Ab 235 470 DIQMTQSPSTLSASVGDRVIITCRASQSVNSWLAWYQQKPGKAPKLLIYQASSLESG ADI-20982 Light chain variable region VPSRFSGSGSGTEFTLTINSLQPDDFATYYCQQYKTFSRPFGQGTKVEIK (“LC”) amino acid sequence Ab 236 471 EVQLVESGGALVQPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVSAINNFG ADI-20983 Heavy chain variable region DKTYYTDSVEGRFTISRDNSKKTLYLQMSSLRPEDTAVYYCVKDRGYCSSPSCYAVPY (“HC”) amino acid sequence YYFYGMDVWGQGTTVTVSS Ab 236 472 EIVMTQSPSSLSASVGDRVTITCQASQGISNYLHWYQQKPGKAPKLLIYDASNLEAG ADI-20983 Light chain variable region VPSRFSGSGAGTDFTFTISSLQPEDVATYYCQHYNNLPFTFGPGTKVDIK (“LC”) amino acid sequence Ab 237 473 EVQLLETGAEVKKPGASVKVSCHVSGYGLTDLSMHWVRQAPGKRLQWMGSFDP ADI-20984 Heavy chain variable region QYGETIDTQNFQGRVTMTVDTSTATLYMQLSGLRSEDTAMYYCATPQSTGALDN (“HC”) amino acid sequence WGQGTLVTVSS Ab 237 474 DIRVTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPRLVIFAASNLQSGV ADI-20984 Light chain variable region PSRFSGTGSSRFSDSGSWTDFTLTISSLQPEDFAIYYCQQTYITPFTFGQGTKVDIK (“LC”) amino acid sequence Ab 238 475 EVQLVESGGGLVQPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVANIKE ADI-20986 Heavy chain variable region DGSEIKYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTEDSSSWFVAID (“HC”) amino acid sequence YYNYMDVWGKGTTVTVSS Ab 238 476 DIQVTQSPGTLSLSPGERATLSCRASQTVSSSYLAWYQQKPGQAPRLLFYGASSRAT ADI-20986 Light chain variable region DIPDRFSASGSGTDFTLTIHRLEPEDFAVYYCQLYGRSPPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 239 477 QVQLVQSGGGVVHPGRSLRLSCAASGFSFSDYGMHWVRQAPGKGLEWVAVIWY ADI-20987 Heavy chain variable region DGINKYYADSVKGRFAISRDNSKNTLYLQMNSLRAGDTAVYYCARGGIAAAQRYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 239 478 ETTLIQSPGILSLSPGERATLSCRASQTVSSSNLAWYQQKPGQAPRLLIYGASSRAT ADI-20987 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQSGTSFGQGTKVDIK (“LC”) amino acid sequence Ab 240 479 EVQLVESGGEVKKPGASVKVSCKTSGYPFSNYGISWMRLAPGQGLEWMGWISSY ADI-20988 Heavy chain variable region NGNTYYTKKFQGRVSMTTDTSTSTAYMELRSLRSDDTAVYYCARDVPVIAAHTFEY (“HC”) amino acid sequence WGQGTLVTVSS Ab 240 480 ETTLTQSPLSLPVTLGQPASISCRSSESLVYSDGNTYLSWFQQRPGQSPRRIIYKVSNR ADI-20988 Light chain variable region DSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQATHWPRDTFGQGTKVDIK (“LC”) amino acid sequence Ab 241 481 EVQLLESGPGLVKPSGTLSLTCAVSGGSIINSNWWSWVRQSPGKGLEWIGDIYHSG ADI-20989 Heavy chain variable region STTYNPSLKSRVTISVDRSKNQYSLRLTSVTAADTAVYYCAKIGPDNRSGPDYYYFM (“HC”) amino acid sequence DVWGKGTTVTVSS Ab 241 482 EIVLTQSPSSLPASVGDRVTISCRASQSISNYVYWYQQKPGKAPKLLIYAASSLQSGV ADI-20989 Light chain variable region PSRFSGSGSGTDFTLSISSLQFEDFATYFCQQSYSTPPTFGQGTKLEIK (“LC”) amino acid sequence Ab 242 483 EVQLVESGGGVVQPGRSLRLSCSASGFPFHSYAMHWVRQAPGKGLEWVAGIWYE ADI-20990 Heavy chain variable region GSSESYADSVKGRLTISRDNSRNTLYLQMNSLRVEDTAVYYCARRGSFSGFDSWGQ (“HC”) amino acid sequence GSLVTVSS Ab 242 484 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLISLGSN ADI-20990 Light chain variable region RASGVPDRFSGSVAGTDFTLKISRVEAEDVGVYYCMQSSQTPYTFGQGTKVDIK (“LC”) amino acid sequence Ab 243 485 EVQLVESGGNLVKPGGSLRLSCAASGFTFSGYYMSWIRQAPGKGLEWISDISGGSS ADI-20991 Heavy chain variable region YTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAMYYCARVEYDTTGPFHFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 243 486 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNR ADI-20991 Light chain variable region PSGVPDRLSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGIGTKVTVL (“LC”) amino acid sequence Ab 244 487 EVQLVESGGGLVQPGGSLRLSCVVSGFTFKSYWMTWVRQAPGKGLEWVANIKED ADI-20992 Heavy chain variable region GSEKYYVDSVKGRFTISRDNARNSLFLQMNSLRADDTAVYYCARNLEVSNEFYVVT (“HC”) amino acid sequence DNYYLMDVWGQGTTVTVSS Ab 244 488 DIQLTQSPSSLSASVGDRVTITCRASQSISFFLNWYRQKPGKAPKLLIYAASTLQSGVP ADI-20992 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFASYYCQQSYSTPHTFGQGTKVEIK (“LC”) amino acid sequence Ab 245 489 EVQLVESGGGVVQPGRSLRLICAASGFPFSSYAMHWVRQAPGKGLEWVAVTWY ADI-20993 Heavy chain variable region DGPNRDYADSVKGRFTVSRDNSKNTLYLQMTSLRADDTAVYYCARRGSWGSFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 245 490 DIVMTQSPLSLSATPGEPASISCRPSQSLLHSNGYNYLEWYLQKPGQSPQLLIYLGSN ADI-20993 Light chain variable region RASGVPDRFSGGGSGTDFTLRISRVEADDVGVYYCMQASQTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 246 491 QVQLVQSGAEVKKPGASVKVSCKASGYTFSSNVIGWVRQAPGQGLEWMGWIST ADI-20994 Heavy chain variable region NNGNTKYGQKFQGRVIMITDPSTSTAYMELRSLRSDDTAFYYCARESLGMGGFYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 246 492 QPVLTQPPSVSVAPGQTARITCGGDNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-20994 Light chain variable region GIPERFSGSNSGNTASLTISRVEAGDEADYCCQVWDSGSDLWVFGGGTKLTVL (“LC”) amino acid sequence Ab 247 493 QVQLVESGPALVKPTQTLTLTCTFSGFSLTTRGMCVSWIRQPPGKALEWLARIDWD ADI-20996 Heavy chain variable region DDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARASTLTTAGYYLHYK (“HC”) amino acid sequence DVWGNGTTVTVSS Ab 247 494 DIRMTQSPSSLSASVGDRVTITCRASQSIGTYLNWFQQKPGKAPNLLIYAASILHSGV ADI-20996 Light chain variable region PSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSYPTVTFGQGTKVEIK (“LC”) amino acid sequence Ab 248 495 EVQLVESGGGVVQPGRSLRLSCAASGFPFNSYGMHWVRQAPGKGLEWLAVIYFD ADI-20997 Heavy chain variable region ESTAYYADSVKGRFTISRDNSKSTLYLQMNSLRAADTAIYYCTTTVMIPYGGVFWG (“HC”) amino acid sequence QGTLVTVSS Ab 248 496 EIVMTQSPGTLSLSPGDRATLSCRASQSVGSTHFAWYQQKPGQAPRLLIYAASIRAT ADI-20997 Light chain variable region GIPDRFSGGGSGTDFTLTISRLAPEDFAVYYCQQYGSTPITFGQGTRLEIK (“LC”) amino acid sequence Ab 249 497 QVQLVQSGGGVVQPGRSLRLSCAASGFTLSTYGMHWVRQAPGKGLEWVAVIYYD ADI-20998 Heavy chain variable region ESNKFYADSVQGRFTISRDDSKNTLFLQMNSLRAEDTAVYYCARESRPRGYSYSDFD (“HC”) amino acid sequence SWGQGTLVTVSS Ab 249 498 QPGLTQPRSVSGSPGQSVTISCTGTSSDVGTFNYVSWYQQHPGKAPKLMIYDVNQ ADI-20998 Light chain variable region RPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCAYAGYYSFGGGTKLTVL (“LC”) amino acid sequence Ab 250 499 QVQLQESGPVLVKPSETLSLICTVSGGSITSSAYYWGWIRQPPGKGLEWIGSVSYSG ADI-20999 Heavy chain variable region TTSYTPSLKSRVTISGDASKEQFSLNLRSVTAADTAVYYCARQTKAFGRRDYGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 250 500 QPVLTQPPSVSAAPGQKVTISCSGSNSNIGSNFVSWYQQLPGTAPKLLIYENNKRPS ADI-20999 Light chain variable region GIPDRFSGSKSGPSATLGITGLQTEDEADYYCGTWDTGLSAHWVFGGGTKLTVL (“LC”) amino acid sequence Ab 251 501 EVQLVESGPVLVKPRGTLTLTCTVSGFSLSDARMGVSWIRQPPGKALEWLAHIFWD ADI-21000 Heavy chain variable region DEKSYSTSLKNRLTISKDTSRGQVVLRMTNMDPVDTGTYFCARVNTYHSGGYYLYY (“HC”) amino acid sequence FDVWGQGTLVTVSS Ab 251 502 EIVLTQSPSSLSASVGDRVTITCRASQIIASYLNWYQQKPGQAPKLLIYAASSLQSGVP ADI-21000 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTRMYTFGQGTKVEIK (“LC”) amino acid sequence Ab 252 503 EVQLVESGPGLVKPSETLSLTCTVSGGSISDIDYYWGWIRQPPGKGLEWIGSIYYSGS ADI-21001 Heavy chain variable region TYYNPSLESRVTISVDTSKNQFSLKLRSVSAADTALYHCARHGPPWVVTAIRGHAFD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 252 504 DIRVTQSPDSLAVSLGERATINCKSSQSILYSSNNKNYLAWYQQKPGQPPKLLIYWA ADI-21001 Light chain variable region STRESGVPDRFSGSGSGTDFILTISSLQAEDVAVYYCQEYYSYPPMYTFGQGTKVDI (“LC”) amino acid sequence K Ab 253 505 QVQLVESGPGLVKPSGTLSLTCAVSGDSINSGNWWNWVRQAPGKGLEWIGEIYH ADI-21002 Heavy chain variable region RGTSNYNPSLKSRVTISVDQSKNQFSLKVTSLTAADTAIYYCARARGYSSGPSYYYYL (“HC”) amino acid sequence DVWGKGTLVTVSS Ab 253 506 EIVMTQSPSSLSASVGDRVTISCRASQSISTYLNWYQQKPGKAPKVIIYGASNLQSGV ADI-21002 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQKSFNPCVFGQGTKVDIK (“LC”) amino acid sequence Ab 254 507 QVQLQQWGAGLLKPSETLSLSCAVSGGSFSGYYWTWIRQPPGKGLEWIGEINHSG ADI-21003 Heavy chain variable region STNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARARYFDYLAHWSFDLW (“HC”) amino acid sequence GRGTLVTVSS Ab 254 508 GIQMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYKYLDWYLQKPGQSPQLLIYLGSD ADI-21003 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPWTFGQGTKLEIK (“LC”) amino acid sequence Ab 255 509 QVQLQESGGGVVQPGRSLTLSCAASGFTFSSYGMHWVRQAPGKGLDWVAEIWY ADI-21004 Heavy chain variable region DGSNKYYVDSVKGRFTISRDNSKNTLYLQMKSLRAEDTAIYYCARDGGYESPFFDK (“HC”) amino acid sequence WGQGTLVTVSS Ab 255 510 EIVMTQSPDSLGVSLGERATINCKSSQSLYTSNHENSLAWYQQKPGQPPRLLIYWA ADI-21004 Light chain variable region STRELGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYHTTPLTFGPGTKVEIK (“LC”) amino acid sequence Ab 256 511 EVQLVESGGAVVQPGGSLRLSCVASGLAFDEYTMHWVRQSSAKGLEWISLISWNG ADI-21005 Heavy chain variable region GITYYADSVKGRFTISRDNSKNSLYLQMNSLRTEDTATYFCARLGYGSGSDYGDDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 256 512 ETTLTQSPGTLSLSPGERATLSCRASQSVSNNYLAWYQQKPGQAPRLLIHGASTRVT ADI-21005 Light chain variable region GIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHSSPRTFGQGTKVDIK (“LC”) amino acid sequence Ab 257 513 QVTLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWIRQPPGKALEWLAVMYWD ADI-21006 Heavy chain variable region DDKRYSPSLKTRLTITKDTSKNQVVLTMTNMAPVDTAIYYCAHLWFGEAAFDPWG (“HC”) amino acid sequence QGTLVTVSS Ab 257 514 EIVLTQSPLSLPVTLRQTASISCRSGQSLLYSDGNTYLNWFQQRPGQSPRRLISIVSKR ADI-21006 Light chain variable region DSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 258 515 QVQLVQSGADVKKPGASVKVSCKSSGYTFSNHSMHWVRQAPGQGLEWMGRIHP ADI-21007 Heavy chain variable region SSGTTTYAQKFQGRVTMTRDTSTSTVYMEVSSLRSEDTAVYYCARSPFFDFDFWG (“HC”) amino acid sequence QGTMVTVSS Ab 258 516 SYVLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSAPTSVIYEDNQRPS ADI-21007 Light chain variable region GVPDRFSGSIDSTSNSASLTISGLKTEDEADYYCQSYYSSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 259 517 QVQLQESGAGLLKPSETLSLTCTVYGGTFSGYHWNWIRQPPGKGLEWIGEINHRE ADI-21008 Heavy chain variable region NTDYNASLESRVTISVDTSKRQFSLKMNSVTVADTAVYYCARGIQVLTNLGTEVRVH (“HC”) amino acid sequence QFLDLWGRGTLVTVSS Ab 259 518 DIVLTQTPATLSLSPGERATLSCRASQSVSTYLAWYQQKPGQAPRLLIYDASNRAAGI ADI-21008 Light chain variable region PARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRTNWLPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 260 519 QVQLVQSGAEMKTPGASVKVSCKASGYSFSNYGFTWVRQAPGQGLEWMGWIS ADI-21009 Heavy chain variable region GYSAKTNYAQDLQGRVTMTIDTSTSTSYMELRSLRSDDTAVYYCARDPLGYFGSGT (“HC”) amino acid sequence YRGGAFDFWGQGTTVTVSS Ab 260 520 QSALTQPASVSGSPGQSITLSCTGTNNDVGSYHLVSWYQQYPGKAPKLVIYEVTKR ADI-21009 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQPEDEADYYCCSYAGDRRIFGGGTKVTVL (“LC”) amino acid sequence Ab 261 521 EVQLVESGGGVVQPGRSLRLSCAASGFSFSTYGMHWVRQAPGKGLEWVGVIWY ADI-21010 Heavy chain variable region DETTKYYADSVKGRFSISRDNSKNMVYVQMNSLRADDTALYYCAREVWGGVFDI (“HC”) amino acid sequence WGQGTTVTVSS Ab 261 522 DIQMTQSPATLSASVGDRVTITCRASQNIVTWLAWYQQKPGKAPNLLIYKASSLES ADI-21010 Light chain variable region GVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYNSYSGAFGQGTKVDIK (“LC”) amino acid sequence Ab 262 523 QVQLQESGPGLVKPSETLSLSCTASGDSISDYYWSWIRQPPGKGLEWIGFVSDTWG ADI-21011 Heavy chain variable region TNYSPSLTSRVAISLDTSRSQVSLRLRSVTAADTAVYYCVRTHLYDRGGYYLYYFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 262 524 DIRMTQSPPSLSASVGDRVTITCRASQRIASYLNWYQQKPDTAPKLLIYAASNLQTG ADI-21011 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 263 525 QVQLVQSGPAVVKPTQTLTLTCSFSGFSLSTSRMSVSWIRQPPGKALEWLARIDWD ADI-21012 Heavy chain variable region GDKYYSTSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARGSYYVSSGYYLNYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 263 526 DIRMTQSPSSLSASVGDRVTITCRTSQTIASYLNWYQQKPGKAPNLLIYAASILQTGV ADI-21012 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYGTPQTFGQGTKVEIK (“LC”) amino acid sequence Ab 264 527 QVQLQESGPGVVKPSETLSLTCTVSGGSISNTHSYWGWIRQSPGKGLEWIGSIYYT ADI-21013 Heavy chain variable region GSTYYNPSFRSRVTLSVDTSKNQFSLKLSSVTAADTAVYYCAAPDYFVLTDYKSTFDY (“HC”) amino acid sequence WGRGALVTVSS Ab 264 528 DIVMTQSPGTLSLSPGGRATLSCRASQSVGSSSLAWYQQKPGQAPRLLIYGASSRA ADI-21013 Light chain variable region AGIPDRFSGSGSGTDFTLTINRLEPEDFAMYYCQQYGSSPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 265 529 QVQLQESGPGLVKPSETLSLICTVSGGSISNYYWSWIRQPPGKGLEWIGYVWFGTT ADI-21014 Heavy chain variable region KYNPSLKNRVTISVDTGKNQVSLKVNSVTAADTAIYYCARDSSIWYRGAFEIWGQG (“HC”) amino acid sequence TTVTVSS Ab 265 530 DIRLTQSPSSLSASVGDRVTITCQASQDISNHLNWYQQRPGKAPELLIYDASTLETG ADI-21014 Light chain variable region GPSRFSGSGSGTDFTLTISSLQPEDFADYYCQQYDNLPVTFGGGTKVDIK (“LC”) amino acid sequence Ab 266 531 QVQLVQSGAEVKKPGASVRVSCKVPGNTLSDLSMHWVRHTPGEGLEWMGSFDP ADI-21015 Heavy chain variable region EYGETIPAQRFQGRVTMTEDTSTDTAYMELTSLRFEDTAVYYCAAPHASGALQHW (“HC”) amino acid sequence GQGTLVTVSS Ab 266 532 DIVMTQSPSSLSASVGDRVTITCRASQIISAYLNWYQQKAGKAPKLLIYAASSLQSGV ADI-21015 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYITPFTFGQGTKLEIK (“LC”) amino acid sequence Ab 267 533 QVQLVESGTEVKKPGASVKVSCKASGYTFTNYGITWVRQAPGQGLEWMGCISGY ADI-21017 Heavy chain variable region NGNTNYAQNLQGRVTMTTDTSTNTAYMELRSLISDDTAVYYCARDTGLTAAALLD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 267 534 DIVLTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLSWFQQRPGQSPRRLIYKVSN ADI-21017 Light chain variable region RDSGVPDRFGGSGSGTYFTLKISRVEAEDVGIYYCMQAIHWPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 268 535 EVQLLESGGGLVKPGGSLRLSCAGSGFTLSSYGMNWVRQAPGQGLEWISSISSSSS ADI-21018 Heavy chain variable region YINYADSVKGRFTISRDNAQNSLYLQLNSLRAEDTAVYYCARGGLGYDYGLGSYTYA (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 268 536 QSVVTQPPSVSGAPGQRVTISCTGSSSNTGAGYDIHWYQQLPGTGPKLLIYGNKNR ADI-21018 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKVTVL (“LC”) amino acid sequence Ab 269 537 EVQLLESGGGLVRPGGSLRLSCAVSGFTFSGNALTWIRRAPGKGLEWVSTIGDSGG ADI-21019 Heavy chain variable region GSYYADSVKGRFTISRDNSKSTLYLQMNSLTAEDTAVYYCARDPYGDYRDYYGIDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 269 538 EIVMTQSPLSLPVTPGEPASISCRSSQSLRHSNGYNYVDWYLQKPGQSPQLLIYLGS ADI-21019 Light chain variable region NRASGVPDRFRGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGQGTKVEIK (“LC”) amino acid sequence Ab 270 539 QVQLQQWGAGLLKPSETLSLTCAVHGGSFSGFYWSWIRQSPGKGLEWIAEINDSG ADI-21021 Heavy chain variable region NTNHNPSLKSRVTISIDTSKNQFSLNVSSVTAADTAVYYCAKNGGGHHYVGTLRFRS (“HC”) amino acid sequence RAFDIWGQGTMVTVSS Ab 270 540 EIVMTQSPSTLSASVGDRVTITCRASQSIGNRLAWYQQKPGKAPKLLISLASGLETGV ADI-21021 Light chain variable region PSRFSGSGSGTEFTLTITSLQPDDFATYYCQQYSSYGTFGQGTKLEIK (“LC”) amino acid sequence Ab 271 541 EVQLVETGPGLVKPSETLSLTCSVSGGSISSYYWSWLRQPPGKGLEWIGYIYNSGRT ADI-21022 Heavy chain variable region NYNPSLRSRVTISVDTSQNQFSLRLGSVTAADTAVYYCARGGAGDDLLRGSYRYLNF (“HC”) amino acid sequence WGQGTLVTVSS Ab 271 542 QSVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDTERPS ADI-21022 Light chain variable region GIPERISGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPDLLFGGGTKLTVL (“LC”) amino acid sequence Ab 272 543 EVQLVESGGGLVKPGGSLRLSCAASGFRFSSYGMHWVRQAPGRGLEWVSSITAGS ADI-21023 Heavy chain variable region SYMDYADSVKGRFSISRDNAKTSLYLQMNSLRAEDTAIYYCARENYDTGRGLNWF (“HC”) amino acid sequence DPWGQGTLVTVSS Ab 272 544 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYRQLPGTAPEVLIYGNNN ADI-21023 Light chain variable region RPSGVPDRFSGSKTGTSASLAITGLLAEDGADYYCQSYDRSQLWVFGGGTQLTVP (“LC”) amino acid sequence Ab 273 545 EVQLVESGGGLVRPGGSLRLSCEASGLKLSGYSMNWVRQAPGKGLEWVSSISASSS ADI-21025 Heavy chain variable region YIHYADSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVASWLTPGWFDPWGQ (“HC”) amino acid sequence GTLVTVSS Ab 273 546 QPVLTQPPSVSGAPGQTVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNR ADI-21025 Light chain variable region PSGVPDRFSGSKSGTSASLAVTGLQAEDEGDYYCQSYDSSLSGSAFGGGTKLTVL (“LC”) amino acid sequence Ab 274 547 QVQLVQSGPGLVKPSQTLSLTCTVSGVSISSGGFYWSWIRQHPGKGLEWIGHIYYS ADI-21026 Heavy chain variable region RSTYYNPSLKSRVTMSLNMSKNQFSLRLSSVTAADTAVYYCARERREWLHGELDY (“HC”) amino acid sequence WGQGTTVTVSS Ab 274 548 DIQMTQSPDSLAVSLGEGATINCKSSQSVLDSSKNKNYLAWYQQRPGQPPKLLISW ADI-21026 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYSCQQYFSPPATFGQGTKLEIK (“LC”) amino acid sequence Ab 275 549 QVQLQESGPGLVKPSGTLSLTCVVSGGSIRSHNYWTWVRQPPGKGLEWIGEIYHS ADI-21027 Heavy chain variable region GNTNYNPSLKSRVTLSIDKSKNVFSLRLNSVTAADTAVYYCVGGGPFAPYYFENWG (“HC”) amino acid sequence QGTLVTVSS Ab 275 550 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYAVHWYHQLPGTAPKLLIYDNNNR ADI-21027 Light chain variable region PSGVPDRFSGSKSGSSASLAITGLQAEDEADYYCQSYDRSLSGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 276 551 EVQLVESGGALVKPGGSLRLSCVASGFTFSDYYMHWVRQAPGKGLEWVSYISSTSS ADI-21028 Heavy chain variable region FTNYADSVKGRFIISRDNAKNSLYLQLNSLRAEDTAVYYCARDESSGWQTRRHFGM (“HC”) amino acid sequence DVWGQGTLVTVSS Ab 276 552 EIVMTQSPSTLSASVGDRVTITCRASQSLNTWLAWYQHKPGKAPKLLISTASSLQSG ADI-21028 Light chain variable region VPSRFSASGSGTEFTLTISSLQPDDFATYYCQQFRGTFGPGTKVEIK (“LC”) amino acid sequence Ab 277 553 QVQLVQSGAEVRKPGESLKISCKASGYSFTNYWIGWVRQMPGKGLEWMGIVYPA ADI-21029 Heavy chain variable region DSHPVYSPSFQGQVTFSTDKSINTAYLQWSSLKASDTAMYFCARRDGGTDYLSDAF (“HC”) amino acid sequence DIWGQGTMVTVSS Ab 277 554 DIVMTQSPSSLSASVGDRVTITCRTSQSIRRYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-21029 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPNTFGQGTKVEIK (“LC”) amino acid sequence Ab 278 555 EVQLVESGGGLVKPGGSLRLSCAASGFKFSTYYMSWIRQAPGKGLEWVSNISGGSS ADI-21030 Heavy chain variable region YSNHADSVKGRFTISRDNAKNSLYLEMNSLRAEDTAVYYCAREDLMGVSGLAYFEY (“HC”) amino acid sequence WGQGILVTVSS Ab 278 556 QPVLTQPPSVSGAPGQRVTISCTGRSSNIGAGYDVNWYKQLPGAVPKVLIYGNTNR ADI-21030 Light chain variable region PSGVPDRFSGSKSGNSASLAITGLQAEDEADYYCQSYDRNLGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 279 557 EVQLVESGPGLVKPSQTLSLTCTVSGGSISNSNYFWSWIRQPAGKGLEWIGRVHSS ADI-21031 Heavy chain variable region GTTSYNPSLKSRITISVDASESQFSLNLTSVTAADTAIYYCARDSSDWGLGWYFDLW (“HC”) amino acid sequence GRGTLVTVSS Ab 279 558 ETTLTQSPATLSLSPGERATLSCRASQSVTFYLAWYQHKPGQAPRLLIFDASKRATGI ADI-21031 Light chain variable region PARFSGSGSGTDFTLTISSLEPEDFALYYCQQRSDWPQTFGQGTKVDIK (“LC”) amino acid sequence Ab 280 559 EVQLVESGGGLVKPGGSLRLSCAVSGFKFSSYTMNWVRQAPGKGLEWVSSVSASS ADI-21032 Heavy chain variable region SYIFYADSVQGRFIISRDNAQNSLYLQMNSLRADDTAVYYCTRDQYGPGHYYNPA (“HC”) amino acid sequence WFDPWGQGTLVTVSS Ab 280 560 QPVLTQPPSASGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKVLIYGNTNR ADI-21032 Light chain variable region PSGIPDRFSGSKSGTSASLAIIGLQAEDEADYYCQSYDRNGSKVFGTGTKLTVL (“LC”) amino acid sequence Ab 281 561 QVQLVQSGAEVRKPGDSLKISCKFSENIFTTYYWTGWVRQMPGRGLEWMGIIFPG ADI-21033 Heavy chain variable region DSDTRYSPSFQGHVTISVDKSIATAFLQWSSLKASDSAMYYCARAKYEGSFDMWG (“HC”) amino acid sequence QGTMVTVSS Ab 281 562 DIQVTQSPSSLSASVGDRVSITCQASQDIRNRLNWYQQKPGKAPKLLIYDASILETGV ADI-21033 Light chain variable region PSRFSGSGSGTDFTFSISSLQPEDFATYYCQQYDSFSLFTFGPGTKVEIK (“LC”) amino acid sequence Ab 282 563 QVQLQQSGAEVKKPGESLTISCKGSGYSFGNYWISWVRQMPGKGLEWMGRIDPS ADI-21034 Heavy chain variable region DSYVNYSPSFQGNVTMSVDKSSSTAYLQWSSLKASDTAMYYCARLAGYSTLWGQ (“HC”) amino acid sequence GTLVTVSS Ab 282 564 EIVLTQSPGTLSLSPGERATLSCRASQSFGSIYLAWYQQKPGQAPRLLIYGTSSRATGI ADI-21034 Light chain variable region PDRFSGSGSGTDFTLTIRRLEPEDFAVYYCLYYGSSPGATFGPGTKVDIK (“LC”) amino acid sequence Ab 283 565 EVQLVESGHEVKKPGASVKVSCKASGYTFPSYGISWVRQAPGQGLEWMGWIVPY ADI-21035 Heavy chain variable region NGNTKYAQRFQGRITMTTDSPTSTASMELRGLRSDDTAVYYCARVFGDGYSYGYE (“HC”) amino acid sequence YWGQGTLVTVSS Ab 283 566 DIVLTQSPSTLSASVGDRVTITCRASQSISIWLAWYQQKPGKAPKLLIYKTSELVSGVP ADI-21035 Light chain variable region SRFSGSGSGTEFTLTISGLQPDDFATYYCQQGNSYSHTFGQGTKVEIK (“LC”) amino acid sequence Ab 284 567 QVQLVQSGAEVKEPGKSLKISCKGSGNHFGNYWIAWVRQMPGKGLEWMGIIYPG ADI-21036 Heavy chain variable region DSDTRYSPSFQDQVTISVDKSINTVYLQWSSLKAADTATYYCAGSKLGNSWYTIYDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 284 568 NFMLTQPASVSGSPGQSITISCAGPSALIGVYNLVSWYQQVPGKAPKLIIYEGSKRPS ADI-21036 Light chain variable region GVSHRFSGSKSGYTASLTISGLQTEDEADYYCCSYAGSGTSVVFGGGTKVTVL (“LC”) amino acid sequence Ab 285 569 QVQLVQSGGGVVQPGRSLRLSCAASGFPFSSYAMHWVRQAPGKGLEWVAVIWY ADI-21037 Heavy chain variable region PGGEKYSADSVTGRFTISRDNSKNTLYLQMSSLRVEDTAVYYCARRSVGAFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 285 570 DIQMTQSPLSLPVTPGEPASISCRSSQSLLNSNGYNYLDWYLQKPGQSPQVLIYLGS ADI-21037 Light chain variable region HRASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQAVQTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 286 571 QVQLVQSGAEVKKPGESLKISCQGFGFSFTSYWIGWVRQTPGKGLEWMGTIYPGD ADI-21038 Heavy chain variable region SETRKSPSIQGQVTFSADRSISTAYLQWSGLTASDTAVYYCARLKGGWGTTMAGIR (“HC”) amino acid sequence DYFYYGLDVWGQGTTVTVSS Ab 286 572 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATG ADI-21038 Light chain variable region IPDRFTGSGSGTDFTLTISRLEPEDFAVYYCQQYATSLGGFTFGPGTKVDIK (“LC”) amino acid sequence Ab 287 573 EVQLVQSGAEVKKPGASVKVSCKASGYTFISYYIHWVRQAPGQGLEWMGVINPSG ADI-21039 Heavy chain variable region GITDYAPKFQGRVSMTRDTSTRTVYLELSSLRSDDTAVYYCARDLCITTSCPRYYDYA (“HC”) amino acid sequence WRSYRSEGYFDSWGQGTLVTVSS Ab 287 574 EIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-21039 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQAQQAPFTFGGGTKVEIK (“LC”) amino acid sequence Ab 288 575 EVQLLESGPGLVKPSGTPSLTCAVSGVSITNSNNWWTWVRQPPGKGLEWIGEIYSS ADI-21040 Heavy chain variable region GSTNYSPSLKSRVTISLDKSKNQFSLKLSSVTAADTAVYYCARVLGYYGSGGGHLHS (“HC”) amino acid sequence WGPGTLVTVSS Ab 288 576 SYELTQPPSASGTPGQRVTISCSGSSSNIGAGYDVHWYQQLPGTAPKLLISVNSNRP ADI-21040 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEANYYCQSYDNSLSGYVVFGGGTKLTVL (“LC”) amino acid sequence Ab 289 577 EVQLVESGGVVVQPGGSLRLSCAASGFTFDDYTMHWVRQAPGKGLEWVSLISWV ADI-21041 Heavy chain variable region GDTTYYADSVKGRFTISRDNSKNSLYLQMNSLRTEDTALYYCAKGGYYDGSGYYYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 289 578 DIRLTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLMYAASSLQSG ADI-21041 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYSCQQSYSTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 290 579 EVQLVESGPRLVKPSQTLSLTCNVSGVPVNTGGYYWSWIRRHPIKGLEWIGYIYYSG ADI-21042 Heavy chain variable region STHYNPSLRGRATMSVDTSKNQFSLRLSSVTAADTAVYYCAKDTITVLRGVAKKGVF (“HC”) amino acid sequence DPWGQGILVTVSS Ab 290 580 DIQMTQSPSTLSASVGDRVIITCRASQSISSWLAWYQYKPGKAPNLLIYKATTLDSG ADI-21042 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYDSYPTFGQGTKVEIK (“LC”) amino acid sequence Ab 291 581 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGITWVRQAPGQGLEWMGWISTY ADI-21043 Heavy chain variable region NGKTNYAQKFKGRVTMTTDTSTSTAYVELTSLRSDDTAVYYCAREFPTRIVDSFYM (“HC”) amino acid sequence DVWGKGTTVTVSS Ab 291 582 SYELTQPPSVSVAPGQTARITCGGSNIGSETVHWYQQKPGQAPVLVVYGDSDRPS ADI-21043 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSRSDDFHVFGSGTKLTVL (“LC”) amino acid sequence Ab 292 583 QVQLVQSGAELKKPGESLKISCKTSGYTFANYWIGWVRQMPGKGLEWMGIIYPGD ADI-21044 Heavy chain variable region SDTRYSPSFQGQVTFSADKSINSAYLQWHSLKASDSAIYYCARRFSPDYSDGAAPPT (“HC”) amino acid sequence LSDAFDVWGQGTTVTVSS Ab 292 584 DIVMTQSPSSLSASVGDRVTITCRASQNINIYLNWYQQKPGKAPKLLIYAASTLQSG ADI-21044 Light chain variable region VPSRFSGSGSATDFTLTISSLQPEDFATYYCQQSYRTPNDFGRGTKVDIK (“LC”) amino acid sequence Ab 293 585 EVQLVESGGGLVKPGGSLRLSCLASGFKFRSYSMNWVRQAPGTGLVWVASISASSS ADI-21045 Heavy chain variable region FIFYADSLKGRFTISRDNDKNSLYLQMNSLTVEDTAVYYCVRDMSGISSGGKTFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 293 586 QSVLTQPPSVSGAPGQRVTISCTGSSSNLGAGYDVQWYQQLPGTAPKLLIYGNNN ADI-21045 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLRAEDEADYYCQSYDTSPVFGGGTKLTVL (“LC”) amino acid sequence Ab 294 587 EVQLVESGAEAKKPGESLRISCTVSGYSFSKYWVGWVRQTPGKGLEWMGIIDPTDS ADI-21046 Heavy chain variable region DTRYSPSFQGQVTISVDNSINTAYLQWSSLKASDTAIYYCARRGQAKCVGNCPRDF (“HC”) amino acid sequence MDVWGKGTTVTVSS Ab 294 588 SYVLTQPPSVSGAPGQRVTISCAGSSSNIGAGYEVHWYQQLPGTAPKLLIYANRNR ADI-21046 Light chain variable region PSGVPDRFSGSRSGTSASLAISGLQAEDEADYYCQSYDNNLSGSWVFGGGTKLTVL (“LC”) amino acid sequence Ab 295 589 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGKYWSWIRQPPGKGLEWIGEFNHD ADI-21047 Heavy chain variable region GTTYYNPSLKSRVTISADTPKNQFSLTLHSVTAADTAVYYCARLTILSDWGQGTLVTV (“HC”) amino acid sequence SS Ab 295 590 DIRMTQSPSSLSASVGDRVTITCQASQDISNYLHWYQQKPGKAPKLLIYDASNLETG ADI-21047 Light chain variable region VPSRFSGSGSGTDFTFTIHSLQPEDLATYYCQQYYDLPRTFGQGTKLEIK (“LC”) amino acid sequence Ab 296 591 EVQLVESGAEVKKPGASVKVSCKASGYTFSSHAISWVRQAPGHGLEWMGWISVF ADI-21048 Heavy chain variable region NGNTNYAQKFQGRVTMTTDTSTSTAYMELRSLRSDDAAVYYCAREVIGVGEFYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 296 592 QSVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKAGQAPVLVVYDDSDRPS ADI-21048 Light chain variable region GIPERFLGSNSGNTATLTISRVEAGDEADYYCQVWDSSGDFHVFGTGTKVTVL (“LC”) amino acid sequence Ab 297 593 EVQLVESGGGLVKPGGSLRLSCSASGFAFSSYSMNWVRQAPGKGLEWVSSISASSS ADI-21049 Heavy chain variable region YIFYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAFYYCARALSPGYGDYRDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 297 594 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGAAPKLLIYGNNN ADI-21049 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQAEDEADFYCQSYDHNLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 298 595 QVQLVQSGAEVKKPGASVKVSCTASGYTFANNGISWVRQAPGQGLEWMGWISA ADI-21050 Heavy chain variable region YNGNTKYAQTVQGRVILTIDTSTSTAYMELRSLTSDDTAVYYCAREMGVDAAATF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 298 596 EIVMTQSPLFLSVTLGQPASISCRSSQSLVYSDTNTYLTWFQQRPGQSPRRLIYKVSN ADI-21050 Light chain variable region RDSGVPDRFSGSGSGTYFTLKISRVEAEDIGVYYCMQAIHWPRTFGQGTKLEIK (“LC”) amino acid sequence Ab 299 597 QVQLVESGPGLVRPSQTLSLTCNVSGDFISRGTYYWSWIRQSAGKGLEWIGRIYTS ADI-21051 Heavy chain variable region GITDYSPSLKSRVTISVDTSKNQFFLKLASVTAADTAVYYCARGRGYYDSPWGQGTL (“HC”) amino acid sequence VTVSS Ab 299 598 ETTLTQSPATLSLSPGERATLSCRASESVSTFLGWYQQKPGQAPRLLIYDASNRASG ADI-21051 Light chain variable region VPARFSGSGSGTDFTLTISSLEPEDFAVYYCQLRNKWLTFGPGTKVDIK (“LC”) amino acid sequence Ab 300 599 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAY ADI-21052 Heavy chain variable region NGNTNYAQNLQGRVTMTTDTSTSTAYMELRSLRSDDTAMYYCARDAFSRVGYWY (“HC”) amino acid sequence FDLWGRGTLVTVSS Ab 300 600 SYELTQPPSVSVAPGQAARITCGGNNIGSKTVHWYQQKPSQAPVLVVYDDSDRPS ADI-21052 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSGDHPVFGGGTKLTVL (“LC”) amino acid sequence Ab 301 601 QVQLQESGPGLVKPSQTLSLTCTVSGVSISNSSGGYYWSWIRQHPGKGLEWIGYIYY ADI-21053 Heavy chain variable region SGSTYYNPSSGSTYYNPSLKSRVTVSVDTSKNQFSLKLTSVTAADTAVYYCARDIRGP (“HC”) amino acid sequence HKHSLYNWFHPWGQGTLVTVSS Ab 301 602 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQTG ADI-21053 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLRTFGQGTKVDIK (“LC”) amino acid sequence Ab 302 603 QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVVGISFD ADI-21054 Heavy chain variable region GSYIFHGGSVTGRFNISRDNSKNTLYLQVNSVRAEDTAVYYCARDPQYYDDWSGYS (“HC”) amino acid sequence GLLHYYLYMDVWGKGTTVTVSS Ab 302 604 DIQLTQSPSTLSASVGDRVTITCRASQSIGTSLAWYQQIPGKAPKLLIYRASSLESGVP ADI-21054 Light chain variable region SRFSGGGSGTQFTLTISSLQPDDFATYYCQQYNNYSPTFGQGTKLEIK (“LC”) amino acid sequence Ab 303 605 EVQLVESGGGVVQPGRSLRLSCVGSGFTFSRYGMQWVRQAPGKGLEWAAVIWN ADI-21055 Heavy chain variable region DGSNEHYADSVKGRFTISRDNSKNTMYLQMNSLRAEDTALYYCAREGEYSSSWSH (“HC”) amino acid sequence WSYLDLWGRGTLVTVSS Ab 303 606 QPGLTQPPSASGTPGQRVTISCSGSTSNIGGNTVNWYQQLPGTAPTVLIYQNRQRP ADI-21055 Light chain variable region SGVPDRFSGSKSGTSASLAISGLQSDDEADYYCAAWDDSLNGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 304 607 EVQLLESGGGLVKPGGSLKLSCAASGFTLRSYYMHWVRQAPGRGLEWVSSISASSS ADI-21056 Heavy chain variable region YINYVDAVKGRFTVSRDNAKNSLFLQMNSLRAEDTAVYYCAREGGAMTNFGVVIDI (“HC”) amino acid sequence WGQGTMVTVSS Ab 304 608 SYVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYTNTNRP ADI-21056 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQSDDEADYYCQSYDSSLSGPVVFGGGTKLTVL (“LC”) amino acid sequence Ab 305 609 QVQLVQSGAEVKKPGESLKISCKASGYSLSNNWIAWVRQMPGKGLEWMGIVYLG ADI-21057 Heavy chain variable region DSDARYSPSFQGQVTFSADKSISTAYLQWSSLQASDTAMYFCARHHGDLVVTSDSR (“HC”) amino acid sequence YFYGLDVWGQGTTVTVSS Ab 305 610 DIVMTQSPATLSVSPGERATLSCRASQSISSNLAWYQQKPGQAPRLLIYGASTRATG ADI-21057 Light chain variable region IPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPSDTFGQGTRLEIK (“LC”) amino acid sequence Ab 306 611 QVQLQESGPGLVKPSETLSLTCTVSGGSISGTTYYWAWIRQPPGKGLEWIGTIFYSG ADI-21058 Heavy chain variable region STYYNPSLQSRVTTSVDASKNQMSLRLSSVTAADTAMYYCARHTSIYDNLTGFYSHL (“HC”) amino acid sequence TGVLDMWGQGTMVTVSS Ab 306 612 DIQLTQSPATLSVSPGERATLSCRASQSVSTNLAWYQQKRGQAPRLLIYGASTRAIGI ADI-21058 Light chain variable region PARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPAYTFGQGTKVDIK (“LC”) amino acid sequence Ab 307 613 QVQLVQSGAEVKRPGDSLKISCKGSGYSFTTSWIGWVRQVPGKGLEWMGIIYPGD ADI-21059 Heavy chain variable region SNTVYGPSLQGQVTISADKSTNTAYLQWSSLKASDTAMYYCARRDGGTDYLSDAF (“HC”) amino acid sequence DIWGQGTFVTVSS Ab 307 614 DIQMTQSPSSLSASVGDRVTITCRTSQNIVIYLNWYQQKPGKAPKLLIFAASSLPSGV ADI-21059 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDVATYYCQQSYNTPGTFGQGTKVDIK (“LC”) amino acid sequence Ab 308 615 EVQLVESGGGLVKPGGSLRLSCEASGFRLSDYYMTWIRQAPGKGLECISYISGGSTF ADI-21060 Heavy chain variable region KSYSDSVKGRFTISRDNTNLYLQMNSLRVEDTAVYYCARAPYLIYYMDVWGKGTTV (“HC”) amino acid sequence TVSS Ab 308 616 QPVLTQPPSVSGAPGQRVSISCTGSNSNIGAGYDVHWYQQLPGTPPKLLIYDNNN ADI-21060 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNRLSGSQVLFGGGTKVTV (“LC”) amino acid sequence L Ab 309 617 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYPISWVRQAPGHGLEWMGRVVPT ADI-21061 Heavy chain variable region VGLANYAQNLQGRVTITADTSTNTVYMELRSLRSEDTGLYYCARRAVVDTYAFDIW (“HC”) amino acid sequence GQGTLVTVSS Ab 309 618 QSALIQPASVSGFPGQSITISCTGASSDVGGYNFVSWYQQHPGKAPKLIIYEVTKRPS ADI-21061 Light chain variable region GVSNRFSGSESGNTASLTISGLQAEDEADYYCSSFRYTSSIVYVFGSGTKVTVL (“LC”) amino acid sequence Ab 310 619 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYDMIWVRQAPGKGLEWVSSISRGSD ADI-21062 Heavy chain variable region YIYYADSLKGRFTISRDNARNSVTLQMNSLRAGDTALYFCARAELLDSGGYYLYYFD (“HC”) amino acid sequence HWGQGTLVTVSS Ab 310 620 DIRMTQSPSSLSASVGDRVTITCRASQIIASYVNWYQKKPGKAPKVLIYAASRLQNG ADI-21062 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSYSTSFTFGQGTKVDIK (“LC”) amino acid sequence Ab 311 621 EVQLVESGGGLVQPGGSLRLSCSASGFTFRTYVMQWVRQAPGKGLEYVSAISSDG ADI-21063 Heavy chain variable region GSTDYADSVKGRFTVSRDNSKNTLYLQMSSLRAEDTAVYYCVKRGEGGNDYLYYY (“HC”) amino acid sequence MDVWGKGTTVTVSS Ab 311 622 DIQVTQSPSSLSASVGDRVTITCRASQSITNYLNWYQQKPGKAPKVLIYAASSLQSG ADI-21063 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYLRPPTFGGGTKVEIK (“LC”) amino acid sequence Ab 312 623 EVQLVESGGEVKKPGASVKVSCKASGYIFSNHGVSWVRQAPGQGLEWMGWISAY ADI-21064 Heavy chain variable region NGNAIYAQNLQGRVILTIDTSTSTAYMELTSLTSDDTAIYYCARESGATAAAVMDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 312 624 DIVLTQTPLSLPVILGQPASISCRSSQSLVYSDGNTYLTWFQQRPGQSPRRLIYKVSN ADI-21064 Light chain variable region RDSGVPDRFSGSGSDTDFTLKISRVEAEDVGVYYCMQGIDWPRTFGQGTKVDIK (“LC”) amino acid sequence Ab 313 625 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSGISGSG ADI-21065 Heavy chain variable region ESTYYADSVKGRFTISRDSSKNTVYLQMNSLRADDTAVYYCAKDQGYGVVVPAATR (“HC”) amino acid sequence ALPPRRYGMDVWGQGTTVTVSS Ab 313 626 EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATG ADI-21065 Light chain variable region IPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 314 627 QVQLQESGPGLVKPSGTLSLICVVSGGSIKSHNYWTWVRQPPGKGLEWVGEIYQS ADI-21068 Heavy chain variable region GRTNYNPSLNSRVTLSMDKSKNQLSLRLTSVTAADTAVYFCVGGGPFAPYYFQTW (“HC”) amino acid sequence GQGTLVTVSS Ab 314 628 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYNNNNR ADI-21068 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDTSLSGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 315 629 EVQLVESGAEVRKPGASVKVSCKASGYTFSSNAISWVRQAPGQGLEWMGYISVFN ADI-21069 Heavy chain variable region GNTKYAQNLQGRVTMTTDTATSTVYMELRSLRYDDTAIYYCARESLGMGGFYFDH (“HC”) amino acid sequence WGQGTLVTVSS Ab 315 630 SYELTQPPSVSVAPGQTARITCGANNIGSDSVHWYQQKPGQAPVLVVFDDRDRPS ADI-21069 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWMTSDRSVFGGGTKLTVL (“LC”) amino acid sequence Ab 316 631 EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYAMGWVRQAPGKGLEWVSTISDSG ADI-21070 Heavy chain variable region GSTFYADSVEGRFTIARDSSKNTLSLHMNSLRAEDTAIYYCAREAYSSSWYSGGWFD (“HC”) amino acid sequence RWGQGTLVTVSS Ab 316 632 ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATG ADI-21070 Light chain variable region IPARFSGSGSGAEFTLTINSLQSEDFAIYYCQQYNNWPQYTFGQGTKVDIK (“LC”) amino acid sequence Ab 317 633 EVQLVESGGGVVQPGKSLRLSCAVSGFTFSDHDMHWVRQAPGKGLEWVAAIWS ADI-21071 Heavy chain variable region DRTTKYYGDFVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGQIYKSGGYYLV (“HC”) amino acid sequence HLDHWGQGTLVTVSS Ab 317 634 DIQVTQSPSSLSASVGDRVTITCRASQSIASYLNWYQQKPGKAPNLLIYAASNLQSE ADI-21071 Light chain variable region VPSRFSGSGSGTDFTLTISGLQPEDFATYYCQQSYNIRLLTFGGGTKVEIK (“LC”) amino acid sequence Ab 318 635 QVQLVQSGGGLVKPGGSLRLSCEASGFNFRSYHMSWVRQAPGKGLEWVSSITAG ADI-21072 Heavy chain variable region SSYINYADSVKGRFTISRDNAKNSVLQMNSLSAEDTAVYYCAREGLNMGVGGTW (“HC”) amino acid sequence FDPWGQGTLVTVSS Ab 318 636 QAVVTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNN ADI-21072 Light chain variable region RPSGVPDRFSGSKSATSASLAITGLQADDEADYYCQSYDRSLSGSWVFGIGTKVTVL (“LC”) amino acid sequence Ab 319 637 EVQLVESGGGLVRPGRSLRLSCAASGFTFSMFSMNWVRQAPGKGLEWLAYIGGS ADI-21073 Heavy chain variable region GSTIDYANSVSGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARIGLQTYNSHSSSSS (“HC”) amino acid sequence PARAFDVWGQGTTVTVSS Ab 319 638 DIVLTQSPSSLSASVGDRVTITCRASQSIGRFLNWYQQKPGKAPKLLIYAASSLESGV ADI-21073 Light chain variable region PSRFSGSGSGTQFSLTISSLQPEDFTTYYCQQSYSTPTTFGGGTKVDIK (“LC”) amino acid sequence Ab 320 639 EVQLVESGGGLVKPGGSLRLSCAASGFSFSNYYMSWVRQAPGKGLEWISYISGGST ADI-21075 Heavy chain variable region YANLADSVKGRFTISRDNTKNSMYLQMTSLRPDDTAVYYCARIHGTHGPFYFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 320 640 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIHANSNR ADI-21075 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLNAYYVFGTGTKLTVL (“LC”) amino acid sequence Ab 321 641 EVQLVESGGGLVRPGGSLRLSCAASGFTFSSYAMDWVRQAPGKGLEWVSSISASSS ADI-21076 Heavy chain variable region FISYTDSVKGRFTISRDNAKNSLFLQMDNVTAEDTAVYYCARDYYESGRYFYGNPFD (“HC”) amino acid sequence IWGQGTMVTVSS Ab 321 642 QPVLTQPPSVSGAPGQRVTISCTGSGSNIGAGFDVHWYQQLPGTAPKLLIYANSDR ADI-21076 Light chain variable region PSGVPDRFSASKSGTSASLAITGLQAEDEAHYYCQSYDNSLGGLCVFGIGTKLTVL (“LC”) amino acid sequence Ab 322 643 QVQLVESGGGLVKPGGSLRLSCVVSGFTFRDYYMSWIRQAPGKGLEWISYISPSSTY ADI-21077 Heavy chain variable region TNYADSVRGRFTISRDNAENSLYLQMNSLRAEDTAVYYCARVNIAATGAGGVFLDY (“HC”) amino acid sequence WGQGTTVTVSS Ab 322 644 QPVLTQPPSVSGAPGQRVTISCAGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNINR ADI-21077 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSYVFGIGTKVTVL (“LC”) amino acid sequence Ab 323 645 EVQLVESGGGLVKPGGSLRLSCAASGFRLSDYYMSWIRQAPGKGLEWISDISGGST ADI-21078 Heavy chain variable region YTNYADSVKGRLTISRDNAQNSLYLQMNSLRAEDTAVYYCARWGSGGPDAFHFW (“HC”) amino acid sequence GQGTTVTVSS Ab 323 646 QSVLTQPPSVSGVPGQRVTISCTGSRSNIGAGYDVHWYRQLPGTAPKLLIYGNSNR ADI-21078 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQADDEADYYCQSYDSSLSGSVIFGGGTKVTVL (“LC”) amino acid sequence Ab 324 647 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSNISGGST ADI-21079 Heavy chain variable region YTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREAYGSGNYYNPNW (“HC”) amino acid sequence LDPWGQGTLVTVSS Ab 324 648 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNRNR ADI-21079 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL (“LC”) amino acid sequence Ab 325 649 EVQLLESGGGLVKPGGSLRLSCEVSGFRLSDYYMSWIRQAPGKGLEWVSHISGGST ADI-21080 Heavy chain variable region YTNYADSVKGRFTISRDNGKKSMYLQMNSLRAEDTALYYCAKWGSGGPEAFDIW (“HC”) amino acid sequence GRGTMVTVSS Ab 325 650 QSALIQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQIPGTAPKWYGNNNR ADI-21080 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 326 651 EVQLLESGGGLVKPGGSLRLSCAASRFAFSNYYMTWIRQAPGKGLEWISNISGGSTF ADI-21081 Heavy chain variable region TNYADSVKGRFTISRDNAKNSVHLQMNSLRAEDTAVYYCVREASVAAGTPEGFDI (“HC”) amino acid sequence WGQGTMVTVSS Ab 326 652 QSVLTQPPSVSGAPGQRVIISCTGSSSNIGAGYDVNWYQQLPGTAPKLLMYGNRN ADI-21081 Light chain variable region RASGVPDRFSGSKSGTSASLAITGLQAEDEADYYCHSYDSSLGGSVFGGGTKLTVL (“LC”) amino acid sequence Ab 327 653 EVQLVESGGGLVKPGGSLKLSCVASGLKFSSYSMNWVRQAPGKGLEWVSSVSAGS ADI-21082 Heavy chain variable region SYTNYADSVKGRFTISRDNAKNSLYLQMNSLRVDDTAVYYCATERCSGGSCYLHGF (“HC”) amino acid sequence DPWGQGTTVTVSS Ab 327 654 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIFDNIIRP ADI-21082 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQADDEADYYCQSYDKSGDYVFGTGTKVTVL (“LC”) amino acid sequence Ab 328 655 QVQLQESGPGLVKPSGTLSLICAVSGDSITTSNWWSWVRQPPGKGLEWIGEIYHS ADI-21083 Heavy chain variable region GVTRYNPSLKSRLSISLDKSRNQFSLKLSSVTAADTAVYYCARDEALFGHWFDPWG (“HC”) amino acid sequence QGTLVTVSS Ab 328 656 QSVLTQPRSVSGSPGQSVTISCTGSSSDIGSYNYVSWYQQHPGKAPKLMLYDVSKR ADI-21083 Light chain variable region PSGVPDRFSGSKSVKTASLTISGLQAEDEADYYCCTYAGNSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 329 657 EVQLVESGAEVKKPGASVTVSCKASGYTFTSNTISWLRQAPGQGLEWLGWVSASN ADI-21084 Heavy chain variable region GNTKYAQKFQGRVTMTTDTSATTAYMEVRTLRHDDTAIYYCARDILDMGGFHFD (“HC”) amino acid sequence NWGQGTLVTVSS Ab 329 658 SYVLTQPPSVSVAPGQTARITCGGNNIGNKHVHWYKQKPGQAPVLVVYDDSDRPS ADI-21084 Light chain variable region GIPERFSGSNSGNTATLTVSRVEAGDEADFYCQVWDNTNDHPVFGGGTKVTVL (“LC”) amino acid sequence Ab 330 659 EVQLVETGGGLVKPGGSLRLSCEASGFNFRSYSMNWVRQAPGKGLEWVSSISASSS ADI-21085 Heavy chain variable region YINYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTGVYYCARVLVHYYYGMDVWG (“HC”) amino acid sequence QGTTVTVSS Ab 330 660 QSVLTQPPSVSAAPGQRVTISCTGTSSNIGAGYDVHWYQQLPGRAPKLLILGNNNR ADI-21085 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQTYDKTLMEIFGGGTKLTVL (“LC”) amino acid sequence Ab 331 661 EVQLVETGGGLVKPGGSLRLSCAASPFAFSNYYMSWIRQAPGKGLEWISNISGGST ADI-21086 Heavy chain variable region FTNYADSVKGRFTISRDNARNSLYLLMNNLRTEDTAVYYCAREASVAAGTPEGFDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 331 662 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVNWYQQFPGTAPKLLIYGNRNR ADI-21086 Light chain variable region PSGVPARFSGSKSGASASLAITGLQAEDEADYYCHSYDSGLSGSVFGGGTKLTVL (“LC”) amino acid sequence Ab 332 663 EVQLVESGGGLVQPGGSLRLSCAASGFTFSGYEMNWVRQAPGKGLEWLSYISSSG ADI-21087 Heavy chain variable region GIIYYADSVKGRFTISRDNARNSLFLQMNSLRAEDTAVYSCARARLLDGFDIWGQGT (“HC”) amino acid sequence MVTVSS Ab 332 664 DIQVTQSPSTLSASVGDRVTITCRASQSIGSWLAWYQQKPGKAPKLLIYKASSLESG ADI-21087 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGQGTKVEIK (“LC”) amino acid sequence Ab 333 665 EVQLLESGGGLVKPGGSLRLSCVASGFRFTSYSMNWVRQAPGKGLEWVSSISASSS ADI-21089 Heavy chain variable region YVDYADSLKGRFTISRDNAQNSLFLQMNSLRAEDTAVYYCARDYYDSGNYHSPFP (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 333 666 QSVLTQPPSVSGAPGQRVTISCTGSRSNIGAGYDVHWYQQLPGTAPKLLIYGNNKR ADI-21089 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSGPIFGGGTKVTVL (“LC”) amino acid sequence Ab 334 667 EVQLLESGGGLVKPGGSLRLSCAASGFTSGFTFSDFYMSWIRLTPGKGLEWISYISTH ADI-21090 Heavy chain variable region STSTNYADSVRGRFIISRDDARNSLFLQMNSLRAEDTAVYYCAGYYYGSGSYFFDH (“HC”) amino acid sequence WGQGTLVTVSS Ab 334 668 ETTLTQSPATLSVSPGERATLSCRASQSVSSNVAWYQQKPGQAPRLLIYSASSRDTG ADI-21090 Light chain variable region IPVRFSGSGSGTEFTLSISSLQSEDFAVYYCQQYSDWPTFGQGTKVEIK (“LC”) amino acid sequence Ab 335 669 QVQLVQSGAEVKKPGESLRISCQYSAYGFSTYWISWVRQLPGKGLEWMGRIDPSD ADI-21091 Heavy chain variable region SHTTYSPSFQGHVTLSADKSISTVYLQWSSLKASDTAMYYCARHQEYSGSDLDSWG (“HC”) amino acid sequence QGTLVTVSS Ab 335 670 QPVLTQPPSVSAAPGQRVTISCSGTRSNIGYNFVSWYQQLPGTAPKLLIYDNNKRPS ADI-21091 Light chain variable region GIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDSSLSALFGGGTKVTVL (“LC”) amino acid sequence Ab 336 671 EVQLLESGGGVVQPGRSLRLSCVASGFTFSTYGVHWVRQAPGKGLEWVAVISYDG ADI-22756 Heavy chain variable region ANKDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMITRVLPGGFDR (“HC”) amino acid sequence WGQGTLVTVSS Ab 336 672 EIVMTQSPGTLSLSPGERATLSCRASQSVSSAYLAWYQQKPGQAPRLLIYDASRRAT ADI-22756 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRFTFGQGTKVEIK (“LC”) amino acid sequence Ab 337 673 EVQLLESGAEVKKPGASVKVSCKASGYTFSNYGISWVRQAPGQGLEWMGWISVY ADI-22757 Heavy chain variable region NGNTEYAQKFQGRLTMTTDTSTSTAYMELRSLRSDDTAVYYCARDPPAVAASFMD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 337 674 EIVLTQSPLSLPVTLGQPASISCRSSQSLVHSEGNTYLSWFQQRPGQSPRRLIYKVSN ADI-22757 Light chain variable region RDSGVPDRFSGSGSGTDFTLKISRVEAEDVGLYFCMQGTHWPPTFGGGTKVEIK (“LC”) amino acid sequence Ab 338 675 QVQLVESGGGLVKPGGSLRLSCAASGFSISSYSMNWVRQAPGKGLEWVSSISGSSS ADI-22758 Heavy chain variable region YIYYGDSVKGRFTISRDNARNSLYLQMNSLRAEDTAVYYCARGDIAAAGTITYYFAH (“HC”) amino acid sequence WGQGTLVTVSS Ab 338 676 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLTGTAPKLLIFGNNNR ADI-22758 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGAVFGGGTQLTVL (“LC”) amino acid sequence Ab 339 677 EVQLLESGGGLVKPGGSLRLSCAASGFSFSSYTMNWVRQAPGKGLEWVSSITGGSS ADI-22759 Heavy chain variable region YIDYAGSLKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARDFPNIAVGGKTLDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 339 678 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWFQQLPGTAPKLLIYVNNNR ADI-22759 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRLSAVVFGGGTKVTVL (“LC”) amino acid sequence Ab 340 679 EVQLVESGGGLVQPGRSLRLSCVASGFTFDDYAMHWVRQAPGKGLEWVSGINW ADI-22760 Heavy chain variable region NSGGIGYADSVKGRFTISRDNTKNSLYLQMNSLRAEDTALYYCAKDGSALMGYGVE (“HC”) amino acid sequence VWGQGTTVTVSS Ab 340 680 SYELTQPPSASGTPGQRVTISCSGSNSNIGNNYVYWYQQLPGTAPKLLIYRNNQWP ADI-22760 Light chain variable region SGVPDRFSASKSGTSASLAISGLRSEDEADYYCASWDDSLSALVFGGGTKLTVL (“LC”) amino acid sequence Ab 341 681 EVQLVESGPGLVKPSQTLSLTCAISGDSVSSNSVAWNWIRQSPSRGLEWLGRTYYQ ADI-22762 Heavy chain variable region SKWYNDYAVSVKSRISVNPDTSKNQFSLQLNSLTPEDTAVYYCVRGCSWGFGWYF (“HC”) amino acid sequence DLWGRGTLVTVSS Ab 341 682 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAIYDVHWYQQFPGTAPKLLIYGNTNRP ADI-22762 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 342 683 EVQLVESGGGLIQPGGSLRLSCAASGFTFSTYEMNWVRQAPGKGLEWVSSISTSGS ADI-22763 Heavy chain variable region TKDYAGSVKGRFTVSRDNAKNSLYLQMNSLRAEDTAIYYCARVYYYDSSGYYLALFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 342 684 EIVLTQSPSSLSASVGDRVTITCRASQSIASYLNWYQQKPGKAPKLLIYAASSLRSGVP ADI-22763 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPSLTFGGGTKLEIK (“LC”) amino acid sequence Ab 343 685 QVQLVESGPGLVRPSGTLSLTCAVSGGSISGKNWWSWVRQPPGKGLEWIGEIDHS ADI-22764 Heavy chain variable region GSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARTGLYDSSGYYLYYFN (“HC”) amino acid sequence YWGQGTLVTVSS Ab 343 686 EIVMTQSPSSLSASVGDRVTISCRASQTIASYVNWYQQRPGKAPNLLIFAASNLQTG ADI-22764 Light chain variable region VPSRFRGSGSGTVFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVDIK (“LC”) amino acid sequence Ab 344 687 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-22765 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGDGYNYDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 344 688 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-22765 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVGGGGTKVTVL (“LC”) amino acid sequence Ab 345 689 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW ADI-22766 Heavy chain variable region NSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDGRFSLSHTYYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 345 690 QPVLTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKR ADI-22766 Light chain variable region PSGVPNRFSGSKSGNTASLIVSGLQAEDEADYYCSSYAGSNNLYVFGTGTKVTVL (“LC”) amino acid sequence Ab 346 691 QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-22767 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREANWGVAFDIWGQ (“HC”) amino acid sequence GTMVTVSS Ab 346 692 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-22767 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSYVFGIGTKVTVL (“LC”) amino acid sequence Ab 347 693 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSG ADI-22768 Heavy chain variable region STIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKSYIYDSSGYYLYYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 347 694 EIVMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-22768 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPGTFGQGTKVDIK (“LC”) amino acid sequence Ab 348 695 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRN ADI-22769 Heavy chain variable region KANSYTTEYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARVGYYYYYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 348 696 SYVLTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-22769 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTPLFGGGTKVTVL (“LC”) amino acid sequence Ab 349 697 QVTLKESGPALVKPTQTLTLTCTFSGFSLSTSGMCVSWIRQPPGKALEWLALIDWD ADI-22770 Heavy chain variable region DDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARSPGRAVAGTDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 349 698 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-22770 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVVFGGGTKLTVL (“LC”) amino acid sequence Ab 350 699 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-22771 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDYSSGWYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 350 700 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-22771 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL (“LC”) amino acid sequence Ab 351 701 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYD ADI-22772 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAVEQQLFIWYYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 351 702 SYELIQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-22772 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTDVVFGGGTQLTVL (“LC”) amino acid sequence Ab 352 703 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAY ADI-22773 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARESALSRDGYNY (“HC”) amino acid sequence GDVDYWGQGTLVTVSS Ab 352 704 ETTLTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSN ADI-22773 Light chain variable region RDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKLEIK (“LC”) amino acid sequence Ab 353 705 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-22774 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGASGYNYRYYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 353 706 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQFPGAAPKLLIYGNNN ADI-22774 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQADDEADYYCQSYDSSLSGYVVFGGGTKLTVL (“LC”) amino acid sequence Ab 354 707 EVQLLESGGGVVQPGRSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAVIWYD ADI-22775 Heavy chain variable region GSYKYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARESLQTHDAFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 354 708 DIQMTQSPSSLSASVGDRVTITCRASQGISNSLAWYQQKPGKAPKLLLYAASRLESG ADI-22775 Light chain variable region VPSRFSGSGSGTDYTLTINSLQPEDFATYFCQQYYSTLTWTFGQGTKVDIK (“LC”) amino acid sequence Ab 355 709 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGST ADI-22776 Heavy chain variable region IYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREIGGSYTGGAFDIWG (“HC”) amino acid sequence QGTMVTVSS Ab 355 710 SYELTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-22776 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKVTVL (“LC”) amino acid sequence Ab 356 711 QVQLVQSGAEVKRPGASVKVSCKASEYTFNFHDINWVRQAPGQGLEWMGWMN ADI-22777 Heavy chain variable region PKSGNTGYAQKFQGRVTMTRDTSKNTAYLELSSLRSEDTAVYYCARGYGTSWSSDS (“HC”) amino acid sequence WWGQGTLVTVSS Ab 356 712 SYELTQLPSVSVSPGQTARITCSGDALSKQFVYWYQQKPGLAPMLVIYKDTNRPSW ADI-22777 Light chain variable region IPERFSGSGSGTTATLTISEVQAEDEADYYCQSVDNSGTYGWVFGGGTKVTVL (“LC”) amino acid sequence Ab 357 713 EVQLVESGPGLVKPSETLSLTCTVSGGSINSYSWTWIRQPPGKGLEWLGSFDYSGSN ADI-22778 Heavy chain variable region TYNPSLKSRVTIAVDTSKNQFSLKLTSATAADTAVYYCARAPVYDSSGYYLYYFDNW (“HC”) amino acid sequence GQGTLVTVSS Ab 357 714 DIQMTQSPSSLSASVGDRVTITCRASQSIASYLNWYQQKPGKAPKLLIFAASNLHSG ADI-22778 Light chain variable region VPSRFSGSGSGTTFTLTISSLQPEDFATYYCQQSYSIRFFTFGPGTKLEIK (“LC”) amino acid sequence Ab 358 715 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYSWTWIRQPPGKGLEWIGEISHTGI ADI-22779 Heavy chain variable region TNYNPSLKSRVNISVDTSKNQFSLKLSSVTAADTAVYYCARADAYDSSGYYVYYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 358 716 DIQVTQSPPSLSASVGDRVTITCRASQTIASYLNWYHQKPGKAPELLIYAASSLQSGV ADI-22779 Light chain variable region PSRFSGSGSGTAFTLTISSLQPEDFATYYCQQSYSAPPSFGQGTKVEIK (“LC”) amino acid sequence Ab 359 717 EVQLVESGPTLVKPTQTLTLICTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDD ADI-22780 Heavy chain variable region DKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRGRQYSYGYYYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 359 718 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSNR ADI-22780 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSTLDVFGTGTKVTVL (“LC”) amino acid sequence Ab 360 719 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSG ADI-22781 Heavy chain variable region STIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGAVAGTRTGGFDI (“HC”) amino acid sequence WGQGTTVTVSS Ab 360 720 SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGI ADI-22781 Light chain variable region PERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYQVFGGGTKLTVL (“LC”) amino acid sequence Ab 361 721 EVQLVESGGGLVKPGGSLRLSCAASGFIFSDYYMSWIRQAPGKGLEWVSNISGGSS ADI-24792 Heavy chain variable region FTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLGYCSSNSCLDAF (“HC”) amino acid sequence DIWGQGTTVTVSS Ab 361 722 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNR ADI-24792 Light chain variable region PSGVPDRFSGSRSGTSASLAITGLQAEDEADYYCQSYDSSLSGSLFGGGTKVTVL (“LC”) amino acid sequence Ab 362 723 QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGD ADI-24793 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMFYCVMGSYSYYFDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 362 724 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNLRPS ADI-24793 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNQVFGGGTKLTVL (“LC”) amino acid sequence Ab 363 725 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24795 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGYSSSSGAFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 363 726 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24795 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKVTVL (“LC”) amino acid sequence Ab 364 727 QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWY ADI-24796 Heavy chain variable region DGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTAYGSGSYPIYY (“HC”) amino acid sequence YYYMDVWGKGTTVTVSS Ab 364 728 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-24796 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 365 729 EVQLLESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTN ADI-24798 Heavy chain variable region YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARILGHCSGGSCYRIIDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 365 730 QPVLTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSG ADI-24798 Light chain variable region IPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTGVFGGGTKLTVL (“LC”) amino acid sequence Ab 366 731 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24799 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRDGYNYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 366 732 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24799 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL (“LC”) amino acid sequence Ab 367 733 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24800 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVRGGYSYGYGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 367 734 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGFDVHWYQQLPGTAPKLLIYGNSNR ADI-24800 Light chain variable region PSGVPDQFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 368 735 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAY ADI-24801 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVTARTFGGIRK (“HC”) amino acid sequence GYYYGMDVWGQGTTVTVSS Ab 368 736 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-24801 Light chain variable region PERFSGSNSGNTATLTISGTQVMDEADYYCQAWDSSTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 369 737 EVQLLESGGGLVLPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGI ADI-24803 Heavy chain variable region YTYYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCAKGSLGMAYSAFDIWG (“HC”) amino acid sequence LGTTVTVSS Ab 369 738 DIQLTQSPGTLSLSSGERATLSCRASQSVSSNYLAWYQQKPGQPPRLLIYGASSRAT ADI-24803 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 370 739 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-24805 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGYSSSSGYYYYMD (“HC”) amino acid sequence VWGKGTTVTVSS Ab 370 740 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24805 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGIGTKVTVL (“LC”) amino acid sequence Ab 371 741 EVQLVESGPGLVKPSETLSLICTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGS ADI-24807 Heavy chain variable region TYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHVNPYYDSSGTPYYYYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 371 742 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-24807 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSGTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 372 743 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN ADI-24808 Heavy chain variable region PNSGGTNYAQKFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCARGDPAANDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 372 744 QPVLTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKR ADI-24808 Light chain variable region PSGVPDRFSGSKSGNTASLIVSGLQAEDEADYYCSSYAGSNNVVFGGGTKLTVL (“LC”) amino acid sequence Ab 373 745 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMN ADI-24811 Heavy chain variable region PNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARGLPGQWLEY (“HC”) amino acid sequence YFDYWGQGTLVTVSS Ab 373 746 SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGI ADI-24811 Light chain variable region PERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPVFGGGTKVTVL (“LC”) amino acid sequence Ab 374 747 EVQLVESGGGLVQPGGSLRLSCAASGFSFSTYAMSWVRQAPGKGLEWVSAISGGG ADI-24812 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLQVNSLRAEDTAVYYCARGGYCSSDSCYPFDF (“HC”) amino acid sequence WGQGTLVTVSS Ab 374 748 QPVLTQPPSVSVSPGQTAMITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPS ADI-24812 Light chain variable region GIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADNSGSYAVFGGGTQLTVL (“LC”) amino acid sequence Ab 375 749 EVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWN ADI-24813 Heavy chain variable region SGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDGDSSSWRDSNF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 375 750 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24813 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 376 751 EVQLLESGGGVVQPGRSLRLSCAASGFTFNSYTMHWVRQAPGKGLEWVAVISYD ADI-24814 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRPYDFWSGYYT (“HC”) amino acid sequence DYYYYMDVWGKGTTVTVSS Ab 376 752 EIVLTQSPGTLSLSPGERATLSCRASQSVYSNYLAWYQQKPGQAPRLLIYGASSRAT ADI-24814 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQCGSSWTFGQGTKVEIK (“LC”) amino acid sequence Ab 377 753 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24815 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGYSSSSGYYYMDV (“HC”) amino acid sequence WGKGTTVTVSS Ab 377 754 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24815 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGIGTKVTVL (“LC”) amino acid sequence Ab 378 755 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMN ADI-24816 Heavy chain variable region PNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARGIPGYYYYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 378 756 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-24816 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTYVFGIGTKVTVL (“LC”) amino acid sequence Ab 379 757 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24817 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDSMALLYSNYWFDP (“HC”) amino acid sequence WGQGTLVTVSS Ab 379 758 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24817 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL (“LC”) amino acid sequence Ab 380 759 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN ADI-24818 Heavy chain variable region PNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGTGVEFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 380 760 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-24818 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTQLTVL (“LC”) amino acid sequence Ab 381 761 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24819 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARESGSGWYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 381 762 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24819 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDGSLSGVFGGGTKVTVL (“LC”) amino acid sequence Ab 382 763 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILG ADI-24820 Heavy chain variable region IANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDPPYLRAFDIWGQGT (“HC”) amino acid sequence TVTVSS Ab 382 764 ETTLIQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-24820 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLLTFGGGTKVEIK (“LC”) amino acid sequence Ab 383 765 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW ADI-24821 Heavy chain variable region NSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDKDNWNYDAF (“HC”) amino acid sequence DIWGQGTMVTVSS Ab 383 766 SYELTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPS ADI-24821 Light chain variable region GVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL (“LC”) amino acid sequence Ab 384 767 QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24822 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDSGLGSRGDAFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 384 768 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24822 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGIGTKVTVL (“LC”) amino acid sequence Ab 385 769 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24823 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGDYYGSGRPFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 385 770 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24823 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 386 771 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGST ADI-24824 Heavy chain variable region NYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAISLYGDYRTDAFDIWGQGT (“HC”) amino acid sequence TVTVSS Ab 386 772 EIVLTQSPSSFSASTGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVP ADI-24824 Light chain variable region SRFSGSGSGTDFTLTISCLQSEDFATYYCQQYYSYPLFGGGTKVEIK (“LC”) amino acid sequence Ab 387 773 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMN ADI-24825 Heavy chain variable region PNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCSSVGGYYYYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 387 774 EIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-24825 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTLYTFGQGTKVEIK (“LC”) amino acid sequence Ab 388 775 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24826 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYGSGALDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 388 776 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-24826 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 389 777 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSDG ADI-24827 Heavy chain variable region STYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARCSTYGDYIDWYFDL (“HC”) amino acid sequence WGRGTLVTVSS Ab 389 778 ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATG ADI-24827 Light chain variable region IPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLSFGGGTKLEIK (“LC”) amino acid sequence Ab 390 779 EVQLVESGGGLVKPGGSLRLACAASGFSFRSYRMNWVRQAPGKGLEWVSSISSSSS ADI-24828 Heavy chain variable region YIDYADSVKGRFTISRDNAKNTVYLQVNSLRAEDTAVYYCARDGRTIFGVVIDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 390 780 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNR ADI-24828 Light chain variable region PSGVPDRFSGSKSGTSASLVITGLQAEDEADYYCQSYDSSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 391 781 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24829 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGFHYYGSGSHDAFDI (“HC”) amino acid sequence WGQGTMVTVSS Ab 391 782 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24829 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVFGGGTKLTVL (“LC”) amino acid sequence Ab 392 783 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIF ADI-24830 Heavy chain variable region GTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGSMVRGLGFDP (“HC”) amino acid sequence WGQGTLVTVSS Ab 392 784 DIQLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-24830 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKLEIK (“LC”) amino acid sequence Ab 393 785 QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24831 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVPSDFWSGYYNDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 393 786 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24831 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSWVFGGGTKLTVL (“LC”) amino acid sequence Ab 394 787 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISASSS ADI-24832 Heavy chain variable region YIFYSDLVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAGYYYGSGSYYVDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 394 788 QSVLTQPPSVSGAPGQRVAISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24832 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYGSSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 395 789 QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24833 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARALTYYYDSSGHGADY (“HC”) amino acid sequence WGQGTLVTVSS Ab 395 790 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24833 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 396 791 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISGS ADI-24834 Heavy chain variable region GGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATWKRWGSGYYYS (“HC”) amino acid sequence YMDVWGKGTTVTVSS Ab 396 792 DIQLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDAFSLESGV ADI-24834 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSVTFGGGTKVEIK (“LC”) amino acid sequence Ab 397 793 EVQLVESGGGLVKPGGSLRLSCAASGFPFSTSSMNWVRQAPGKGLEWVSSISSSSS ADI-24835 Heavy chain variable region YIDYADSVKGRFTISRDNAKNSLYLQMNSLRAGDTAVYYCARVPRSDWYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 397 794 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKFLIYDNKYR ADI-24835 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 398 795 EVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWN ADI-24836 Heavy chain variable region SGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDLRGGTYYYYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 398 796 DIRVTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-24836 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGGGTKVEIK (“LC”) amino acid sequence Ab 399 797 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGST ADI-24837 Heavy chain variable region NYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAIYYYDSSGYYYVGDAFDI (“HC”) amino acid sequence WGQGTTVTVSS Ab 399 798 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENNKRPS ADI-24837 Light chain variable region GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKLTVL (“LC”) amino acid sequence Ab 400 799 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24838 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQGVGTVTTWNYYYY (“HC”) amino acid sequence YMDVWGKGTTVTVSS Ab 400 800 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24838 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSWVFGGGTKLTVL (“LC”) amino acid sequence Ab 401 801 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24839 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVLVATAYGNAFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 401 802 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24839 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 402 803 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24840 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDQVYSYGYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 402 804 QSVLAQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24840 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSHVVFGGGTKLTVL (“LC”) amino acid sequence Ab 403 805 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWIN ADI-24841 Heavy chain variable region AGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARDGFPTNYDFW (“HC”) amino acid sequence SGYSDDAFDIWGQGTMVTVSS Ab 403 806 DIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRAT ADI-24841 Light chain variable region GIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPLTFGQGTKVDIK (“LC”) amino acid sequence Ab 404 807 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-24842 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVPPHDYGGYYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 404 808 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYRNSNR ADI-24842 Light chain variable region PSGVPDRFSGSKSGTSASLAIIGLQAEDEADYYCQSYDSSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 405 809 EVQLVESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSG ADI-24843 Heavy chain variable region STYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESIVGAVDYWGQGTL (“HC”) amino acid sequence VTVSS Ab 405 810 DIQMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYW ADI-24843 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPHTFGQGTKLEIK (“LC”) amino acid sequence Ab 406 811 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24845 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDYCSGGSCYLAAFDI (“HC”) amino acid sequence WGQGTTVTVSS Ab 406 812 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNR ADI-24845 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPVVFGGGTKLTVL (“LC”) amino acid sequence Ab 407 813 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24846 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDDGILWLDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 407 814 QPGLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPS ADI-24846 Light chain variable region GVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGQVFGGGTKLTVL (“LC”) amino acid sequence Ab 408 815 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSN ADI-24847 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRIAAYTFDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 408 816 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24847 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLPYVFGTGTKVTVL (“LC”) amino acid sequence Ab 409 817 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24848 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDTVVAGIYFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 409 818 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24848 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 410 819 QVQLVQSGGVVVQPGGSLRLSCAASGFTFDDYTMHWVRQAPGKGLEWVSLIGW ADI-24849 Heavy chain variable region DGGSTYYADSVKGRFTISRDNSKYSLYLQMNSLRTEDTALYYCAKDLGSSSGYFLGR (“HC”) amino acid sequence DYYGMDVWGQGTTVTVSS Ab 410 820 DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETG ADI-24849 Light chain variable region VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYNNLPTFGGGTKLEIK (“LC”) amino acid sequence Ab 411 821 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-24850 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREDYGDYYYYYMDV (“HC”) amino acid sequence WGKGTTVTVSS Ab 411 822 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24850 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 412 823 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN ADI-24851 Heavy chain variable region PNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARAYELELDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 412 824 QSVLIQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKR ADI-24851 Light chain variable region PSGVPDRFSGSKSGNTASLIVSGLQAEDEADYYCSSYAGSNNVVTGGGTKLTVL (“LC”) amino acid sequence Ab 413 825 QVQLVESGAEVKKPGASVKVSCKASGYTFTSYAIHWVRQAPGQRLEWMGWINAG ADI-24852 Heavy chain variable region NGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCASEESGYFDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 413 826 SYELMQPPSVPVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDRKRPS ADI-24852 Light chain variable region GIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKVTVL (“LC”) amino acid sequence Ab 414 827 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24854 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRRFGELFYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 414 828 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24854 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGNWVFGGGTKLTVL (“LC”) amino acid sequence Ab 415 829 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24855 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRYCTNGVCYDAFDI (“HC”) amino acid sequence WGQGTMVTVSS Ab 415 830 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24855 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSYVFGTGTKVTVL (“LC”) amino acid sequence Ab 416 831 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAY ADI-24856 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARAGIVVVPKYYYY (“HC”) amino acid sequence MDVWGKGTTVTVSS Ab 416 832 DIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRAT ADI-24856 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPMYTFGQGTKVEIK (“LC”) amino acid sequence Ab 417 833 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24857 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGYYYGSGSYLDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 417 834 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24857 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 418 835 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24858 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGYSYGYSFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 418 836 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24858 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 419 837 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-24859 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGSPINWVSPFPFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 419 838 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24859 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTQLTVL (“LC”) amino acid sequence Ab 420 839 EVQLLESGGGLVKPGGSLRLSCAASGLTFSDYYMSWIRQAPGKGLEWVSYISGGSS ADI-24860 Heavy chain variable region YSNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYCSGSSCYEAFDI (“HC”) amino acid sequence WGQGTTVTVSS Ab 420 840 SYVLTQPPSVSGAPGQRVTISCTGSSSNIGAGFDVHWYQQLPGTAPKLLIYGNSDRP ADI-24860 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 421 841 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISGGS ADI-24861 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREAYYYDSSGLKWFD (“HC”) amino acid sequence PWGQGTLVTVSS Ab 421 842 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24861 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 422 843 EVQLLESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSG ADI-24862 Heavy chain variable region STYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARLEIGDGSGSYLHWYFD (“HC”) amino acid sequence LWGRGTLVTVSS Ab 422 844 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-24862 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL (“LC”) amino acid sequence Ab 423 845 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSRS ADI-24863 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGSGGSGTYGDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 423 846 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-24863 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 424 847 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25462 Heavy chain variable region YIYYADSVKGRFTISRHNAKNSLYLQMNSLRAEDTAVYYCARGSSSSWFCFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 424 848 SYVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25462 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSYVFGTGTKLTVL (“LC”) amino acid sequence Ab 425 849 GVQLVESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTN ADI-25467 Heavy chain variable region YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYYDSSGYYPNDAFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 425 850 DIQVTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-25467 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 426 851 QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGD ADI-25468 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARHVGQVYCSSTSCYT (“HC”) amino acid sequence SREYYFDYWGQGTLVTVSS Ab 426 852 SYVLTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-25468 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVVFGGGTKLTVL (“LC”) amino acid sequence Ab 427 853 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25472 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDDSSSWYYFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 427 854 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25472 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGIGTKVTVL (“LC”) amino acid sequence Ab 428 855 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25478 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDYSNYYYYMDVWG (“HC”) amino acid sequence KGTTVTVSS Ab 428 856 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25478 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 429 857 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25479 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGYSYGAYYYYYMD (“HC”) amino acid sequence VWGKGTTVTVSS Ab 429 858 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25479 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYWVFGGGTKLTVL (“LC”) amino acid sequence Ab 430 859 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25480 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGYSYGAYYYYYMD (“HC”) amino acid sequence VWGKGTTVTVSS Ab 430 860 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25480 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYWVFGGGTKVTVL (“LC”) amino acid sequence Ab 431 861 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25484 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSIAVAGTGYGMDVW (“HC”) amino acid sequence GQGTTVTVSS Ab 431 862 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25484 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 432 863 EVQLLESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSG ADI-25491 Heavy chain variable region STYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREVVPAAIRAGYYFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 432 864 SYELMQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSG ADI-25491 Light chain variable region IPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTGGVFGTGTQLTVL (“LC”) amino acid sequence Ab 433 865 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-25495 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYCTNGVCYLDAFD (“HC”) amino acid sequence IWGQGTTVTVSS Ab 433 866 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-25495 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPVVFGGGTKVTVL (“LC”) amino acid sequence Ab 434 867 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-25496 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVASEVWFFDLWGR (“HC”) amino acid sequence GTLVTVSS Ab 434 868 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25496 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 435 869 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQD ADI-25497 Heavy chain variable region GSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGLLQYDFWSGY (“HC”) amino acid sequence YDYWGQGTLVTVSS Ab 435 870 EIVLTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGV ADI-25497 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPFTFGPGTKVDIK (“LC”) amino acid sequence Ab 436 871 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIF ADI-25502 Heavy chain variable region GTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDHWSNPLYYYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 436 872 SYELTQPPSVSVSPGQTARITCSGDVLAKKYARWFQQKPGQAPVLVIYKDSERPSGI ADI-25502 Light chain variable region PERFSGSSSGTTVTLTISGAQVEDEADYYCYSAADNNLGVFGGGTQLTVL (“LC”) amino acid sequence Ab 437 873 EVQLLESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFG ADI-25503 Heavy chain variable region TANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSRYSGSYYYYYGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 437 874 QPVLTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSG ADI-25503 Light chain variable region IPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTYVFGTGTKLTVL (“LC”) amino acid sequence Ab 438 875 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25505 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVVGYSGSYLDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 438 876 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25505 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 439 877 EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFG ADI-25514 Heavy chain variable region TANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSRYSGSYYYYYGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 439 878 SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-25514 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTYVFGIGTKLTVL (“LC”) amino acid sequence Ab 440 879 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN ADI-25517 Heavy chain variable region PNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDWAWDAFD (“HC”) amino acid sequence IWGQGTMVTVSS Ab 440 880 QPGLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSN ADI-25517 Light chain variable region RPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL (“LC”) amino acid sequence Ab 441 881 EVQLVESGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINP ADI-25518 Heavy chain variable region NSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDWAWDAFDI (“HC”) amino acid sequence WGQGTMVTVSS Ab 441 882 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-25518 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTQLTVL (“LC”) amino acid sequence Ab 442 883 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25524 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREWSPIVVVTNAFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 442 884 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25524 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKVTVL (“LC”) amino acid sequence Ab 443 885 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-25532 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGSSSSWYYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 443 886 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25532 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSYVFGIGTKVTVL (“LC”) amino acid sequence Ab 444 887 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN ADI-25533 Heavy chain variable region PNSGGTNYAQKFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCARDANWGAFD (“HC”) amino acid sequence IWGQGTMVTVSS Ab 444 888 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-25533 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL (“LC”) amino acid sequence Ab 445 889 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSG ADI-25542 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDYYYDSSGYPPYGI (“HC”) amino acid sequence GVWGQGTTVTVSS Ab 445 890 QTVVTQEPSFSVSPGGTVTLTCGLSSGSVSTSYYPSWYQQTPGQAPRTLIYSTNTRS ADI-25542 Light chain variable region SGVPDRFSGSILGNKAALTITGAQADDESDYYCVLYMGSGIWVFGGGTKVTVL (“LC”) amino acid sequence Ab 446 891 EVQLLESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGS ADI-25547 Heavy chain variable region TYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGIADAFDIWGQGT (“HC”) amino acid sequence MVTVSS Ab 446 892 ETTLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSG ADI-25547 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPRTFGQGTKLEIK (“LC”) amino acid sequence Ab 447 893 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGG ADI-25548 Heavy chain variable region STYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPQFGVSYSSGWYS (“HC”) amino acid sequence FDYWGQGTLVTVSS Ab 447 894 QSVLIQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKR ADI-25548 Light chain variable region PSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTFVVFGGGTKLTVL (“LC”) amino acid sequence Ab 448 895 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-25549 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVSSGWYGGGAYYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 448 896 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25549 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSALYVFGIGTKVTVL (“LC”) amino acid sequence Ab 449 897 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-25555 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQRGGIAVAGTYFDL (“HC”) amino acid sequence WGRGTLVTVSS Ab 449 898 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25555 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 450 899 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-25556 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQRGGIAVAGTYFDL (“HC”) amino acid sequence WGRGTLVTVSS Ab 450 900 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25556 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSTVVFGGGTKVTVL (“LC”) amino acid sequence Ab 451 901 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25557 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYGSGSYLDYFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 451 902 QPGLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25557 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGFYVFGTGTKLTVL (“LC”) amino acid sequence Ab 452 903 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25559 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDAAAKYYFDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 452 904 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25559 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGKVFGTGTKLTVL (“LC”) amino acid sequence Ab 453 905 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSSS ADI-25562 Heavy chain variable region YTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGYSSSWYNYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 453 906 SYVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25562 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPVFGGGTKLTVL (“LC”) amino acid sequence Ab 454 907 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25565 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARIRFDYGSGSYAFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 454 908 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25565 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL (“LC”) amino acid sequence Ab 455 909 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSG ADI-25567 Heavy chain variable region STNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGLPRFGVVTPNWFDP (“HC”) amino acid sequence WGQGTLVTVSS Ab 455 910 EIVLTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWA ADI-25567 Light chain variable region STRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 456 911 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLVWVSRINSD ADI-25569 Heavy chain variable region GSSTSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAREGDSSGWPGGA (“HC”) amino acid sequence FDIWGQGTMVTVSS Ab 456 912 SYVLTQPPSVSVSPGQAARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGI ADI-25569 Light chain variable region PERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTFYVFGTGTKLTVL (“LC”) amino acid sequence Ab 457 913 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN ADI-25572 Heavy chain variable region PNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDPYSSSSYYY (“HC”) amino acid sequence YGMDVWGQGTTVTVSS Ab 457 914 DIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-25572 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTLYTFGQGTKVDIK (“LC”) amino acid sequence Ab 458 915 EVQLVESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPS ADI-25573 Heavy chain variable region GGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGPYDSSGYCDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 458 916 SYELMQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-25573 Light chain variable region GTPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDQVFGGGTKVTVL (“LC”) amino acid sequence Ab 459 917 EVQLVESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPS ADI-25575 Heavy chain variable region GGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGPYDSSGYCDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 459 918 SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-25575 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDQVFGGGTKLTVL (“LC”) amino acid sequence Ab 460 919 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLVWVSRINSD ADI-25576 Heavy chain variable region GSSTSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGLYNWNHDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 460 920 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPS ADI-25576 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNVVFGGGTKVTVL (“LC”) amino acid sequence Ab 461 921 QVTLKESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25577 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARYSSSLGAFDIWGQGT (“HC”) amino acid sequence MVTVSS Ab 461 922 QSALTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25577 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSDVFGTGTKLTVL (“LC”) amino acid sequence Ab 462 923 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWY ADI-25587 Heavy chain variable region DGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSTYSEAFDIW (“HC”) amino acid sequence GQGTMVTVSS Ab 462 924 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-25587 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKVTVL (“LC”) amino acid sequence Ab 463 925 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25588 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARYSSSLGAFDIWGQGT (“HC”) amino acid sequence TVTVSS Ab 463 926 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25588 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSDVFGTGTKVTVL (“LC”) amino acid sequence Ab 464 927 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-25595 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARYQSSSWYYFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 464 928 SYVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-25595 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 465 929 QVQLQESGPGLVKPSETLSLTCTVSPPSISSSSYYWGWIRQPPGKGLEWIGSIYYSGS ADI-25598 Heavy chain variable region TYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARPDSSGAFDIWGQGTMV (“HC”) amino acid sequence TVSS Ab 465 930 SYELTQPPSVSVSPGQTARITCSADALPKQYAYWYQQKPGQAPVLVIYKDSERPSGI ADI-25598 Light chain variable region PERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYVVFGGGTKLTVL (“LC”) amino acid sequence Ab 466 931 EVQLVQSGAEVKKPGASVRVYCKASGYTFTTYYIHWVRQAPGQGLEWMGMINPS ADI-36669 Heavy chain variable region GGTTSYAQKFQGRLTMTGDTSTSTVYMELNYLRSEDTAVYYCTRDFIYFYGSGDGF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 466 932 EIVMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPKRLIYAASSLQS ADI-36669 Light chain variable region GVPSRFSGSGSGTEFTLTITSLQPEDFATYYCLQHNSYPFTFGPGTKVEIK (“LC”) amino acid sequence Ab 467 933 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTYTINWVRQAPGQGLEWMGRITPSL ADI-36670 Heavy chain variable region GVPLSAQKFQGRITISADKSTTTAYMELSSLGSEDTAVYYCASLNYYDTTDYYLGYSD (“HC”) amino acid sequence SWGQGTLVTVSS Ab 467 934 DIVLTQTPATLSVSPGERATLSCRASHSVSNNLAWYQQKPGQAPRLLIYSASTRATGI ADI-36670 Light chain variable region PARFSGRGSGTEFTLTISSLQPEDFAVYYCQQYNNWPPEYTFGQGTKVDIK (“LC”) amino acid sequence Ab 468 935 EVQLLESGGGLVKPGGSLRLSCAASGFTFSGYYMTWIRQAPEKGLEWVSYISGGSTY ADI-36671 Heavy chain variable region TNYADSVRGRFTISRDNARNSLYLQMNSLRAEDTAVYYCARDGGYGIGPLYWGQG (“HC”) amino acid sequence SLVTVSS Ab 468 936 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAPFDVHWYQQLPGTAPKPLIYGNSNR ADI-36671 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLGGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 469 937 EVQLVESGGGLVKPGGSLRLSCAASGFAFNNYYMNWVRQAPGKGLEWVSSISSAS ADI-36672 Heavy chain variable region TYTDYADSVKGRFTISRDNAKNSLYLHLNSLRAEDTAVYYCARDYYGSGNYYNPKPL (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 469 938 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYRQFPGTAPELLIYGNTNR ADI-36672 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLKGVFGGGTKLTVL (“LC”) amino acid sequence Ab 470 939 EVQLLESGGGLVKPGGSLRLSCAASGFKFRSYSMNWVRQAPGKGLEWVSSISSSSS ADI-36674 Heavy chain variable region YVDYAGSLKGRFTISRDNAENSLYLQMNSLRAEDTAMYYCARAGSVPVAGTYNDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 470 940 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQHLPGTAPKLLIHGNNNR ADI-36674 Light chain variable region PAGVPDRFSGSKSGTSASLVITGLQADDEADYYCQSYDRSLSVLFGGGTKVTVL (“LC”) amino acid sequence Ab 471 941 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWISYISSSG ADI-36677 Heavy chain variable region DTKYYADSVKGRFTVSRDNAKYSLYLQMDSLRAEDTAVYYCASLYDSRGYYWVFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 471 942 DIVMTQSPSSLSASVGDRVTITCQASQDISTYLNWYQHKPGKAPNLLIYDASNLEPG ADI-36677 Light chain variable region VPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHDNLPPTFGQGTKVDIK (“LC”) amino acid sequence Ab 472 943 QVQLVQSGAEVKKPGESLKISCKGSGYSFRSYWIAWVRQMPGKGLEWMGTIFPG ADI-36679 Heavy chain variable region DSDVTYSPSFQGQVTISVDKSTSTAYLQWGSLKASDTAIYYCARRYDYIDFWGQGTL (“HC”) amino acid sequence VTVSS Ab 472 944 DIQMTQSPSSLSASVGDRVTITCQASQDIINHLNWYQQKPGKAPKLLIYDASNLHP ADI-36679 Light chain variable region GVPSRFSGSGSGTYFTFTISSLQPDDFATYYCQQYDFLAHITFGPGTKVDIK (“LC”) amino acid sequence Ab 473 945 QVTLKESGAELRKPGESLKISCKASGYRFTNYWIGWVRQMPGKGLEWMGVIYPGD ADI-36680 Heavy chain variable region SDTKYSPSFQGQVTMSADKSINTAYLQWSSLKASDTAIYYCVSLFGDYDYGALDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 473 946 ETTLIQSPATLSMSPGERATLSCRASQSVGRNLAWYQQKPGQAPRLLIYGASIRAT ADI-36680 Light chain variable region GILARFSGSGSGTEYTLTISSLQPEDFAVYYCQQYHDWPSFTFGPGTKVDIK (“LC”) amino acid sequence Ab 474 947 EVQLVESGAEVKKPGESLKISCKASGYSFTRYWIGWVRQMPGKGLEWMGIIFPGD ADI-36681 Heavy chain variable region SDTRYCPSFEGQVTISADRSINTAYLQWSSLKASDSAMYYCVTLYTDYDYGAPDHW (“HC”) amino acid sequence GQGTLVTVSS Ab 474 948 DIVLTQSPATLSVSPGERATLSCRASQSLSGDLAWYQQKPGQAPRLLIYATSTRATGI ADI-36681 Light chain variable region PARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYYDWPLLTFGPGTKVEIK (“LC”) amino acid sequence Ab 475 949 EVQLVQSGAEVKKPGGSVKVSCKASGYTFSEYYMHWVRQAPGQGPEWVGRINPK ADI-41144 Heavy chain variable region SGRTNYAQNFQGRVTMTRDRSISTVYMDLSRLRSDDTAVYYCARWEVMDYGSGI (“HC”) amino acid sequence YYNQDHFDYWGQGTLVTVSS Ab 475 950 DIRVTQSPSSLSASVGDRVTITCRASQDITNYLAWFQQKPGKAPKSLMYAASTLQSG ADI-41144 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYKTYPITFGQGTRLEIK (“LC”) amino acid sequence Ab 476 951 QVQLVQSGPGLVKPSETLSLTCTVSAGSISNFYWSWIRQPPGKGLEWIGYIYYSGST ADI-41145 Heavy chain variable region SYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARSRSGWSLYDYWGQGTLV (“HC”) amino acid sequence TVSS Ab 476 952 DIQVTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLIYVASSLQSGV ADI-41145 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNTPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 477 953 QVQLVQSGAEVKKPGESLKISCKGSGHSFATFWIGWVRQVPGNGLELMGIINLGD ADI-41146 Heavy chain variable region SDTKYSPSFQGQVTISADESIGTAYLQWSSLKASDTAMYYCARVSLPHYYYYMDVW (“HC”) amino acid sequence GKGTTVTVSS Ab 477 954 DIVMTQSPSSVSASVGDRVTITCRASQGISTWLAWYRQKPGKAPELLIYAASRLQSG ADI-41146 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFLGAFGPGTKLEIK (“LC”) amino acid sequence Ab 478 955 EVQLVESGGGLVKPGGSLRLSCAASGFTLSGYYMSWVRQAPGKGLEWISYISGGST ADI-41147 Heavy chain variable region YTNYADSVNGRFTISRDNAKNSLYLQMDSLRAEDTAVYYCARLEYGDYGPYYLGLW (“HC”) amino acid sequence GRGTLVTVSS Ab 478 956 QSVLTQPPSVSGAPGQRVTISCTGTSSNIGAGYDVHWYQKLPGTAPKLLIYANNNR ADI-41147 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDTSLSAHYVFGTGTKLTVL (“LC”) amino acid sequence Ab 479 957 QVQLVQSGGGVVQPGRSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAVIWF ADI-41149 Heavy chain variable region DGSNKNYADSVKGRFTISRDNSMNTLYLQMNNLRAEDTAVYYCARAPYSFWSGYY (“HC”) amino acid sequence LDYWGQGSLVTVSS Ab 479 958 DIVMTQSPATLSVSPGERATLSCRASQSISSNLAWYQQKSGQAPRLLIYGASTRATG ADI-41149 Light chain variable region IPARFSGSGSGTEFTLTISSLQSEDFAVYSCQQYSKWPQTFGQGTKVEIK (“LC”) amino acid sequence Ab 480 959 EVQLVESGGGLVKPGGSLRLSCAASQFTFSTYDMSWVRQAPGKGLEWVASISSGS ADI-41153 Heavy chain variable region TYIYYADSVKGRFTISRDNAKHSLFLQMKSLRAEDTALYYCARQVLYDRGGYYLYYFD (“HC”) amino acid sequence HWGQGTLVTVSS Ab 480 960 DIQVTQSPSSLSASVGDRVTITCRASQTIASYLNWYQQKPGKAPNLLIYAASNLQSG ADI-41153 Light chain variable region VPSRFSGSGSGTEFTLTINTLQPEDFATYYCQQSYNFPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 481 961 QVQLQQWGAGLSKPSETLSVTCAVYGGSLSGHYWSWFRQPPGKGLEWIGEIDHS ADI-41154 Heavy chain variable region GSTTYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAMYYCARATRYNYGYTFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 481 962 DIPLTQSPSSLSASVGDRVTITCRASQIISSYLNWYQQKPGKAPKLLIYAASTLQSGVP ADI-41154 Light chain variable region SRFSGSRSGTDFTLTISSLQPEDFASYYCQQSYIIPFTFGPGTKVEIK (“LC”) amino acid sequence Ab 482 963 QVQLQESGPGLVKPSETLSLTCTVSGGSIGNNFYYWGWIRQPPGKGLEWIGSIYYS ADI-41155 Heavy chain variable region GTTYDNPSLKSRVTISVEPSKNQFSLKLSSVTAADTAVYHCARRYCDSTRCYEAFDIW (“HC”) amino acid sequence GQGTTVTVSS Ab 482 964 SYELTQPPSASGTPGQRVTISCSGSSSNIGSNYVSWYQQLPGTAPKLLIYKNDQRPS ADI-41155 Light chain variable region GVPDRFSGSKSGTSASLAISGLRSEDEAEYYCAAWDDSLSGFYVFGTGTKVTVL (“LC”) amino acid sequence Ab 483 965 QVQLVQSGGGLVQPGGSLRLSCVASGFIFSSYEMNWVRQAPGKGLEWVSYISSSG ADI-41156 Heavy chain variable region STIYYADSVKGRFTISRDNAKNSLYLQMNSLGAEDTAVYYCARAILYFDYWGQGTLV (“HC”) amino acid sequence TVSS Ab 483 966 GIRLTQSPSSLSASVGDRVTITCRASQSITNYINWYQQKPGKAPKLLIYAISRLQSGVP ADI-41156 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTMYTFGQGTKVEIK (“LC”) amino acid sequence Ab 484 967 EVQLVESGPGLVKPSETLSLTCTVSGGSISTYYWSWIRQPPGKGLEWIGYIYYTGSTN ADI-41157 Heavy chain variable region YNPSLKSRVTISLDTSKNQFSLKLSSVSAADTAFYYCARSPPVPGTRSWFDPWGQGT (“HC”) amino acid sequence LVTVSS Ab 484 968 SPGLTQPQSAFGTPGQRVTISCFGSSSNIGRNHIYWYQQVPGTAPKLLIYRNNQRPS ADI-41157 Light chain variable region GVPDRFFGSKFGTSASLAISGVRSEDEADYFCAAWDDSLSGPVFGGGTKLTVL (“LC”) amino acid sequence Ab 485 969 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNIAWVRQAPGKGLEWISYISSSSSVI ADI-41158 Heavy chain variable region YYADSVRGRFTISRDNAKNSLYLQMNSLRDEDTAMYYCARAGNDYNFWSGRSSEY (“HC”) amino acid sequence FDYWGQGTLVTVSS Ab 485 970 DIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRAT ADI-41158 Light chain variable region GIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYDNWPLYTFGQGTKLEIK (“LC”) amino acid sequence Ab 486 971 EVQLVESGAEVKKPGESLKISCKGSGYSFTTYWIGWVRQMPGKGLEWMGIMYPG ADI-41159 Heavy chain variable region DSQTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGGYCSGGSCYRG (“HC”) amino acid sequence LDYWGQGTLVTVSS Ab 486 972 EIVMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPNLLIYAASSLLSGV ADI-41159 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHSTPQTFGQGTKLEIK (“LC”) amino acid sequence Ab 487 973 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYPIIWVRQAPGQGLEWMGRIIPILGI ADI-41160 Heavy chain variable region ASYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNSDFYYGMDVWGQG (“HC”) amino acid sequence TTVTVSS Ab 487 974 QSALIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQHHPGKAPKLMIYDVSNR ADI-41160 Light chain variable region PSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSLYVFGTGTKVTVL (“LC”) amino acid sequence Ab 488 975 EVQLVESGGGLVQPGGSLRLSCAASGFTFSTFEFNWVRQAPGKGLEWLSYISSDDT ADI-41161 Heavy chain variable region TRYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAYYYCVRGGPYDYVWGTYRYF (“HC”) amino acid sequence DFWGQGTLVTVSS Ab 488 976 QSVLTQPASVSGSPGQSITISCTGTSSDIGGYNYVSWYQQHPGKAPKLMIYDVTNR ADI-41161 Light chain variable region PLGVSNRFSGSKSGNTASLIISGLQAEDEAEYYCCSYTSSNSLVFGGGTKLTVL (“LC”) amino acid sequence Ab 489 977 EVQLVQSGAEVKKPGSSVKVSCKASGVTGGTFSSYAISWVRQAPGQGLEWMGGI ADI-41162 Heavy chain variable region MPMFGTTNYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDYRDFSPHL (“HC”) amino acid sequence DYYYMDVWGKGTTVTVSS Ab 489 978 DIRLTQSPGTLSLSPGERATLSCRASQSVSTSYLAWYQQKPGQAPRLLIYGASNRAT ADI-41162 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRTSWTFGQGTKVDIK (“LC”) amino acid sequence Ab 490 979 QVQLVQSGGGVVQPGRSLRLSCAASGFPFHSYAMHWVRQAPGKGLEWVAVIWY ADI-41163 Heavy chain variable region EGSEKHYADSVQGRFTISRDNSKNMLYLQMNNLRVADTAVYYCARRGAWGFDIW (“HC”) amino acid sequence GQGTTVTVSS Ab 490 980 DIVMTQTPLSLPVTPGEPASISCRSSQSVLHSTGYNSLDWYLQKPGQSPQLLIFLGSN ADI-41163 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGLQTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 491 981 QVQLVQSGGDLVQPGGSLRLSCAASGFTFSDYEVNWVRQAPGKGLEWLSYISSSG ADI-41164 Heavy chain variable region RIIHYADSVRGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAAGQWLVTYYYYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 491 982 QSVMTQSPSTLSASVGDTVTITCRASQSIINRLAWYQQKPGKPPKLLIYKSSSSESGV ADI-41164 Light chain variable region PSKFSGSGSGTEFTLTINSLQPDDFATYYCQHYNSYLYTFGQGTKVEIK (“LC”) amino acid sequence Ab 492 983 EVQLVETGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGD ADI-41165 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARRYDYIDIWGQGTM (“HC”) amino acid sequence VTVSS Ab 492 984 DIRVTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETG ADI-41165 Light chain variable region VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLAHITFGPGTKVEIK (“LC”) amino acid sequence Ab 493 985 EVQLVQSGAEVKKPGASVKVSCKTSGYTFTGDYLHWVRQAPGQGLEWMGRLNP ADI-41166 Heavy chain variable region KSGGTVYAQRFQGRVTMTGDTSVTTAYMQLTRLRSDDTAIYYCARGIPVSGPVSID (“HC”) amino acid sequence YWGQGTLVTVSS Ab 493 986 QSVLTQPASLSGSPGQSITISCTGTSSDVGGYGYVSWYQQHPGKAPKLMIYDVANR ADI-41166 Light chain variable region PSGVSHRFSGSKSGNTASLTISGLQADDEADYYCSSYTRSNTVVFGGGTKLTVL (“LC”) amino acid sequence Ab 494 987 EVQLVETGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYD ADI-41168 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCAKGGGYYYYYMDV (“HC”) amino acid sequence WGKGTTVTVSS Ab 494 988 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYGVNN ADI-41168 Light chain variable region RPSGVSNRFSGSKSGNTASLTISGLQGEDEADYYCNSYRSGITVVFGGGTKLTVL (“LC”) amino acid sequence Ab 495 989 EVQLVESGAEVKKPGESLKISCEAFGYSFTSYWIGWVRQVPGRGLEWIGVIYPGDSD ADI-41169 Heavy chain variable region IRYTPSFRGQVTISADRSISTAYLQWNNLKASDTAMYYCARPGRDINYYHSRDYGAL (“HC”) amino acid sequence DIWGQGTTVTVSS Ab 495 990 DIQLTQSPDSLAVSLGERVTINCKSSQSFLYSSNNKNYLAWYQQKPGQPPKLLIYWA ADI-41169 Light chain variable region SVRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQEYYSPPMFTFGQGTKVEIK (“LC”) amino acid sequence Ab 496 991 EVQLLESGGGLIQPGGSLRLSCAASGFTFNNYVMSWVRQAPGKGLEWVAAISSSG ADI-41170 Heavy chain variable region VSTYYAASVKGRFTISRDNSKNMLYVQLNSLRAEDTAVYYCAKETGSYYYFDSWGQ (“HC”) amino acid sequence GTLVTVSS Ab 496 992 ETTLTQSPSTLSGSVGDRVTITCRASESISSWLAWYQQKPGKAPKLLIYKASNLESGV ADI-41170 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYLITFGQGTRLEIK (“LC”) amino acid sequence Ab 497 993 EVQLVESGPGLVKPSQTLSLTCTVSGGSISSGGDYWSWVRQRPGKGLEWIGYIYNS ADI-41171 Heavy chain variable region GSGYYNPSLKNRVSMSMHTSRNQFSLRLSSVTAADTAFYYCARDPFYRSGGIHYFD (“HC”) amino acid sequence YWGQGALVTVSS Ab 497 994 DIVLTQTPGTLSLSPGEGATLSCRASPSVGSTSLAWYQQKPGQAPRLLIYGASSRAT ADI-41171 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQDGGLPITFGLGTRLEIK (“LC”) amino acid sequence Ab 498 995 EVQLLESGGGLVQPGGSLRLSCSASGFTFSVYAMHWVRLAPGKGLEYVSTISGNGG ADI-41172 Heavy chain variable region STYYGDSVKGRFTTSRDNSKNTVYLQMSSLRAEDTAVYYCVKAPARDHYEILTLLGY (“HC”) amino acid sequence FDYWGQGTLVTVSS Ab 498 996 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSSNKNYLAWYQQKPGQPPKLLIYW ADI-41172 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTIPPWTFGQGTKVEI (“LC”) amino acid sequence K Ab 499 997 QVQLVQSGAEMKKPGSSAKVSCKASGGTLSSYAINWVRQAPGQGLEWMGGIIPIF ADI-41173 Heavy chain variable region GTTKYAPKFQDRVTITVDESTSTAYMELSSLRSEDTAVYYCSRESSTWDVAHYFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 499 998 DIVMTQTPSAISASVGDRVTITCRASQGISNYLAWVQQKPGKVPKRLIYGASSLQSG ADI-41173 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 500 999 EVQLVESGAEVEKPGASVKVSCKASGYTFINYDIIWVRQAPGQGLEWMGWISGYK ADI-41174 Heavy chain variable region GNTNYAQKLQGRITMSTDTSTRTAYMELRSLTSDDTAVYYCARVGGTARSTTPYYY (“HC”) amino acid sequence GMDVWGQGTTVTVSS Ab 500 1000 SYVLTQPPSVSVSPGQTARITCSGDAVPKQFSYWYQQKPGQAPVLVIYKDIERPSGI ADI-41174 Light chain variable region PERFSGSSSGTTVTLTISGVQAEDEADYYCQSAHTSGTYHVFGTGTKLTVL (“LC”) amino acid sequence Ab 501 1001 EVQLLESGGGVVQPGRSLRLSCATSGFTFSSYGMHWVRQAPGKGLEWVAVIYYEG ADI-41175 Heavy chain variable region SNKYYGDSVKGRFTISRDNSKSTLYLQMNRLRAEDTAVYYCARRPAGGFDYWGPG (“HC”) amino acid sequence TLVTVSS Ab 501 1002 EIVMTQSPLSLPVTPGEPASISCRSSQNLLNSNGYNYLDWYLQKPGQSPQLLIYLGS ADI-41175 Light chain variable region NRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 502 1003 EVQLVESGPGLVKPSETLSLTCTVSGGSIGNDYYYWGWIRQPPGKGLEWIGNISYSG ADI-41176 Heavy chain variable region STYYNPSLKSRVTISVGTSKNQFSLKLTSVSAADTAVYHCVGRTFWRDCSSTSCYEYY (“HC”) amino acid sequence FDYWGQGTLVTVSS Ab 502 1004 ETTLIQSPTSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKVLIYAASTLQSGV ADI-41176 Light chain variable region SSRFSGSGSGTGFTLTISNLQPEDVATYYCQNYNSAPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 503 1005 QVQLVQSGAEVKKPGASVKVSCKASGYMFTGYYMHWVRQAPGQGLEWMGRIN ADI-41177 Heavy chain variable region PNSGGTNYAQKFQGRVTMTRDTSISTGYMELSRLRSDDTAVYFCARDFFPLVIPTLI (“HC”) amino acid sequence VGRGLYDMDVWGQGTMVTVSS Ab 503 1006 QPGLTQPPSASGTPGQRVTISCSGRSSNIGSNTVNWYQQLQGTAPKLLIYKNNQRP ADI-41177 Light chain variable region SGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKVTVL (“LC”) amino acid sequence Ab 504 1007 QVQLVESGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRINP ADI-41178 Heavy chain variable region NSGGTNYAQKFQGRVTMTRDTSISTAYMELSSLRSDDTAVYYCARDLTAGGYGST (“HC”) amino acid sequence WYSCGDYWGQGTLVTVSS Ab 504 1008 EIVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGI ADI-41178 Light chain variable region PARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRWTFGQGTKVEIK (“LC”) amino acid sequence Ab 505 1009 QVQLVQSGAEVKKPGSSVKISCKASGGTFSSHPISWVRQAPGQGLEWMGRIVPIF ADI-41179 Heavy chain variable region GIANYAQKFQGRVTMIADKSTNTAYMELSNLRSEDTAVYYCANPVYDSSGFQWG (“HC”) amino acid sequence QGTLVTVSS Ab 505 1010 QPVLTQPRSVSGSPGQSVTISCTGTSGDGGFYNYVSWYQQHPGKTPKLMIYDVDQ ADI-41179 Light chain variable region RPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYPGNPLYVFGTGTKVTVL (“LC”) amino acid sequence Ab 506 1011 EVQLVQSGGGLVKPGGSLRLSCAASGFTFIDYYMSWIRQAPGKGLEWVSSISGGST ADI-41180 Heavy chain variable region YTTYADSVKGRFTISRDNGKNSLYLQMDSLRAEDTAVYYCARLGGYSYYMDVWGK (“HC”) amino acid sequence GTTVTVSS Ab 506 1012 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQHLPGAAPKLLIYDNTNR ADI-41180 Light chain variable region PSGIPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLDWVFGGGTKVTVL (“LC”) amino acid sequence Ab 507 1013 QVQLVQSGAEVKKPGSSVKVSCKASGGSFSSYTLNWVRQAPGQGLEWMGRFVPI ADI-41181 Heavy chain variable region VGIANYAQKFQGRVTITADKSTSTVYMELSSLRSEDTAVYYCATAPTAYCSGDCYSLF (“HC”) amino acid sequence DPWGQGTLVTVSS Ab 507 1014 QSVLIQPASVSGSPGQSITISCTGISSDVGSYNLVSWYQQHPGKAPKLIIYEVNKRPS ADI-41181 Light chain variable region GVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAVSRTSLYVFGTGTKVTVL (“LC”) amino acid sequence Ab 508 1015 QVQLVQSGAEVKKPGESLKISCQGSGYSFTSYWIGWVRQMPGKDLEWMGIIYPSD ADI-41182 Heavy chain variable region SDTRYSPSFQGQVTISVDKSINTAYLQWTSLKASDTAMYYCARCDGAVYWYFDLW (“HC”) amino acid sequence GRGTLVTVSS Ab 508 1016 EIVLTQSPATLSVSPGERVTLSCRASRSVSSHLAWYQQKPGQAPRLLMYGASTRAT ADI-41182 Light chain variable region GIPARFSGSGSGTEFTLTISSLQSEDFGVYYCQQYNNWPPALTFGGGTKLEIK (“LC”) amino acid sequence Ab 509 1017 QVQLQESGAGLVKPSETLSLTCGVYGESFSGHSWSWIRQPPGRGLEWIGEINQSGT ADI-41183 Heavy chain variable region TKYNPSLRSRVTISVDRSKNEFSLKVSSVTAADTAVYFCARYFRSFYTIGPDYYYMDV (“HC”) amino acid sequence WGKGTTVTVSS Ab 509 1018 EIVLTQSPSSLSASVGDRVTITCRASQNINNYLNWYQQKPGKAPRLLIYAASSLQSGV ADI-41183 Light chain variable region PSRFTGSGSGTDFTLTIRSLQSEDFATYYCQHSYSSSLLTFGGGTKVDIK (“LC”) amino acid sequence Ab 510 1019 EVQLLETGGGLVQPGGSLRLSCAASGFTFSSYDMNWVRQAPGKGLEWVSTISGSG ADI-41184 Heavy chain variable region GPTYYAGSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKAQLYDTSGYYLYYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 510 1020 DIRMTQSPSSLSASVGDRVTITCRASQRITSYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-41184 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSYSTSFTFGPGTKVDIK (“LC”) amino acid sequence Ab 511 1021 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSSYYYSWIRQPPGKGLEWIGEINQSGS ADI-41185 Heavy chain variable region TNYNPSLKSRVTISVDTSKNEFSLKLSSVTAADTAVYYCARIVREFNTRWYDYYYMD (“HC”) amino acid sequence VWGKGTTVTVSS Ab 511 1022 DIRVTQSPATLSLSPGERATLSCRTSQSISSSYLAWYQQKFGQAPRLLIYGASSRATGI ADI-41185 Light chain variable region PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGISPPMYTFGQGTKVEIK (“LC”) amino acid sequence Ab 512 1023 EVQLLESGAEVKKPGESLKISCKGSGYSFSSYWIAWVRQMPGKGLEWMGIIYPSDS ADI-41186 Heavy chain variable region DTKYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARQAGIQRPLDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 512 1024 EIVMTQSPATLSVSPGERATLSCRASQSVRSNLAWYQQKPGQAPRLLIYDASTRAT ADI-41186 Light chain variable region GISARFSGSGSGTEFTLTISSLQSEDFAVYYCQQFHNWPPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 513 1025 QVQLQQWGAGLLKSSETLSLTCAVYGGSFSGYYWSWIRQSPGKGLEWIGEINHSG ADI-41188 Heavy chain variable region SANYNPSLKNRVTISRDTSKNQFSLWLSSVTAADTAVYYCARTSRSPEPDNYYYYM (“HC”) amino acid sequence DVWGRGTTVTVSS Ab 513 1026 QSVLTQPPSVSGAPGQRVSISCTGSSSDIGAGYDVHWYQQFPGTAPKLLMYANNN ADI-41188 Light chain variable region RPSGVPDRFSGSRSGTSASLAITGLQAEDEADYYCQSYDSNLDVVVFGGGTKLTVL (“LC”) amino acid sequence Ab 514 1027 QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSMSSS ADI-41189 Heavy chain variable region SGYIDYADSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARRNAVVVPSLMVV (“HC”) amino acid sequence ADYYYGMDVWGQGTTVTVSS Ab 514 1028 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-41189 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDTSLSGPGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 515 1029 QVQLVQSGAEVKKPGASVKVSCKAFGYTFRSYDMQWVRQAPGQRLEWMGWIN ADI-41190 Heavy chain variable region AVNGDTKYSQKFQGRVTITRDTSATTVYMELSSLRSEDTAVYYCARWGRFWNSRS (“HC”) amino acid sequence LDYYAMDVWGQGTTVTVSS Ab 515 1030 DIVMTQSPGTLSLSPGERATLSCRASQSISSSYLVWYQHKPGQAPRLLIYGASTRATD ADI-41190 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTRLEIK (“LC”) amino acid sequence Ab 516 1031 QVQLVQSGAEVKRPGASVKVSCKASGYIFSHYGISWVRQAPGQGLEWMAWISAY ADI-41191 Heavy chain variable region NGNTNYAQKLQGRVIVTIDTSTSTAYMELRSLRSDDTAVYYCAREPPSLSAAATLD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 516 1032 EIVMTQSPLSLPVTLGQPASISCRSNQSLVYSDGNIYLSWFQQRPGQSPRRLIYKVSN ADI-41191 Light chain variable region RDSGVPDRFSGSGSGTDFTLKISRVEAEDVAVYYCMQVTHWPHEFGQGTKLEIK (“LC”) amino acid sequence Ab 517 1033 QVQLVQSGAEVKKPGASVKVSCRTSGYTFTDYEINWVRQAPGQGLEWMGGISAY ADI-41192 Heavy chain variable region NGKTDYAQNLQDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIFYYDRSGYYLA (“HC”) amino acid sequence LFDSWGHGTLVTVSS Ab 517 1034 DIQMTQSPSSLSASVGDRVTITCRASQRIASYLNWYQQKPGKAPKLLIYAASSLQSG ADI-41192 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPTLTFGGGTKMDIK (“LC”) amino acid sequence Ab 518 1035 EVQLVESGGGLVKPGMSLRLSCAASGFRFSDHYMNWIRQAPGKGLEWVSYISSSS ADI-41193 Heavy chain variable region TYTDYTDSVKGRFTISRDNSKNSVYLQMNSLRAEDTAIYYCARVAPIRHNGDYIDYW (“HC”) amino acid sequence GQGTTVTVSS Ab 518 1036 NFMLTQPPSASGTPGQRVTISCTGSSSNIGAGYDVHZYQQIPGTAPKWYGNNNRP ADI-41193 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQTEDEADYYCQSYDRGLSGRVFGTGTKVTVL (“LC”) amino acid sequence Ab 519 1037 QVQLQESGPGLVKPSQMLSLTCTVSGDSISSGDYYWSWIRHHPGKGLEWIGYISYS ADI-41194 Heavy chain variable region GSTYNNPSLKSRVTVSVDTSKNQFFLKLTSVTAADTAVYYCARATKPYHSYFYMDV (“HC”) amino acid sequence WGKGTTVTVSS Ab 519 1038 EIVLTQSPGTLSLSPGERATLSCRASQSGSRSYLAWYQQRPGQAPRLLIYGASNRAT ADI-41194 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNAPTFGGGTKVDIK (“LC”) amino acid sequence Ab 520 1039 EVQLVESGGGLVQPGGSLRLSCIVSGFPFNTYAMSWVRQAPGKGLEWVSVVSASG ADI-41196 Heavy chain variable region GNTDYADSVKGRFTISRDNSKKTLYLQMNSLRAEDTAVYYCARTESNTLAPSWSGR (“HC”) amino acid sequence YVTDWYFDLWGRGTLVTVSS Ab 520 1040 EIVMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLISAASSLQSGV ADI-41196 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSIPTFGQGTRLEIK (“LC”) amino acid sequence Ab 521 1041 QVQLVQSGAEVKKPGASVKVSCKASGYTFSGYYMHWVRQAPGQGLEWVGRINP ADI-41197 Heavy chain variable region KSGDTVYAQKFQGRVTMTRDTSISTAYMELSRLISDDTAKYYCARQEDHYYGSGNF (“HC”) amino acid sequence YNSFDFWGQGTLVTVSS Ab 521 1042 ETTLTQSPSSLSASVGDRVTITCRASQSISSNLNWYQQKPGKAPKLLIYGASTLQSGV ADI-41197 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDLATYYCQQSYSNPGKTFGQGTKVDIK (“LC”) amino acid sequence Ab 522 1043 EVQLVQSGGVVIQPGGSLRLSCAASGFSFDEYLMHWVRQLPGKGLEWVALISWH ADI-41198 Heavy chain variable region GDITYYADSVKGRFTISRDNSRYSLYLQMNSLRSDDTALYYCVKDGWIEGAFNHTFG (“HC”) amino acid sequence IGYYFENWGQGTLVTVSS Ab 522 1044 DIVLTQTPSSLSASVGDRVTITCQASQDINNCLNWYQQKPGKAPEVLIFDASNLETG ADI-41198 Light chain variable region VPLRFSGSGSGTHFTLTISSLQPEDIATYYCQQHENVPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 523 1045 QVQLVESGGGLVKPGGSLRLSCGASGFTFPDYYMSWIRQAPGKGLEWLSYISSSSSF ADI-41199 Heavy chain variable region TDYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTAVYYCARVRADYVGNSRIHFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 523 1046 DIVMTQSPVTLSVSPGERATLSCRASQSLNGYLAWYQQKPGQAPRLLIYGASTRAT ADI-41199 Light chain variable region EPGWDTSGRGSGTEFTLTISSLQSEDFAVYYCQQYNDWPFTFGQGTRLEIK (“LC”) amino acid sequence Ab 524 1047 EVQLLESGGGLVKPGGSLRLSCAASGLTFSDHDMSWVRQAPGKGLEWVSGIGGSG ADI-41200 Heavy chain variable region SNTYYAGSVKGRFTISRDNSKNTLYLQMDSLRVEDTAVYYCAKDPYGDYRDYYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 524 1048 DIVLTQTPFSLPVTPGEPASISCRSSQSLLKSNGYNYLDWFLQKPGQSPQLLIYLGSN ADI-41200 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQTLQALYTFGQGTKVEIK (“LC”) amino acid sequence Ab 525 1049 EVQLLESGGGLVQPGGSLRLSCAASGFAFDIYSMNWVRQAPGKGLEWLSYISSRGE ADI-41201 Heavy chain variable region TIYYADSVKGRFTISRDNARNSLYLQMNGLRDEDTATYYCYYYGSGISSHGGAFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 525 1050 DIVMTQTPATLSLSPGERATLTSRASQSVSSFLAWYQQKPGQAPRLLIYDVSNRATG ADI-41201 Light chain variable region VPARFSGSGSGTDFTLTISSLEPEDIAVYYCQQRNTWPAITFGQGTKVEIK (“LC”) amino acid sequence Ab 526 1051 QVQLVESGAEVKKPGSSVKISCKASGGTFSSHPISWVRQAPGQGLEWMGRIVPIFG ADI-41202 Heavy chain variable region IANYAQKFQGRVTMIADKSTNTAYMELSNLRSEDTAVYYCASPVYDSSGFQWGQG (“HC”) amino acid sequence TLVTVSS Ab 526 1052 QSALIQPRSVSGSPGQSVTISCTGTSGDGGFYNYVSWYQQHPGKTPKLMIYDVDQ ADI-41202 Light chain variable region RPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYPGNPLYVFGTGTKLTVL (“LC”) amino acid sequence Ab 527 1053 QVQLVQSGAEVRKPGESLKISCKASGYRFTNYWIGWVRQMPGKGLEWMGVIYPG ADI-41203 Heavy chain variable region DSDTRYSPSFQGQVTMSADKSTNTAYLQWSSLKASDTAIYYCVSLYSDYDYGALDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 527 1054 EIVMTQSPATLSVSPGERATLSCRASENVGRNLAWYQQKPGQAPRLLIYGASIRAT ADI-41203 Light chain variable region GILARFSGSGSGTEYTLTISSLQSEDFAVYYCQQYHDWPSFTFGPGTKVDIK (“LC”) amino acid sequence Ab 528 1055 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISAGSS ADI-41204 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVPSYETTPYFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 528 1056 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDLHWYQQLPGTAPKLLIYVNSNRP ADI-41204 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 529 1057 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSTNWWSWVRQPPGKGLEWIGEIYHS ADI-41205 Heavy chain variable region GSTNYNPSLKSRVTISVDKSNNQFSLNLSSVTAADTAVYYCARGVITYRGSWFLQYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 529 1058 DIRVTQSPDSLAVSLGERATINCKSSQSLFYSSNNQNYLAWYQQKPGQPPKLLIYW ADI-41205 Light chain variable region ASTRQSGVPHRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSSPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 530 1059 EVQLLESGGGLVKPGGSLRLSCAGSGFSFSSYSMNWVRQAPEKGLEWVSSISASSSF ADI-41206 Heavy chain variable region INYADSVKGRFIISRDNAKNSLFLQMDSLRAEDTAVYYCARDGVHPGGYIFGGYIDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 530 1060 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWFRQLPGTAPKLLIYGNNNR ADI-41206 Light chain variable region PSGVPDRFSGSKSGSSASLIITGLQAQDEATYYCQSYDSSLSGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 531 1061 QVQLVQSGPALVKPTQTLTLTCTFSGFSLSTKGMCVSWIRQPPGKALEWLALIDWD ADI-41207 Heavy chain variable region DDKFYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARTLYFYGSGSLSDYC (“HC”) amino acid sequence FDYWGQGTPVTVSS Ab 531 1062 QPVLTQPRSVSGSPGQSVTISCTGTSRDVGNYNFVSWYQQHPGKAPKLIIYDVTKR ADI-41207 Light chain variable region PSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGTYTWVFGGGTKVTVL (“LC”) amino acid sequence Ab 532 1063 QVQLVESGGDLVKPGGSLRLSCAASGFTLSGHYMSWIRQPPGKGLEWVSSISGGST ADI-41208 Heavy chain variable region YTNYADSVKGRFTISRDNAENSLYLQMNSLRAEDTAVYYCARLAYSDYGPFYFDLW (“HC”) amino acid sequence GRGTLVTVSS Ab 532 1064 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLTGTAPKLLIFDNNNR ADI-41208 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSRLSAPYVFGTGTKLTVL (“LC”) amino acid sequence Ab 533 1065 QVQLQESGAGLLKPSETLSLTCAVSGASFSGYSWSWIRQPPGKGLEWIGDIDHSGS ADI-41209 Heavy chain variable region TNYNSSLNSRVTISVDTSKNQFSLNLTSVTAADTAIYYCARVGGRSAYWGQGTLVTV (“HC”) amino acid sequence SS Ab 533 1066 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGFNYLDWYLQKPGQSPQLLIYLGSN ADI-41209 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTLTFGGGTKVEIK (“LC”) amino acid sequence Ab 534 1067 QVQLVQSGAEVKKPGASVKVSCKASGYTFNNYGISWVRQAPGQGLEWMGWISA ADI-41210 Heavy chain variable region YNGDIKYAQKFQGRVTVTTDTSTSTAYMELRSLRSDDTAVYYCARDTPVGGGTQTF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 534 1068 ETTLTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLNWFQQRPGQSPRRLIYTVS ADI-41210 Light chain variable region NRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQATHRPGTFGQGTKVEIK (“LC”) amino acid sequence Ab 535 1069 EVQLLESGAEVKKPGASVKVSCKASGYTFTDYYIHWVRQAPGQGLEWMGRINPKN ADI-41212 Heavy chain variable region GDAIYAQNFQGRVTMTRDTSISTAYMEVSRLTSDDTAVYYCARDQMWLVLDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 535 1070 QSALTQPASVSGSPGQSITISCTGTSSDVGGYDYVSWYQQHPGKAPKLMIHDVTN ADI-41212 Light chain variable region RPSGISHRFSGSKSGNTASLTISGLQAGDEADYYCSSYTRSNTKVFGTGTKVTVL (“LC”) amino acid sequence Ab 536 1071 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAAGKGLEWVSLIYSGD ADI-41213 Heavy chain variable region STYYADSVKGRFTISRDNSQNTLYLQMNSLRAEDTAVYYCARDASPNVGYYGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 536 1072 DIVLTQPPSVSVSPGQTASITCSGGKLGDTYACWYQQKPGQSPVLVIYQDSKRPSGI ADI-41213 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTARYVFGTGTKVTVL (“LC”) amino acid sequence Ab 537 1073 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVATIKQD ADI-41214 Heavy chain variable region GSEKYSVDSVKGRFTISRDNPKKSLYLQMNSLRAEDTAVYYCARDYRVEYYHSSDKL (“HC”) amino acid sequence KRYYYYGMDVWGQGTTVTVSS Ab 537 1074 DIRVTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKFLIYAASSLESGVP ADI-41214 Light chain variable region SRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSIPITFGQGTRLEIK (“LC”) amino acid sequence Ab 538 1075 QVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINW ADI-41215 Heavy chain variable region SGGSTDYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKEGQEWELLPW (“HC”) amino acid sequence YFDLWGRGTLVTVSS Ab 538 1076 QPVLTQPASVSGSPGQSITIPCTGTSSDVGIYNLVSWYQQHPGKAPKLMIYDVSKRP ADI-41215 Light chain variable region SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGGSTYVFGTGTKLTVL (“LC”) amino acid sequence Ab 539 1077 EVQLVESGGGLVKPGESLRLSCAASGFRFSDHYMSWIRQAPGKGLEWISYISSSSSYI ADI-41216 Heavy chain variable region HYADSVTGRFTISRDNAKNSMYLQMNSLRAEDTAVYYCAREIGRSYYMDVWGKG (“HC”) amino acid sequence TTVTVSS Ab 539 1078 QSALIQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNR ADI-41216 Light chain variable region PSGVPDRFSASKSGISASLAITGVQTEDEADYYCQSYDRSLSEFYVFGSGTKVTVL (“LC”) amino acid sequence Ab 540 1079 EVQLVQSGGGLVKPGGSLRLSCVASGFTFSSYSMNWVRQAPGKGLEWVSSISASSS ADI-41217 Heavy chain variable region YIDYADSVKGRFTISRDNDKKSLYLQMSSLRAEDTAVYYCAREDYDSLTGYYSPKRFD (“HC”) amino acid sequence PWGQGTLVTVSS Ab 540 1080 QSVLTQPPSLSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNR ADI-41217 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRSLSVVFGGGTKVTVL (“LC”) amino acid sequence Ab 541 1081 QVQLVQSGAEVKKPGASVKVSCKASGYTFISDGISWVRQAPGQGLEWMGWINPH ADI-41218 Heavy chain variable region NENTNYAQKFQGRVTMTTDTSTSTAYLELRGLRSDDTAVYYCARDPYHWSYLDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 541 1082 QSVVTQPPSVSGAPGQRVTITCTGSSSNIGANSDVHWYQQIPGTAPKLLIFGNSNR ADI-41218 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRSLSGSRVFGGGTRLTVL (“LC”) amino acid sequence Ab 542 1083 EVQLVESGGGLVQPAGSLRLSCAASGFTFSNYVMNWVRQAPGKGLEWVSYISSSG ADI-41219 Heavy chain variable region RTIHYADSVKGRFTISRDNAKNSLYLEMNSLRAEDTAVYYCARDPNYGGNSNRFDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 542 1084 DIVMTQTPSSLSASVGDRVTITCRASQTISNYLNWYQQKPGKAPKLLIFAASSLQSG ADI-41219 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSAPRVTFGPGTKVDIK (“LC”) amino acid sequence Ab 543 1085 EVQLLESGGGLVKPGGSLRLSCAASGFTFSDYTMNWVRQAPGKGLEWVSSISITSS ADI-41221 Heavy chain variable region HIYYADSVKGRFTISRDNAKNSLYLQINSLRAEDTAAYYCARELGFASSSYSYYYGMD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 543 1086 QSALTQPRSVSGSPGQSVTISCTGTSSDVGDYNSVSWYQQHPGTAPKLIIFDVTQR ADI-41221 Light chain variable region PSGVPDRFSGSKSANTASLTISGLQPEDEADYYCCSFAGNYVFGTGTKVTVL (“LC”) amino acid sequence Ab 544 1087 QVTLKESGGGVVQPGRSQRLSCTASGFNFHNYAMHWVRQAPGKGLEWVAVISY ADI-41222 Heavy chain variable region DGSNKNFADSVKGRFTISRDNSKNTLNLQMNNLRAEDTAVYYCVRDIVRGSPLFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 544 1088 QPVLTQPPSLSVAPGQTAWITCGGNNIGSKIVHWYQQKPGQAPVVVVYDDDDRP ADI-41222 Light chain variable region SGIPERFSGSNSGNTATLTIRRVEVGDEADYYCQVWDRSSDNYVFGTGTKVSVL (“LC”) amino acid sequence Ab 545 1089 QVQLVESGGGVVQPGRSLRISCAASGFTFSNYGMHWVRQAPGKGLEWVAVLSYD ADI-41223 Heavy chain variable region GSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKNLNDYNISWYKC (“HC”) amino acid sequence FDLWGRGTLVTVSS Ab 545 1090 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQHHPGKAPKLIIYDVNNR ADI-41223 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYICSSYTTITTFVVFGGGTKLTVL (“LC”) amino acid sequence Ab 546 1091 EVQLVETGGGLVQPGRSLRLSCTASGFTFGDYAMNWVRQAPGKGLEWIGIIRTKT ADI-41224 Heavy chain variable region YGGTTEYAASVKGRFTISRDDSKGIAYLQMNSLKTEDTGVYYCTMPVLNMDVWG (“HC”) amino acid sequence QGTTVTVSS Ab 546 1092 QPVLTQPHSVSESPGKTVTISCTRNIGNIASNYVQWYQQRPGSSPTTVIYEDNQRPS ADI-41224 Light chain variable region GVPDRFSGSIDISSNSASLTISGLKTEDEADYYCQSYDSNNPWVFGGGTQLTVL (“LC”) amino acid sequence Ab 547 1093 EVQLVESGGGLVKPGGSLRLSCAASGFSLSDYYMTWLRQAPGKGLEWVSSIGTTST ADI-41225 Heavy chain variable region YTNYAESVKDRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDWGFGVERGYFDL (“HC”) amino acid sequence WGRGTLVTVSS Ab 547 1094 DIVLTQTPSTLSASVGDRVTITCRASQSISFWLAWYQQKPGKAPKLLIYKASTLESGV ADI-41225 Light chain variable region PSRFSGRGSGTDFTLTISSLQPDDFATYYCQQYNTYTWTFGQGTKVEIK (“LC”) amino acid sequence Ab 548 1095 EVQLVESGGGLVKPGGSLRLSCAASRFTFAGYYMSWIRQAPGKGLEWVSDISPSST ADI-41226 Heavy chain variable region YTNYADSVKGRFTISRDNAGTSVSLQMDSLRADDTAVYYCARITPYGGSHYFDSWG (“HC”) amino acid sequence QGTLVTVSS Ab 548 1096 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDLHWYQQLPGTAPKLLIYGNSNR ADI-41226 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGFYVFGTGTKVTVL (“LC”) amino acid sequence Ab 549 1097 RSSWCSVGAEVKKRGSSVKVSCKASGGTFGGYAVSWVRQAPGQGLEWMGGIIP ADI-41227 Heavy chain variable region MFYTTKYAQKLQGRVTITADESTNTAYMDLSSLTSDDTAIYFCAREWHLGRTAVTG (“HC”) amino acid sequence TGAFLDAFDIWGQGTMVTVSS Ab 549 1098 SYELTQPPSVSEAPRQRVTISCSGSSSNIGNNAVNWYQQLPGKAPKLLIYYDDLLPS ADI-41227 Light chain variable region GVSDRFSGSKSGTSASLAISGLQSEDEADYYCSAWDDSLNGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 550 1099 EVQLLESGPGLVKPSETLSLTCTVSGGSISSYQWNWIRQPPGKGLEWLGYVYYSGST ADI-41228 Heavy chain variable region NYNPSLKSRVILSVDTSKNQFSLKLSSVTAADTAVYYCARDRRDGSFVFDYWGQGT (“HC”) amino acid sequence LVTVSS Ab 550 1100 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-41228 Light chain variable region PSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSTTLVFGTGTKVTVL (“LC”) amino acid sequence Ab 551 1101 QVQLVQSGGGVVQPGRSLKLSCAASGFTFKSYGMHWVRQAPGKGLEWVAVISYD ADI-41229 Heavy chain variable region EINKYYADSVKGRFTISRDYSKNTLSLQMNSLTTEDTAMYYCAKPKTTGYYYLDAFD (“HC”) amino acid sequence FWGQGTMVTVSS Ab 551 1102 ETTLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETG ADI-41229 Light chain variable region VPSRFSGSGSGTDFTFTISSLQSEDIATYYCQQHDNVPPTFGQGTKVDIK (“LC”) amino acid sequence Ab 552 1103 QVQLVQSGAEVKKPGESLKISCKASGYSFTSHYWIGWVRQMPGKGLEWMGFIFP ADI-41230 Heavy chain variable region GDSDTRYSPSLQGQVTISADKSTNTAYLQWNSLKASDTAMYYCARLEYLVSGFEYW (“HC”) amino acid sequence GQGTLVTVSS Ab 552 1104 QPGLTQPHSVSESPGKTVTISCTRSSGSIASNYVHWYQQRPGSFPTTVIYEDNQRPS ADI-41230 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLRTEDEADYYCQSYDSSNPVVFGGGTKVTVL (“LC”) amino acid sequence Ab 553 1105 QVQLVQSGAEVKKPGESLKISCKGSGYSFTNNWVGWVRQMPGKGLEWMGIIFPG ADI-41231 Heavy chain variable region DSDTRYSPSFRGQVTISVDTSINTAFLQWNSLGASDTAMYYCAMTDYNYSFKSWG (“HC”) amino acid sequence QGTLVTVSS Ab 553 1106 NFMLTQPHSVSESPGKTITISCTRSSGNIGNNYVQWYQQRPGSSFTTVIYEDYQRPS ADI-41231 Light chain variable region GVPDRFSGSIDSSSNSATLTISGLKTEDEADYYCQSYDSSNPYVFGTGTKVTVL (“LC”) amino acid sequence Ab 554 1107 QVQLVQSGAEVKKPGASVKVSCKASGYTFTHYGISWVRQAPGQGLEWMAWISAY ADI-41232 Heavy chain variable region NGNTNYAQKLQDRVIVTIDTSTSTAYMELRSLRSDDTALYYCARDSMGGTTLFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 554 1108 DIVLTQTPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSN ADI-41232 Light chain variable region RDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPMYTFGQGTKLEI (“LC”) amino acid sequence K Ab 555 1109 EVQLLESGGGLVKPGGSLRLSCAASGFIFRDYYMIWIRQAPGKGLEWVSYISSSSTYT ADI-41233 Heavy chain variable region NNADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLFASRSDGAFDIWGQ (“HC”) amino acid sequence GTTVTVSS Ab 555 1110 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPETAPKLLIYDNNNR ADI-41233 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTTVTVL (“LC”) amino acid sequence Ab 556 1111 QVQLVQSGGGVVQPGRSLRLSCAASGFTVSSYAIHWVRQSAGKGLEWVAVEGRF ADI-41234 Heavy chain variable region TISRDNSKNTLYLQMNSLRAEDTAVYYCARLSEALVEPAAHTQYKYHYGLDVWGQ (“HC”) amino acid sequence GTTVTVSS Ab 556 1112 EIVLTQSPLSLPVTPGEPASISCKSSQSLLDSNGYNYLDWYLQKPGQSPQLLIYLVSNR ADI-41234 Light chain variable region ASGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQALQTPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 557 1113 QVQLQQWGAGLLKPSETLSLTCGVYGESFSGHYWSWIRQPPGKGLEWMGEIHHS ADI-41235 Heavy chain variable region GTTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARNPAEDILTGYSPPFH (“HC”) amino acid sequence YYYMDVWGKGTTVTVSS Ab 557 1114 QSVLIQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQIPGTAPKLLIHSNNNR ADI-41235 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 558 1115 QVQLVQSGGGLVKPGGSLRLSCTASGFTFSDYYMDWIRQAPGKGLEWVSSISSSST ADI-41236 Heavy chain variable region YTKYADSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCVRNLGPYCSSTSCFVFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 558 1116 QSVLTQPPSVSGAPGQRVSISCTGSSSNIGAGYEVHWYKQVPGTAPRLLMYDNTN ADI-41236 Light chain variable region RPSGVPDRVSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLNKSVFGGGTKVTVL (“LC”) amino acid sequence Ab 559 1117 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSDISPSSS ADI-41237 Heavy chain variable region YTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAMYYCARRGSCTGGVCSFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 559 1118 QPGLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVNWYQQLPGTAPKLLIYDNSNR ADI-41237 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADFYCQSYDSSLSGFVFGTGTKVTVL (“LC”) amino acid sequence Ab 560 1119 EVQLLESGGGLVKPGGSLRLSCAASGFTFRDYYMSWIRQAPGKGLEWVSYISSSSSY ADI-41238 Heavy chain variable region TEYADSVKGRFTISRDNAKKSLYLQMNSLRTEDTAVYYCARVITQAGTGTTYYMDV (“HC”) amino acid sequence WGKGTTVTVSS Ab 560 1120 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGTGYDVHWYQQLPGTAPKLLIYANNNR ADI-41238 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSLVFGGGTKLTVL (“LC”) amino acid sequence Ab 561 1121 QITLKESGPTLVKPTQTLTLTCTFSGFSLTTTGVGVGWIRQPPGKALEWLALIYWDD ADI-41239 Heavy chain variable region DKRYSPSLKNRITITKDTSKKQVVLTMTNMDPADTATYYCAHISTVVTYDSSGSYYVL (“HC”) amino acid sequence INWFDPWGQGTLVTVSS Ab 561 1122 EIVMTQSPLSLPVTPGEPASISCRSSHSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-41239 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGQGTKVDIK (“LC”) amino acid sequence Ab 562 1123 QVQLQQWGAGLLKPSETLSLICDVYGGSFSDYYWSWIRQSPGKGLEWIGEINHSG ADI-41240 Heavy chain variable region STSFHPSLKSRISISIDTSNNQFSLNLSSMTAADTAVYYCARGTLRGYFDYWGQGTLV (“HC”) amino acid sequence TVSS Ab 562 1124 EIVLTQSPSTLSAFVGDRVTITCRASQSISRWLAWYQQKPGKAPNLLISEASSLESGV ADI-41240 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDLGTYYCQQYNGYLWTFGQGTKVEIK (“LC”) amino acid sequence Ab 563 1125 QVQLVQSGAEVKKPGASVQVSCKASGYTFTGDYMHWVRQAPGQGLEWMGRIN ADI-41241 Heavy chain variable region PNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARAAAEYSSSSP (“HC”) amino acid sequence TSYYYMDVWGKGTTVTVSS Ab 563 1126 EIQMTQSPSSLSASVGDRVTITCRASQNIYSFLNWYQQKPGKAPKLLIYAASSLQSG ADI-41241 Light chain variable region VPSRFSGSGSATDFTLTISSLQPEDFATYYCQQSYSPPQITFGQGTKVDIK (“LC”) amino acid sequence Ab 564 1127 EVQLVESGGGVVQPGRSLRLSCAASGFPFSSYAMHWVRQAPGKGLEWVAVIWFE ADI-41242 Heavy chain variable region GNEKYFADSVEGRFTISRDNSKNTLYLQMNSLRAEDTARYYCARFYFGAFDIWGQG (“HC”) amino acid sequence TLVTVSS Ab 564 1128 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNSLDWYLQKPGQSPQLLIYLASN ADI-41242 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 565 1129 QVQLVQSRAEVKKPGESLKISCKGSLHSFSNNWIGWVRQMPGKGLEWMGIIFPD ADI-41243 Heavy chain variable region DSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAIYYCGTVVTLIQGVADWGQ (“HC”) amino acid sequence GTLVTVSS Ab 565 1130 QPVLTQPHSVSESPGKTVTISCTRSSGSIDSSYVQWYQQRPGSSPTTVIYEDNLRPSG ADI-41243 Light chain variable region VPDRFSGSIDSSSNSASLTISGLKTEDEAEYYCQSYDSSNPVVFGGGTKLTVL (“LC”) amino acid sequence Ab 566 1131 QVTLKESGGGLIQPGGSLRLSCAVSGFTVSSKYMSWVRQAPGKGLEWVSVIYGGG ADI-41244 Heavy chain variable region STYYTDSVKGRFTISRDNSNNTLYLQMNSLRAEDTAIYYCAREARSYNYDYVGNDAF (“HC”) amino acid sequence DIWGQGTTVTVSS Ab 566 1132 DIVLTQTPDSLAVSLGERATINCKSSQSVLNNFNNKNYLAWYQQKPGQPPKLLIYW ADI-41244 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTITSLQAEDVAIYYCQQYYRTPPYTFGQGTKVDIK (“LC”) amino acid sequence Ab 567 1133 QVQLVESGGGLVKPGGSLRLSCAASGFSFSAYYMSWIRQAPGKGLEWISNISGGSS ADI-41245 Heavy chain variable region YANYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREFQTYYYMDVWGK (“HC”) amino acid sequence GTTVTVSS Ab 567 1134 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYEVHWYQQLPGTAPKLLIYGNNNR ADI-41245 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL (“LC”) amino acid sequence Ab 568 1135 EVQLLESGPGLVKPSETLSLTCIVSGGSISSYNWNWIRQPPGKGLEWIGYIYNSGSTN ADI-41246 Heavy chain variable region YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARYFDYGSGGFDYWGQGTLV (“HC”) amino acid sequence TVSS Ab 568 1136 ETTLIQSPGILSLSPGERATLSCRASQSVTSTYLAWYQQKPGQAPRLLIYGASSRAT ADI-41246 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDSSLTFGGGTKVEIK (“LC”) amino acid sequence Ab 569 1137 QVQLVQSGAEVKKPGASLQVSCKASGYTFTDSYFHWVRQAPGQGLEWMGRISPH ADI-41247 Heavy chain variable region SGGTNYAQKFQGRVTMTRDTSISTAYLELSRLRSDDTAVYYCATEGPRGPFRFDPW (“HC”) amino acid sequence GQGTLVTVSS Ab 569 1138 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPS ADI-41247 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLMTEDEADYYCQSYDSSNWVFGGGTKLTVL (“LC”) amino acid sequence Ab 570 1139 QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYSMHWVRQAPGKGLEWMAVCW ADI-41248 Heavy chain variable region YDGSNIYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARDDRYCSGGTC (“HC”) amino acid sequence LSAFDIWGQGTMVTVSS Ab 570 1140 ETTLIQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGRAPKLLIYTTSSLQSGVS ADI-41248 Light chain variable region SRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYSTPNTFGQGTKVEIK (“LC”) amino acid sequence Ab 571 1141 QVQLVQSGAEVKKPGESLKISCQVSRDTSTTYWIGWVRQMPGKGLEWMGIIFPG ADI-41249 Heavy chain variable region DSDTRYSPSFQGQVTISADKSIMTAYLQLTSLKASDTAMYYCATQALRGAFDIWGQ (“HC”) amino acid sequence GTMVTVSS Ab 571 1142 DIRLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASYLETGV ADI-41249 Light chain variable region PSRFSGSGSGTDFTFTISSLQPEDFATYYCQQYDDLLFTFGPGTKLEIK (“LC”) amino acid sequence Ab 572 1143 QVQLQQWGAGLLKPSETLSLTCAVSGESLTGYFWSWIRQPPGKGLEWIGEVSHSG ADI-41250 Heavy chain variable region STNYNPSLKSRVIMSVDTSKTQFSLKLNSVTAADTAVYYCARGYDYWSGTARYFDY (“HC”) amino acid sequence WGQGILVTVSS Ab 572 1144 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-41250 Light chain variable region PSGVSSRFSGSKSGNTASLTISGLQAEDEGDYYCSSYRSSTTSRVFGGGTKVTVL (“LC”) amino acid sequence Ab 573 1145 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMTWIRQAPGKGLEWVSNISGGSS ADI-41251 Heavy chain variable region YTNYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCARVGCSGGVCNFFLDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 573 1146 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNTNR ADI-41251 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 574 1147 EVQLVQSGAEVKKPGESLKISCMGSGYNFPNYWIGWVRQMSGKGLEWMGIIYPD ADI-41252 Heavy chain variable region DSDTTYSPSFQGQVIFSADKSISTAYLQWSSLKASDTAMYFCVRLDKTTQIDFWGQ (“HC”) amino acid sequence GTLVTVSS Ab 574 1148 EIVLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDVSNLETGV ADI-41252 Light chain variable region PSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHDNLPLTFGQGTRLEIK (“LC”) amino acid sequence Ab 575 1149 EVQLVQSGPGLVKPSETLSLTCTVSGDSISSSDYSYYWGWIRQPPGKGLEWIASLSYS ADI-41253 Heavy chain variable region GKTYSQSSLKSRVIISVDTSKKQFSLKLSSVTAADTAVYYCAVTRCYVCTSEGDSFDM (“HC”) amino acid sequence WGQGTMVTVSS Ab 575 1150 DIVLTQTPGTLSLSPGERATLSCRASQSISGNYLAWYQHKPGQAPRLLIYGASTRATG ADI-41253 Light chain variable region IPDRFSGSGSGTDFPLTISRLEPEDFAVYYCQQYATSPYTFGQGTKVDIK (“LC”) amino acid sequence Ab 576 1151 EVQLVESGGGLVQSGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYTTNN ADI-41254 Heavy chain variable region GRTIYYADSVKGRFTISRDNAKNSLFLQMNGLRAEDTAVYYCARGIQFSRVDYAMD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 576 1152 SYELTQPPSVSGTPGQRITISCSGSSSNIASNTVNWYQHLPGTAPKLLIYSDNQRPSG ADI-41254 Light chain variable region VPDRFSGSKSGTSASLAISGLQSEDEADYYCAIWDDSLNASYVFGTGTKLTVL (“LC”) amino acid sequence Ab 577 1153 EVQLVESGGGLVQPGGSLRISCAASGLTFSSYAMSWVRQAPGQGLEWVSSVSGSG ADI-41255 Heavy chain variable region VSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEDYYHFYMDVWG (“HC”) amino acid sequence NGTTVTVSS Ab 577 1154 ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRAAG ADI-41255 Light chain variable region IPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHDNWPSYTFGQGTKVEIK (“LC”) amino acid sequence Ab 578 1155 QVQLVQSGAEVKSPGSSATVSCKASGGTFGSYGISWVRQAPGQGLEWIGAIMPM ADI-41256 Heavy chain variable region FGTTNYAQKFQGRVTMTADESTSTVYMDVSSLRPDDTAVYYCVRDVFYDILTGYYD (“HC”) amino acid sequence ADYYHHYMDVWGKGTTVTVSS Ab 578 1156 DIVMTQSPLSLPVTLGQPASISCRSGQSLVHSDGNTYLNWFQQRPGQSPRRLIYKV ADI-41256 Light chain variable region SNRGSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTHWPRTFGQGTKVDI (“LC”) amino acid sequence K Ab 579 1157 QVQLVESGAEVKKPGSSVKVSCKASEGTFSSYGISWVRQAPGQGPEWMGEINPM ADI-41257 Heavy chain variable region FGTAKYAQKFQGRVTITVDESTSTADMELSSLTSEDTAVYYCAREFLGQCSETNCPT (“HC”) amino acid sequence PSRHLDYWGQGTLVTVSS Ab 579 1158 EIVMTQSPSSLSASVGDRVTITCRASRTISSYLNWYQQKPGKAPKLLIYATSNLQSGV ADI-41257 Light chain variable region PSRFSGSGSGADFTLTISSLQPEDFATYYCQQTYSTPGFGPGTKVDIK (“LC”) amino acid sequence Ab 580 1159 QVQLVQSGGGLVQRGGSLRLSCAASGFSFRSYAMSWVRQAPGKGLEWVSSISDS ADI-41258 Heavy chain variable region GDNTFYADSVKGRFSISRDNSRDTLYLQMNSLRAEDTAVYYCARGGYCSGGNCFPF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 580 1160 SYELMQLPSVSVSPGQTARITCSGDALPKQYGYWYQQKPGQAPVLVIYKDSERPSG ADI-41258 Light chain variable region IPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSGGTYVMFGGGTKLTVL (“LC”) amino acid sequence Ab 581 1161 QVQLVESGGRLVKPGGSLRLSCAASGFTFSDFYMSWIRQAPGKGLEWVSYISSSGD ADI-41259 Heavy chain variable region DPNYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCARDEVGWNNLDYYFG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 581 1162 DIVMTQSPLSLPVTLGQPASISCRSSQSLVHSDGNTYLSWFHQRPGQSPRRLIYKVS ADI-41259 Light chain variable region NRDSGVPNRFSGGGSGTDFTLKISRVEAEDVGFFYCMQGTHWQKTFGQGTKVEIK (“LC”) amino acid sequence Ab 582 1163 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPM ADI-41261 Heavy chain variable region FGAANYAQKFQGRVTITAETSTSTAFMELSSLRSDDTAVYYCARIRWVPNWGGTA (“HC”) amino acid sequence TSFYNGMDVWGQGTTVTVSS Ab 582 1164 EIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRAT ADI-41261 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSLFTFGPGTKVDIK (“LC”) amino acid sequence Ab 583 1165 QVQLVQSGAEVKKPGASVKVYCKASGYTFTSHYIHWVRQAPGQGLEWMGRMNP ADI-41263 Heavy chain variable region SGGSPMYAQKFQERVTMTRDTSTSTAYMELRSLRSEDTAVYYCAMAKFYSFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 583 1166 QSVLTQPHSVSESPGKTVTISCTRSSGSIASYFVHWYQQRPGSAPTIVIYEDNQRPSG ADI-41263 Light chain variable region VPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNWVFGGGTKLTVL (“LC”) amino acid sequence Ab 584 1167 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNTWMSWVRQAPGKGLEWVGHIKSK ADI-41264 Heavy chain variable region TDGGTTDYAAPVKGRFTISRDDSKSILNLHLNSLKTEDSAVYYCAALPPISGWYYTPG (“HC”) amino acid sequence FWGQGTLVTVSS Ab 584 1168 SYELTQPPSMSVSPGQTARITCFGDAVPKKYVYWYQQKSGQAPVMVIYDDRRRPS ADI-41264 Light chain variable region GIPERFSGSSSGARATLTISGAQVEDEADYYCYSTDGSGNPSFGGGTKLTVL (“LC”) amino acid sequence Ab 585 1169 EVQLVQSGAEVKKPGESLTISCKDSGYSFTSYWIGWVRQVPGKGLEWMGIVYPGD ADI-41265 Heavy chain variable region SRYSPSFQGHVTMSADKSINTAYLQWSTLKASDTAMYYCAKVVTYGSAIRWFESW (“HC”) amino acid sequence GQGTLVTVSS Ab 585 1170 QSVLTQPPSVSAAPGQKVSISCSGSSSNIGNNFVSWYQQVPGTAPKLLIIDNNKRPS ADI-41265 Light chain variable region GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSRLSAEVFGGGTKLTVL (“LC”) amino acid sequence Ab 586 1171 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYY ADI-41266 Heavy chain variable region RSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDLPQVDYFDG (“HC”) amino acid sequence ASFYFFDFWGQGTLVTVSS Ab 586 1172 QPVLTQPPSVSVAPGQTASITCGGNIIGNKGVHWYQQKPGRAPVLVVYDDSDRPS ADI-41266 Light chain variable region GIPERFSGSNSGNTATLTISRVEAADEADYYCQVWDTGSHPVVFGGGTKVTVL (“LC”) amino acid sequence Ab 587 1173 QVQLVQSGPGLVKPSGTLSLTCAVSGGSISTTHWWSWVRQPPGKGLEWIGEIYHS ADI-41267 Heavy chain variable region GSTNYNPSLKSRVTISVDKSRSQFSLKLTSVTAADTAVYYCARGDPLCSGGICYSGYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 587 1174 SYVLTQPPSVSVSPGQTATITCSGDKLGDQYACWYQQKSGQSPVLVIYRDNKRPSG ADI-41267 Light chain variable region IPERFSGSNSGNTATLTISETQAMDEADYYCQAWGSSSVVFGGGTKVTVL (“LC”) amino acid sequence Ab 588 1175 EVQLVESGGGLVKPGGSLRLSCVASGFGFTSYSMNWVRQAPGKGLEWVSSISASST ADI-41268 Heavy chain variable region YIHYADSVKGRFTISRDNARNSLYLQMISLRADDTAVYYCSRDGPTYGSGVHVWGQ (“HC”) amino acid sequence GTMVTVSS Ab 588 1176 QSALIQPVSVSGSPGQSITISCTGTRSDVGGYNYVSWYQQHPGKAPKLMIYEVRNR ADI-41268 Light chain variable region PSGVSDRFSGSKSGNTASLTISGLQAEDEGDYYCSSYTSSDTLFYVFGSGTKLTVL (“LC”) amino acid sequence Ab 589 1177 EVQLVESGGGVVQPGQSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVISYD ADI-41270 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLSLQVNSLRAEDTAVYYCARVSAEGSMGRFSD (“HC”) amino acid sequence FNYWGLGTLVTVSS Ab 589 1178 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVRKR ADI-41270 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSDTYVFGTGTKLTVL (“LC”) amino acid sequence Ab 590 1179 QVQLQESGPGLVKPSQTLSLTCAISGDSVSSNNAAWNWIRQSPSRGLEWLGRTYY ADI-41271 Heavy chain variable region RSKWYNDYAVSVKSRITINPDTSKNQLSLQLNSVTPEDTAVYYCARAGVRQWLVRG (“HC”) amino acid sequence MDAFDIWGQGTMVTVSS Ab 590 1180 DIRLTQSPDSLAVSLGERATVNCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYW ADI-41271 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNTPHTFGQGTKVEIK (“LC”) amino acid sequence Ab 591 1181 EVQLLESGGDLVRPGGSLRLSCTASGFSFSSSEMNWVRQAPGKGLEWVASINSGG ADI-41273 Heavy chain variable region DDIYYADSVKGRFTISRDNAKNSLSLQMDSLRAEDTALYYCARSRSGYSSGWSRFFG (“HC”) amino acid sequence NWGQGTLVTVSS Ab 591 1182 QSALTQPRSVSGSPGQSVTISCTGTISDIGAYNYVSWYQQHPGKAPKVMIYDVSKR ADI-41273 Light chain variable region PSGVPDRFSGSKSGFTASLTISGLQAEDEADYYCCSYAGRWVFGGGTKLTVL (“LC”) amino acid sequence Ab 592 1183 EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYAMNWVRQAPGKGLQWVSSISAGS ADI-41274 Heavy chain variable region SYIDYADSVKGRFTISRDNAENSLFLQMNSLRVEDTAVYYCARVGSYTHGYEFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 592 1184 QPVLTQPPSVSGAPGQRVTISCTGSNSNIGAGYDVHWYQQLPGTAPKLLIYASTIRP ADI-41274 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRNLSVVFGGGTKVTVL (“LC”) amino acid sequence Ab 593 1185 EVQLVESGGGLVKPGGSLRLSCAASGFMFSTYSMNWVRQAPGKGLEWVSFITGSS ADI-41275 Heavy chain variable region SDKYYAHSVKGRFTISRDNAKRTLYLQLNSLRAEDTAVYYCARFRGLYCDGDCSSRG (“HC”) amino acid sequence NTYYNYYGMDVWGQGTTVTVSS Ab 593 1186 EIVMTQSPLSLSVIPGEPASISCRSSKSLLHSNGYTYLDWYLQKPGQSPQLLIHLGSNR ADI-41275 Light chain variable region ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVFYCMQALQAPPTFGPGTKVEIK (“LC”) amino acid sequence Ab 594 1187 EVQLVESGGGLVQPGRSLRLSCRASGFTFRNYAMSWVRQAPGKGLEWVGFIRGK ADI-41276 Heavy chain variable region GYGGTTEYAASVKGRFTISSDDSRSIAYLQMNSLKTEDTAVYYCTRVREDGVIAVAE (“HC”) amino acid sequence YYFDYWGQGTLVTVSS Ab 594 1188 GIQMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIHGASSRAT ADI-41276 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYHCQQYGSSPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 595 1189 QVQLQESGPGLVKPSGTLSLTCAVSGGSITGRNWWSWVRQPPGKELERIGEIYHG ADI-41277 Heavy chain variable region GSTEYNPSLKGRVTISVDKSKNQFSLRLNSVTAADTAVYYCARVAHYDSNGYYIGYF (“HC”) amino acid sequence DLWGRGTLVTVSS Ab 595 1190 EIVLTQSPPSLSASVGDRVTITCRASQSISIYLNWYQQKPGKAPKLLIFAASSLQSGVP ADI-41277 Light chain variable region LRFSGSGSGTDFTLTISSLQPEDFATYYCHQSYSAPWTFGQGTKVDIK (“LC”) amino acid sequence Ab 596 1191 EVQLVESGPALVKPTQTLTLTCTFSGFSLSTKRMGVSWIRQPPGKALEWLARIDWD ADI-41278 Heavy chain variable region DDKFYSTSLKTRLTISKDTSKNQVVLTLANMDPVDTATYFCARTTVYASGGYYLYYLD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 596 1192 DIVMTQTPSSLSASVGDRVTLTCRASQRIASYVNWYHQKPGKAPNLLIYAASNLQS ADI-41278 Light chain variable region GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKLEIK (“LC”) amino acid sequence Ab 597 1193 QVQLVQSGAEVKKAGETLKISCRGPAHTFTSFWIGWVRQTPGKGLEWMGNIYPG ADI-41279 Heavy chain variable region DTDTTYSPSFRGQVTISADKSISTAYLQWNSLKASDTAIYYCATRVRHGYSSSGSFES (“HC”) amino acid sequence WGQGTMVTVSS Ab 597 1194 QSVVTQPPSVSGAPGQRITISCTGSNSNTGAGYDVHWYQQLPGAAPKLLIFANNN ADI-41279 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSAYVFGTGTKLTVL (“LC”) amino acid sequence Ab 598 1195 QVQLVESGPGLVKPSETLALTCTVSGGSLSTYYWSWIRQPPGKGLEWIGYIYYSGTT ADI-41280 Heavy chain variable region YYNPSLKSRVTISEDRSKNQFSLKLTSVTAADTAVYYCARHGPKTEFWSAQYYLELW (“HC”) amino acid sequence GRGTLVTVSS Ab 598 1196 EIVLTQSPGTLSLSPGERATLSCRASQSVSSDYLAWYQQKPGQAPSLLIYGVSTRATG ADI-41280 Light chain variable region IPDRISGSGSGTDFTLTISRLEPEDFAVYYCHQYGTSPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 599 1197 QVQLVQSGAEVKKPGASVKVSCKASGYSFTNHGIHWVRQAPGQRLEWMGWINV ADI-41281 Heavy chain variable region ANGFTAYSQNLQGRVTFTRDTSASTAYLELTSLRSEDTAVYHCARDESYCSAGYCYL (“HC”) amino acid sequence YFDYWGQGTTVTVSS Ab 599 1198 DIQVTQSPSSLSASVGDRVTITCRASQNIITYVNWYQQKPGKAPELLIFGASSVQSG ADI-41281 Light chain variable region VPSRFSGSGSGTDFTLTISSLRPDDFATYYCQQSYSNPRTFGGGTKVEIK (“LC”) amino acid sequence Ab 600 1199 QVQLVQSGGGVVQPGRSLRLSCAASGFMFTIYSMHWVRQAPGKGLEWVAVISN ADI-41282 Heavy chain variable region DGVNKYYSDSVKGRFTISRDNSKNTLYLQMNNLRAEDTAVYYCASDIVVLVTATDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 600 1200 ETTLTQSPVTLSLSPGERATLSCRTSQSFSSPLLAWYQQKPGQAPRLLIYGASNRATG ADI-41282 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPVDFAVYYCQQYGSSPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 601 1201 QVTLKESGPTLVKPTQTLTLTCTFSGFSLSTFGVAVGWIRQPPGKALEWLALIYWDD ADI-41283 Heavy chain variable region DKRYSPSLKSRLTITKDISKNQVVLTMTNMDPVDTATYYCAHRLRSLTARGVFDIWG (“HC”) amino acid sequence QGTTVTVSS Ab 601 1202 DIRLTQSPSSLSASVGDRVTITCRASQSINNFLNWYQQRPGKAPTLLIYSASSLQSGV ADI-41283 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYFCQQTDSFPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 602 1203 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSE ADI-41284 Heavy chain variable region VDGGTADYAANVKGRLTISRDDSKNMMYLQMNSLKTEDTAVYYCTTDPGVGWIF (“HC”) amino acid sequence GEVKLFRTDPEYWGQGTLVTVSS Ab 602 1204 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNHYVSWYQQLPGTSPKLLIYDNNKRPS ADI-41284 Light chain variable region GIPDRFSGSKSGTSATLGITGLQPGDEADYYCGTWDSSLSAVRVFGGGTKVTVL (“LC”) amino acid sequence Ab 603 1205 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYAISWVRQAPGQGLEWMGGIIPIL ADI-41285 Heavy chain variable region GTVKNAQKFQGRVTITADKITSIAYMELSSLRHEDTAVYYCARDYYDSSGYYYNGYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 603 1206 QSVLIQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNDQRPS ADI-41285 Light chain variable region GVPDRFSGSKSGTSASLAISGLRSGDEADYYCAAWDDSLGGPIWVFGGGTKLTVL (“LC”) amino acid sequence Ab 604 1207 QVQLVQSGAEVKKPGASVKVSCKASGYTFISYGISWVRQAPGQGPEWMGWISTH ADI-41286 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDERSIAVEVYLG (“HC”) amino acid sequence STFDIWGQGTMVTVSS Ab 604 1208 DIQVTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASTLQSG ADI-41286 Light chain variable region VPSRFSGSGSGTDFTLTISRLQPEDFATYYCQQANIFGVTFGPGTKVDIK (“LC”) amino acid sequence Ab 605 1209 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSSISWH ADI-41287 Heavy chain variable region SADIGYAASVEGRFTISRDNAKNSLFLQMNSLRPEDTALYYCAKEIVSTSWYSGYFQ (“HC”) amino acid sequence DWGQGTLVTVSS Ab 605 1210 QPVLTQPRSVSGSPGQSVTISCTGTSSDVGDYNYVSWYQQHPGKAPKLMIYDVSK ADI-41287 Light chain variable region RPSGVPDRFSGSKSGNTASLTISGLQGEDEADYYCCSYAGRHTFVFGTATKVTVL (“LC”) amino acid sequence Ab 606 1211 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAAGKGLEWVSAISGSG ADI-41288 Heavy chain variable region DDTFYADSVKDRFIISRDSSKRKVYLQMNSLRVEDTAVYYCAKTDIMVTFGGVVVD (“HC”) amino acid sequence AYYFDHWGQGTLVTVSS Ab 606 1212 ETTLIQSPGILSLSPGERATLSCRASQFVFRSYLAWYQQRPGQPPRLLIYGASSRATG ADI-41288 Light chain variable region IPDRFSGRGSGTEFTLTISRLEPEDFAMYYCQHYDSSPPGTFGGGTKVEIK (“LC”) amino acid sequence Ab 607 1213 EVQLVQSGAEVKKPGESLKISCKGSGYSFSSFWIGWVRQMPGKGLEWMGIIYPGD ADI-41289 Heavy chain variable region SDTRYSPSFQGQVTISADQSIRTAYLQWNSLKASDTGLYYCAKGGLGDVEMATIAV (“HC”) amino acid sequence WGQGTLVTVSS Ab 607 1214 QSVLIQPASVSGSPGQSITIPCTGTSSDVGSYNLVSWYQHHPGKAPKLIISEGSKRPL ADI-41289 Light chain variable region GVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYVRSRTFNYVFGTGTKLTVL (“LC”) amino acid sequence Ab 608 1215 QVQLQQWGAGLLKPSETLSLTCVVYGESFSDSGYYWTWIRQPPEKGLEWIGEINH ADI-41291 Heavy chain variable region GGSTSYNPSLKSRVTISVDTSENQFSLKVTSVTGADTAVYYCARLRLGCSGGSCYSRF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 608 1216 DIQLTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPVLLIHAASSLQGG ADI-41291 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNTRWTFGHGTKVDIK (“LC”) amino acid sequence Ab 609 1217 EVQLLESGGGVVQPGRSLRLSCAASGFSFSSYGIHWVRQAPGKGLECVALMSYDGS ADI-41292 Heavy chain variable region EKYYADSVKGRFTISRDNSKNTLYLHMNSLRREDTAVYYCAKGSHLRWSHLDYYFHL (“HC”) amino acid sequence WGRGTLVTVSS Ab 609 1218 DIVMTQSPSTLSASVGDRVTITCRASQSLSTWLAWYQQKPGKAPKLLISDASNLESG ADI-41292 Light chain variable region VPSRFSGRGSGTEFTLTISGLQPDDFATYYCQQERTFGQGTKVDIK (“LC”) amino acid sequence Ab 610 1219 QVQLQQSGPGLAKPSQTLSLTCTVSGGPISGVDYYWSWIRQPPGKGLEWIGYIYYS ADI-41293 Heavy chain variable region GSTYYNPSLKSRVTISVDTSKKQFSLKMSSVTAADTAVYYCARDVGATPYYYYGMD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 610 1220 DIVLTQSPDTLSLSPGERATLSCRASQSVRSNYLAWYQHKPGQAPRLLIYGASSRVA ADI-41293 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPSVTFGGGTKVEIK (“LC”) amino acid sequence Ab 611 1221 EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYEMNWVRQAPGKGLEWVSYISSSG ADI-41294 Heavy chain variable region SNKHYADSVKGRFTISRDNAKNSLHLHMNSLRAEDTALYYCTRPHQEEWELLPNDA (“HC”) amino acid sequence FDLWGQGTMVTVSS Ab 611 1222 QSALTQPPSASGSPGQSVTISCTGTSTDVGAYTYVSWYQQHPGKAPKLIIYEVYKRP ADI-41294 Light chain variable region SGVPNRFFGSKSGNTASLTVSGLQAEDEADYYCSSYGGSNNFGLFGGGTKLIVL (“LC”) amino acid sequence Ab 612 1223 EVQLVESGVEVKKPGESLKISCRGSGYTFYNYWIAWVRQKPGKGLEYMGTIYLDDS ADI-41296 Heavy chain variable region ETIYSPSFQGEVTISADKSINTAYLQWNSLKASDTANYYCARQMDFYFDVWGRGTL (“HC”) amino acid sequence VTVSS Ab 612 1224 SYELMQPPSVSVSPGQTARITCSGDPLPRESAYWYQQKPGQAPVVIIFNDIERPLGI ADI-41296 Light chain variable region PERFSGSRSGTTVTLTISGAQAEDEADYYCQSADSRKTFVFGTGTKLTVL (“LC”) amino acid sequence Ab 613 1225 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTDAISWVRQAPGQGLEWMGGIIPLF ADI-41297 Heavy chain variable region GTANYAQKFQGRVTITADESTSTAYMELNSLRSVDTAVYYCGRTGAFDGEVVVRP (“HC”) amino acid sequence HLDLWGQGTLVTVSS Ab 613 1226 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYDYVSWYQHHPGKAPKLMIYEVSNR ADI-41297 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQADDEAAYYCSSYTRSNTLLFGGGTKLTVL (“LC”) amino acid sequence Ab 614 1227 EVQLVESGGGLVHPGRSLRLSCGASGFTFRSFAMHWVRQAPGKGLEWVAVISYD ADI-41299 Heavy chain variable region GSDEYYADSVKGRFTISRDNSRNTLFLQMNRLRPEDTAIYYCARAYCSTSNCPVLDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 614 1228 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYSLVSWYQQHPGKAPKLIIFEGNKRPA ADI-41299 Light chain variable region GVSDRFSGSKYGDTASLTISGLQAEDEADYYCCSYAGGHSVFGGGTKVTVL (“LC”) amino acid sequence Ab 615 1229 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMQWVRQAPGKGLEWVAVMTN ADI-41302 Heavy chain variable region DGDDKYYADSVRGRFTISRDNSKNTLYLQMNNLRPEDTAVYYCARDLFEWWELLG (“HC”) amino acid sequence YCYAMDVWGQGTTVTVSS Ab 615 1230 QSVLTQPPSASGSPGQSVTISCTGTSSDVGAYNYVSWYQQHPGKAPKLIIYEVYKRP ADI-41302 Light chain variable region SGVPDRFFGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNTLGVFGGGTKVTVL (“LC”) amino acid sequence Ab 616 1231 QVQLVQSGGGLVRPGGSLRVSCAASGFIFNNYALTWVRQAPGKGLEWVSAISGSG ADI-41303 Heavy chain variable region SSTYYADSVKGRFTISRENSNNRLYLQLSGLRAEDTAVYFCARVRGLVWFEGRIDPY (“HC”) amino acid sequence PNVFDYWGQGTLVTVSS Ab 616 1232 DIVLTQSPGTLSLSPGERATLSCRASQSVSNDYLAWYQQKPGQAPRLLIYDASSRAI ADI-41303 Light chain variable region GIPDRFSGSGSGTDFTLIISRLEPEDFAVYYCHHPGKFGQGTKVEIK (“LC”) amino acid sequence Ab 617 1233 EVQLVESGPGLVKPSQTLSLTCTVSGGSIRSHDYYWSWIRQPPGKGLEWIGYSYYSG ADI-41304 Heavy chain variable region STYYNPSLKSRVIISLDTSKNQFSLNLTSVTAADTAMYYCARDRPHTSSWIPGWFDP (“HC”) amino acid sequence WGQGTLVTVSS Ab 617 1234 SYELTQPPSASGTPGQRVTISCSGSSSNIGSNTVSWYQQFPGKAPKLLIYSNNERPSG ADI-41304 Light chain variable region GPDRFSGSKSGTSASLAIGGLQSEDEANYYCAAWDDSLYAVVFGGGTKLTVL (“LC”) amino acid sequence Ab 618 1235 QVTLKESGPGLVKPSQTLSLICTVSGGSISGGGYYWSWIRQLPGKGLQWIGCIYDS ADI-41305 Heavy chain variable region GTTYYNPSLKSLVTISIDTSKNQFSLKLSSVTAADTAVYYCARGGSLDDFWSATWYFA (“HC”) amino acid sequence LWGRGTLVTVSS Ab 618 1236 EIVLTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYGASSRATG ADI-41305 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAFYYCQQYGRSPYTFGPGTKLEIK (“LC”) amino acid sequence Ab 619 1237 QVQLVESGPRLVKPSQTLSLICTVSGGSIYRGDYDWNWIRQPPGKGLEWIGYISYT ADI-41306 Heavy chain variable region GNTHYNSSLKSRLSISADTSGTHFSLKLSSVTAADTAIYYCARDVGYGGNAAHYYYYA (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 619 1238 ETTLTQSPATLSLSPGERATLSCRASQSVGSSLAWYQQKVGQAPRLLIYDASSRVTGI ADI-41306 Light chain variable region PARFSGSGSGTDFTLTISSLEPGDFAVYYCQQRSNSLTFGGGTKVEIK (“LC”) amino acid sequence Ab 620 1239 QVQLVESGGGLVKPGGSLRLSCAASGFPLSPYALNWVRQAPGKGLEWVSSITSSSA ADI-41307 Heavy chain variable region YIYYADSVKGRFTVSRDNPTNSLYLQMNSLRAEDTAVYYCARTIPQHYYDNNGDYY (“HC”) amino acid sequence NYGMDVWGQGTTVTVSS Ab 620 1240 DIVLTQSPATLSVSPGQRITLSCRASQTVRSNLAWYQQKPGQPPRLLIYGASTRATG ADI-41307 Light chain variable region VPARFTGSGSGTEFTLTITSLQSDDFAVYYCHQYNDRPLTFGPGTKVEIK (“LC”) amino acid sequence Ab 621 1241 EVQLVESGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLERMGRTYYR ADI-41308 Heavy chain variable region SKWYDDYAVSVKSRIIINPDTSKNQFSLQLNSVTPEDTAVYYCARGISTFGGVIYALEI (“HC”) amino acid sequence WGQGTMVTVSS Ab 621 1242 SYVLTQPASVSGSPGQSITISCTGLTSDVGGYNFVSWYQQHPGKAPKLIIYDVSHRPS ADI-41308 Light chain variable region GVSNRFSGSESGNTASLTISGLQAEDEAHYYCSSYTRTSIVVFGGGTKLTVL (“LC”) amino acid sequence Ab 622 1243 EVQLLESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWVRQPPGKGLEWIGNIYHS ADI-41309 Heavy chain variable region GSTYYKPSLKSRVSISLDTSKNQFSLKLSSVTAADTAIYYCARDGGENYVWGTFRFLD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 622 1244 DIRLTQSPGILSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGVSSRATG ADI-41309 Light chain variable region IPDRFSGSGSGTDFTLTINRLEPEDFALYHCQQYGSSPHTFGQGTKVEIK (“LC”) amino acid sequence Ab 623 1245 QVQLVQSGVEVKKPGESLKISCRGSGYSFYNYWIAWVRQKPGKGLEYMGTIYLDDS ADI-41310 Heavy chain variable region DTIYSPSFQGEVTISADKSINTAYLQWNSLKASDTANYYCARQMDFYFDVWGRGTL (“HC”) amino acid sequence VTVSS Ab 623 1246 SYELTQPPSVSVSPGQTARITCSGDPLPRESAYWYQQKPGQAPVVVIFNDIERPLGI ADI-41310 Light chain variable region PGRFSGSRSGATATLTINGAQAEDEADYYCQSADSRKTFVFGAGTKLTVL (“LC”) amino acid sequence Ab 624 1247 QVTLKQSGPALVKPTQTLTLTCTFSGFSLSTKRMGVSWIRQPPGKALEWLARIDWD ADI-41311 Heavy chain variable region DDKYYSTSLRTRLTISKDTSKNQVVLTMTDMDPVDTATYYCARIQPYTSGGYYSYYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 624 1248 DIQVTQSPSSLSASIGDRVTITCRASQTIASYLNWYQQKPGKAPKLLIYIASSLQSGVP ADI-41311 Light chain variable region SRFSGSGSGTDFTLTISTLQPEDFATYYCQQSYGTPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 625 1249 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWNWVRQPPGKGLEWIGEIYHS ADI-41312 Heavy chain variable region GRTNYNPSLKSRVSISIDKFKSQFSLNLNSVTAADTAVYYCARDLPGTPYDIVPGYYP (“HC”) amino acid sequence GLRRHDAFDIWGQGTMVTVSS Ab 625 1250 QSVLTQPPSASGTPGQRVTMSCSGSSSNIGSDTVNWYQQLPGTAPKLLIYSNNQR ADI-41312 Light chain variable region PSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 626 1251 EVQLVESGAEVKKPGASVKVSCKASGYTFNNYDISWVRQAPGQGLEWMGWISTY ADI-41313 Heavy chain variable region NGNTNYAQKFQGRATMTTDTSTTTAYMELRSLRSDDSAIYYCARVYCGGDCHNPF (“HC”) amino acid sequence FLYFDLWGRGTLVTVSS Ab 626 1252 SYVLTQPLSVSVALGQTARITCGGNNIGSKSVHWYQQKPGQAPLLVIYRDNNRPSG ADI-41313 Light chain variable region IPERFSGSTSGNTATLTISRAQAGDEADYSCQVWDNSDWVFGGGTKLTVL (“LC”) amino acid sequence Ab 627 1253 QVQLVQSGAEVKKPGSSVKVSCKAFGGIFSSYAISWVRQAPGQGLEWMGGIIPIFG ADI-41314 Heavy chain variable region TTKYAQKFQGRVTITADKSTSTVYMEVSSLRFEESAVYFCARAYCSGGTWYGGADY (“HC”) amino acid sequence WGQGTLVTVSS Ab 627 1254 QSVLTQPPSVSVSPGQTARITCSGDVLPKQYAYWYQQKPGQAPLLVMYKDTERPS ADI-41314 Light chain variable region GIPERFSGSSSVTAVTLTISGVQAEDEADYYCQSADSTQELFGGGTKLTVL (“LC”) amino acid sequence Ab 628 1255 EVQLLESGPGLVKPSETLSLTCAVSGGSISNYYWSWIRQPPGKGLEWIAYISYSGTTN ADI-41315 Heavy chain variable region YNPSLESRVTISVDTSKNQFSLKLNSVTAADTAVYYCARHEFLVLPDVWGQGTLVTV (“HC”) amino acid sequence SS Ab 628 1256 ETTLIQSPGILSLSPGERATLSCRASQSVSSTFLAWYQQKPGQAPRLLIYAASSRATG ADI-41315 Light chain variable region IPDRFSGSGSGTDFTLIISRLEPEDFAVYYCQQYRSSPFSFGPGTKVEIK (“LC”) amino acid sequence Ab 629 1257 QVQLVQSGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGKGLEWVAVLSF ADI-41316 Heavy chain variable region DGINKYYADSARGRFTISRDNSKNTLYLQMNSLRAEDTALYYCAKDRQEYSSGWTH (“HC”) amino acid sequence DACDIWGQGTMVTVSS Ab 629 1258 EIVMTQSPATLSVSPGERATLSCRASQNVNNNLAWYQQNPGQAPRLLIFGASTRA ADI-41316 Light chain variable region TGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKLEIK (“LC”) amino acid sequence Ab 630 1259 EVQLVESGGGLVQPGGSLRLSCEASRFKFSTFWMAWVRQAPGKGLEWVANIKQD ADI-41317 Heavy chain variable region GSETYYLDSVKGRFTISRDNAKNSLFLQMKSLRAEDTAVYYCAGLWWGDLENWFD (“HC”) amino acid sequence PWGQGTLVTVSS Ab 630 1260 QSVLTQPPSVSGAPGQRVTISCTGSSSNLGTGFDVHWYRQLPGTAPQLLIYGSTNR ADI-41317 Light chain variable region PSGVPDRFSGSKYGTSASLAITGLQAEDEADYYCQSYDSNLRAYVFGTVTKVTVL (“LC”) amino acid sequence Ab 631 1261 EVQLLESGAEVKKPGSSVRVSCKAFGGTFSSYAFSWVRQAPGQGLEWMGGITPM ADI-41318 Heavy chain variable region FGTENYAPNFQGRVTITADKLTTTVYMELSRLRSEDSAVYYCAREGGRLGTTMGAF (“HC”) amino acid sequence DMWGQGTMVTVSS Ab 631 1262 DIRLTQSPSSLSASVGDRVTITCRASHGISSALAWYQQRPGRVPQVLIFHASTLESGV ADI-41318 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 632 1263 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIFYSG ADI-41319 Heavy chain variable region TTYYNPSLKSRVTISLDTSQNQFSLKLSSVTAADTAVYYCARDGDEVDYVWGTRRYL (“HC”) amino acid sequence DSWGRGTLVTVSS Ab 632 1264 EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIHGASSRAT ADI-41319 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCLQYGSLPKTFGQGTKVEIK (“LC”) amino acid sequence Ab 633 1265 QVQLVQSGVEVKKPGESLKISCRGFGYSAYNYWIAWVRQKPGKGLEYMGTIYLDD ADI-41320 Heavy chain variable region SDTIYSPSFQGEVTISADRSINTAYLQWNSLKASDTANYYCARQMDFYFDVWGRGT (“HC”) amino acid sequence LVTVSS Ab 633 1266 QSVLTQPPSVSVSPGQTARITCSGDPLPRESAYWYQQKPGQAPVVVIFNDIERPLGI ADI-41320 Light chain variable region PARFSGSRSGTTVTLTISGAQAEDEADYYCQSADSRKTFVFGPGTKLTVL (“LC”) amino acid sequence Ab 634 1267 QVQLVQSGAEVKKPGSSVRVSCKASGGSFSSYATSWVRQAPGQGLEWMGGIIPM ADI-41322 Heavy chain variable region YDAVNYAQKFQGRVTITADESTTTAYMELSSLRSEDTAVYYCARSSGYTGINFFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 634 1268 DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQQKPGKAPKLLIYTASSLQSG ADI-41322 Light chain variable region VPSRFSGSGSGTDFTLTISRLQPEDFATYYCQQANSFPRVTFGGGTKVEIK (“LC”) amino acid sequence Ab 635 1269 EVQLLESGGGVVRPGGSLRLSCAASGFTFDDYAMGWVRQAPGKGLEWVSGITW ADI-41323 Heavy chain variable region NAGSTAYAGSVKGRFTISRDNAKNSLFLQMNSLRAEDTAFYLCARHVDSSGPVARH (“HC”) amino acid sequence FDYWGQGTLVTVSS Ab 635 1270 NFMLTQPHSVSESPGKTVTISCTRSSGSIARNYVQWYQQRPGSAPTIVIYEDNQRPS ADI-41323 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDPSNVVFGGGTKLTVL (“LC”) amino acid sequence Ab 636 1271 EVQLVESGGGLVQPGGSLRLSCAASGFTVSNNYMRWVRQAPGKGLEWVSVIYSS ADI-41324 Heavy chain variable region GSTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERTLFYYDSSGFFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 636 1272 ETTLTQSPGTLSLSPGERATLSCRASQSVDSSYLAWYQQKPGQAPRLLIYGASNRAT ADI-41324 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSLTFGGGTKLEIK (“LC”) amino acid sequence Ab 637 1273 QVQLVQSGAEVKTPGSSVKVSCKASGGTFRSYPITWVRQAPGQGLEWMGTVIPVF ADI-41340 Heavy chain variable region DTVNYAPKFQGRVSITADESTNTAYMELSSLRSDDSAVYYCARDLGWLRPMTTVTS (“HC”) amino acid sequence PHFDYWGQGTLVTVSS Ab 637 1274 QSVLTQPASVSGSPGQSITISCTGTSSDVGGYDFVSWYQQHPGKAPKLMISEVTDR ADI-41340 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCTSYTSSRTYVFGTGTKLTVL (“LC”) amino acid sequence Ab 638 1275 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYATHWVRQAPGQGLEWMGGIIPIF ADI-41341 Heavy chain variable region GRATYAQKFQGRVTISADESTSTAYMELSSLRSEDTAVYYCARGRDDRSGDHIAFLY (“HC”) amino acid sequence HYGMDVWGQGSTVTVSS Ab 638 1276 QSVLTQPPSVSAAPGQKVSISCSGSSSNIGINHASWYQHLPGTAPKLLIYDNNKRPS ADI-41341 Light chain variable region GIPDRFSGSKSGTSATLGISGLQTGDEAAYYCGTWDTGLSAVVFGGGTKLTVL (“LC”) amino acid sequence Ab 639 1277 QVQLVQSGAEVKKPGSSVKVSCKASGGTLTSYGVSWVRQAPGQGLEWMGGIIPIF ADI-41342 Heavy chain variable region GTVDYAQKFQGRVTITADEPTSTAYMELSSLTSDDTAVYYCARDPWVSGPVEFYYY (“HC”) amino acid sequence FDVWGRGTLVTVSS Ab 639 1278 DIVLTESPATLSLSPGERATLSCRASQSINNRYLAWYQQKPGQAPRLLIFGASSRATG ADI-41342 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSTPPTFGQGTKVEIK (“LC”) amino acid sequence Ab 640 1279 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSSISGGS ADI-41343 Heavy chain variable region SYISYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVDTPMVRGYYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 640 1280 QSVLTQPPSVSGAPGRRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIFANSNRP ADI-41343 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKVTVL (“LC”) amino acid sequence Ab 641 1281 EVQLVESGGGLVKPGGSLRLSCAASGSSFSSYYMNWVRQAPGKGLEWVSSISSSST ADI-41344 Heavy chain variable region YIDYADSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCARVSSPMIRGYYLDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 641 1282 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLVIHGNSN ADI-41344 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQGEDEADYYCQSYDSSLSGSVFGGGTKLTVL (“LC”) amino acid sequence Ab 642 1283 EVQLVQSGAEVRKPGESLKISCKGSGYNFASYWIAWVRQMPGKGLEWMGIIFPGD ADI-41345 Heavy chain variable region SDTRYSPSFQGQVTISVDKSISTAYLQWSSLKASDTAIYYCATSKYTFGYLDWGQGTL (“HC”) amino acid sequence VTVSS Ab 642 1284 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRP ADI-41345 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDTSNQVFGTGTKVTVL (“LC”) amino acid sequence Ab 643 1285 QVQLVQSGPEVKKPGESLKISCTLSASGLTTYWIGWVRQMPAKGLEWMGIIFPGD ADI-41346 Heavy chain variable region SDTRYSPSFQGQVTISADKSTNTAYLQWSGLKASDTAIYYCATLQTPVTGLDQWGQ (“HC”) amino acid sequence GTLVTVSS Ab 643 1286 NFMLTQPHSVSESPGKTVTISCTRSSGNIARSYVQWYQQRPGSAPTTVIHEDDQRP ADI-41346 Light chain variable region SGVPDRFSGSIDTSSNSASLTISGLKTEDEADYYCQSYDPSNYVFGTGTKVTVL (“LC”) amino acid sequence Ab 644 1287 EVQLVESGPGLVKPSGTLSLTCAVSGGSVSSDNWWSWVRQPPGKGIEWIGEIYPS ADI-41347 Heavy chain variable region GGTNYNPSLNSRVTISVDKSKNQFSLKLNSVTAADTAIYYCARAPFDSSGYHSNSVW (“HC”) amino acid sequence GQGTLVTVSS Ab 644 1288 ETTLTQSPLSLPVTPGEPASISCRSSQSLLHSNGHNYLDWYVQKPGQSPQLLIYLSSN ADI-41347 Light chain variable region RASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQPLQTPQTFGQGTKVEIK (“LC”) amino acid sequence Ab 645 1289 QVQLQESGPGLVKPSQTLSLTCAVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYS ADI-41348 Heavy chain variable region GSTYYNPSLKSPVTISVDTSKNQFSLKLTSVTAADTAVYYCARGDYYFDGSGRTTAAF (“HC”) amino acid sequence DIWGQGTMVTVSS Ab 645 1290 DIQVTQSPSSLSASVGDRVTITCRASQSISTFLNWYQQKPGRAPKLLIYDASNLQSGV ADI-41348 Light chain variable region PSRVSGSGSGTDFTLTISSLHPEDFATYYCQQSYTTPYTFGQGTKVDIK (“LC”) amino acid sequence Ab 646 1291 EVQLLESGGGLVQPGRSLRLSCTGSGFTFGDYAMNWVRQAPGKGLEWVGLIRSKD ADI-41349 Heavy chain variable region YGGTTEFAASLKGRLTISRDDSKSIAYLQMHSLKTEDSAVYYCTRAHLTDYTDINGYQ (“HC”) amino acid sequence YYFDYWGQGSPVTVSS Ab 646 1292 DIQMTQSPSSLSASVGDRVTITCQASQDISNFLNWYQQRPGKAPKLLIHDASNLET ADI-41349 Light chain variable region GVPSRFSGSGSRTEFTFTISSLQPEDIGTYYCQHYDNFPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 647 1293 EVQLVESGAGLVQPGGSLRLSCAASGFTFSTYAVSWVRQAPGKGLEWVSAISGSG ADI-41350 Heavy chain variable region ASTYFADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKARLELRPYYYGMD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 647 1294 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLIIYEVSNRP ADI-41350 Light chain variable region SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSSTLSTTYVFGTGTKVTVL (“LC”) amino acid sequence Ab 648 1295 QVQLVQSGGGLVQPGGSLRLSCSASGFTFSSKSMHWVRQAPGKGLEYVSAIRSDG ADI-41351 Heavy chain variable region VSTYYGDSVKGRFTVSRDNAKNTVYLRMSSLRREDTAVYYCVKGPYGDFQYNWFD (“HC”) amino acid sequence TWGQGTLVTVSS Ab 648 1296 ETTLIQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASIRATGI ADI-41351 Light chain variable region PARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYDNWPPGDTFGQGTKVEIK (“LC”) amino acid sequence Ab 649 1297 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYRMNWVRQAPGKGLEWVSYIDISSS ADI-41352 Heavy chain variable region TIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDQLVWEPLIRNHYYY (“HC”) amino acid sequence AMDVWGQGTTVTVSS Ab 649 1298 EIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYW ADI-41352 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSSPPTFGQGTKVEIK (“LC”) amino acid sequence Ab 650 1299 EVQLVESGVEVKKPGESLKISCRGSGYSFHNYWIAWVRQKPGKGLEYMGTIYVDDS ADI-41353 Heavy chain variable region DTIYSPSFQGEVTISADKSINTAYLQWNSLKASDTANYYCARQMDFYFDVWGRGTL (“HC”) amino acid sequence VTVSS Ab 650 1300 SYELTQPPSVSVSPGQTARITCSGDPLPRESAYWYQQKPGQAPVVVIFNDIERPLGI ADI-41353 Light chain variable region PERFSGSRSGTTVTLTISGAQAEDEADYYCQSADSRKTFVFGSGTKLTVL (“LC”) amino acid sequence Ab 651 1301 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSG ADI-41354 Heavy chain variable region GTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSPVNINCGGDCD (“HC”) amino acid sequence VAYWGQGTLVTVSS Ab 651 1302 EIVMTQSPSSLSASVGDTVTITCQASQDISYSLNWYQQKPGKAPNLLIFDASHLQTG ADI-41354 Light chain variable region VPSRFSGGGDGKHFSFTISSLQPEDVATYYCQQYDSLMYTFGQGTKVEIK (“LC”) amino acid sequence Ab 652 1303 EVQLVESGGGLVKPGGSLRLSCTASGFTFSDYYMNWIRQAPGKGLEWVSYISGDG ADI-41355 Heavy chain variable region NTIYYTDSVKGRFTISRDNAKNSLFLQMNSLRGEDSAVYYCAGPVRGYTYGIFDYW (“HC”) amino acid sequence GQGALVTVSS Ab 652 1304 YYVLTQPPSVSVAPGQAARITCGGNNIGSRSVNWYQQKPGQAPVVVIYGDSVRPS ADI-41355 Light chain variable region GIPERFSGSNSGNTATLTFSRVEAGDEADYYCQVWETNSDHPVVFGGGTKVTVL (“LC”) amino acid sequence Ab 653 1305 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQATGQGLEWMGWMN ADI-41356 Heavy chain variable region RNNGNTGYARKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARGGDFYAMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 653 1306 SYELTQPPSVSVSPGQTASITCSGDKLGDKYASWYQQKPGQSPVLVIYQDTKRPSG ADI-41356 Light chain variable region VPERFSGSNSGNTATLTISGTQAVDEADYYCQVWDGSIAFGGGTKVTVL (“LC”) amino acid sequence Ab 654 1307 EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYGMNWVRQAPGKGLEWVSYIGGS ADI-41357 Heavy chain variable region GRIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDQHIVLVTGSTPD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 654 1308 EIVLTQSPSSLSASVGDRVTITCRASHAISNYLAWFQQKPGKAPKSLIYAASTLQSGV ADI-41357 Light chain variable region PSKFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 655 1309 EVQLVESGGGLVKPGGSLRLSCEASGFTLTSYSMNWVRQAPGKGLEWVSSISSSST ADI-41358 Heavy chain variable region YIHYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDKVMVTKYNGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 655 1310 QSVLTQPPAVSGAPGQRVTISCTGSSSNIGAGHDVHWYQQLPGTAPKLLIYGNSNR ADI-41358 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAGDEADYYCQSYDSSLSGSLFGGGTKLTVL (“LC”) amino acid sequence Ab 656 1311 EVQLVESGGGLVKPGGSLRLSCAASGFTISGYSMDWVRQAPGKGLEWVSSISSSSS ADI-41359 Heavy chain variable region YIHYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATNPREGGAFDIWGQ (“HC”) amino acid sequence GTTVTVSS Ab 656 1312 QSVLTQPPSMSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYNNSNR ADI-41359 Light chain variable region PSGVPDRFSASKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTRVTVP (“LC”) amino acid sequence Ab 657 1313 EVQLVESGGGLVQPGGSLRLSCAASGLTFSRYSMNWVRQAPGKGLEWVSYISSTG ADI-41360 Heavy chain variable region RRIQYADSVKGRFTISRDDGKNSLYLQMNSLRAEDTAVYYCARDPLNYHDNTAYW (“HC”) amino acid sequence SYWGQGTLVTVSS Ab 657 1314 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRP ADI-41360 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNPLVFGGGTKLTVL (“LC”) amino acid sequence Ab 658 1315 QVQLQESGGGVVQPGRSLRLSCAASGFAFSDYAMDWVRQAPGKGLEWVAVISFD ADI-41361 Heavy chain variable region GSNKFYADSVKGRFTISRDNSENTLFLQMNSLRAEDTAVYYCVRDFVPCSGATCYLP (“HC”) amino acid sequence PVYWGRGTLVTVSS Ab 658 1316 EIVLTQSPATLSVSPGERATLSCRASQSVSSDLAWYQQKPGQAPRLLIYGASTRATGI ADI-41361 Light chain variable region PARFSGSGSGTEFTLTISRLQSEDFAVYFCQQYNNWPSWTFGQGTKVEIK (“LC”) amino acid sequence Ab 659 1317 EVQLVESGGGLVQPGGSLRLSCAASGFTFSDHWMNWVRQTPGKGLEWVANIKP ADI-41362 Heavy chain variable region DGRETYYVDSVKGRFTISRDNSKKSVYLQMNSLRAEDTAVYYCVRDGHIVVVTAVP (“HC”) amino acid sequence PGFFDLWGRGTLVTVSS Ab 659 1318 DIQVTQSPSSLSASVGDRVTITCQASQDLTKYLNWYQQKPGKAPKLLIYDISNLETG ADI-41362 Light chain variable region VPSRFSGSGFGTEFTLTISSLQPEDVATYYCQQYQNLPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 660 1319 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAITWVRQAPGQGLEWMGGIIPLF ADI-41363 Heavy chain variable region GTAKYAQQFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGEVCTNGFCWFL (“HC”) amino acid sequence DWGLGTLVTVSS Ab 660 1320 DIRVTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASKLETG ADI-41363 Light chain variable region VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQNYGNFPHFGGGTKLEIK (“LC”) amino acid sequence Ab 661 1321 EVQLLESGAEVKKPGASVKVSCKASGYTFTDHSIHWVRQAPGRGLEWMGWFNPH ADI-41364 Heavy chain variable region TGVTDYAQKFQGWVTMTSDTSISTAYMELSSLKSDDTAIYFCARDQWETDGAYFL (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 661 1322 QSALTQPASVSGSPGQSITISCTGTSSDVGNFKLVSWYQQHPGKAPKLMIYEGNKR ADI-41364 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSSAVSSTFFGTGTKLTVL (“LC”) amino acid sequence Ab 662 1323 EVQLVESGGGLVKPGGSLRLSCATSGFTFSDYYMTWIRQAPGKGLEWVSYISSSGG ADI-41365 Heavy chain variable region YTNYADSVRGRFTISRDNAKRSLYLQMNSLRAEDTAVYYCARVEFSSGDVPSLFDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 662 1324 QSVLTQPPSVSGAPGQRVTISCTGSSSNLGAGYHVHWYQQFPGTAPKPLIYGNTN ADI-41365 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGVQAEDEADYYCQSYDYSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 663 1325 QVQLVQSGAEVKKPGESLKISCKASGYSSTTYWIGWVRQISGKGLEWMGIIYPGDS ADI-41366 Heavy chain variable region DTRYSPSFQGQVTISADRSTKTAYLQWSSLKASDTAMYYCGTSGFGVATPFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 663 1326 NFMLTQPHSVSESPGKTVTISCTRTSGSIAGNYVHWYQQRPGSAPTTVIYEDNQRP ADI-41366 Light chain variable region SGVPDRFSGSIDRSSNSASLTISGLKTEDEADYYCQSYASGIHGVFGGGTKVTVL (“LC”) amino acid sequence Ab 664 1327 QVQLVQSGAAVKRPGASVKVSCKASGYTFSTNALHWVRQAPGQSLEWMGWINT ADI-41367 Heavy chain variable region DNGIPKYSERFHGRVTFTRDTSASTVYMDLSGLRSGDTAVYYCARDGSSGHWLGLS (“HC”) amino acid sequence VLDNWGQGTLVTVSS Ab 664 1328 QSALIQPASVSGSPGQSITISCTGTSDDVGAYNYVSWYQQYPNKAPKLVIYEVSHRP ADI-41367 Light chain variable region SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTRSATPYVFGTGTKLTVL (“LC”) amino acid sequence Ab 665 1329 EVQLVESGGGVVQPGRSLRLSCAASGFIFRNYGMHWVRQAPGKGLEWVAGTSFE ADI-41368 Heavy chain variable region GRNKDYGHSVKGRFTISRDNSKDTLYLQMNSLRPEDTAVYSCAKGSSLQWSHLDW (“HC”) amino acid sequence YFDLWGRGTLVTVSS Ab 665 1330 DIVMTQSPSTLSASVGDRVTITCRASQSFSSWLAWYQQKPGKAPNLLIYDASTLESG ADI-41368 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQERTFGQGTKVEIK (“LC”) amino acid sequence Ab 666 1331 EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISHD ADI-41369 Heavy chain variable region GNNKYYGDSVKGRFTISRDNSKNTLHLQMNSLRGDDTAVYYCGKDPLKGDCSGGS (“HC”) amino acid sequence CYQRIDYWGQGTLVTVSS Ab 666 1332 NFMLTQPHSVSESPGKTVTISCTGSSGRIASNYVQWYQQRPGSAPATVIYDDNQRP ADI-41369 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDRSNHVIFGGGTKLTVL (“LC”) amino acid sequence Ab 667 1333 EVQLVESGGGLVKPGGSLRLSCAASGFTFSGFSMNWVRQAPGKGLEWVSSISSTSR ADI-41370 Heavy chain variable region YIYYADSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDPGGSASFVPYYYG (“HC”) amino acid sequence MDVWGQGATVTVSS Ab 667 1334 SYELIQPPSVSVSPGQTARITCSGDALPNQYVYWYQKKPGQAPVLVIYKDTEGPLGI ADI-41370 Light chain variable region PERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYPYVVFGGGTKLTVL (“LC”) amino acid sequence Ab 668 1335 QVQLQESGPRLVKPSQTLSLTCTVSGGSITTGEHYWSWIRQSPGRGLEWIGYISYSG ADI-41371 Heavy chain variable region STYYNPSLKSRVTISVDTSKTRISLNLRSVTAADSAVYYCARDQEDSDYIWGSSRVFDI (“HC”) amino acid sequence WGQGTMVTVSS Ab 668 1336 ETTLTQSPGTLSLSPGERATLSCRASQNVGNNYLAWYQQKPGQAPRVLIQDASTRA ADI-41371 Light chain variable region TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYHCQQYGSAPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 669 1337 QVQLVQSGAEVKKPGSSVKVSCKASGGISSSYAISWVRQAPGQGLEWMGGIIPIFG ADI-41372 Heavy chain variable region TTNYAQKFQGRVTITADKSTSTVYMELSSLRSEDSAVYFCARAYCSGGTCYGGADY (“HC”) amino acid sequence WGQGTLVTVSS Ab 669 1338 SYELTQPPSVSVSPGQTARITCSGDVLPKQYAYWYQQKLGQAPLLVMYKDTERPSG ADI-41372 Light chain variable region IPERFSGSSSVTAVTLTISGVQAEDEADYYCQSADSTQELFGGGTKLTVL (“LC”) amino acid sequence Ab 670 1339 QVTLKESGGGLVKPGGSLRLSCAASGFTFSDYFMTWIRQAPGKGLEWVSYISSNSG ADI-41373 Heavy chain variable region YTKYAEDVKGRFSISRDNAKKTLFLQLNSLSAEDTAVYYCARVEFSSGDVPSLFDLW (“HC”) amino acid sequence GQGTLVTVSS Ab 670 1340 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYHVHWYQQLPGTAPKVLIHGNNN ADI-41373 Light chain variable region RPSGVPDRFSGSRSGTSASLAITGLQAEDEADYYCQSYDFSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 671 1341 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNHAIDWVRQAPGQGLEWMGRIIPM ADI-41374 Heavy chain variable region VGLATYTRKFQGRVTISVDKSTSTAYMELSSLISDDTAVYYCARRTPEMAWGYWG (“HC”) amino acid sequence QGTTVTVSS Ab 671 1342 DIVMTQTPSSLSASVGDRVTITCQASQDIRYYVNWYQQKPGKAPKLLIYDASTLETG ADI-41374 Light chain variable region VPSRFSGRGSGTDFTLIISSLQPEDIATYYCQQYGDLPTFGQGTRLEIK (“LC”) amino acid sequence Ab 672 1343 QVQLVQSGGGVVQPGRSLRLSCATSGFTFSDYAIHWVRQAPGKGLEWVAVISYDG ADI-41375 Heavy chain variable region SHKYYGDSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCARSRSGSYYSSAIDNW (“HC”) amino acid sequence GQGTLVTVSS Ab 672 1344 DIQMTQSPSSLSASVGDRVTIACRASQGISSALAWYRQRPGKAPELLIYDASTLESG ADI-41375 Light chain variable region VPSRFSGYGAGTDFTLTISSLQPEDFATYYCQQFNSYPSITFGQGTKVEIK (“LC”) amino acid sequence Ab 673 1345 QVQLQESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISFD ADI-41376 Heavy chain variable region GTANKYYADSVKGRFAISRDNSKNTLYLQMNSLRAEDTAVYYCAKDDAIYSGGWV (“HC”) amino acid sequence GDAFDLWGQGTMVTVSS Ab 673 1346 EIVLTQSPATLSVSPGERATLSCRASQGVNSNLAWYQQKPGQAPRLLMYGASTRAT ADI-41376 Light chain variable region GIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVDIK (“LC”) amino acid sequence Ab 674 1347 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSDSATWNWIRQSPSRGLEWLGRAYY ADI-41377 Heavy chain variable region RSKWYYDYAPSVKSRLTINPDTSKNQFSLQLTSVTPQDTAVYFCARDLPPLEYFDGS (“HC”) amino acid sequence GYYFLDHWGQGTLVTVSS Ab 674 1348 SYELTQPPSVSVAPGQTARLSCGGHNIGSKSVQWYQQKPDQAPVLVVYDDHDRPS ADI-41377 Light chain variable region GIPDRFSGSNSGDMATLTISRVEAGDEADYYCQVCESGRDPMVFGGGTKVTVL (“LC”) amino acid sequence Ab 675 1349 EVQLVESGPGLVKPSGTLSLTCAVSGDSISSSNWWSWVRQPPGKGLEWIGEVSHS ADI-41378 Heavy chain variable region GNTDYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARPSPCSGGSCYWFFD (“HC”) amino acid sequence LWGRGTLVTVSS Ab 675 1350 DIRLTQSPSSLSASVGDRVTITCRASQTINAYLNWYQQRPGKAPNLLIYAASSLQSGV ADI-41378 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYKTAYTFGQGTKVEIK (“LC”) amino acid sequence Ab 676 1351 QVQLVQSGAEVKKPGESLKISCKGSGYSFSSFWIGWVRQMPGKGLEWMGIIYPGD ADI-41379 Heavy chain variable region SDTRYSPSFKGQVTISADTSISTAYLQWSSLKASDTAMYYCAKSIVGSTGSFDPWGQ (“HC”) amino acid sequence GTLVTVSS Ab 676 1352 DIQMTQSPSSLSASVGDRVTITCQASQDISNFLNWYQQKPGKAPKLLIYDASNLRT ADI-41379 Light chain variable region GVPSRFSGSGSGTEFTFTISSLQPEDIATYYCQQYHDLPPLTFGGGTKVDIK (“LC”) amino acid sequence Ab 677 1353 QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGD ADI-41380 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCASSRAYYDILTGYYVAS (“HC”) amino acid sequence AETQTKAAFDIWGQGTTVTVSS Ab 677 1354 DIQVTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETG ADI-41380 Light chain variable region VPSRFSGSGSGTDFSFTISSLQPEDIATYYCQQYDNLITFGQGTKVEIK (“LC”) amino acid sequence Ab 678 1355 QVQLQESGPGLVKPSQTLSLTCTVSGDSISGGEHYWSWIRQPPGKGLEWIGSIYYS ADI-41381 Heavy chain variable region GTTYYNPSLKSRLTVSVDTFKNQFSLMLSYVTAADTAVYYCARDASPAYHDYIWGS (“HC”) amino acid sequence CRYFDKWGQGTLVTVSS Ab 678 1356 EIVLTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRILIHGASSRATG ADI-41381 Light chain variable region IPDRFSGSGSGTDFTLTVSRLEPEDFAVYYCQQYGSTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 679 1357 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWS ADI-41382 Heavy chain variable region GDTRGYAESVKGRFTITRDNAKKYLYLQMNSLRAEDTAFYYCAKDAYYFGSGNEKF (“HC”) amino acid sequence YYGMDVWGQGTTVTVSS Ab 679 1358 DIVLTQTPATLSVSPGERATLSCRASQNVISNLAWYQQKPGQAPRLLIYGASTRATGI ADI-41382 Light chain variable region PARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPQTFGQGTKVEIK (“LC”) amino acid sequence Ab 680 1359 QVQLVQSGAEVKKPGSSVRVSCKASGGTFSRYAISWVRQAPGQGLEWMGGVIPR ADI-41384 Heavy chain variable region FDKTNYAQKFQGRVMITADKSTSTAYMELSSLRSDDTAVYYCAGDRLDTKITHTWY (“HC”) amino acid sequence GFGDFWGQGTTVTVSS Ab 680 1360 EIVLTQSPGTLSLSPGERATLSCRASQSVTSNFLAWYQQRPGQAPRLLIYGASVRAID ADI-41384 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGDPFRTFGQGTKVEIK (“LC”) amino acid sequence Ab 681 1361 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYD ADI-41385 Heavy chain variable region GNNEKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARPTQKYSSSWYW (“HC”) amino acid sequence EDSIDYWGQGTLVTVSS Ab 681 1362 QSVLTQPPSVFGAPGQRVTISCTGSSSNIGAGYPVHWYQQLPGTAPKLLIYGNSNR ADI-41385 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 682 1363 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGNYIHWVRQAPGQGLEWMGGINP ADI-41386 Heavy chain variable region NSGATNYARKFQGRISMTRDTSINTAYMEVSSLRSDDTATYYCARDAPPVVIPAAIH (“HC”) amino acid sequence WFDAWGQGTLVTVSS Ab 682 1364 SYELTQPPSASGTPGQRVTISCSGSSSNIGRNTVNWYQQFSGTAPRLLIYRTNQRPS ADI-41386 Light chain variable region GVPDRFSGSKSGTSASLVISGLQSEDEADYYCASWHDTLNDVVFGGGTKLTVL (“LC”) amino acid sequence Ab 683 1365 EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAIHWVRQAPGKGLEWVAAISYDG ADI-41389 Heavy chain variable region GNKFYADSVKGRFTISRDNSRNTLYLQMNSLRPEDTAVYYCARDRWELNYGIDVW (“HC”) amino acid sequence GQGTTVTVSS Ab 683 1366 SYELMQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSG ADI-41389 Light chain variable region IPERFSGSTSGTTVTLTISGVQAEDEADYYCQSADSSSTFFYVFGTGTKLTVL (“LC”) amino acid sequence Ab 684 1367 EVQLVESGGGLVKPGGSLRLSCAASGFSSSSYFMNWVRQAPGKGPEWVSSISGSSS ADI-41390 Heavy chain variable region FINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAVLPAGVGGYWFDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 684 1368 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQHLPGRAPKLLIYGNSNR ADI-41390 Light chain variable region PSGVPDRFSGSKSGTSASLVITGLQAEDEADYCCQSYDSSLSGAVFGGGTQLTVL (“LC”) amino acid sequence Ab 685 1369 EVQLLESGPGLVKPSETLSLTCTVSGGSISGYYWSWIRQPPGKGLEWIGYIYHSGGST ADI-41391 Heavy chain variable region NYNPSLKSRVTISVDTSKNQFSLKVSSVTAADTAVYYCARLARVVTTFDFWGQGAL (“HC”) amino acid sequence VTVSS Ab 685 1370 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQKPGTAPKLMIFDVSNR ADI-41391 Light chain variable region PSGVSNRFSGSKSDNTASLTISGLQAEDEADYYCSSYTSSTNLVFGGGTKLTVL (“LC”) amino acid sequence Ab 686 1371 EVQLVESGGGVVQPGGSLRLSCAASGFEFRDYAMHWVRQAPGKGLEWVALISYD ADI-41392 Heavy chain variable region GSKIHYADSVQGRFSISRDNSKNSLYLQMNSLRSEDSAKYYCVQDHWLVPAFWGQ (“HC”) amino acid sequence GAQVTVSS Ab 686 1372 QPVLTQPASVSGSPGQWITISCTGTSSDIGYYDYVSWYQQYPGKAPKLIIYEVSHRPS ADI-41392 Light chain variable region GVSNRFSGSKSGNTASLSISGLQAEDEADYYCSSYTTSNAGVFGTGTKLTVL (“LC”) amino acid sequence Ab 687 1373 QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGD ADI-41393 Heavy chain variable region SDTRYSPSFQGQVTISADKSTSTAYLQWSSLKASDSAMYYCARSEFSSSFDFWGQG (“HC”) amino acid sequence TLVTVSS Ab 687 1374 NFMLTQPHSVSESPGKTVTISCTGSSGSIASYYVQWYQLRPGSAPTTVIYEDNQRLS ADI-41393 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYRSGIPWVFGGGTKLTVL (“LC”) amino acid sequence Ab 688 1375 QVQLVQSGAEVKKPGSSVKVSCKASGGTFNTYAISWVRQAPGQGLEWMGGIIPIL ADI-41394 Heavy chain variable region GVSNYAQRFQGRVTFSADELTNTAYMELSSLRSEDTAVYFCARPVGAYTLGDAFEI (“HC”) amino acid sequence WGRGTTVTVSS Ab 688 1376 QPVLTQSSSASASLGSSVKLTCTLSSGHSDFIIAWHQQQPGKAPRYLMKFEGNGRY ADI-41394 Light chain variable region SKGSGIPDRFSGSSSGADRCLTISNLQSEDEADYYCETWDSNTHVVFGGGTKLTVL (“LC”) amino acid sequence Ab 689 1377 EVQLVESGGGLVNPGGSLRLSCVVSGFAFSSYGMNWVRQAPGKGLEWVSSISASS ADI-41396 Heavy chain variable region SYIDYADSVKGRFIISRDNAKNSLHLQMNSLRAEDTAVYYCARLGYDSSTYYTNWFD (“HC”) amino acid sequence PWGRGTLVTVSS Ab 689 1378 QSVVTQEPSVSGAPGQRVTISCTGSSSNIGTGYDVHWYQQLPGAAPKLLIYGNSNR ADI-41396 Light chain variable region PSGVPDRISGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 690 1379 EVQLVESGGGLVKPGGSLRLSCAASGFKFSSYYLNWVRQAPGKGLEWVSSISGGSS ADI-41397 Heavy chain variable region YINYADSVKGRFTISRDNAKNTLDLQMSNLRAEDTAVYYCARVVGATGPLYFDLWG (“HC”) amino acid sequence RGTLVTVSS Ab 690 1380 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQFPGTAPKLLIYGNNNR ADI-41397 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGAGTKVTVL (“LC”) amino acid sequence Ab 691 1381 EVQLLESGAEVKKPGASVKVSCKASGYTFTNYGISWVRQAPGQGLEWMGWISAY ADI-41398 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDGGVIAAATLG (“HC”) amino acid sequence YWGQGTLVTVSS Ab 691 1382 EIVLTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLSWFQQRPGQSPRRLIYKISNR ADI-41398 Light chain variable region DSGVPNRFSGSGSGTDFTLKISRVEAEDVGIYYCMQGIYWPPTFGQGTKVEIK (“LC”) amino acid sequence Ab 692 1383 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTFAIHWVRQAPGQRLEWMGWINA ADI-41399 Heavy chain variable region GNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARPEISSSSLNEKDD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 692 1384 QPVLIQPASVSGSPGQSITISCTGTSSDVGAYDFVSWYQQHPGKAPKFMIYEVSHR ADI-41399 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSNTLVFGGGTKLTVL (“LC”) amino acid sequence Ab 693 1385 EVQLLESGGGLIQPGGSLRLSCAASKFTFSDYEMNWVRQAPGKGLEWLSYISSSGGI ADI-41400 Heavy chain variable region MYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYFCARAGRLLSGLDVWGHG (“HC”) amino acid sequence TTVTVSS Ab 693 1386 EIVLTQSPSTLSASVGDRVTITCRASQSISPWLAWYQQKPGKAPKLLIYRASSLETGV ADI-41400 Light chain variable region PPRFSGSGSGTEFTLTISSLQPDDFATYYCQHYNSYLYSFGQGTKVEIK (“LC”) amino acid sequence Ab 694 1387 EVQLLESGGGLVHPGRSLRLSCAASGFTFGDYAMHWVRQAPGKGLEWVSGISWN ADI-41401 Heavy chain variable region SDTIEYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDFGSSWEAYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 694 1388 DIVLTQSPSYLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLISAASSLQSGVT ADI-41401 Light chain variable region SRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSTALTFGGGTKVEIK (“LC”) amino acid sequence Ab 695 1389 EVQLVESGGGLVKPGGSLRLSCAASGFTFGTYTMNWVRQAPGKGLEWVSSISSSSS ADI-41403 Heavy chain variable region HIYYADSVKGRFTISRDNARKALYLQMNSLRPEDTAVYFCARFLGDYGGDGNTYYY (“HC”) amino acid sequence YYGMDVWGQGTTVTVSS Ab 695 1390 EIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGKNYLDWYLQKPGQSPQLLIHLGS ADI-41403 Light chain variable region NRASGVPDRFSGSGSGTDFTLQISRVEAEDVGVYYCMQALQTPTFGGGTKLEIK (“LC”) amino acid sequence Ab 696 1391 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIF ADI-41404 Heavy chain variable region GTVSYAQKFRGRLTITAHEPTSTAYMDLSSLRSEDTAVYYCARINGRGWELSSLNYY (“HC”) amino acid sequence YGMDVWGQGTTVTVSS Ab 696 1392 EIVLTQSPGTLSLSPGERGTLSCRASQSVASSYLAWYQQKPGQAPRLLIYGATSRATG ADI-41404 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSLFTFGGGTKVDIK (“LC”) amino acid sequence Ab 697 1393 EVQLLESGGGLVQPGGSLRLSCAASGFSFSIYSMNWVRQAPGKGLEWISYITSTGSP ADI-41405 Heavy chain variable region TYYADSVKGRFTISRDNAKNSLYLQMSSLRAEDTAVYYCVTYCSSSSCPAEFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 697 1394 EIVLTQSPATLSLSPGERATLSCRASQSVNSYLAWYQQKPGQAPRLLIYDASNRATGI ADI-41405 Light chain variable region PARFSGSGSGTDFTLTISSLEAEDFAVYYCQHRNNWPALTFGGGTKVEIK (“LC”) amino acid sequence Ab 698 1395 EVQLVESGGNLVQPGGSLRLSCAASGFTFSSYVMNWVRQAPGKGLEWVSGISGS ADI-41406 Heavy chain variable region GGTSYYADSVKGRFTISRDNSNNTLYLQMKSLRAEDTAVYYCAKDPRFQKWLIEGT (“HC”) amino acid sequence NWFDSWGQGTLVTVSS Ab 698 1396 DIQVTQSPSSLSASVGDRVTITCRASQDVSNYLAWFQQKPGTAPKSLIYAASILQSG ADI-41406 Light chain variable region VPSKFRGSGSGTDFSLTISSLQPEDFATYYCQQYRSFPPTFGGGTKVEIK (“LC”) amino acid sequence Ab 699 1397 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSNAMSWVRQAPGKGLEWVSYISGGS ADI-41407 Heavy chain variable region ATKSYADSVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCVGGSAYYSGFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 699 1398 DIVMTQSPSSLSASVGDRVTISCRASQDIRNYLAWYQQKPGKVPNLLIYAASTLESG ADI-41407 Light chain variable region VPSRFSGSGYGTDFTLTISGLQPEDVATYYCQKYDSAPPFTFGPGTKVDIK (“LC”) amino acid sequence Ab 700 1399 QVQLVESGAEVKKPGESLKISCRDSGYSFSSFWIGWVRQMPGKGLEWVGIIYPGDS ADI-41408 Heavy chain variable region DIRYSPSFQGRVTISADKSISTAYLQWRSLKASDSAMYYCARSEKLGSFDRWGQGTL (“HC”) amino acid sequence VTVSS Ab 700 1400 DIQMTQSPSSLSASVGDRVTITCQANRDISNCLNWYQQRPGKAPELLIYDASYLETG ADI-41408 Light chain variable region VPSRFTGSGSGTDFTFTISSLQPEDIATYYCQQYDNLLFTFGPGTKVEIK (“LC”) amino acid sequence Ab 701 1401 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGISWVRQAPGQGLEWMGWISA ADI-41409 Heavy chain variable region YNGNTNYAQKFQDRVTMTTDTSTSTAYMELRSLRYDDTAVYYCARDTPGEYASA (“HC”) amino acid sequence MFDHWGQGTLVTVSS Ab 701 1402 DIVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLSWFQQRPGQSPRRLIYKVS ADI-41409 Light chain variable region NRDSGVPDRFSGSGSGTDFTLKISGVEAEDVGVYYCMQGTHWPPTFGQGTKLEIK (“LC”) amino acid sequence Ab 702 1403 EVQLLESGGGLAQPGRSLKVSCAASGVTVTSTYMGWVRQAPGKGLQWVSVIYSD ADI-41414 Heavy chain variable region GTTYYADSVKGRFTISRDHYKNTLYLQMNSLRAEDTALYYCARGNRRTDFGYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 702 1404 EIVMTQSPSTLSASVGDRVTITCRASQTISNWLAWYQQKPGKAPKLLIYQASTLESG ADI-41414 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYYTFGPGTKVEIK (“LC”) amino acid sequence Ab 703 1405 QVTLKESGPALVKPTQTLTLICTFSGFSLSTSRTRVSWIRQPPGKALEWLARVDWD ADI-41415 Heavy chain variable region DDKFYNPVLKTRLSISKDPSKNQVVLTMTNVDPVDTATYYCVRMAHYGSGGYYVE (“HC”) amino acid sequence YFQDWGQGTLVTVSS Ab 703 1406 DIQLTQSPASLSASAGDRVTITCRASQNINRYLNWYQQQSGKAPKLLIYAASILQSG ADI-41415 Light chain variable region VPSRFSGSGSGTDFTLTITSLQPEDFAIYYCQQSYTTPKYTFGQGTKVEIK (“LC”) amino acid sequence Ab 704 1407 EVQLVESGGGLVKPGGSLRLSCAASGFKFSSYTMNWVRQAPGKGLEWVSSITGGS ADI-41416 Heavy chain variable region SFINYADSVKGRFTISRDNAKNSLYLQMVSLRAEDTAVYYCARDLSSHITIFGAVSDY (“HC”) amino acid sequence WGRGTTVTVSS Ab 704 1408 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDAHWFQQLPGSAPKLLIYANTNR ADI-41416 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSTLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 705 1409 QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISAGS ADI-41417 Heavy chain variable region SYIYYADSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVNTHYYDSSAYHNF (“HC”) amino acid sequence DSWGQGTLVTVSS Ab 705 1410 QPVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNR ADI-41417 Light chain variable region PSGVPERFSGSKSGTSASLAITGLQAEDEADYYCQSYDTNLSAPWVFGGGTKLTVL (“LC”) amino acid sequence Ab 706 1411 EVQLVESGGGLVKPGGSLRLSCAASGLSFTDAWMGWVRQAPGKGLEWVGHIKKK ADI-41418 Heavy chain variable region TDYGPTAYAAPVRGRFTVSRDDSKNTLYLQMTSLKTEDTAVYYCITERGYNFGYND (“HC”) amino acid sequence YFGVDVWGQGTLVTVSS Ab 706 1412 QPGLTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVMIIYEDNKRPSG ADI-41418 Light chain variable region IPERFSGSTSGTMATLTISGAQMEDEADYYCFSTDSGDDQSGVFGGGTRLTVL (“LC”) amino acid sequence Ab 707 1413 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW ADI-41419 Heavy chain variable region NSGSVGYSDSVKGRFTISRDNAKSSLYLQMNNLRAEDTALYYCARDMAHTQDYFD (“HC”) amino acid sequence TSEYDSWGQGTLVTVSS Ab 707 1414 QPVLTQPASVSGSPGQSITISCTGTSSDIGAYNYVSWYQQHPGKAPKLVVYEVNNR ADI-41419 Light chain variable region PSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTVSATLVFGGGTKLTVL (“LC”) amino acid sequence Ab 708 1415 EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDG ADI-41420 Heavy chain variable region SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVPCSSTSCYTTDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 708 1416 QPVLTQPPSVSGSPGQSVTISCTGTSSDVGSYNRVSWYQQPPGTAPKLMIYEVSNR ADI-41420 Light chain variable region PSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSPVFGGGTKVTVL (“LC”) amino acid sequence Ab 709 1417 QVQLVESAAEVKRPGASLKVSCKASGYTFIDYDISWVRQAPGQGLDWMGWISTY ADI-41421 Heavy chain variable region DGSAKYPENLQARVAMTTDTSTSTAYMELESLTSDDTAVYYCARARRGSSGWVST (“HC”) amino acid sequence TGPTPFFDYWGRGTLVTVSS Ab 709 1418 SYELTQPPSVSVSPGQTARITCSGDALPKRYAYWYQQKSGQAPVLVIYEDNKRPSGI ADI-41421 Light chain variable region PERFSGSSSGTVATLTISGAQVEDEADYSCYSTDATGNHRGLFGGGTKLTVL (“LC”) amino acid sequence Ab 710 1419 QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-41423 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDPSSSWNRNDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 710 1420 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-41423 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVVFGGGTKVTVL (“LC”) amino acid sequence Ab 711 1421 QVQLVQSGAEVREPGASVKVSCKPSGYTFANYGISWVRQAPGQGLEWMAWISAY ADI-41424 Heavy chain variable region NGNTNYAPKVQGRVSVTTDSSTGIGYMELRSLRSDDTAVYYCVRDTPAIAGAATLD (“HC”) amino acid sequence FWGQGTLVTVSS Ab 711 1422 DIVLTQSPLSLAVTPGQSASISCRSRQSHVFSDGNTYVSWFQQRPGRSPRRLIYRVSY ADI-41424 Light chain variable region RDSGVPDRFSGSGSGSDFTLRISRVEAEDVGVYYCMQGTHWPRTFGQGTKLEIK (“LC”) amino acid sequence Ab 712 1423 EVQLLESGPAVVKPTQTLTLTCTVSGLSLSSPRMSVSWIRQPPGKGLEWLARIDWD ADI-41425 Heavy chain variable region GDKYYGTSLKTRLSISKDTSKNQVVLTMTNMDPVDTGTYYCAQTSIYASNAYYLARL (“HC”) amino acid sequence DPWGQGMLVTVSS Ab 712 1424 EIVMTQSPSLLSASVGDRVTITCRASQNIATYLNWYQQKPGKAPRLLIYAASNLQSG ADI-41425 Light chain variable region VPSGFSGSGSGTVFTLTISSLQPEDFATYFCQQSYETSLTFGGGTKVEIK (“LC”) amino acid sequence Ab 713 1425 QVQLVESGPGLVKPSETLSLTCTVSGGSIGGYYWSWIRQPPGKGLEWIGYMYYSGS ADI-41427 Heavy chain variable region TNYNPSLKSRVIMSVDTSKNQFSLKLTSVTAADTAVYYCARVLRFLVGGMDVWGQ (“HC”) amino acid sequence GTTVTVSS Ab 713 1426 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLIIYEVSNRPS ADI-41427 Light chain variable region GVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTTIATLVFGTGTKVTVL (“LC”) amino acid sequence Ab 714 1427 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIF ADI-41429 Heavy chain variable region GTVNYAQKFPGRVTITADESTSTAYMELSSLRSEDTAIYYCARDSPSYTGSLLFSQYYY (“HC”) amino acid sequence GMDVWGQGTTVTVSS Ab 714 1428 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYDYVSWYQHHPGKAPKLMIYEVSNR ADI-41429 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSFTTSSPRVFGTGTKLTVL (“LC”) amino acid sequence Ab 715 1429 QVQLVQSGAEVKKPGASVRVSCTASGYRFFTYGITWVRQAPGQGLEWMGWISAY ADI-41431 Heavy chain variable region NGNTKFAQKFQGRLTMTTDAPTSTADMELRGLRSDDTAVYYCAREEGGYHGTGS (“HC”) amino acid sequence NNYWGQGTLVTVSS Ab 715 1430 QSVLTQPPSVSAAPGQKVTISCSGSGSNVGGNDVSWYQQFPGTAPKLLIYDNSKRP ADI-41431 Light chain variable region SGIPDRFSGSKSGTSATLVITGLQTGDEADYYCGTWDSSLSVGVFGTGTKLTVL (“LC”) amino acid sequence Ab 716 1431 QVQLVQSGAEVKKPGYSVKVSCKASGGTFSTFGISWVRQAPGLGLEWMGGIIPLF ADI-41432 Heavy chain variable region GTADYSKKYQGRVTITADESTSTGYMELNSLTPEDTAVYYCARSPGHLWSRYDAFE (“HC”) amino acid sequence VWGQGTTVTVSS Ab 716 1432 QPVLTQPRSVSGSPGQSVTISCSGTSSDVGGYNYVSWYQQYPGKAPKLIIYDVNKR ADI-41432 Light chain variable region PSGVPDRFSGSKSDNTASLTISGLQADDESDYFCCSYAGSHTFEVFGTGTKVTVL (“LC”) amino acid sequence Ab 717 1433 EVQLLESGGGAVQPGRFLRLSCAASGFTFRSYGMHWVRQAPGKGLEWVAVISYD ADI-41433 Heavy chain variable region GSDKYYADSVKGRFTISRDNSKNTLFLLMNGLRAEDAAVYYCAKDIASAGTLRGSDV (“HC”) amino acid sequence WGQGTMVTVSS Ab 717 1434 QPVLTQPRSVSGSPGQSVTISCTGTSSDVGGFNYVSWYQQHPGKAPKLMIYDVRV ADI-41433 Light chain variable region RPSGVPDRFSGSKSGNTASLTISGLQGEDEADYYCCSYTVTYTLVFGGGTKLTVL (“LC”) amino acid sequence Ab 718 1435 EVQLVESGGGLVQPGRSLRLSCEASGFTFDDYAMHWVRQTPGKGLEWVSGISWN ADI-41434 Heavy chain variable region SGSIVYADSVKGRFTISRDNAKNSLYLQMHSLRPEDTALYYCAKDNYTFGNYYYYYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 718 1436 EIVLTQSPVTLSVSPGERATLSCRASQNVISNLAWYQQKPGQAPRLLIYGASTRATGI ADI-41434 Light chain variable region PARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLSFGGGTKVEIK (“LC”) amino acid sequence Ab 719 1437 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSLNWVRQAPGKGLEWVSSISSSGTY ADI-41435 Heavy chain variable region IFYADSVKGRFTISRDNAKDSLFLQMNSLRAEDTAVYYCARARDMGNYDILTGYYR (“HC”) amino acid sequence VDAFDIWGQGTMVTVSS Ab 719 1438 QSVLTQPPSASKTPGQRVTISCSGSSSNIGGNTVNWYQQLPGTAPKLLIYTNDQRPS ADI-41435 Light chain variable region GVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 720 1439 EVQLLESGGGVVQPGRSLRLSCAASGFTFSDYAMHWVRQAPGKGLEWVALISFDG ADI-41436 Heavy chain variable region SNEYYADSVKGRFTISRDNSRNTVYLQVNTLRPDDTAVFYCARDSHLRLTTRGWGS (“HC”) amino acid sequence FDYWGQGTLVTVSS Ab 720 1440 NFMLTQPHSVSESPGKTVTIACTRSSGSIARNYVQWYQQRPGRSPTMVIYEDNQR ADI-41436 Light chain variable region PSGVPDRFSGSIDTSSNSASLTISGLKTEDEADYYCQPYDPDNLVFGGGTKLTVL (“LC”) amino acid sequence Ab 721 1441 QVQLVQSGGEVKKPGASVKVSCKASGYTFTHYGISWARQAPGQGIEWMGWINV ADI-41437 Heavy chain variable region HNGNTEYAQRFQGRVTMTTDTSTNTAYMEMTSLTSDDTAVYYCARDKIVVVVVP (“HC”) amino acid sequence NYHGMDVWGQGTLVTVSS Ab 721 1442 EIVLTQSPDSLAVSLGERATINCKSSQSVLYRANNRNYLAWYQQKPGQPPKLLIYWA ADI-41437 Light chain variable region STRESGVPDRFSGSGSGTDFTLTISSLQAEDVALYYCHQYHSSPRTFGQGTKVDIK (“LC”) amino acid sequence Ab 722 1443 QVQLVQSGAEMRRPGSSVRLPCKASGYTFVSHTIVWVRQAPGQGLEWMGGIIPS ADI-41438 Heavy chain variable region LRTPNYAQNFQDRLTITADESARTAYMELSSLTSNDTAVYYCARETFQGGYYLDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 722 1444 EIVMTQSPGTLSVSPGDTAALSCRASQSVGRNLAWYQQKPGQAPRLLIFGASTRAA ADI-41438 Light chain variable region DIPGRFSGSGSGTEFTLTITSLQSEDFAVYYCQQYNKWPPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 723 1445 QVQLVQSGTEVKNPGASVKVSCKASGYTFSNYGITWVRQAPGQGLEWMAWISAY ADI-41439 Heavy chain variable region NGNILYAQNVQGRVTMTTDTSTSTGYMELRSLRSDDTAVYYCARDAPAGTLILLDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 723 1446 DIVMTQTPLSLPVTLGQPASISCRPSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVS ADI-41439 Light chain variable region NRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQGSHWPYAFGQGTKVEIK (“LC”) amino acid sequence Ab 724 1447 EVQLVESGGGLVKPGGSLRLSCAVSGFTFSDYTMNWVRQAPGKGLEWVSSISGSG ADI-41440 Heavy chain variable region TYIYYGDSVKGQFTISRDNAKNSLYLQMNSLRAEDTAVYYCARELPAKTIFGVDFLG (“HC”) amino acid sequence GTTAYDCWGQGTPVTVSS Ab 724 1448 EIVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSATTRATG ADI-41440 Light chain variable region VPARFSGSGSGTEFTLTISSLRSEDFAVYYCQQYNNGGTFGPGTKVEIK (“LC”) amino acid sequence Ab 725 1449 EVQLVQSGPGLVKPSETLSLICSVSGASISRYHYYWGWIRQSPGKGLEWIGTIYYSG ADI-41441 Heavy chain variable region TTYYNPSLESRVTISADTSKNQVSLKLTSVTAADTAVYYCARGSGDTALDFSFEYWG (“HC”) amino acid sequence QGALVTVSS Ab 725 1450 DIQLTQSPSFLSASVGDRITITCRASQGISNSLAWYQQKPGKAPKLLIYAASTLQFAV ADI-41441 Light chain variable region PSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLDSYPLTFGGGTKLEIK (“LC”) amino acid sequence Ab 726 1451 EVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWH ADI-41442 Heavy chain variable region SGSIVYADSVKGRFTISRDNAKNSLYLQMSSLRAEDTALYYCVKDHYNWNDNPHFH (“HC”) amino acid sequence YGLDVWGQGTTVTVSS Ab 726 1452 EIVLTQSPATLSVSPGERATLSCRASQSVISNLAWYQQKPGQAPRLFIYGASTRATGI ADI-41442 Light chain variable region PARFSGSGSGTEFTLTISSLQSEDFAVYFCQQYNNWPITFGQGTRLEIK (“LC”) amino acid sequence Ab 727 1453 EVQLVESGGGVVQPGKSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVSVIWYE ADI-41443 Heavy chain variable region DSDKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARKSGGFGGLDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 727 1454 DIVMTQSPLSLPVTPGEPASISCKSSQSLLTANGYNYLDWYVQKPGQSPHVLISLGS ADI-41443 Light chain variable region NRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQAIETPITFGQGTRLEIK (“LC”) amino acid sequence Ab 728 1455 EVQLVESGPRLVKPSQTLSLTCTVSGGSIGTGDYHWTWIRQSPGKGLEWIGNIYYN ADI-41444 Heavy chain variable region GRTFYNPSLKGRGSISRDASKNQFSLNLSSVSAADTAVYYCARDRAAKGFDHWGQ (“HC”) amino acid sequence GTLVTVSS Ab 728 1456 DIQLTQSPSTLSASVGDRVTITCRASQNINGWLAWYQQKPGRVPKLLIYKASTLESG ADI-41444 Light chain variable region VPSRFSGSASGTEFTLTINNLLPDDFATYYCQQYNDYPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 729 1457 QVQLVQSGAEVKRPGSSVKVSCKAFGGSFSNYAINWVRQAPGQGLEWMGGISPV ADI-41445 Heavy chain variable region LGTAIYAKRFQGKVTITADKFANTAYMDLSSLRFEDTAVYYCARSPPHVEFPLTKWF (“HC”) amino acid sequence DPWGQGTLVTVSS Ab 729 1458 EIVMTQSPGTLSLSPGERATLSCRASQSVNSGYLAWYQHKPGRAPRLLIYGASNRAT ADI-41445 Light chain variable region GVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDNSLFTFGPGTKVDIK (“LC”) amino acid sequence Ab 730 1459 EVQLLESGGGLVQPGGSLRLSCAASGFTYYSYAMNWVRQAPGKGLEWVSAISGG ADI-41446 Heavy chain variable region GDNTFYAESVKGRFTISRDNAKNTLYLQMDSLRAEDTAVYYCAKDLQGYTSLYCFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 730 1460 EIVMTQSPATLSLSPGERAALSCRASQSVFNYVAWYQQKPGQAPRLLIYDTSKRAT ADI-41446 Light chain variable region GIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRYNWPGLIFGGGTKVEIK (“LC”) amino acid sequence Ab 731 1461 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSTISGSG ADI-41447 Heavy chain variable region GSTYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAPTPWCSGGSCYV (“HC”) amino acid sequence SYWGQGTLVTVSS Ab 731 1462 DIVMTQTPGTLSLSPGERGTLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRAT ADI-41447 Light chain variable region GIPDRFGGSGSGTDFTLTISTLEPEDFAVYYCQQYQSSPWTFGQGTKLEIK (“LC”) amino acid sequence Ab 732 1463 TVQLVESGAEVKSPGSSVRVSCQASGGSSNSYAISWVRQAPGQGLEWMGMISPLF ADI-41448 Heavy chain variable region GTTRFSQRFQGRVTITADKSTSTAYMELSSLNSEDTALYYCARGRFDFWSGPTRFYY (“HC”) amino acid sequence TMDVWGQGTMVTVSS Ab 732 1464 QSVLIQPASVSGSPGQSITISCSGTSSDIGGYNYVSWYQQHPGKAPKLLISDVTDRPS ADI-41448 Light chain variable region GISDRFSGSKSGTSASLTISGLQADDEADYYCTSYTTSSTWVFGGGTKLTVL (“LC”) amino acid sequence Ab 733 1465 EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYRVNWVRQAPGKGLEWVSSITGGSS ADI-41449 Heavy chain variable region FIDYADSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYFCARDSMTTVTNSLAFDI (“HC”) amino acid sequence WGQGTMVTVSS Ab 733 1466 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGVGYDVQWYQQLPGTAPKLLIYSNNKR ADI-41449 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRSLSVVFGGGTKVTVL (“LC”) amino acid sequence Ab 734 1467 EVQLVESGGGLVKPGGSLRLSCAASGFAFSSYGINWVRQVPGKRLEWVSSISGGSS ADI-41450 Heavy chain variable region FINYADSVKGRFTISRDNAGNSVYLQMNSLRAEDTAVYFCARESYGSGSSLNWFDP (“HC”) amino acid sequence WGQGTLVTVSS Ab 734 1468 QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAGYDVHWYQQLPGIAPRLVIFGNRNR ADI-41450 Light chain variable region PSGVPDRISGSKSDTSASLAITGLQAEDEGDYYCQSYDKRLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 735 1469 EVQLVESGGGLVQPGGSLRLSCAAAGFTFNNYEMHWVRQAPGKGLEWVSCVTSS ADI-41451 Heavy chain variable region GTATYYADSVKGRFTVSRDNAKKSLQLQMNSLRAEDTAVYYCARELYLGEDYYYGL (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 735 1470 SYELTQPPSVSVSPGQTASISCSGDKLRNKHTCWYQHKSGQSPVLLIYQDNRRPSGI ADI-41451 Light chain variable region PDRLSGSKSGTTATLTISWTQAMDEAEYYCQAWDSNSAVIFGGGTKLTVL (“LC”) amino acid sequence Ab 736 1471 QVQLVQSGAELKKPGASVKVSCKASGHTFATYAIHWVRQAPGQSLEWLGWINTA ADI-41452 Heavy chain variable region NGDTKYSQKFRATVTIHGDTSANTVYLELSRLRSEDTAVYYCASPPLVGAINLEFWG (“HC”) amino acid sequence PGILVTVSS Ab 736 1472 QSVLTQPASVSGSVGQSITISCTGTSSDVGGYNSVSWYQHHPDKAPKLIIYEVSNRP ADI-41452 Light chain variable region SGVSHRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSDTLIFGGGTKVTVL (“LC”) amino acid sequence Ab 737 1473 QVQLVQSGAEVRKPGASVKVSCKASGYTFSIYDMNWVRQAPGQGLEWMGWM ADI-41453 Heavy chain variable region NPNSGNTGYAQKFQGRVTMTGDTSISTAYMELSSLTSEDTAVYYCAVMYGDYPGY (“HC”) amino acid sequence WGQGSLVTVSS Ab 737 1474 SYELTQPLSVSVALGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYRDAKRPSGI ADI-41453 Light chain variable region PERFSGSNSGNTATLTISGAQAGDEADYYCQVWDSNAWIFGGRTKLTVL (“LC”) amino acid sequence Ab 738 1475 QVQLVQSGAEVKKPGASVKVSCKASGYTFTHFGISWVRQAPGQGLEWMGWISIY ADI-41454 Heavy chain variable region NGNTNYAQKIQGRATMTTDASTSTAYMELRSLTSDDTAVYYCAREPPSTTAAATSD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 738 1476 DIVMTQSPLSLPVTLGQPASISCRSSQSLVYIEGNTYLSWFQQRPGQSPRRLIYKVSN ADI-41454 Light chain variable region RDSGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQGTHWPRTFGQGTKLEIK (“LC”) amino acid sequence Ab 739 1477 QVQLQESGPGLVKPSQTLSLTCSVSEGSVISGDYYWSWIRQSPGKGLEWLGYIHYS ADI-41455 Heavy chain variable region GSTYYNPSLKSRVTISVDTSKKQFSLKLSSVTAADTAVYYCARDLGCIGGVCSAYGLE (“HC”) amino acid sequence HNYYFGMDVWGQGTTVTVSS Ab 739 1478 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYTASNRATGI ADI-41455 Light chain variable region PARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSWPPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 740 1479 EVQLLESGGGLFHPGGSLTLSCVASGFTLSTYYMHWVRQAPGKGLVWVARINSDG ADI-41456 Heavy chain variable region GYTTYADSVKGRFTVSRDNAKNTLYLQMNSLRVEDTAVYYCAREWVEFDSWGQG (“HC”) amino acid sequence TLVTVSS Ab 740 1480 NFMLTQPHSVSASPGKTVTISCTRSSGNIASNYVQWYQQRPGSSPTTVITEDNQRP ADI-41456 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSTYVFGTGTKLTVL (“LC”) amino acid sequence Ab 741 1481 EVQLVESGGGLVRPGGSLRVSCAASGFTFIRYDMHWVRQAPGKGLEWVSGIGTA ADI-41457 Heavy chain variable region GDTYYAASVQGRFTISRENAKNSLYLQMSNLRPGDTAVYYCAGSMAATGIDQWG (“HC”) amino acid sequence QGTLVTVSS Ab 741 1482 EIVMTQSPLTLPVTPGEPASISCRSSQSLLHSNGFTYLDWFLQKPGQSPQLLIFLGSN ADI-41457 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQALQTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 742 1483 EVQLLESGSGLVKPSQTLSLTCAVSGDSLNSALYSWSWIRQPPGKGLEWIGYIYYSG ADI-41458 Heavy chain variable region STYYNSSLKSRVTISIDRSKNQFSLNLNSVTAADTAVYYCASLQTGYSSGWFFDFWG (“HC”) amino acid sequence PGILVTVSS Ab 742 1484 EIVLTQSPGTLSLSPGERATLSCRASQSVSRTYLTWYQQKPGQAPRLLIYGASNRATG ADI-41458 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSTPLFGQGTKVEIK (“LC”) amino acid sequence Ab 743 1485 QVQLVESGGGLVQPGGSLRLSCAASGFPFSAYGINWVRQAPGKGLEWVSYISSTST ADI-41459 Heavy chain variable region TIKYADSVKGRFTISRDDAKNSLYLQLRSLRPEDTAVYYCAGGVWSGYYIDFWGQG (“HC”) amino acid sequence TPVTVSS Ab 743 1486 NFMLTQPQSVSESPGKTVTISCTRSSGSIGSNFVQWYQQRPGSSPTTVIYEDYQRPS ADI-41459 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDADMMVFGGGTKLTVL (“LC”) amino acid sequence Ab 744 1487 QVTLKESGPALVKPTQTLTLICTFSGFSLNTRGMCVSWVRQPPGKALEWLARIDW ADI-41460 Heavy chain variable region DDDKNYSTSLRTRLTISKDTSRNQVVLAMANMDPVDTATYYCARCARYDRSGYYV (“HC”) amino acid sequence WYLDSWGQGTLVTVSS Ab 744 1488 DIQMTQSPSSLSASVGDRVTITCRASQTIASYLNWYQQKPGKAPKLLIYVASTLQSG ADI-41460 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSLTQWTFGQGTKVEIK (“LC”) amino acid sequence Ab 745 1489 QVQLVQSGAEVKKPGASVKVSCRASGYTFSSYDINWVRQATGQGLEWMGWMS ADI-41461 Heavy chain variable region PNSANTGYAQKFQGRVIMIRDTSINTAYMELSSLSSEDTAVYYCARFLGYCSGGSC (“HC”) amino acid sequence YPGYGMDVWGQGTTVTVSS Ab 745 1490 EIVLTQSPDSLAVSLGERATINCKSSQNVLYSSNNKDYLSWYQQKPGQPPKLLIYWA ADI-41461 Light chain variable region STRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYGTPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 746 1491 QVQLQQWGAGLVKPSETLSLSCDVYGGSFSGYYWTWIRQPPGKGLEWIGEINHS ADI-41462 Heavy chain variable region GRTNYNPSLKNRVTISVDTSKKQFSLKLSSVTAADTAVYFCARAPYYDIVTDYNITTA (“HC”) amino acid sequence YFYGMDVWGQGTTVTVSS Ab 746 1492 DIQMTQSPDSLAVSLGERATINCRSSQSVLYSSNNKNYLTWYQQKPGQPPKLLIYW ADI-41462 Light chain variable region ASTRESEVPDRFSGSGSGTDFSLTISSLQAEDVAVYYCQQYYNTPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 747 1493 QVQLVQSGAEVKKPGASVKVSCTASGYSFTDYDISWVRQAPGQGLEWMGWISAY ADI-41463 Heavy chain variable region NGNTNYAQKFQDRVTMNTDTSTNTAYMELRGLRSDDTAVYYCARNCYYGSGTCYI (“HC”) amino acid sequence EDYYFDYWGQGTLVTVSS Ab 747 1494 DIQMTQSPSSLSASVGDRVTITCRASQDIKNDLGWYQQKPGKPPKRLIYGASRSQS ADI-41463 Light chain variable region GVPSRFSGSGSGTDFTLTIYSLQPEDFATYYCLQHSDYPFTFGQGTRLEIK (“LC”) amino acid sequence Ab 748 1495 QVQLVESGPGLVRPSGTLSLICTVSGDSVNSYRWSWIRQSPGKGLEWIGYISYSGET ADI-41464 Heavy chain variable region NYNPSLKSRVSISVGTSRYQFFLKLSSVTAADTATYYCARDKTTIFGVSHYYFGVDVW (“HC”) amino acid sequence GQGTTVTVSS Ab 748 1496 DIVMTQTPLSLPVTPGEPASISCRSSQSLLKSDGYNSLDWYLQRPGQSPQLLIYLGSN ADI-41464 Light chain variable region RASGVPARFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVEIK (“LC”) amino acid sequence Ab 749 1497 QVQLVQSGGGVVQPGRSLRLSCAASGFTFTSYDMHWVRQAPGKGLEWVAIISHD ADI-41465 Heavy chain variable region GSKQFYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAMYYCAKDTPSWGLLAEFF (“HC”) amino acid sequence RHWGQGTLVTVSS Ab 749 1498 EIVLTQSPDSLAVSLGERATINCKSSQSVLYSSNDKDYLAWYQHKPGQPPKLLIYWA ADI-41465 Light chain variable region STRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYGTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 750 1499 QVQLVQSGAEVKKPGASVKVSCKASGYTFNFYYMHWVRQAPGQGLEWMGWIN ADI-41466 Heavy chain variable region PKSGGTSYAQKFQGRVIMTGDTSISTTYMELSRLRSDDTAVYYCARADTGLELDVW (“HC”) amino acid sequence GQGTTVTVSS Ab 750 1500 QSALIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLILYDVSKRP ADI-41466 Light chain variable region SGVSNRFSGSKSGNTASLTISGLQAEDESDYFCSSYTRSNTVVFGGGTKVTVL (“LC”) amino acid sequence Ab 751 1501 EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYNMNWVRQAPGKGLEWVSSISGGS ADI-41467 Heavy chain variable region SFVNYADSVKGRFTISRDNAKNSLYLQMSSLKAEDTAIYYCARDPVYCSAASCSAYF (“HC”) amino acid sequence DSWGQGSLVTVSS Ab 751 1502 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNR ADI-41467 Light chain variable region PSGVPDRFSGFKSGSSASLAITGLQAEDEADYYCQSYDIGLSDSHVVFGGGTQLTVL (“LC”) amino acid sequence Ab 752 1503 QVQLQQWGAGPLKSSETLSLTCEVYGGPFSGYSWSWIRQPPGKGLEWIGEINHSG ADI-41468 Heavy chain variable region STNYNPSLKSRVSFSVDTSKNQFSLKLSSVTAADTAVYYCARGAGFCTSTSCPPGLYY (“HC”) amino acid sequence YYGMDVWGHGTTVTVSS Ab 752 1504 SYELTQPLSVSVALGQTARITCGGNNIESKNVHWYQQMPGLAPVMVIYRDTNRPS ADI-41468 Light chain variable region GIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSGTVIFGGGTKLTVL (“LC”) amino acid sequence Ab 753 1505 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYD ADI-41469 Heavy chain variable region GSFIKYADSMMGRFTISRDNSKNTLYLQMSSLRPEDTATYYCAKDALIPEYWGQGT (“HC”) amino acid sequence LVTVSS Ab 753 1506 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQKHPDKAPRVIIYEVSNRP ADI-41469 Light chain variable region SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYTSTSGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 754 1507 QVQLVQSGADVKKPGSSVKISCKASGGSFITNSLSWVRRAPGQGLEWMGGIIPVS ADI-41471 Heavy chain variable region GTTTYAQKFLGRVTFTADESTSTAYMELNSLRSEDTAVYYCARFLGTPYPNVHYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 754 1508 DIRVTQSPSSLSASVGARVTITCRASQSISTYLNWYQEKPGKAPKLLIYAASSLQRGV ADI-41471 Light chain variable region PSRFSGSGSETTFTLTISSLQPEDFATYYCQQSYTAAYNFGQGTKVEIK (“LC”) amino acid sequence Ab 755 1509 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPVL ADI-41472 Heavy chain variable region DITNYAQKFQGRVTIMADKSTSTAYMELSSLRSEDTAIYYCARETSNFYFYYNAMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 755 1510 QPVLTQPPSASGSPGQSVTISCTGTSSDVGGDNYVSWYQQHPGKAPKLLIYEVSKR ADI-41472 Light chain variable region PSGVPDRFSGSRSGHTASLTVSGLQAEDEADYYCSSYAGRNNLGVFGGGTKLTVL (“LC”) amino acid sequence Ab 756 1511 QVQLVQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWSWIRQSPSRGLEWLGRTYYR ADI-41473 Heavy chain variable region SKWYYDHAVSVEGRITINADTSKNHFSLQLNSVTPEDTAVYYCARDPDSGNYFHYY (“HC”) amino acid sequence GMDVWGQGTTVTVSS Ab 756 1512 ETTLTQSPATLSLSPGERATLSCRTSQSVSSYLAWYQQKPGQAPRLLIYDASRRATGI ADI-41473 Light chain variable region PARFSGSGSGTHFTLTITSLEPEDFAVYYCQQRSKWPPYSFGQGTKVDIK (“LC”) amino acid sequence Ab 757 1513 QVQLVQSGAEVKRPGASVKVSCKISGYTFTSHYIHWLRQAPGQGLEWMGWINPN ADI-41474 Heavy chain variable region TGDTKYEQKFQGRVTMTRDTSLSTAYMELRRLRSDDTAVYYCARDSFYAANGYYFV (“HC”) amino acid sequence WFDPWGQGALVTVSS Ab 757 1514 DIQMTQSPTSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPRFLIYAASSLQSG ADI-41474 Light chain variable region VPSRFRGSGSGTDFTLTISSLQPEDFATYYCQQSYSSPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 758 1515 QVQLQESGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYR ADI-41475 Heavy chain variable region SKWWTDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDPDSGNYFHYY (“HC”) amino acid sequence GMDVWGQGTTVTVSS Ab 758 1516 ETTLTQSPATLSLSPGERATLSCRASQSASSYLAWYQQKPGQAPRLLIYDASKRATGI ADI-41475 Light chain variable region PARFSGSGSGTDFSLTISSLEPEDFAVYYCQLRSKWPPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 759 1517 EVQLLESGGGLVQPGGSLRLSCATSGFRFTRYWMHWVRQAPGKGLEWVARINFD ADI-41476 Heavy chain variable region GTTTNYADSVKGRFTVSRDNAKNTLYLQINSLRAEDTAVYFCARDQTFLEWLPFES (“HC”) amino acid sequence WGQGTLVTVSS Ab 759 1518 QTVVTQEPSFSVSPGGIVTLICGLTSGSVSTSYYPSWYQQTPGQAPRTLIYNTKTRF ADI-41476 Light chain variable region SGVPDRFSGSILGNKAALTITGAQADDESDYYCVLYMSGGMVFGGGTKLTVL (“LC”) amino acid sequence Ab 760 1519 QVQLVQSGAEVKKPGASVRVSCKASGYPFISYYIHWVRQAPGQGLEWMGMINTN ADI-41477 Heavy chain variable region GGSTHYAQKFQGRVTMTRDTSTTTIYMELSRLKSEDTAYYFCARDNTETVLHGFWS (“HC”) amino acid sequence GYGSYLDYWGQGTLVTVSS Ab 760 1520 EIVLTQSPGTLSLSPGGRATLSCRASQSVTSSYLAWYQQRPGQAPRLLIYGASSRAA ADI-41477 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSAPLTFGGGTKLEIK (“LC”) amino acid sequence Ab 761 1521 QVQLVQSGAEVKKPGESLKISCKGSGYSFISYWIGWVRQMPGKGLEWMGIIYPAD ADI-41479 Heavy chain variable region SDTRYSPSFQGQVTISVDKSISTAYLQWSSLKASDTGMYYCVRYGVGGTAPRYWG (“HC”) amino acid sequence QGTTVTVSS Ab 761 1522 NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVHWYQQRPGSAPTTVIYEDNQRP ADI-41479 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDISNLWVFGGGTKLTVL (“LC”) amino acid sequence Ab 762 1523 EVQLLESGPGLVRPSGTLSLTCTVSGDSISGSNWWAWVRQPPGRRLEWIGEIYYRG ADI-41480 Heavy chain variable region ATDYNSSLKSRVIISVDNSKNQFSLNLRSVTAADTAIYYCARVEKFATSGYYISYFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 762 1524 DIRVTQSPSSLSASVGDRVTITCRASQSISTYLNWYQHNPGKAPKLLIYAASSLQSGV ADI-41480 Light chain variable region PSRFSGSGSGTHFTLTISSLQPADFSTYYCQQSYSSPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 763 1525 QVQLVESGPGLVKPSETLSLACSVSGVSISTYYWTWIRQPPGKGLEWIGYISYSGST ADI-41481 Heavy chain variable region NYNPSLKSRVTISADTSKNQFSLRLNSVTAADTAVYYCARTYYDFWSTYYGEFDHW (“HC”) amino acid sequence G HGTLVTVSS Ab 763 1526 SYELTQPLSVSVALGQTARITCGGNNIESKNVHWYQQKPGQAPVVVMYRDTNRPS ADI-41481 Light chain variable region GIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSGTAGVVFGGGTKVTVL (“LC”) amino acid sequence Ab 764 1527 QVQLVQSGAEVKKPGSSVKVSCKASGGTFGSYTINWVRQAPGQGLEWMGGIIPIF ADI-41482 Heavy chain variable region GATNYAQNFQGRVSITADKSTATAYMDLISLRSEDTAVYYCARLGRSSPLNSCTTTS (“HC”) amino acid sequence CYFWGRGMDVWGQGTTVTVSS Ab 764 1528 QSVLIQPASVSGSPGQSITISCTGTISDVGIYNYVSWYQQHPGKAPKLIISDVSDRPS ADI-41482 Light chain variable region GVSNRFSGSKSGITASLTITGLQAEDEADYYCSSYSSSSTLYVFGTGTKLTVL (“LC”) amino acid sequence Ab 765 1529 EVQLVESGPGLVKPSEALSLTCTVSGASISSYYWTWIRQSPRKGLEWIGYIYHTGRTN ADI-41484 Heavy chain variable region YNPSLKRRVTMSVDWSKNQFSLTLSSVTAADTAVYYCARLKVVPAALESAILEHHFG (“HC”) amino acid sequence LDVWGQGTTVTVSS Ab 765 1530 DIVMTQTPSTLSASIGDRVTLTCRASQSINRWLAWYQQKPGKAPKLLIYKASTLESG ADI-41484 Light chain variable region VPSRFSGSGSGTEFTLTISGLQPDDFATYYCQQYNNFPYTFGPGTKVDIK (“LC”) amino acid sequence Ab 766 1531 EVQLLESGPGLVRPSETLSLTCTVSGGSLDSGPHYWNWIRQPPGKGLEWIGYIYYSV ADI-41485 Heavy chain variable region STNYNPSLKSRVTISMDTSKNQFSLNLTSVTAADTAVYYCASFQLIYGPQIWGQGKK (“HC”) amino acid sequence VTVSS Ab 766 1532 DIVLTQSPSSVSASVGDRVTITCRASQAISSWLIWSQHKPGKAPKVLIYAASSLQSGV ADI-41485 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANNFPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 767 1533 QVQLQQWGAGLLKPSETLSLTCSVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSG ADI-41486 Heavy chain variable region STNYNPSLKSRITISVDTSKNQFSLKLNSVTAADTAVYYCARGDYAFVTFDYWGQGT (“HC”) amino acid sequence LVTVSS Ab 767 1534 QSVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNR ADI-41486 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPVFGGGTKLTVL (“LC”) amino acid sequence Ab 768 1535 QVQLVESGGGLVKPGGSLRLSCAASGFTFSTYTMNWVRQAPGKGLEWVSSISGSS ADI-41487 Heavy chain variable region AYIYYADSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCARLQGLVLPAVMPSYY (“HC”) amino acid sequence YYSGMDVWGQGTTVTVSS Ab 768 1536 EIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLASN ADI-41487 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPQAFGQGTKVEIK (“LC”) amino acid sequence Ab 769 1537 EVQLVESGPGLVKPSETLSLTCTVSGGSINSDYWNWIRQTPGKGLEWIGYIFYSGNT ADI-41488 Heavy chain variable region NYNPSLKSRVTISIDTSKKKFSLQVTSVTAADTAVYYCARMGTLKFDFDNWGQGTL (“HC”) amino acid sequence VTVSS Ab 769 1538 QSALTQPRSVSGSPGQSVTIPCTGTSSDVGAYKYVSWYQQHPGKAPKLIIYDVTKRP ADI-41488 Light chain variable region SGVPNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGTHTYWVFGGGTKVTVL (“LC”) amino acid sequence Ab 770 1539 EVQLVESGGGVVQPGRSLRLSCAASGFNFHNYAFHWVRQAPGKGLDWVAVTSYD ADI-41489 Heavy chain variable region GSSAFYADSVKGRFTISRDNSKKILYLQMTSLRAEDTALYYCARGSSSWSGDYFDYW (“HC”) amino acid sequence GQGILVTVSS Ab 770 1540 DIVMTQSPVTLSVSPGERATLSCRASQSVGSNLAWYQQKHGQTPRLLIYDASTRAT ADI-41489 Light chain variable region SIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNKWPSYTFGQGTKVEIK (“LC”) amino acid sequence Ab 771 1541 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYMSSD ADI-41491 Heavy chain variable region RSAIYYSDSVKDRFTISRDNAKNSLYLQMHSLRAEDTAVYYCARRYCSSTSCYRGLGY (“HC”) amino acid sequence YYGMDVWGQGTTVTVSS Ab 771 1542 SYELTQPPSVSVAPGQTARITCGGSNIGNKDVHWYQQKPGQAPVLVVYDDSDRPS ADI-41491 Light chain variable region GIPERFAGSNSGNTATLTISRVEAGDEADYYCQVWHSAGDHVVFGGGTKLTVL (“LC”) amino acid sequence Ab 772 1543 QVQLVQSGAEVRKPGSSVKVSCKASGGTFNSFVISWVRQAPGQGLEWMGRIIPIL ADI-41492 Heavy chain variable region ATVDYAQKFQGRVTITADKSTTTAYMELSGLTSEDTAVYYCARDPPRWDTTMADY (“HC”) amino acid sequence YYQGMDVWGQGTTVTVSS Ab 772 1544 DIRVTQSPASLSAFVGDRVTISCRASQSIGSFLNWYQQKPGKAPKLLIYAASSLQSGV ADI-41492 Light chain variable region PSRFSGSGSGTDFTLAISSLQPEDFATYYCQQSYRSTPTFGGGTKVEIK (“LC”) amino acid sequence Ab 773 1545 QVQLVQSGAEVKKPGESLKISCKGSGYSFTKYWIGWVRQLPGKGLEWMGIIYPGD ADI-41493 Heavy chain variable region SETIYSPSFQGQVTISADKSVSTAYLQWSSLKASDTAMYYCARQTFVFWGESHDAF (“HC”) amino acid sequence DIWGQGTTVTVSS Ab 773 1546 QPVLTQPPSASGSPGQSVTISCTGTSSDVGAHNYVSWYQQHPGKAPKLMIYEVSK ADI-41493 Light chain variable region RPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNWVFGGGTKLTVL (“LC”) amino acid sequence Ab 774 1547 EVQLVESGGGLVQPGRSLRLSCTTSGFTFGDYAVTWVRQAPGKGLEWIGIMKSKTY ADI-41494 Heavy chain variable region RGTTDYAASLRGRFSISRDDSKSIAYLQMTSLKSEDTGVYYCVRGHDYGDPFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 774 1548 QSVLTQPASVSGSPGQSITISCTGGSSDVGYYNYVSWYQQHPGKAPKLLIYDVNNR ADI-41494 Light chain variable region PSGVSDRFSGSKSGNTASLTISGLQPEDEADYYCSSYTRSRTWVFGGGTKLTVL (“LC”) amino acid sequence Ab 775 1549 QVQLVQSGGGLVEPGGSLRLSCAASGFTFSNTWMNWVRQAPGKGLTWVGRIKR ADI-41495 Heavy chain variable region KTDFGTSDYAAPVKGRFTISRDDSKNMVFLQMNSLKIEDTGVYYCTTHPRPYLDTT (“HC”) amino acid sequence AVVYWGQGTLVTVSS Ab 775 1550 QPVLTQPHSVSESPGKTVTISCIGSSGSITSNYVQWFQQRPGSAPTTVIYEDDQRPS ADI-41495 Light chain variable region GVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYHHTNPWVFGGGTKLTVL (“LC”) amino acid sequence Ab 776 1551 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSDDINWVRQATGQGLEWMGWMN ADI-41496 Heavy chain variable region PNSGDTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYCARVRIQCSGGRC (“HC”) amino acid sequence SYWFFDLWGRGTLVTVSS Ab 776 1552 QSALTQPASVSGSPGQSITISCIGTSSDVGNYNLVSWYQHHPGKAPKVMIYEVNER ADI-41496 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGRSTWVFGGGTKLTVL (“LC”) amino acid sequence Ab 777 1553 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNHAMHWVRQAPGKGLEWLSFISYD ADI-41497 Heavy chain variable region GGVNFYRDSVKGRFTISRDNSKNTLYLQMSSLRPEDTAVYYCARDRVGRVVGASYY (“HC”) amino acid sequence LDYWGRGALVTVSS Ab 777 1554 QSVVTQPPSVSVAPGQTASITCGGKHIGSKSVHWYQQKPGQSPVLVVHDDSDRPS ADI-41497 Light chain variable region GILERFSGSNSGNTATLTINRVEAGDEADYYCQVWDNASDHPYVFGPGTKVTVL (“LC”) amino acid sequence Ab 778 1555 EVQLLESGGGLVKPGGSLRLSCAASGFIFSDYAMNWVRQTPGKGLEWVSSISDSSA ADI-41498 Heavy chain variable region YKYYTGSVSGRFTISRDNAKNSLYLQMNDLRPEDTAVFYCARGQWRCSGASCYSPF (“HC”) amino acid sequence DSWGQGTLVTVSS Ab 778 1556 SYELTQPPSVSVAPGQTARIPCGGNNIESKNVHWYQQKPGQAPVLVVYDDSDRPS ADI-41498 Light chain variable region GIPERFSGSNSGSTATLTISRVEAGDEADYYCHVWHRSGDLREVFGSGTKVTVL (“LC”) amino acid sequence Ab 779 1557 EVQLVESGGVVVQPGGSLRLSCAASGFSFDDYTMYWVRQAPEKGLEWISLISWNG ADI-41499 Heavy chain variable region GVTYYPDSVKGRFTVSRDNNKNSLYLQMDSLRPEDSAFYYCAKESLESSGHFLDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 779 1558 QPVLTQSRSVSGSPGQSVTISCIGTNSDVGGYHYVSWFQHHPGKAPKLMIYDVSRR ADI-41499 Light chain variable region PSGVPARFSGSKSGNTASLSISGLRAEDEADYYCCSFAGTYTPYVFGTGTKLTVL (“LC”) amino acid sequence Ab 780 1559 QVQLVQSGAEVKKPGSSVKVSCKASGGIFSDFAISWVRQAPGQGLEWMGGIITIIG ADI-41501 Heavy chain variable region TPEYAQKFQGRVRITADESTTTVFMELSRLTSEDTAVYYCARDSRYGSGWYWDHW (“HC”) amino acid sequence GQGTLVTVSS Ab 780 1560 DIVMTQTPDSLAVSLGERATINCKSSQSVLYISNNKNYLAWYQQKPGQPPKLLIYW ADI-41501 Light chain variable region ASTRDSGVPDRFSGSGSGTDFTLSISSLQPEDVAVYYCQQYYDTPRTFGQGTKLEIK (“LC”) amino acid sequence Ab 781 1561 QVQLVQSGAEVKKPGSSVKVSCKASGGPFSSDAMSWVRQAPGQGLEWMGGIIPI ADI-41502 Heavy chain variable region LGSATYAQKFKGRVTIAADESTSTSYMELSGLKYEDTAVYYCARPFYDPLTGYFDTFN (“HC”) amino acid sequence VWGQGTTVTVSS Ab 781 1562 QSVLTQPRSVPGSPGQSVTISCTGTSGDVGGYNYVSWYQQHPGKAPKLVIYDVTK ADI-41502 Light chain variable region RPSGVPDRFSGSKSGNRASLTISGLQAEDEADYYCCSYAGSQTGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 782 1563 EVQLLESGGGLVQPGGSLRLSCAASGFTFSDFPLSWVRQAPGKGLVWVSAISSSGG ADI-41503 Heavy chain variable region DTYYADSVKGRFTISRDSSKNALYLQMNSLRAEDTAVYYCAKGQELLRPYYYGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 782 1564 QSALIQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIFEVSNR ADI-41503 Light chain variable region PSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCSSCTSRFTYVFGTGTKLTVL (“LC”) amino acid sequence Ab 783 1565 EVQLLESGPGLLKTSETLSLTCTVSDGSISGYYWTWIRQPPGKGLECIGYISYSGSTNY ADI-41504 Heavy chain variable region SPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAKIGGYCNPTKCYGWFDPWGQ (“HC”) amino acid sequence GTLVTVSS Ab 783 1566 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIFGNTNR ADI-41504 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEAAYYCQSYDSSLFYVVLGGGTKLTVL (“LC”) amino acid sequence Ab 784 1567 QVQLQQSGAGLLKPSETLSLTYVVYGGSFSGYYWSWIRQPPGKGLEWVGDINHST ADI-41505 Heavy chain variable region TTNYNPSLESRITISIDTSKNQFSLNLSSVTAADSAVYYCARGPKECTSSSCDRFGVDY (“HC”) amino acid sequence FYYGMDVWGRGTTVTVSS Ab 784 1568 QSVLTQPPSVSGAPGQRVTISCTGSSANIGAGYDVHWYQQFPGTAPKLLIFGNSNR ADI-41505 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAGDEADYYCQSYDGTLGGWVFGGGTQLTVL (“LC”) amino acid sequence Ab 785 1569 QVTLKESGPTLVKPTQTLRLTCTFSGFSLNVISGVGVGWIRQPPGKALEWLALIYWD ADI-41507 Heavy chain variable region DDKRYSPSLKSRLTIAKDTSKNQVVLTMTNMDPVDTATYYCAHKGGSIEAAVGFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 785 1570 QSVLTQPPSVSGAPGQRVIISCTGSSSNIGAGFAVHWYQQLPGTAPKLLIYANTNRP ADI-41507 Light chain variable region SGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDTSLSGFYVFGTGTKLTVL (“LC”) amino acid sequence Ab 786 1571 QVQLVQSGAEVRKPGASVKVSCKASGYGFRSYDLTWVRQAPGKGLEWVGWISAY ADI-41508 Heavy chain variable region SGGTNYAQTLQGRVTMTTDTSTSTAYMELRSLGPDDTAVYYCARAGLYGSGSPDG (“HC”) amino acid sequence FDSWGQGTLVTVSS Ab 786 1572 SYELTQPPSVSVSPGQTASITCSGDKLGDKYASWYQQRPGQSPVLVISQDTKRPSGI ADI-41508 Light chain variable region PERFSGSTSGNTAILTISGTQAMDEADYYCLAWDSSTAWVFGGGTKLTVL (“LC”) amino acid sequence Ab 787 1573 QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGKGLVWVSSISGS ADI-41515 Heavy chain variable region GKFTYYEDSLRGRVTISRDNSKNTVYLHMNSLRTEDTALYYCARLRIPVINEVDGAM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 787 1574 SYELTQLPSVSVSPGQTARITCSGDALPKKFAYWYQQKSGQAPVLVIYEDTGRPSGI ADI-41515 Light chain variable region PERFSGSTSGTTATLTINGAQVEDEGDYYCYSADSSDNQGVFGGGTKVTVL (“LC”) amino acid sequence Ab 788 1575 EVQLLESGPRLVKPSETLSLTCIVSGGFISYDYWSWIRQPAGKGLEWIGRIYAGGIPK ADI-41516 Heavy chain variable region YNPSLKSRVIMSLDMSNNQFSLRLKSVTAADSAVYYCARAEPCSGDCFLGENPFDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 788 1576 QSVLTQPPSASGTPGQRVTISCSGSSSSIGSNYVYWYQQLPGTAPKLLIHKDNERPS ADI-41516 Light chain variable region GVPDRFSGSKSGTSASLAISGLRSEDEGDYSCAAWDDSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 789 1577 QVQLVQSGGGLVQPGGSLRLACAASGFTLSGYAMNWVRQAPGKGLEWVSSISGS ADI-41517 Heavy chain variable region GGSTYYADSVKGRFTTSRDNSKNTVFLHMNSLRAEDTAIYYCATVPWETGPFDHW (“HC”) amino acid sequence GQGTLVTVSS Ab 789 1578 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYAVHWYQQLPGTAPKLLIHGTTNR ADI-41517 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSRLSGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 790 1579 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-41518 Heavy chain variable region YINYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDLGYCSDTSCTPGIG (“HC”) amino acid sequence YWGQGTLVTVSS Ab 790 1580 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-41518 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSGLSPWVFGGGTKLTVL (“LC”) amino acid sequence Ab 791 1581 QVQLVESGPGLVKPSETLSLTCNVSGGSIITSGSYWGWIRQPPGKGLTWIGSISYSG ADI-41519 Heavy chain variable region TTYYNPSLRSRLTISLDTSRNHFSLQLTSVSAADTAVYYCARAFYEVWTGSEIPGDFD (“HC”) amino acid sequence RWGQGTLVTVSS Ab 791 1582 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRAIDI ADI-41519 Light chain variable region PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFRRSPWTFGQGTKVDIK (“LC”) amino acid sequence Ab 792 1583 EVQLLESGGGVVRPGGSLRLSCAASGFSFDDYGMTWVRQAPGKGLEWVSGINW ADI-41520 Heavy chain variable region NGISTDYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTALYYCARIGGVVVIASTAY (“HC”) amino acid sequence YYGMDVWGQGTTVTVSS Ab 792 1584 DIQLTQSPSSLSAYVGDRVTITCRASQSIRNHLNWYQQKPGKAPQLLIYTASSLQDG ADI-41520 Light chain variable region VPSRFSGSGSGTDFTLAISSLQPEDFATYYCQQSHSMPPTFGQGTRLEIK (“LC”) amino acid sequence Ab 793 1585 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDFAMDWVRQVPGKGLEWVSGISWN ADI-41521 Heavy chain variable region GVSKDYAGSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYFCAKARRDVYNWGDA (“HC”) amino acid sequence FDIWGQGTMVTVSS Ab 793 1586 DIRLTQSPGTLSLSPGERATLSCRASQPLNSNYLAWYRQKPGQAPRLLIFDASSRAT ADI-41521 Light chain variable region GVPDRISGSGSGTDFTLTVSRLEPEDIAVYYCQQYASSPWTFGLGTKVEIK (“LC”) amino acid sequence Ab 794 1587 QVQLVQSGAEVKKPGSSVKVSCKASGGTFNNFPISWVRQAPGQGLEWMGGIIPM ADI-41522 Heavy chain variable region FGRANYAQKFQGRVTITADESTTTVYMALRSLRSEDTAVYYCARPDYDVLTGFEGA (“HC”) amino acid sequence FDIWGQGTMVTVSS Ab 794 1588 QSALTQPASVSGSPGQLITISCTGTSRDVGGYNYVSWYQQHPGKAPKLMIYDVTNR ADI-41522 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCSSYTSTTTWVFGGGTKLTVL (“LC”) amino acid sequence Ab 795 1589 QVQLVQSGAEVKKPGESLRISCKGSGDTFSNYWIGWVRQMPGKGLEWMGIIYPG ADI-41523 Heavy chain variable region DSDTRYSPSFQGQVTFSADKSISTAYLQWSSLKASDTAMYYCVRQVGGVVVTDTD (“HC”) amino acid sequence NYYYGMDVWGQGTTVTVSS Ab 795 1590 DIRLTQSPSSLSASVGDRVTITCRASQSIRSYLNWYQQKPGKAPKLLIYSASSLQSGVP ADI-41523 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHSTPLTFGPGTKVDIK (“LC”) amino acid sequence Ab 796 1591 EVQLVESGGGLVQPGRSLRLSCTGSGFTFGDYAISWFRQAPGKGLEWVGFIRSKPY ADI-41524 Heavy chain variable region GGTTEYAASVKGTFTISRDDSKSIAYLQMNSLKTGDTAVYFCTRGIWGITMIVPWSD (“HC”) amino acid sequence PWGQGTLVTVSS Ab 796 1592 DIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGFNYLAWYLQKPGQSPQLLIYLNSN ADI-41524 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGPGTKLEIK (“LC”) amino acid sequence Ab 797 1593 QVQLVQSGAEMKKPGSSVKVSCKASGRTFKYFALNWMRRAPGHGLEWIGGDIPIS ADI-41525 Heavy chain variable region GSTNYAQKFQGRVTITADESASTAYMEVSRLRSDDTAVYYCASLHYDVSTGFSDAF (“HC”) amino acid sequence DIWGQGTMVTVSS Ab 797 1594 QSVLTQPASVSGSPGQSITISCTGTSSDVGAYNYVSWYQHHPGKAPKLMIFDVSNR ADI-41525 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYRSTFSYVFGTGTKVTVL (“LC”) amino acid sequence Ab 798 1595 QVQLVQSGAEVKKPGASVKVSCEASGYTFTDYYMHWVRQAPGQGLEWMGWIN ADI-41526 Heavy chain variable region PNSGVTKIAQNFQGRVTMTRDTSITTAYMDLSRLRSDDTAVYYCARVVDGDYDN (“HC”) amino acid sequence WFDFWGQGTLVTVSS Ab 798 1596 SYVLTQPPSASGTPGQRVTISCSGSTSNIGTNTVNWYQQPPGMAPKLLIYANNQRP ADI-41526 Light chain variable region SGVPDRFSGSKSGTSASLAISGLQSEDEADYHCAVWDDSLPGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 799 1597 EVQLLESGGGLVQPGGSLRLSCAASGFTFTSYWMSWVRQAPGQGLEWVATIKQD ADI-41527 Heavy chain variable region GSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLGAEDTAVYYCARDMYCSTTTCYFF (“HC”) amino acid sequence ETYYYNGMDVWGQGTTVTVSS Ab 799 1598 DIRLTQSPSSVSASVGDRVTITCRASQVTSTWLAWYQQNPGKAPKLLIYAASRLQSG ADI-41527 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 800 1599 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISFD ADI-41528 Heavy chain variable region GSSDYYADSVKGRFTISRDSSKNTLYLRMNSLRAEDTAVYYCARRAVEYSIYNNDAF (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 800 1600 SYELTQPPSVSVSPGQTASITCSGDKLGNKFTFWYQQKSGQSPVLVIYQETKRPSGIP ADI-41528 Light chain variable region ERFSGSNSGNTATLTISGTQSMDEADYYCQAWDSSTAFFGGGTKLTVL (“LC”) amino acid sequence Ab 801 1601 EVQLVQSGAEVRRPGSSVKVSCKASGGTLDTDSISWVRQVPGQGLVWVGGVIPIL ADI-41529 Heavy chain variable region GSVVYARKFQGRVTITADGSTSTAYMELRSLRSEDTAMYYCASQFYDFRRGYFDAF (“HC”) amino acid sequence DIWGQGTTVTVSS Ab 801 1602 ETTLTQSPGILSLSPGERATLSCRATQTVISNYINWYQQKPGQAPRLLIYGASSRATGI ADI-41529 Light chain variable region PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQRYDSSPPGFTFGPGTKVDIK (“LC”) amino acid sequence Ab 802 1603 QVQLVESGAEVKKPGASVKVSCRASGYTFSAYDINWVRQAPGQGLEWVGWMNP ADI-41530 Heavy chain variable region NSGNTGYALRFQGRVTMTRDTSINTAYMELSSLRSDDTAVYYCAAQLWYPNWGQ (“HC”) amino acid sequence GTLVTVSS Ab 802 1604 SYELTQPPSVSVGLGQTASITCGGNNIGSKSVHWYQQKPGQAPTLVIYRDTNRPSGI ADI-41530 Light chain variable region PERFSGSNSENTATLTISRAQAGDEADFYCQVSDNYSWVFGGGTKLTVL (“LC”) amino acid sequence Ab 803 1605 EVQLLESGGDLVQPGGSLRLSCAASGFTFFSYALNWVRRTPGKGLEWVSGISGSGG ADI-41531 Heavy chain variable region STYYADSVKGRFTISRDNSKSTLYLQMNSLKVDDTAVYFCAKDFQHDYGDPYRSYYF (“HC”) amino acid sequence DHWGQGTLVTVSS Ab 803 1606 DIQLTQSPSSLAASVGDRVTITCQASRDIRKSLNWYQVKPGKAPKLLISDASYLETGV ADI-41531 Light chain variable region PPRFSGSGFGTH FTFTISSLQPEDIATYYCQQYDNLPPPTFGGGTKVDIK (“LC”) amino acid sequence Ab 804 1607 QVQLVQSGAEVKKPGESLKISCKGSGYSFTSSWIGWVRQMPGKGLEWMGIIYPGD ADI-41532 Heavy chain variable region SDTRYSPSIQGRVTISADKSITTAYLQWSSLKASDTATYYCAKFGGYADAYFYHGMD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 804 1608 SYVLTQPPSASGTPGQRVTISCSGSSSNVGSNTVNWYQQLPGTAPKLLIHFNNQRP ADI-41532 Light chain variable region SGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNTWVFGGGTKVTVL (“LC”) amino acid sequence Ab 805 1609 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWLAVISFD ADI-41533 Heavy chain variable region GSSEFYGDSVRGRFTISRDNSKNTLYLRVNSLRAEDTALYYCARRSLKYSMYNNDAF (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 805 1610 QPVLTQPPSVSVSPGQTASITCSGDKLGNKFTFWYQQKSGQSPVLVIYQESQRPSGI ADI-41533 Light chain variable region PERFSGSNSGNTATLTIRGAQAMDEADYYCQAWDSSTAFFGGGTKLTVL (“LC”) amino acid sequence Ab 806 1611 QVQLVQSGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQAPGKGLEWVTLISYD ADI-41534 Heavy chain variable region GSAQDYADSVKGRITISRDNSKNTLYLQMSSLRPEDTAVYYCARYYCTNDVCSSSAL (“HC”) amino acid sequence DIWGQGTTVTVSS Ab 806 1612 SYELIQPPSVSVSPGQTASITCSGDKLGNKFTCWYQQKPGQSPVLVIYQDSKRPSGIP ADI-41534 Light chain variable region ERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGRTKLTVL (“LC”) amino acid sequence Ab 807 1613 QVTLKESGPALVKPTQTLTLTCTFSGFSLSTSRMCVSWIRQSPGKALEWLARIDWD ADI-41535 Heavy chain variable region DDKFFSTSLKTRLTISKDTSRNQVVLTMTNMDPVDTATYYCARTTVYASGGYYLYYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 807 1614 DIQLTQSPSSLPASVGDRVTITCRASQRIASYLNWYQQKPGKAPKVLIYAASNLQSG ADI-41535 Light chain variable region VPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYTTPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 808 1615 EVQLVESGAGLLKPSETLSLTCVVYGGSFSGYYWSWIRQPPGKGLEWVGDINHSTT ADI-41536 Heavy chain variable region TNYNPSLESRITISIDTSKNQFSLNLSSVTAADSAVYYCARGPKECTSSSCDRFGVDYF (“HC”) amino acid sequence YYGMDVWGRGTTVTVSS Ab 808 1616 QSVLTQPPSVSGAPGQRVTISCTGSSANIGAGYDVHWYQQFPGTAPKLLIFGNSNR ADI-41536 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDGTLGGWVFGGGTQLTVL (“LC”) amino acid sequence Ab 809 1617 EVQLLESGGGLVQPGGSLRLSCAASEFTFSRYPMSWVRQAPGKGLEWVSGISVSG ADI-41537 Heavy chain variable region DSTYYADSVKGRLTISRDNSKNTLYLQMNSLRAEDTAVYYCAIDHYDTSGYYGMDV (“HC”) amino acid sequence WGQGTTVTVSS Ab 809 1618 DIRLTQSPLSLPVTPGEPASISCRSSRSLLRSNGYNYLDWYLQKPGQSPQLLIYLGSNR ADI-41537 Light chain variable region ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQSSYTFGQGTKLEIK (“LC”) amino acid sequence Ab 810 1619 EVQLVESGGGLVKPGGSLRLSCAASGFTLSTYGVNWVRQAPGKGLEWVSSISSSGN ADI-41538 Heavy chain variable region NIHYADSVKGRFTVFRDNAKHSMYLQMNSLRAEDTAVYYCARSLDYSNYYYYYGLD (“HC”) amino acid sequence VWGQGTTVTVSS Ab 810 1620 EIVLTQSPDSLAVSLGERATINCKSSQSIFYSSNNMNYLAWYQQKAGQPPKLLIYWA ADI-41538 Light chain variable region STRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSIPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 811 1621 QVQLVESGAEVKKPGASVKVSCKASGYNFIDYGISWVRQAPGQGLEWVGWISAY ADI-41539 Heavy chain variable region NGNTNYAQKLQGRVTMTTDTSTNTAYMELRSLRSDDTALYYCARDSSSLHPTYYYY (“HC”) amino acid sequence YPMDVWGQGTTVTVSS Ab 811 1622 DIVMTQSPATLSVSPGERATLSCRASQSVSSRLAWYQQKPGQAPRLLIYGASTRAT ADI-41539 Light chain variable region DVPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPERTFGQGTKVEIK (“LC”) amino acid sequence Ab 812 1623 QVQLQQWGAGLLKPSETLSLTCGVYGGSFTGYQWSWIRQSPGKGLEWIGDIDHG ADI-41540 Heavy chain variable region GNTNYRPSLKSRIITSVNMSKKEFSLKLASVTAADTAVYYCARGVGFLEFSGGPTGRR (“HC”) amino acid sequence RNWFDSWGQGTLVTVSS Ab 812 1624 DIQLTQSPGTLSLSPGEGATLSCRASQSVGGSYLAWYQQRPGQAPRLLIYGASNRA ADI-41540 Light chain variable region ADSPDRFSGSGSATDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 813 1625 QITLKESGPTLVKPTQTLTLTCTFSGFSLSSSGVGVGWIRQPPGKALEWLALIYWDD ADI-41541 Heavy chain variable region DKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRGPYYYDMSGYYYE (“HC”) amino acid sequence AFDIWGQGTTVTVSS Ab 813 1626 SYELMQPPSVSVAPGQTARITCGGNNIGSKGVHWYQQKPGQAPVLVVYDDNDRP ADI-41541 Light chain variable region SGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHHYVFGTGTKVTVL (“LC”) amino acid sequence Ab 814 1627 EVQLVESGVAVKKPGESLKISCKGSGYNFDSFWIGWVRQLPGKGLEWMGIIFPGDS ADI-41542 Heavy chain variable region DTRYGPSFQGQVTISADKSINTAYLQWRSLKASDTAMYYCARHGLGGYDNSGYNL (“HC”) amino acid sequence WGHGTMVTVSS Ab 814 1628 DIVMTQSPSSLSASVGDRVTITCQASHDISTSLNWYQQKPGKAPNLLISDASTLERG ADI-41542 Light chain variable region VPSRFSGGGSGTEFTFTISSLQPEDIATYYCQQFENLPITFGQGTRLEIK (“LC”) amino acid sequence Ab 815 1629 QVQLVQSGAEVKKPGASVRVSCKASGYTLTGYYIHWLRQAPGQGLEWVGRINPNT ADI-41543 Heavy chain variable region GETSYSQKFQGRVIMTRDTSVSTAYVDLSRLRSRDTAVYFCARSDVMITVTAEGDFS (“HC”) amino acid sequence YYYYRFDVWGQGTTVTVSS Ab 815 1630 DIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGHNYLDWYLQKPGQSPQLLIYLGSI ADI-41543 Light chain variable region RASGVSDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQALQTPHFGGGTKVEIK (“LC”) amino acid sequence Ab 816 1631 QVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIFPA ADI-41544 Heavy chain variable region DSDTRYSPSFQGQVTISADKSVSTAYLQWTSLKASDTAIYYCARLGVAAAGGYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 816 1632 DIQVTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIHDASTLETG ADI-41544 Light chain variable region VPSRFSGRGSGTDFTFTISSLQPEDIATYYCQQYDNLPPTFGGGTKVEIK (“LC”) amino acid sequence Ab 817 1633 QVQLVESGPGLVKPSETLSLTCTVSGGSISRYYWSWIRQSPGKGLEWIGYIYHSVITN ADI-41545 Heavy chain variable region YNPSLKSRVTISIDMSKNQFSLKLSSVTAADTAVYYCASRPLINGYGPDNYFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 817 1634 SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQRKPGQAPVLVVYDDSDRPS ADI-41545 Light chain variable region GIPERFSGSNSGNTATLTIIRVEAGDEADYYCQVWDNSSDHPVFGGGTKLTVL (“LC”) amino acid sequence Ab 818 1635 QVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIFSAD ADI-41546 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARQWGITGDAFDIWG (“HC”) amino acid sequence QGTMVTVSS Ab 818 1636 DIQVTQSPSFLSASVGDRVTITCRASQGISGYLAWYQQKPGKAPKLLIYAASTLQSG ADI-41546 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 819 1637 QVQLVQSGAEVKKPGSSVKVSCKASGGSFSSNTINWVRQAPGQGLEWMGGIIPVF ADI-41547 Heavy chain variable region ETPNYAQKFQGRVSFTADESTRTAYMELSSLRSEDTAVYFCARQGMSYYDTNGNY (“HC”) amino acid sequence YVGWFDTWGQGTLVTVSS Ab 819 1638 EIVLTQSPGTLSLSPGERATLSCRASQSLNNNYLAWYQRKPGQAPRLLIYGAGAFSR ADI-41547 Light chain variable region ATGIPDRFSGSGSGTDFTLTISRLEPEDFALYYCQQYGSSPLTFGQGTRLEIK (“LC”) amino acid sequence Ab 820 1639 QVQLQQWGPGLVKPSETLSLTCTVSGASITSHYWSWLRQPAGKGLEWIGRFYPSG ADI-41548 Heavy chain variable region TTEKTPSLKSRVTLSVDTSKNHFSLKLTSVTAADTAVYYCARDSYDDIAGSYEYYFAD (“HC”) amino acid sequence WGQGTLVTVSS Ab 820 1640 EIVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYDISTRATGV ADI-41548 Light chain variable region PARFSGSGSGTEFTLTITSLQSEDFTVYYCQQYNNWPPTFGQGTKLEIK (“LC”) amino acid sequence Ab 821 1641 EVQLLESGGGVVQPGGSLRLSCAASGFTFSGYGMHWVRQAPGKGLEWVAFIQYN ADI-41549 Heavy chain variable region GSNKYYADSVKGRFTISRDNSKNTLYVQLNSLRAEDTAVYYCATDILVVPAATPLISY (“HC”) amino acid sequence YFGMDVWGQGTTVTVSS Ab 821 1642 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQYPGKAPKLMIYEVTNR ADI-41549 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYTSTNTRVFGTGTKVTVL (“LC”) amino acid sequence Ab 822 1643 QVQLVQSGAEVKMPGASVRVSCKASGYTLGSHGITWVRQAPGQGLEWMGWISA ADI-41550 Heavy chain variable region NNFNTHYAQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREVMGHMVET (“HC”) amino acid sequence ISFDYWGQGTLVTVSS Ab 822 1644 QPVLTQPPSVSVAPGQTARITCGGNNIGSESVHWYQQKPGQAPVLVVHDDSDRP ADI-41550 Light chain variable region SGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDFTPDHPVFGGGTKVTVL (“LC”) amino acid sequence Ab 823 1645 QVQLQESGGGVVQPGGSLRLSCAASGFTFSRHWMHWVRQVPGKGLVWVSRINS ADI-41551 Heavy chain variable region DESTIDYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCVRDMVAVPGTTG (“HC”) amino acid sequence GDYWGQGTLVTVSS Ab 823 1646 SYELTQPPSVSVSPGQTADITCSGDKLGDKYACWYQQRAGQSPILVLYQDTRRPSGI ADI-41551 Light chain variable region PERFSGSNSGDTATLTISGTQAMDEADYYCQAWDSSTAWVFGGGTKLTVL (“LC”) amino acid sequence Ab 824 1647 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-43643 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVLSGYSYGYDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 824 1648 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-43643 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGTGTKVTVL (“LC”) amino acid sequence Ab 825 1649 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSG ADI-43644 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDFTVVHPLQQLTYY (“HC”) amino acid sequence YFDYWGQGTLVTVSS Ab 825 1650 DIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGI ADI-43644 Light chain variable region PARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPGFTFGGGTKVEIK (“LC”) amino acid sequence Ab 826 1651 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIF ADI-43645 Heavy chain variable region GTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGWRGGGMTGSYY (“HC”) amino acid sequence YYGMDVWGQGTTVTVSS Ab 826 1652 DIQVTQTPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGV ADI-43645 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQHRGTFGQGTKVDIK (“LC”) amino acid sequence Ab 827 1653 EMQLMQSGGVVVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSLIS ADI-43646 Heavy chain variable region WDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTALYYCAKDFDPLVVPAA (“HC”) amino acid sequence MCFDYWGQGTLVTVSS Ab 827 1654 QSVLIQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNR ADI-43646 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKLTVL (“LC”) amino acid sequence Ab 828 1655 EVQLVESGGGLVQLGGPLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSG ADI-43647 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGFERDYADAFDIW (“HC”) amino acid sequence GQGTTVTVSS Ab 828 1656 DIRMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSG ADI-43647 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK (“LC”) amino acid sequence Ab 829 1657 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMN ADI-43648 Heavy chain variable region PNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCATRPAALDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 829 1658 QPVLIQPLSVSVALGQTARITCGGNNIGSKNVHWYQQKPGQAPVLIIYRDSNRPSG ADI-43648 Light chain variable region IPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTWVFGGGTKLTVL (“LC”) amino acid sequence Ab 830 1659 QVQLVQSGGGLVKPGGSLRLSCAASGFTFRDFYMSWIRQAPGKGLEWVSNISPSS ADI-36673 Heavy chain variable region TYTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVKSEGYSSGWYDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 830 1660 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVNWYHQLPGAAPKLLIYTNSNR ADI-36673 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 831 1661 EVQLVESGGGLVQPGGSLRLSCAASGFTFNRFAMSWVRQAPGKGLEWVSGISGS ADI-36675 Heavy chain variable region GGSTLYADSVKGRFTISRDNSKNTLYLQINSLRVEDTAVYYCASRSSYDDVWNGYVD (“HC”) amino acid sequence WDWGFDFYYYGMDVWGQGTTVTVSS Ab 831 1662 QAVVTQEPSMSAAPGQKVTISCSGGDSNIRNNYVFWYQQLPGTAPKLLIYDNTKR ADI-36675 Light chain variable region PSGIPGRFSGSKSGASATLDITGLQTGDEADYYCGTWDSSLSALVFGGGTQLTVL (“LC”) amino acid sequence Ab 832 1663 EVQLLESGGGVVQPGRSLRLSCAASGFSFRNYDMHWVRQAPGKGLEWVAIISYDG ADI-36676 Heavy chain variable region SNKYADSVKGRFTISRDTSKNTLYLQMNSLRVEDTAVYYCARADSSGYYKGSEYFQH (“HC”) amino acid sequence WGQGTLVTVSS Ab 832 1664 SYELTQLPSVSVAPGQTARITCGGNNIGTKSVQWYQHKPGQAPVLVVYDDSDRPS ADI-36676 Light chain variable region DIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKLTVL (“LC”) amino acid sequence Ab 833 1665 EVQLVQSGGGLVQPGGSLRVSCAASGLTVSTNYMSWVRQLPGKGLEWVSVIYSG ADI-36678 Heavy chain variable region GNTYYADSVKGRFTISRDNSKNIVYLEMNSLRIEDTAVYYCARAHLNNWFVSVTDT (“HC”) amino acid sequence KDYYFDYWGQGTLVTVSS Ab 833 1666 SYELTQPPSVSVLPGQTASITCSGDKLGDKYASWYQQKPGQSPILVVFQDDKRPSGI ADI-36678 Light chain variable region PERFSGSNSGNTATLTISGTQATDEADYYCQACDRNTGVFGTGTKLTVL (“LC”) amino acid sequence Ab 834 1667 EVQLLESGGGLVQPGGSLRLSCAASGFTFSPYSMNWVRQAPGKGLEWVSYISRSG ADI-41552 Heavy chain variable region SFKYYADSVKGRFTISRDDAKNSLYLHMNSLRDDDTAVYYCVSYCSSATCHQRFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 834 1668 EIVLTQSPATLSLSPGERATLSCRASQSVNSYLAWYQQKPGQAPRLLIYDASNRATGI ADI-41552 Light chain variable region PARFSGSGSGTDFTLTISSLEPEDFAVYYCQERNSWPKLTFGGGTKVEIK (“LC”) amino acid sequence Ab 835 1669 EVQLVESETEVKKPGASVKVSCKASGYTFTKYGISWVRQAPGQGLEWMGWISAYN ADI-41553 Heavy chain variable region GNTMYPHKLLGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQTYYDFWSGYY (“HC”) amino acid sequence TYWGQGTLVTVSS Ab 835 1670 DIVMTQTPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESG ADI-41553 Light chain variable region FTLTISSLQPDDSATYYCQQYNSYSRTFGQGTKVEIK (“LC”) amino acid sequence Ab 836 1671 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYPMNWVRQGPGKGLEWVSSISSSG ADI-41554 Heavy chain variable region ASPYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAREDYYYYYMDVWG (“HC”) amino acid sequence KGTTVTVSS Ab 836 1672 ETTLTQSPSTLSASVGDRVTITCRASESISSWLAWYQQKPGKAPKLLIFKASTVQSGV ADI-41554 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYLLTFGGGTKVEIK (“LC”) amino acid sequence Ab 837 1673 EVQLVESGPGLVKPSQTLSLTCSVSGGSISSGIHYWSWIRQHPGKGLEWIGYIYYSGS ADI-41555 Heavy chain variable region TYYNPSLESRITISVDTSKNQFSLKVSSVTAADTAVYYCARVNRASRMTTFGVANERS (“HC”) amino acid sequence IYYFMDVWGKGTTVTVSS Ab 837 1674 ETTLTQSPATLSLSPGERATLSCRATQSVGNYLAWYQQKPGQAPRLLIHDASNRAT ADI-41555 Light chain variable region GIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQLRINWLFTFGPGTKVEIK (“LC”) amino acid sequence Ab 838 1675 EVQLLESGGGLVKPGGSLRLSCAASGFSFSSYSMHWVRQAPGKGLEWVSSISSSSTY ADI-41556 Heavy chain variable region IYYADSVKGRFTISRDNAKTSLFLQMNSLRAEDTAVYYCARDPYSSGWYWDWGQG (“HC”) amino acid sequence TTVTVSS Ab 838 1676 EIVMTQSPATLSVSPGERATLSCRASQSVSGNLAWYQQKPGQAPRLLIYGASTRAT ADI-41556 Light chain variable region GIPARFSGSGSGTEFTLTISSLQSEDFAVYYCHQYNNRPATFGQGTKVDIK (“LC”) amino acid sequence Ab 839 1677 EVQLLESGPGLVKPSETLSLTCNVSGGSISSYYWSWIRQSPGKGLEWIGHIYDTGYT ADI-41557 Heavy chain variable region NYNPSLKSRVTMSVDTSKNRFSLKLDSVTAADTAVYYCARGRGWRNLYNWFDPW (“HC”) amino acid sequence GQGTLVTVSS Ab 839 1678 DIVMTQSPATLSVSPGERATLSCRTSQSFSSMLAWYQQKPGQAPRLLIYGASTRAT ADI-41557 Light chain variable region GIPARFSGSGSATEFTLTISNLQSEDVAVYYCQQYNSWPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 840 1679 EVQLLESGGGLVKPGGSLRLSCEVSGFPFSDYYVSWIRQAPGKGLEWLSYSSRGGIY ADI-41558 Heavy chain variable region TNYADSVKGRFTISRDNDKNSLFLQMNSLRAEDTAVYYCARDRSDIWSGRVGFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 840 1680 DIVMTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRAT ADI-41558 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYNKSPPGYIFGPGTKVDIK (“LC”) amino acid sequence Ab 841 1681 QVQLVQSGPTLVKPTQTLTLTCSFSGFSLTNTGVGVGWIRQPPGKALEWLALIYWD ADI-41561 Heavy chain variable region DDKRYRPSLKSRLTITKDTSKSQVVLTMTNMDPLDTATYYCAHRRSAYDPIYFDYW (“HC”) amino acid sequence GQGALVTVSS Ab 841 1682 DIRVTQSPSSVSASVGDRVTITCRASRSINNWLAWYQQKPGKAPKLLIYAASSLQSG ADI-41561 Light chain variable region VPSRFSGSGYGTDFTLTISSLQPEDFATYYCQQAHSFPSITFGQGTRLEIK (“LC”) amino acid sequence Ab 842 1683 QVQLVQSGAEVKKPGASVRVSCKTSGYAFSKYGISWVRQAPGQGLEWIGWISAYN ADI-41562 Heavy chain variable region ENTHFSHKFLGRVTMTTDTSTGIAYMDLRSLKSDDTAVYYCARDWYSLGSDWYFG (“HC”) amino acid sequence PMFDYWGQGTLVTVSS Ab 842 1684 EIVLTQSPDTLSVSPGERATLSCRASQSVTTNLAWYQQKPGHAPRLLIYGASTRATGI ADI-41562 Light chain variable region PARFSGSGSGTEFTLTISSLQSEDFAIYYCQQYTNWPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 843 1685 QVQLVESGPGLVKPSETLSLTCTVSDDSITNNFWTWIRQPPGKGLEWIGYIYYSGST ADI-41563 Heavy chain variable region NYNPSLKSRITMSVDLSKNQFSLKLSSVTAADTAVYYCARLTSGGVDYWGQGTLVT (“HC”) amino acid sequence VSS Ab 843 1686 QSVLTQPPSLSGAPGQRVTISCTGSSSNIGADYHVHWYQQLPGTAPKLLIYQNTNR ADI-41563 Light chain variable region PSGVPDRFSASKSGTSVSLAITGLQAEDEADYYCQSYDSSLSAWVFGGGTKLTVL (“LC”) amino acid sequence Ab 844 1687 QVQLVQSGAEVKKPGSSVKVSCKAFGGTLRRYALSWVRQAPGQGLEWMGGIIPV ADI-41564 Heavy chain variable region FGTRRYAQKFQGRITITADGSTSTASMEVSSLRFEDTAIYYCATVYFDFVSGPPPTYY (“HC”) amino acid sequence YYYMDVWGKGTTVTVSS Ab 844 1688 DIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRAT ADI-41564 Light chain variable region GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDSSLRVLTFGGGTKVDIK (“LC”) amino acid sequence Ab 845 1689 QVQLQQWGAGLLKPSETLSLTCEVYGGSFSGYYWTWFRQPPGEGLEWIGEINHSG ADI-41567 Heavy chain variable region GTNYNPSLKSRVTMSVDASINQFSLQLSSVTAADTSVYYCARGHYYNTNDFYGLFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 845 1690 DIRLTQSPSFLSASVGDRVTITCRASQGISTYLAWYQQKPGKAPKLLLYAASTLHSGV ADI-41567 Light chain variable region PSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNRYPPSTFGPGTKLEIK (“LC”) amino acid sequence Ab 846 1691 QVQLQQWGARLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPGKGLEWIGEINHSG ADI-41568 Heavy chain variable region STNYNPSLKSRVTISRDTSKKQFSLKVSSVTAADTAVYYCARDPPIRCNGDSCKSDQY (“HC”) amino acid sequence RYGMDVWGQGTTVTVSS Ab 846 1692 QPGLTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIHKDNERPS ADI-41568 Light chain variable region GIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADTSGSYRLFGGGTKLTVL (“LC”) amino acid sequence Ab 847 1693 EVQLLESGAEVKKPGSSVKVSCKASGGTFSTYAISWVRQAPGQGLEWMGGIIPVLG ADI-41569 Heavy chain variable region TTKYAQKFQDRVTITADESTSTAYMDLSGLRSDDTAVYYCARGVWGDCGRASCLF (“HC”) amino acid sequence DWYFDLWGRGTLVTVSS Ab 847 1694 EIVMTQSPATLSVSPGERVTLSCSASQTVSSNLAWYQQKPGQAPRLLIYGASIRATDI ADI-41569 Light chain variable region PARFSGSGSRTEFTLTISSLQSEDFAVYYCQQYNNRPPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 848 1695 QVQLVQSGAEVKKPGSSVKVSCMASGGTFSNSAINWVRQAPGQGLEWMGGTIPI ADI-41570 Heavy chain variable region FGAANYAQRFQARVTITADKSTSTAYMELTSLRSDDTAVYYCVRTPHRSSDHIWGS (“HC”) amino acid sequence YRYFDSWGQGTLVTVSS Ab 848 1696 QSVVTQEPSVSAAPGQKITISCSGSTSNIGINYVSWYQQFPGTAPKLLIYDNDKRPSG ADI-41570 Light chain variable region IPDRFSGSKSGTSATLGITGLQAGDEADYYCGTWDSSLSAGHIFGGGTKVTVL (“LC”) amino acid sequence Ab 849 1697 EVQLLESGGGLVKPGGSLRLSCEASGFPFNSYHMNWIRQSPGKGLEWVSYITGGSS ADI-41571 Heavy chain variable region FSNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTTLDCTSTSCHYRFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 849 1698 QSVLTQPPSVSGAPGQRITISCNGSNSNIGAGYDVHWYQQLPGKAPKLLIYSNNNR ADI-41571 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQGEDEADYYCQSHDTRLSGNVVFGGGTKLTVL (“LC”) amino acid sequence Ab 850 1699 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVAWIRQPPGKALEWLALIYWDD ADI-41574 Heavy chain variable region DKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHSSVYTTPFDYWGQ (“HC”) amino acid sequence GSLVTVSS Ab 850 1700 DIQLTQSPSTLSASVGDRVTITCRASQSISDWLAWYQQKPGKAPKLLIYKAFTLESGV ADI-41574 Light chain variable region PSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYTSYWTFGQGTKVEIK (“LC”) amino acid sequence Ab 851 1701 QVTLKESGPTLVKPTQTLTLSCSFSGFSLSAYAVGVGWIRQPPGKALEWLALIYWDD ADI-41576 Heavy chain variable region DKRYSPSLETRLTITKDTSKNQVVLTMTKMDPVDTATYYCVYSYNGYYEYMDVWG (“HC”) amino acid sequence NGTTVTVSS Ab 851 1702 DIVMTQSPATLSLSPGERATLSCRASQSVSNYLAWYQQKPGQAPRLLISGASNRAT ADI-41576 Light chain variable region GIPDRFSGSGSGTDFTLTITTPEPEDFAVYYCQQRNAWPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 852 1703 EVQLVESGGGVVQPGRSLRLSCAASGFTLSSYVMDWVRQAPGKGLEWVAVISYD ADI-41578 Heavy chain variable region GSSKYYADSVKGRFTVSRDNSNNAMYLQMNSLRAEDTAVYYCARDPYYDILTGYSY (“HC”) amino acid sequence FDYWGHGTTVTVSS Ab 852 1704 SYVLTQPPSVSGAPRQTATITCGGNNIGSKSVNWYQQKPGQAPVLVVYDDSARPS ADI-41578 Light chain variable region GIPERFSGSNSGNTATLTVSSVEAGDEADYFCQVWDTSSAPYPWVFGGGTKLTVL (“LC”) amino acid sequence Ab 853 1705 QVQLVESGAEARKPGSSVKVSCKLSGGTFSTDPISWVRQAPGQGLEWMGRIIPLLG ADI-41579 Heavy chain variable region IANYAQKFQGRVTIIADKSTSTVYMELRNLRFEDTAVYFCARRGDGYYGMDVWGQ (“HC”) amino acid sequence GTTVTVSS Ab 853 1706 QSVLTQPASVSGSPGQSITISCTGTSNDIGGYDYVSWYQQHPGKAPKLMIYDVHNR ADI-41579 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSFSDSGNLYVFGTGTKLTVL (“LC”) amino acid sequence Ab 854 1707 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEMNHS ADI-41580 Heavy chain variable region GGSNYNPSFKSRVTISVDTSKKYFSLNLSSVTAADTAIYYCARTPFYYESTGYYYYYYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 854 1708 DIVMTQTPDSLAVSLGERATINCKSSQSVSHSSNNKNYLSWYQQKPGQPPKLLIYW ADI-41580 Light chain variable region ASIRESEAPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQQYYTAPITFGQGTRLEIK (“LC”) amino acid sequence Ab 855 1709 EVQLLESGSELKKPGASVKISCKTSGYTFTNYLMNWVRQAPGQGLEWMGWINTH ADI-41581 Heavy chain variable region TGNPTYAQDFTGRFVFSLDTSVNTAYLQISSLKAEDTAIYYCARDGLEAFSGYNGVD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 855 1710 DIVMTQTPLSLPVTPGEPASISCRSSPSLLHSNGYNYLDWYLQKPGQSPQLLIYLGST ADI-41581 Light chain variable region RASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQALQIPLTFGQGTKLEIK (“LC”) amino acid sequence Ab 856 1711 EVQLVESGPGLVKPSQTLSLTCTVSGGPISSGVYYWSWIRQHPGKGLESIGYIYYSGS ADI-41582 Heavy chain variable region THYNPSLKTRVTISLDTSKNQFSLKLSSVTAADTAVYYCARGCSGGSCYLYAFDIWG (“HC”) amino acid sequence QGTTVTVSS Ab 856 1712 QPVLTQPPSVSVAPGQTARITCGGNNIGTKSVHWYQQKPGQAPLLVVYDDSDRPS ADI-41582 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADFYCQVWDYATDHVVFGGGTKLTVL (“LC”) amino acid sequence Ab 857 1713 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRHTITWVRQAPGQGLEWMGRIAPIV ADI-41583 Heavy chain variable region GFANYAQKFQGRVTITADKSTSTAYMELRSLRSEDTAVYYCARRSEDYYGLDVWG (“HC”) amino acid sequence QGTTVTVSS Ab 857 1714 DIVMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYEASNLETG ADI-41583 Light chain variable region VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLFGGGTKLEIK (“LC”) amino acid sequence Ab 858 1715 QVQLVESGAEVKKPGASVKVSCKASGYTFTDYYIHWVRQAPGQGLEWVGRINPNS ADI-41584 Heavy chain variable region GYINYAQKFQGRLTMTRDTSISTAYLELSSLRSDDTAVYYCTRLPLLEPLNFFDYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 858 1716 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKVLIYGNNN ADI-41584 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSFDSSLSSSYVFGTGTKLTVL (“LC”) amino acid sequence Ab 859 1717 EVQLLESGGGLVKPGGSLRLSCAASGFTFADYYMSWIRQAPGKGLEWVSYISGGSS ADI-41585 Heavy chain variable region FTNYADSVKGRFTISRDNAKNSLYLQMNSLRADDTAVYYCARGISPALGGGEYFQD (“HC”) amino acid sequence WGQGTLVTVSS Ab 859 1718 QPVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQHLPGTAPKLLIYGNSNR ADI-41585 Light chain variable region PSGVPDRFSGSKSSTSASLAITGLQAEDEADYYCQSYDSSLGGYVFGTGTKVTVL (“LC”) amino acid sequence Ab 860 1719 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYSWSWIRQPPGKGLEWIGDIDHD ADI-41586 Heavy chain variable region GSTYYNSSLKSRVIMSIDTSKNQFSLKLSSVTAADTAVYYCARVGGNSGYWGQGTL (“HC”) amino acid sequence VTVSS Ab 860 1720 DIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGFNYLDWYLQKPGQSPQLLIYLGSN ADI-41586 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTLTFGPGTKVEIK (“LC”) amino acid sequence Ab 861 1721 QVQLVQSGAGLLKPSETLSLTCAVYGGSFSGYSWSWIRQPPGKGLEWIGEINYSVS ADI-41587 Heavy chain variable region TSYNSSLKSRVSISVDTSKNQFSLKLTSVTAADTAVYYCARVGGAVADWGQGTLVT (“HC”) amino acid sequence VSS Ab 861 1722 EIVLTQSPLSLPVTPGEPASISCRSSQRLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-41587 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQNLQTLTFGGGTKVDIK (“LC”) amino acid sequence Ab 862 1723 QVQLVESGPTLVKPTQTLTLTCTFSGFSLSTNGVGVAWIRQPPGKALEWLAIIYWD ADI-41588 Heavy chain variable region DDKRYSPSLKSRLTITKDTSKNQVVLTVTDMDPVDTATYYCAHTIGVPAATRFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 862 1724 SYELTQPPSVSVSPGQTASITCSGDKLGDKFACWYQQKPGQSPVLVIYQDNKRPSGI ADI-41588 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTASYVFGTGTKLTVL (“LC”) amino acid sequence Ab 863 1725 EVQLLESGGGLVQPGGSLRLSCAASGFTFNFFALTWVRQAPGKGLEWVSAISGSGE ADI-41589 Heavy chain variable region STYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFARSGDYASFFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 863 1726 DIRVTQSPDSLAVSLGERATINCKSSQNVFYSSNNKNFLAWYQQKPGQPPKLLIYW ADI-41589 Light chain variable region ASTRESGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTKFTFGPGTKVEIK (“LC”) amino acid sequence Ab 864 1727 EVQLVQSGGGLVKPGGSLRLSCTASGFTFSDHYMSWIRQAPGKGLEWISYISSTSSF ADI-41590 Heavy chain variable region TNYANSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRSILYSGYSLDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 864 1728 DIQMTQSPSSLSASVGDRVTISCRASQSILNYLNWYQHKPGKAPKLLIYAASSLQSG ADI-41590 Light chain variable region VPSRFSGSGSGTDFTLTISGLQPEDFATYYCQQSDSTRTFGQGTKVEIK (“LC”) amino acid sequence Ab 865 1729 QVTLKESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSSSY ADI-41591 Heavy chain variable region TNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREAVAAAGTDYFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 865 1730 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQPPRTAPKLLIYGNSNR ADI-41591 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKLTVL (“LC”) amino acid sequence Ab 866 1731 EVQLVESGSELKKPGASVKVSCKASGYTFRTYVMNWVRQAPGQGLEWMGWINT ADI-41592 Heavy chain variable region NTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARESIDDYDSSGYGR (“HC”) amino acid sequence TFDYWGQGTLVTVSS Ab 866 1732 SYELTQPPSVSVSPGQTASIPCSGDKVGKTYVYWYQQTPGQSPGLVIYQDTKRPSGI ADI-41592 Light chain variable region PERFSGSSSGNTATLTISGTQTMDEADYYCQAWDTSTASYVFGTGTKLTVL (“LC”) amino acid sequence Ab 867 1733 QVQLVQSGVEVKKPGESLKISCKGSGYSFTNYWIAWVRQMPGKGLEWMGIIYPG ADI-41593 Heavy chain variable region DSDTRYSPSFQGQVTISADKSISTAYVQWSSLKASDTAIYYCARGDILTNSGPDAFDI (“HC”) amino acid sequence WGQGTMVTVSS Ab 867 1734 DIQMTQSPSSFSASTGDRVTITCRASQAISSYLAWFQQKPGKAPKLLIYAASTLQSG ADI-41593 Light chain variable region VPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQYYSYPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 868 1735 EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYYMNWVRQAPGKGLEWVSSISPSSS ADI-41594 Heavy chain variable region YTNYADSVKGRFTISRDNAKDSLYLQMNSLRAEDTAVYYCARDGLLGITIFGVVQDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 868 1736 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNR ADI-41594 Light chain variable region PSGVPDRFSASKSGTSASLAITGLQAEDEADYYCQSYDSSLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 869 1737 QVQLVQSGGGVVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAVISD ADI-41595 Heavy chain variable region GGSNQYSADSVRGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCAKARIAARAIFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 869 1738 DIQLTQSPSSLSASVGERITITCQASRDVRIYLNWYQHKPGKAPKLLIYDASNLETGV ADI-41595 Light chain variable region PSRYSGSGSGTDFTFTISSLQPEDIATYFCQQYDLLPPTFGVGTKVEIK (“LC”) amino acid sequence Ab 870 1739 QVQLQQWGAGLLKPSETLSLTCAVYGDSFSGYFWTWIRQPPGKGLEWIGEINLSG ADI-41596 Heavy chain variable region STNYNPSLKSRVTILVDTSKNQFSLKLSSVTAADTAVYYCARGLHVSDDQDSSGYYF (“HC”) amino acid sequence HPGSFDYWGQGTLVTVSS Ab 870 1740 DIRMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLINW ADI-41596 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLAISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 871 1741 QVQLQESGPGLVKPSETLSLTCTVSGASVSSNNYYWSWIRQPPGKGLEWIGYIYYS ADI-41597 Heavy chain variable region GSTNYNASLKSRVTISVDTSKNQFSLKLSSVTAADTALYYCAGEHFGVASPFEAPFD (“HC”) amino acid sequence YWGQGTMVTVSS Ab 871 1742 SSELSQPPSVSVAPGKTARITCGGNNIGIKSVHWYQQKPGQAPVLVIYSDSDRPSGI ADI-41597 Light chain variable region PERFSGSNSGNTATLTITRVEAGDEADYYCQVWDSSSDHFVFGIGTKVTVL (“LC”) amino acid sequence Ab 872 1743 EVQLVESGPGLVKPSETLSLTCTVSGGSITPYYWSWIRQPPGKGLEWIGNISYSGSTT ADI-41598 Heavy chain variable region YNPSLKSRVTISVDRSKDQFSLRLRSVTAADTAVYYCARVVTLVLGVSLNDAFDIWG (“HC”) amino acid sequence QGTMVTVSS Ab 872 1744 DIQMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQHKPGKAPILLIYAATTLESGV ADI-41598 Light chain variable region PPRFSGSGSGTDFSLTISSLQPEDFATYYCQQSYSVPLTFGGGTKLEIK (“LC”) amino acid sequence Ab 873 1745 EVQLLESGGGLVQPGGSLRLSCAASGFIFSNYEMNWVRQAPGKGLEWISHITPTGN ADI-41599 Heavy chain variable region SIYYADSVKGRFTISRDNAKNAQYLQMHSLRPDDTAIYYCARGEDPIAATGGFDSW (“HC”) amino acid sequence GQGTLVTVSS Ab 873 1746 EIVLTQSPSSLSASVGDRVTIPRRSSQNVDKFLHWYQQRPGKAPKLLIYAAFSLQSGV ADI-41599 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGQGTKVEIK (“LC”) amino acid sequence Ab 874 1747 EVQLLESGGNMVQPGKSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVISKD ADI-41600 Heavy chain variable region GNNEHYADSVRARFTVSRDNSKNTLFLQMNSLRPEDTAVYYCAIGGLSGSYFGEYF (“HC”) amino acid sequence QHWGRGTLVTVSS Ab 874 1748 DIQMTQSPSSMSASLGDRVTITCRASQGISTWLAWYQQKPGEAPKLLIYAAFGLQS ADI-41600 Light chain variable region GVPSRFSGSGSGTDFTLTINNLQPEDFATYYCQQAISFPFTFGGGTKVEIK (“LC”) amino acid sequence Ab 875 1749 EVQLLESGGGLVKPGGSLRLSCAGSGFRFSDYYMTWIRQAPGKGLEWVSYISSSSTY ADI-41601 Heavy chain variable region TYYTDSVKGRFTVSRDNAKNSLYLQMNTLRAEDTAIYYCAISNRYDSRTFYYDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 875 1750 QSVLTQPPSVSGAPGQRVIISCTGSSSNIGAGYDVHWYQQFPGTAPKLLIYGNNNR ADI-41601 Light chain variable region PSGVPERFSGSKSGTSASLAITGLQADDEADYYCQSYDSLSEVVFGGGTKVTVL (“LC”) amino acid sequence Ab 876 1751 EVQLQESGPGLVKPSETLSLTCTVSGGSLSGYYWSWIRQPPGKGLEWIGYIYHSGST ADI-41602 Heavy chain variable region NYNPSLESRVTISVDTSKNQFSLKVNAVTAADTAVYYCAKVERLLRFDPWGQGTLV (“HC”) amino acid sequence TVSS Ab 876 1752 QSVLIQPASVSGSPGQSITISCIGSSSDVGGYNYVSWYQHYPGKAPKLMIYDVSNRP ADI-41602 Light chain variable region SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSTSYVFGTGTKVTVL (“LC”) amino acid sequence Ab 877 1753 EVQLVESGGGLVKPGRSLRLSCTTSGFTFGDYAMSWFRQAPGKGLEWVGFIRSKPY ADI-41603 Heavy chain variable region GGATAYAASVRGRFTISNDDSKSIAYLQMESLKIEDTAVYYCARDYDDFFFYDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 877 1754 DIRMTQSPATLSVSPGERATLSCRASENIYSNLAWYQQKPGQAPRLLIYGASTRATG ADI-41603 Light chain variable region LPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPAFGGGTKVEIK (“LC”) amino acid sequence Ab 878 1755 QVTLKESGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGRINP ADI-41604 Heavy chain variable region NSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREASRFGGFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 878 1756 DIVLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETG ADI-41604 Light chain variable region VPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLLGYTFGQGTKVEIK (“LC”) amino acid sequence Ab 879 1757 QVQLVESGPGLVKPSQTLSLTCSVSGGSISSDDHYWSWIRQHPGKGLEWIGYIYYS ADI-41605 Heavy chain variable region GYTNYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCARETDITIFGVVPVGYF (“HC”) amino acid sequence DYWGQGTLVTVSS Ab 879 1758 DIQVTQSPDSLAVSLGERATINCKSSQSILSSTNNKNFLAWYQQKPGQPPKLLLHW ADI-41605 Light chain variable region ASTREFGVPDRFSGSGSGTEFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 880 1759 EVQLLESGPGLVKPSETLSLTCTVSGGSVSSGGYYYTWIRQPPGKGLEWIGYAFYSG ADI-41606 Heavy chain variable region DTNYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCASTYTFGASGFDFWGQG (“HC”) amino acid sequence TLVTVSS Ab 880 1760 DIVMTQSPSFMSASVGDRVTITCRASQGISNWLLWYQQKPGKAPKLLIYAASSLQS ADI-41606 Light chain variable region GVPSRFSGSRSGTDFTLTISSLQPEDFAIYYCQQANSFPLTFGQGTRLEIK (“LC”) amino acid sequence Ab 881 1761 EVQLVESGPGLVKPSQTLSLTCTVSGGSINIGGYYWSWIRQHPEKGLEWIGYIYYSG ADI-41607 Heavy chain variable region TTYYNPSLESRVTISIDTSKNQFSLNLSSVTAADTAVYYCASVDQIGATRFDYWGQG (“HC”) amino acid sequence TLVTVSS Ab 881 1762 QPVLTQPRSVSGSPGQSVTLSCTGTSSDVGTYNYVSWYQHHPGKAPKLIIYDVNKR ADI-41607 Light chain variable region PSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTLNYVFGTGTKLTVL (“LC”) amino acid sequence Ab 882 1763 QVQLVQSGDEVKKPGESLKISCKGSEHTFTNYWIAWVRQMPGKGLECMGVIWPD ADI-41608 Heavy chain variable region DSDTKYSPSFQGQVTISADKSINTAYLHLSSLRASDTAMYYCATSKFRTGFDFWGQG (“HC”) amino acid sequence TLVTVSS Ab 882 1764 NFMLTQPHSVSESPGKTVIISCTRSSGNIASNYVQWYQQRPGSSPTTVVYEDNQRP ADI-41608 Light chain variable region SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNPWVFGGGTKLTVL (“LC”) amino acid sequence Ab 883 1765 QVQLVESGAEVKKPGASVKVSCKASGYSFTSYYMHWVRQAPGQGLEWMGVISTN ADI-41609 Heavy chain variable region GGTASYSQNFRGRVILTRDTSTSTAYMELSSLTSEDTAVYYCVREGYCNGGSCSYFD (“HC”) amino acid sequence SWGQGTLVTVSS Ab 883 1766 QSVLTQPPSVSGAPGQRVSISCTGSSSNIGAGYDVHWYQQLPGTAPKVLIYGNNYR ADI-41609 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQTEDEADYYCQSYDSRLSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 884 1767 EVQLLESGGGVVQPGRSLRLSCAASELSFRNYGMHWVRQAPGKGLEWVAVISYD ADI-41610 Heavy chain variable region GNDKYYADSVKGRFTISRDNSKKTLYLQMDSLRAEDTAVYYCAKEGAYCGGDCFSS (“HC”) amino acid sequence WGQGTLVTVSS Ab 884 1768 GIQLTQSPSSLSASVGDRVTITCRASQSSSSYLNWYQQKPGKAPKLLIYAASSLQSGV ADI-41610 Light chain variable region PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFGGGTKVEIK (“LC”) amino acid sequence Ab 885 1769 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYSMNWVRQAPGKGLEWVSSTSSGS ADI-41611 Heavy chain variable region TYIYYADSVKGRFTISRDNGKNSLYLQMNSLRAEDTAVYYCARAFRLGYDALDIWG (“HC”) amino acid sequence QGTMVTVSS Ab 885 1770 DIRMTQSPSSLSASVGDRVTIICRASQSISNYLNWYQQKPGKAPKLLIYVASNLQSG ADI-41611 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSPPPTFGGGTKLEIK (“LC”) amino acid sequence Ab 886 1771 EVQLQESGPGLVKPSGTLSLTCAVAGGFISSGNWWSWIRQPPGKGLEWIGEVYHS ADI-41626 Heavy chain variable region GRTSYNPSLKSRVTISVDNSKNQFSLKMSSVTAADTAVYYCARVESYSSSGYYIAYD (“HC”) amino acid sequence NWGQGNLVTVSS Ab 886 1772 DIVLTQSPSSLSASVGDRVTITCRASQSISRYLSWYQQKPGKAPKLLIYAAFSLQTGVP ADI-41626 Light chain variable region SRFSGSGSGTDFTLTISSFQTEDSATYYCQQSYSAPVTFGGGTKVEIK (“LC”) amino acid sequence Ab 887 1773 QVQLQQWGPGLVKPSETLSLSCAVSGGSLRGHFWSWIRQPPGKGLEWIGEINHG ADI-41644 Heavy chain variable region GRTNFNPSLKSRLTISEDSSKNQFSLKLSSVTAADTAVYYCARRWGYDSSGYYFFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 887 1774 EIQMTQSPATLSVSPGERATLSCRASQTLGFNLAWYQQKPGQSPRLLIYGASTRAT ADI-41644 Light chain variable region GIPARFSGSGAGTEFTLTISSLQSEDFAVYFCQQYSNYYTFGQGTKVEIK (“LC”) amino acid sequence Ab 888 1775 EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRNAISWVRQAPGQGLEWMGGIIPIF ADI-41660 Heavy chain variable region GAANYPQKFQGRVTITADKSTSTAYMELSSLRSEDTALYYCARTMGEMTTTPVSIYY (“HC”) amino acid sequence YGMDVWGQGTTVTVSS Ab 888 1776 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGINYVSWYQQLPGTAPKLLIYDNNKRPS ADI-41660 Light chain variable region GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGYVFGSGTKLTVL (“LC”) amino acid sequence Ab 889 1777 QVQLVQSGAEVKKAGESLKISCKGPRHSFTSYWIGWVRQMPGKGLEWMASIYPG ADI-41662 Heavy chain variable region DSDSRYSPSFEGQVTISADKSIDTAFLQWSSLKASDTAMYFCARYVGAVPGGNWYF (“HC”) amino acid sequence DLWGRGTLVTVSS Ab 889 1778 SYELIQLPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYDDNKRPSGI ADI-41662 Light chain variable region PARFSGSSSGTMATLTISGAQVEDEGDYYCYSTDSTGDHRGVFGGGTKLTVL (“LC”) amino acid sequence Ab 890 1779 EVQLVQSGDEVKKPGASVKVSCKASGYPFSTYGISWVRQAPGQGLEWMGWIGVY ADI-41664 Heavy chain variable region TGGTNYAQKFQGRVILTIDTSTSTAYMELRSLRSDDTAVYYCARGTGSYMTATYFD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 890 1780 SYELTQPPSVSVAPGQTARITCGGNNIGSKAVHWYQQKPGQAPVLVVYDDYDRPS ADI-41664 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDYVFGTGTKLTVL (“LC”) amino acid sequence Ab 891 1781 QVTLKESGPALVKPTQTLTLTCTFSGFSLSTSRMCVSWIRQPPGKALEWLARIDWD ADI-41677 Heavy chain variable region GDIYYSTSLRTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARTSIYATGGYYLYYSD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 891 1782 EIVMTQSPSSLSASVGDRVTITCRASQSIASYVNWFQQKPGKAPKLLIYAASNVHSG ADI-41677 Light chain variable region VPSRFSGSGSGTGFTLTISSLQPEDSAIYYCQQSYTTPWTFGQGTKLEIK (“LC”) amino acid sequence Ab 892 1783 EVQLVESGGGVVQPGGSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVISYD ADI-41678 Heavy chain variable region GSNKYYADSLMGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKCFVPGSGGWYE (“HC”) amino acid sequence YYFDYWGQGTLVTVSS Ab 892 1784 QSVLTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKR ADI-41678 Light chain variable region PSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGINNSVLFGGGTKLTVL (“LC”) amino acid sequence Ab 893 1785 QVQLVQSGAEVKKPGESLRISCKGSGYSFSSHWIGWVRQKPGKGLEWMGIIYPGD ADI-41690 Heavy chain variable region SDTRYSPSFQGHVTISADKSISTAYLRWSSLKASDTAIYYCAKRMVGDYYGMNLWG (“HC”) amino acid sequence QGTTVTVSS Ab 893 1786 EIVMTQSPSSLSASVGDRVTITCQASQDISNRLNWYQQKPGKAPKLLIYDASNLETG ADI-41690 Light chain variable region VPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDYLLWFTFGPGTKVDIK (“LC”) amino acid sequence Ab 894 1787 QVQLVQSGAEVKKPGESLKISCQASGYSFTTYWIGWVRQTPGKGLEWMGIIYPGD ADI-41701 Heavy chain variable region SDTRYTPSFQGQVTISADKSISTAYLHWSSLKASDTAMYYCARLSGGYTFGFDYWGL (“HC”) amino acid sequence GTLVTVSS Ab 894 1788 NFMLTQPHSVSESPGKTVTISCTRSSGNIARYYVQWYQQRPGRAPTTVIYEDDQRP ADI-41701 Light chain variable region SGVPDRFSGSIDRSSNSASLTISGLKTEDEADYYCQSYDASNYVFATGTKVTVL (“LC”) amino acid sequence Ab 895 1789 EVQLLESGSGLVKPLQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGYIYPSGS ADI-41703 Heavy chain variable region TYYNPSLKSRVTMSIDRSKNQFSLRLTSVTAADTAVYYCARGDGNDFWSADSSHAF (“HC”) amino acid sequence AIWGQGTMVTVSS Ab 895 1790 EIVMTQSPGILSLSPGERATLSCRASQIVGNSYLAWYQQKPGQAPRLLIYGASSRAT ADI-41703 Light chain variable region GIPERFSGSGSGTDFTLTISRLEPEDFAVYHCQQYGSSPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 896 1791 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSVIWFD ADI-41720 Heavy chain variable region GSKKYYEDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAVYYCAREAPVRLGELSLYGY (“HC”) amino acid sequence FDYWGQGTLVTVSS Ab 896 1792 DIQMTQSPSTLSASVGDRVTITCRASQSFSSWLAWYQQKPGKAPKLLIYDASTLESG ADI-41720 Light chain variable region VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSWTFGQGTKLEIK (“LC”) amino acid sequence Ab 897 1793 QVQLQESGPGLVKPSQTLSLTCTVSGGSMISGDFYWSWIRQPPGKGLEWIGYIYYS ADI-41737 Heavy chain variable region GTTYYSPSLKSRVSMSIDTSKSQFSLKLSSVTAADTAVYYCARKYSYGEKAYHYWGQ (“HC”) amino acid sequence GTLVTVSS Ab 897 1794 EIVLTQSPGTLSLSPGERATLSCRASQTVGNNYLAWYQQKPGQAPRLLIYGASSRAT ADI-41737 Light chain variable region GIPDRFSGSGSGTDFTLTISRLESEDFAVYHCHQYGTSPQTFGQGTKVEIK (“LC”) amino acid sequence Ab 898 1795 EVQLVESGSGLVKPSQTLSLTCSVSGGSISSGGYSWSWIRQPPGKGLEWIGFIYNTG ADI-41743 Heavy chain variable region STYSNPSLKSRLTLSVDRSNNRFSLKLNSVTAADTGVYFCARSGNVRQCDATGHCST (“HC”) amino acid sequence NYYFEYWGLGTLVTVSS Ab 898 1796 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRAT ADI-41743 Light chain variable region GIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHDDWPPLTFGGGTKVEIK (“LC”) amino acid sequence Ab 899 1797 EVQLLESGGGVVQPGRSLRLSCAASGLSFNSFGMHWVRQAPGKGLEWVAVIAYD ADI-41756 Heavy chain variable region GSNKYYADSVKGRFSISRDNSKNTLYLQMDSLRAEDTAVYYCAKAEAPNFSWSGYL (“HC”) amino acid sequence SAFDIWGQGTTVTVSS Ab 899 1798 QPVLIQPASVSGSPGQSVIVSCTGTSDDVGDYNYVSWYQQHPGKAPKLLIFEVSD ADI-41756 Light chain variable region RPSGVSTRFSGSKSGNTASLTISGLQTEDEADYYCSSYTSRNLYVFGTGTKVTVL (“LC”) amino acid sequence Ab 900 1799 EVQLVESGGGLVQPGRSLRLSCAASGFTFGDYAMHWVRQAPGKGLEWVSGITW ADI-41768 Heavy chain variable region NSGRVVYADSVKGRFTISRDNAKNSLYLQINSLRAEDTALYYCVKGSCNGGICYSAD (“HC”) amino acid sequence YWGQGTLVTVSS Ab 900 1800 NFMLTQPHSVSESPGKTVTISCTRSSGSIARNFVHWYQQRPGSSPTTVIYEDNQRPS ADI-41768 Light chain variable region GVPGRFSGSIDSSSNSASLTISGLRSEDEADYYCQSYDSDNWVFGGGTKLTVL (“LC”) amino acid sequence Ab 901 1801 EVQLLESGGGLVEPGTSLRLSCEASGFTFSDYYMSWIRQAPGKGPEWVADISSRGV ADI-41772 Heavy chain variable region VTYYADSVKGRFTISRDNAKNSLYLQLNSLGAEDTAVYYCARLREVTYIMPTIDYFDY (“HC”) amino acid sequence WGQGTLVTVSS Ab 901 1802 SYELTQPPSVSVSPGQTARITCSGDAFVKKYAYWYHQKSGQAPVVVIYEDTKRPSGI ADI-41772 Light chain variable region PERFSGSSSGTTATLTISGAQVEDEGDYYCYSRDFSGDHGVFGGGTKLTVL (“LC”) amino acid sequence Ab 902 1803 QVQLVESGGGQGQPGRSLRLSCAASGFTFDDYAMHWVRQVPGKGLEWVSGIN ADI-41778 Heavy chain variable region WNSGYIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKANNPIDSSGY (“HC”) amino acid sequence NRGFDTWGQGTLVTVSS Ab 902 1804 QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVNK ADI-41778 Light chain variable region RPSGVPDRFSGSKSDNTASLTISGLQAEDESDYFCCSYAGTYTWVFGGGTKVTVL (“LC”) amino acid sequence Ab 903 1805 QVQLVQSGAEVRKPGASVKVSCKAFGYTFTNFAISWVRQAPGQGLEWMGWIGP ADI-41781 Heavy chain variable region YNGDTDYEQKFQGRVTMTADTSSSTVFMELRSLRFDDTAVYYCARGKGSTIPLGYYI (“HC”) amino acid sequence GMDVWGQGTTVTVSS Ab 903 1806 ETTLTQSPSSLSASVGDRVTMTCRASQGISNYLAWYQQKPGKPPKLLIYLASSLQSG ADI-41781 Light chain variable region VPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPLTFGGGTKLEIK (“LC”) amino acid sequence Ab 904 1807 QVQLVQSGDEVKKPGASVKVSCKSSGYTFTHFGVSWVRQAPGQGLEWMGWISG ADI-41783 Heavy chain variable region YNGNTNYAQKLQGRVTMTTDTSTTTAYMELTSLRSDDTAVYYCARDSPAGTVTLD (“HC”) amino acid sequence FWGQGTTVTVSS Ab 904 1808 DIVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVS ADI-41783 Light chain variable region NRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMHGTHWPPEYTFGQGTKVE (“LC”) amino acid sequence IK Ab 905 1809 EVQLLESGGGVVQPGRSLRLSCAASGFTFSSSGMHWVRQAPGKGLEWVAIISSDG ADI-41787 Heavy chain variable region SKHYYADSVKGRFTISRDNSKNTLYLEMNSLRAEDSAVYYCAREGVWSGFFVDTGT (“HC”) amino acid sequence DFRHHGMDVWGQGTTVTVSS Ab 905 1810 SYELTQPPSVSVSPGQTARITCSGDALPKKFAFWYQQKSGQAPLLVIHEDNKRPSGI ADI-41787 Light chain variable region PERFSGSSSGTLATLTISGAQVEDEADYYCYSIDTSANLGVFGGGTKLTVL (“LC”) amino acid sequence Ab 906 1811 QVQLVQSGAEVKKPGASVKVSCQASGYTLTTYDINWVRQAPGQGLEWMGWMN ADI-41788 Heavy chain variable region ANSGNTGYAQKFQGRVTMTRNISISTAYMELSSLGPEDTAVYYCARGFYKWNDW (“HC”) amino acid sequence SFDYWGQGTLVTVSS Ab 906 1812 QSVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-41788 Light chain variable region GIPERFSGSNSGNTAPLTISRVEAGDEADYYCQVWDGDSAHHAVFGGGTQLTVL (“LC”) amino acid sequence Ab 907 1813 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYGISWVRQAPGQGLERLGGIIPIYG ADI-41790 Heavy chain variable region TANHAQNFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGTFVRYYGMDVW (“HC”) amino acid sequence GQGTTVTVSS Ab 907 1814 EIVLTQSPATLFLSPGERATLSCRASQSVSNYLAWFQQKPGQAPRLLIYDTSIRATGIP ADI-41790 Light chain variable region ARFSGSGSGTDFTLTISSLEPEDFAFYYCQQRSNWPPTFGGGTKLEIK (“LC”) amino acid sequence Ab 908 1815 QVQLVQSGGGLVKHGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWASSISSSS ADI-41792 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTEYSSSSPIFDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 908 1816 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLTYGNSNR ADI-41792 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKVTVL (“LC”) amino acid sequence Ab 909 1817 EVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSG ADI-41794 Heavy chain variable region STNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGTRTIVYCDGDCYQP (“HC”) amino acid sequence WAYHYYGMDVWGQGTTVTVSS Ab 909 1818 QSVVTQEPSVSAAPGQKVTISCSGGSSNIGNNYVSWYQHLPGTAPKLLIYDNDKRP ADI-41794 Light chain variable region SGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVL (“LC”) amino acid sequence Ab 910 1819 QVQLVQSGAEVKKPGSSVKVSCQASGGTFSTHALSWVRQTPGHGLEWVGGVLPV ADI-41799 Heavy chain variable region FGATKYPRKFQGRVTITADKSTNTAYMELSSLRSDDTAVYYCARVVVHSTITTAKDF (“HC”) amino acid sequence FSGVHDIWGQGTMVTVSS Ab 910 1820 DIRMTQSPSTLSASVGDRVTITCRASQTVSSWLAWYQQKPGKAPKLLIYQASSLESG ADI-41799 Light chain variable region VPSRFSGSGSGTEFTLTISGLQPDDFATYFCQHYNSYSPVTFGGGTKVEIK (“LC”) amino acid sequence Ab 911 1821 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWLAWINP ADI-41800 Heavy chain variable region YTGGTNYAQKFQGRVTLTRDTSVSTTYMEVTRLRSDDTAVYYCARGESFHHWGQ (“HC”) amino acid sequence GTLVTVSS Ab 911 1822 QSALTQPASVSGSPGQSITISCTGTSSDIGGYDYVSWYQQHPGKVPKLMIYEVSTRP ADI-41800 Light chain variable region SGVSIRFSGSKSGNTASLTISGLQAEDEADYYCSSYTRSTITSVVFGGGTKLTVL (“LC”) amino acid sequence Ab 912 1823 RCTLQQWGAGRVKPSETLSLTCAVYRGPFSGYYWSWIRQPPGKGLEWIGEINLGE ADI-41803 Heavy chain variable region TNPGGSTHYNPSLRSRLSMSIDTSKKQFSLRVNSVTAADTAVYYCTRGPVSRIYDTS (“HC”) amino acid sequence GSYSLNYYGMDVWGQGTTVTVSS Ab 912 1824 DIRMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGRAPERLIYPASSLQG ADI-41803 Light chain variable region GVPSRFIASGSGTEFTLTISNLQPEDFATYYCLQHNSYPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 913 1825 QVQLQQWGAGLLKPSETLSLTCSVLGGSFSGYYWTWIRQPPGKGLEWIGEITHDG ADI-41804 Heavy chain variable region SSNYNPSLNSRVTISVDTSNYQFSLKMRSVTAADTAVYYCARSPDLTIFGGLYFYYGI (“HC”) amino acid sequence SVWGQGTTVTVSS Ab 913 1826 DIQMTQSPSSLSASMGDRVTITCRASQDISNYLAWYQQKPGKVPNLLIYAASTLQG ADI-41804 Light chain variable region GVPSRFSGSGSGTDFTLTISSLQPEDVAIYYCQKYKSAPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 914 1827 QVQLVQSGAEVKKPGESLKISCKASGYSFTSYWIAWVRQMPGKGLEWMGIIFPGD ADI-41805 Heavy chain variable region SDTRYSPSFQGQVTISADKSISTAYLQWSSLEASDTAMYYCAKSTTYYYYGLDVWG (“HC”) amino acid sequence QGTTVTVSS Ab 914 1828 QPVLTQPASVSGSPGQSITISCTGTSSDVGGYDYVSWYQQYPGKAPKLMIYEVSNR ADI-41805 Light chain variable region PLGVSNRFSGSRSGYTASLTISGLQAEDETNYYCSSYTSSRTWVFGGGTKLTVL (“LC”) amino acid sequence Ab 915 1829 EVQLLESGPALVKPTQTLTLTCTFSGFSLTTTRMSVSWIRQPPGKALEWLARIDWD ADI-41807 Heavy chain variable region DDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYFCARVNVYAANGYYSYY (“HC”) amino acid sequence LDYWGQGTLVTVSS Ab 915 1830 DIVMTQTPSSLSASVGDRVTITCRTSQSSSRYLNWYQKEPGKAPRLLIYLASALRSGV ADI-41807 Light chain variable region PSRFSGSGSGTDFTLTISSLQSEDFATYYCQQTYSIPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 916 1831 QVQLVQSGAELKKPGSSVRISCKVSGVTSDNYAITWVRQAPGQGLEWMGRVIPIF ADI-41808 Heavy chain variable region PVPQYAQKFQGRVTLSADKSTRTAYLELHSLRSEDTATYYCATHRPSDSWGQGTLV (“HC”) amino acid sequence TVSS Ab 916 1832 DIRVTQSPSTLSASVGDRVTITCRASQNINSWLAWYQQKPGKAPKLLIFKASSLESG ADI-41808 Light chain variable region VPARFSGSGFGTEFTLTITSLQPDDFASYYCQQYDTYPYPFGQGTKVEIK (“LC”) amino acid sequence Ab 917 1833 QVTLKESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAISHSD ADI-41809 Heavy chain variable region SRTFYADSVKGRFTISRDNSKNTLFLQMDSLRAHDTAVYYCANVDPSSVTYYGYYYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 917 1834 QSVLTQPPSASGTPGQRVTISCSGSSSNIGKNFVYWYQQFPGTAPKRLIYRNNQRP ADI-41809 Light chain variable region SGVPDRFSGSRSGTSASLAISGLRSEDEADYYCATWDDSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 918 1835 QVQLVQSGGGVVQPGRSLRLSCAASGFNFHNYAMHWVRQAPGKGLEWVAVISY ADI-41810 Heavy chain variable region DGGNKHYADSVKGRFTISRDNSKNTLYLQMNSLRPDDTAVYYCARGHSDWRGDY (“HC”) amino acid sequence FDFWGQGTLVTVSS Ab 918 1836 DIQLTQSPATLSVSPGERAILSCRASQNVGTNLAWYQQKPGQAPRLLIYDASTRATG ADI-41810 Light chain variable region IPARFSGSGAGTDFTLTISGLQSEDFAVYYCQQYINWPPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 919 1837 QVQLQQSGPRLVKPSHTLSLTCVISGDSVSSGSAAWSWIRQSPSRGLEWLGRTYYR ADI-41811 Heavy chain variable region SKWYYDYAVSVKGRIIQPDTSKNQFSLQLNSVSPEDTAVYYCARDPDSGNYFHYYG (“HC”) amino acid sequence MDVWGQGTTVTVSS Ab 919 1838 DIVMTQSPATLSLSPGERATLSCRASQSVDVYFAWYQQKPGQAPRLLIYDASKRAS ADI-41811 Light chain variable region GVPARFSGSASGTDFTLTISSLEPEDFAVYYCQQRAKWPPYTFGQGTKLEIK (“LC”) amino acid sequence Ab 920 1839 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISAGSS ADI-41812 Heavy chain variable region YTDYAESVKGRFTISRDNAKNSLYLKMNSLRAEDTAVYYCARDPGYCSSNSCTVAM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 920 1840 SYELTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNR ADI-41812 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRTLVIFGGGTKLTVL (“LC”) amino acid sequence Ab 921 1841 EVQLLESGPTLVKPTQTLTLTCTFSGFSLSTFGVGVGWIRQPPGKALECLALIYWDD ADI-41814 Heavy chain variable region DKRYSPSLKSRLTITRDTSKNQVVLTMTNMDPVDTATYYCAHRRSSTVTTGFFDYW (“HC”) amino acid sequence GRGTLVTVSS Ab 921 1842 QPVLTQPPSVSGAPGQRVTVSCTGNSSNIGAGHGAHWYQQLPGTAPKLLIYGSTD ADI-41814 Light chain variable region RPSGVPDRFFGSQSGTSASLVITELRAEDEADYYCQSFDSSLSIWVFGGGTKLTVL (“LC”) amino acid sequence Ab 922 1843 EVQLLESGGGLVKPGGSLRLSCGASGFTFSTSSFNWVRQAPGKGLEWVSSISSTSSY ADI-41815 Heavy chain variable region VFYADSVKGRFTVSRDNAQNSLYLQMNSLRAEDTAVYYCARARGVGATIGFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 922 1844 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-41815 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK (“LC”) amino acid sequence Ab 923 1845 QVQLVQSGAEVKKPGASVKVSCEASGYTFTDSYIHWVRQAPGQGLEWMGWINP ADI-41816 Heavy chain variable region NSGGTNYAQKFQGRVTMTRDTSTSTAFIELSRLRSDDTAVYYSARGVRQQWLVNT (“HC”) amino acid sequence GDPDYYFDFWGQGTLVTVSS Ab 923 1846 SYVLTQPPSVSVSPGQTASITCSGDKLGDKYSCWYQQKPGQSPVLVIYQDYKRPSGI ADI-41816 Light chain variable region PERFSGSNSGNTATLTISGTQAMDEADYYCQAWDRNAGVFGTGTKLTVL (“LC”) amino acid sequence Ab 924 1847 QVQLVQSGAEVKKPGESLKISCKGPGYSFTTYWIGWVRQMPGKGLEWMGIIYPG ADI-41817 Heavy chain variable region DSDTKYSPSFQGQVTITADKSIATAYLQWSRLKASDTAVYYCATVVTYADNIRWFDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 924 1848 QSALTQPASVSGSPGQSITISCTGTSGDVGGYKFVSWYQHHPGKAPKLVIYDVANR ADI-41817 Light chain variable region PSGVSDRFSGSKSGTTASLTISGLQAEDEADYYCSSYTSSSTYVFGTGTKVTAL (“LC”) amino acid sequence Ab 925 1849 EVQLVESGGGLVQPGGSLRLSCAASGFTVNTNYMSWVRQAPGKGLEWVSIIYSSG ADI-41818 Heavy chain variable region STSYADSVKGRFTISRDNSENTLYLQMHTLRAEDTAVYYCVRERTPFYYVSSGYWDS (“HC”) amino acid sequence WGQGTLVTVSS Ab 925 1850 EIVLTQSPGTLSLSPGERATLSCRASQSVDSSYLAWYQQKPGQAPRLLIFGASSRATG ADI-41818 Light chain variable region IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGFSYTFGQGTKVEIK (“LC”) amino acid sequence Ab 926 1851 EVQLVESGGGVVQPGRSLRLSCAVSGFTFSTYGMHWVRQTPGRGLEWVAVISYD ADI-41820 Heavy chain variable region GNHKYYADSVMGRFTISRDNSKDTLYLQVNSLRPEDSAVYYCAKDRIHCPNGVCYV (“HC”) amino acid sequence HSSFYGLDVWGQGTTVTVSS Ab 926 1852 QTVVTQEPSLIVSPGGIVTLICGSSTGAVTSGHYPYWLQQKPGQAPRTLIYDTTNK ADI-41820 Light chain variable region DSWTPARFSGSLLGGKAALTLSGAQPEDEAQYYCLLSENGPYWVFGGGTKVTVL (“LC”) amino acid sequence Ab 927 1853 EVQLSESAGGVVQPGGSLRLTCAASGFSFSTNGMHWVRQAPGKGLEWVAFIRYD ADI-41827 Heavy chain variable region GSKKYYAESVKGRFTISREDSNNTLYLQMNSLRPEDTAVYYCAKEDCSGGTCYHERN (“HC”) amino acid sequence YYYYGMDVWGQGTTVTVSS Ab 927 1854 QPVLTQPPSLPVSPGQTASITCSGDKLEYKYACWYQHKPGQSPVLVIYQDNKRPSGI ADI-41827 Light chain variable region PERFSGSNSGNTATLTISGTQPMDEADYYCQAWDSSTVVFGGGTKVTVL (“LC”) amino acid sequence Ab 928 1855 EVQLVESGGGLVQPGGSLRLSCADSDFTFSTYSMNWVRQAPGKGLEWISYITGRSS ADI-41828 Heavy chain variable region AIYYADSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCTTFMAGYSFGHGDAFD (“HC”) amino acid sequence IWGQGTTVTVSS Ab 928 1856 SYELTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS ADI-41828 Light chain variable region GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWNSNSDHPHWVFGGGTQLTVL (“LC”) amino acid sequence Ab 929 1857 EVQLVESGGGLVKPGGSLRLSCAASGFTSSGYNMNWVRQAPGKGLEWVSSISGSS ADI-41829 Heavy chain variable region SYIHYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATVGALPGHFDNWG (“HC”) amino acid sequence QGTLVTVSS Ab 929 1858 QAVVTQEPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNTNR ADI-41829 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSRLTYVFGTGTKVTVL (“LC”) amino acid sequence Ab 930 1859 QVQLVQSGPAVKKPGASVKVSCKASGYIFTSYGVSWVRQAPGQGLEWMGWISGY ADI-41830 Heavy chain variable region NGNTDYAQKFQGRVTLTVDSSTGTVYMDLRSLRSDDTAIYYCARAPPLPGQVYDG (“HC”) amino acid sequence AGSYLLHGYWGQGTLVTVSS Ab 930 1860 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN ADI-41830 Light chain variable region RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 931 1861 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYAMHWVRQPPGKGLEWVSSISASSS ADI-41831 Heavy chain variable region FINYADSVKGRFTISRDGARNSLYLQMNSLRAEDTAVYYCVREDYDSSGYGLHWFD (“HC”) amino acid sequence PWGQGTTVTVSS Ab 931 1862 SYVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQFPGTAPKLLMYGNTN ADI-41831 Light chain variable region RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRSLSGWVFGGGTKLTVL (“LC”) amino acid sequence Ab 932 1863 EVQLVESGGGLVQPGGSLRLSCAASGFTFSKYAMNWVRQAPGKGLEWVSSISDSG ADI-41832 Heavy chain variable region DSRYYADSVKGRFTISRDSSKNTLNLQMNSLRAEDTAVYYCAKAGWELFSPQGAFD (“HC”) amino acid sequence LWGQGTMVTVSS Ab 932 1864 EIVMTQSPGTLSLSPGERATLSCRASQSVSSSHLAWYQQKPGQAPRLLIYGASSRDS ADI-41832 Light chain variable region GIPDRFSGSGSGTDFTLSISRLEPEDFAVYYCQHYGNSPYTFGQGTKVDIK (“LC”) amino acid sequence Ab 933 1865 EVQLLESGGGLVQPGGSLRLSCAASRFTFSTYAMSWVRQAPGKGLEWVSSISGSG ADI-41833 Heavy chain variable region DKTFYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESYYELWTGTYPG (“HC”) amino acid sequence WELDYWGQGTLVTVSS Ab 933 1866 DIQLTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKPPKLLIYAASILESGAP ADI-41833 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDVGTYYCQKSNSAPRPFGQGTKVEIK (“LC”) amino acid sequence Ab 934 1867 EVQLLESGGRLVQPGRSLRLSCAASGFTVSGSYMSWVRQAPGKGLEWVSVIYIDG ADI-41834 Heavy chain variable region GTKYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARDSSLWYRGGDYWG (“HC”) amino acid sequence QGTLVTVSS Ab 934 1868 DIQMTQSPSSLSASVGDRVTITCQANHDISNYLNWYQQKPGKAPKLLIYDASILEAG ADI-41834 Light chain variable region VPSRFSGSGSGTHFTFTISSLQPEDIATYYCQQFDFRALTFGGGTKVEIK (“LC”) amino acid sequence Ab 935 1869 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSIISDSG ADI-41835 Heavy chain variable region GSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKATPLKWELLIGSTP (“HC”) amino acid sequence GYYFDYWGQGTTVTVSS Ab 935 1870 SYELTQLPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVVIMYQDNKRPS ADI-41835 Light chain variable region GIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTGVFGGGTKVTVL (“LC”) amino acid sequence Ab 936 1871 EVQLLESGAEVKKPGASVKVSCRASGYTFTSNTLHWVRQAPGQGLEWMGWINAD ADI-41836 Heavy chain variable region NGNTRYSQKFQGRVTITRDTSANTAYMELSSLISEDTAVYYCAREWSGFWSGLNW (“HC”) amino acid sequence FEPWGQGTLVTVSS Ab 936 1872 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGNDVHWYQQFPGTAPKVLIYVNSIRP ADI-41836 Light chain variable region SGVSDRFSGSKSGTSASLAITGLRAEDEADYYCQSYDSSLNGVAFGGGTKLTVL (“LC”) amino acid sequence Ab 937 1873 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAY ADI-41837 Heavy chain variable region SGDTDYAQKLQGRVTMTTDTATSTAYMELRSLRSDDTAVYYCARDAHCSSTNCYID (“HC”) amino acid sequence LGGAPVDYWGQGTLVTVSS Ab 937 1874 DIVLTQTPLSLSVTLGQPASISCRSSQSLVYIDGYTYLNWFQQRPGQSPRRLIYKVSN ADI-41837 Light chain variable region RDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGAHWPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 938 1875 EVQLLESGGGVVQPGRSLRLSCAASEFTFRSYAMHWVRQAPGMGLEWVAVTPYD ADI-41838 Heavy chain variable region GISKYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCARGFPEPITSWPGYF (“HC”) amino acid sequence YAMDVWGQGTTVTVSS Ab 938 1876 QSALTQPASVSGSPGQSITISCTGTTSDVGVYNYVSWYQQHPGKAPKLMIYDVSNR ADI-41838 Light chain variable region PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTNSDTPVVFGGGTKLTVL (“LC”) amino acid sequence Ab 939 1877 EVQLLESGGGVVQPGGSLRLSCVASGFTFSAYGMHWVRQAPGKGPEWVAMTRS ADI-41839 Heavy chain variable region DGNKIYYADSVKGRFTISRDDSKNTLYLEMNSLRPDDTAVYFCAKEVGYGGNSLHY (“HC”) amino acid sequence WGQGTLVTVSS Ab 939 1878 SYELIQPPSVSVAPGQTAKITCGGNNIGSKSVHWYQQKPGQAPVLVVFDDSDRPSG ADI-41839 Light chain variable region IPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDFSSDLWVFGGGTKLTVL (“LC”) amino acid sequence Ab 940 1879 QVQLVQSGAEVKKPGSSVKVSCKASGDTFSGYAIYWVRQAPGRGLELMGGIIPILG ADI-41840 Heavy chain variable region TSSYAQRFLGRTSFTADESTSTAYMDLSSLTSADTAMYYCARKRVTVPVPFDSWGQ (“HC”) amino acid sequence GTLVTVSS Ab 940 1880 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKLGQAPRLLIYGASTRATD ADI-41840 Light chain variable region IPARFSGSGSGTEFTLTISSLQSEDFVVYYCQQYNNWPWTFGQGTKVEIK (“LC”) amino acid sequence Ab 941 1881 EVQLLESGGGLVKPGGSLRLSCAASGFSFSYYSMNWVRQTPGKGLEWVSSISDRSS ADI-41841 Heavy chain variable region YISYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDQYESYAFDIWGQG (“HC”) amino acid sequence TTVTVSS Ab 941 1882 DIQVTQSPSSLSASVGDRITITCQASQDVGNYLNWYQQKVGKAPKLLIHDASDLET ADI-41841 Light chain variable region GVPSRFSGSGSGTYFTFTISSLQPEDFATYYCQPYDNLRPVTFGQGTRLEIK (“LC”) amino acid sequence Ab 942 1883 QVQLVQSGAEVKKPGASVRVSCKASGYTFTHYDINWVRQAPGQGLEWMGWINP ADI-41842 Heavy chain variable region NSGDTDYAQKFQGRVTMTVDTSISTAYLDLRSLTSADAAVYYCARGGAYAINGYYII (“HC”) amino acid sequence WFDPWGQGTLVTVSS Ab 942 1884 DIVVTQSPSSLSASVGDRVTITCRASQSISRYLNWFQKKPGKAPHLLIYAASILQSEVP ADI-41842 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNSPYTFGPGTKVDIK (“LC”) amino acid sequence Ab 943 1885 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSG ADI-43638 Heavy chain variable region STNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVPVLRYFDWLRFGY (“HC”) amino acid sequence GMDVWGQGTTVTVSS Ab 943 1886 EIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYW ADI-43638 Light chain variable region ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPPLTFGGGTKLEIK (“LC”) amino acid sequence Ab 944 1887 QVQLVQSGSELKKPGASVKVSCKASGYTFTSYAMNWVRQAPGQGLEWMGWINT ADI-43639 Heavy chain variable region NTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCAAYGIHDAFDIWGQ (“HC”) amino acid sequence GTMVTVSS Ab 944 1888 DIRLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVP ADI-43639 Light chain variable region SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK (“LC”) amino acid sequence Ab 945 1889 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSS ADI-43640 Heavy chain variable region SYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRDGYNYNFDYW (“HC”) amino acid sequence GQGTLVTVSS Ab 945 1890 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-43640 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL (“LC”) amino acid sequence Ab 946 1891 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSSSY ADI-43641 Heavy chain variable region TNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDFSGQWLVLGYGM (“HC”) amino acid sequence DVWGQGTTVTVSS Ab 946 1892 QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-43641 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPVFGGGTKLTVL (“LC”) amino acid sequence Ab 947 1893 EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSS ADI-43642 Heavy chain variable region YIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGADSSYYYYMDVW (“HC”) amino acid sequence GKGTTVTVSS Ab 947 1894 QAVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNR ADI-43642 Light chain variable region PSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL (“LC”) amino acid sequence

EXEMPLARY EMBODIMENTS

1. An isolated antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRH3 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRH3 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 465 as disclosed in Table 5.

2. An isolated antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRH2 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRH2 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

3. An isolated antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRH1 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRH1 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

4. An isolated antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRL3 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRL3 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

5. An isolated antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRL2 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRL2 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

6. An isolated antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising a CDRL1 amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a CDRL1 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

7. The isolated anti-RSV F antibody of any one of embodiments 1 to 6, comprising (i) the CDRH3 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (ii) the CDRH2 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (iii) the CDRH1 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (iv) the CDRL3 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (v) the CDRL2 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; (vi) the CDRL1 amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; or (vii) any combination of two or more of (i), (ii), (iii), (iv), (v), and (vi).

8. An isolated antibody or antigen-binding fragment thereof that cross-competes for binding or specifically binds to the same epitope(s) of a Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) as an antibody or antigen-binding fragment thereof comprising (i) a heavy chain variable region (V_(H)) that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a V_(H) amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5, and/or (ii) a light chain variable region (V_(L)) that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a V_(L) amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

9. The isolated anti-RSV F antibody of embodiment 8, comprising (i) the V_(H) amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5; and/or (ii) the V_(L) amino acid sequence of an antibody selected from Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

10. The isolated anti-RSV F antibody of any one of embodiments 1 to 9, which is selected from the group consisting of Antibody Number 1 through Antibody Number 947 as disclosed in Table 5.

11. The isolated anti-RSV F antibody of any one of embodiments 1 to 10, which binds to an epitope comprising site Ø, site I, site II, site III, site IV, or site V of RSVF.

12. The isolated anti-RSV F antibody of any one of embodiments 1 to 11, which binds to an epitope on prefusion F (preF), preferably antigenic site III.

13. The isolated anti-RSV F antibody of any one of embodiments 1 to 12, which binds to prefusion F (preF) with high affinity but does not bind to or binds with low affinity to postfusion F (postF).

14. The isolated anti-RSV F antibody of any one of embodiments 1 to 12, which binds to an epitope on postfusion F (post F), preferably antigenic site I.

15. The isolated anti-RSV F antibody of any one of embodiments 1 to 14, which does not compete with D25 for binding to RSV F.

16. The isolated anti-RSV F antibody of any one of embodiments 1 to 15, which competes with MPE8 and/or motavizumab for binding to RSV F.

17. The isolated anti-RSV F antibody of any one of embodiments 1 to 16, which is a neutralizing antibody.

18. The isolated anti-RSV F antibody of embodiment 17, which has a neutralizing activity (IC₅₀) of less than 100 μg/ml, 50 μs/ml, 25 μs/ml, 10 μg/ml, 5 μg/ml, 1 μg/ml, 0.5 μg/ml, 0.1 μg/ml, or 0.05 μg/ml.

19. The isolated anti-RSV F antibody of any one of embodiments 1 to 18, which binds to RSV prefusion F with a K_(D) value of less than 50 nM, 25 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, or

0.1 nM as measured by surface plasmon resonance.

20. The isolated anti-RSV F antibody of any one of embodiments 1 to 19, which binds to RSV prefusion F through one or both of the following interactions:

-   -   a) Tyr33 in CDRL1 and Tyr93 in CDRL3 both contact the α6-α7 loop         of RSV prefusion F; and     -   b) five consecutive serine residues, preferably followed by a         tyrosine residue (Tyr56), in CDRH2 form a network of hydrogen         bonds with Asp310 on (36 of RSV prefusion F.

21. The isolated anti-RSV F antibody of any one of embodiments 1 to 20, which has a clean or low polyreactivity profile.

22. The isolated anti-RSV F antibody of any one of embodiments 1 to 21, which is a full-length IgG1 monoclonal antibody.

23. The isolated anti-RSV F antibody of any one of embodiments 1 to 22, which comprises a Fc region that has been modified to alter effector function, half-life, proteolysis, and/or glycosylation.

24. The isolated anti-RSV F antibody of any one of embodiments 1 to 23, which is derivatized.

25. An isolated nucleic acid sequence or nucleic acid sequences encoding an antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 24.

26. An expression vector or vectors comprising the isolated nucleic acid sequence according to embodiment 25.

27. A host cell comprising the isolated nucleic acid sequence(s) according to embodiment 25 or the expression vector(s) according to embodiment 26.

28. The host cell of embodiment 27, which is a mammalian cell, a bacterial cell, a fungal cell, a yeast cell, or an insect cell.

29. A method for producing an isolated antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) fusion glycoprotein (F) (“an anti-RSV F antibody”) comprising expressing the nucleic acid sequence(s) of embodiment 25 or culturing the host cell of embodiment 27 or 28 under conditions that provide for expression of the anti-RSV F antibody and optionally recovering the anti-RSV F antibody from the host cell and/or culture medium.

30. The method of embodiment 29, wherein the host cell is a yeast cell or a mammalian cell.

31. A pharmaceutical composition comprising (i) the anti-RSV F antibody of any one of embodiments 1 to 24, the nucleic acid sequence(s) of embodiment 25, the expression vector(s) of embodiment 26, or the host cell of embodiments 27 or 28; and (ii) a pharmaceutically acceptable carrier and/or excipient.

32. The pharmaceutical composition of embodiment 31 for use in preventing or treating a RSV infection in a subject.

33. The pharmaceutical composition of embodiment 32, wherein the subject is a human, preferably an infant.

34. A method of preventing or treating a Respiratory Syncytial Virus (RSV) infection in a subject, comprising administering to the subject in need thereof an effective amount of the anti-RSV F antibody of any one of embodiments 1 to 24, the isolated nucleic acid sequence(s) of embodiment 25, the expression vector(s) of embodiment 26, or the host cell(s) of embodiment 27 or 28, optionally in association with a further prophylactic and/or therapeutic agent.

35. The method of embodiment 34, wherein the further prophylactic and/or therapeutic agent is selected from an antiviral agent; a vaccine specific for RSV; a vaccine specific for influenza virus; a vaccine specific for metapneumovirus (MPV); an siRNA specific for a RSV antigen; an siRNA specific for a MPV antigen; a second anti-RSV antibody; an anti-MPV antibody; an anti-IL4R antibody; an anti-influenza antibody; and a NSAID.

36. The method of embodiment 34 or 35, wherein the subject is human, preferably an infant.

37. A method of preventing or treating a Respiratory Syncytial Virus (RSV) infection in a human subject, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of any one of embodiments 31 to 33.

38. The method of embodiment 37, wherein the human subject is an infant.

39. A method for detecting a Respiratory Syncytial Virus (RSV) infection in a subject, comprising obtaining a sample from the subject; contacting the sample with the anti-RSV F antibody of any one of embodiments 1 to 24; and detecting the presence of a complex between the anti-RSV F antibody and the RSV fusion glycoprotein (F), wherein detection of the complex indicates the presence of RSV.

40. The method of embodiment 39, wherein the subject is a human, preferably an infant.

41. An isolated antibody or antigen-binding polypeptide comprising a VH CDR3 having an amino acid sequence according to an antibody number in Table 9B.

42. An isolated antibody or antigen-binding polypeptide comprising a VH CDR3 having an amino acid sequence according to an ADI listed in Table 8.

43. An isolated antibody or antigen binding polypeptide characterized by ability to neutralize respiratory syncytial virus (RSV).

44. An isolated antibody or antigen binding polypeptide characterized by high affinity binding to RSV F.

45. An isolated antibody or antigen binding polypeptide characterized by high affinity binding to RSV prefusion F (preF).

46. An isolated antibody having an amino acid sequence according to:

(i) Antibody Number 2, 71, 112, 217, 227, 228, 249, 466, 467, 469, 470, 832, 471, 516, 527, 532, 543, 544, 551, 554, 571, 578, 581, 592, 615, 641, 843, 868, or 870;

(ii) an Antibody Number of (i) with no more than 3 amino acid substitutions, additions, or deletions;

(iii) an Antibody Number of (i) with no more than 3, 2, or 1 amino acid substitution(s), addition(s), or deletion(s) in a CDR; or

(iv) an Antibody Number of (i) with no more than 3, 2, or 1 amino acid substitution(s), addition(s), or deletion(s) in CDRH3.

47. An antibody or antigen-binding polypeptide according to any preceding embodiment having an IC₅₀ of less than 300 pM for neutralization of RSV.

48. An antibody or antigen-binding polypeptide according to any preceding embodiment having an IC₅₀ of less than 200 pM for neutralization of RSV.

49. An antibody or antigen-binding polypeptide according to any preceding embodiment having an IC₅₀ of less than 100 pM for neutralization of RSV.

50. An antibody or antigen-binding polypeptide according to any preceding embodiment characterized by binding affinity to pre-F with a kD of less than 10 nM.

51. An antibody or antigen-binding polypeptide according to any preceding embodiment characterized by a binding affinity to pre-F that is at least 10, 100, or 1000 fold greater than binding affinity to post-F.

52. An antibody or antigen-binding polypeptide according to any preceding embodiment characterized by high affinity binding to RSV F site III.

53. A nucleic acid molecule encoding an antibody or antigen binding protein according to any preceding embodiment.

54. A vector comprising a nucleic acid molecule encoding an antibody or antigen binding protein according to any preceding embodiment.

55. A cell comprising a vector according to claim 54. 

What is claimed is:
 1. A composition comprising an antibody component, wherein: the antibody component consists of: a first antibody, or antigen binding fragment thereof, that has heavy and light chain CDRs found in antibody number 843; and a second antibody, or antigen binding fragment thereof, that has heavy and light chain CDRs found in an antibody that is selected from the group consisting of antibody numbers 554, 466, 2, 71, 112, 217, 227, 228, 249, 467, 469, 470, 832, 471, 516, 527, 532, 543, 544, 551, 571, 578, 581, 592, 615, 641, 868, and 870; wherein each of the first and second antibodies, or antigen binding fragments thereof, specifically binds to and neutralizes RSV F; and further wherein the composition does not include any antibodies other than the antibody component.
 2. The composition of claim 1, wherein either the first and/or second antibody has an IC50 of less than 300 pM for neutralization of RSV.
 3. The composition of claim 1, wherein either the first and/or second antibody has an IC50 of less than 200 pM for neutralization of RSV.
 4. The composition of claim 1, wherein either the first and/or second antibody has an IC50 of less than 100 pM for neutralization of RSV.
 5. The composition of claim 1, wherein each of the first and second antibody is characterized by binding affinity to pre-F with a k_(D) of less than 10 nM.
 6. A method of treating an RSV infection in a mammal, comprising administering the composition of claim
 1. 7. The method according to claim 6, wherein the method further comprises administering to the mammal an additional prophylactic or therapeutic agent.
 8. The method according to claim 7, wherein the additional prophylactic or therapeutic agent is one or more of: an antiviral agent; a vaccine specific for RSV; a vaccine specific for influenza virus; a vaccine specific for metapneumovirus (MPV); an siRNA specific for a RSV antigen; an siRNA specific for a MPV antigen; a further anti-RSV antibody; an anti-MPV antibody; an anti-IL4R antibody; an anti-influenza antibody; and a NSAID.
 9. The method according to claim 6, wherein the mammal is a human.
 10. The composition of claim 1, wherein the first antibody has framework regions with at least 90% sequence identity to those of antibody number 843, and/or the second antibody has framework regions with at least 90% sequence identity to the framework regions of the antibody in which its heavy and light chain CDRs are found.
 11. The composition of claim 1, wherein the first antibody and/or second antibody comprise a heavy chain IgG Fc region.
 12. The composition of claim 11, wherein the heavy chain IgG Fc region is a variant associated with increased antibody serum half-life, improved stability, modified effector function, or a combination thereof.
 13. The composition of claim 1, which composition consists of: the antibody component; and a carrier for parenteral administration.
 14. The composition of claim 1, which composition is formulated for parenteral administration.
 15. The composition of claim 13, which composition is in powder form.
 16. The composition of claim 1, which composition is formulated for intravenous-, intramuscular-, intradermal-, transdermal-, intraperitoneal, intranasal-, inhalation, and/or subcutaneous-administration and/or intramuscular administration.
 17. The composition of claim 14, disposed within a syringe.
 18. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 554. 19. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 466. 20. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 2. 21. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 71. 22. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 112. 23. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 217. 24. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 227. 25. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 228. 26. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 249. 27. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 467. 28. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 469. 29. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 470. 30. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 832. 31. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 471. 32. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 516. 33. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 527. 34. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 532. 35. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 543. 36. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 544. 37. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 551. 38. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 571. 39. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 578. 40. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 581. 41. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 592. 42. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 615. 43. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 641. 44. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 868. 45. The composition of claim 1, wherein the second antibody, or antigen binding fragment thereof, has heavy and light chain CDRs found in antibody number
 870. 